<SEC-DOCUMENT>0001437749-25-007743.txt : 20250314
<SEC-HEADER>0001437749-25-007743.hdr.sgml : 20250314
<ACCEPTANCE-DATETIME>20250314163105
ACCESSION NUMBER:		0001437749-25-007743
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250314
DATE AS OF CHANGE:		20250314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NRX Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001719406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				822844431
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38302
		FILM NUMBER:		25740503

	BUSINESS ADDRESS:	
		STREET 1:		1201 ORANGE STREET
		STREET 2:		SUITE 600
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801
		BUSINESS PHONE:		484-254-6134

	MAIL ADDRESS:	
		STREET 1:		1201 ORANGE STREET
		STREET 2:		SUITE 600
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Big Rock Partners Acquisition Corp.
		DATE OF NAME CHANGE:	20171012
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nrxp20241231c_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:nrxp="http://www.nrxpharma.com/20241231" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>nrxp20241231c_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/14/2025 5:45:03 PM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001719406</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">NRX Pharmaceuticals, Inc.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-15356">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-15357">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-15358">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-15359">2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="c125342692" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="c125341744" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="c125341745" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="c125342699" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="c125342700" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="c125341750" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonFraction id="c125344265" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c125344266" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c125342639" contextRef="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342640" contextRef="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342641" contextRef="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000,000</ix:nonFraction>
<ix:nonFraction id="c125342642" contextRef="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000,000</ix:nonFraction>
<ix:nonFraction id="c125342643" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342644" contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342645" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,000,000</ix:nonFraction>
<ix:nonFraction id="c125342646" contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,000,000</ix:nonFraction>
<ix:nonFraction id="c125342647" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342649" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342648" contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction>
<ix:nonFraction id="c125342650" contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction>
<ix:nonFraction id="c125342651" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342652" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342653" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c125342654" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c125342655" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,591,505</ix:nonFraction>
<ix:nonFraction id="c125342657" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,591,505</ix:nonFraction>
<ix:nonFraction id="c125342656" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,391,956</ix:nonFraction>
<ix:nonFraction id="c125342658" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,391,956</ix:nonFraction>
<ix:nonFraction id="c125342666" contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,519</ix:nonFraction>
<ix:nonFraction id="c125342674" contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">27</ix:nonFraction>
<ix:nonFraction id="c125342682" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">197</ix:nonFraction>
<ix:nonFraction id="c125342690" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">975</ix:nonFraction>
<ix:nonFraction id="c125341386" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:RepaymentsOfInsuranceLoans" scale="3" format="ixt:num-dot-decimal" decimals="-3">725</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125341895" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c125342005" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="Pure" name="nrxp:DebtInstrumentNumberOfTranches" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c125344324" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementCumulativePayments" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction>
<ix:nonFraction id="c125342703" contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="us-gaap:PaymentsForRoyalties" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342704" contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:PaymentForLicenseAgreementMaintenanceFee" scale="0" format="ixt:num-dot-decimal" decimals="INF">150,000</ix:nonFraction>
<ix:nonFraction id="c125342705" contextRef="d_2023-01-01_2023-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342120" contextRef="d_2024-03-21_2024-03-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction>
<ix:nonFraction id="c125342129" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000,000</ix:nonFraction>
<ix:nonFraction id="c125342130" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c125342133" contextRef="d_2023-08-01_2023-08-31_ClassOfWarrantOrRightAxis-ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" unitRef="Share" name="nrxp:ClassOfWarrantOrRightIssuedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c125342706" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342158" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c125342246" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342251" contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.1</ix:nonFraction>
<ix:nonFraction id="c125342708" contextRef="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="nrxp:ClassOfWarrantOrRightExercisesInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342709" contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,448,856</ix:nonFraction>
<ix:nonFraction id="c125342710" contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">344,886</ix:nonFraction>
<ix:nonFraction id="c125342711" contextRef="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonFraction id="c125342277" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.5</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342283" format="ixt-sec:duryear">5.5</ix:nonNumeric>
<ix:nonFraction id="c125342289" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.5</ix:nonFraction>
<ix:nonFraction id="c125342299" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.5</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342311" format="ixt-sec:duryear">5.5</ix:nonNumeric>
<ix:nonFraction id="c125342316" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.6</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342325" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c125342328" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction>
<ix:nonFraction id="c125342340" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342350" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342360" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342378" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342399" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342416" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c125342419" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342426" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c125342446" contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember" unitRef="Pure" name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.316</ix:nonFraction>
<ix:nonFraction id="c125342477" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125342486" format="ixt-sec:durmonth">6</ix:nonNumeric>
<ix:nonFraction id="c125342492" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125341634" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember" unitRef="USD" name="nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">4,190</ix:nonFraction>
<ix:nonFraction id="c125342722" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c125342723" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c125342519" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342724" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342527" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342725" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="c125342539" format="ixt:date-monthname-day-year-en">December 31, 2035</ix:nonNumeric>
<ix:nonFraction id="c125342726" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342727" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342568" contextRef="d_2024-07-01_2024-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c125342730" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonFraction id="c125342610" contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonFraction id="c125342623" contextRef="d_2025-01-28_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" format="ixt:num-dot-decimal" decimals="INF">7</ix:nonFraction>
<ix:nonNumeric contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c125342628" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c125342638" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c125342736" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c125342737" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c125342738" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="nrxp-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-03-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:NondesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:NondesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-08-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-14_2024-08-14_CounterpartyNameAxis-AnsonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:AnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonSecondTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-10_2024-10-10_CounterpartyNameAxis-AnsonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:AnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-10</xbrli:startDate><xbrli:endDate>2024-10-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-10_2024-10-10_DebtInstrumentAxis-StreetervileComplaintMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-10</xbrli:startDate><xbrli:endDate>2024-10-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrxp:AnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrxp:AnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-02_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-01_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-01_2024-06-30_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-04</xbrli:startDate><xbrli:endDate>2022-11-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-30_2023-03-30_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-30</xbrli:startDate><xbrli:endDate>2023-03-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-10_2023-07-10_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-07</xbrli:startDate><xbrli:endDate>2023-07-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-07</xbrli:startDate><xbrli:endDate>2023-07-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-09</xbrli:startDate><xbrli:endDate>2024-02-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:PrincipalRepaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:InterestRepaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:PrincipalRepaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:InterestRepaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-24_2024-04-24_LitigationCaseAxis-StreetervileComplaintMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-29_2024-07-29_LitigationCaseAxis-StreetervileComplaintMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-29</xbrli:startDate><xbrli:endDate>2024-07-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-12</xbrli:startDate><xbrli:endDate>2024-08-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-15_2024-08-15_LitigationCaseAxis-StreetervileComplaintMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-01_2024-10-31_LitigationCaseAxis-StreetervileComplaintMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-12_ClassOfWarrantOrRightAxis-AnsonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonSecondTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-10</xbrli:startDate><xbrli:endDate>2024-10-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonSecondTrancheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:EndOfPhaseIClinicalTrialsOfLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:EndOfPhaseIIClinicalTrialsOfLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:EndOfPhaseIIIClinicalTrialsOfLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInUsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:FirstCommercialSaleOfLicensedProductInUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInEuropeMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:FirstCommercialSaleOfLicensedProductInEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-AnnualRevenueThresholdMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:AnnualRevenueThresholdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByLicensedPatentsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:ProductsCoveredByLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByValidClaimsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:ProductsCoveredByValidClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-16_2021-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">nrxp:PatentLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">nrxp:PatentLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nrxp:LeaseContractualTermOfficeSpaceRentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nrxp:LeaseContractualTermOfficeSpaceRentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-12</xbrli:startDate><xbrli:endDate>2024-08-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-31</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-21_2024-03-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">nrxp:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-04-01_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">nrxp:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-04-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-30_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-01_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:PreferredStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-01_2023-08-31_ClassOfWarrantOrRightAxis-ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:PreferredStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RangeAxis-MinimumMember_StatementClassOfStockAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">nrxp:NRXPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-08_2023-02-08_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:HCWainwrightCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-08</xbrli:startDate><xbrli:endDate>2023-02-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:HCWainwrightCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-06_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:HCWainwrightCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-15_2023-05-15_DebtInstrumentAxis-StreetervilleCapitalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-04_2023-08-04_DebtInstrumentAxis-StreetervilleCapitalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-30_2023-08-30_DebtInstrumentAxis-StreetervilleCapitalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-30</xbrli:startDate><xbrli:endDate>2023-08-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-17_2023-07-17_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-02_2024-01-02_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtToCommonStockMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfDebtToCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-20_2024-07-29_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-20</xbrli:startDate><xbrli:endDate>2024-07-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-07-29_RangeAxis-MinimumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-07-29_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-14_2023-08-14_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryUnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryUnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryOverallotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryUnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryOverallotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-06</xbrli:startDate><xbrli:endDate>2024-03-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryOverallotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-29_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilUnderwriterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilUnderwriterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilOverallotmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-April2024OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:April2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilOverallotmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilOverallotmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-28_2024-08-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-28</xbrli:startDate><xbrli:endDate>2024-08-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-24_BusinessAcquisitionAxis-NeuroRxMember_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nrxp:NeuroRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:SubstituteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:SubstituteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:SubstituteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-08_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-28_2023-08-28_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-28</xbrli:startDate><xbrli:endDate>2023-08-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-28_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-28</xbrli:startDate><xbrli:endDate>2023-08-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-24_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-24</xbrli:startDate><xbrli:endDate>2023-10-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-05_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-19_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-05-23_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-07_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-07</xbrli:startDate><xbrli:endDate>2024-02-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-14_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nrxp:NeuroRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2016OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-12_2022-07-12_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-28</xbrli:startDate><xbrli:endDate>2023-12-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputMarketRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputVolumeVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputVolumeVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputCostOfDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputCostOfDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputMarketRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputMarketRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByLiabilityClassAxis-WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-01_2024-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-06_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MinimumMember_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">nrxp:NRXPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithDrJonathanJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithDrJonathanJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-03-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApplicationDateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">nrxp:UnrestrictedUponNewDrugApplicationDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-03-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApprovalDateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">nrxp:UnrestrictedUponNewDrugApprovalDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-03-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-03-13_2025-03-13_ConsolidatedEntitiesAxis-HopeTherapeuticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">nrxp:HopeTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-13</xbrli:startDate><xbrli:endDate>2025-03-13</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:ThirdTrancheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-01-28_ClassOfWarrantOrRightAxis-ThirdTrancheNotesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ThirdTrancheNotesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-28_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:ThirdTrancheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-28</xbrli:startDate><xbrli:endDate>2025-01-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:RDPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-27</xbrli:startDate><xbrli:endDate>2025-01-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:RDPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:RDPurchaseAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ConsiderationWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-27_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ConsiderationWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-27</xbrli:startDate><xbrli:endDate>2025-01-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
   &#160;
  </div>
  <div>
   &#160;
  </div>
  <div><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2024-01-01_2024-12-31" id="ixv-18915">10-K</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Mark One)</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18916">&#9746;</ix:nonNumeric>&#160; ANNUAL REPORT PURSUANT TO SECTION</b>&#160;<b>13 OR 15(d)</b>&#160;<b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Fiscal Year Ended: <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2024-01-01_2024-12-31" id="ixv-18917">December 31, 2024</ix:nonNumeric> </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18918">&#9744;</ix:nonNumeric>&#160; TRANSITION REPORT PURSUANT TO SECTION</b>&#160;<b>13 OR 15(d)</b>&#160;<b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from to</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-18919">001-38302</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NRX PHARMACEUTICALS, INC.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2024-01-01_2024-12-31" id="ixv-18920">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align:bottom;width:1%;">&#160;</td><td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-18921">82-2844431</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</p> </td><td style="vertical-align:bottom;width:1%;">&#160;</td><td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p> </td></tr>
<tr><td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation or organization)</p> </td><td style="vertical-align:bottom;width:1%;">&#160;</td><td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification No.)</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2024-01-01_2024-12-31" id="ixv-18922">1201 Orange Street, Suite 600</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2024-01-01_2024-12-31" id="ixv-18923">Wilmington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2024-01-01_2024-12-31" id="ixv-18924">DE</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2024-01-01_2024-12-31" id="ixv-18925">19801</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2024-01-01_2024-12-31" id="ixv-18926">484</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-18927">254-6134</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:20.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class:</b></p> </td><td style="vertical-align:bottom;width:0.8%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol(s)</b></p> </td><td style="vertical-align:bottom;width:0.8%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered:</b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:20.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember" id="ixv-18928">Common Stock, par value $0.001 per share</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:0.8%;">&#160;</td><td style="vertical-align:bottom;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember" id="ixv-18929">NRXP</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:0.8%;">&#160;</td><td style="vertical-align:bottom;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember" id="ixv-18930">Nasdaq</ix:nonNumeric> Stock Market LLC</p> </td></tr>
<tr><td style="vertical-align:bottom;width:20.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember" id="ixv-18931">Warrants to purchase one share of Common Stock</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:0.8%;">&#160;</td><td style="vertical-align:bottom;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember" id="ixv-18932">NRXPW</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:0.8%;">&#160;</td><td style="vertical-align:bottom;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember" id="ixv-18933">Nasdaq</ix:nonNumeric> Stock Market LLC</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Securities registered pursuant to Section 12(g) of the Act: None</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;Yes &#9744; &#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2024-01-01_2024-12-31" id="ixv-18934">No</ix:nonNumeric> &#9746;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; &#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2024-01-01_2024-12-31" id="ixv-18935">No</ix:nonNumeric> &#9746;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2024-01-01_2024-12-31" id="ixv-18936">Yes</ix:nonNumeric> &#9746; &#160;No &#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2024-01-01_2024-12-31" id="ixv-18937">Yes</ix:nonNumeric> &#9746; &#160;No &#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 78%; margin-left: 72pt; margin-right: auto;"><tbody><tr><td style="vertical-align:bottom;width:15.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer</p> </td><td style="vertical-align:top;width:3.8%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p> </td><td style="vertical-align:bottom;width:11.5%;">&#160;</td><td style="vertical-align:bottom;width:20.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer</p> </td><td style="vertical-align:top;width:4.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p> </td></tr>
<tr><td style="vertical-align:bottom;width:15.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2024-01-01_2024-12-31" id="ixv-18938">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align:top;width:3.8%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p> </td><td style="vertical-align:bottom;width:11.5%;">&#160;</td><td style="vertical-align:bottom;width:20.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company</p> </td><td style="vertical-align:top;width:4.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18939">&#9746;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:bottom;width:15.3%;">&#160;</td><td style="vertical-align:top;width:3.8%;">&#160;</td><td style="vertical-align:bottom;width:11.5%;">&#160;</td><td style="vertical-align:bottom;width:20.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company</p> </td><td style="vertical-align:top;width:4.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18940">&#9744;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18941">&#9744;</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#160;<ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18942">&#9744;</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-18943">&#9744;</ix:nonNumeric> &#160;No&#160;&#9746;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant&#8217;s common stock as reported on the Nasdaq Global Market on June 30, 2024, was $<ix:nonFraction name="dei:EntityPublicFloat" scale="6" unitRef="USD" decimals="1" format="ixt:num-dot-decimal" contextRef="i_2024-06-30" id="ixv-18944">21.5</ix:nonFraction> million.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As of March 14, 2025, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2025-03-14" id="ixv-18945">16,915,647</ix:nonFraction> shares of common stock outstanding.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Documents Incorporated by Reference</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The registrant incorporates information required by Part III (Items 10, 11, 12, 13, and 14) of this report by reference to portions of the registrant&#8217;s definitive proxy statement to be filed pursuant to Regulation 14A with respect to its 2025 Annual Meeting of Stockholders.&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
  Page 2
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" title="toc" href="#"></a>Annual Report on Form 10-K </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part1" style="-sec-extract:exhibit;"><b>Part I.</b></a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1" style="-sec-extract:exhibit;">Item 1. Business</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item1">5</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1a" style="-sec-extract:exhibit;">Item 1A. Risk Factors</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item1a">37</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1b" style="-sec-extract:exhibit;">Item 1B. Unresolved Staff Comments</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item1b">70</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1c" style="-sec-extract:exhibit;">Item 1C. Cybersecurity</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item1c">71</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item2" style="-sec-extract:exhibit;">Item 2. Properties</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item2">71</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item3" style="-sec-extract:exhibit;">Item 3. Legal Proceedings</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item3">71</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item4" style="-sec-extract:exhibit;">Item 4. Mine Safety Disclosures</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item4">72</a></td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part2" style="-sec-extract:exhibit;"><b>Part II</b></a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item5" style="-sec-extract:exhibit;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item5">73</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item6" style="-sec-extract:exhibit;">Item 6. [Reserved]</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item6">74</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item7" style="-sec-extract:exhibit;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item7">75</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item7a" style="-sec-extract:exhibit;">Item 7A. Quantitative and Qualitative Disclosure about Market Risk</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item7a">89</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item8" style="-sec-extract:exhibit;">Item 8. Financial Statements and Supplementary Data</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item8">88</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9" style="-sec-extract:exhibit;">Item 9. Changes in Disagreements with Accountants on Accounting and Financial Disclosure</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item9">89</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9a" style="-sec-extract:exhibit;">Item 9A. Controls and Procedures</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item9a">89</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9b" style="-sec-extract:exhibit;">Item 9B. Other Information</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item9b">89</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9c" style="-sec-extract:exhibit;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item9c">89</a></td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part3" style="-sec-extract:exhibit;"><b>Part III.</b></a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item10" style="-sec-extract:exhibit;">Item 10. Directors, Executive Officers, and Corporate Governance</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item10">90</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item11" style="-sec-extract:exhibit;">Item 11. Executive Compensation</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item11">90</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item12" style="-sec-extract:exhibit;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item12">90</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item13" style="-sec-extract:exhibit;">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item13">90</a></td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item14" style="-sec-extract:exhibit;">Item 14. Principal Accounting Fees and Services</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item14">90</a></td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:bottom;width:46.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part4" style="-sec-extract:exhibit;"><b>Part IV.</b></a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:5%;">&#160;</td>
     <td style="vertical-align:bottom;width:41.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item15" style="-sec-extract:exhibit;">Item 15. Exhibits and Financial Statement Schedules</a></p> </td>
     <td style="vertical-align: bottom; width: 3.8%; text-align: right;"><a class="tocPGNUM" href="#item15">91</a></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAUTIONARY STATEMENT</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">This document and the information incorporated by reference herein include &#8220;forward-looking statements&#8221; within the meaning of the &#8220;safe harbor&#8221; provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company&#8217;s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company&#8217;s management. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;goals,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;shall,&#8221; and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. These forward- looking statements are, by their nature, subject to significant risks and uncertainties, many of which involve factors or circumstances that are beyond the Company&#8217;s control. These risks and uncertainties include, but are not limited to, our relatively limited operating history; our ability to expand, retain and motivate our employees and manage our growth; risks associated with general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company&#8217;s ability to accurately predict future market conditions; manufacturing difficulties or delays; changes in laws, rules or regulations relating to any aspect of the Company&#8217;s business operations, or general economic, market and business conditions; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company&#8217;s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Furthermore, there can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The Company assumes no obligation and does not intend to update or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. As a result of these and other risks, uncertainties and assumptions, forward-looking events and circumstances discussed herein might not occur in the way that the Company&#8217;s management expects, if at all. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="part1" title="part1" href="#"></a>PART I</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Unless the context requires otherwise, references in this annual report to </i>&#8220;<i>NRx,</i>&#8221;<i> </i>&#8220;<i>Company,</i>&#8221;<i> </i>&#8220;<i>we,</i>&#8221;<i> </i>&#8220;<i>us</i>&#8221;<i> and </i>&#8220;<i>our</i>&#8221;<i> and similar designations refer to NRx Pharmaceuticals, Inc. and its subsidiaries.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item1" title="item1" href="#"></a>Item 1. Business</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Summary</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRX&#8221; or the &#8220;Company&#8221;) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc. (&#8220;NeuroRx&#8221;), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#8220;PTSD&#8221;) and now schizophrenia. All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate (&#8220;NMDA&#8221;) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. The Company has two lead drug candidates that are expected to be submitted by year end for Food and Drug Administration ("FDA") approval with anticipated FDA decision dates under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) by the end of June 2025: NRX-101, an oral fixed dose combination of D-cycloserine and lurasidone and NRX-100, a preservative-free formulation of ketamine for intravenous infusion. In February 2024, NRx incorporated HOPE Therapeutics, Inc. (&#8220;HOPE&#8221;), a medical care delivery organization focused on interventional psychiatric treatment of the above conditions with NMDA-targeted and other psychedelic drugs, neuromodulatory devices, such as Transcranial Magnetic Stimulation (&#8220;TMS&#8221;), digital therapeutics, and medication management.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">NeuroRx is organized as a traditional research and development ("R&amp;D") company, whereas HOPE is organized as a medical care delivery company intended to own and/or operate clinics that serve patients with suicidal depression, PTSD, and other serious Central Nervous System (CNS) disorders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The 2024 fiscal year marked a period of both expansion and change for NRx. Throughout this time, the Company implemented a restructuring of its leadership to address challenges related to capital formation, clinical trial enrollment, and corporate development. These efforts led to measurable achievements in 2024 and positioned the Company for growth and the achievement of our development objectives in 2025. Management&#8217;s plan, through the establishment of HOPE is to transform NRx from a pre-revenue biotechnology company to a revenue-generating enterprise that continues to develop life-saving drugs and technologies (through NRx) while also treating patients (through HOPE). During 2024 and through the date of this Annual Report, the Company has achieved the following:&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Recent Developments</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Financing</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">We consummated a series of financing agreements with an institutional investor for up to $16.3 million in debt capital, for which we closed on $10.87 million in 2024 and subsequently closed $8.5 million in a combination of convertible debt and an above-market common stock and warrant offering in January 2025. We were presented with and are currently negotiating a term sheet with a publicly-traded strategic investor to provide additional capital to support the expansion of HOPE clinics. In addition, management is negotiating with several commercial lenders to provide additional financing to support the acquisition of additional clinics on standard commercial loan terms. Although no assurances can be given, and assuming we&#8217;re able to consummate the proposed financings, management believes that we will have sufficient financing to consummate our previously announced acquisitions, execute our business plan and achieve our projected revenue objectives.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td colspan="3" style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Drug Development</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We filed module 3 (manufacturing) of our NDA for NRX-100 (preservative-free sterile ketamine) in a tamper-resistant, diversion resistant packaging presentation. NRX-100 was previously granted Fast Track Designation by FDA in combination with use of NRX-101. Ketamine efficacy data is in hand from four clinical trials. Three manufacturing lots are now completed with filed stability data suitable for shelf life exceeding two years at room temperature. The anticipated PDUFA date for this settlement is prior to December 30, 2025. We also anticipate filing an Abbreviated New Drug Application (&#8220;ANDA&#8221;) for the use of preservative-free ketamine in all currently-indicated clinical applications.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">We initiated the filing of a New Drug Application (&#8220;NDA&#8221;) in the fourth quarter of 2024 for Accelerated Approval under Breakthrough and Priority Review of NRX-101 in treatment of bipolar depression in people at risk of akathisia, based on the Phase 2b/3 and STABIL-B data. Three manufacturing lots are now completed with more than 24 months of room temperature shelf-stability. The anticipated PDUFA date for this application is prior to December 31, 2025. Work is ongoing to prepare the module 3 manufacturing section documenting our transition from manufacturing at WuXi Apptec in Shanghai to manufacturing of NRX-101 in North Carolina with manufacture of three commercial lots.</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We accepted a non-binding offer from a commercial pharmaceutical company to license and distribute NRX-100 (preservative-free ketamine) that provides for $325 million in potential milestones plus a sliding scale royalty that ranges from 11% - 16% of sales.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">We initiated development of and plan to file a citizen&#8217;s petition with the FDA to remove benzethonium chloride, a known neurotoxic substance from presentations of ketamine intended for intravenous use. Management believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of benzethonium chloride in current generic products.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">As a next-generation product, we developed a novel, patentable pH neutral formulation for ketamine (designed as HTX-100) that will be suitable for both intravenous and subcutaneous administration. Initial laboratory lots demonstrate shelf stability and ongoing stability is being assessed. Ketamine in its current commercial presentations cannot be administered subcutaneously because of its high acidic (pH 3.5-4.0) properties, an acidity range that is known to cause pain and skin ulcers. We anticipate long-term patent protection on this novel product. This product is expected to undergo clinical testing in 2025/2026 and be ready for FDA approval in 2027.</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">NRX-101 in the treatment of Complicated Urinary Tract Infection (&#8220;cUTI&#8221;) was granted Qualified Infectious Disease Product (&#8220;QIDP&#8221;), Fast Track, and Priority Review designations in 2024. We have now demonstrated that NRX-101 does not damage the microbiome of the gut, in contrast to all other advanced antibiotics and is less likely to cause C. Difficile infection (a potentially lethal side effect of antibiotic treatment). NRx is reviewing partnership options.</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We executed a Memorandum of Understanding with Foundation FundaMental for rights to develop a potential disease modifying drug for schizophrenia, autism, and acute mania. If successful, this would represent the first drug to reverse the underlying disease mechanism of these conditions, rather than simply treating symptoms.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td colspan="3" style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td colspan="3" style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>HOPE Therapeutics </i></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td colspan="3" style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We partnered with representatives of ketamine clinic operators to construct a care platform that will include ketamine, operational support, and digital therapeutic extensions. In advance of FDA&#160;approval, HOPE anticipates that it will supply ketamine under 503b pharmacy licensure to meet the national ketamine shortage declared by FDA.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We signed non-binding letters of intent to acquire three precision psychiatry centers, the closing of which is subject to execution of definitive agreements.&#160; Although no assurances can be given, we are also currently negotiating the terms for the acquisition of six additional psychiatry centers, which are subject to due diligence review and execution of a letter of intent.&#160; Upon closing, the acquisitions will form the foundation for the development of HOPE to achieve our objective of creating a national network offering interventional psychiatry to treat suicidal depression and PTSD.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We engaged BTIG, a leading investment bank, to support us in identifying and acquiring additional clinic candidates to join the HOPE network&#160;sufficient to achieve management&#8217;s revenue targets by year-end 2025.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 96%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our potential acquisition targets have contracts with the Veterans Administration for the treatment of depression and, assuming closing of our previously announced acquisitions, we expect to expand to the treatment of PTSD by year-end 2025.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Developments</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">On November 2022, the Company issued a Convertible Promissory Note to Streeterville, LLC, (&#8220;Streeterville Notes&#8221;) as previously disclosed. In March 2024, Streeterville deemed a proposed dividend of HOPE shares to constitute a basis of default under the Streeterville Notes. Subsequent arbitration found that the proposed HOPE dividend was not a basis for default. In August 2024 the Company signed a settlement agreement with Streeterville to redeem the Streeterville Notes at a discount to the amounts claimed and completed payments of $5.55 million in satisfaction of all claims under the Streeterville Notes in October 2024.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">On March 28, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to effect a 1-for-10 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the Company&#8217;s Common Stock, which Reverse Stock Split was effective as of April 1, 2024. All references in this Annual Report to number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Split on a retroactive basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Company Overview</b></p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company has two lead compounds today, NRX-100, a proprietary presentation of ketamine and NRX-101, a patented fixed-dose combination of D-cycloserine and lurasidone. Both products have Fast Track designation from the FDA for the treatment of suicidal bipolar depression. NRX-101 additionally has Breakthrough Therapy Designation and a Biomarker Letter of Support from the FDA for this purpose. To the Company&#8217;s knowledge, NRX-101 is the only oral antidepressant demonstrated to reduce suicidal ideation in a phase 2 trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For mechanistic reasons unrelated to its central nervous system N-methyl-D-aspartate (&#8220;CNS NMDA&#8221;) antagonist properties, NRX-101 interferes with cell wall formation in certain bacteria, rendering it a potent antibiotic and is demonstrated to kill certain treatment-resistant urinary tract bacteria. Accordingly, NRX-101 has been awarded Qualified Infectious Disease Product Designation and Fast Track Designation by the FDA to treat Complicated Urinary Tract Infection and Pyelonephritis. Our strategy is to apply innovative science to known molecules in the pursuit of therapies for high unmet needs, including lethal conditions (NeuroRx) and to distribute ketamine and ancillary therapies to qualified clinics and practitioners who treat patients with suicidal depression (HOPE). The Company has previously announced plans to spin off HOPE as a majority-owned company, with a minority interest held by new shareholders resulting from planned financings.&#160; &#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">NeuroRx was founded in 2015 by Professors Jonathan Javitt, MD, MPH and Daniel Javitt, PhD, MD, as a privately-funded R&amp;D company targeting psychiatry drug development and attracted sufficient capital to enter phase 2b/3 research in 2016. Over the subsequent three years it formulated and manufactured clinical supplies of NRX-101, initiated and completed the STABIL-B trial and established the first Special Protocol Agreement issued by the FDA Division of Psychiatry Products to conduct a confirmatory trial of NRX-101 following induction with NRX-100 in hospital Emergency Department patients with acutely suicidal bipolar depression. That trial was initiated in November 2019 and suspended in February 2020 because of the COVID pandemic lockdown.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The COVID lockdown ended in March 2022 and the Company&#8217;s Board unanimously voted to return our focus to CNS drug development. Accordingly, in June 2022 the Company launched a clinical trial of NRX-101 in the treatment of suicidal ideation among patients with bipolar depression (the &#8220;003 trial) and in June 2024 announced results indicating that NRX-101 was not superior to standard of care medication for decreasing symptoms of depression (the primary endpoint) but was superior to standard of care for reducing symptoms of suicidal ideation (the declared secondary endpoint).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In late 2023, the Company recognized the need to create a model for integrated care of patients with suicidal depression, PTSD, and related conditions that combines NMDA-targeted medication therapy (such as NRX-100 and NRX-101) with transcranial magnetic stimulation (&#8220;TMS&#8221;), psychiatric medication management, and digital therapeutics. Accordingly, in January 2024, management incorporated HOPE as a wholly-owned subsidiary for this purpose. Management recognized that the complexity of these life-threatening diseases required an integrated care model that is largely unavailable today. Throughout 2024, the Company developed HOPE&#8217;s business plan, attracted initial capital, and identified key pillar acquisitions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>2024 Financings</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>August 2024 SPA</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On August 12, 2024, the Company executed a Securities Purchase Agreement (the &#8220;August SPA&#8221;) and related agreements, under which the Company agreed to sell and issue, and certain purchasers agreed to purchase, an aggregate of $16.3 million&#160;of securities. The consideration payable by the purchasers under the August SPA was comprised of three equal closings of $5.435 million, each subject to certain closing conditions. The securities to be issued and sold by the Company include up to $16.3 million of senior secured convertible notes (the &#8220;Notes&#8221;) and warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;). The&#160;proceeds arising from the sale of the Notes and the Warrants were&#160;used to settle the Company&#8217;s outstanding amounts owed to Streeterville (as defined below)&#160;and other working capital needs.&#160;The Company has, as of the date of this Annual Report, consummated the first tranche, second tranche, and third tranche under the August SPA, with gross proceeds to the Company of $16.3 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The Notes bear interest at the rate of 6% per annum and mature in 15 months following their date of issuance. The Notes may be settled in cash or in shares of the Company&#8217;s common stock, at the sole discretion of the holder, at the applicable conversion price. The Notes may not be prepaid by the Company however, the holders of the Notes may elect to convert the Notes, in whole or in part, into shares of the Company&#8217;s common stock at any time after the original issuance date. The conversion price: (A) for the Notes issued in the first tranche will equal the lower of (i) $2.4168, or (ii) a price equal to 92% of the lowest volume-weighted average price during the seven-trading day period immediately preceding the applicable conversion date (the &#8220;Alternative Conversion Price&#8221;); (B) &#160;for the Notes issued in the second tranche will equal the lower of (i) $1.766, or (ii) the Alternative Conversion Price; and (C) for the Notes issued in the third tranche will equal the lower of (i) $3.78, or (ii) the Alternative Conversion Price. The Notes include certain redemption, protection features and default interest and penalties. The Notes are secured by all assets of the Company, including its intellectual property.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The Warrants have a term of 5 years, an exercise price of $2.4168 per share for the Warrants issued in the first tranche, $1.766 per share for the Warrants issued in the second tranche, and $3.78 per share for the Warrants issued in the third tranche, each subject to adjustment as more specifically set forth in the Warrants, and are exercisable immediately upon issuance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>April 2024 Offering</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On April 18, 2024, the Company entered into an underwriting agreement (the &#8220;April Underwriting Agreement&#8221;) with EF Hutton LLC (the &#8220;Representative&#8221;), as the representative of the several underwriters named therein (the &#8220;April Underwriters&#8221;), relating to an underwritten public offering (the &#8220;April 2024 Public Offering&#8221;) of 607,000 shares (the &#8220;April Shares&#8221;) of&#160;Common Stock. The public offering price for each share of Common Stock was $3.30. On April 19, 2024, the offering closed. Aggregated proceeds from the offering were approximately $2.4 million (including proceeds from the exercise of the over-allotment option granted to the Representative, as more fully described below), before deducting underwriting discounts and commission and estimated expenses payable by the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the April Underwriting Agreement and the engagement letter dated April 18, 2024, by and between the Company and Representative, the Company agreed to issue to the Representative in connection with the April Offering, a warrant to purchase up to a number of shares of Common Stock representing 5.0% of the Shares and any April Option Shares (as defined below) sold, at an initial exercise price of $3.63 per share, subject to certain adjustments (the &#8220;April Underwriter's Warrant&#8221;). On April&#8239;19, 2024, the Company issued to the Representative the April Underwriter's Warrant&#160;to purchase up to 30,350 shares of Common Stock. The April Underwriter's&#160;Warrants and Over-Allotment Warrants is exercisable nine months following the date of the Underwriting Agreement and terminates on the five-year anniversary of the date of the April Underwriting Agreement.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the April Underwriting Agreement, the Company also granted the Representative a 45-day option to purchase up to an additional 91,050 shares (the &#8220;April Option Shares&#8221;) of the Common Stock on the same terms as the April Shares sold in the April 2024 Public Offering (the &#8220;April Over-Allotment Option&#8221;). In connection with the April Overallotment Exercise, we issued an additional April Underwriter's Warrant to purchase up to 4,553 shares of Common Stock. The April Overallotment Exercise was exercised in full and closed.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>At-The-Market Offering Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On April 15, 2024, the Company increased the maximum aggregate offering amount of the shares of Common Stock issuable under that certain At the Market Offering Agreement, dated August 14, 2023 (the &#8220;Offering Agreement&#8221;), with H.C. Wainwright &amp; Co., and filed a prospectus supplement (the &#8220;Prospectus Supplement&#8221;) under the Offering Agreement for an aggregate of $4.9 million (the &#8220;ATM Offering&#8221;). On August 14, 2024, the Company reduced the amount to under the Offering Agreement to $0 and suspended the ATM Offering. Though&#160;December 31, 2024, the Company received&#160;aggregate gross cash proceeds to the Company from the ATM Offering of approximately $1.8&#160;million.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>February&#160;2024 Offerings</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On February 27, 2024, we entered into an underwriting agreement (the &#8220;February Underwriting Agreement&#8221;) with the Representative (as defined above), as the representative of the several underwriters named therein (the &#8220;February Underwriters&#8221;), relating to an underwritten public offering (the &#8220;February 2024 Public Offering&#8221;) of 500,000 shares (the &#8220;February Shares&#8221;) of the Company&#8217;s Common Stock. The public offering price for each share of Common Stock was $3.00, and the February Underwriters purchased the shares of Common Stock pursuant to the February Underwriting Agreement at a price for each share of Common Stock of $2.76. On February 28, 2024, the February 2024 Public offering closed. Aggregate gross proceeds from the February 2024 Public Offering were approximately $1.9&#160;million (including proceeds from the exercise of the over-allotment option granted to the Representative, as more fully described below), before deducting underwriting discounts and commissions and estimated expenses payable by the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the February Underwriting Agreement and the engagement letter, dated as of February 22, 2024, by and between the Company and the Representative, the Company agreed to issue to the Representative in connection with the February 2024 Public Offering, a warrant to purchase up to a number of shares of Common Stock representing 5.0% of the shares of Common Stock and any February Option Shares (as defined below) sold, at an initial exercise price of $3.30 per share, subject to certain adjustments (the &#8220;February Underwriter&#8217;s Warrant&#8221;). On February 28, 2024, the Company issued to the Representative the February Underwriter&#8217;s Warrant to purchase up to 25,000 shares of Common Stock. The February Underwriter&#8217;s Warrant is exercisable six months following the date of the February Underwriting Agreement and terminates on the five-year anniversary of the date of the February Underwriting Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the February Underwriting Agreement, the Company also granted the Representative a 45-day option to purchase up to an additional 75,000 shares (the &#8220;February Option Shares&#8221;) of the Common Stock on the same terms as the February Shares sold in the February 2024 Public Offering (the &#8220;February Over-Allotment Option&#8221;). On March 5, 2024, the February Underwriters exercised the February Over-Allotment Option to purchase the February Option Shares. In connection with the February Overallotment Exercise, we issued an additional February Underwriter&#8217;s Warrant to purchase up to 3,750 shares of Common Stock. The February Overallotment Exercise closed on March 6, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On February 29, 2024, we entered into a securities purchase agreement with an investor providing for the issuance and sale of 270,000 shares of Common Stock and warrants to purchase up to 270,000 shares of Common Stock (the &#8220;February Warrants&#8221;) at a price of $3.80 per share of Common Stock and accompanying warrant, which represents a 26.7% premium to the offering price in February 2024 Public Offering. The Common Stock and the February Warrants were offered pursuant to a private placement (the &#8220;February 2024 Private Placement&#8221;) under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The February Warrants will have an exercise price of $3.80 per share, are initially exercisable beginning six months following the date of issuance, and will expire 5 years from the date of issuance. The aggregate net cash proceeds to the Company from the February 2024 Private Placement were approximately $1.0 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>2025 Financings</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">As set forth below, subsequent to December 31, 2024, the Company secured $8.5 million in new financing and anticipates supplementing existing capital with commercial credit and strategic investments sufficient to satisfy our working capital requirements through the end of the fiscal year ending December 31, 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>January 2025 Securities Purchase Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On January 27, 2025, the Company entered into a securities purchase agreement (the &#8220;RD Purchase Agreement&#8221;) with Anson Funds (the &#8220;Investors&#8221;) for the sale by the Company of 1,215,278 shares (the &#8220;RD Shares&#8221;) of Common Stock to the Investors, at a purchase price of $2.88 per share, in a registered direct offering (the &#8220;Registered Direct Offering&#8221;). Concurrently with the sale of the RD Shares, pursuant to the RD Purchase Agreement the Company also sold to the Investors unregistered Common Stock purchase warrants (the &#8220;RD Warrants&#8221;) to purchase up to an aggregate of 1,215,278 shares of Common Stock (the &#8220;RD Warrant Shares&#8221;), in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of Common Stock, subject to adjustments as provided under the terms of the RD Warrants. The RD Warrants are exercisable for five years from the RD Closing Date (as defined below). The closing of the sales of these securities under the RD Purchase Agreement occurred on or about January 29, 2025 (the &#8220;RD Closing Date&#8221;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The gross proceeds to the Company from the offerings were approximately $3,500,000, before deducting offering expenses, and excluding the proceeds, if any, from the exercise of the RD Warrants. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The RD Shares were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on June 9, 2022, and subsequently declared effective on June 21, 2022 (File No. 333-265492) (the &#8220;Registration Statement&#8221;), and the base prospectus dated as of June 21, 2022, contained therein.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The RD Warrants and the RD Warrant Shares were sold and issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On January 27, 2025, the Company and the Investors entered into a Consent and Waiver Agreement (the &#8220;CWA&#8221;), relating to certain rights and prohibitions arising under the August SPA and the Notes. In the CWA, each of the Investors provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the August SPA and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and the Investors dated August 14, 2024, until March 31, 2025. As consideration for entering into the CWA, in the event that the VWAP of the Common Stock is less than the per share purchase price of the Common Stock sold to the Investors in the Registered Direct Offering on the Trading Day (as defined in the RD Purchase Agreement) immediately prior to the date that the Investors submit their first conversion notice to convert any portion of the Notes issued or to be issued in the Second Closing (as defined in the August SPA) or the Third Closing (as defined in the August SPA), respectively, into shares of Common Stock, the Company agreed to issue to the Investors: (i) that number of shares of Common Stock equal to (a) the quotient of (I) aggregate purchase price to be paid for all securities in the Registered Direct Offering, divided by (II) the price per share of Common Stock after giving effect to the VWAP-Based Adjustment (as defined below), minus (b) the number of shares of Common Stock issued, or to be issued, to the Investors at or upon the consummation of the Registered Direct Offering (the &#8220;Consideration Shares&#8221;), and (ii) Common Stock purchase warrants to purchase shares of Common Stock equal to 100% of the aggregate number of Consideration Shares to be issued, with an exercise price equal to the dollar value of the VWAP-Based Adjustment (the &#8220;Consideration Warrants&#8221;). For purposes of the CWA, the &#8220;VWAP Based-Adjustment&#8221; means that amount, in dollars, equal to the greater of either (a) the VWAP of the Common Stock on the Trading Day immediately prior to the date that the Investors submit their first conversion notice to convert any portion of the Notes issued and to be issued in the Second Closing or Third Closing into shares of the Company&#8217;s Common Stock, or (b) 80% of the closing price of the Common Stock on the Trading Day immediately prior to the closing of the Registered Direct Offering.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Proposed Strategic Investment and Commercial Funding</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The Company was presented with and is currently negotiating a term sheet with a publicly-traded entity engaged in the manufacture of FDA-cleared devices for Transcranial Magnetic Stimulation to provide acquisition capital to support the expansion of HOPE, and is also currently in negotiations with several commercial banks to provide additional acquisition financing for HOPE. Although no assurances can be given, assuming consummation of the financings on terms currently contemplated by management, we will achieve our objective of financing less than 50% of the proposed acquisition costs, thereby enabling the Company to optimize its cost of acquisition capital as it expands the HOPE clinic network.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Terminated January 2025 Financing</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company was a party to definitive stock purchase agreements with an Arizona-based investment firm, Smith and Sauer, through their affiliate, JGS Holdings, LLC (&#8220;JGS Holdings&#8221;) whereby JGS Holdings committed to invest $2.0 million in NRx&#8217;s common stock, with an additional commitment of $25.0 million to be invested directly in HOPE.&#160;JGS Holdings defaulted under the terms of the agreements, despite several extensions of the closing date.&#160;The Company formally terminated the stock purchase agreement on March 13, 2025.&#160; Although no assurances can be given, assuming management is able to consummate the financing referenced above with an alternative strategic investor to replace the investment contemplated with JGS Holdings, together with alternative sources of equity and debt capital, management believes it will able to fund its previously announced acquisitions on terms more favorable to our shareholders.&#160;&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NRx Products in Development</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>NRX-101</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">NRX-101 is a combined NMDA/5-HT<sub>2A</sub>-targeted medicine designed to address both depression and suicidal ideation, consisting of a patented, oral, fixed dose combination of D-cycloserine (&#8220;DCS&#8221;) and lurasidone. Although DCS has been known for more than 70 years as an anti-infective, its propensity to cause psychedelic side-effects, together with challenges in maintaining drug stability, limited its clinical use and by the year 2000, DCS was rarely used in the United States. Previously, the critical doses of DCS required to achieve a clinical effect in treatment of these conditions was not understood.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The key discovery by Daniel Javitt that the psychedelic side-effects of DCS can be attenuated by the concomitant use of serotonin-targeted drugs creates a new life for this promising molecule, whose use was previously limited by hallucinogenic effects. The manufacture of DCS was similarly limited by propensity to form inactive dimers and trimers of the cycloserine ring and no modern manufacturing program was undertaken over the past 50 years. The Company has now modernized the required analytic methodology, achieved control over impurities as required for modern commercial drug manufacture, and solved the stability challenges in a manner that achieved five-year shelf stability in the Company&#8217;s phase 2 program and management anticipates we can replicate that stability at commercial scale.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Currently, there are numerous atypical antipsychotic drugs targeting the 5-HT2A receptor approved for treatment of bipolar depression. However, all are known to increase a side effect known as akathisia, which is closely linked to suicidal ideation and behavior, and all carry a black box warning on the label regarding the potential for increased risk of suicide. In contrast, DCS has been demonstrated in at least two clinical trials (Nierenberg 2022<sup style="vertical-align:top;line-height:120%;">6</sup>, Chen 2019<sup style="vertical-align:top;line-height:120%;">7</sup>) to reduce suicidal ideation, a finding also demonstrated for ketamine (Abbar 2022<sup style="vertical-align:top;line-height:120%;">8</sup>, Grunebaum 2017<sup style="vertical-align:top;line-height:120%;">9</sup>). Because its effect is synergistic to the antidepressant effects of serotonin-targeted drugs and because of the specific effect on suicidal ideation, the NMDA receptor of the brain is increasingly viewed as a key target for treating depression and suicidality. To the Company&#8217;s knowledge, NRX-101 is the first investigational medicine to advance for severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (&#8220;ASIB&#8221;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">A safe, oral medicine for suicidal depression represents a key unmet medical need because the only currently approved treatment for this condition today is electroconvulsive therapy (&#8220;ECT&#8221;). Although the effects of NMDA antagonist drugs were first reported by Javitt in 1989, the development of NMDA-targeted medicines has been hampered by the known propensity of direct-acting NMDA-targeted drugs to cause neurotoxicity, addiction, psychedelic effects, and blood pressure elevation. Javitt discovered and patented the finding that when serotonin-targeted drugs are added to NMDA-targeted drugs, the hallucinogenic side effects of NMDA-targeted drugs are blocked and, at the same time, the NMDA component blocks the akathisia that is a known side effect of serotonin-targeted drugs &#8211; a side effect associated with suicidal ideation and behavior.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">DCS, the NMDA-targeting component of NRX-101, is a mixed NMDA agonist/antagonist that has been demonstrated in nonclinical studies to have no potential for neurotoxicity&#160;or addiction.&#160;Although it may have psychedelic effects when given as monotherapy, psychedelic effects of DCS have not been seen in four different studies where DCS was administered together with serotonin-targeted drugs. Javitt additionally discovered and patented the finding that DCS is a mixed NMDA agonist/antagonist and a critical dose of DCS must be administered (in the region of 400mg &#8211; 500mg per day) to exert its NMDA antagonist properties. This finding explains the failure of DCS to demonstrate clinical effects in a number of published trials at lower doses, where it acts as an agonist at the NMDA receptor.<sup style="vertical-align:top;line-height:120%;">11</sup></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Although development of NRX-101 began in 2015, when NeuroRx, Inc. was privately funded, the COVID pandemic interrupted clinical development in March 2020 because of study site closures. The Company was hampered in continuing to manufacture its investigational product in China because of global supply chain and other international challenges. Accordingly, when the Company raised funds in February 2022 to reinitiate the psychiatric drug development program, a strategic decision was made to transfer all manufacture to the United States and to upgrade the Chemical Manufacturing Controls (CMC) level of NRX-101 to a commercial standard prior to entering phase 3 trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Manufacturing is a key component of drug approvals and current estimates suggest that more phase 3 biotechnology products fail or experience delays over manufacturing issues than over safety and efficacy. Moreover, registrational studies require either that the trial be conducted with commercial grade investigational product or compel the sponsor to conduct subsequent bridging studies to prove biological equivalence to commercial grade product. In March 2022, the Company executed a tender process and selected Alcami, Inc. (&#8220;Alcami&#8221;) (Wilmington, NC) as its manufacturing partner. Technology transfer was accomplished within 3 months and a first phase 3/commercial-scale batch was completed by August 2022. In January 2023, the Company achieved alignment with the FDA on its proposed registration manufacturing and stability plan in a Type C meeting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In February 2023, the Company aligned with FDA in a Type B meeting to outline the clinical &amp; preclinical requirements for registration of NRX-101. Overall, the FDA suggested expanding the safety data base of NRX-101 to allow for chronic/intermittent use of NRX-101, as well as a broadening of the addressable population of the indication (under the SPA or otherwise) to patients with severe bipolar depression and recent acute suicidality regardless of how the initial stabilization was achieved. This broader indication would enable the Company to potentially demonstrate the use of NRX-101 to maintain stabilization from acute suicidality in patients stabilized either with ketamine (NRX-100) or with other standard of care therapeutic approaches. FDA encouraged the Company to request a Breakthrough Therapy Planning Meeting for NRX-101.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In late 2022 we confronted the challenges associated with recruiting suicidal patients in the traditional clinical trial site model. &#160;We learned that the &#8220;suicidality state&#8221; is sufficiently transient that simply having trial sites offer our therapy to existing databases of known patients with bipolar disorder was both insufficient to attract sufficient numbers of patients to a clinical trial and overly prone to attracting participants seeking secondary gain. We implemented an artificial intelligence (&#8220;AI&#8221;) based national recruitment strategy designed to identify and recruit participants who are sincerely looking for the potential benefit offered by NRX-101. We paired this with a distributed clinical trial model developed by Science37, Inc., where traveling nurses are able to visit prospective clinical trial participants who are then treated by their own physicians, rather than relying on our ability to identify participants who live within traveling distance of a &#8220;bricks and mortar&#8221; study site. Thus, in order to achieve clinical trial feasibility for an enormously complex and potentially lethal disease, in 2023 we invented and demonstrated a new model of clinical trial recruitment and implementation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Psychiatry trials succeed or fail based on a high degree of confidence that psychometric ratings are implemented in a reliable manner that is consistent from one study site to the next. An entire industry has emerged of third party rating companies that seek to achieve this consistency on behalf of sponsors. Unfortunately, the lag time between site-rating and central rating is inconsistent with achieving real-time quality control. Accordingly we developed in internal capability to review a study site rating within 24 hours, using an in-house team of master raters. The industry standard has traditionally allowed a 10% difference between site raters and third party rating companies as the standard for &#8220;concordance&#8221; and has allowed a 90% concordance rate between study sites and central raters. &#160;We tightened that standard to allowing only 5% difference between site raters and central master raters and demonstrated that 94% concordance could be maintained, with the exception of one study site that was excluded from the study and replaced at the direction of our Independent Data Safety and Monitoring Committee early in the study (prior to any data unblinding) for failure to maintain rating quality.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">We applied the above technologic infrastructure to our clinical trial of NRX-101 for the treatment of severe bipolar depression in patients with sub-acute suicidal ideation and behavior (&#8220;SSIB&#8221;), an indication we now call &#8220;Suicidal Treatment Resistant Bipolar Depression.&#8221; Between 700,000 and 1,000,000 Americans suffer from Suicidal Treatment Resistant Bipolar Depression and 25,000 &#8211; 50,000 kill themselves each year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">In 2024, the Company announced completion of a clinical trial to compare NRX-101 to lurasidone alone in patients with bipolar depression and subacute suicidal ideation (NCT03395392). In previous studies (the STABIL-B trial), NRX-101 administered after the use of ketamine in acutely suicidal patients was superior to lurasidone alone in maintaining remission from depression and suicidality.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">
   <img alt="nrxgraph1.jpg" src="nrxgraph1.jpg"/></div>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">
   &#160;
  </div>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
       Page 12
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   &#160;
  </div>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <div style="text-align: center;">
    <img alt="nrxtable1.jpg" src="nrxtable1.jpg"/></div>
   <div style="text-align: justify;">
    &#160;
   </div>
   <div style="text-align: justify;">
    <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="font-size:9pt;"><i>Figure 1:</i> <i>(Graph) Primary Endpoint for those infused with ketamine vs. placebo in phase I (n=22) and those who responded to ketamine in phase I and were randomized in Phase 2 to receive either NRX-101 or lurasidone (n=17). Table depicts primary and secondary endpoints for those randomized in Phase 2 (n=17).; *, P&lt;0.05. Source: Nierenberg et al., 2023</i><i><sup style="vertical-align:top;line-height:120%;">6</sup></i></span><i> </i></p>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In this trial, NRX-101 was found to be equivalent to lurasidone in achieving remission from depression (i.e. both drugs were effective), but was superior to lurasidone (P=.05) in achieving remission from suicidality.&#160; Additionally, NRX-101 was seen to achieve a 76% superiority to lurasidone alone in achieving remission from akathisia (P=.026) a symptom of all known serotonin-targeted antidepressants that is closely-linked to suicidality.</p>
    <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
    <div style="text-align: center;">
     <img alt="nrxgraph2.jpg" src="nrxgraph2.jpg"/></div>
    <div style="text-align: center;">
     &#160;
    </div>
    <div>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><i>Figure 2: Superiority of NRX-101 vs. lurasidone alone in reducing symptoms of Akathisia. Presented at the 2004 American Society of Clinical Psychopharmacology</i></p>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In this trial, conducted under a Special Protocol Agreement with the FDA, there was no placebo group because suicidal patients were compared to the standard of care and it would not have been ethical to randomize actively suicidal patients to placebo. The Company believes that based on these data, New Drug Approval for NRX-101 can be achieved by conducting a properly-powered phase III trial comparing NRX-101 to placebo in patients with bipolar depression who do not have active suicidal ideation. The Company is in discussion with commercial partners to conduct such a trial.&#160; In the interim, the Company believes that accelerated approval for NRX-101 can be obtained for treatment of patients with active suicidal ideation and akathisia despite treatment with currently approved medicines.&#160;</p>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">&#160;</p>
    </div>
   </div>
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>NRX-100 and other Ketamine Products in Development</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">NRX-100 is racemic ketamine that is FDA-approved as a generic anesthetic. NRX-100 has shown efficacy in some clinical studies of depression and suicidality.<sup style="vertical-align:top;line-height:120%;">12</sup> In the Company&#8217;s STABIL-B Study, NRX-100 was used for the initial stabilization of patients with bipolar depression who were also acutely suicidal, prior to receiving NRX-101 or lurasidone. The Company has opened an Investigational New Drug (&#8220;IND&#8221;) file with the FDA for the purpose of developing ketamine as a rapid induction agent in the treatment of Severe Bipolar Depression with Acute Suicidal Ideation and Behavior. The FDA awarded Fast Track Designation to this use.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Although the Company did not initially plan to develop ketamine as a monotherapy for rapid treatment of suicidal depression, the FDA guided NRx to do so in January 2023. Because of the urgent need, the company elected to license data from several well-controlled, publicly funded clinical trials that had not been submitted to the FDA and to prepare those data in the rigorous patient-level electronic form that is required for FDA review of clinical trial data. These trials demonstrate clear benefit of ketamine over both placebo and active comparator (midazolam), as well as non-inferiority of ketamine to the standard of care electroconvulsive therapy. The Company similarly entered into a manufacturing contract with Nephron Pharmaceuticals (West Columbia, SC) to create a proprietary formulation of ketamine for commercial sale. The company has initiated the filing of a New Drug Application for NRX-100 and anticipates filing the full NDA package by June 2025, aiming for a 2025 PDUFA date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The basis of the NDA filing consists of efficacy data gathered from several large clinical trials, representing the experience of more than 1000 patients together with real-world data gathered from more than 20,000 patients that consistently demonstrate the effectiveness of ketamine in treating symptoms of both depression and suicidality. The illustration below has been presented by the Company in public conferences as illustrative of some of the data to be presented as part of the NDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">New Drug Approval of intravenous ketamine HCl is not anticipated to yield long-term patent protection because ketamine is an old, well-known compound, although the preservative-free presentation of ketamine, together with the proprietary Risk Evaluation Management Strategy (REMS) that will likely be required for FDA approval will confer some degree of market protection. However, ketamine &#8211; in any form &#8211; is not currently approved for use in psychiatry, although a form of S-ketamine is approved and commands a substantial price in the marketplace.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">FDA regulations do provide for a three-year period of data exclusivity (&#8220;Paragraph 4 protection&#8221;) for sponsors who obtain a new FDA approval for an already-approved medication. NRx anticipates benefiting from this exclusivity in the case of NRX-100. In recent months, there has been increased support voiced by at senior levels of the U.S. Government for the approval of ketamine and other psychedelic drugs for the treatment of depression and related conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="margin-left: 18pt;">
   <img alt="nrxpic.jpg" src="nrxpic.jpg"/></div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">Although the use of ketamine is widespread and not currently subject to US patent, all known prior art and commercial presentations of ketamine have included the use of Benzethonium Chloride, a toxic preservative as part of the intravenous administration of ketamine. Benzethonium Chloride is widely used in antibacterial cleaning solutions and cosmetics for topical use. The manufacturer of benzethonium chloride classifies it as toxic if swallowed, capable of causing severe skin burns and eye damage, and corrosive, although those effects are not seen at the levels used in intravenous preparations. However, it has never been shown to be safe for intravenous use in humans and has been demonstrated to be neurotoxic to the cornea when used in eyedrops (Invest Ophthalmol Vis Sci 2012 Apr 18;53(4):1792&#8211;1802). For this reason, benzethonium chloride and related preservatives have increasingly been removed from various eyedrops. The inclusion of benzethonium chloride is a remnant from a time when sterile product manufacturing techniques required toxic preservatives to maintain stability and sterility. NRx has demonstrated the ability to maintain stability and sterility for more than two years of room temperature shelf life with its preservative-free presentation of NRX-100.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">While the use of a preservative in ketamine may be safe when ketamine is used for single doses of anesthesia, the repeated use of benzethonium chloride-preserved ketamine has never been shown to be safe in either animals or patients. FDA has published warnings about potential neurotoxicity associated with the repeated use of ketamine, which may be related both to the preservative and to potential excitatory neurotoxicity caused by repeated use of ketamine itself. The Company intends to file a citizens petition with the FDA seeking to have benzethonium chloride removed from ketamine intended for intravenous use. The US Food Drug and Cosmetics Act requires that all ingredients in US drugs have demonstrated safety. The recently confirmed Secretary of Health and Human Services has emphasized in various public comments the importance of removing toxic substances from the US food and drug supply chain. Should the Company be successful in effecting the removal of benzethonium chloride from current preparations of ketamine, the Company may gain additional exclusivity rights with regard to NRX-100.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>NRX-100 and NRX-101 Commercial Licensing</i></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In early March 2024, the Company entered into a non-binding term sheet from a private equity-owned commercial stage pharmaceutical company for the licensing and distribution rights to NRX-100 in the U.S., subject to final regulatory due diligence. The proposed license agreement provides for an immediate milestone payment with proposed milestones and a sliding scale royalty based on sales volume. Under the terms of the proposed license, the Company retains all rights ex-US and future rights to HTX-100 (pH neutral ketamine) should that development path succeed.&#160; The Company is in additional discussions with the prospective commercial partner around the licensing of NRX-101.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>HTX-100 (pH neutral ketamine)</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">One path through which the Company has potential to achieve longer term exclusivity around the use of ketamine is through the development of a novel composition of matter that confers benefits not achievable via NRX-100. Although ketamine has demonstrated clear benefit in treating patients with depression and suicidality, ketamine HCl, the generic form of ketamine, is acidic (pH 3.5-4.0) and therefore suitable for dilute intravenous administration, but not for subcutaneous administration. Compounds at this level of acidity are known to cause skin ulceration and cannot be approved for subcutaneous use. Accordingly, ketamine for psychiatric purposes can be administered in clinic settings with trained perfusion nurses and staff, but is unsuitable for office use. Some have attempted to address this problem through oral administration of ketamine or buccal (i.e. allowing ketamine to dissolve against the inside of the mouth) administration. However, these modalities have unpredictable pharmacokinetics and, in the Company&#8217;s view are unlikely to result in approvable drugs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">Experience with insulin compounds has yielded a large array of approved medical devices that would be capable of delivering a pH neutral form of ketamine in the office or home setting. In 2024, the Company developed a pH neutral form of ketamine (HTX-100) that is expected to be patentable through 2040 and is expected to be suitable for subcutaneous use. In 2025, the company expects to achieve formulation of this product under Good Manufacturing Practices (GMP) and to initiate a clinical trial of HTX-100 for subcutaneous use.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Additional Potential Psychiatry Products</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>NRX-101 for the Treatment of Chronic Pain</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Chronic pain is commonly defined as pain that lasts beyond three months and extends past normal tissue healing time. Between 18% and 34% of Americans are believed to suffer from chronic pain. The use of opiates to treat chronic pain has led to a national crisis resulting in widespread addiction and death. Few alternatives to opiates have emerged that both treat chronic pain and potentially decrease craving for opiates among chronic pain sufferers. Recent epidemiologic studies indicate that Chronic Back Pain is the leading cause of disability in the US and the seventh leading cause worldwide.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Various non-clinical studies have suggested that NMDA antagonist drugs may be useful in treating animal pain models. Intravenous ketamine has been widely used off-label to treat chronic pain at doses similar to those used in depression studies. A meta-analysis of 7 studies representing 94 participants demonstrated a consistent improvement in pain score but a consistent finding of nausea and psychomimetic effects associated with ketamine administration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">A pilot study of DCS in the treatment of chronic pain was undertaken by Schnitzer and coworkers in patients with chronic low back pain.&#160;The study randomized 41 participants to a placebo-controlled dose-escalation study of 100mg, 200mg, and 400mg (each dose for two weeks) vs. placebo. The primary outcome measure was back pain intensity on a 1-10 numeric rating scale. The study was deemed not to have met its primary endpoint to detect a difference between DCS and placebo over 6 weeks. However, post-hoc analysis demonstrates a significant difference between baseline and six weeks (P&lt;0.01), which is the point in time that the 400mg DCS dose was reached.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Based on the above data, the Company licensed a method patent for the use of DCS in Chronic Pain from Prof. Apkar Apkarian.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">A 400 person efficacy trial was funded by the US Department of Defense, sponsored by Northwestern University, and achieved primary completion in February 2024. The investigators have not yet released findings from this clinical trial.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 23pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NRX-101 for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">DCS is a broad-spectrum antibiotic that is currently FDA-approved to treat pulmonary or extrapulmonary tuberculosis disease and urinary tract infection (UTI).&#160;The drug inhibits two sequential enzymes in the bacterial cell wall peptidoglycan biosynthetic pathway, alanine racemase and D-Ala-D-Ala ligase.&#160;DCS also antagonizes a third bacterial enzyme, D-amino acid dehydrogenase.&#160;DCS is bactericidal or bacteriostatic depending on the concentration or microorganism of interest. Since DCS is mostly excreted unchanged by the kidney, the drug reaches substantial levels in the urine. Indeed, DCS was used to treat various types of infections in the 1950s and 60s, including UTI, with numerous reports showing its clinical efficacy.&#160;The use of DCS as an antibiotic for the treatment of UTI fell out of favor in the 1970s, however, due to its potential to cause CNS side effects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">The incidence of multi-drug-resistant urinary tract pathogens is outpacing the development of new antimicrobial agents. Only 17 new systemic antibiotics and 1 related biologic have been approved by the FDA between 2010 and 2022, and very few antibiotics are in clinical development.&#160;This has forced a renewed interest in older antimicrobial drugs. The addition of lurasidone should permit DCS to be administered at dosages that would permit bactericidal action in the urinary tract with dose-limiting side-effects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">NRx tested DCS and NRX-101 (DCS + lurasidone) against various urinary tract pathogens including several multidrug resistant strains. DCS showed activity against all bacterial isolates tested (Table 1) with minimal inhibitory concentrations (MICs) below levels that can be achieved in the urine. As expected, lurasidone alone had no antibacterial activity, nor did it interfere with the antibacterial activity of DCS. Based on these results, the FDA has awarded Qualified Infectious Disease Product and Fast Track Designation to NRX-101 for the treatment of complicated UTI including acute pyelonephritis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><i>Table 1. Minimum Inhibitory Concentrations of DCS and Lurasidone in Cation-Adjusted Mueller Hinton Broth</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 27pt; margin-right: auto;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Strain</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reference</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Antibiotic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(&#956;g/mL)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Lurasidone </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(</b>&#956;<b>g/mL)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DCS (</b>&#956;<b>g/mL)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DCS + Lurasidone (</b>&#956;<b>g/mL)</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>E. coli 35218 </i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>E. coli 25922 </i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>E. coli 700928 </i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2-4<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>E. coli 700336 </i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>E. coli 2469 </i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.03-0.062<sup style="vertical-align:top;line-height:120%;">b</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64-128</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>E. coli </i>Xen 16</p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>P. aeruginosa </i>PA01</p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1<sup style="vertical-align:top;line-height:120%;">c</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">256</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>P. aeruginosa 27853 </i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.5<sup style="vertical-align:top;line-height:120%;">c</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">256</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>P. aeruginosa </i>Xen 41</p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.5<sup style="vertical-align:top;line-height:120%;">c</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>P. aeruginosa </i>BAA 3105</p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64<sup style="vertical-align:top;line-height:120%;">c</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>K. pneumoniae </i>1705</p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">128</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>A. baumannii 19606</i></p> </td>
     <td style="vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">32<sup style="vertical-align:top;line-height:120%;">a</sup></p> </td>
     <td style="vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">No growth</p> </td>
     <td style="vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">512</p> </td>
     <td style="vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">256</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>A. baumannii 1605</i></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64<sup style="vertical-align:top;line-height:120%;">d</sup></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&gt;142.3</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 8.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">512</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1024</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">a, Gentamicin; b, Colistin; c, Tobramycin; d, Ciprofloxacin</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Development of HOPE Therapeutics</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Psychiatric care for depression, PTSD, and related CNS disorders is experiencing a period of rapid change, based on the discovery of NMDA-targeted and other psychedelic drugs (see above) and Transcranial Magnetic Stimulation (&#8220;TMS&#8221;). Both are therapies that have been shown to induce new synapse (i.e. nerve connection) within the brain, a process known as &#8220;neuroplasticity&#8221; or &#8220;synaptic plasticity,&#8221; Recent science sponsored in part by NRx shows that these disease states are associated with atrophy of the electrical connections between brain cells, rumination on negative &#8211; frequently suicidal &#8211; thoughts, and ultimately suicidal behavior. NMDA-targeted and other psychedelic drugs are demonstrated to create bursts of glutamine and glutamate in the brain with resulting sprouting of the dendrites that create new synapses and corresponding decreases in depressive and suicidal ideation. TMS is believed to achieve a similar benefit through the application of strong magnetic fields to brain cells and has been demonstrated to relieve symptoms of depression. Accordingly, TMS has been approved for this purpose in the US.&#160; In Europe, TMS has been approved for a far broader set of indications including PTSD, treatment of alcohol and drug abuse, stroke, Parkinsons, and brain injury.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the first time in human history, responsible scientists are discussing treatments that induce neuroplasticity as potentially curative for depression, PTSD, and related conditions, in contrast to 70 years of serotonin-targeted drugs that were thought to treat the symptoms of these diseases. However, it is increasingly believed that no individual medication, device, or other therapy will be sufficient to achieve comprehensive benefit for patients. Unfortunately, few centers have mastered the art of combining these treatments into a comprehensive approach for treating serious and lethal psychiatry disorders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In January 2024, the Company incorporated HOPE Therapeutics as a wholly-owned subsidiary of NRx Pharmaceuticals for the purpose of developing a new clinical paradigm for the treatment of depression, PTSD, obsessive-compulsive disorder, and related CNS conditions. Based on clinical observations with the Company&#8217;s drugs, the Company came to the realization that the rapidly-emerging class of NMDA-targeted and other psychedelic drugs have the potential to be paradigm-changing for patients with life-threatening CNS disorders but may not be sufficient to achieve the full clinical benefit that patients require to achieve and maintain a complete, long-term recovery.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div style="text-align: center;">
   <img alt="totalcareumbrella.jpg" src="totalcareumbrella.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">We estimate that ketamine and TMS individually have reported remission rates of approximately 50% in patients with severe depression. However, anecdotal observation and the emerging body of evidence suggests that when patients are offered the full array of currently available treatments in an integrated manner, a far greater proportion of patients may achieve long-term remission from conditions that only a few years ago were treated with hospitalization and electroshock therapy. Company executives recently traveled to Israel, where these treatments &#8211; together with hyperbaric oxygen therapy &#8211; are being used to significant effect in the treatment of soldiers with PTSD from recent combat, with dramatic efficacy results in university-based clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">During the second half of 2024, the Company began outlining the plan for HOPE as a national and ultimately international network of interventional psychiatry centers that would combine neuroplastic treatments in an integrated and reproducible manner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>HOPE Acquisition Targets</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In 2024, the Company announced a non-binding term sheet to acquire Kadima, LLC, a pioneering interventional psychiatry clinic in La Jolla, CA.&#160; Kadima&#8217;s founder, Dr. David Feifel agreed to serve as HOPE&#8217;s Chief Medical Innovation Officer post-acquisition. He is one of the first academic psychiatrists to move ketamine and TMS therapy to the community care model and was recently featured on Dr. Sanjay Gupta&#8217;s feature entitled &#8220;The Wild West of Ketamine Treatment&#8221; as an advocate for how ketamine therapy can be delivered reliably and responsibly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">Additionally, the Company has entered into a non-binding term sheet to acquire two additional clinics in Florida. The Company is in the process of finalizing definitive purchase agreements with both entities. In addition to these acquisitions, the Company is negotiating to acquire an additional six clinics in Florida with the objective of acquiring 15-20 facilities in Florida by year-end 2025, as depicted in the following graphic:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="map01.jpg" src="map01.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Figure 1: Representative potential targeted 2025 acquisition opportunities in Florida.</i></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">HOPE Financing/Acquisition Model</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The clinical centers that are being incorporated in the 2025 acquisition program are currently operating and are profitable centers that the Company believes can experience substantial revenue growth through the addition of a broader array of comprehensive services. Management estimates that the acquisition of 20 clinic networks, each with current revenue of approximately $5.0 million will be required to meet our 2025 growth objectives.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Based on the financing proposals received to date and existing capital, the Company is targeting a blended financing cost of acquisition of under 10%.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Future Medical Indications for HOPE</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The founding of HOPE began with the Company&#8217;s commitment to the treatment of suicidal depression with a plan to utilize (i) current FDA approval for S-ketamine, (ii) TMS, and (iii) if approved by the FDA, NRX-100. Over time, the vision for HOPE has significantly expanded. European approvals are already in place for the use of TMS to treat PTSD, Traumatic Brain Injury, Alzheimer&#8217;s, Parkinson&#8217;s disease, and alcohol and tobacco addiction. Moreover, Kadima has been a leading research organization in the development of psychedelic drugs and HOPE expects to merge Kadima&#8217;s research capabilities with those of NRx Pharmaceuticals. As an example of that expertise, NRx recently published a report in a leading peer-reviewed journal documenting its ability to achieve &gt;95% reliability in the measurement of depression scores across research sites, a reliability factor considerably above industry standards (J Clin Psychopharmacol.&#160;2025 Jan-Feb;45(1):28-31). Hence, HOPE Therapeutics expects to be involved in the treatment of a broad array of CNS diseases that &#8211; until now &#8211; have offered little in the way of new hope to patients.&#160; Unlike the process of drug development, where FDA approval is a protracted process, the use of approved devices for new uses is generally regarded as within the practice of medicine, although insurance reimbursement is frequently tied to FDA-labeled indications.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Summary of NRx Material In-licensing Obligations (NRx-100/101)</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Development and License Agreement (&#8220;Glytech DLA&#8221;)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The Company was founded based upon a development agreement with Glytech, a Company founded by Daniel Javitt (&#8220;DLA&#8221;). The initial Glytech development agreement was signed on August 6, 2015, and subsequently amended on May 2, 2016, October 19, 2016, June 13, 2018, April 16, 2019, December 31, 2020, August 6, 2022, November 6, 2022 and January 31, 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>The License</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Pursuant to the Glytech DLA, Glytech granted to NeuroRx an irrevocable, perpetual, exclusive (even as to Glytech) royalty-free license, with the right to sublicense, to use the Licensed Technology (as defined below) to develop, manufacture and offer for sale drug products for the treatment of depression and suicide associated with bipolar disorder in humans, including all products containing (a) DCS (including metabolites and structural variants thereof) combined with an antidepressant agent or an antipsychotic agent (including but not limited to lurasidone), or (b) DCS (including metabolites and structural variants thereof) for treatment of all types of bipolar, depressive and/or anxiety disorders and/or symptoms thereof. The key composition of matter patent (U.S. Patent No. 10,583,138) that supports NRx was assigned to us by Glytech in January 2021 and is no longer the subject of a license grant under the Glytech DLA; and (2) Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology (as defined below) which are not essential for the manufacture or sale of NRX-101 to NRx for no additional consideration at any time upon receipt of written notice from us if, on or prior to March 31, 2024, (i) the value of the Glytech equity holdings in NRx (the &#8220;Glytech Equity&#8221;) has an aggregate value of at least $50 million for twenty (20) consecutive trading days immediately preceding any given date and (ii) there are no legal or contractual restrictions on selling all of the securities represented by the Glytech Equity then applicable to Glytech (or reasonably foreseeable to be applicable to Glytech within the following twenty trading days). The Company is working with Glytech to extend this option.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Glytech also agreed to transfer and assign the Licensed Technology and the Excluded Technology to us for no additional consideration simultaneously with the closing of a merger, acquisition or other transaction involving NRx, where, as a result of such transaction, Glytech receives at the closing thereof, by virtue of its status as a stockholder of NRx, at least $50 million in cash proceeds.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">As used in this section of the Glytech DLA, the term &#8220;Aggregate Liquidity Value&#8221; for any given date means the sum of each trading day&#8217;s Daily Liquidity Value during the Eligible Measurement Period applicable for such date, and &#8220;Daily Liquidity Value&#8221; for any particular trading date means the aggregate proceeds Glytech would receive if it sold that number of shares of Glytech Equity on such trading date equal to 5% of the total number of shares of common stock or successor stock sold on such trading date. &#8220;Licensed Technology&#8221; means the patent rights and know how that disclose, describe or claim subject matter relating to use of DCS in combination with one or more antidepressants or one or more atypical antipsychotics (e.g., lurasidone) that are controlled by Glytech or its affiliates. &#8220;Excluded Technology&#8221; means any other patent right and knowhow owned by Glytech that does not relate specifically to compositions containing either DCS or lurasidone. Regardless of the option, NRx has the intellectual property necessary to perform it&#8217;s business as currently anticipated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>NRx Obligations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The Glytech DLA imposes certain obligations on NRx in connection with maintaining the Glytech License, which include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx is required to pay to Glytech a fixed annual support payment in the amount of $250,000 per year and to reimburse reasonable, documented travel expenses not exceeding $50,000 per year to support travel to meetings related to patent prosecutions.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx has assumed responsibility for the payment of ongoing patent prosecution costs and related costs required to perfect the Licensed Technology and related intellectual property rights.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to the assignment of the Licensed Technology and Excluded Technology by Glytech to NRx (such date, the &#8220;Assignment Date&#8221;), NRx is required to pay or reimburse Glytech for the full costs of defending any patent rights included in the Licensed Technology and Excluded Technology.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to the Assignment Date, NRx has an obligation to institute, prosecute and control any action or proceeding with respect to any suspected or actual infringement or misappropriation by a third party of any Licensed Technology and Excluded Technology at its own expense. After the Assignment Date, NRx will be the owner of the Licensed Technology and the Excluded Technology, and as such will have full discretion in the institution and prosecution of any infringement action involving the Licensed Technology and the Excluded Technology.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx has agreed to indemnify Glytech and certain related parties from and against any liability or expense (including attorneys&#8217;&#160;fees) resulting from suits or claims by any third party arising out of (i) NRx&#8217;s, or its permitted sublicensee&#8217;s, sale or experimental use of products developed from any advice or assistance provided by Glytech hereunder; or (ii) the death of or injury to any person or any damage to property, arising from the development, manufacture, marketing, sale or use of any product developed from the Licensed Technology. NRx&#8217;s obligation to indemnify Glytech does not apply to any losses arising from the gross negligence or willful misconduct of Glytech or its related parties or any breach by Glytech of the Glytech DLA.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Glytech Termination Rights</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The term of the Glytech DLA continues for an indefinite period unless terminated by one or both parties in accordance with its terms. Glytech has an independent right to terminate the Glytech DLA in the event that (a) NRx is in material breach of the Glytech DLA, including material breaches of the obligations set forth above, and does not rectify such breach within thirty (30) days of notification (unless such breach is not capable of rectification within such thirty (30) day period and NRx acts diligently in a commercially reasonable manner to correct such breach) or (b) if NRx becomes insolvent or has proceedings in voluntary or involuntary bankruptcy instituted against it.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">If Glytech terminates the Glytech DLA, then the Glytech License is withdrawn and NRx is required to transfer and assign all of its assets to Glytech, including without limitation any inventions, patent rights and knowhow developed by NRx from the Licensed Technology and all data and research, in whatever format, relating to the Licensed Technologies and the products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">NRx is currently in compliance with its obligations under the Glytech DLA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Sarah Herzog Memorial Hospital License Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The initial clinical trial of D-cycloserine was conducted by Drs. Uri Hersco-Levy and Daniel Javitt at the Sarah Herzog Memorial Hospital (&#8220;SHMH&#8221;) in Jerusalem and resulted in a patent owned by SHMH in which Heresco-Levy and Javitt share inventorship. NeuroRx entered into an Exclusive License Agreement with SHMH, dated April 16, 2019 (the &#8220;SHMH License Agreement&#8221;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The SHMH License Agreement grants NeuroRx an exclusive, worldwide, royalty bearing license to U.S. Patent No. 9,789,093, certain patent applications pending at that time as well as subsequently filed patent applications in the same priority families, and patents issuing therefrom, including corresponding foreign patents and patent applications (together, the &#8220;Licensed Patents&#8221;), to develop, manufacture, offer for sale and otherwise commercialize drug products for the treatment of depression and suicide associated with bipolar disorder in humans, including certain products containing (a) DCS (including metabolites and structural variants thereof) combined with an antidepressant agent or an antipsychotic agent (including but not limited to lurasidone), or (b) DCS (including metabolites and structural variants thereof) ((a) and (b) collectively the &#8220;Licensed Products&#8221;) for treatment of all types of bipolar, depressive and/or anxiety disorders and/or symptoms thereof. We have the right to grant sub-licenses, subject to the agreed sub-licensing procedure, but are liable to SHMH for any breaches of a sub-license by a sub-licensee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>NRx Obligations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">We are required to make certain payments in order to maintain the license, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase I Clinical Trials of Licensed Product</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase II Clinical Trials of Licensed Product</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase III Clinical Trials of Licensed Product</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in U.S.</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in Europe</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual Revenues Reach $100,000,000</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">750,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The milestone payments due above may be reduced by 25% in certain circumstances, and by the application of certain sub-license fees. During the years ended December 31, 2024 and 2023, no payments were made.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Royalties</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">A royalty in an amount equal to: (a) 1% of revenues from the sale of any product incorporating a Licensed Product when at least one Licensed Patent remains in force, if such product is not covered by a Valid Claim (as defined below) in the country or region in which the sale occurs, or (b) 2.5% of revenues from the sale of any Licensed Product that is covered by at least one Valid Claim in the country or region in which such product is manufactured or sold. A &#8220;Valid Claim&#8221; means any issued claim in the Licensed Patents that remains in force and that has not been finally invalidated or held to be unenforceable. The royalty rates above may be doubled if we commence a legal challenge to the validity, enforceability or scope of any of the Licensed Patents during the term of the SHMH License Agreement and do not prevail in such proceeding.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of 8.5% of the payments received by us from sub-licensees in connection with such sales. During the years ended December 31, 2024 and 2023, no royalties were made.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Annual Maintenance Fee</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">A fixed amount of $100,000 was paid on April 16, 2021 and, thereafter, a fixed amount of $150,000 is due on the anniversary of such date during the term of the SHMH License Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Costs of Licensed Patents</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">We are required to reimburse SHMH for any costs incurred in filing and prosecuting the Licensed Patents during the term of the SHMH Agreement. We are also responsible for paying directly any ongoing costs associated with the maintenance of the Licensed Patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Obligations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The SHMH License Agreement imposes certain other obligations on us, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The use of commercially reasonable efforts to develop, test, manufacture, obtain regulatory approval for and actively market at least one product using the Licensed Patents.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The indemnification of SHMH and certain of its affiliates against any claims, proceedings, and liabilities, including legal expenses, resulting from any third-party claims arising from (i) the development, manufacture, marketing, sale or use of Licensed Products or (ii) arising from any material breach of the SHMH License Agreement. The indemnification obligation does not apply to the extent of the gross negligence or misconduct of SHMH or its affiliates.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The maintenance at Company expense of clinical trial and general commercial liability insurance in amounts not less than $1 million per occurrence/aggregate of $3 million for death or personal injury and $1 million per occurrence/aggregate of $3 million for property damage, with SHMH named as an additional insured under such policies.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Record keeping and reporting requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Our exclusive rights under the Licensed Patents are at risk if we fail to fulfill our payment and other obligations under the SHMH License Agreement, including the obligations described above. We are currently in compliance with our obligations under the SHMH License Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>SHMH Termination Rights</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The term of the SHMH License Agreement continues until the expiration of the last-to-expire Licensed Patent or a final judgment of invalidity or unenforceability of the last Licensed Patent.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">SHMH has the independent right to terminate the SHMH License Agreement in the event that NRx (a) is in material breach and does not rectify such breach within sixty (60) days of written notification of such breach or (b) becomes insolvent, or has proceedings in voluntary or involuntary bankruptcy instituted against and such proceeding is not set aside within sixty (60) days. If we make an application or claim that challenges the validity, enforceability or scope of any of the Licensed Patents, SHMH also has the right to terminate the SHMH License Agreement in respect of the Licensed Patents that are included in such proceeding.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Upon termination of the SHMH License Agreement, the license to use the Licensed Patents will terminate, and all rights included therein shall revert to SHMH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">As of the date hereof, we have not received any notice from SHMH alleging any material breach of the SHMH License Agreement by NRx.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NRx Patent Portfolio</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I.</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Glytech-licensed Patents/Patent Applications</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jurisdiction</p> </td>
     <td style="vertical-align:bottom;width:1.1%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patent/Appl.&#160;No.</p> </td>
     <td style="vertical-align:bottom;width:1.1%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Status/Notes</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">9,737,531</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">9,486,453</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10,660,887</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">European Patent Convention</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">EP 2 872 139</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted; validated in France, Germany, Ireland, Italy, Netherlands, Poland, Portugal, Spain, Great Britain</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">European Patent Convention</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">EP 3 263 108</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted; validated in France, Germany, Ireland, Italy, Netherlands, Poland, Portugal, Spain, Great Britain</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Japan</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">JP 6416762</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Australia</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">AU 2013288827</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Australia</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">AU 2018203371</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">China</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CN 104507477</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">China</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CN 107875389</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">16/166,101</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Israel</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IL 271371</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">US 11,576,911</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">European Patent Convention</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">EP 18731195.6</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Japan</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">JP 7305560</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Japan</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">JP 2023-105697</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Canada</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CA 3,067,162</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Australia</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">AU 2018284335</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Brazil</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">BR 11 2019 026449 3</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mexico</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">MX/393,950</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">South Korea</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">KR 10-2609676</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">South Africa</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ZA 2019/08616</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">New Zealand</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NZ 760542</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">New Zealand</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NZ 799961</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Israel</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IL 270916</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">17/586,828</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Japan</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">JP 7308761</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Canada</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CA 3,064,846</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Australia</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">AU 2018274767</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Brazil</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">BR 11 2019 024802-1</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mexico</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">394,875</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">South Korea</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10-2608479</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">South Africa</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ZA 2019/08617</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">New Zealand</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NZ 760544</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">II.</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">SHMH-licensed Patents and Patent Applications</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jurisdiction</p> </td>
     <td style="vertical-align:bottom;width:1.1%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patent/Appl.&#160;No.</p> </td>
     <td style="vertical-align:bottom;width:1.1%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Status/Notes</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">9,789,093</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Europe</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">EP 2 670 409</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted; validated in Switzerland, Germany, Spain, France, Great Britain, Ireland, Italy, Netherlands</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">17/502,606</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pending</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">11,013,721</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Canada</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CA 2,826,180</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Israel</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IL 227611</p> </td>
     <td style="vertical-align:top;width:1.1%;">&#160;</td>
     <td style="vertical-align:top;width:22.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>NeuroRx-owned Patents and Patent Applications</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jurisdiction</p> </td>
     <td style="vertical-align:bottom;width:1.3%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:14.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patent/Appl.&#160;No.</p> </td>
     <td style="vertical-align:bottom;width:1.4%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Status/Notes</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">USA</p> </td>
     <td style="vertical-align:top;width:1.3%;">&#160;</td>
     <td style="vertical-align:top;width:14.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10,583,138</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Granted</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Manufacturing Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">In 2022, the Company has entered into a manufacturing agreement with Alcami (Wilmington, NC) for the manufacturing of NRX-101. This enabled the technology transfer of manufacturing processes previously done in China to the U.S. In October of 2022 the Company submitted a Module 3 IND amendment to the FDA, allowing it to manufacture clinical supplies in the U.S.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaborations with Nephron Pharmaceuticals and Alcami as contract manufacturers, and with the Polypeptide Group as a supplier of active pharmaceutical ingredient (&#8220;API&#8221;). This technology transfer does not affect our ability to contract with Alcami and Nephron for other purposes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">In 2023, the Company entered into a development and manufacturing agreement with Nephron Pharmaceuticals, Inc. for the manufacture of ketamine HCl (NRX-100, HTX-100) that the Company intends to distribute via its HOPE franchise. Manufacture will initially consist of the generic formulation of ketamine in a novel diversion-resistant presentation. Under the development portion of the agreement the Company intends to develop a pH-balanced new formulation of ketamine that will be suitable for subcutaneous use and that may be suitable for oral administration with predictable systemic absorption.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Government Regulation and Product Approval</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Government authorities in the U.S. and in other countries, at the Federal, state and local level, extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export, pricing, and government contracting related to pharmaceutical products such as those we are developing. The processes for obtaining marketing approvals in the U.S. and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>U.S. Government Regulation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA&#8221;) and its implementing regulations. The process of obtaining marketing approvals and the subsequent compliance with appropriate Federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions or other actions, such as the FDA&#8217;s delay in review of or refusal to approve a pending NDA, withdrawal of an approval, imposition of a clinical hold or study termination, issuance of Warning Letters or Untitled Letters, mandated modifications to promotional materials or issuance of corrective information, requests for product recalls, consent decrees, corporate integrity agreements, deferred prosecution agreements, product seizures or detentions, refusal to allow product import or export, total or partial suspension of or restriction of or imposition of other requirements relating to production or distribution, injunctions, fines, debarment from government contracts and refusal of future orders under existing contracts, exclusion from participation in federal and state healthcare programs, FDA debarment, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">The process required by the FDA before a new drug may be marketed in the U.S. generally involves the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">submission to the FDA of an IND application which must become effective before human clinical trials may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">approval by local or central IRBs who are charged with protecting safety of research subjects before each clinical trial may be initiated;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">performance of human studies that meet the legal standard of &#8220;adequate and well-controlled clinical trials&#8221;, in accordance with cGCP and other regulations in order to establish the safety and efficacy of the proposed drug product for each indication;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">submission to the FDA of an NDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">satisfactory completion of an FDA advisory committee review, if applicable;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">satisfactory completion of an FDA inspection of selected clinical trial sites to determine GCP compliance;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with GMP regulations and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">FDA review and approval of the NDA.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Additionally, if a drug is considered a controlled substance, prior to the commencement of marketing, the DEA must also determine the controlled substance schedule, taking into account the recommendation of the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Preclinical Studies and IND Submission</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 21pt;">Preclinical studies include laboratory evaluation of product chemistry, pharmacology, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, among other things, the FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk. The FDA may raise concerns or questions related to one or more proposed clinical trials and place the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Implications for NRX-100/101</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We have filed INDs and the FDA has accepted INDs 134025 and 129194 for NRX-100 and NRX-101 respectively. The FDA has advised us that no further preclinical studies are needed for submission of an NDA for NRX-100. The FDA has advised us and we have agreed that a genotoxicity study and a non-clinical maternal/fetal study for potential fetal effects are required prior to filing of an NDA for NRX-101. Furthermore, drugs that are potentially used chronic or chronic/intermittently do need to show preclinical carcinogenicity studies. &#160;Based on our latest FDA interactions we may be required to do so, even if our initial target indication is for 6 weeks. However, FDA indicated that they would review our request for an exemption, which we intend to submit.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Clinical Trials</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Clinical trials involve the administration of the IND to human subjects under the supervision of qualified investigators in accordance with Current Good Clinical Practices (&#8220;cGCP&#8221;) requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial, and review and approval by an Institutional Review Board (&#8220;IRB&#8221;). Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated, and a statistical analysis plan. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, a central or local IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial, including any changes, while it is being conducted. Information about certain clinical trials, including a description of the study and study results, must be submitted within specific timeframes to the NIH for public dissemination on their clinicaltrials.gov website.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Human clinical trials are typically conducted in three sequential Phases, which may overlap or be combined. In Phase 1, the drug is initially introduced into healthy human subjects or subjects with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. In Phase 2, the drug typically is administered through well-controlled studies to a limited subject population with the target disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. In Phase 3, the drug is administered to an expanded subject population, generally at geographically dispersed clinical trial sites, in two adequate and well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product. Furthermore, depending on the expected use of a drug (e.g., acute, intermittent, chronic), regulatory requirements may include a safety database that goes beyond the number of subjects in the efficacy studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The manufacture of investigational drugs for the conduct of human clinical trials is subject to current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements. Investigational drugs and active pharmaceutical ingredients imported into the U.S. are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outside of the U.S. is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the FFDCA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Progress reports and other summary information detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if certain unexpected Serious Adverse Events occur or other significant safety information is found. Phase I, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk or the trial is not being conducted in accordance with the applicable regulatory requirements or the protocol. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to subjects. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (&#8220;DSMB&#8221;) or data monitoring committee (&#8220;DMC&#8221;). This group regularly reviews accumulated data and advises the study sponsor regarding the continuing safety of trial subjects, potential trial subjects, and the continuing validity and scientific merit of the clinical trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Implications for NRX-100/101</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In the case of NRX-100/101, the FDA has agreed with us in writing that the investigational product meets the standards for a 505.b.2 (commonly called drug-repurposing) pathway, whereby the extensive safety literature regarding the individual components of NRX-101 may be cited in lieu of repeating various preclinical and Phase I clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Because of examples in recent years where sponsors have received Complete Response Letters based on lack of agreement with the FDA regarding the research path required for NDA submission, we worked collaboratively with the FDA for one year in order to negotiate a FDA SPA that would govern the development of NRX-101 and would define the Phase 2I trial required for the target indication., should the clinical trial be successful. This FDA SPA was issued to us in April 2018 and defines the single clinical trial required for submission of NRX-101 for treatment of bipolar depression with acute suicidal ideation or behavior. In addition to the defined requirements in the FDA SPA, the FDA may require additional clinical safety data, especially if the use of the drug could be intermittent or chronic/intermittent as deemed by the FDA. As mentioned before, we recently received written guidance from the FDA that the Company is evaluating.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Marketing Approval</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. These user fees must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. A waiver from the application user fee may be sought by an applicant. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have a drug product that has been approved under a human drug application and introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first human drug application. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has agreed to certain performance goals regarding the timing of its review of an application. The FDA aims to review 90% of all standard review applications within ten months of acceptance for filing and six months of acceptance for filing for priority review applications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In addition, under the Pediatric Research Equity Act, an NDA, or supplement to an NDA, for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The FDA may also require submission of a Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) program either during the application process or after the approval of the drug to ensure the benefits of the drug outweigh the risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries or other risk tracking and minimization tools.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Under the FFDCA, before approving a drug for which no active ingredient (including any ester or salt of active ingredients) has previously been approved by the FDA, the FDA must either refer that drug to an external advisory committee or provide in an action letter, a summary of the reasons why the FDA did not refer the drug to an advisory committee. The external advisory committee review may also be required for other drugs because of certain other issues, including clinical trial design, safety and effectiveness, and public health questions. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications by the manufacturer and all of its subcontractors and contract manufacturers. Additionally, before approving an NDA, the FDA will inspect one or more clinical trial sites to assure compliance with GCP regulations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The testing and approval process for an NDA requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent marketing approval. The FDA may not grant approval of an NDA on a timely basis, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing, or other information, in order for FDA to reconsider the application. The FDA has a review goal of completing its review of 90% of resubmissions within two or six months after receipt, depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a black boxed warning, require that post-approval studies, including Phase IV clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post- marketing studies or surveillance programs. After approval, certain circumstances may require FDA notification, review, or approval, as well as further testing. These may include some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, or new safety information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Special FDA Expedited Review and Approval Programs</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The FDA has various programs, including Fast Track designation, accelerated approval, priority review and Breakthrough Therapy (as defined below) designation, that are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions, and demonstrate the potential to address unmet medical needs or present a significant improvement over existing therapy. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if the product will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy, safety, or public health factors. If Fast Track designation is obtained, drug sponsors may be eligible for more frequent development meetings and correspondence with the FDA. In addition, the FDA may initiate review of sections of an NDA before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides and the FDA approves a schedule for the remaining information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In some cases, a Fast Track product may be eligible for accelerated approval or priority review.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. A priority review means that the goal for the FDA is to review an application in six months, rather than the standard review of ten months under current PDUFA guidelines. These six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs, which typically adds approximately two months to the timeline for review and decision from the date of submission. Products that are eligible for Fast Track designation may also be considered appropriate to receive a priority review.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses or conditions and that fill an unmet medical need may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoints, and the drug may be subject to accelerated withdrawal procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Moreover, under the provisions of the new Food and Drug Administration Safety and Innovation Act enacted in 2012, a sponsor can request designation of a product candidate as a &#8220;Breakthrough Therapy.&#8221; A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as Breakthrough Therapies are eligible for the Fast Track designation features as described above, intensive guidance on an efficient drug development program beginning as early as Phase I trials, and a commitment from the FDA to involve senior managers and experienced review staff in a proactive collaborative, cross-disciplinary review.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Implications for NRX-101</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Subsequent to the issuance of the FDA SPA, in November 2018, the FDA also issued a Breakthrough Therapy designation to NRX-101. Breakthrough Therapy designation is awarded to drugs that have demonstrated preliminary evidence of efficacy for the treatment of a serious medical condition for which there is an unmet medical need.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Post-Approval Requirements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, manufacturing, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product and drug shortages. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase IV clinical trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and list drugs manufactured at their facilities with the FDA. These facilities are further subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMP and other regulatory requirements. Changes to the manufacturing process are strictly regulated and may require prior approval by the FDA or notification to the FDA before or after being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product becomes available in the market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">fines, Warning Letters or Untitled Letters, holds or termination of post-approval clinical trials or FDA debarment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">delay or refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">regulatory authority, including the FDA, issued safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">mandated modifications to promotional material or issuance of corrective information;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">product seizure or detention, or refusal to permit the import or export of products; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">injunctions or the imposition of civil or criminal penalties, including imprisonment, disgorgement and restitution, as well as consent decrees, corporate integrity agreements, deferred prosecution agreements and exclusion from federal healthcare programs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Although physicians in the practice of medicine may prescribe approved drugs for unapproved indications, pharmaceutical companies are prohibited from marketing or promoting their drug products for uses outside of the approved indications in the approved prescribing information. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly marketed or promoted off-label uses may be subject to significant liability, including criminal and civil penalties under the FFDCA and False Claims Act, exclusion from participation in federal healthcare programs, debarment from government contracts and refusal of future orders under existing contracts, and mandatory compliance programs under corporate integrity agreements or deferred prosecution agreements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which, among other things, regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Moreover, the recently enacted Drug Quality and Security Act, imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing. Among the requirements of this new legislation, manufacturers will be required to provide certain information regarding drug products to individuals and entities to which product ownership is transferred, label drug products with a product identifier, and keep certain records regarding drug products. The transfer of information to subsequent product owners by manufacturers will eventually be required to be done electronically. Manufacturers will also be required to verify that purchasers of the manufacturers&#8217; products are appropriately licensed. Further, under this new legislation, manufactures will have drug product investigation, quarantine, disposition, and FDA and trading partner notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products such that they would result in serious adverse health consequences or death, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Regulation under the Drug Enforcement Administration</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We are required to evaluate the abuse potential of our product candidates. If any of our product candidates are considered controlled substances, we will need to comply with additional regulatory requirements. NRX-100 (ketamine) is a controlled substance with high abuse potential. Both components of NRX-101 are approved drugs (DCS and lurasidone) and neither is a controlled substance. We have completed abuse liability studies for DCS and identified no abuse potential.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Certain drug products may be regulated as &#8220;controlled substances&#8221; as defined in the Controlled Substances Act of 1970 and the DEA&#8217;s implementing regulations. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. The FDA provides a recommendation to the DEA as to whether a drug should be classified as a controlled substance and the appropriate level of control. If DEA scheduling is required, a drug product may not be marketed until the scheduling process is completed, which could delay the launch of the product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Depending on the Schedule, drug products may be subject to registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA, which are directly applicable to product applicants, contract manufacturers and to distributors, prescribers and dispensers of controlled substances. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging in order to prevent loss and diversion into illicit channels of commerce.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. Similarly, separate registrations are also required for separate facilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The DEA typically inspects a facility to review its security measures prior to issuing a registration and on a periodic basis. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Records must be maintained for the handling of all controlled substances, and periodic reports may be required to made to the DEA for the distribution of certain controlled substances. Reports must also be made for thefts or significant losses of any controlled substance. To enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in administrative, civil or criminal enforcement. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those registrations. In some circumstances, violations could result in criminal proceedings or consent decrees. Individual states also independently regulate controlled substances.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Federal and State Healthcare related, Fraud and Abuse and Data Privacy and Security Laws and Regulations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state fraud and abuse, and other laws regulations, and requirements restrict business practices in the biopharmaceutical industry. These laws include anti-kickback and false claims laws and regulations, state and federal transparency laws regarding payments or other items of value provided to health care professionals, as well as data privacy and security laws and regulations and other requirements applicable to the healthcare industry, including pharmaceutical manufacturers. There are also laws, regulations, and requirements applicable to the award and performance of federal contracts and grants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are narrowly drawn. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The reach of the Anti-Kickback Statute was also broadened by the Affordable Care Act, which, among other things, amended the intent requirement of the Federal Anti-Kickback Statute and certain provisions of the criminal health care fraud statute (discussed below) such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim for payment for items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Penalties for violation of the Anti-Kickback Statute include criminal fines, imprisonment, civil penalties and damages, exclusion from participation in Federal healthcare programs and corporate integrity agreements or deferred prosecution agreements. Conviction or civil judgments are also grounds for debarment from government contracts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Federal Civil False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the U.S. Government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, including payments under a federal grant. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. Government. The False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil False Claims Act. Several pharmaceutical and other healthcare companies have been sued under these laws for allegedly providing free product to customers with the expectation that the customers would bill Federal programs for the product. Companies have also been sued for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, or off-label, uses. In addition, Federal health care programs require drug manufacturers to report drug pricing information, which is used to quantify discounts and establish reimbursement rates. Several pharmaceutical and other healthcare companies have been sued for reporting allegedly false pricing information, which caused the manufacturer to understate rebates owed or, when used to determine reimbursement rates, caused overpayment to providers. Violations of the civil False Claims Act may result in civil penalties and damages as well as exclusion from Federal healthcare programs and corporate integrity agreements or deferred prosecution agreements. The U.S. Government may further prosecute conduct constituting a false claim under the criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the U.S. Government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil False Claims Act, requires proof of intent to submit a false claim. Violations of the criminal False Claims Act can result in criminal fines and/or imprisonment, as well as exclusion from participation in Federal healthcare programs. Conviction or civil judgments and other conduct are also grounds for debarment from U.S. Government contracts and grants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">HIPAA also created Federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. As discussed above, the Affordable Care Act amended the intent standard for certain of HIPAA&#8217;s healthcare fraud provisions such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations of HIPAA&#8217;s fraud and abuse provisions may result in fines or imprisonment, as well as exclusion from participation in Federal healthcare programs, depending on the conduct in question. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a Federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Veterans Health Care Act requires manufacturers of covered drugs to offer them for sale on the Federal Supply Schedule, which requires compliance with applicable Federal procurement laws and regulations and subjects us to contractual remedies as well as administrative, civil and criminal sanctions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, there has been a recent trend of increased Federal and state regulation of payments made to physicians and other health care providers. The Affordable Care Act created new Federal requirements for reporting, by applicable manufacturers of covered drugs, payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members. Certain states also require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the U.S. Government, or otherwise restrict payments or the provision of other items of value that may be made to healthcare providers and other potential referral sources; impose restrictions on marketing practices; and/or require drug manufacturers to track and report information related to payments, gifts and other items of value to physicians and other healthcare providers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We may also be subject to data privacy and security regulation by both the U.S. Government and the states in which we conduct our business. HIPAA, as amended by HITECH and its implementing regulations, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Penalties for violating HIPAA include civil penalties, criminal penalties and imprisonment. Among other things, HITECH, through its implementing regulations, makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in Federal courts to enforce the Federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing Federal civil actions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, other Federal and state laws govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Coverage and Reimbursement</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The commercial success of our product candidates and our ability to commercialize any approved product candidates successfully will depend in part on the extent to which governmental authorities, private health insurers and other third-party payers provide coverage for and establish adequate reimbursement levels for our therapeutic product candidates. In the U.S., the European Union and other potentially significant markets for our product candidates, government authorities and third-party payers are increasingly imposing additional requirements and restrictions on coverage, attempting to limit reimbursement levels or regulate the price of drugs and other medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be. For example, in the U.S., Federal and state governments reimburse covered prescription drugs at varying rates generally below average wholesale price. Federal programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and clinics and mandatory rebates on retail pharmacy prescriptions paid by Medicaid and Tricare. These restrictions and limitations influence the purchase of healthcare services and products. Legislative proposals to reform healthcare or reduce costs under government programs may result in lower reimbursement for our product candidates or exclusion of our product candidates from coverage. Moreover, the Medicare and Medicaid programs increasingly are used as models for how private payers and other governmental payers develop their coverage and reimbursement policies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, the increased emphasis on managed healthcare in the U.S. and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and utilization, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, competition within therapeutic classes, availability of generic equivalents, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, coverage and reimbursement policies and pricing in general. The cost containment measures that healthcare payers and providers are instituting and any healthcare reform implemented in the future could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Impact of Healthcare Reform on Coverage, Reimbursement, and Pricing</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The Medicare Modernization Act imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription, pharmacy drugs pursuant to federal regulations. Part D plans include both standalone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. In general, Part D prescription drug plan sponsors have flexibility regarding coverage of Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class, with certain exceptions. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for any products for which we receive marketing approval. However, any negotiated prices for our future products covered by a Part D prescription drug plan will likely be discounted, thereby lowering the net price realized on our sales to pharmacies. Moreover, while the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from Medicare Part D may result in a similar reduction in payments from non-governmental payers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The American Recovery and Reinvestment Act of 2009 provides funding for the U.S. Government to compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the NIH, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payers, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our product candidates. If third-party payers do not consider our product candidates to be cost-effective compared to other available therapies, they may not cover our product candidates, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The U.S. and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including, most recently, the Affordable Care Act, which became law in March 2010 and substantially changes the way healthcare is financed by both governmental and private insurers. Among other cost containment measures, the Affordable Care Act establishes an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; expansion of Medicaid benefits and a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program; and expansion of the 340B drug discount program that mandates discounts to certain hospitals, community centers and other qualifying providers. In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit the prices we are able to charge or the amounts of reimbursement available for our product candidates once they are approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The Foreign Corrupt Practices Act</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Activities that violate the FCPA, even if they occur wholly outside the U.S., can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts.&#160; The FCPA is currently under a temporary pause in enforcement.&#160; This pause was initiated by an executive order from President Trump on February 10, 2025 for a 180-day period.&#160; The order aims to reassess the guidelines and policies surrounding FCPA investigations and enforcement actions with a focus on promoting U.S. economic competitiveness and national security.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exclusivity and Approval of Competing Products</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Hatch-Waxman Patent Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application (&#8220;ANDA&#8221;) or 505(b)(2) NDA. Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths, dosage form and route of administration as the listed drug and has been shown to be bioequivalent through in vitro or in vivo testing or otherwise to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the reference listed drug. 505(b)(2) NDAs generally are submitted for changes to a previously approved drug product, such as a new dosage form or indication.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The ANDA or 505(b)(2) NDA applicant is required to provide a certification to the FDA in the product application concerning any patents listed for the approved product in the FDA&#8217;s Orange Book, except for patents covering methods of use for which the applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the required patent information has not been filed;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the listed patent has expired;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the listed patent is invalid, unenforceable, or will not be infringed by the new product.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except when the ANDA or 505(b)(2) NDA applicant challenges a listed patent or if the listed patent is a patented method of use for which approval is not being sought. A certification that the proposed product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. We may seek Paragraph IV Certification for our product candidates. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all the listed patents claiming the referenced product have expired.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, a decision in the infringement case that is favorable to the ANDA applicant or other period determined by a court.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Hatch-Waxman Non-Patent Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Market and data exclusivity provisions under the FFDCA also can delay the submission or the approval of certain applications for competing products. The FFDCA provides a five-year period of non- patent data exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non- infringement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The FFDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing NDA or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well- controlled clinical trials necessary to demonstrate safety and effectiveness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Pediatric Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the U.S. and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent exclusivity period described above. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection that cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Orphan Drug Designation and Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Orphan Drug Act provides incentives for the development of drugs intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals annually in the U.S., or affecting more than 200,000 in the U.S. and for which there is no reasonable expectation that the cost of developing and making the drug available in the U.S. will be recovered from U.S. sales.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Additionally, sponsors must present a plausible hypothesis for clinical superiority to obtain orphan drug designation if there is a drug already approved by the FDA that is intended for the same indication and that is considered by the FDA to be the same drug as the already approved drug. This hypothesis must be demonstrated to obtain orphan drug exclusivity. Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and user fee waivers. In addition, if a product receives FDA approval for the indication for which it has orphan drug designation, the product is generally entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Foreign Regulation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In order to market any product outside of the U.S., we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. For example, in the European Union, we must obtain authorization of a clinical trial application in each member state in which we intend to conduct a clinical trial. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>European Union Drug Approval Process</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">To obtain marketing authorization of a drug in the European Union, we may submit MAAs either under the so-called centralized or national authorization procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Centralized procedure</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the EMA that is valid in all European Union member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee of Medicinal Products for Human Use (the &#8220;CHMP&#8221;). Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>National authorization procedures</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">There are also two other possible routes to authorize medicinal products in several European Union countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized procedure.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic marketing authorization in the European Union during a period of eight years from the data on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic applicant from commercializing its product in the European Union until ten years have elapsed from the initial authorization of the reference product in the European Union. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 36
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1a" title="item1a" href="#"></a>Item 1A. Risk Factors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>We are an early-stage company with a history of losses and our business faces significant risks and uncertainties, which are summarized below and are more fully described in the following section. Our business, prospects, financial condition, and results of operations could be materially and adversely affected if one or more of these risks occurs. In addition, other events that we do not currently anticipate, or that we currently deem immaterial, may also affect our business, prospects, financial condition and results of operations. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in or incorporated by reference into this annual report and our other public filings with the SEC. The following summary of the Risk Factors is subject to the full description of the Risk Factors set forth in this Item 1A.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risk Factors Summary</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We have a limited operating history upon which to base an investment decision.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We are an early-stage company with a history of losses. We have not been profitable historically and may not achieve or maintain profitability in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We need to raise additional capital to operate our business and finance&#160;our proposed acquisitions. If we fail to obtain the capital necessary to fund our operations, we will be unable to continue as a going concern, complete our product development or fund our proposed acquisitions.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">NRX-101 is still Phase 2/3 in clinical testing and we cannot predict with any certainty if or when we might submit an NDA for regulatory approval. &#160;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We have not yet scaled manufacturing of our drug products to levels that are required for sustained sales.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The outcome of any current or future disputes, claims, arbitration and litigation could have a material adverse effect on our business, financial condition and results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we fail to obtain or maintain FDA and other regulatory clearances for our products, or if such clearances are delayed, we will be unable to commercially distribute and market our products in the U.S.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our products will face significant competition in the markets for such products and future products may never achieve market acceptance. We are faced with rapid technological change and developments by competitors may render our products or technologies obsolete or non-competitive.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Global economic, political and social conditions, armed conflicts and uncertainties in the market that we serve may adversely impact our business.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our relationships with potential customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and administrative burdens.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Managing our growth as we expand operations may strain our resources and we may not successfully manage our growth.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">While we have entered into non-binding letters of intent to acquire certain psychiatry clinics and for sources of funding for such acquisitions, we have not entered into definitive agreements, and cannot assure you that such transactions will be consummated on the terms set forth in the letters of intent, if at all.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We will need to acquire additional financing to fund our potential obligations under certain non-binding letters of intent, and we cannot guaranty that the terms of such financings will be favorable and such financings may result in additional dilution, and if such financing cannot be acquired, it could have a material adverse effect on our business.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">A significant portion of our growth strategy focuses on our subsidiary, Hope Therapeutics, Inc., and ability to purchase psychiatry clinics, and failure to consummate any such transactions may have a material adverse effect on our ability to increase assets, revenues, and net income, or on our business and the trading price of our common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Failure to achieve and maintain effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could impair our ability to produce timely and accurate financial statements or comply with applicable regulations and have a material adverse effect on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Even if a drug product is approved, the regulators may impose limitations on the use or marketing of such product.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we are unable to design, conduct and complete clinical trials successfully, our drug candidates will not be able to receive regulatory approval. We cannot predict whether regulatory agencies will determine that the data from our clinical trials of our product candidates supports marketing approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">There is no guarantee that regulators will grant NDA approval of our current or future product candidates and failure to obtain necessary clearances or approvals for our current and future product candidates would adversely affect our ability to grow our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If an adverse event occurs during a clinical trial, the regulators or an internal review board may delay or terminate the trial.&#160;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Discussions and guidance of clinical trials are not binding obligations on the part of regulatory authorities. The results of our current or future clinical trials may not support our product candidate claims or may result in the discovery of unexpected adverse side effects.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Delays in the commencement or completion of pharmaceutical development, manufacturing or clinical efficacy and safety testing could result in increased costs to us and delay our ability to generate revenues.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Even if our products are approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA regulation or if we experience unanticipated problems with our products, these products could be subject to market restrictions or withdrawals.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Conducting clinical trials of our drug candidates or commercial sales of a drug candidate may expose us to expensive product liability claims and we may not be able to maintain product liability insurance on reasonable terms or at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The use of a controlled substance in our NRX-100 drug candidate subjects us to DEA scrutiny and compliance, which may result in additional expense and clinical delays.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Modifications to our products may require new NDA approvals and some of our other product candidates will require Risk Evaluation and Mitigation Strategies.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our business relies on certain licensing rights that can be terminated in certain circumstances.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our business depends upon securing and protecting critical intellectual property. If we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue development or sale of our products, and/or pay damages.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Breaches by our employees or other parties may allow our trade secrets to become known to our competitors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may not receive royalty or milestone revenue relating to our product candidates under our collaboration and future license agreements for several years, or at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We do not have direct control of third parties performing preclinical and clinical trials. If such third parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We have no manufacturing capabilities and depend on other parties for manufacturing operations. These manufacturers may fail to satisfy our requirements and applicable regulatory requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our issuance of additional shares of common stock or convertible securities could make it difficult for another company to acquire us, may dilute your ownership of us and could adversely affect our stock price. Future sales, or the perception of sales, of our common stock by us or our existing stockholders could cause the market price for our common stock to decline.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our announced spin-off of HOPE into an independent, publicly traded company may not be completed on the previously announced timeline, or if at all, and if completed, may not achieve the intended benefits and expose us to new risks, any of which could have a material adverse impact on our business and results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We qualify as a &#8220;smaller reporting company&#8221;&#160;within the meaning of the Securities Act, which could make our securities less attractive to investors and may make it more difficult to evaluate our performance.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Anti-takeover provisions in our governing documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain of our stockholders have effective control of NRx, and their interests may conflict with NRx&#8217;s or yours in the future. We are no longer a &#8220;controlled company&#8221;&#160;under the corporate governance rules of Nasdaq. However, we continue to rely on certain exceptions from corporate governance standards.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we fail to meet the applicable continued listing requirements of the Nasdaq Capital Market, Nasdaq may delist our common stock, in which case the liquidity and market price of our common stock could decline.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8226;&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We do not intend to pay cash dividends on our common stock for the foreseeable future.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to an Early-Stage Company</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are an early-stage company with a history of losses. We have not been profitable historically and may not achieve or maintain profitability in the future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We experienced net losses in each year since inception, including net losses of $25.1 million and $30.2 million for the years ended, December 31, 2024 and 2023, respectively. We believe we will continue to incur operating losses and negative cash flow in the near-term as we continue to invest significantly in our business, in particular across our research and development efforts, clinical trial programs and future sales and marketing efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">These investments may not result in revenue or growth in our business. In addition, as a newly- public company, we incur significant additional legal, accounting and other expenses that we did not incur as a private company. These increased expenditures may make it harder for us to achieve and maintain future profitability. Until we have a product candidate approved by the FDA, which could take several years, revenue growth will not be possible, and we are unlikely to achieve or maintain profitability. Further, there can be no assurance that the products under development by us will be approved for sales in the U.S. or elsewhere.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We expect a substantial portion of our revenue going forward to be generated from the sale and distribution of our product candidates, but until one of our product candidates is approved for sale, it is difficult for us to predict our future operating results. Even if we succeed in developing and commercializing one or more of our product candidates, we expect to incur substantial net losses and negative cash flows for the foreseeable future due in part to increasing research and development expenses, including clinical trials, and increasing expenses from leasing additional facilities and hiring additional personnel. As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. Even if we do achieve profitability, we may not be able to sustain or increase profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We may incur significant losses in the future for a number of reasons, and we may encounter unforeseen expenses, difficulties, complications and delays and other unknown events. As a result, our losses may be larger than anticipated, we may incur significant losses for the foreseeable future, and we may not achieve profitability when expected, or at all, and even if we do, we may not be able to maintain or increase profitability. Furthermore, if our future growth and operating performance fail to meet investor or analyst expectations, or if we have future negative cash flow or losses resulting from our investment in acquiring customers or expanding our operations, this could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our operating results and financial condition may fluctuate from period to period.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If and when any of our product candidates are successfully commercialized, we anticipate that our operating results and financial condition will fluctuate from quarter-to-quarter and year-to-year due to a number of factors, many of which will not be within our control. Both our business and the pharmaceutical industry are changing and evolving rapidly, and our operating results in any given year may not be useful in predicting our future operating results. If our operating results do not meet the guidance that we provide to the marketplace or the expectations of securities analysts or investors, the market price of our common stock will likely decline. Fluctuations in our future operating results and financial condition may be due to a number of factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to manufacture our products in sufficient quantities with chemical manufacturing controls (&#8220;CMC&#8221;) that meet governmental regulatory standards;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the degree of acceptance and differentiation of our products and services in the broader healthcare industry;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to compete with competitors and new entrants into our markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the products and services that we are able to sell during any period;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the timing of our sales and distribution of our products to customers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the geographic distribution of our sales;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in our pricing policies on those of our competitors, including our response to price competition;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in the amount that we spend to research and develop new products or technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">expenses and/or liabilities resulting from litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">delays between our expenditures to research and develop new or enhanced products or technologies, the necessary regulatory approvals and the generation of revenue from those products or technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">unforeseen liabilities or difficulties in integrating any businesses that we choose to acquire;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">disruptions to our information technology systems or our third-party contract manufacturers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">general economic and industry conditions that affect customer demand;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the impact of the COVID-19 pandemic on our customers, suppliers, manufacturers and operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in accounting rules and tax laws; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">global geopolitical conditions.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have a limited operating history upon which to base an investment decision.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our limited operating history may hinder your ability to evaluate our prospects due to a lack of historical financial data and our unproven potential to generate profits. You should evaluate the likelihood of financial and operational success in light of the risks, uncertainties, expenses and difficulties associated with an early-stage business, many of which may be beyond our control, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our potential inability to continue to undertake preclinical studies, pharmaceutical development and clinical trials,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our potential inability to obtain regulatory approvals, and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our potential inability to manufacture, sell and market our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary technology and intellectual property and undertaking preclinical studies and early-stage clinical trials of our principal product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We need to raise additional capital to operate our business. If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and we may not be able to continue as a going concern.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">We are a company focused on product development and have not generated any product revenues to date. Until, and if, we receive approval from the FDA and other regulatory authorities for our product candidates, we cannot sell our drugs and will not have product revenues.<i> </i>We had cash and cash equivalents of approximately $1.4 million as of December 31, 2024. However, we will need to continue to seek capital from time to time to continue the development and potential commercialization of our product candidates, including any expansion of our clinical programs to facilitate a larger safety database for the use of NRX-101 as a chronic, or chronic-intermittent, treatment as advised by FDA in our recent Type B meeting, and to acquire and develop other product candidates. Accordingly, we believe that we will need to raise substantial additional capital to fund our continuing operations and the development and potential commercialization of our product candidates during calendar year 2025. We may raise capital through future share offerings, the issuance of debt instruments and grant monies. Our actual capital requirements will depend on many factors. For instance, our business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred depression treatment. If we experience unanticipated cash requirements, we may need to seek additional sources of financing, which may not be available on favorable terms, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may not be able to secure funding when we need it or on favorable terms. If we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale-back or eliminate our research and development activities, clinical studies or future operations and we may be unable to complete planned nonclinical studies and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue product development, reduce or forego sales and marketing efforts and attractive business opportunities, reduce overhead, or be unable to continue as a going concern. We may also be required to obtain funds through arrangements with collaborators, which arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could result in sharing revenues which we might otherwise retain for ourselves. Any of these actions may harm our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The amount of capital we may need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope of our nonclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative, licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be unable to access the capital markets and even if we can raise additional funding, we may be required to do so on terms that are dilutive.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The capital markets have been unpredictable in the recent past for unprofitable companies such as ours. In addition, it is generally difficult for companies to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends on variables that are beyond our control. As a result, we cannot assure you that we will be able to secure financing on terms attractive to us, or at all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds are not available on acceptable terms, or at all, our business, results of operations, financial condition and our continued viability will be materially adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We will have broad discretion in using the proceeds of shares sold to investors, and we may not spend the proceeds in an effective manner.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are not limited in the use of proceeds of shares sold to investors. We may use such proceeds for working capital and general corporate purposes to support our growth, to pay dividends on our outstanding securities, or for acquisitions or other strategic investments. We have not allocated such funds to any particular purpose, and our management will have the discretion to allocate the proceeds as it determines. We may not apply the proceeds effectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business and Industry</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>NRX-101 is still in Phase 2/3 of clinical testing.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">NRX-101 is in Phase 2b/3 of clinical testing with Breakthrough Therapy designation, a Biomarker Letter and a Special Protocol Agreement issued by the FDA on April 20, 2018. A Special Protocol Agreement is a mechanism by which the FDA indicates that the proposed clinical trial, if successful, will be adequate to support an application for drug approval. FDA approval requires that a drug candidate complete a Phase 2I study program, which tests the safety and efficacy of the drug candidate on a large sample of patients. We are conducting a new registrational study of NRX-101 for severe bipolar depression in patients with ASIB after initial stabilization with NRX-100 (ketamine). We are using newly-manufactured material that was manufactured using the expected commercial process. In addition, we have initiated a Phase 2 clinical study for bipolar depression with sub-acute suicidal ideation and behavior. This population is significantly larger than the Bipolar Depression population with ASIB, and does not require initial stabilization with NRX-100. On January 3, 2023, the Company announced that its first clinical trial site had been contracted for a Phase II/III clinical trial of NRX-101 for the treatment of Severe Bipolar Depression in patients with Acute Suicidal Ideation and Behavior, a potentially lethal condition that currently takes the lives of thousands of Americans each year. Because NRX-101 is a Breakthrough Therapy, we anticipate being able to file a New Drug Application (&#8220;NDA&#8221;) based upon a single, successful Phase 2I trial. While we cannot predict with any certainty if or when we might submit an NDA for regulatory approval of NRX-101, we aim to submit an NDA to the FDA on a rolling basis for the regulatory approval and commercialization of NRX-101 in the U.S. in 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our product candidates are newly-formulated and we have not yet scaled manufacturing to levels that will be required for sustained sales.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">NRX-101 has been formulated under Current Good Manufacturing Practices (&#8220;cGMP&#8221;) and long-term stability (<i>i.e.</i>, five years) has been achieved for our solid dose formulation of NRX-101. Although the Company completed a Type C meeting in which FDA agreed to the Company's Chemical Manufacturing Control and stability program for drug manufacture, and production of NRX-101 has been transferred to a commercial scale cGMP manufacturing facility in South Carolina, we have yet to attempt large scale manufacturing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The outcome of any current or future disputes, claims, arbitration and litigation could have a material adverse effect on our business, financial condition and results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract disputes, employment actions, employee benefits, taxes, environmental, health and safety, fraud and abuse, personal injury and product liability matters.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We are in litigation with a former employee of the Company regarding their termination of their employment. While the Company will vigorously defend the claims asserted in this matter, the litigation is ongoing and we may be subject to other lawsuits, claims, or proceedings. See &#8220;Item 3. Legal Proceedings&#8221; for a full description of such proceedings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to obtain or maintain FDA and other regulatory clearances for our products, or if such clearances are delayed, we will be unable to commercially distribute and market our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our products are subject to rigorous regulation by national regulators around in the world, and by the FDA in the U.S. The process of seeking regulatory clearance or approval to market a drug product is expensive and time consuming and, notwithstanding the effort and expense incurred, clearance or approval is never guaranteed. If we are not successful in obtaining timely clearance or approval of our products from the FDA, we may never be able to generate significant revenue in the U.S. and may be forced to focus on international markets where we currently do not have a presence or an established partnership, which will limit the revenue potential of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In the U.S., the FDA permits commercial distribution of a new drug product only after the product has received approval of an NDA filed with the FDA, seeking permission to market the product in interstate commerce in the U.S. The NDA process is costly, lengthy and uncertain. Any NDA application filed by us will have to be supported by extensive data, including, but not limited to, technical, nonclinical, clinical trial, manufacturing and labelling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the product for its intended use.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Obtaining clearances or approvals from the FDA and from the regulatory agencies in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other resources. The FDA and other agencies could ask us to supplement our submissions, collect non-clinical data, conduct additional clinical trials or engage in other time-consuming actions, or they could simply deny our applications. In addition, even if we obtain an NDA approval or pre-market approvals in other countries, the approval could be revoked or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and cash flow may be adversely affected, and our ability to grow domestically and internationally may be limited. Additionally, even if cleared or approved, our products may not be approved for the specific indications that are most necessary or desirable for successful commercialization or profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are subject to certain contractual obligations and limitations on our ability to consummate future financings under the August SPA (as defined below) and the Notes (as defined below) issued by us to the Investors (as defined below).</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Pursuant to a securities purchase agreement we entered into on August 12, 2024 (the &#8220;August SPA&#8221;) with certain accredited investors (the &#8220;Investors&#8221;), we issued an aggregate gross total of $16.3 million&#160;of Senior Secured Convertible Promissory Notes (the &#8220;Notes&#8221;), and warrants to purchase shares of common stock equal to 50%. In connection with the issuance of the Notes, we are subject to certain restrictions on our ability to issue securities during the term of the Note. Specifically, we have agreed, among other things, to obtain the Investor&#8217;s consent prior to issuing any debt securities or certain equity securities where the pricing of such equity securities is tied to the public trading price of our common stock. If we are unable to obtain the Investor&#8217;s consent prior to issuing any debt or certain equity securities, such issuance may be a breach of the August SPA, and we may be obligated to indemnify the Investors for loss or damage arising as a result of any breach or alleged breach by us of the August SPA, which may affect our business operations and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Furthermore, from August 12, 2024 until the 12-month anniversary of the date on which the Notes or Warrants are no longer outstanding, we also must offer the Investors the right to purchase up to 50% of future equity and debt securities offerings, subject to certain exceptions and limitations (the &#8220;Participation Right&#8221;). If we are unable to obtain the Investor&#8217;s consent prior to issuing any debt securities or certain equity securities, we may be obligated to pay to the Investors certain damages.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have granted a first priority security interest in substantially all of our assets, which could materially and adversely affect our business, financial condition, and ability to operate.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In connection with the August SPA, we entered into a Security Agreement, Patent Security Agreement, and Subsidiary Guaranty, pursuant to which we granted the Investors a security interest in substantially all of our assets to secure the Company&#8217;s obligations under the August SPA and the Notes. As a result, if we fail to meet our obligations under the August SPA or the Notes, our secured creditors may exercise their rights to foreclose upon or seize our assets, which could materially and adversely affect our ability to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The existence of liens on our assets may also limit our ability to obtain additional financing, as potential lenders may be unwilling to provide additional credit that is subordinate to the secured interests of the Investors. Furthermore, restrictive covenants in the August SPA and the Notes may limit our operational flexibility, including our ability to incur additional debt, make investments, pay dividends, or dispose of assets, which could negatively impact our ability to execute our business strategy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Additionally, the conversion of the principal and interest due under the Notes into shares of our common stock could lead to significant dilution for our existing stockholders. The Notes are convertible into shares of the Company&#8217;s common stock, and the issuance of such shares could result in downward pressure on our stock price and reduce the ownership percentage of existing investors. The potential for such conversions, or market anticipation of conversions, could increase the volatility of our stock price.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">If we are unable to generate sufficient cash flow from operations or otherwise obtain funds necessary to meet our debt obligations, we may be forced to seek alternative financing, which may not be available on favorable terms, or at all. In the event of default, the Investors could accelerate our repayment obligations and exercise remedies against our pledged assets, which could force us into bankruptcy or liquidation and result in a loss of value for our shareholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our revenue stream will depend upon third-party reimbursement.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Once our product candidates are cleared or approved by the regulatory authorities, the commercial success of our products in both domestic and international markets will be substantially dependent on whether third-party coverage and reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly approved drugs is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products are approved by national regulatory authorities as safe and efficacious. Many patients using existing approved therapies are generally reimbursed all or part of the product cost by governmental and non-governmental insurance plans. Such payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally does not occur prior to the filing of an NDA for that product and may not be granted for as long as many months after NDA approval. In order to obtain reimbursement arrangements for these products, we or our commercialization partners may have to agree to a net sales price lower than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may have conflicts with our partners that could delay or prevent the development or commercialization of our product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We are not aware of any material commercial conflicts that could delay or prevent development or commercialization. However, commercial conflicts such as the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property could arise in any joint development activity. If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us a share in profits that we believe are due to us under a collaboration; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness on the part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our products will face significant competition in the markets for such products, and if they are unable to compete successfully, our business will suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our product candidates face, and will continue to face, intense competition from large pharmaceutical companies, specialty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by: (i) rapid technological change, (ii) evolving industry standards, (iii) emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with our products and technologies and may develop and commercialize additional products and technologies that will compete with our products and technologies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Because several competing companies and institutions have greater financial resources than us, they may be able to: (i) provide broader services and product lines, (ii) make greater investments in research and development, and (iii) carry on larger R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially greater experience in undertaking non-clinical and clinical testing of products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us. Our chief competitors in the psychiatry area include companies such as Johnson &amp; Johnson, Pfizer, Eli Lilly, Sage Therapeutics, Axsome, and Relmada, among others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are faced with intense competition and rapid technological change, which may make it more difficult for us to achieve significant market penetration. If we cannot compete successfully for market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The market for our product candidates is characterized by intense competition and rapid technological advances. If our product candidates receive regulatory approval in any jurisdiction, they will compete with a number of existing and future drugs and therapies developed, manufactured and marketed by others. If our competitors&#8217; existing products or new products are more effective than or considered superior to our future products, the commercial opportunity for our product candidates will be reduced or eliminated. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost. We face competition from fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. If we are successful in penetrating the relevant markets for treatment with our product candidates, other companies may be attracted to the market. Many of our competitors have products already approved or in development. In addition, many of these competitors, either alone or together with their collaborative partners, are larger than we are and have substantially greater financial, technical, research, marketing, sales, distribution and other resources than we do. Our competitors may develop or market products that are more effective or commercially attractive than any that we are developing or marketing. Our competitors may obtain regulatory approvals, and introduce and commercialize products before we do. These developments could have a significant negative effect on our financial condition. Even if we are able to compete successfully, we may not be able to do so in a profitable manner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Future products may never achieve market acceptance.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Future products that we may develop may never gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of any of our products will depend on a number of factors, including the actual and perceived effectiveness and reliability of our products; the results of any long-term clinical trials relating to use of our products; the availability, relative cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using our products are approved for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning our products. The failure of any of our products to significantly penetrate current or new markets would negatively impact our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>To be commercially successful, physicians must be persuaded that using our products are effective alternatives to existing therapies and treatments.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We believe that doctors and other physicians will not widely adopt our products unless they determine, based on experience, clinical data, and published peer reviewed journal articles, that the use of our products provides an effective alternative to other therapies and treatments. Patient studies or clinical experience may indicate that treatment with our products does not provide patients with sufficient benefits and/or improvement in quality of life. We believe that recommendations and support for the use of our products from medical societies and / or influential physicians will be essential for widespread market acceptance. Our products are still in the development stage and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be obtained. If our products do not receive such support from these physicians and from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase, our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The testing and marketing of medical products entails an inherent risk of product liability. We may be held liable if serious adverse reactions from the use of our product candidates occur. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, alone or with corporate collaborators. We currently carry clinical trials liability insurance, but we do not currently carry product liability insurance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">While we plan to obtain product liability insurance as we near commercialization, we, or any corporate collaborators, may not be able to obtain insurance at a reasonable cost, if at all. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate if any claim arises.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be able to obtain Hatch-Waxman Act marketing exclusivity or equivalent regulatory data exclusivity protection in other jurisdictions for our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Should we not obtain or fail to maintain patent protection on our products, we intend to rely, in part, on Hatch-Waxman exclusivity for the commercialization of our products in the U.S. The Hatch- Waxman Act provides marketing exclusivity to the first applicant to gain approval of an NDA under specific provisions of the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA&#8221;) for a product using an active ingredient that the FDA has not previously approved (<i>i.e., </i>five years) or for a new dosage form, route or indication (<i>i.e., </i>three years). This market exclusivity will not prevent the FDA from approving a competitor&#8217;s NDA if the competitor&#8217;s NDA is based on studies it has performed and not on our studies. However, there can be no assurance that we will obtain Hatch-Waxman exclusivity for our products or that such exclusivity, if obtained, will protect us from direct competition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Similarly, in the European Union, new products authorized for marketing (<i>i.e.</i>, reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization, which, if obtained, would prevent generic applicants from relying on our preclinical and clinical trial data. However, there can be no assurance that European authorities will grant data exclusivity for our products. Even if European data exclusivity is granted for our products, that may not protect us from direct competition. A competitor with a generic version of our products may be able to obtain approval of their product during our product&#8217;s period of data exclusivity by submitting a marketing authorization application (&#8220;MAA&#8221;) with a less than full package of nonclinical and clinical data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>In the future, we may undertake international operations, which would subject us to risks inherent with operations outside of the U.S.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Although we do not have any foreign manufacturing or distribution operations at this time, we may seek to obtain market clearances in foreign markets that we deem could generate significant opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves inherent risks, including, but not limited to: difficulties in staffing, funding and managing foreign operations; unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We would need to obtain approvals from the appropriate regulatory, pricing and reimbursement authorities to market any of our proposed products internationally, and we may be unable to obtain foreign regulatory approvals. Pursuing foreign regulatory approvals would be time-consuming and expensive. The regulations can vary among countries and foreign regulatory authorities may require different or additional clinical trials than the trials we conducted to obtain FDA approval for our product candidates. In addition, adverse clinical trial results in such countries, such as death or injury due to side effects, could jeopardize not only regulatory approval, but if approval is granted, may also lead to marketing restrictions. Our product candidates may also face foreign regulatory requirements applicable to controlled substances.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If we were to experience any of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition may suffer and cause us to reduce or discontinue our international development and registration efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>International commercialization of our product candidates requires successful collaborations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We plan to commercialize some of our products internationally through collaborative relationships with foreign partners. We have limited foreign regulatory, clinical and commercial resources. Future partners are critical to our international success. However, we may not be able to enter into collaboration agreements with appropriate partners for important foreign markets on acceptable terms, or at all. Future collaborations with foreign partners may not be effective or profitable for us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business activities could face disruption due to pandemics and other public health emergencies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We monitor pandemics and other public health emergencies and have made certain assumptions regarding their potential impact on our business, operations and financial condition and results for purposes of our operational planning and financial projections, including assumptions regarding the duration and severity of the pandemic and the global macroeconomic impact of the pandemic. Despite careful tracking and planning, however, we are unable to accurately predict the extent of the impact of pandemics and other public health emergencies on our business, operations and financial condition and results. If a new pandemic and public health emergency arises, the research and development of our products will be delayed and we may be unable to perform fully on our contracts, which will likely result in increases in costs and reduction in revenue. These cost increases may not be fully recoverable or adequately covered by insurance. The long-term effects of any pandemic to the global economy and to us will be difficult to assess or predict and may include a decline in the market prices of our products, risks to employee health and safety, risks for the deployment of our products and services and reduced sales in geographic locations impacted. Any prolonged restrictive measures put in place in response to public health emergencies in any of our targeted markets may have a material and adverse effect on our business operations and results of operations. Prior concerns about potential business disruption from the COVID-19 pandemic are no longer relevant to the Company&#8217;s business operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Global economic, political and social conditions, armed conflicts and uncertainties in the market that we serve may adversely impact our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our performance depends on the financial health and strength of our potential customers, which in turn is dependent on the economic conditions of the markets in which we and our customers operate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The recent declines in the global economy, difficulties in the financial services sector and credit markets, continuing geopolitical uncertainties and other macroeconomic factors all affect the spending behavior of potential customers. The economic uncertainty in Europe, the U.S., India, China and other countries may cause end-users to further delay or reduce technology purchases.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We also face risks from financial difficulties or other uncertainties experienced by our suppliers, distributors or other third parties on which we rely. If third parties are unable to supply us with required materials or components or otherwise assist us in operating our business, our business could be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">For example, the possibility of trade disputes and tariffs between countries with whom we are engaged may impact the cost of raw materials, finished products or components used in our products and our ability to sell our products in various markets. In addition, the consequences of the ongoing conflict between Russia and Ukraine, including related sanctions and countermeasures, and the effects of rising global inflation, are difficult to predict, and could adversely affect our business and operations. Other changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment could also adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business, financial condition, and results of operations may be materially adversely affected by the negative impact on the global economy and capital markets resulting from new international conflicts or any other geopolitical tensions.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">U.S. and global markets generally experience volatility and disruption as a result of geopolitical tensions and military conflicts, including significant volatility in commodity prices, credit and capital markets, as well as supply chain disruptions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Additionally, international sanctions and other penalties can disrupt payment systems and imports/exports and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Any such disruptions may also magnify the impact of other risks described in this annual report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in hiring and retaining key employees and contractors.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our future operations and successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon to manage our business, including our Chief Executive Officer. If he terminates his relationship with us, such a departure could have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our future success also depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory personnel. We will need to hire additional qualified personnel with expertise in nonclinical pharmacology and toxicology, pharmaceutical development, clinical research, regulatory affairs, manufacturing, sales and marketing. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals, particularly in the U.S., is intense, and we may not be able to hire sufficient personnel to support our efforts. There can be no assurance that these professionals will be available in the market, or that we will be able to retain existing professionals or to meet or to continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation, which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish and maintain an effective management team and work force could adversely affect our ability to operate, grow and manage our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">comply with FDA regulations or similar regulations of comparable foreign regulatory authorities; provide accurate information to the FDA or comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">report financial information or data accurately; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">disclose unauthorized activities to us.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Business Code of Conduct and Anti-Corruption Policy, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our relationships with potential customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose use to criminal sanctions, civil penalties, contractual damages, reputational harm, and administrative burdens.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under Federal and state healthcare programs such as Medicare and Medicaid;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits, among other things, any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Office of Foreign Assets Control, which prohibits, among other things, transactions or dealings with specified countries, their governments, and in certain circumstances, their nationals, and with individuals and entities that are specially designated, including narcotics traffickers and terrorists or terrorist organization;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Committee on Foreign Investment in the U.S., which has regulatory oversight over the sources and amounts of investment we may accept from non-US investors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">state and foreign anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">HIPAA and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">federal laws requiring drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal open payments program, as well as other state and foreign laws regulating marketing activities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Managing our growth as we expand operations may strain our resources and we may not successfully manage our growth.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We expect to need to grow rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our drug candidates, which will place a significant strain on our financial, managerial and operational resources. In order to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities. Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our expenses and may require us to raise additional capital sooner than expected. If we grow significantly, such growth will place a significant strain on our management and on our administrative, operational and financial resources. To manage this growth, we must expand our facilities, augment our operational, financial and management systems, internal controls and infrastructure and hire and train additional qualified personnel. Our future success is heavily dependent upon growth and acceptance of our future products. If we are unable to scale our business appropriately or otherwise adapt to anticipated growth and new product introduction, our business and financial condition will be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may expand our business through the acquisition of rights to new drug candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders</i></b>&#8217;<b><i> ownership interests in our company.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our business strategy includes expanding our products and capabilities, and we may seek acquisitions of drug candidates or technologies to do so. Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuances of equity securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating the acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key employees of the acquired companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We cannot assure you that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired product, company or business. Any such transaction could also result in impairment of goodwill and other intangibles, write-offs and other related expenses. In addition, our future success would depend in part on our ability to manage the rapid growth associated with some of these acquisitions. We cannot assure you that we will be able to make the combination of our business with that of acquired products, businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business or companies may require a substantial capital investment by us. We may not have these necessary funds or they might not be available to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute each current stockholder&#8217;s ownership interest in NRx.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Business interruptions could limit our ability to operate our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our operations as well as those of our collaborators on which we depend are vulnerable to damage or interruption from computer viruses, human error, natural disasters, electrical and telecommunication failures, international acts of terror and similar events. We have not established a formal disaster recovery plan and our back-up operations and our business interruption insurance may not be adequate to compensate us for losses we may suffer. A significant business interruption could result in losses or damages incurred by us and require us to cease or curtail our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cyber security attacks, internal system or service failures may adversely impact our business and operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Any system or service disruptions, including those caused by projects to improve our information technology systems, if not anticipated and appropriately mitigated, could disrupt our business and impair our ability to effectively provide products and related services to our customers and could have a material adverse effect on our business. We could also be subject to systems failures, including network, software or hardware failures, whether caused by us, third-party service providers, intruders or hackers, computer viruses, natural disasters, power shortages or terrorist attacks.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Cyber security threats are evolving and include, but are not limited to, malicious software, phishing and other unauthorized attempts to gain access to sensitive, confidential or otherwise protected information related to us or our products, customers or suppliers, or other acts that could lead to disruptions in our business. Since the COVID-19 pandemic, many of our employees have shifted to work-from-home arrangements, which increases our vulnerability to email phishing, social engineering or &#8220;hacking&#8221; through our remote networks, and similar cyber-attacks aimed at employees working remotely. Because the techniques used by cyber-attackers to access or sabotage networks change frequently and may not be recognized until launched against a target, we may be unable to anticipate these tactics. Any such failures to prevent or mitigate cyber-attacks could cause loss of data and interruptions or delays in our business, cause us to incur remediation costs or subject us to claims and damage our reputation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, the failure or disruption of our communications or utilities could cause us to interrupt or suspend our operations or otherwise adversely affect our business. Although we utilize various procedures and controls to monitor and mitigate the risk of these threats and training our employees to recognize attacks, there can be no assurance that these procedures and controls will be sufficient. Our property and business interruption insurance may be inadequate to compensate us for all losses that may occur as a result of any system or operational failure or disruption which would adversely affect our business, results of operations and financial condition. Moreover, expenditures incurred in implementing cyber security and other procedures and controls could adversely affect our results of operations and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Failure to achieve and maintain effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could impair our ability to produce timely and accurate financial statements or comply with applicable regulations and have a material adverse effect on our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our management has significant requirements for enhanced financial reporting and internal controls as a public company. The process of designing and implementing effective internal controls is a continuous effort that will require us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If we are unable to establish and maintain appropriate internal financial reporting controls and procedures, in accordance with Section 404 of the Sarbanes-Oxley Act, it could impact our operating results, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations on a timely basis. Testing and maintaining internal controls may divert management&#8217;s attention from other matters that are important to our business. Our independent registered public accounting firm may be required to attest to the effectiveness of our internal control over financial reporting on an annual basis in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Matters impacting our internal controls may cause us to be unable to report our financial information on a timely basis and thereby subject us to adverse regulatory consequences, including sanctions by the SEC or violations of applicable stock exchange listing rules, which may result in a breach of the covenants under existing or future financing arrangements. There also could be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements. Confidence in the reliability of our financial statements also could suffer if we or our independent registered public accounting firm continue to report a material weakness in our internal controls over financial reporting. This could materially adversely affect us and lead to a decline in the market price of our common stock.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Risks Related to Hope Therapeutics</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Our plans to partially spin-off Hope as an independent, publicly traded company may not be completed on the currently contemplated timeline or at all and, if completed, may not achieve the intended benefits and expose us to new risks.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">We have previously announced our plan partially spin-off Hope as a separately traded company. A spin off would be through a partial pro rata distribution of shares to our common stockholders resulting in two distinct, publicly traded companies. The proposed spin-off is subject to various conditions, is complex in nature, and may be affected by unanticipated developments, credit and equity markets, or changes in market conditions. As independent, publicly traded companies, each of the resulting companies will be smaller and less diversified than the existing company, with a narrower business focus, and they may be more vulnerable to changing market conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">We may not be able to achieve the full strategic and financial benefits that we anticipate to result from the spin-off, or such benefits may be delayed or not occur at all. We may experience negative reactions from financial markets if we do not complete the separation in a reasonable time period, or at all. Following the proposed spin-off, the combined value of the shares of the two publicly traded companies may not be equal to or greater than what the value of our common stock would have been had the proposed separation not occurred. In addition, the cost and resources required to effectuate the separation may be significantly higher than what we currently anticipate, and we will likely incur one-time costs in connection with the proposed spin-off that may negate some of the benefits we expect to achieve. Moreover, we may determine to change our strategy, including to pursue, modify or abandon such spin-off at any time, and, in any event, there can be no assurance we will be successful in executing on our current strategy or any changed strategy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Any of these factors could have a material adverse effect on our business, financial condition, results of operations, cash flows or the price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>While we have entered into non-binding letters of intent with Kadima Neuropsychiatry Institute and Dura Medical, we have not entered definitive agreements, and we cannot assure you that the transactions will be consummated or, if consummated, that they will be consummated on the terms set forth in such letters of intent or that they will be accretive to stockholder value.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">As previously reported by the Company, we entered into non-binding letters of intent with each of Kadima Neuropsychiatry Institute and Dura Medical pursuant to which we agreed to explore an acquisition of each of the clinics. We are also negotiating a letter of intent with a strategic investor (the &#8220;LOI&#8217;s&#8221;), to partially fund our planned acquisitions of Kadima Neuropsychiatry Institute and Dura Medical, the first step in creating our planned international network of interventional psychiatry clinics.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">We currently do not have binding commitments to fully finance the proposed acquisitions, and the LOI&#8217;s do not include many of the material terms to any potential transaction with each individual party, and there is no guarantee that we will agree to terms or definitive agreements with such parties in order to affect the proposed transactions. Further, even if we are able to agree to terms with each of the counterparties for a transaction, no assurances can be given that the terms will be favorable to our stockholders, that the transaction will be completed in the time frame or in the manner currently anticipated, that we will recognize the anticipated benefits of the transactions, or that we will be able to obtain adequate financing to fund the acquisitions.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>We may engage in future acquisitions or strategic transactions, which may require us to seek additional financing or financial commitments, increase our expenses and/or present significant distractions to our management.</i></b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">We will need to acquire additional financing to fund our potential obligations under the LOI&#8217;s, or to fund other potential acquisitions or strategic transactions (particularly, if the acquired entity is not cash flow positive or does not have significant cash on hand). Obtaining financing through the issuance or sale of additional equity and/or debt securities, if possible, may not be at favorable terms and may result in additional dilution to our current stockholders. Additionally, any such transaction may require us to incur non-recurring or other charges, may increase our near and long-term expenses and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, an acquisition or strategic transaction may entail numerous operational and financial risks, including the risks outlined above and additionally:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">exposure to unknown liabilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products or technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">higher than expected acquisition and integration costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">write-downs of assets or goodwill or impairment charges;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">increased amortization expenses;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inability to retain key employees of any acquired businesses.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>We may not be able to identify, audit, negotiate, finance or close future acquisitions</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">A significant component of our growth strategy for HOPE focuses on acquiring majority equity ownership interests in interventional psychiatry clinics. However, we may not be able to identify, audit, or acquire such equity ownership interests on acceptable terms, if at all. No guarantee or assurance whatsoever can be given that discussions/negotiations with any potential acquisition candidates will result in any letter of intent or definitive agreements. If we do enter any letter of intent or definitive agreements, we may need to finance all or a portion of the purchase price for an acquisition by incurring indebtedness or by selling shares of our common or convertible preferred stock. There can be no assurance that we will be able to obtain financing on terms that are favorable, if at all, which will limit our ability to acquire such equity ownership interests in the future. Target companies may not decide to proceed forward with mergers that are the subject of letters of intent. Failure to acquire such equity ownership interests on acceptable terms, if at all, may have a material adverse effect on our ability to increase assets, revenues and net income. The foregoing risks may have a material adverse effect on our Company and the trading price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Developments by competitors may render our products or technologies obsolete or non-competitive.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Alternative technologies and products are being developed to treat depression and some may target suicidal bipolar depression and post-traumatic stress disorder (&#8220;PTSD&#8221;). Many of the organizations competing with us have substantially greater capital resources, larger research and development staffs and facilities, greater experience in drug development and in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. Our competitors may market less expensive or more effective drugs that would compete with our drug candidates or reach market with competing drugs before we are able to reach market with our drug candidates. These organizations also compete with us to attract qualified personnel and partners for acquisitions, joint ventures or other collaborations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Risks Related to Clinical and Regulatory Matters</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to obtain the necessary regulatory approvals, or if such approvals are limited, we will not be allowed to commercialize our drug candidates, and we will not generate product revenues.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Satisfaction of all regulatory requirements for commercialization of a drug candidate typically takes many years, is dependent upon the type, complexity and novelty of the product candidate, and requires the expenditure of substantial resources for research and development. Our research and clinical approaches may not lead to drugs that regulators consider safe for humans and effective for indicated uses we are studying. Regulators may require additional studies, in which case we and any product collaborators would have to expend additional time and resources and would likely delay the date of potentially receiving regulatory approval. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in regulatory policy that occur prior to or during our regulatory review.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Delays in obtaining regulatory approvals would:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">delay commercialization of, and product revenues from, our product candidates; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">diminish the competitive advantages that we may have otherwise enjoyed, which would have an adverse effect on our operating results and financial condition.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Even if we comply with all regulatory requirements, our product candidates may never obtain regulatory approval. If we fail to obtain regulatory approval for any of our product candidates we will have fewer commercial products, if any, and corresponding lower product revenues, if any.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Even if a drug product is approved, the regulators may impose limitations on the use or marketing of such product.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Even if our product candidates receive regulatory approval from regulators, they may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a black boxed warning. Regulators may also require us or our collaborators to commit to perform lengthy Phase IV post-approval clinical efficacy or safety studies, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms that could materially affect the potential market and profitability of the product. Our expending of additional resources on such trials or programs would have an adverse effect on our operating results and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">After approval, certain circumstances may require additional regulatory notification, review, or approval, as well as further testing. These may include some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, or new safety information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>After approval, later discovery of previously unknown problems with a product will have adverse consequences for us.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">fines, Warning Letters or Untitled Letters, holds or termination of post-approval clinical trials or FDA debarment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">delay or refusal of regulators to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">regulatory authority, including the FDA, issued safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">mandated modifications to promotional material or issuance of corrective information;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">product seizure or detention, or refusal to permit the import or export of products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">injunctions or the imposition of civil or criminal penalties, including imprisonment, disgorgement and restitution, as well as consent decrees, corporate integrity agreements, deferred prosecution agreements and exclusion from federal healthcare programs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to design, conduct and complete clinical trials successfully, our drug candidates will not be able to receive regulatory approval.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In order to obtain regulatory approval for any of our drug candidates, we must submit an NDA or request for EUA that demonstrates with substantive evidence that the drug candidate is both safe and effective in humans for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Results from Phase I clinical programs may not support moving a drug candidate to Phase 2 or Phase 2I clinical trials. Phase 2I clinical trials may not demonstrate the safety or efficacy of our drug candidates. Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. Results of later clinical trials may not replicate the results of prior clinical trials and preclinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Even if the results of Phase 2I clinical trials are positive, we may have to commit substantial time and additional resources to conducting further preclinical studies and clinical trials before obtaining FDA approval for any of our drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous requirements. The clinical trial process also consumes a significant amount of time. Furthermore, if participating patients in clinical trials suffer drug-related adverse reactions during the course of such clinical trials, or if we or the FDA believe that participating patients are being exposed to unacceptable health risks, such clinical trials will have to be suspended or terminated. Failure can occur at any stage of the clinical trials, and we could encounter problems that cause abandonment or repetition of clinical trials. The success in clinical trials depends on reaching statistically significant changes in patients&#8217; symptoms based on clinician-rated scales. Due in part to a lack of consensus on standardized processes for assessing clinical outcomes, these scores may or may not be reliable, useful or acceptable to regulatory agencies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We do not know whether any of our planned clinical trials will result in marketable drugs. In addition, completion of clinical trials can be delayed by numerous factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">delays in identifying and agreeing on acceptable terms with prospective clinical trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">slower than expected rates of patient recruitment and enrollment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">unanticipated patient dropout rates; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">increases in time required to complete monitoring of patients during or after participation in a clinical trial.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Any of these delays could significantly impact the timing, approval and commercialization of our drug candidates and could significantly increase our overall costs of drug development.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Even if clinical trials are completed as planned, their results may not support expectations or intended marketing claims. The clinical trials process may fail to demonstrate that our drug candidates are safe and effective for indicated uses. Such failure would cause us to abandon a drug candidate and could delay development of other drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We cannot predict whether regulatory agencies will determine that the data from our clinical trials of our product candidates supports marketing approval.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The FDA&#8217;s and other regulatory agencies&#8217; decision to approve our drug candidates will depend on our ability to demonstrate with substantial clinical evidence through well-controlled clinical trials, that the product candidates are effective, as measured statistically by comparing the overall improvement in actively- treated patients against improvement in the control group (usually a placebo control). However, there is a possibility that our data may fail to show a statistically significant difference from the placebo-control or the active control. Alternatively, there is a possibility that our data may be statistically significant, but that the actual clinical benefit of the product candidates may not be considered to be clinically significant, clinically relevant or clinically meaningful. Consequently, we believe that regulators may consider additional data, such as a &#8220;responder&#8221; analysis, secondary efficacy endpoints and safety when evaluating whether our product candidates can be approved. We cannot predict whether the regulatory agencies will find that our clinical trial results provide compelling &#8220;responder&#8221; or other secondary endpoint data. Even if we believe that the data from our trials will support marketing approval in the U.S. or in Europe, we cannot predict whether the agencies will agree with our analysis and approve our applications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>There is no guarantee that regulatory authorities will grant NDA approval of our current or future product candidates and failure to obtain necessary clearances or approvals for our current and future product candidates would adversely affect our ability to grow our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">We initiated a Phase 2b/3 clinical research program of NRX-101 during the second half of 2017 under an FDA Investigational New Drug (&#8220;IND&#8221;) application that was granted Fast Track designation by the FDA in August 2017 and was granted the Breakthrough Therapy designation by the FDA in November 2018. In April 2018, the FDA granted a Special Protocol Agreement. We successfully completed a Phase 2 clinical trial of NRX-101 in patients with severe bipolar depression and acute suicidal ideation following stabilization with a single dose of ketamine and saw a statistically significant reduction in depression (P=0.04) and suicidal ideation (P=0.02) compared to lurasidone alone over 42 days of treatment. If this statistically-significant advantage is replicated in the current Phase 2I clinical trial, under the terms agreed to with the FDA in our Special Protocol Agreement, we aim to submit a NDA to the FDA on a rolling basis for the regulatory approval and commercialization of NRX-101 in the U.S. in 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We cannot assure investors that the FDA or any other regulator will approve or clear NRX-101 or other product candidates for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for NDA market approval of new products, new intended uses or indications to existing or future products. Failure to receive approval for our new products would have an adverse effect on our ability to expand our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>With respect to clinical trials, discussions and guidance are not binding obligations on the part of regulatory authorities.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Regulatory authorities may revise previous guidance or decide to ignore previous guidance at any time during the course of our clinical activities or after the completion of our clinical trials. Even with successful clinical safety and efficacy data, including such data from a clinical trial conducted pursuant to a special protocol agreement, we may be required to conduct additional, expensive clinical trials to obtain regulatory approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The results of our current or future clinical trials may not support our product candidate claims or may result in the discovery of unexpected adverse side effects.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Even if our clinical trials are completed as planned, we cannot be certain that their results will support our drug candidates&#8217; claims or that the regulatory authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. In particular, our clinical trials performed until now involve a relatively small patient population. Because of the small sample size, their results may not be indicative of future results. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate&#8217;s profile. Accordingly, the clinical trial process may fail to demonstrate that our drug candidates are safe and effective for the proposed indicated uses. If the FDA concludes that the clinical trials for any of our products for which we might seek clearance have failed to demonstrate safety and effectiveness, we would not receive regulatory clearance to market that product in the applicable countries for the indications sought. In addition, such an outcome could cause us to abandon the product candidate and might delay development of others. Any delay or termination of our clinical trials will delay the filing of any product submissions with regulatory authorities and, ultimately, our ability to commercialize our product candidates and generate revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Delays in the commencement or completion of pharmaceutical development, manufacturing or clinical efficacy and safety testing could result in increased costs to us and delay our ability to generate revenues.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We do not know whether our pharmaceutical development, manufacturing or clinical efficacy and safety testing will begin on time or be completed on schedule, if at all. For example, we may encounter delays during the manufacture of pilot scale batches including delays with our contract development or manufacturing organization, sourcing satisfactory quantities of active pharmaceutical ingredient, narcotic import and export permits, sourcing of excipients, contract disputes with our third-party vendors and manufacturers, or failure of the product to meet specification.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The commencement and completion of clinical trials can be disrupted for a variety of reasons, including difficulties in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">finding suitable clinical sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">recruiting and enrolling patients to participate in a clinical trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">obtaining regulatory approval to commence a clinical trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">reaching agreement on acceptable terms with prospective clinical research organizations and trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">manufacturing sufficient quantities of a product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">investigator fraud, including data fabrication by clinical trial personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">diversion of controlled substances by clinical trial personnel; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a clinical trial may also be suspended or terminated by us or by regulatory authorities due to a number of factors, including:</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to conduct the clinical trial in accordance with regulatory requirements or in accordance with our clinical protocols;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inspection of the clinical trial operations or trial site by regulatory authorities resulting in the imposition of a clinical hold;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">unforeseen safety issues; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inadequate patient enrollment or lack of adequate funding to continue the clinical trial.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes, which could impact the cost, timing or successful completion of a clinical trial. If we experience delays in the commencement or completion of our clinical trials, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenues will be delayed. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also lead to the denial of regulatory approval of a product candidate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators; support staff; the number of ongoing clinical trials in the same indication that compete for the same patients; and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products. Pandemic or pandemic-like conditions may limit the ability of patients to participate in studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Regulators may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. They may also require additional data on certain categories of patients, should it emerge during the conduct of our clinical trials that certain categories of patients are likely to be affected in different and/or additional manner than most of the patients. In addition to regulatory authority requirements, our clinical trial requires the approval of the institutional review board (&#8220;IRB&#8221;) at each site selected for participation in our clinical trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Additional delays to the completion of clinical studies may result from modifications being made to the protocol during the clinical trial, if such modifications are warranted and/or required by the occurrences in the given trial.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We may choose to make modifications to a clinical trial protocol during the clinical trial if such modifications are warranted and/or required by the occurrences in the trial. Each of such modifications has to be submitted to a regulatory authority. This could result in the delay or halt of a clinical trial while the modification is evaluated. In addition, depending on the magnitude and nature of the changes made, the regulatory authority could take the position that the data generated by the clinical trial cannot be pooled because the same protocol was not used throughout the trial. This might require the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying clearance or approval of a product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>There can be no assurance that the data generated using modified protocols will be acceptable to regulators.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">There can be no assurance that the data generated using modified protocols will be acceptable to the regulators or that if future modifications during the trial are necessary, any such modifications will be acceptable to regulators. If the regulators believe that prior approval is required for a particular modification, they can delay or halt a clinical trial while they evaluate additional information regarding the change.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If an adverse event occurs during a clinical trial, the regulators or an IRB may delay (clinical hold) or terminate the trial, which could adversely affect our business and prospects.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Serious injury or death resulting from a failure of one of our drug candidates during current or future clinical trials could result in the regulators delaying our clinical trials or denying or delaying clearance or approval of a product. Even though an adverse event may not be the result of the failure of our drug candidate, the regulators or an IRB could delay or halt a clinical trial for an indefinite period of time while an adverse event is reviewed, and likely would do so in the event of multiple such events.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Any delay or termination of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in costs and delays in the filing of any product submissions with the FDA, delay the approval and commercialization of our products or result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays in the completion of clinical trials of our products would adversely affect our business and prospects and could cause us to cease operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Developments by competitors may establish standards of care that affect our ability to conduct our clinical trials as planned.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Changes in standards related to clinical trial design could affect our ability to design and conduct clinical trials as planned. For example, regulatory authorities may not allow us to compare our drug candidates to placebo in a particular clinical indication where approved products are available. In that case, both the cost and the amount of time required to conduct a clinical trial could increase. Our NRX-101 clinical trial is against a strong active ingredient as opposed to a placebo.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Even if our products are approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA regulation or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Any product for which we obtain clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA. In particular, we and our suppliers are required to comply with the FDA&#8217;s Quality System Regulations (&#8220;QSR&#8221;), and International Standards Organization (&#8220;ISO&#8221;), regulations for the manufacture of our products and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain clearance or approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Regulatory bodies, such as the FDA, enforce these regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues could result in, among other things, enforcement actions by the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If any of these actions were to occur it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Even if regulatory clearance or approval of a product is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce the potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that the product promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we or our commercialization partners cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider such training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with adverse event and pharmacovigilance reporting requirements, including the reporting of adverse events which occur in connection with, and whether or not directly related to, our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to recall, replace or refund the cost of any product we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Future government regulation may affect the commercialization of our product candidate.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Any of these events could prevent us from marketing our drugs and our business could suffer. If time and resources devoted are limited or there is a failure to fund the continued development of our drug candidates or there is otherwise a failure to perform as we expect to do, we may not achieve clinical and regulatory milestones and regulatory submissions and related product introductions may be delayed or prevented, and revenues that we would receive from these activities will be less than expected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Conducting clinical trials of our drug candidates or commercial sales of a drug candidate may expose us to expensive product liability claims and we may not be able to maintain product liability insurance on reasonable terms or at all.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The risk of product liability is inherent in the testing of pharmaceutical products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or terminate testing of one or more of our drug candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the commercialization of our drug candidates. We currently carry clinical trial insurance but do not carry product liability insurance. If we successfully commercialize one or more of our drug candidates, we may face product liability claims, regardless of FDA approval for commercial manufacturing and sale. We may not be able to obtain such insurance at a reasonable cost, if at all. Even if our agreements with any current or future corporate collaborators entitle us to indemnification against product liability losses, such indemnification may not be available or adequate should any claim arise.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The use of a controlled substance in our NRX-100 drug candidate subjects us to DEA scrutiny and compliance, which may result in additional expense and clinical delays.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) regulates chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk of substance abuse and Schedule V substances the lowest risk. One of the ingredients in NRX-100 is ketamine, a Schedule III controlled substance with high abuse potential. Consequently, the manufacture, research, shipment, storage, sale and use of this drug candidate is subject to a high degree of oversight and regulation. None of our other drugs currently under development, including NRX-101, include a scheduled chemical compound.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">DEA oversight and regulation can have the following impact on our efforts to develop new drug candidates:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">interference with, or limits on, the supply of the drugs used in clinical trials for our product candidates, and, in the future, the ability to produce and distribute our products in the volume needed to meet commercial demand;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA provides recommendations to DEA as to whether a drug should be scheduled as a controlled substance and the appropriate level of control; if DEA scheduling is required, a drug product may not be marketed until the scheduling process is completed, which could delay the launch of the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">depending on the Schedule, drug products may be subject to registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA, which are directly applicable to product applicants, contract manufacturers, distributors, prescribers and dispensers of controlled substances; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging in order to prevent loss and diversion into illicit channels of commerce, which limits our ability to increase the availability of any controlled substances needed for clinical trials or commercial manufacturing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. Similarly, separate registrations are also required for separate facilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>There are substantial penalties for failing to comply with DEA regulations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The DEA typically inspects a facility to review its security measures prior to issuing a registration and on a periodic basis. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. However, records must be maintained for the handling of all controlled substances, and periodic reports may be required to be made to the DEA for the distribution of certain controlled substances. Reports must also be made for thefts or significant losses of any controlled substance. To enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in administrative, civil or criminal enforcement. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those registrations. In some circumstances, violations could result in criminal proceedings or consent decrees. Individual states also independently regulate controlled substances.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>There are limitations on the availability of controlled substances used in NRX-100 that may limit the availability of the active ingredients for this drug product.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The DEA limits the availability and production of all scheduled substances, including ketamine, through a quota system. The DEA requires substantial evidence and documentation of expected legitimate medical and scientific needs before assigning quotas to manufacturers. In future years, we may need greater amounts of controlled substances to sustain our Phase 2b/3 development program for NRX-101 after stabilization with NRX-100, and we will need significantly greater amounts to implement our commercialization plans if the FDA approves our proposed formulations. Any delay or refusal by the DEA in establishing the procurement quota or a reduction in our quota for scheduled controlled substances or a failure to increase it over time as we anticipate could delay or stop the clinical development or commercial sale of some of our products or product candidates. This could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be able to demonstrate the reduced risk we believe is applicable.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Schedule III drugs have lower abuse potential than Schedule I and II drugs. However, despite the foregoing reduced risk of abuse from Schedule III drugs, when compared to Schedule II drugs, there is no assurance that such reduced risk can be demonstrated in well controlled non-clinical and/or clinical studies in models of physical dependence, psychic dependence, addiction or precipitated withdrawal, or in studies of addiction or abuse liability in addicts, ex-addicts or recreational drug users. In the event that a reduced risk of abuse from Schedule III drugs, when compared to Schedule II drugs, is demonstrated in well controlled non- clinical and/or clinical studies, there is no assurance that the FDA will agree to incorporation of such favorable language in the products prescribing information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The use of controlled substances in our product candidates may generate controversy.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Products containing controlled substances may generate public controversy. Opponents of these products may seek restrictions on marketing and withdrawal of any regulatory approvals. In addition, these opponents may seek to generate negative publicity and media stories in an effort to persuade the medical community to reject these products. Political pressures and adverse publicity could lead to additional regulatory hurdles, delays in, increased expenses for, and limit or restrict the introduction and marketing of, our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may need to focus our future efforts in new therapeutic areas where we have little or no experience</i></b><i>.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Although our primary strategic interests are in the areas of depression therapies, NRX-101 has potential benefits in other therapeutic areas. If our drug development efforts in bipolar depression fails, or if the competitive landscape or investment climate for antidepressant drug development therapies is less attractive, we may need to change our strategic focus to include development of our product candidates, or of newly acquired product candidates, for therapeutic areas other than depression. We have very limited drug development experience in other therapeutic areas and we may be unsuccessful in making this change to a company with a focus in areas other than depression or a company with a focus in multiple therapeutic areas including depression.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Some of our products for clinical trials may be manufactured outside the U.S.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Currently, clinical trial supplies for NRX-101 are being manufactured in the U.S., and no supplies are sourced from outside the U.S. Switching or adding manufacturing capability outside the U.S. can involve substantial cost and require extensive management time and focus, additional regulatory filings and compliance with import/ export regulations. In addition, there is a natural transition period when a new manufacturing facility commences work. As a result, delays may occur, which can materially impact our ability to meet our desired timelines, thereby increasing our costs and reducing our ability to generate revenue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Modifications to our products may require new NDA approvals</i></b><i>.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Once a particular company product receives FDA approval or clearance, expanded uses or uses in new indications of our products may require additional human clinical trials and new regulatory approvals or clearances, including additional IND and NDA submissions and premarket approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new clearances or approvals for a particular use or indication, we may be required to conduct additional clinical studies, which would require additional expenditures and negatively impact our operating results. If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Conducting clinical trials and obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals could adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Some of our other product candidates will require Risk Evaluation and Mitigation Strategies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The FDA Amendments Act of 2007 implemented safety-related changes to product labeling and requires the adoption of REMS. Some of our product candidates, including the controlled substance-based products and potentially others, will require REMS. The REMS may include requirements for special labeling or medication guides for patients, special communication plans to health care professionals and restrictions on distribution and use.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We cannot predict the specific REMS to be required as part of the FDA&#8217;s approval of any of our products. Depending on the extent of the REMS requirements, our costs to commercialize our products may increase significantly. Furthermore, controlled substances risks that are not adequately addressed through proposed REMS for our product candidates may also prevent or delay their approval for commercialization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are reliant on third party manufacturers to produce controlled substances that conform to our specifications and the FDA</i></b>&#8217;<b><i>s strict regulatory requirements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The facilities of any of our future manufacturers of controlled substances must be approved by the FDA after we submit our NDA and before approval. We are dependent on the continued adherence of third-party manufacturers to cGMP manufacturing. If our manufacturers cannot successfully produce material that conforms to our specifications and the FDA&#8217;s strict regulatory requirements, they will not be able to secure FDA approval for their manufacturing facilities. If the FDA does not approve these facilities for the commercial manufacture, we will need to find alternative suppliers, which would result in significant delays in obtaining FDA approvals. These challenges may have a material adverse impact on our business, results of operations, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations will involve the use of hazardous materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business relies on certain licensing rights that can be terminated in certain circumstances.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Our ability to continue to develop our product candidates is dependent on the use of certain intellectual property that is licensed to us, or in the process of being licensed to us, by third parties. These licenses are granted, or being granted, pursuant to agreements setting forth certain terms and condition for maintaining such licenses. In the event that the terms and conditions are not met, the licenses are at risk of being revoked and the granting process may be terminated. The primary license agreements include the Development and License Agreement, as amended, between Glytech LLC (&#8220;Glytech&#8221;) and NeuroRx (the &#8220;Glytech DLA&#8221;) and the Exclusive License Agreement, dated as of April 16, 2019, by and between NeuroRx and Sarah Herzog Memorial Hospital Ezrat Nashim.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may require additional licensing rights in the future, which may not be attainable.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our ability to fully develop the full commercial potential of our product candidates may require us to acquire additional licensing rights from third parties in the future. There are no assurances that such rights will be available in the market when required, or that an agreement could be reached to license such rights from a third party on terms acceptable to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not succeed at in-licensing drug candidates or technologies to expand our product pipeline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We may not be able to successfully in-license (<i>i.e.</i>, licensing of patent technology or know-how developed by a third party in lieu of developing the technology ourselves) drug candidates or technologies to expand our product pipeline. The number of such candidates and technologies is limited. Competition among large pharmaceutical companies and biopharmaceutical companies for promising drug candidates and technologies is intense because such companies generally desire to expand their product pipelines through in- licensing. If we are unable to carry out such in-licensing and expand our product pipeline, our potential future revenues may suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business depends upon securing and protecting critical intellectual property.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Our commercial success will depend in part on our obtaining and maintaining patent, trade secret, copyright and trademark protection of our technologies in the U.S. and other jurisdictions as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable intellectual property protection, such as patents or trade secrets, cover them. In particular, we place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes. Furthermore, the degree of future protection of our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. Moreover, the degree of future protection of our proprietary rights is uncertain for products that are currently in the early stages of development because we cannot predict which of these products will ultimately reach the commercial market or whether the commercial versions of these products will incorporate proprietary technologies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our patent position is highly uncertain and involves complex legal and factual questions.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Our patent position is highly uncertain and involves complex legal and factual questions. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example, we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">As a result, the validity of our owned and licensed patents may be challenged and we may not be able to obtain and enforce patents and to maintain trade secret protection for the full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We or our licensors have applied for and will continue to apply for patents for certain products. Such applications may not result in the issuance of any patents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because of such patents, any preferred position held by us would be lost. If we are unable to secure or to continue to maintain a preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our patents would adversely affect our business and operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Patents issued or licensed to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further, such litigation can go on for years and the time demands could interfere with our normal operations and may absorb significant management time. There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Unpatented trade secrets, improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of confidentiality agreements with our corporate partners, collaborators, employees and consultants and other appropriate means, these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access to, the same or similar information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid, is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. These types of mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Conversely, we may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings), or we may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the Canadian Intellectual Property Office (&#8220;CIPO&#8221;) the European Patent Office (&#8220;EPO&#8221;) or another foreign patent office. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, CIPO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. Any of the foregoing could have a material adverse effect on our business financial condition, results of operations and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We currently have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. For example, patents covering therapeutic methods of treating humans are not available in many foreign countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we do not have or have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the U.S. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal and political systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could be impossible or impractical due to sanctions or trade disputes between countries, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the development or sale of our products, and/or pay damages.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our manufacturing processes and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our ability to protect and enforce our patents does not guarantee that we will secure the right to commercialize our patents.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">A patent is a limited exclusionary right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention. This exclusionary right is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using his invention. While a patent gives the holder this right to exclude others, it is not an authorization to commercialize the invention, where other permissions may be required for permissible commercialization to occur. For example, a drug cannot be marketed without the appropriate authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented itself, may not be able to be successfully commercialized if it infringes the valid patent rights of another party.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our competitors.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We rely on trade secrets that we seek to protect through confidentiality agreements with our employees and other parties. If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies against our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If we are unable to obtain the statutory patent extension related to the review time in the U.S., we may need to rely on the 3-year Hatch-Waxman Act marketing exclusivity, the six-month pediatric exclusivity, any approved Orphan Drug exclusivities, potential future formulation patents and up to ten years of data exclusivity in Europe. See &#8220;<i>Risks Related to Clinical and Regulatory Matters </i>&#8212;<i> We may not be able to obtain Hatch-Waxman Act marketing exclusivity or equivalent regulatory data exclusivity protection in other jurisdictions for our products</i>.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not receive royalty or milestone revenue relating to our product candidates under our collaboration and future license agreements for several years, or at all</i></b><i>.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We expect that our future collaboration agreements and future license agreements relating to our product candidates will provide for payments on achievement of development or commercialization milestones and for royalties on product sales. However, because none of our drug candidates has been approved for commercial sale, many of our drug candidates are at early stages of development and drug development entails a high risk of failure, we may never realize much of the milestone revenue provided for in our future collaboration and future license agreements and we do not expect to receive any royalty revenue for several years, if at all. Similarly, drugs we select to commercialize ourselves, or partner for later stage co-development and commercialization, may not generate revenue for several years, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Reliance on Third Parties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We do not have direct control of third parties performing preclinical and clinical trials.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We may depend on independent investigators and collaborators, such as universities and medical institutions, to conduct our preclinical and clinical trials under agreements with us. These investigators and collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such activities ourselves. If these investigators or collaborators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, the approval of our regulatory submissions and our introductions of new drugs will be delayed or prevented.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our potential collaborators may also have relationships with other commercial entities, some of which may compete with us. If outside collaborators assist our competitors to our detriment, the approval of our regulatory submissions will be delayed and the sales from our products, if any are commercialized, will be less than expected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We do not have the ability to independently conduct all the pre-clinical and clinical trials for our products and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have no manufacturing capabilities and depend on other parties for our manufacturing operations. If these manufacturers fail to meet our requirements and strict regulatory requirements, our product development and commercialization efforts may be materially harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We currently depend on contract manufacturers. We plan to enter into long-term commercial supply agreements for our product candidates. If any manufacturer is unable to produce required quantities on a timely basis or at all, our operations would be delayed and our business harmed. Our reliance on contract manufacturers exposes us to additional risks, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure of our future manufacturers to comply with strictly-enforced regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to manufacture to our specifications, or to deliver sufficient quantities in a timely manner;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility that we may terminate a contract manufacturer and need to engage a replacement;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility that our future manufacturers may not be able to manufacture our product candidates and products without infringing the intellectual property rights of others;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility that our future manufacturers may not have adequate intellectual property rights to provide for exclusivity and prevent competition; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">insufficiency of intellectual property rights to any improvements in the manufacturing processes or new manufacturing processes for our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Any of these factors could result in significant delay or suspension of our clinical trials, regulatory submissions, receipt of required approvals or commercialization of our products and harm our business. If we are not able to secure favorable arrangements with such third parties, our business and financial condition could be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We must enter into agreements with, and depend upon, one or more partners to assist us in commercializing our product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our ability to commercialize depends upon our continued ability to purchase raw materials from suppliers, our ability to arrange manufacture at contract manufacturers, our ability to deploy commercial sales force via third party partnerships, and our ability to manage shipping and logistics. Any collaboration agreement we enter into may contain unfavorable terms, for example, with respect to product candidates covered, control over decisions and responsibilities, termination rights, payment, and other significant terms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Our ability to receive any significant revenue from our product candidates covered by the collaboration agreement will be dependent on the efforts of our collaboration partner and may result in lower levels of income to us than if we marketed our product candidates entirely on our own. The collaboration partner may not fulfill its obligations or commercialize our product candidates as quickly as we would like. Even if the collaboration partner performs well, there is no assurance that our proposed products will achieve acceptance by patients, health care providers and insurance companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We could also become involved in disputes with our partner, which could lead to delays in or termination of our commercialization programs and time-consuming and expensive litigation or arbitration. If a collaboration partner terminates or breaches its agreement with us, or otherwise fails to complete its obligations in a timely manner, the chances of successfully developing or commercializing our product candidates would be materially and adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Additionally, depending upon the collaboration partner that we choose, other companies that might otherwise be interested in developing products with us could be less inclined to do so because of our relationship with the collaboration partner. If our ability to work with present or future strategic partners or collaborators is adversely affected as a result of our collaboration agreement, our business prospects may be limited, and our financial condition may be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Upon commercialization of our products, we may be dependent on third parties to market, distribute and sell our products. If we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be disappointing.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We have no experience selling, marketing or distributing products and no internal capability to do so. In order to commercialize our products, if any are approved by the FDA, we will either have to develop such capabilities internally or collaborate with third parties who can perform these services for us. We have entered into a partnership and collaboration agreement with Alvogen (as defined below) for the commercialization of NRX-101. If we decide to commercialize NRX-101, notwithstanding these agreements, or any future drugs ourselves, we may not be able to hire the necessary experienced personnel and build sales, marketing and distribution operations which are capable of successfully launching new drugs and generating sufficient product revenues. In addition, establishing such operations will take time and involve significant expense.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">If we decide to enter into new co-promotion or other licensing arrangements with third parties, we may be unable to locate acceptable collaborators because the number of potential collaborators is limited and because of competition from others for similar alliances with potential collaborators. Even if we are able to identify one or more acceptable new collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, any revenues we receive would depend upon our collaborators&#8217; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, business combinations or other factors outside of our control. Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable terms, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Ownership of Our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our issuance of additional shares of common stock or convertible securities could make it difficult for another company to acquire us, may dilute your ownership of us and could adversely affect our stock price</i></b><i>.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">From time to time in the future, we may issue additional shares of our common stock or securities convertible into common stock pursuant to a variety of transactions, including acquisitions. The issuance by us of additional shares of our common stock or securities convertible into our common stock would dilute your ownership of us and the sale of a significant amount of such shares in the public market could adversely affect prevailing market prices of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In the future, we expect to obtain financing or to further increase our capital resources by issuing additional shares of our capital stock or offering debt or other equity securities, including senior or subordinated notes, debt securities convertible into equity, or shares of preferred stock. Issuing additional shares of our capital stock, other equity securities, or securities convertible into equity may dilute the economic and voting rights of our existing stockholders, reduce the market price of our common stock, or both.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred stock, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of our common stock. Our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing or nature of our future offerings. As a result, holders of our common stock bear the risk that our future offerings may reduce the market price of our common stock and dilute their percentage ownership. See the &#8220;Description of Capital Stock&#8221; filed as an exhibit to this annual report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Future sales, or the perception of future sales, of our common stock by us or our existing stockholders in the public market could cause the market price for our common stock to decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The sale of substantial amounts of shares of our common stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In addition, the shares of common stock reserved for future issuance under the NRx 2021 Omnibus Incentive Plan (the &#8220;Incentive Plan&#8221;) are eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements, lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144 of the Exchange Act, as applicable. The original number of shares reserved for future issuance under the Incentive Plan was 380,182. In addition, the Incentive Plan includes an evergreen feature that will allow our Board, in its sole discretion, to reserve additional shares of common stock for future issuance under the Incentive Plan each calendar year, beginning January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (A) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (B) a smaller number of shares determined by the Board.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Accordingly, our stockholders and the holders of insider shares may sell large amounts of common stock or warrants in the open market or in privately negotiated transactions when permitted, which could have the effect of increasing the volatility in the trading price of the common stock or the warrants or putting significant downward pressure on the price of the common stock or the warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Further, sales of common stock or warrants upon expiration of any applicable lockup periods could encourage short sales of our common stock or warrants by market participants. Generally, short selling means selling a security, contract or commodity not owned by the seller. The seller is committed to eventually purchase the financial instrument previously sold. Short sales are used to capitalize on an expected decline in the security&#8217;s price. Short sales of our common stock or warrants could have a tendency to depress the price of our common stock or warrants, respectively, which could increase the potential for short sales.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">We cannot predict the size of future issuances of our common stock or warrants or the effect, if any, that future issuances and sales of shares of our common stock or warrants will have on the market price of our common stock or warrants. Sales of substantial amounts of common stock, or the perception that such sales could occur, may adversely affect prevailing market prices of our common stock or warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We qualify as a </i></b>&#8220;<b><i>smaller reporting company</i></b>&#8221;<b><i> within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to smaller reporting companies, it could make our securities less attractive to investors and may make it more difficult to compare our performance to the performance of other public companies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">We qualify as a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two (2) years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anti-takeover provisions in our governing documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Charter, the Bylaws and DGCL contain provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by our Board. Among other things, the Charter and/or the Bylaws include the following provisions:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a staggered board, which means that our Board is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for &#160;cause;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">limitations on convening special stockholder meetings, which could make it difficult for our stockholders to adopt desired governance changes;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a prohibition on stockholder action by written consent, which means that our stockholders will only be able to take action at a meeting of stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a forum selection clause, which means certain litigation against us can only be brought in Delaware;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without further action by our stockholders; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">advance notice procedures, which apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. We have elected in the Charter not to be subject to Section 203 of the DGCL, which prevents interested stockholders, such as certain stockholders holding more than 15% of our outstanding common stock, from engaging in certain business combinations unless (i) prior to the time such stockholder became an interested stockholder, the Board approved the transaction that resulted in such stockholder becoming an interested stockholder, (ii) upon consummation of the transaction that resulted in such stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the common stock, or (iii) following board approval, such business combination receives the approval of the holders of at least two-thirds of our outstanding common stock not held by such interested stockholder at an annual or special meeting of stockholders. However, the Charter contains provisions that have the same effect as Section 203 of the DGCL, except they provide that Jonathan Javitt and Daniel Javitt and their respective affiliates will not be deemed to be &#8220;interested stockholders&#8221; regardless of the percentage of common stock owned by them and, accordingly, will not be subject to such restrictions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Any provision of the Charter, the Bylaws or DGCL that has the effect of delaying, preventing or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The Charter and the Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders</i></b>&#8217;<b><i> ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Charter and the Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the (a) Court of Chancery of the State of Delaware (the &#8220;<i>Chancery Court</i>&#8221;) (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action, suit or proceeding brought on our behalf; (ii) any action, suit or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or stockholders to us or to our stockholders; (iii) any action, suit or proceeding asserting a claim arising pursuant to the DGCL, the Charter or the Bylaws; or (iv) any action, suit or proceeding asserting a claim governed by the internal affairs doctrine; and (b) subject to the foregoing, the federal district courts of the U.S. shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, such forum selection provisions shall not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts of the U.S. have exclusive jurisdiction. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Additionally, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As noted above, the Charter and the Bylaws will provide that the federal district courts of the U.S. shall have jurisdiction over any action arising under the Securities Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Accordingly, there is uncertainty as to whether a court would enforce such provision. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Certain of our stockholders have effective control of NRx, and their interests may conflict with NRx</i></b>&#8217;<b><i>s or yours in the future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">Jonathan Javitt and Daniel Javitt beneficially own approximately 9.0% and 5.8% of the outstanding shares of common stock, respectively. For so long as Jonathan Javitt and Daniel Javitt continue to own a significant percentage of common stock, Jonathan Javitt and Daniel Javitt will still be able to significantly influence the composition of our Board and the approval of actions requiring stockholder approval. Accordingly, for such period of time, Jonathan Javitt and Daniel Javitt will have significant influence with respect to our management, business plans and policies. In particular, for so long as Jonathan Javitt and Daniel Javitt continue to own a significant percentage of common stock, Jonathan Javitt and Daniel Javitt will be able to influence the composition of our Board and could preclude any unsolicited acquisition of NRx. The concentration of ownership could deprive you of an opportunity to receive a premium for your shares of common stock as part of a sale of NRx and ultimately might affect the market price of common stock. So long as Jonathan Javitt and Daniel Javitt continue to own a significant amount of our combined voting power, even if such amount is less than 50%, Jonathan Javitt and Daniel Javitt will continue to be able to strongly influence or effectively control our decisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Notwithstanding Jonathan Javitt&#8217;s and Daniel Javitt&#8217;s substantial influence over NRx, we may from time to time enter into transactions with Jonathan Javitt and Daniel Javitt and their respective affiliates, or enter into transactions in which Jonathan Javitt and Daniel Javitt or their respective affiliates otherwise have a direct or indirect material interest. We have adopted a formal written policy for the review and approval of transactions with related persons. A description of the policy we adopted with respect to the approval or ratification of transactions in which related persons, such as Jonathan Javitt and Daniel Javitt and their respective affiliates, have a direct or indirect material interest is included in this annual report. For more information, see &#8220;<i>Certain Relationships and Related Party Transactions</i>&#8221; section of this annual report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Charter will not prevent Jonathan Javitt and Daniel Javitt and their respective affiliates from engaging in business activities which compete with us or otherwise conflict with our interests.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Although Jonathan Javitt and Daniel Javitt are precluded from engaging, directly or indirectly, in the same business activities or similar business activities or lines of business in which our Company operates based on Jonathan Javitt&#8217;s prior employment contract and current consulting contract with us and the Glytech DLA, respectively, our Charter provides that none of Jonathan Javitt and Daniel Javitt or their respective affiliates will have any duty to refrain from engaging, directly or indirectly, in the same business activities or similar business activities or lines of business in which NRx operates. Jonathan Javitt and Daniel Javitt also may pursue corporate opportunities that may be complementary to our business and, as a result, those corporate opportunities may not be available to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are no longer a </i></b>&#8220;<b><i>controlled company</i></b>&#8221;<b><i> under the corporate governance rules of Nasdaq. However, we continue to rely on an exception in the listing requirements to allow a non-independent director to sit on the Nominating and Governance Committee.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Previously, Jonathan Javitt and Daniel Javitt controlled the votes of the majority of our common stock. As a result, we were a &#8220;controlled company&#8221; for purposes of the Nasdaq corporate governance rules and were exempt from certain governance requirements otherwise required by Nasdaq, including requirements that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are no longer a </i></b>&#8220;<b><i>controlled company</i></b>&#8221;<b><i> under the corporate governance rules of Nasdaq. Under the Nasdaq listing requirements, a company that ceases to be a </i></b>&#8220;<b><i>controlled company</i></b>&#8221;<b><i> must comply with the independent board committee requirements as they relate to the nominating and corporate governance</i></b><b>. </b>&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">Previously, Jonathan Javitt and Daniel Javitt controlled the votes of the majority of our common stock. As a result, we were a &#8220;controlled company&#8221; for purposes of the Nasdaq corporate governance rules and were exempt from certain governance requirements otherwise required by Nasdaq, including requirements that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">We are no longer a &#8220;controlled company&#8221; under the corporate governance rules of Nasdaq. Under the Nasdaq listing requirements, a company that ceases to be a &#8220;controlled company&#8221; must comply with the independent board committee requirements as they relate to the nominating and corporate governance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The Company is now subject to all the requirements of Nasdaq.</i></b><b> </b><b><i>Our common stock may become the target of a</i></b>&#160;&#8220;<b><i>short squeeze</i></b>&#8221;<b><i>.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">In recent years, the securities of several companies have increasingly experienced significant and extreme volatility in stock price due to short sellers of common stock and buy-and-hold decisions of longer investors, resulting in what is sometimes described as a &#8220;short squeeze.&#8221; Short squeezes have caused extreme volatility in those companies and in the market and have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Sharp rises in a company&#8217;s stock price may force traders in a short position to buy the shares to avoid even greater losses. Many investors who have purchased shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the price per share has declined steadily as interest in those shares have abated. We may be a target of a short squeeze, and investors may lose a significant portion or all of their investment if they purchase our shares at a rate that is significantly disconnected from our underlying value.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>General Risk Factors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our common stock price may be volatile or may decline regardless of our operating performance. You may lose some or all of your investment.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The trading price of our common stock is likely to be volatile. The stock market recently has experienced extreme volatility. This volatility often has been unrelated or disproportionate to the operating performance of particular companies. You may not be able to resell your shares at an attractive price due to a number of factors such as those listed in &#8220;&#8212; <i>Risks Related to Our Business and Industry</i>&#8221; and the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the impact of a resurgence of the COVID-19 pandemic on our financial condition and the results of operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our operating and financial performance and prospects;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our quarterly or annual earnings or those of other companies in our industry compared to market expectations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">conditions that impact demand for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">future announcements concerning our business, our product users&#8217;&#160;businesses or our competitors&#8217;&#160;businesses;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the public&#8217;s reaction to our press releases, other public announcements and filings with the SEC;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the size of our public float;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">coverage by or changes in financial estimates by securities analysts or failure to meet their expectations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">market and industry perception of our success, or lack thereof, in pursuing our growth strategy;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">strategic actions by us or our competitors, such as acquisitions or restructurings;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in laws or regulations which adversely affect our industry or &#160;us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in accounting standards, policies, guidance, interpretations or principles;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in senior management or key personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">issuances, exchanges or sales, or expected issuances, exchanges or sales of our capital stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in our dividend policy;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">adverse resolution of new or pending litigation against us; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 9pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in general market, economic and political conditions in the U.S. and global economies or financial markets, including those resulting from natural disasters, terrorist attacks, acts of war and responses to such events.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance. In addition, price volatility may be greater if the public float and trading volume of our common stock is low. As a result, you may suffer a loss on your investment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Securities litigation could have a substantial cost and divert resources and the attention of executive management from our business regardless of the outcome of such litigation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If securities analysts do not publish research or reports about us, or if they issue unfavorable commentary about us or our industry or downgrade our common stock, the price of our common stock could decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">The trading market for our common stock will depend in part on the research and reports that third-party securities analysts publish about us and the industries in which we operate. We may be unable, or slow, to attract and maintain research coverage and if one or more analysts cease coverage of us, the price and trading volume of our securities would likely be negatively impacted. If any of the analysts that may cover us change their recommendation regarding our securities adversely, or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst that may cover us ceases covering us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price or trading volume of our securities to decline. Moreover, if one or more of the analysts who cover us downgrades our common stock, or if our reporting results do not meet their expectations, the market price of our common stock could decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The obligations associated with being a public company will involve significant expenses and will require significant resources and management attention, which may divert from our business operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">As a public company, we are subject to the reporting requirements of the Exchange Act and the Sarbanes- Oxley Act. The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and financial condition. The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal control over financial reporting. As a result, we will incur significant legal, accounting and other expenses that we did not previously incur. Our entire management team and many of our other employees will need to devote substantial time to compliance and may not effectively or efficiently manage our transition into a public company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In addition, the need to establish the corporate infrastructure demanded of a public company may also divert management&#8217;s attention from implementing our business strategy, which could prevent us from improving our business, results of operations and financial condition. We have made, and will continue to make, changes to our internal control over financial reporting, including IT controls, and procedures for financial reporting and accounting systems to meet our reporting obligations as a public company. However, the measures we take may not be sufficient to satisfy our obligations as a public company. If we do not continue to develop and implement the right processes and tools to manage our changing enterprise and maintain our culture, our ability to compete successfully and achieve our business objectives could be impaired, which could negatively impact our business, financial condition and results of operations. In addition, we cannot predict or estimate the amount of additional costs we may incur to comply with these requirements. We anticipate that these costs will materially increase our general and administrative expenses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">These rules and regulations result in our incurring legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board, our Board committees or as executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>As a public reporting company, we are subject to rules and regulations established from time to time by the SEC regarding our internal control over financial reporting. If we fail to establish and maintain effective internal control over financial reporting and disclosure controls and procedures, we may not be able to accurately report our financial results or report them in a timely manner.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">As a public reporting company, we are subject to the rules and regulations established from time to time by the SEC and Nasdaq. These rules and regulations require, among other things that we establish and periodically evaluate procedures with respect to our internal control over financial reporting. Reporting obligations as a public company are likely to place a considerable strain on our financial and management systems, processes and controls, as well as on our personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:21pt;">In addition, as a public company, we are required to document and test our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act so that our management can certify as to the effectiveness of our internal control over financial reporting. For additional information related to the risks and uncertainties of our compliance with the Sarbanes-Oxley Act, see &#8220;<i>Risk Related to an Early-Stage Company </i>&#8212;<i> Failure to achieve and maintain effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could impair our ability to produce timely and accurate financial statements or comply with applicable regulations and have a material adverse effect on our business.</i>&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to meet the applicable continued listing requirements of the Nasdaq Capital Market, Nasdaq may delist our common stock, in which case the liquidity and market price of our common stock could decline. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our common stock is currently listed on the Nasdaq Capital Market. In order to maintain that listing, we must satisfy certain continued listing requirements. &#160;On August 6, 2024, we received a written notification from the Staff indicating that we were not in compliance with Nasdaq Listing Rule&#160;5550(b)(2) because we had not maintained a minimum market value of listed securities (&#8220;MLVS&#8221;) of $35,000,000 for the previous 33 consecutive business days. We were provided an initial compliance period of 180 calendar days, or until February 3, 2025, to regain compliance with the minimum MVLS requirement. If the Company did not regain compliance by the Compliance Date, Nasdaq was to provide written notice to the Company that its securities are subject to delisting. On January 17, 2025, the Company received a written notice from Nasdaq that the Company had regained compliance with the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There is no guaranty that we will continue to meet the continued listing requirements to be traded on Nasdaq. If our Common Stock is delisted, an active trading market for our common stock may not be sustained and the market price of our common stock could decline. Delisting of our common stock could adversely affect our ability to raise additional capital through the public or private sale of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Market price of our common stock may be volatile, which could subject us to securities class action litigation and result in substantial losses for our stockholders.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus as well as other factors others beyond our control. Furthermore, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations as well as general economic, political and market conditions, such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock. In addition, such fluctuations could subject us to securities class action litigation, which could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could potentially harm our business. As a result of this volatility, our stockholders may not be able to sell their shares of our common stock at or above the price at which they purchased their shares of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We do not intend to pay cash dividends on our common stock for the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, we do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our Board and will depend on, among other things, our business prospects, results of operations, financial condition, cash requirements and availability, legal requirements, certain restrictions related to our indebtedness, industry trends and other factors that our Board may deem relevant. Any such decision will also be subject to compliance with contractual restrictions and covenants in the agreements governing our current and future indebtedness. In addition, we may incur additional indebtedness, the terms of which may further restrict or prevent us from paying dividends on our common stock. As a result, you may have to sell some or all of your common stock after price appreciation in order to generate cash flow from your investment, which you may not be able to do. Our inability or decision not to pay dividends, particularly when others in our industry have elected to do so, could also adversely affect the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item1b" title="item1b" href="#"></a>Item 1B. Unresolved Staff Comments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="c2867418" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1c" title="item1c" href="#"></a>Item <em style="font: inherit;">1C.</em> Cybersecurity </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="c125342691">The Company maintains a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The underlying processes and controls of NRx&#8217;s cyber risk management program incorporate recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework (&#8220;CSF&#8221;). NRx has an annual assessment performed by a third-party specialist of the Company&#8217;s cyber risk management program against the NIST CSF. The annual risk assessment identifies, quantifies, and categorizes material cyber risks. In addition, the Company, in conjunction with the third-party cyber risk management specialists develop a risk mitigation plan to address such risks and, where necessary, remediate potential vulnerabilities identified through the annual assessment process.</ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In addition, NRx maintains policies over areas such as access and account management to help govern the processes put in place by management designed to protect NRx&#8217;s IT assets, data, and services from threats and vulnerabilities. NRx employs additional key practices within the cybersecurity risk management program including, but <em style="font: inherit;">not</em> limited to maintenance of an IT assets inventory, identity access management controls including restricted access of privileged accounts, and critical data backups to reduce cybersecurity risk. &#160; &#160; &#160; &#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Cybersecurity partners to the Company, including consultants, are a key part of NRx&#8217;s cybersecurity risk management strategy and infrastructure. The cybersecurity partners provide services including, but <em style="font: inherit;">not</em> limited to cybersecurity strategy, cyber risk advisory, assessment, and remediation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="c125342693">NRx&#8217;s management team, in conjunction with cybersecurity service providers are responsible for oversight and administration of NRx&#8217;s cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. The Company&#8217;s management team has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes via engagement of strategic third-party partners. The Company also relies on threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by NRx for strategic cyber risk management, advisory and decision making.</ix:nonNumeric></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c125342695">The Audit Committee of the Board of Directors oversees NRx&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx&#8217;s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.</ix:nonNumeric></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="c125342701">NRx faces risks from cybersecurity threats that could have a material adverse effect on its business, financial condition, results of operations, cash flows or reputation. NRx acknowledges that the risk of cyber incident is prevalent in the current threat landscape and that a future cyber incident may occur in the normal course of its business. However, prior cybersecurity incidents have not had a material adverse effect on NRx&#8217;s business, financial condition, results of operations, or cash flows. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, investors, and additional stakeholders, which could subject the Company to additional liability and reputational harm. In response to such risks, the Company has implemented initiatives such as a cybersecurity risk assessment process and development of an incident response plan. See Item 1A. "Risk Factors" for more information on cybersecurity risks.</ix:nonNumeric>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item2" title="item2" href="#"></a>Item 2. Properties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Our principal executive office is located at 1201 Orange Street, Suite 600 Wilmington, DE 19801. We believe that our current facilities are suitable and adequate to meet our current needs. We believe that suitable additional space or substitute space will be available in the future to accommodate our operations as needed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item3" title="item3" href="#"></a>Item 3. Legal Proceedings.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On November 12, 2022, the Company entered into a Settlement Agreement and Asset Purchase Agreement (&#8220;APA&#8221;) with Relief Therapeutics Holding AG and Relief Therapeutics International (the &#8220;Relief Parties&#8221;) to settle the outstanding lawsuit with respect to the Binding Collaboration Agreement dated September 18, 2020 between the Company and the Relief Parties (the &#8220;Collaboration Agreement&#8221;). The closing under the APA occurred on December 17, 2022 and the parties dismissed their respective claims against each other.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On August 12, 2022, the Company received a demand for arbitration (the &#8220;Demand&#8221;) from GEM Yield Bahamas Limited and GEM Global Yield LLC SCS (collectively, &#8220;GEM&#8221;). &#160;The Demand claims that the Company&#8217;s subsidiary, NeuroRx, Inc. (&#8220;NeuroRx"), failed to satisfy its obligation to pay GEM a commitment fee in the amount of HK$ 15,000,000 (approximately US$1,914,087 at current exchange rates) pursuant to a Share Subscription Facility Agreement, executed on October 18, 2019, by and among NeuroRx and GEM (the &#8220;Agreement&#8221;). &#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On July 17, 2023, the Company and GEM entered into a settlement and release agreement (the &#8220;Settlement Agreement&#8221;) pursuant to which the parties agreed to dismiss the arbitration proceeding with prejudice. Pursuant to the Settlement Agreement on August 31, 2023, the Company issued 67,568 shares of common stock to GEM in full satisfaction of the Settlement Agreement for the approximately $0.3 million which was previously accrued and expensed as &#8220;Settlement expense.&#8221; The shares are registered under a prospectus supplement to the Company&#8217;s registration statement on Form S-3 and are subject to a restriction that they cannot be sold or traded for a period of six months from the effective date of the Settlement Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company was a defendant in litigation filed by Streeterville in the Third Judicial District Court of Salt Lake County, Utah. The Complaint sought, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing common stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but no less than $6,537,027, or the amounts currently outstanding under the Streeterville Note. On July 29, 2024, in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin the planned Spin-Off of 49% of shares in HOPE to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#8217;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a national exchange. The arbitrator also denied Streeterville&#8217;s petition to enjoin the Company from selling additional shares of common stock to finance ongoing operations.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On August 12, 2024, the Company and Streeterville entered into a Settlement and Release of Claims (the &#8220;Settlement Agreement&#8221;), whereby the Company and Streeterville agreed to settle all disputes between the parties and release the Company from all obligations arising from the Notes at certain Securities Purchase Agreement, dated November 4, 2022 (&#8220;Streeterville Notes&#8221;), between the Company and Streeterville, and that certain Convertible Promissory Note, dated November 4, 2022, issued to Streeterville by the Company, in exchange for a payment of $2.5 million upon the initial closing of the sale of the Anson Notes, and within 60 days thereafter, a second payment of $3.05 million. The Company made the $2.5 million payment upon the Anson Notes closing on&#160;August 15, 2024. The Company made the $3.05 million payment in October 2024 in satisfaction of the Streeterville Note.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In addition to the matters described above, we may become involved in various legal actions incidental to our business. As of the date of this annual report, we are not involved in any other legal proceedings that we believe could have a material adverse effect on our financial position or results of operations, but regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, and diversion of management resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item4" title="item4" href="#"></a>Item 4. Mine Safety Disclosures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 72
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="part2" title="part2" href="#"></a>PART II</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item5" title="item5" href="#"></a>Item 5. Market for Registrant</b>&#8217;<b>s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Principal Market or Markets</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Our shares of common stock are currently quoted on the Nasdaq Capital Market under the symbol &#8220;NRXP.&#8221; Our common stock commenced trading on the Nasdaq Capital Market on May 25, 2021. Prior to such date, our shares of common stock were traded on the Nasdaq Capital Market under the symbol &#8220;BRPA.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Approximate Number of Holders of Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">As of December 31, 2024, there were approximately 59&#160;record holders of the Company&#8217;s common stock. The actual number of stockholders is greater than the number of record holders because stockholders who are beneficial owners but whose shares are held in street name by brokers or other nominees are not counted as separate record holders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Dividends</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">Holders of our common stock are entitled to receive such dividends as may be declared by our Board.&#160;No cash dividends have been declared or paid with respect to our common stock and no cash dividends are anticipated to be paid in the foreseeable future.&#160;Any future decisions as to the payment of dividends will be at the discretion of our Board, subject to applicable law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Sales by the Company of Unregistered Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">We entered into a Confidential Settlement Agreement and Release, dated July 17, 2023 (the &#8220;Settlement Agreement&#8221;), with NeuroRx, Inc., GEM Yield Bahamas Limited and GEM Global Yield LLC SCS, pursuant to which we agreed to issue an aggregate of 67,568 shares (the &#8220;Settlement Shares&#8221;) of common stock to GEM Global Yield LLC SCS. On August&#160;31, 2023, we issued the Settlement Shares to GEM in a private placement under the terms of the Settlement Agreement and, accordingly, we did not receive any proceeds in connection with the issuance of the Settlement Shares. The Settlement Shares were issued pursuant to an exemption to registration requirement of the Securities Act in reliance on Section 4(a)(2) of the Securities Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">On August&#8239;28, 2023, the Company entered into a securities purchase agreement (the &#8220;Preferred Stock Securities Purchase Agreement&#8221;) with certain purchasers (the &#8220;August Investors&#8221;), pursuant to which the Company issued 3,000,000 shares of the Company&#8217;s Series&#8239;A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#8239;A Preferred Stock&#8221;), and one (1)&#8239;investor warrant (each an &#8220;August Investor Warrant&#8221;) for every share of Series&#8239;A Preferred Stock issued. The shares of Series A Preferred Stock and the August Investor Warrants were offered pursuant to a private placement under Section 4(a)(2) of the Securities Act. Each August Investor Warrant entitles the holder to purchase one (1)&#8239;share of common stock at a purchase price of&#8239;$4.00&#8239;per share. The aggregate purchase price for each share of Series&#8239;A Preferred Stock and associated August Investor Warrant was $4.00. The August Investor Warrants are exercisable starting on the six-month anniversary of the date of issuance and will have a term of five years from the date of issuance. The August Investor Warrants may also be exercised during the initial six-month period after issuance, at the option of the August Investors, if the closing share price of the common stock equals or exceeds $1.20&#8239;per share on any trading day. The aggregate net cash proceeds to the Company from the August Offering were approximately $1.0 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">On February 7, 2024, we entered into the First Amendment (the &#8220;Amendment&#8221;) to the License Agreement (as defined below) with Alvogen, effective as of the same date. Pursuant to the terms of the Amendment, we issued to Alvogen 419,598 warrants to purchase the Company&#8217;s common stock, at a strike price of $4.00 per share with three (3) year term (&#8220;Alvogen Warrants&#8221;). The Alvogen Warrants were issues pursuant to an exemption to registration requirement of the Securities Act in reliance on Section 4(a)(2) of the Securities Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 20pt;">On February 29, 2024, we entered into a securities purchase agreement with an investor providing for the issuance and sale of 270,000 shares of common stock and warrants to purchase up to 270,000 shares of common stock (the &#8220;February Warrants&#8221;) at a price of $3.80 per share of common stock and accompanying warrant, which represents a 26.7% premium to the offering price in February 2024 Public Offering. The common stock and the February Warrants were offered pursuant to a private placement (the &#8220;February 2024 Private Placement&#8221;) under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The February Warrants will have an exercise price of $3.80 per share, are initially exercisable beginning six months following the date of issuance, and will expire 5 years from the date of issuance. The aggregate net cash proceeds to the Company from the February 2024 Private Placement were approximately $1.0 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">On August 12, 2024, the Company executed a Securities Purchase Agreement (the &#8220;August SPA&#8221;) and related agreements, under which the Company agreed to sell and issue, and certain purchasers agreed to purchase, an aggregate of $16.3 million&#160;of securities. The consideration payable by the purchasers under the August SPA will be comprised of three equal closings of $5.435 million, each subject to certain closing conditions. The securities to be issued and sold by the Company include up to $16.3 million of senior secured convertible notes (the &#8220;Notes&#8221;) and warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;). On each of August, 14, 2024, October 10, 2024, and January 28, 2025, the consummated the first tranche, second tranche, and third tranche, respectively, under the August SPA, with gross proceeds to the Company of $16.3 million. The Notes and Warrants were offered pursuant to a private placement under Section 4(a)(2) of the Securities Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:20pt;">The Notes bear interest at the rate of 6% per annum and mature in 15 months following their date of issuance. The Notes may be settled in cash or in shares of the Company&#8217;s common stock, at the sole discretion of the holder, at the applicable conversion price. The Notes&#160;may not be prepaid by the Company however, the holders of the Notes may elect to convert the Notes, in whole or in part, into shares of the Company&#8217;s common stock at any time after the original issuance date. The conversion price: (A) for the Notes issued in the first tranche will equal the lower of (i) $2.4168, or (ii) a price equal to 92% of the lowest volume-weighted average price during the seven-trading day period immediately preceding the applicable conversion date (the &#8220;Alternative Conversion Price&#8221;); (B) for the Notes issued in the second tranche will equal the lower of (i) $1.766, or (ii) the Alternative Conversion Price; and (C) for the Notes issued in the third tranche will equal the lower of (i) $3.78, or (ii) the Alternative Conversion Price. The Notes include certain redemption, protection features and default interest and penalties. The Warrants have a term of 5 years, an exercise price of $2.4168 per share for the Warrants issued in the first tranche, $1.766 per share for the Warrants issued in the second tranche, and $3.78 per share for the Warrants issued in the third tranche, each subject to adjustment as more specifically set forth in the Warrants, and are exercisable immediately upon issuance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Repurchases of Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Proceeds</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The Company intends to use the net proceeds from the offerings detailed above for working capital and general corporate purposes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item6" title="item6" href="#"></a>Item 6. [Reserved]</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 74
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item7" title="item7" href="#"></a>Item 7. Management</b>&#8217;<b>s Discussion and Analysis of Financial Condition and Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>You should read the following discussion and analysis of NRx Pharmaceuticals</i>&#8217;<i> financial condition and plan of operations together with NRx Pharmaceuticals' consolidated financial statements and the related notes appearing elsewhere herein. In addition to historical information, this discussion and analysis contains forward looking statements that involve risks, uncertainties and assumptions. NRx Pharmaceuticals</i>&#8217;<i> actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section entitled </i>&#8220;<i>Risk Factors</i>&#8221;<i> included elsewhere herein.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;<i>NRX</i>&#8221; or the &#8220;<i>Company</i>&#8221;) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiaries, NeuroRx, Inc. (&#8220;<i>NeuroRx</i>&#8221;), and HOPE Therapeutics, Inc. (&#8220;<i>HOPE</i>&#8221;), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#8220;<i>PTSD</i>&#8221;) and now schizophrenia. All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate (&#8220;<i>NMDA</i>&#8221;) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. NeuroRx is organized as a traditional research and development ("<i>R&amp;D</i>") company, whereas HOPE is organized as a specialty pharmaceutical company intended to distribute ketamine and other therapeutic options to clinics that serve patients with suicidal depression and PTSD. The Company has two lead drug candidates that are expected to be submitted by year end for Food and Drug Administration ("<i>FDA</i>") approval with anticipated FDA decision dates under the Prescription Drug User Fee Act (&#8220;<i>PDUFA</i>&#8221;) by the end of June&#160;2025: NRX-101, an oral fixed dose combination of D-cycloserine&#160;and lurasidone and NRX-100, a preservative-free formulation of ketamine for intravenous infusion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The 2024 fiscal year marked a period of both expansion and change for NRx. During the year the Company implemented a restructuring of its leadership to address challenges related to capital formation, clinical trial enrollment, and corporate development. These efforts led to measurable achievements in 2024 and positioned the Company for growth and the achievement of our development objectives in 2025. During 2024 and through the date of this Annual Report, the Company has achieved the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Financing</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 20pt;">We consummated a series of financing agreements with an institutional investor for up to $16.3 million in debt capital, for which we closed on $10.87 million in 2024 and subsequently closed $8.5 million in a combination of convertible debt and an above-market common stock and warrant offering in January 2025. We were presented with and are currently negotiating a term sheet with a publicly-traded strategic investor to provide additional capital to support the expansion of HOPE clinics. In addition, management is negotiating with several commercial lenders to provide additional financing to support the acquisition of additional clinics on standard commercial loan terms. Although no assurances can be given, and assuming we&#8217;re able to consummate the proposed financings, management believes that we will have sufficient financing to consummate our previously announced acquisitions, execute our business plan and achieve our projected revenue objectives.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:95.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Drug Development</i></p> </td>
     <td colspan="2" style="vertical-align:middle;width:11.1%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We initiated the filing of a New Drug Application (&#8220;NDA&#8221;) in the fourth quarter of 2024 for Accelerated Approval under Breakthrough and Priority Review of NRX-101 in treatment of bipolar depression in people at risk of akathisia, based on the Phase 2b/3 and STABIL-B data.&#160;Three manufacturing lots are now completed with more than 12 months of room temperature shelf-stability. The anticipated PDUFA date for this application is prior to June 30, 2025.&#160;&#160;Work is ongoing to prepare the module 3 manufacturing section documenting our transition from manufacturing at WuXi Apptec in Shanghai to manufacturing of NRX-101 in the United States.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We accepted a non-binding offer from a commercial pharmaceutical company to license and distribute NRX-100 (preservative-free ketamine) that provides for $325 million in potential milestones plus a sliding scale royalty that ranges from 11% - 16% of sales.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We retained counsel to file a citizen&#8217;s petition with the FDA to remove benzethonium chloride, a known neurotoxic substance from presentations of ketamine intended for intravenous use. Management believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of benzethonium chloride in current generic products.</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: auto;">&#160;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We filed module 3 (manufacturing) of its NDA for NRX-100 (preservative-free sterile ketamine) in a tamper-resistant, diversion resistant packaging presentation. NRX-100 was previously granted Fast Track Designation by FDA in combination with use of NRX-101. Ketamine efficacy data is in hand from four clinical trials. Three manufacturing lots are now completed with filed stability data suitable for shelf life exceeding two years at room temperature. The anticipated PDUFA date for this settlement is prior to December 30, 2025.&#160;&#160;We also anticipate filing an Abbreviated New Drug Application (&#8220;ANDA&#8221;) for the use of preservative-free ketamine in all currently-indicated clinical applications.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">As a next-generation product, we developed a novel, patentable pH neutral formulation for ketamine (designed as HTX-100) that will be suitable for both intravenous and subcutaneous administration. Initial laboratory lots demonstrate shelf stability and ongoing stability is being assessed. Ketamine in its current commercial presentations cannot be administered subcutaneously because of its high acidic (pH 3.5-4.0) properties, an acidity range that is known to cause pain and skin ulcers. We anticipate that this product will begin clinical testing in by 2026.</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: auto;">&#160;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">NRX-101 in the treatment of Complicated Urinary Tract Infection (&#8220;cUTI&#8221;) was granted Qualified Infectious Disease Product (&#8220;<i>QIDP</i>&#8221;), Fast Track, and Priority Review designations. We have now demonstrated that NRX-101 does not damage the microbiome of the gut, in contrast to all other advanced antibiotics and is less likely to cause <i>C. Difficile</i>&#160;infection (a potentially lethal side effect of antibiotic treatment). NRx is reviewing partnership options.</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: auto;">&#160;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We executed a Memorandum of Understanding with Foundation FundaMental for rights to develop a potential disease modifying drug for schizophrenia, autism, and acute mania. If successful, this would represent the first drug to reverse the underlying disease mechanism of these conditions, rather than simply treating symptoms.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:90.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>HOPE Therapeutics</i></p> </td>
     <td colspan="2" style="vertical-align:middle;width:16.2%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We partnered with representatives of ketamine clinic operators to construct a care platform that will include ketamine, operational support, and digital therapeutic extensions. In advance of FDA&#160;approval, HOPE anticipates that it will supply ketamine under 503b pharmacy licensure to meet the national ketamine shortage declared by FDA;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">We signed non-binding letters of intent to acquire three precision psychiatry centers, the closing of which is subject to execution of definitive agreements. We are also currently negotiating the terms and conditions for the acquisition of six other psychiatry centers, which are subject to due diligence review and execution of definitive agreements. Upon closing, the acquisitions will form the foundation for the development of HOPE to achieve our objective of creating a national network offering interventional psychiatry to treat suicidal depression and PTSD;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#9679;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We engaged BTIG, a leading investment bank, to support us in identifying and acquiring additional clinic candidates to join the HOPE network, sufficient to achieve management&#8217;s forecasted revenue targets by year-end 2025.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our potential acquisition targets have contracts with the Veterans Administration for the treatment of depression and, assuming closing of our previously announced acquisitions, we expect to expand to the treatment of PTSD by year-end 2025.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Developments</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In November 2022, the Company issued a Convertible Promissory Note to Streeterville, LLC (&#8220;Streeterville Notes&#8221;) as previously disclosed. In March 2024, Streeterville deemed a proposed dividend of HOPE shares to constitute a basis of default under the Streeterville Notes. Subsequent arbitration found that the proposed HOPE dividend was not a basis for default. In August 2024 the Company signed a settlement agreement with Streeterville to redeem the Streeterville Notes at a discount to the amounts claimed and completed payments of $5.55 million in satisfaction of all claims under the Streeterville Notes in October 2024.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On March 28, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to effect a 1-for-10 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the Company&#8217;s Common Stock, which Reverse Stock Split was effective as of April&#160;1, 2024. All references in this Annual Report to number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Split on a retroactive basis.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Company Overview</b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company has two lead compounds today, NRX-100, a proprietary presentation of ketamine and NRX-101, a patented fixed-dose combination of D-cycloserine and lurasidone. Both products have Fast Track designation from the FDA for the treatment of suicidal bipolar depression. NRX-101 additionally has Breakthrough Therapy Designation and a Biomarker Letter of Support from the FDA for this purpose. To the Company&#8217;s knowledge, NRX-101 is the only oral antidepressant demonstrated to reduce suicidal ideation in a phase 2 trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For mechanistic reasons unrelated to its central nervous system N-methyl-D-aspartate (&#8220;CNS NMDA&#8221;) antagonist properties, NRX-101 interferes with cell wall formation in certain bacteria, rendering it a potent antibiotic and is demonstrated to kill certain treatment-resistant urinary tract bacteria. Accordingly, NRX-101 has been awarded Qualified Infectious Disease Product Designation and Fast Track Designation by the FDA to treat Complicated Urinary Tract Infection and Pyelonephritis. Our strategy is to apply innovative science to known molecules in the pursuit of therapies for high unmet needs, including lethal conditions (NeuroRx) and to distribute ketamine and ancillary therapies to qualified clinics and practitioners who treat patients with suicidal depression (HOPE). The Company has announced plans to spin off HOPE to a freestanding company, to be owned by the Company, current investors in the Company, and future investors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">NeuroRx was founded in 2015 by Professors Jonathan Javitt, MD, MPH and Daniel Javitt, PhD, MD, as a privately-funded R&amp;D company targeting psychiatry drug development and attracted sufficient capital to enter phase 2b/3 research in 2016. The Company was forced to suspend CNS drug development in January 2020, due to the COVID pandemic. However, activities related to development of COVID drugs (as disclosed in prior filings) enabled the Company to continue operations and attract capital to return to CNS development.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The COVID lockdown ended in March 2022 and the Company&#8217;s Board unanimously voted to return NRx&#8217;s focus to CNS drug development and to recruit a new Chief Executive Officer with legal and business skills that would complement the scientific strength of the Company&#8217;s Founder, Chairman, and Chief Scientist. Subsequently, in June 2022, the NIH trial announced futility in its attempt to replicate the survival benefit reported for Aviptadil in patients on ventilators for COVID-19 and subsequently disclosed its failure to fully treat 30% of those randomized to Aviptadil. The trial could not be restarted because it was unrecruitable in the aftermath of the pandemic. In December 2022, the Company agreed to return all Aviptadil assets to Relief in exchange for a commitment by Relief to use commercially-reasonable efforts to develop Aviptadil and to pay NRx more than $30 million in royalties and milestones from its future success, if any.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In December 2023, the Company&#8217;s reorganized Board of Directors re-elected Dr. Javitt as its Chairman. At the same time, the Company announced its plan to form HOPE Therapeutics as a specialty pharmaceutical company to develop a clinical market for ketamine and other treatments for suicidal depression. In November 2024, the Board asked Dr. Javitt to return as interim CEO and appointed him CEO in December 2024.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>2024 Financings&#160;</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>August 2024 SPA</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On August 12, 2024, the Company executed a Securities Purchase Agreement (the &#8220;August SPA&#8221;) and related agreements, under which the Company agreed to sell and issue, and certain purchasers agreed to purchase, an aggregate of $16.3 million&#160;of securities. The consideration payable by the purchasers under the August SPA will be comprised of three equal closings of $5.435 million, each subject to certain closing conditions. The securities to be issued and sold by the Company include up to $16.3 million of senior secured convertible notes (the &#8220;Notes&#8221;) and warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;). The&#160;proceeds arising from the sale of the Notes and the Warrants were&#160;used to settle the Company&#8217;s outstanding amounts owed to Streeterville (as defined below)&#160;and other working capital needs.&#160;The Company has, as of the date of this Annual Report, consummated the first tranche, second tranche, and third tranche under the August SPA, with gross proceeds to the Company of $16.3 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Notes bear interest at the rate of 6% per annum and mature in 15 months following their date of issuance. The Notes may be settled in cash or in shares of the Company&#8217;s common stock, at the sole discretion of the holder, at the applicable conversion price. The Notes&#160;may not be prepaid by the Company however, the holders of the Notes may elect to convert the Notes, in whole or in part, into shares of the Company&#8217;s common stock at any time after the original issuance date. The conversion price: (A) for the Notes issued in the first tranche will equal the lower of (i) $2.4168, or (ii) a price equal to 92% of the lowest volume-weighted average price during the seven-trading day period immediately preceding the applicable conversion date (the &#8220;Alternative Conversion Price&#8221;); (B) for the Notes issued in the second tranche will equal the lower of (i) $1.766, or (ii) the Alternative Conversion Price; and (C) for the Notes issued in the third tranche will equal the lower of (i) $3.78, or (ii) the Alternative Conversion Price. The Notes include certain redemption, protection features and default interest and penalties. The Notes are secured by all assets of the Company, including its intellectual property.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Warrants have a term of 5 years, an exercise price of $2.4168 per share for the Warrants issued in the first tranche, $1.766 per share for the Warrants issued in the second tranche, and $3.78 per share for the Warrants issued in the third tranche.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On January 27, 2025, the Company and the Investors entered into a Consent and Waiver Agreement (the &#8220;CWA&#8221;), relating to certain rights and prohibitions arising under the August SPA and the Notes. In the CWA, each of the Investors provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the August SPA and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and the Investors dated August 14, 2024, until March 31, 2025. As consideration for entering into the CWA, in the event that the VWAP of the common stock is less than the per share purchase price of the common stock sold to the Investors in the Registered Direct Offering on the Trading Day (as defined in the RD Purchase Agreement) immediately prior to the date that the Investors submit their first conversion notice to convert any portion of the Notes issued or to be issued in the Second Closing (as defined in the August SPA) or the Third Closing (as defined in the August SPA), respectively, into shares of common stock, the Company agreed to issue to the Investors: (i) that number of shares of common stock equal to (a) the quotient of (I) aggregate purchase price to be paid for all securities in the Registered Direct Offering, divided by (II) the price per share of common stock after giving effect to the VWAP-Based Adjustment (as defined below), minus (b) the number of shares of common stock issued, or to be issued, to the Investors at or upon the consummation of the Registered Direct Offering (the &#8220;Consideration Shares&#8221;), and (ii) common stock purchase warrants to purchase shares of common stock equal to 100% of the aggregate number of Consideration Shares to be issued, with an exercise price equal to the dollar value of the VWAP-Based Adjustment (the &#8220;Consideration Warrants&#8221;). For purposes of the CWA, the &#8220;VWAP Based-Adjustment&#8221; means that amount, in dollars, equal to the greater of either (a) the VWAP of the common stock on the Trading Day immediately prior to the date that the Investors submit their first conversion notice to convert any portion of the Notes issued and to be issued in the Second Closing or Third Closing into shares of the Company&#8217;s common stock, or (b) 80% of the closing price of the common stock on the Trading Day immediately prior to the closing of the Registered Direct Offering, subject to adjustment as more specifically set forth in the Warrants, and are exercisable immediately upon issuance.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>April 2024 Offering</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On April 18, 2024, the Company entered into an underwriting agreement (the &#8220;April Underwriting Agreement&#8221;) with EF Hutton LLC (the &#8220;Representative&#8221;), as the representative of the several underwriters named therein (the &#8220;April Underwriters&#8221;), relating to an underwritten public offering (the &#8220;April 2024 Public Offering&#8221;) of 607,000 shares (the &#8220;April Shares&#8221;) of&#160;common stock. The public offering price for each share of common stock was $3.30. On April 19, 2024, the offering closed. Aggregated proceeds from the offering were approximately $2.4 million (including proceeds from the exercise of the over-allotment option granted to the Representative, as more fully described below), before deducting underwriting discounts and commission and estimated expenses payable by the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the April Underwriting Agreement and the engagement letter dated April 18, 2024, by and between the Company and Representative, the Company agreed to issue to the Representative in connection with the April Offering, a warrant to purchase up to a number of shares of common stock representing 5.0% of the Shares and any April Option Shares (as defined below) sold, at an initial exercise price of $3.63 per share, subject to certain adjustments (the &#8220;April Underwriter's Warrant&#8221;). On April&#8239;19, 2024, the Company issued to the Representative the April Underwriter's Warrant&#160;to purchase up to 30,350 shares of common stock. The April Underwriter's&#160;Warrants and Over-Allotment Warrants is exercisable nine months following the date of the Underwriting Agreement and terminates on the five-year anniversary of the date of the April Underwriting Agreement.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the April Underwriting Agreement, the Company also granted the Representative a 45-day option to purchase up to an additional 91,050 shares (the &#8220;April Option Shares&#8221;) of the common stock on the same terms as the April Shares sold in the April 2024 Public Offering (the &#8220;April Over-Allotment Option&#8221;). In connection with the April Overallotment Exercise, we issued an additional April Underwriter's Warrant to purchase up to 4,553 shares of common stock. The April Overallotment Exercise was exercised in full and closed.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>At-The-Market Offering Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On April 15, 2024, the Company increased the maximum aggregate offering amount of the shares of common stock issuable under that certain At the Market Offering Agreement, dated August 14, 2023 (the &#8220;<i>Offering Agreement</i>&#8221;), with H.C. Wainwright &amp; Co., and filed a prospectus supplement (the &#8220;<i>Current Prospectus Supplement</i>&#8221;) under the Offering Agreement for an aggregate of $4.9 million (the &#8220;<i>ATM Offering</i>&#8221;). On August 14, 2024, the Company reduced the amount to under the Offering Agreement to $0 and suspended the ATM Offering. Though&#160;December 31, 2024, the Company received&#160;aggregate net cash proceeds to the Company from the ATM Offering of approximately $1.6 million.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>February</i>&#160;<i>2024 Offerings</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On February 27, 2024, we entered into an underwriting agreement (the &#8220;February Underwriting Agreement&#8221;) with the Representative (as defined above), as the representative of the several underwriters named therein (the &#8220;February Underwriters&#8221;), relating to an underwritten public offering (the &#8220;February 2024 Public Offering&#8221;) of 500,000 shares (the &#8220;February Shares&#8221;) of the Company&#8217;s common stock. The public offering price for each share of common stock was $3.00, and the February Underwriters purchased the shares of common stock pursuant to the February Underwriting Agreement at a price for each share of common stock of $2.76. On February 28, 2024, the February 2024 Public offering closed. Aggregate gross proceeds from the February 2024 Public Offering were approximately $1.7 million (including proceeds from the exercise of the over-allotment option granted to the Representative, as more fully described below), before deducting underwriting discounts and commissions and estimated expenses payable by the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the February Underwriting Agreement and the engagement letter, dated as of February 22, 2024, by and between the Company and the Representative, the Company agreed to issue to the Representative in connection with the February 2024 Public Offering, a warrant to purchase up to a number of shares of common stock representing 5.0% of the shares of common stock and any February Option Shares (as defined below) sold, at an initial exercise price of $3.30 per share, subject to certain adjustments (the &#8220;February Underwriter&#8217;s Warrant&#8221;). On February 28, 2024, the Company issued to the Representative the February Underwriter&#8217;s Warrant to purchase up to 25,000 shares of common stock. The February Underwriter&#8217;s Warrant is exercisable six months following the date of the February Underwriting Agreement and terminates on the five-year anniversary of the date of the February Underwriting Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the February Underwriting Agreement, the Company also granted the Representative a 45-day option to purchase up to an additional 75,000 shares (the &#8220;February Option Shares&#8221;) of the common stock on the same terms as the February Shares sold in the February 2024 Public Offering (the &#8220;February Over-Allotment Option&#8221;). On March 5, 2024, the February Underwriters exercised the February Over-Allotment Option to purchase the February Option Shares. In connection with the February Overallotment Exercise, we issued an additional February Underwriter&#8217;s Warrant to purchase up to 3,750 shares of common stock. The February Overallotment Exercise closed on March 6, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On February 29, 2024, we entered into a securities purchase agreement with an investor providing for the issuance and sale of 270,000 shares of common stock and warrants to purchase up to 270,000 shares of common stock (the &#8220;February Warrants&#8221;) at a price of $3.80 per share of common stock and accompanying warrant, which represents a 26.7% premium to the offering price in February 2024 Public Offering. The common stock and the February Warrants were offered pursuant to a private placement (the &#8220;February 2024 Private Placement&#8221;) under Section 4(a)(2) of the Securities Act. The February Warrants will have an exercise price of $3.80 per share, are initially exercisable beginning six months following the date of issuance, and will expire 5 years from the date of issuance. The aggregate net cash proceeds to the Company from the February 2024 Private Placement were approximately $1.0 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>2025 Financings</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">As set forth below, subsequent to December 31, 2024, the Company secured $8.5 million in new financing and anticipates supplementing existing capital with commercial credit and strategic investments sufficient to satisfy our working capital requirements through the end of the fiscal year ending December 31, 2025.<br/> &#160;<br/> <i>January 2025 Securities Purchase Agreement</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">On or about January 27, 2025, the Company entered into a securities purchase agreement (the &#8220;RD Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;) for the sale by the Company of 1,215,278 shares (the &#8220;RD Shares&#8221;) of common stock to the Investors, at a purchase price of $2.88 per share, in a registered direct offering (the &#8220;Registered Direct Offering&#8221;). Concurrently with the sale of the RD Shares, pursuant to the RD Purchase Agreement the Company also sold to the Investors unregistered common stock purchase warrants (the &#8220;RD Warrants&#8221;) to purchase up to an aggregate of 1,215,278 shares of common stock (the &#8220;RD Warrant Shares&#8221;), in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of common stock, subject to adjustments as provided under the terms of the RD Warrants. The RD Warrants are exercisable for five years from the RD Closing Date (as defined below). The closing of the sales of these securities under the RD Purchase Agreement occurred on or about January 29, 2025 (the &#8220;RD Closing Date&#8221;).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The gross proceeds to the Company from the offerings were approximately $3,500,000, before deducting offering expenses, and excluding the proceeds, if any, from the exercise of the RD Warrants. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The RD Shares were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on June 9, 2022, and subsequently declared effective on June 21, 2022 (File No. 333-265492) (the &#8220;Registration Statement&#8221;), and the base prospectus dated as of June 21, 2022, contained therein.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The RD Warrants and the RD Warrant Shares were sold and issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.<br/> &#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Proposed Strategic Investment and Commercial Funding</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The Company is currently in negotiations with a publicly-traded entity engaged in the manufacture of FDA-cleared devices for Transcranial Magnetic Stimulation to provide acquisition capital to support the expansion of HOPE, and is currently in negotiations with several commercial banks to provide additional acquisition financing for HOPE. Although no assurances can be given, assuming consummation of the financings on terms currently contemplated by management, we will achieve our objective of financing less than 50% of the proposed acquisition costs, thereby enabling the Company to optimize its cost of acquisition capital as it expands the HOPE clinic network.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Terminated January 2025 Financing</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company was a party to definitive stock purchase agreements with an Arizona-based investment firm, Smith and Sauer, through their affiliate, JGS Holdings, LLC (&#8220;JGS Holdings&#8221;) whereby JGS Holdings committed to invest $2.0 million in NRx&#8217;s common stock, with an additional commitment of $25.0 million to be invested directly in HOPE.&#160;JGS Holdings defaulted under the terms of the agreements, despite several extensions of the closing date.&#160;The Company formally terminated the stock purchase agreement on March 13, 2025.&#160; Although no assurances can be given, management is currently negotiating with an alternative strategic investor to replace the investment contemplated with JGS Holdings, and, together with alternative sources of equity and debt capital, management believes it will able to fund its previously announced acquisitions on terms more favorable to our shareholders.&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Results</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Since inception, NRx has incurred significant operating losses. For the years ended December 31, 2024 and 2023, NRx Pharmaceuticals&#8217; net loss was $25.1 million and $30.2 million, respectively. As of December 31, 2024, NRx Pharmaceuticals had an accumulated deficit of $278.3 million, a stockholders&#8217; deficit of $23.5 million and a working capital deficit of $18.8 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Going Concern</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company&#8217;s ongoing clinical activities continue to generate losses and net cash outflows from operations. The Company plans to pursue additional equity or debt financing or refinancing opportunities in 2025 to fund ongoing clinical activities, to meet obligations under its current debt arrangements and for the general corporate purposes of the Company. Such arrangements may take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures or other agreements. The sale of equity could result in additional dilution to the Company&#8217;s existing shareholders. The Company cannot make any assurances that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company&#8217;s business and operations and could also lead to a reduction in the Company&#8217;s operations. We will continue to carefully monitor the impact of our continuing operations on our working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements. The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one of the Company&#8217;s product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Nasdaq Listing Requirements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On July 20, 2023, we received a written notification (the &#8220;Notice&#8221;) from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that NRx Pharmaceuticals is not in compliance with Nasdaq Listing Rule&#160;5450(b)(2)(A) &#8211; Market Value of Listed Securities (&#8220;MVLS&#8221;) because the Company had not maintained a minimum MVLS of $50,000,000 for the last thirty-three (33) consecutive business days. Pursuant to Nasdaq Listing Rule&#160;5810(c)(3)(C), we have been provided an initial compliance period of 180 calendar days, or until January&#160;22, 2024, to regain compliance with the MVLS requirement. To regain compliance, our MVLS must meet or exceed $50,000,000 for a minimum period of ten consecutive business days prior to January&#160;22, 2024. If we do not regain compliance within the allotted compliance period Nasdaq will provide notice that our shares of common stock will be subject to delisting and may potentially be traded on the Over-the-Counter market thereafter.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On October 17, 2023, we received formal notice from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;) indicating that, based upon our non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule&#160;5550(a)(2) (the &#8220;Rule&#8221;), our securities were subject to delisting unless we timely request a hearing before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which such hearing was timely requested and subsequently held on January 4, 2024. On January 16, 2024, the Panel granted our request for an exception to the Nasdaq Listing Rules until April 16, 2024, to demonstrate compliance with the Minimum Bid Price Requirement, subject to our filing all necessary documentation required to transfer our listing from the Nasdaq Global Market to the Nasdaq Capital Market on or before January 19, 2024, and our demonstrating compliance with the Minimum Bid Price Requirement on or before April 16, 2024. On February 1, 2024, the Nasdaq Stock Market informed us that it had approved our application to transfer our listing to the Nasdaq Capital Market. Our securities were transferred from the Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on January 19, 2024. The Company subsequently established compliance with the Nasdaq Market Value of Listed Securities requirement and was notified of this by the Nasdaq. &#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On August 6, 2024, we received a written notification from the Staff indicating that we were not in compliance with Nasdaq Listing Rule&#160;5550(b)(2) because we had not maintained a minimum MVLS of $35,000,000 for the previous 33 consecutive business days. We were provided an initial compliance period of 180 calendar days, or until February 3, 2025, to regain compliance with the minimum MVLS requirement. On January 17, 2025, the Company received a written notice from Nasdaq that the Company had regained compliance with the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Components of Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Operating Expense</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and development expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company&#8217;s research and development expense&#160;consists primarily of costs associated with its clinical trials, salaries, payroll taxes, employee benefits, and equity-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>General and administrative expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">General and administrative expense&#160;consists primarily of salaries, stock-based compensation, consultant fees, and professional fees for legal and accounting services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Settlement (income) expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Settlement expense during the year ended December 31, 2023 consists of settlement expenses related to the NeuroRx&#160;and GEM settlement and release agreement (the &#8220;Settlement Agreement&#8221;). See Note 8 &#8220;Commitment and Contingencies&#8221; of the notes to the Company&#8217;s consolidated financial statements included elsewhere in this report for further information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Settlement income during the year ended December 31, 2024&#160;consists of settlement income related to the Company&#8217;s costs related to clinical trials with a specific vendor. A closing cost adjustment was applied to these clinical trial and research expenses, resulting in the issuance of a credit memo for approximately $1.2 million, significantly lower than the original billing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Results of operations for the years ended December 31, 2024 and 2023</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The following table sets forth the Company&#8217;s selected statements of operations data for the following periods (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dollars</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expense:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,199</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,371</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,172</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,505</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,216</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(711</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlement (income) expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,202</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,452</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,502</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,837</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,335</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18,502</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(27,837</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,335</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other (income) expense:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(44</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(494</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">450</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">230</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Convertible note default penalty</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">849</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">849</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of convertible note payable and accrued interest</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,654</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,707</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(53</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of warrant liabilities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,657</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(20</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,677</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Loss on convertible note redemptions</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,278</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,277</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total other (income) expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,624</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,313</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,311</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(25,126</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(30,150</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,024</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Operating Expense</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and development expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the year ended December 31, 2024, the Company recorded $6.2 million of research and development expense compared to approximately $13.4 million for the year ended December 31, 2023. The decrease of $7.2 million is related primarily to a&#160;decrease&#160;of&#160;$7.6 million in clinical trials and development expense due to the conclusion of the phase 2 study related to NRX-101&#160;and the Company's cash conservation efforts,&#160; $0.3 million&#160;in shipping, freight, and delivery,&#160; $0.1 million&#160;in other regulatory and process development costs, and $0.4 million in payroll and payroll related expenses,&#160; partially offset by an increase in&#160;$1.3 million related to Alvogen warrants and&#160;$0.3 million related to stock based compensation. The research and development expenses for the years ended December 31, 2024 and 2023, respectively, include $0.1 million and ($0.2) million, respectively, of non-cash stock-based compensation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>General and administrative expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the year ended December 31, 2024, NRx Pharmaceuticals recorded $13.5 million of general and administrative expenses compared to approximately $14.2 million for the year ended December 31, 2023. The decrease of $0.7 million is related primarily to a decrease of $2.2 million in insurance expense, $1.3 million in employee expense, $0.2 million in stock-based compensation expense, and $0.2 million in patent expense, partially offset by an increase of $1.6 million in consultant fees, and $1.3 million in legal expense. The general and administrative expenses for the years ended December 31, 2024 and 2023, respectively, include $0.4 million and $0.6 million, respectively, of non-cash stock-based compensation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Other (income) expense</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Interest income</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the year ended December 31, 2024, the Company recorded less than $0.1 million of interest income compared to approximately $0.5 million of interest income for the year ended December 31, 2023. The decrease of $0.5 million is due to a large decrease in the balance in the Company&#8217;s money market account at December 31, 2024 as compared to the prior year.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Interest expense</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the year ended December 31, 2024, the Company recorded $0.2 million of interest expense, compared to $0.1 million of interest expense for the year ended December 31, 2023. The increase of $0.1&#160;million is due to premiums for cash payments on the convertible note.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Convertible note default penalty</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">For the year ended December 31, 2024, the Company recorded&#160;$0.8 million of a default penalty, compared to $0 for the year ended December 31, 2023. The increase is due to alleged default in connection with the Streeterville convertible note.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Change in fair value of convertible note payable</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the year ended December 31, 2024, the Company recorded a loss of approximately $2.7 million related to the change in fair value of the convertible notes payable which are accounted for under the fair value option. For the year ended December 31, 2023, the Company recorded a loss of approximately $2.7 million related to the change in fair value of the convertible note payable which is accounted for under the fair value option.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Change in fair value of warrant liabilities </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For the year ended December 31, 2024, the Company recorded a loss of $1.7 million related to the change in fair value of the warrant liabilities compared to a gain of less than $0.1 million for the year ended December 31, 2023. The increase in loss during the year ended December 31, 2024 was attributed to the warrants issued in conjunction with the First and the Second Trenches of the Anson Notes.&#160; &#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Loss on convertible note redemptions</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For year ended December 31, 2024, the Company recorded a loss of $1.3 million related to convertible note redemptions calculated as the difference between the redemption price as calculated as per the terms of the Anson and Streeterville Notes (See Note 7) relative to the fair value of the common stock on the date of redemption.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">The Company has generated no revenues, has incurred operating losses since inception, expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. Until such time as the Company is able to establish a revenue stream from the sale of its therapeutic products, it is dependent upon obtaining necessary equity and/or debt financing to continue operations. The Company cannot make any assurances that sales of NRX-101 will commence in the near term or that additional financings will be available to it on acceptable terms or at all. This could negatively impact our business and operations and could also lead to the reduction of our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>January 2025 Securities Purchase Agreement</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">On or about January 27, 2025, the Company entered into the RD Purchase Agreement with the Investors for the sale by the Company of the RD Shares to the Investors in an aggregate of 1,215,278 shares of common stock, at a purchase price of $2.88 per share, in the Registered Direct Offering. Concurrently with the sale of the RD Shares, pursuant to the RD Purchase Agreement the Company also sold to the Investors the unregistered RD Warrants to purchase the RD Warrant Shares, in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of common stock, subject to adjustments as provided under the terms of the RD Warrants. The RD Warrants are exercisable for five years from the RD Closing Date. The closing of the sales of these securities under the RD Purchase Agreement occurred on or about the RD Closing Date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The gross proceeds to the Company from the offerings were approximately $3,500,000, before deducting offering expenses, and excluding the proceeds, if any, from the exercise of the RD Warrants. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The RD Shares were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on June 9, 2022, and subsequently declared effective on June 21, 2022 (File No. 333-265492) (the &#8220;Registration Statement&#8221;), and the base prospectus dated as of June 21, 2022, contained therein.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The RD Warrants and the RD Warrant Shares were sold and issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>August 2024 SPA</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On August 12, 2024, the Company executed the August SPA and related agreements, under which the Company agreed to sell and issue, and certain purchasers agreed to purchase, an aggregate of $16.3 million&#160;of Notes and Warrants. The consideration payable by the purchasers under the August SPA will be comprised of three equal closings of $5.435 million, each subject to certain closing conditions. The&#160;proceeds arising from the sale of the Notes and the Warrants were&#160;used to settle the Company&#8217;s outstanding amounts owed to Streeterville (as defined below)&#160;and other working capital needs.&#160;The Company has, as of the date of this Annual Report, consummated the first tranche, second tranche, and third tranche under the August SPA, with gross proceeds to the Company of $16.3 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Notes bear interest at the rate of 6% per annum and mature in 15 months following their date of issuance. The Notes may be settled in cash or in shares of the Company&#8217;s common stock, at the sole discretion of the holder, at the applicable conversion price. The Notes&#160;may not be prepaid by the Company however, the holders of the Notes may elect to convert the Notes, in whole or in part, into shares of the Company&#8217;s common stock at any time after the original issuance date. The conversion price: (A) for the Notes issued in the first tranche will equal the lower of (i) $2.4168, or (ii) the Alternative Conversion Price; (B) for the Notes issued in the second tranche will equal the lower of (i) $1.766, or (ii) the Alternative Conversion Price; and (C) for the Notes issued in the third tranche will equal the lower of (i) $3.78, or (ii) the Alternative Conversion Price. The Notes include certain redemption, protection features and default interest and penalties. The Notes are secured by all assets of the Company, including its intellectual property.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Warrants have a term of 5 years, an exercise price of $2.4168 per share for the Warrants issued in the first tranche, $1.766 per share for the Warrants issued in the second tranche, and $3.78 per share for the Warrants issued in the third tranche, each subject to adjustment as more specifically set forth in the Warrants, and are exercisable immediately upon issuance&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>April 2024 Offering</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On April 18, 2024, we entered into the April Underwriting Agreement with the Representative, as the representative of the April Underwriters, relating to the April Offering of the Shares, which April Offering closed on the April Closing Date. The public offering price for each share of common stock was $3.30.&#160;Pursuant to the April Underwriting Agreement, the Company also granted the Representative the April Over-Allotment Option. Aggregated gross proceeds from the April Underwriting Agreement were approximately $2.4 million (including April Overallotment Exercise proceeds), before deducting and commissions and estimated expenses payable by the Company. The Company intends to use the net proceeds from the April 2024 Public Offering for working capital and general corporate purposes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On May 23, 2024, the Underwriters in the April 2024 Public Offering exercised their April Over-Allotment Option to purchase an additional 91,050 April Option Shares. In connection with the April Overallotment Exercise, we issued an additional April Underwriter Warrant to purchase up to 4,553 shares of common stock. The April Overallotment was exercised in full and closed on May 23, 2024.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>February 2024 Offerings </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On February&#160;27, 2024, the Company entered into a February Underwriting Agreement with EF Hutton LLC, as the Representative of the February Underwriters, relating to the February 2024 Public Offering. The public offering price for each share of common stock was $3.00 and the February Underwriters purchased the shares of common stock pursuant to the February Underwriting Agreement at a price for each share of common stock of $2.76. Pursuant to the February Underwriting Agreement, the Company also granted the Representative the February Over-Allotment Option. Aggregate gross proceeds from the February Underwriting Agreement were approximately $1.7 million (including February Overallotment Exercise proceeds), before deducting underwriting discounts and commissions and estimated expenses payable by the Company. The Company intends to use the net proceeds from the February 2024 Public Offering for working capital and general corporate purposes. The Company also used the proceeds from February 2024 Public Offering to repay the Convertible Promissory Note initially issued to Streeterville Capital, LLC in November&#160;2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On March 5, 2024, the Underwriters in the February 2024 Public Offering exercised their February Over-Allotment Option to purchase an additional 75,000 February Option Shares. In connection with the February Overallotment Exercise, we issued an additional February Underwriter&#8217;s Warrant to purchase up to 3,750 shares of common stock. The February Overallotment Exercise closed on March 6, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On February 29, 2024, the Company completed the February 2024 Private Placement. Pursuant to the securities purchase agreement, the Company issued and sold 270,000 shares of common stock and warrants to purchase up to 270,000 shares of common stock at a price of $3.80 per share of common stock and accompanying warrant, which represents a 26.7% premium to the offering price in February 2024 Public Offering. The common stock and the February Warrants were offered pursuant to a private placement under Section 4(a)(2) of the Securities Act. The February Warrants will have an exercise price of $3.80 per share, are initially exercisable beginning six months following the date of issuance, and will expire 5 years from the date of issuance. The aggregate net cash proceeds to the Company from the February 2024 Private Placement were approximately $1.0 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At-The Market Offering Agreement</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">On April 15, 2024, the Company increased the maximum aggregate offering amount of the shares of common stock issuable under that certain At the Market Offering Agreement, dated August 14, 2023 (the &#8220;Offering Agreement&#8221;), with H.C. Wainwright &amp; Co., and filed a prospectus supplement (the &#8220;Current Prospectus Supplement&#8221;) under the Offering Agreement for an aggregate of $4.9 million (the &#8220;ATM Offering&#8221;). On August 14, 2024, the Company reduced the amount to under the Offering Agreement to $0 and suspended the ATM Offering. Through&#160;December 31, 2024, the Company received&#160;aggregate net cash proceeds to the Company from the ATM Offering of approximately $1.6&#160;million.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 86
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash Flows</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The following table presents selected financial information and statistics for each of the periods shown below:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance Sheet Data:</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,443</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,651</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,315</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,257</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,874</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,048</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' (deficit) equity</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(23,223</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,733</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Statement of Cash Flow Data:</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,637</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21,657</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in investing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,485</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,201</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net (decrease) increase in cash</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,152</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(15,459</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">During the year ended December 31, 2024, operating activities used approximately $10.6 million of cash, primarily resulting from a net loss of&#160;$25.1 million, partially offset by (a) net non-cash losses of $9.2 million, including a loss of&#160;&#160;$2.7 million in change in fair value of convertible promissory notes, and loss of&#160;$1.7 million in change in fair value of warrants,&#160;$0.5 million of stock-based compensation, $1.3 million loss in convertible note redemptions, $1.3 million of warrant issuance costs related to Alvogen termination,&#160;$0.8 million of&#160;default penalties,&#160;$0.9&#160;million in debt issuance costs, and (b) changes in operating assets and liabilities of $5.3 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">During the year ended December 31, 2023, operating activities used approximately $21.7 million of cash, primarily resulting from a net loss of $30.2 million, reduced by (a) net non-cash losses of $3.3 million, including $2.7 million in change in fair value of convertible promissory note, $0.4 million of stock-based compensation, and $0.3 million of non-cash settlement expenses, and (b) changes in operating assets and liabilities of $5.2 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Investing activities</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">During the years ended December 31, 2024 investing activities used $0. During the year ended December 31, 2023 investing activities used less than $0.1 million of cash related to the purchase of equipment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Financing activities</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">During the year ended December 31, 2024, financing activities provided&#160;$7.4 million of cash resulting from $1.0&#160;million in proceeds from issuance of common stock and warrants issued in a private placement, $4.9&#160;million in proceeds from issuance of common stock and warrants,&#160;$6.0&#160;million in proceeds from the Anson Notes, and $4.0&#160;million from warrant proceeds attributes to the Anson Notes offset by&#160;$7.9&#160;million in repayments of the convertible notes and $0.9 million in debt issuance costs due to the fair value election on Anson Notes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">During the year ended December 31, 2023, financing activities provided $6.2 million of cash resulting from $8.1 million in proceeds from issuance of common stock and warrants issued in a private placement, $1.2 million in proceeds from issuance of Series A preferred stock and warrants, partially offset by $3.1 million of repayments of convertible notes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Contractual Obligations and Commitments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">See Note 7, Debt, and Note 8, Commitments and Contingencies, of the notes to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024 included elsewhere in this report for further discussion of the Company&#8217;s commitments and contingencies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Pursuant to the legal settlement with Sarah Herzog Memorial Hospital Ezrat Nashim (&#8220;SHMH&#8221;) in September 2018, which included the license of intellectual property rights from SHMH, an ongoing royalty of 1% to 2.5% of NRX-101 gross sales is due to SHMH, together with milestone payments of $0.3 million, upon completion of phase 3 trials and commercial sale of NRX-101. The milestone payments for developmental and commercial milestones range from $0.1 million to $0.8 million. Annual maintenance fees are up to $0.2 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company is not party to any off-balance sheet transactions. The Company has no guarantees or obligations other than those which arise out of normal business operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 87
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company's management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). The preparation of these financial statements requires NRx Pharmaceuticals to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the balance sheet and the reported amounts of expenses during the reporting period. In accordance with GAAP, NRx Pharmaceuticals evaluates its estimates and judgments on an ongoing basis. The most significant estimates relate to the earnout cash liability, stock-based compensation, and the valuation of warrants. NRx Pharmaceuticals bases its estimates and assumptions on current facts, historical experiences, and various other factors that NRx Pharmaceuticals believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company defines its critical accounting policies as those accounting principles that require it to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on its financial condition and results of operations, as well as the specific manner in which the Company applies those principles. While its significant accounting policies are more fully described in Note 3 to its financial statements, the Company believes the following are the critical accounting policies used in the preparation of its financial statements that require significant estimates and judgments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock-based compensation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">We measure stock option awards granted to employees and directors based on the fair value of the award on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. For restricted stock awards, the grant date fair value is the fair market value per share as of the grant date based on the closing trading price for the Company&#8217;s stock. The straight-line method of expense recognition is applied to awards with service-only conditions. We account for forfeitures as they occur.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">We estimate the fair value of each stock option award using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock-based awards, the risk-free interest rate for a period that approximates the expected term of our stock-based awards, and our expected dividend yield. Therefore, we estimate our expected volatility based on the implied volatility of publicly traded warrants on our common stock and historical volatility of a set of our publicly traded peer companies. We estimate the expected term of our options using the "simplified" method for awards that qualify as "plain-vanilla" options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends on common stock and do not expect to pay any cash dividends in the foreseeable future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The assumptions used in determining the fair value of stock-based awards represent reasonable estimates, but the estimates involve inherent uncertainties and the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrant liabilities</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 88
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, or date of modification, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the Private Placement Warrants was estimated using a Black Scholes valuation approach and the fair value of the Substitute Warrants was estimated using a modified Black Scholes valuation approach which applies a probability factor based on the earnout cash milestone and earnout shares milestone probabilities of achievement at each reporting period.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Convertible note payable</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">As permitted under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, Financial Instruments (&#8220;ASC 825&#8221;), the Company elects to account for its convertible promissory notes, which meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. As a result of electing the fair value option, direct costs and fees related to the convertible promissory notes are expensed as incurred.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company estimates the fair value of the convertible notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of our common stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration (i.e. expected termination date) of the convertible note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our expected future equity and volume volatility based on the historical volatility of both our common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six months from the issuance date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using Bloomberg's Default Risk function which uses our financial information to calculate a default risk specific to the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The assumptions used in determining the fair value of the convertible note payable represent reasonable estimates, but the estimates involve inherent uncertainties and the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, the change in fair value of the convertible note payable recorded to other (income) expense could be materially different in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item7a" title="item7a" href="#"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 29pt;">As a smaller reporting company, we are not required to provide the information required by this Item.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 89
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <div>
   &#160;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item8" title="item8" href="#"></a>Item 8. Financial Statements and Supplementary Data</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NRX Pharmaceuticals, Inc.</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;"><tbody><tr><td style="vertical-align:top;width:42.6%;">&#160;</td><td style="vertical-align: top; width: 8.3%; text-align: center;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#audit">Report of Independence Registered Public Accounting Firm</a> (PCAOB firm ID. <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2024-01-01_2024-12-31" id="ixv-18950">106</ix:nonNumeric>)</p> </td><td style="vertical-align: top; width: 8.3%; text-align: right;"><a class="tocPGNUM" href="#audit">F-1</a></td></tr>
<tr><td style="vertical-align:top;width:42.6%;">&#160;</td><td style="vertical-align: top; width: 8.3%; text-align: right;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#balsheet">Consolidated Balance Sheets</a></p> </td><td style="vertical-align: top; width: 8.3%; text-align: right;"><a class="tocPGNUM" href="#balsheet">F-3</a></td></tr>
<tr><td style="vertical-align:top;width:42.6%;">&#160;</td><td style="vertical-align: top; width: 8.3%; text-align: right;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#ops">Consolidated Statements of Operations and Comprehensive Loss</a></p> </td><td style="vertical-align: top; width: 8.3%; text-align: right;"><a class="tocPGNUM" href="#ops">F-4</a></td></tr>
<tr><td style="vertical-align:top;width:42.6%;">&#160;</td><td style="vertical-align: top; width: 8.3%; text-align: right;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#equity">Consolidated Statement of Changes in Stockholders&#8217;&#160;Equity (Deficit)</a></p> </td><td style="vertical-align: top; width: 8.3%; text-align: right;"><a class="tocPGNUM" href="#equity">F-5</a></td></tr>
<tr><td style="vertical-align:top;width:42.6%;">&#160;</td><td style="vertical-align: top; width: 8.3%; text-align: right;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#cashflow">Consolidated Statement of Cash Flows</a></p> </td><td style="vertical-align: top; width: 8.3%; text-align: right;"><a class="tocPGNUM" href="#cashflow">F-6</a></td></tr>
<tr><td style="vertical-align:top;width:42.6%;">&#160;</td><td style="vertical-align: top; width: 8.3%; text-align: right;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#notes">Notes to Consolidated Financial Statements</a></p> </td><td style="vertical-align: top; width: 8.3%; text-align: right;"><a class="tocPGNUM" href="#notes">F-7</a>&#160;&#8212; <a class="tocPGNUM" href="#notesend">F-37</a></td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#160;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<div>
 &#160;
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><img alt="salberglogo.jpg" src="salberglogo.jpg"/></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="audit" title="audit" href="#"></a>Report of Independent Registered Public Accounting Firm</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">To the Stockholders and Board of Directors of:<br/> NRX Pharmaceuticals, Inc.:</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Opinion on the Financial Statements</span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have audited the accompanying consolidated balance sheets of NRX Pharmaceuticals, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Going Concern</span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has no revenues, has suffered operating losses since inception and has a working capital deficit at December 31, 2024. &#160;These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s Plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Basis for Opinion</span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Critical Audit Matters</span></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
  F-1
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The&#160;communication&#160;of&#160;critical&#160;audit&#160;matters&#160;does&#160;not&#160;alter&#160;in&#160;any&#160;way&#160;our&#160;opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they&#160;relate.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Fair Value of the Convertible Note</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As described in Note 3 &#8220;Convertible Notes Payable and Fair Value Election&#8221; and in Notes 7 and 11 to the consolidated financial statements, the Company uses a Monte Carlo simulation model to estimate the fair value of its convertible notes.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We identified the valuation of fair value of the convertible note as of December 31, 2024 as a critical audit matter. Auditing management&#8217;s assumptions and estimates relating to the Monte Carlo simulation model is especially challenging, complex and subjective.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The primary procedures we performed to address this critical audit matter included (a) gained an understanding of management&#8217;s process to develop an estimate of the fair value of the convertible note, (b) tested the data and assumptions used as inputs to the Monte Carlo simulation model for reasonableness, (c) computed an independent expectation of the fair value of the convertible note and (d) compared management&#8217;s valuation to our independent expectation. We agreed with management&#8217;s estimate.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2024-01-01_2024-12-31" id="ixv-18951">Salberg &amp; Company, P.A.</ix:nonNumeric></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">SALBERG&#160;&amp; COMPANY, P.A.</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have served as the Company&#8217;s auditor since 2023<i>.</i></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2024-01-01_2024-12-31" id="ixv-18952">Boca Raton, Florida</ix:nonNumeric></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">March 14, 2025</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-2
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;<a id="balsheet" title="balsheet" href="#"></a>PART I FINANCIAL INFORMATION</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 1. Financial Statements</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NRX PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share and per share data)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ASSETS</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341071" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,443</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341072" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,595</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341073" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,859</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341074" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341075" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,302</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341076" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,884</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341077" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">349</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341078" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">431</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341079" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,651</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341080" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,315</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>LIABILITIES AND STOCKHOLDERS</b>&#8217;<b> DEFICIT</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341081" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">4,130</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341082" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,632</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341083" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,149</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341084" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,714</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued clinical site costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341085" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:AccruedClinicalSiteCostsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341086" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:AccruedClinicalSiteCostsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">524</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Convertible note payable and accrued interest &#8211; short term</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341087" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341088" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Insurance loan payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341089" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LoansPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">320</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341090" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LoansPayableCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341091" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,639</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341092" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341093" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341094" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,048</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Convertible note payable and accrued interest &#8211; long term</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341095" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,011</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341096" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341097" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,874</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341098" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,048</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and Contingencies (Note 8)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c125344265">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c125344266">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders&#8217; deficit:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Preferred stock, $<span style="-sec-ix-hidden:c125342639"><span style="-sec-ix-hidden:c125342640">0.001</span></span> par value, <span style="-sec-ix-hidden:c125342641"><span style="-sec-ix-hidden:c125342642">50,000,000</span></span> shares authorized;</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341099" contextRef="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341100" contextRef="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Series A convertible preferred stock, $<span style="-sec-ix-hidden:c125342643"><span style="-sec-ix-hidden:c125342644">0.001</span></span> par value, <span style="-sec-ix-hidden:c125342645"><span style="-sec-ix-hidden:c125342646">12,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c125342647"><span style="-sec-ix-hidden:c125342649">0</span></span> and <span style="-sec-ix-hidden:c125342648"><span style="-sec-ix-hidden:c125342650">3,000,000</span></span> shares issued and outstanding at December 31, 2024 and 2023, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341101" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341102" contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock, $<span style="-sec-ix-hidden:c125342651"><span style="-sec-ix-hidden:c125342652">0.001</span></span> par value, <span style="-sec-ix-hidden:c125342653"><span style="-sec-ix-hidden:c125342654">500,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c125342655"><span style="-sec-ix-hidden:c125342657">14,591,505</span></span> and <span style="-sec-ix-hidden:c125342656"><span style="-sec-ix-hidden:c125342658">8,391,956</span></span> shares issued and outstanding at December 31, 2024 and 2023, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341103" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341104" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341105" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">255,035</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341106" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">241,406</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341107" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341108" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341109" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">278,273</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341110" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">253,147</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stockholders&#8217; deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341111" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">23,223</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341112" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">11,733</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities and stockholders' deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341113" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,651</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341114" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,315</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ops" title="ops" href="#"></a>NRX PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share and per share data)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years ended December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341121" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,199</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341122" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,371</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341123" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,505</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341124" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,216</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Settlement (income) expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341125" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:LitigationSettlementExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341126" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:LitigationSettlementExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341127" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">18,502</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341128" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,837</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341129" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">18,502</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341130" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">27,837</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other (income) expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341131" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341132" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341133" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-4">230</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341134" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-4">120</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Convertible note default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341135" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:num-dot-decimal" decimals="-3">849</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341136" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Change in fair value of convertible note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341137" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,654</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341138" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341139" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,657</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341140" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss on convertible note redemptions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341141" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,278</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341142" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total other expenses, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341143" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">6,624</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341144" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,313</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341145" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341146" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">30,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deemed dividend - warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341147" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341148" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss attributable to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341149" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341150" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">30,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341151" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341152" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">30,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value of convertible note attributed to credit risk</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341153" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341154" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341155" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341156" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">30,153</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341157" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.36</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341158" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">3.98</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341159" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,644,461</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341160" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,576,176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="equity" title="equity" href="#"></a>NRX PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS</b>&#8217;<b> (DEFICIT) EQUITY</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share data)</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div>
   <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Series A Preferred Stock</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Common Stock</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>Additional</b></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>Paid-in-</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><b>Accumulated</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Other </b></p> <b><b>Comprehensive</b> Income</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><b>Total </b></b> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stockholders&#8217;&#160;</b></p> <b>Equity </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Loss)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Deficit)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Balance - December</b> <b>31,</b> <b>2022</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341166" contextRef="i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341167" contextRef="i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>&#160;</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341168" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,644,299</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341169" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341170" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">230,399</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c125341171" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">222,997</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341172" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341173" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,409</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock and warrants issued, net of issuance costs $<span style="-sec-ix-hidden:c125342666">2,519</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341174" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341175" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341176" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,353,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341177" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341178" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,121</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341179" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341180" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341181" contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,122</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Preferred stock and warrants issued, net of issuance costs $<span style="-sec-ix-hidden:c125342674">27</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341182" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="nrxp:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341183" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341184" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="nrxp:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341185" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341186" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,168</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341187" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341188" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341189" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,171</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Change in fair value of convertible note attributed to credit risk</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341191" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341193" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341194" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341195" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c125341196" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c125341197" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares issued as repayment of principal and interest for convertible note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341198" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341199" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341200" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" format="ixt:num-dot-decimal" decimals="INF">326,423</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341201" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341202" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:num-dot-decimal" decimals="-3">982</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341203" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341204" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341205" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:num-dot-decimal" decimals="-3">982</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to settle GEM settlement liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341206" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341207" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341208" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">67,568</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341209" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341210" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341211" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341212" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341213" contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Adjustment for deferred offering cost settlement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341215" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341217" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341218" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341219" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341220" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341221" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341223" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341225" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341226" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341227" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341228" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341229" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341231" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341233" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341234" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341235" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">30,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341236" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341237" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">30,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Balance December 31, 2023</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>&#160;</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341238" contextRef="i_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341239" contextRef="i_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>&#160;</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341240" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,391,956</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341241" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">8</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b><ix:nonFraction id="c125341242" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">241,406</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c125341243" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">253,147</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c125341244" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>$</b></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c125341245" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">11,733</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Conversion of Series A preferred stock into common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c125341246" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c125341247" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341248" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341250" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">At-the-market &#8220;ATM&#8221; offering, net of offering costs of $<span style="-sec-ix-hidden:c125342682">197</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341254" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341255" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341256" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">385,515</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341257" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341258" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,626</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341259" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341260" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341261" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,627</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock and warrants issued, net of issuance costs $<span style="-sec-ix-hidden:c125342690">975</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341262" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341263" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341264" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,273,050</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341265" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341266" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,256</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341267" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341268" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341269" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,257</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock and warrants issued in private placement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341270" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341271" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341272" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">270,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341273" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341274" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,026</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341275" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341276" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341277" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Vesting of restricted stock awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341278" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341279" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341280" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341281" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341282" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341283" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341284" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341285" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares issued as repayment of principal and interest for convertible note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341286" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341287" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341288" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,820,444</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341289" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341290" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,859</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341291" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341292" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341293" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Issuance of shares related to reverse stock split</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341294" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341296" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:num-dot-decimal" decimals="INF">73,040</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Contract cost related to Alvogen termination (see Note 6)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341303" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="nrxp:APICIncreaseForCostRecognitionContractTermination" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341305" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="nrxp:APICIncreaseForCostRecognitionContractTermination" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341306" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="nrxp:APICIncreaseForCostRecognitionContractTermination" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,336</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341307" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="nrxp:APICIncreaseForCostRecognitionContractTermination" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341308" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="nrxp:APICIncreaseForCostRecognitionContractTermination" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341309" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:APICIncreaseForCostRecognitionContractTermination" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,336</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued in exchange for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341310" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341311" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341312" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">20,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341313" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341314" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341315" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341316" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341317" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Reclassification of AOCI upon settlement of Streeterville Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341319" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341321" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341322" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341323" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341324" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341325" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341327" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341329" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341330" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341331" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341332" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c125341333" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341335" contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341337" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341338" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341339" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341340" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341341" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Balance - December 31, 2024</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341342" contextRef="i_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341343" contextRef="i_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341344" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,591,505</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341345" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341346" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">255,035</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341347" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">278,273</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341348" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341349" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">23,223</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-5
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cashflow" title="cashflow" href="#"></a>NRX PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years ended December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CASH FLOWS FROM OPERATING ACTIVITIES:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341350" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341351" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">30,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341352" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341353" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341354" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341355" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Common stock issued in exchange for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341356" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341357" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341358" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,657</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341359" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Change in fair value of convertible promissory notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341360" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,654</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341361" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss on convertible notes redemptions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341362" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,278</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341363" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expense for debt issuance costs due to fair value election on Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341364" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:DebtIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">896</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341365" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:DebtIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Warrant issuance costs related to Alvogen termination</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341366" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:ContractCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,336</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341367" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:ContractCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Convertible note default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341368" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:num-dot-decimal" decimals="-3">849</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341369" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Non-cash settlement expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341370" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:NoncashLitigationExpense" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341371" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:NoncashLitigationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increases (decreases) in operating assets and liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341372" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">503</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341373" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">3,040</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341374" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341375" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,655</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses and other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341376" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,005</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341377" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">531</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341378" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">10,637</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341379" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">21,657</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CASH FLOWS FROM INVESTING ACTIVITIES</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Purchase of computer equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341380" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341381" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341382" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341383" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CASH FLOWS FROM FINANCING ACTIVITIES</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Repayment of convertible note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341384" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-4">7,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341385" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,092</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Repayment of insurance loan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c125341386">(725)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341387" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:RepaymentsOfInsuranceLoans" scale="3" format="ixt:num-dot-decimal" decimals="-3">943</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expense for debt issuance costs due to fair value election on Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341388" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">896</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341389" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from issuance of insurance loan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341390" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:ProceedsFromInsuranceLoans" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,045</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341391" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:ProceedsFromInsuranceLoans" scale="3" format="ixt:num-dot-decimal" decimals="-3">943</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from Anson convertible notes, net of OID</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341392" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,034</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341393" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from liability classified warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341394" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,966</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341395" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341396" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341397" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,171</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from issuance of common stock and warrants, net of issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341398" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,884</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341399" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341400" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341401" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,122</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341402" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,485</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341403" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,201</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net decrease in cash and cash equivalents</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341404" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,152</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341405" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,459</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341406" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,595</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341407" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">20,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341408" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,443</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341409" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,595</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Supplemental disclosure of cash flow information:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341410" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">374</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341411" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">885</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341412" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaidNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341413" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaidNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Non-cash investing and financing activities</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock as principal and interest repayment for convertible notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341414" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,585</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341415" contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" format="ixt:num-dot-decimal" decimals="-3">982</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock warrants as offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341416" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:StockIssuedAsOfferingCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">188</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341417" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:StockIssuedAsOfferingCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">75</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock for settlement of accrued liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341418" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssued1" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341419" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:StockIssued1" scale="3" format="ixt:num-dot-decimal" decimals="-4">250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion of Series A preferred stock into common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341420" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember" unitRef="USD" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341421" contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember" unitRef="USD" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="width: 100%;">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
    <div class="hf-row">
     <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
      NRX PHARMACEUTICALS, INC.
     </div>
    </div>
    <div class="hf-row">
     <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
      NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
     </div>
    </div>
    <div class="hf-row">
     <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
      DECEMBER 31, 2024 AND 2023
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2867419" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="notes" title="notes" href="#"></a><em style="font: inherit;">1.</em> Organization</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Business</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRX&#8221; or the &#8220;Company&#8221;) is a clinical-stage bio-pharmaceutical company which develops and intends to distribute, through its wholly-owned operating subsidiaries, NeuroRx, Inc., (&#8220;NeuroRx&#8221;) and HOPE Therapeutics, Inc. (&#8220;HOPE&#8221;), and collectively with NRX and NeuroRx, the (&#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#8220;PTSD&#8221;) and now schizophrenia. All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate (&#8220;NMDA&#8221;) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. NeuroRx is organized as a traditional research and development (&#8220;R&amp;D&#8221;) company, whereas HOPE is organized as a specialty pharmaceutical company intended to distribute ketamine and other therapeutic options to clinics that serve patients with suicidal depression and PTSD.&#160;The Company has <em style="font: inherit;">two</em> lead drug candidates that are expected to be submitted by year end for Food and&#160;Drug Administration (&#8220;FDA&#8221;)&#160;approval with anticipated FDA decision dates under the Prescription Drug User Fee Act ("PDUFA") by the end of <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">2025:</em> NRX-<em style="font: inherit;">101,</em> an oral fixed dose combination of D-cycloserine and lurasidone and NRX-<em style="font: inherit;">100,</em> a preservative-free formulation of ketamine for intravenous infusion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operations</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s drug development activities have expanded from its original focus on development of NRX-<em style="font: inherit;">101,</em> a fixed dose combination of D-cycloserine (&#8220;DCS&#8221;) and lurasidone for the treatment of suicidal bipolar depression to encompass the development of NRX-<em style="font: inherit;">101</em> for the treatment of chronic pain and PTSD and to the development of intravenous ketamine (NRX-<em style="font: inherit;">100/HTX</em>-<em style="font: inherit;">100</em>) for the treatment of suicidal depression. These additional indications have been added as the Company has gained access to clinical trials data funded by governmental entities in France and potentially in the United States which has the potential to afford the Company potential safety and efficacy data on key indications at low cost.</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="c2867420" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em> Going Concern</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal&#160;year and has a working capital deficit at <em style="font: inherit;"> December 31, 2024. </em>The Company has <ix:nonFraction id="c125341762" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> revenues and expects to continue to incur operating losses into <em style="font: inherit;">2025.</em> Although the Company projects operating revenue&#160;to be derived from the operation of clinical facilities through its HOPE subsidiary and sales of its pharmaceutical products in <em style="font: inherit;">2025,</em> these projections are subject to completion of anticipated clinical acquisitions in the <em style="font: inherit;">first</em> case and regulatory approvals in the latter case. In the absence of these projected developments, the Company&#8217;s ability to support its ongoing capital needs is dependent on its ability to continue to raise equity and/or debt financing, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be available on favorable terms, or at all, in order to continue operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the Company had $<ix:nonFraction id="c125341767" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.4</ix:nonFraction> million in cash and cash equivalents. On <em style="font: inherit;"> August 12, 2024, </em>the Company entered into that certain Securities Purchase Agreement dated <em style="font: inherit;"> August 12, 2024 (</em>the &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to sell Senior Secured Convertible Promissory Notes (the &#8220;Anson&#160;Notes&#8221;) in the aggregate principal amount of up to approximately $<ix:nonFraction id="c125341768" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">16.3</ix:nonFraction> million in <ix:nonFraction id="c125341769" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="Pure" name="nrxp:DebtInstrumentNumberOfTranches" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> tranches of $<ix:nonFraction id="c125341770" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="nrxp:DebtInstrumentFaceAmountIndividualTranches" scale="6" format="ixt:num-dot-decimal" decimals="-3">5.435</ix:nonFraction> million, and warrants to purchase that amount of shares of the Company&#8217;s common stock, $<ix:nonFraction id="c125341771" contextRef="i_2024-08-12" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> par value (&#8220;Common Stock&#8221;) equal to <em style="font: inherit;">50%</em> of the principal amount of the Notes in the respective tranche divided by the volume weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Purchase Agreement (the &#8220;Anson&#160;Warrants&#8221;).&#160; The Company consummated the sale of the <em style="font: inherit;">first</em> tranche of $<ix:nonFraction id="c125341774" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">5.435</ix:nonFraction> million ($<ix:nonFraction id="c125341775" contextRef="d_2024-08-14_2024-08-14_CounterpartyNameAxis-AnsonMember" unitRef="USD" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.5</ix:nonFraction>&#160;million in net proceeds)&#160;in Notes and Warrants (the &#8220;First Closing&#8221;) on <em style="font: inherit;"> August 14, 2024 (</em>the &#8220;First Closing Date&#8221;), and the <em style="font: inherit;">second</em> tranche of $<ix:nonFraction id="c125341777" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">5.435</ix:nonFraction>&#160;million in Notes and Warrants (the &#8220;Second Closing&#8221;) on <em style="font: inherit;"> October 10, 2024 (</em>the &#8220;Second Closing Date&#8221;), for aggregate gross proceeds of approximately $<ix:nonFraction id="c125341778" contextRef="d_2024-10-10_2024-10-10_CounterpartyNameAxis-AnsonMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-4">10.87</ix:nonFraction> million, before deducting fees, costs, and other expenses including the use of proceeds to repay $<ix:nonFraction id="c125341779" contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-StreetervileComplaintMember" unitRef="USD" name="us-gaap:RepaymentsOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-4">5.55</ix:nonFraction> million of the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has&#160;secured operating capital that it anticipates as sufficient to fund its drug development operations through [&#9679;] and to finance submission of FDA New Drug Applications for NRX-<em style="font: inherit;">100</em> and NRX-<em style="font: inherit;">101.</em> The Company <em style="font: inherit;"> may </em>pursue additional equity or debt financing or refinancing opportunities in <em style="font: inherit;">2025</em> and <em style="font: inherit;">2026</em> to fund ongoing clinical activities, to meet obligations under its current debt arrangements and for general corporate purposes. Such arrangements <em style="font: inherit;"> may </em>take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures or other agreements. The sale of equity could result in additional dilution to the Company&#8217;s existing shareholders. The Company cannot make any assurances that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company&#8217;s business and operations and could also lead to a reduction in the Company&#8217;s operations. The Company will continue to carefully monitor the impact of its continuing operations on the Company&#8217;s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company&#8217;s ability to continue as a going concern for a period of at least <em style="font: inherit;">twelve</em> months from the date of issuance of these consolidated financial statements. The accompanying consolidated financial statements do <em style="font: inherit;">not</em> include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the company be unable to continue as a going concern.&#160;</p>
   <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2867421" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em> Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c125344273" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Presentation and Principles of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of NRX Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:UseOfEstimates" id="c125344274" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the fair value of convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results <em style="font: inherit;"> may </em>differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="nrxp:RisksAndUncertaintiesPolicyTextBlock" id="c125344275" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain Risks and Uncertainties</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on <em style="font: inherit;">third</em> party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c125344276" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ASC <em style="font: inherit;">820,</em> <i>Fair Value Measurements</i>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accounting guidance classifies fair value measurements in <em style="font: inherit;">one</em> of the following <em style="font: inherit;">three</em> categories for disclosure purposes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">1:</em> Quoted prices in active markets for identical assets or liabilities.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">2:</em> Inputs other than Level <em style="font: inherit;">1</em> prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3:</em> Unobservable inputs which are supported by little or <em style="font: inherit;">no</em> market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note <em style="font: inherit;">11</em>)</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c125344277" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are <em style="font: inherit;">not</em> exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, exceed federally insured limits. As of <em style="font: inherit;"> December 31, 2024 </em>the Company&#8217;s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $<ix:nonFraction id="c125341804" contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashUninsuredAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction> million. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. &#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c125344278" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company considers all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less at the time of initial purchase to be cash equivalents, including balances held in the Company&#8217;s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time <em style="font: inherit;"> may </em>exceed the U.S. federally insured limits. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company&#8217;s cash flow requirements, and to attain a market rate of return.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="c125344279" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue Recognition</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for revenue under FASB ASC Topic <em style="font: inherit;">606,</em> <i>Revenue for Contract with Customers</i> (&#8220;<i>ASC <em style="font: inherit;">606</em></i>&#8221;) or other accounting standards for revenue <em style="font: inherit;">not</em> derived from customers. Arrangements <em style="font: inherit;"> may </em>include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which <em style="font: inherit;"> may </em>include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company enters into contractual arrangements that <em style="font: inherit;"> may </em>include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC <em style="font: inherit;">606,</em> the Company evaluates the promised good or services to determine which promises, or group of promises, represent performance obligations. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which <em style="font: inherit;"> may </em>include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement (the &#8220;<i>License Agreement</i>&#8221;) with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, &#8220;<i>Alvogen</i>&#8221;) (as further discussed in Note <em style="font: inherit;">6</em> below) was accounted for in accordance with ASC <em style="font: inherit;">606.</em> In accordance with ASC <em style="font: inherit;">606,</em> the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC <em style="font: inherit;">606,</em> it performs the following <em style="font: inherit;">five</em> steps:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">i. identify the contract(s) with a customer&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">ii. identify the performance obligations in the contract&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">iii. determine the transaction price&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">iv. allocate the transaction price to the performance obligations within the contract&#894; and</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">v. recognize revenue when (or as) the entity satisfies a performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company only applies the <em style="font: inherit;">five</em>-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At contract inception, once the contract is determined to be within the scope of ASC <em style="font: inherit;">606,</em> the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements typically consist of a license to intellectual property and research services. The Company <em style="font: inherit;"> may </em>provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are <em style="font: inherit;">not</em> individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration <em style="font: inherit;"> may </em>be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur when the uncertainty associated with the variable consideration is subsequently resolved.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s revenue arrangements <em style="font: inherit;"> may </em>include the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i>: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company <em style="font: inherit;">first</em> estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would <em style="font: inherit;">not</em> occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research Services</i>: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note <em style="font: inherit;">6</em> below), the Company would have been&#160;reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company would have recognized revenue for the reimbursed costs when the First Milestone Payment contingencies had&#160;been achieved and the Company had&#160;an enforceable claim to the reimbursed costs.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c125344280" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research and Development Costs</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development expense&#160;consists primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DeferredChargesPolicyTextBlock" id="c125344281" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Non-cancellable Contracts</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company <em style="font: inherit;"> may </em>record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs <em style="font: inherit;"> may </em>be recorded as a deferred cost asset.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DebtPolicyTextBlock" id="c125344282" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Convertible Notes Payable and Fair Value Election</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As permitted under FASB ASC Topic <em style="font: inherit;">825,</em> Financial Instruments (&#8220;<i>ASC <em style="font: inherit;">825</em></i>&#8221;), the Company elected to account for its promissory notes, which meet&#160;the required criteria, at fair value at inception. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying consolidated statements of operations and comprehensive loss.&#160;As a result of electing the fair value option, direct costs and fees related to the promissory notes are expensed as incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg&#8217;s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At <em style="font: inherit;"> September 30, 2024, </em>the Streeterville Note valuation&#160;was adjusted to the post settlement amount agreed upon. Interest expense is included within the change in fair value of the notes payable and accrued interest is included within the fair value of the convertible notes payable on the balance sheet. See Note <em style="font: inherit;">7</em> for Streeterville and Anson convertible notes. Management believes those assumptions are reasonable but if these assumptions change, it could materially affect the fair value.</p></ix:nonNumeric><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c125344285" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock-Based Compensation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company&#8217;s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations and comprehensive loss based upon the underlying individual&#8217;s role at the Company.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DerivativesPolicyTextBlock" id="c125344286" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC Topic <em style="font: inherit;">480,</em> <i>Distinguishing Liabilities from Equity</i> (&#8220;<i>ASC <em style="font: inherit;">480</em></i>&#8221;) and FASB ASC Topic <em style="font: inherit;">815,</em> <i>Derivatives and Hedging</i> (&#8220;<i>ASC <em style="font: inherit;">815</em></i>&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own Common Stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company generally determines&#160;fair value of the Common Stock&#160;Warrants (as defined below) using a Black Scholes valuation methodology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which <em style="font: inherit;"> may </em>result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:StockholdersEquityPolicyTextBlock" id="c125344287" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In accordance with ASC <em style="font: inherit;">480,</em> the Company&#8217;s Series A Preferred Stock was classified as permanent equity as it was <em style="font: inherit;">not</em> mandatorily redeemable upon an event that is considered outside of the Company&#8217;s control. Further, in accordance with ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40,</em> <i>Derivatives and Hedging </i>&#8211;<i> Contracts in an Entity</i>&#8217;<i>s Own Equity</i>, the Series A Preferred Stock did <em style="font: inherit;">not</em> meet any of the criteria that would preclude equity classification. The Company concluded that the Series A Preferred Stock was more akin to an equity-type instrument than a debt-type instrument, therefore the conversion features associated with the convertible preferred stock were deemed to be clearly and closely related to the host instrument and were <em style="font: inherit;">not</em> bifurcated as a derivative under ASC <em style="font: inherit;">815.</em></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><em style="font: inherit;"></em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c125344289" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Segment Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who reviews financial information presented for purposes of making operating decisions, assessing financial performance, and allocating resources.&#160;The Company operates as a single operating and reportable segment, consistent with the manner in which the CODM evaluates performance and allocates resources, see Note&#160;<em style="font: inherit;">12</em> for further information.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c125344290" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Income taxes are recorded in accordance with FASB ASC Topic <em style="font: inherit;">740,</em> <i>Income Taxes</i> (&#8220;<i>ASC <em style="font: inherit;">740</em></i>&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than <em style="font: inherit;">not</em> that some or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740.</em> When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than <em style="font: inherit;">not</em> be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than <em style="font: inherit;">not</em> be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c125344291" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Loss Per Share</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company applies the <em style="font: inherit;">two</em>-class method when computing net income or loss per share attributable to common stockholders. In determining net income or loss attributable to common stockholders, the <em style="font: inherit;">two</em>-class method requires income or loss allocable to participating securities for the period to be allocated between common and participating securities based on their respective rights to share in the earnings as if all of the income or loss allocable for the period had been distributed. In periods of net loss, there is <em style="font: inherit;">no</em> allocation required under the <em style="font: inherit;">two</em>-class method as the participating securities do <em style="font: inherit;">not</em> have an obligation to fund the losses of the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c2867422" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341429" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">121,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341430" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">264,983</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341431" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341432" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">124,167</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341433" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,173,766</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341434" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,321,499</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341435" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,920,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341436" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341437" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341438" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c125344292" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recent Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;"> November 2023, </em>the FASB&#160;issued Accounting Standard Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2023&#8209;07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>)-<i>Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>)</i>, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>&#160;should be applied on a retrospective basis.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>&#160;is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted. The Company has adopted the reportable segment disclosure requirements. See Note <em style="font: inherit;">12.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>-Income Taxes (Topic <em style="font: inherit;">740</em>): I<i>mprovements to Income Tax Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>)</i>, which is intended to enhance the transparency and decision usefulness of income tax disclosures, primarily by amending disclosure requirements for the effective tax rate reconciliation and income taxes paid.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;should be applied on a prospective basis, and retrospective application is permitted.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="c2867423" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em></b> <b>Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prepaid expenses and other current assets consisted of the following at the dates indicated (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c2867424" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expense and other current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341439" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">827</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341440" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,078</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid clinical development costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341441" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:PrepaidClinicalDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">824</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341442" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:PrepaidClinicalDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">871</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other prepaid expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341443" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">208</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341444" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">334</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341445" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherReceivablesNetCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341446" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherReceivablesNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total prepaid expense and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341447" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,859</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341448" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="c2867425" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em> Accrued and Other Current Liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accrued and other current liabilities consisted of the following at the dates indicated (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="c2867426" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued and other current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Refund liability (see Note 6)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341450" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,715</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341451" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341452" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,732</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341453" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,686</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Employee costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341454" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">577</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341455" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">835</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued research and development expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341456" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:AccruedResearchAndDevelopmentLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">655</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341457" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:AccruedResearchAndDevelopmentLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,112</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other accrued expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341458" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">470</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341459" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accrued and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341460" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,149</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341461" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,714</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c2867427" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em> Alvogen Licensing Agreement</b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">2023,</em> the Company entered into a License Agreement with Alvogen. Under the License Agreement, the Company granted Alvogen certain license rights&#160;to develop, manufacture, and commercialize the Company&#8217;s candidate therapeutic product, NRX-<em style="font: inherit;">101,</em> for the treatment of bipolar depression with suicidality.&#160;In exchange for the license granted and the participation of the Company in certain development, regulatory and commercial activities, Alvogen was obligated to pay the Company specified regulatory and commercial milestones, the <em style="font: inherit;">first</em> of which was $<ix:nonFraction id="c125341889" contextRef="i_2023-06-02_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementInitialPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">9</ix:nonFraction>&#160;million upon the later of a positive data read-out from the Company&#8217;s ongoing Phase <em style="font: inherit;">2b/3</em> clinical trial and completion of the Type B meeting with the FDA (the &#8220;<i>First Milestone Payment</i>&#8221;). In <em style="font: inherit;"> February 2024, </em>the parties executed an amendment accelerating payment of up to $<ix:nonFraction id="c125341891" contextRef="d_2024-02-01_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementAcceleratingPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">5</ix:nonFraction> million related to the First Milestone Payment, with the remaining $<ix:nonFraction id="c125341892" contextRef="i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementInitialPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">4</ix:nonFraction> million due upon the original agreement&#8217;s terms (see below for advances received through <em style="font: inherit;"> December 31, 2024). </em>As compensation for advancing the milestone, Alvogen received warrants to purchase up to <ix:nonFraction id="c125341893" contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">419,598</ix:nonFraction> shares of the Company's Common Stock, at a strike price of $<ix:nonFraction id="c125341894" contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction> with a <span style="-sec-ix-hidden:c125341895">three</span> year term (See Note <em style="font: inherit;">9</em>). The grant date fair value of the warrants was approximately $<ix:nonFraction id="c125341897" contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million, which the Company planned to account for as&#160;consideration paid to a customer (see below). The <em style="font: inherit;">second</em> portion of the <em style="font: inherit;">first</em> milestone was to be $<ix:nonFraction id="c125341900" contextRef="i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementInitialPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">4</ix:nonFraction> million and, as before, triggered by a positive response to the Company's planned end of phase <em style="font: inherit;">2</em> meeting with FDA.&#160;If the <em style="font: inherit;">first</em> milestone was <em style="font: inherit;">not</em> achieved by <em style="font: inherit;"> September 3, 2024, </em>the Company would have been obligated to repay any amount received against the $<ix:nonFraction id="c125341904" contextRef="d_2024-02-01_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementAcceleratingPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">5</ix:nonFraction> million advance of the First Milestone Payment to Alvogen. As there was significant uncertainty relative to approval of any drug candidate in development, the Company concluded that it was <em style="font: inherit;">not</em> probable that a significant reversal of revenue would <em style="font: inherit;">not</em> occur if the Company were to include the First Milestone Payment, or any advances thereof, in the transaction price prior to receiving FDA approval. Accordingly, the transaction price was fully constrained and advances from Alvogen were recorded as a refund liability until such time as the refund right expired. Further, the Company accounted for the warrants issued to Alvogen within additional paid-in capital consistent with the accounting for unfunded stock subscription agreements until such time as the uncertainty around the First Milestone was resolved. &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Termination</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Under the License Agreement, as amended, Alvogen was granted early termination rights. On <em style="font: inherit;"> June 21, 2024, </em>the Company received a notice of termination from Alvogen effective immediately.&#160;Following the termination of the License Agreement by Alvogen, the amounts advanced pursuant to the amendment&#160;became due and payable to Alvogen. Accordingly, the refund liability has <em style="font: inherit;">not</em> been reclassified to deferred revenue or recorded as revenue as of <em style="font: inherit;"> December 31, 2024 </em>and will remain permanent as refund liability until settled.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination.&#160;As of <em style="font: inherit;"> December 31, 2024, </em>the refund liability due to Alvogen was $<ix:nonFraction id="c125341908" contextRef="i_2024-12-31_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="us-gaap:CustomerRefundLiabilityCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.7</ix:nonFraction>&#160;million, which represents all payments made by Alvogen through <em style="font: inherit;"> December 31, 2024, </em>and is included as a component of accrued expense&#160;and other current liabilities on the consolidated balance sheet (refer to Note <em style="font: inherit;">5</em>).&#160;Following the early termination by Alvogen, the Company does <em style="font: inherit;">not</em> anticipate recognizing any revenue under the License Agreement. Additionally, in <em style="font: inherit;"> June 2024&#160;</em>the Company wrote-off the unfunded stock subscription receivable of $<ix:nonFraction id="c125341911" contextRef="d_2024-06-01_2024-06-30_TypeOfArrangementAxis-AlvogenLicensingAgreementMember" unitRef="USD" name="nrxp:StockSubscriptionsReceivableWriteOff" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million related to the warrants previously classified in additional paid-in capital&#160;to research and development expense following the termination.&#160;</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DebtDisclosureTextBlock" id="c2867428" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em> Debt </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Streeterville Convertible Note</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> November 4, 2022, </em>the Company issued an <ix:nonFraction id="c125341913" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">9</ix:nonFraction>% redeemable promissory note (as amended, the &#8220;<i>Streeterville</i>&#160;<i>Note</i>&#8221;) to Streeterville Capital, LLC, a Utah limited liability company (&#8220;<i>Streeterville</i>&#8221;), for an aggregate principal amount of $<ix:nonFraction id="c125341914" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">11.0</ix:nonFraction> million. The Streeterville Note originally matured&#160;<ix:nonNumeric contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" name="us-gaap:DebtInstrumentTerm" id="c125341915" format="ixt-sec:durmonth">18</ix:nonNumeric> months from the date of issuance subject to certain acceleration provisions. The Streeterville Note carried&#160;an original issue discount of $<ix:nonFraction id="c125341916" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million which was deducted from the principal balance of the Streeterville Note. The net proceeds from the issuance of the Streeterville Note was $<ix:nonFraction id="c125341917" contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million after transaction costs including the original issue discount, legal and other fees are included.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The initial terms of the Streeterville Note included the following provisions, certain of which were subsequently modified, as described below. The Company had&#160;the option to prepay the Streeterville Note during the term by paying an amount equal to <ix:nonFraction id="c125341918" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Pure" name="nrxp:DebtInstrumentPrepaymentPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="1">110</ix:nonFraction>% of the principal, interest, and fees owed as of the prepayment date. The noteholder had&#160;the right to redeem up to $<ix:nonFraction id="c125341919" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:DebtInstrumentRedemptionAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million of the outstanding balance of the Streeterville Note per month starting <em style="font: inherit;">six</em> months after the issuance date (the &#8220;<i>Maximum Monthly Redemption Amount</i>&#8221;). Payments could&#160;be made by the Company at their option in: (i) in cash with a <ix:nonFraction id="c125341921" contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Pure" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>% premium (the &#8220;<i>Redemption Premium</i>&#8221;) for the amount redeemed, (ii) by paying the redemption amount in the form of shares of Common Stock with the number of redemption shares being equal to the portion of the applicable redemption amount divided by the Redemption Conversion Price (as defined below), or (iii) a combination of cash and shares of Common Stock. The &#8220;<i>Redemption Conversion Price</i>&#8221; on any given redemption date equaled&#160;<ix:nonFraction id="c125341922" contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Pure" name="nrxp:DebtInstrumentRedemptionConversionPricePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">85</ix:nonFraction>% multiplied by the average of the <em style="font: inherit;">two</em> lowest daily volume weighted average prices per share of the Common Stock during the <em style="font: inherit;">ten</em> trading days immediately preceding the date that the noteholder delivered&#160;notice electing to redeem a portion of the Streeterville Note. Beginning <em style="font: inherit;"> May 1, 2023, </em>in the event (a) the daily dollar trading volume of the Common Stock of the Company on any given trading day was at least <em style="font: inherit;">fifty</em> percent (<em style="font: inherit;">50%</em>) greater than the lower of (i) the median daily dollar trading volume over the previous <em style="font: inherit;">ten</em> (<em style="font: inherit;">10</em>) trading days or (ii) the daily dollar trading volume on the trading day immediately preceding the date of measurement or (b) if the closing trade price on any given trading day was at least <em style="font: inherit;">thirty</em> percent (<em style="font: inherit;">30%</em>) greater than the Nasdaq Minimum Price, then the lender would be entitled to redeem over the following <em style="font: inherit;">ten</em> (<em style="font: inherit;">10</em>) trading days an amount of indebtedness then outstanding under the Streeterville Note equal to twice the monthly redemption amount of $<ix:nonFraction id="c125341933" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:DebtInstrumentRedemptionAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million solely by payment by stock, if permitted under the agreement, subject to the Maximum Percentage (as defined in the Streeterville Note) and other ownership limitations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Streeterville Note contained&#160;certain Trigger Events (as defined in the Streeterville Note) that generally, if uncured within <em style="font: inherit;">five</em> trading days, could result in an event of default in accordance with the terms of the Streeterville Note (such event, an &#8220;<i>Event of Default</i>&#8221;). Upon an Event of a Default, the Lender could consider the Streeterville Note immediately due and payable. Upon an Event of Default, the interest rate could&#160;also be increased to the lesser of <ix:nonFraction id="c125341937" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Pure" name="nrxp:DebtInstrumentConditionalDefaultInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">18</ix:nonFraction>% per annum or the maximum rate permitted under applicable law (see below).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Due to these embedded features within the Streeterville Note, the Company elected to account for the Streeterville Note at fair value at inception. Subsequent changes in fair value were recorded as a component of other income (loss) in the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><span style="text-decoration: underline; ">Streeterville</span></i><i><span style="text-decoration: underline; ">Convertible Note Amendments</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 30, 2023, </em>the Company entered into an Amendment to the Note (the &#8220;<i>First Amendment</i>&#8221;), pursuant to which the Maximum Percentage was set at <ix:nonFraction id="c125341938" contextRef="d_2023-03-30_2023-03-30_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Pure" name="nrxp:DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" scale="-2" format="ixt:num-dot-decimal" decimals="4">9.99</ix:nonFraction>% of the number of shares of Common Stock outstanding on a given date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 7, 2023, </em>the Company entered into Amendment <em style="font: inherit;">#2</em> to the Streeterville Note with Streeterville (the &#8220;<i>Second Amendment</i>&#8221;). Pursuant to the Second Amendment, the Company agreed to amend the redemption provisions of the Streeterville Note to provide that the Company would pay to Streeterville an amount in cash equal to $<ix:nonFraction id="c125341940" contextRef="d_2023-07-10_2023-07-10_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member" unitRef="USD" name="us-gaap:RepaymentsOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.8</ix:nonFraction> million on or before <em style="font: inherit;"> July 10, 2023, </em>which amount was paid on <em style="font: inherit;"> July 10, 2023. </em>In addition, the Company agreed that, beginning on or before <em style="font: inherit;"> July 31, 2023, </em>and on or before the last day of each month until <em style="font: inherit;"> December 31, 2023, </em>the Company would pay Streeterville an amount equal to $<ix:nonFraction id="c125341941" contextRef="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million in cash, less any amount satisfied by the delivery of Redemption Conversion Shares (as defined below). Notwithstanding the foregoing, Streeterville could also submit a request for redemption of up to an aggregate of $<ix:nonFraction id="c125341942" contextRef="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member_RangeAxis-MaximumMember" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million per month in accordance with the terms of the Second Amendment. However, the portion of each payment that was <em style="font: inherit;">not</em> satisfied by the delivery of Redemption Conversion Shares was the maximum amount of cash the Company would have been&#160;required to pay in accordance with the Second Amendment during the period from <em style="font: inherit;"> July 31, 2023 </em>and on or before the last day of each month until <em style="font: inherit;"> December 31, 2023. </em>The redemption of the Maximum Monthly Redemption Amount in excess of the Minimum Amount would be satisfied by the delivery of additional Redemption Conversion Shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> February 9, 2024, </em>the Company entered into Amendment <em style="font: inherit;">#3</em> to the Streeterville Note (the &#8220;<i>Third Amendment</i>&#8221;), with Streeterville. In accordance with the Third Amendment, the Company and Streeterville agreed to amend the redemption provisions of the Streeterville Note to provide that the Company would pay to Streeterville an amount in cash equal to $<ix:nonFraction id="c125341945" contextRef="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member" unitRef="USD" name="us-gaap:RepaymentsOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.1</ix:nonFraction> million on <em style="font: inherit;"> February 12, 2024, </em>which the amount was paid on <em style="font: inherit;"> February 12, 2024. </em>In addition, beginning on or before <em style="font: inherit;"> February </em><em style="font: inherit;">29,</em> <em style="font: inherit;">2024,</em> and on or before the last day of each month until <em style="font: inherit;"> July 31, 2024, </em>the Company was obligated to pay Streeterville an amount equal to $<ix:nonFraction id="c125341948" contextRef="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million in cash, less any amount satisfied by the delivery of Redemption Conversion Shares. During the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of this amended payment period, Streeterville could <em style="font: inherit;">not</em> request to redeem amounts greater than $<ix:nonFraction id="c125341952" contextRef="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million per month.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">After <em style="font: inherit;"> April&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024,</em> and for the remainder of the payment period through <em style="font: inherit;"> July 31, 2024, </em>Streeterville could redeem any Redemption Amount (as defined in the Streeterville Note), including an amount in excess of the Minimum Payment, subject to the Maximum Monthly Redemption Amount. During the period through <em style="font: inherit;"> July 31, 2024, </em>the Company was&#160;permitted to pay the Redemption Amounts by delivery of the Redemption Conversion Shares (as defined below) without regard to the existence of any Equity Conditions Failure, to the extent Streeterville submits&#160;redemption notices during such month pursuant to the terms of the Streeterville Note, and only for the Redemption Amounts covered by such notices. Moreover, the Redemption Premium would continue to apply to the Redemption Amounts. To the extent there was an outstanding balance under the Streeterville Note after <em style="font: inherit;"> July 31, 2024, </em>the Company would be required to pay such outstanding balance in full in cash by <em style="font: inherit;"> August 31, 2024. </em>As a result of the alleged Event of Default mentioned below, the Company did <em style="font: inherit;">not</em> pay any&#160;Redemption Amounts during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024,</em> prior to the settlement, also as described below.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the Minimum Payment Period (defined in the Streeterville Note, as amended), the Company was&#160;permitted to pay the Redemption Amounts in the form of shares of Common Stock of the Company (the &#8220;<i>Redemption Conversion Shares</i>&#8221;) calculated on the basis of the Redemption Conversion Price (as defined in the Streeterville Note) without regard to the existence of an Equity Conditions Failure. Moreover, the Redemption Premium (as defined in the Streeterville Note) would continue to apply to the Redemption Amounts.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Both the Second Amendment and the Third Amendment (considered cumulatively with the Second Amendment) were deemed to be debt modifications and did&#160;<em style="font: inherit;">not</em> give rise to a debt extinguishment&#160;in accordance with FASB ASC Topic <em style="font: inherit;">470,</em> <i>Debt</i>, which was accounted for prospectively. The modification did <em style="font: inherit;">not</em> result in recognition of a gain or loss in the consolidated statements of operations as the modifications were <em style="font: inherit;">not</em> considered debt extinguishments, but impacted interest expense recognized in subsequent periods, prior to the settlement of the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Convertible Note Fair Value Measurements</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company estimated&#160;the fair value of the Streeterville Note using a Monte Carlo simulation model, which used&#160;as inputs the fair value of its Common Stock and estimated&#160;for the equity volatility and volume volatility of its Common Stock, the time to expiration of the Streeterville Note, the risk-free interest rate for a period that approximated&#160;the time to expiration, and probability of default. Therefore, the Company estimated&#160;its expected future volatility based on the actual volatility of its Common Stock and historical volatility of its Common Stock utilizing a lookback period consistent with the time to expiration. The time to expiration was&#160;based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning <em style="font: inherit;">six</em> months from the issuance date. The risk-free interest rate was&#160;determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default was estimated using either Bloomberg's Default Risk function, which uses&#160;its financial information to calculate a default risk specific to the Company, or&#160;management's estimates which included, the Company's current cash runway,&#160;current efforts to raise financing,&#160;and current economic environment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The discount to the principal amount was included in the carrying value of the Streeterville Note. During <em style="font: inherit;">2022,</em> the Company recorded a debt discount of approximately $<ix:nonFraction id="c125341967" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million upon issuance of the Streeterville Note for the original issue discount of $<ix:nonFraction id="c125341968" contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million. As a result of electing the fair value option, any direct costs and fees related to the Streeterville Note were expensed as incurred. For the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company recorded a gain from the change in fair value of the Streeterville Note&#160;of $<ix:nonFraction id="c125341970" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueAdjustment" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.8</ix:nonFraction> million and $<ix:nonFraction id="c125341971" contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueAdjustment" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.7</ix:nonFraction> million, respectively, which was recognized in other (income) expense on the consolidated statements of operations as a result of the Company&#8217;s election of the fair value option.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2024, </em>the Company made cash principal repayments on the Note of approximately $<ix:nonFraction id="c125341972" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:RepaymentsOfDebt" scale="3" format="ixt:num-dot-decimal" decimals="-2">7.4</ix:nonFraction> million, made cash interest payments on the Note of approximately $<ix:nonFraction id="c125341973" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million, including $<ix:nonFraction id="c125341974" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:RedemptionPremium" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million of redemption premiums, issued shares of Common Stock as principal repayment of $<ix:nonFraction id="c125341975" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million, and issued shares of Common Stock as interest repayment of $<ix:nonFraction id="c125341976" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, and incurred a default penalty&#160;of $<ix:nonFraction id="c125341977" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction>&#160;million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company made cash principal repayments on the Note of approximately $<ix:nonFraction id="c125341978" contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:RepaymentsOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.3</ix:nonFraction> million, made cash interest payments on the Note of approximately $<ix:nonFraction id="c125341979" contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million, including $<ix:nonFraction id="c125341980" contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:RedemptionPremium" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of redemption premiums, issued shares of Common Stock as principal repayment of $<ix:nonFraction id="c125341981" contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction> million, and issued shares of Common Stock as interest repayment of $<ix:nonFraction id="c125341982" contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Note carried a remaining principle balance of $<ix:nonFraction id="c125341984" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and $<ix:nonFraction id="c125341985" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.3</ix:nonFraction> million, respectively. Refer to Note <em style="font: inherit;">11</em> for the reconciliation of the fair values for the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Alleged Default</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> April 24, 2024, </em>the Company received written notice from counsel for Streeterville that an alleged event of default occurred with respect to the Streeterville Note issued by the Company in favor of Streeterville (the &#8220;<i>Notice</i>&#8221;). The Notice alleged that, among other things, (i) the announcement of the plan to partially spin-off of HOPE (the &#8220;<i>Spin-Off</i>&#8221;), constituted a &#8220;Fundamental Transaction&#8221; (as defined in the Streeterville Note) for which the Company failed to obtain Streeterville&#8217;s prior written consent before undertaking such transaction; and (ii) the Company failed to pay the Minimum Payment, as defined in the Streeterville Note, by <em style="font: inherit;"> April 8, 2024, </em>following a Redemption Notice issued on <em style="font: inherit;"> April 3, 2024 </em>by Streeterville to the Company, each of which resulted in the failure to cure a Trigger Event and subsequent Event of Default of the Streeterville Note, resulting in the acceleration of all of the outstanding amounts due thereunder.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Streeterville also filed a complaint (the &#8220;<i>Complaint</i>&#8221;) naming the Company as a defendant in the Third Judicial District Court of Salt Lake County, Utah. The Complaint was seeking, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing Common Stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but <em style="font: inherit;">no</em> less than $<ix:nonFraction id="c125341990" contextRef="d_2024-04-24_2024-04-24_LitigationCaseAxis-StreetervileComplaintMember" unitRef="USD" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction> million, or the amounts currently outstanding under the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 29, 2024, </em>in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company&#160;announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin Spin-Off of <ix:nonFraction id="c125341991" contextRef="d_2024-07-29_2024-07-29_LitigationCaseAxis-StreetervileComplaintMember" unitRef="Pure" name="nrxp:StockholdersEquityNoteSpinoffTransactionPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">49</ix:nonFraction>% of shares in HOPE&#160;to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#8217;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a&#160;national exchange. The arbitrator also denied Streeterville&#8217;s petition to enjoin the Company&#160;from selling additional shares of Common Stock to finance ongoing operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Streeterville Settlement</span></i><span style="text-decoration: underline; ">&#160;</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 12, 2024, </em>the Company and Streeterville entered into a Settlement and Release of Claims (the &#8220;Settlement Agreement&#8221;), whereby the Company and Streeterville agreed to settle all disputes between the parties and release the Company from all obligations arising from the Notes at certain Securities Purchase Agreement, dated <em style="font: inherit;"> November 4, 2022 (</em>&#8220;Streeterville Notes&#8221;), between the Company and Streeterville, and that certain Convertible Promissory Note, dated <em style="font: inherit;"> November 4, 2022, </em>issued to Streeterville by the Company, in exchange for a payment of $<ix:nonFraction id="c125341992" contextRef="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember" unitRef="USD" name="nrxp:LitigationSettlementPaymentInstallmentOne" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.5</ix:nonFraction> million upon the initial closing of the sale of the Anson Notes, and within <em style="font: inherit;">60</em> days thereafter, a <em style="font: inherit;">second</em> payment of $<ix:nonFraction id="c125341995" contextRef="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember" unitRef="USD" name="nrxp:LitigationSettlementPaymentInstallmentTwo" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.05</ix:nonFraction> million. The Company made the $<ix:nonFraction id="c125341996" contextRef="d_2024-08-15_2024-08-15_LitigationCaseAxis-StreetervileComplaintMember" unitRef="USD" name="us-gaap:PaymentsForLegalSettlements" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.5</ix:nonFraction> million payment upon the Anson Notes closing on&#160;<em style="font: inherit;"> August 15, 2024. </em>The Company made the final $<ix:nonFraction id="c125341997" contextRef="d_2024-10-01_2024-10-31_LitigationCaseAxis-StreetervileComplaintMember" unitRef="USD" name="us-gaap:PaymentsForLegalSettlements" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.05</ix:nonFraction> million payment in <em style="font: inherit;"> October 10, 2024 </em>using proceeds from the Second Closing of Anson Convertible Promissory Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluated the terms of the Settlement Amendment in accordance with ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">50,</em> <i>Debt Modifications and Extinguishments</i>. Both the Settlement Amendment and the Third Amendment (considered cumulatively with the Settlement Amendment) were deemed to be debt modifications&#160;and did <em style="font: inherit;">not</em> give rise to a debt extinguishment in accordance with ASC <em style="font: inherit;">Topic&#8239;470,&#8239;</em><i>Debt</i>, which will be accounted for prospectively. The modifications did <em style="font: inherit;">not</em> result in recognition of a gain or loss in the consolidated statements of operations as the modifications were <em style="font: inherit;">not</em> considered debt extinguishments, but will impact interest expense and the determination of fair value&#160;in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Streeterville Note as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ConvertibleDebtTableTextBlock" id="c6A6A5597-C572-4F6C-9419-213A3E3D21D4" escape="true" continuedAt="C3E25792-F6E3-49EC-9178-E2150EE9D837">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Par value of the Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341463" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">11,020</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341464" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">11,020</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized original issue discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341465" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" format="ixt:num-dot-decimal" decimals="-3">497</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341466" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" format="ixt:num-dot-decimal" decimals="-3">497</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341467" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:num-dot-decimal" decimals="-3">849</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341468" contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares and cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341469" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,324</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341470" contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,072</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carrying value of the Note before current period change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341471" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:LongtermDebtTotal" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">952</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341472" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:LongtermDebtTotal" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,451</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cumulative fair value adjustments through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341473" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">952</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341474" contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cumulative fair value adjustments through accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341475" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341476" contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total carrying value of Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341477" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341478" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341479" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341480" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341481" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341482" contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anson Convertible Promissory Notes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 12, 2024, </em>the Company entered into the Purchase Agreement with Investors. The Company agreed to sell, in <span style="-sec-ix-hidden:c125342005">three</span> equal tranches, original issue discount Anson Notes&#160;in the aggregate principal amount of up to approximately $<ix:nonFraction id="c125342006" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">16.3</ix:nonFraction> million&#160;for an aggregate purchase price of up to approximately $<ix:nonFraction id="c125342007" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">15.0</ix:nonFraction> million&#160;and warrants to purchase that amount of shares equal to <ix:nonFraction id="c125342008" contextRef="i_2024-08-12_ClassOfWarrantOrRightAxis-AnsonWarrantsMember" unitRef="Pure" name="nrxp:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% of the principal amount of the Notes divided by the VWAP&#160;of the Company&#8217;s Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Anson Warrants.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the above offering, the Company engaged EF Hutton LLC as placement agent (the &#8220;Placement Agent&#8221;), Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of <ix:nonFraction id="c125342011" contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="Pure" name="nrxp:PlacementAgentFeePercentOfGrossProceeds" scale="-2" format="ixt:num-dot-decimal" decimals="2">7</ix:nonFraction>% of the gross proceeds the Company receives in the offering at closing.&#8239;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; "><em style="font: inherit;">2024</em> Senior Secured Convertible Promissory Notes</span></i><span style="text-decoration: underline; ">&#160;</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 14, 2024, </em>the Company entered into the <em style="font: inherit;">first</em> tranche Senior Secured Convertible Note Agreements (the &#8220;First Tranche Notes&#8221;) with Anson Investment Master Fund LP and Anson East Master Fund LP (collectively &#8220;Anson&#8221;) at various amounts for an aggregate of $<ix:nonFraction id="c125342014" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">5.435</ix:nonFraction> million subject to an original issuance discount of <ix:nonFraction id="c125342015" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="Pure" name="nrxp:DebtInstrumentOriginalIssuanceDiscount" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>% or $<ix:nonFraction id="c125342016" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" format="ixt:num-dot-decimal" decimals="INF">435,000</ix:nonFraction>, less other cash issuance costs of $<ix:nonFraction id="c125342017" contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="nrxp:DebtIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">521,000</ix:nonFraction>, resulting in net cash proceeds of $<ix:nonFraction id="c125342018" contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.5</ix:nonFraction>&#160;million, prior to any allocation to the Anson Warrants. The First Tranche Notes bear interest at a rate of <ix:nonFraction id="c125342019" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">6</ix:nonFraction>% per annum (or <ix:nonFraction id="c125342020" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="Pure" name="nrxp:DebtInstrumentInterestRateInEventOfDefault" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>% during the occurrence of any Event of Default (as defined in the First Tranche Notes)) and have a term of <ix:nonNumeric contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" name="us-gaap:DebtInstrumentTerm" id="c125342021" format="ixt-sec:durmonth">15</ix:nonNumeric> months from the issuance date, maturing on <em style="font: inherit;"> November 14, 2025&#160;(</em>the &#8220;First Tranche Maturity Date&#8221;) (see Note <em style="font: inherit;">9</em>).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 14, 2024, </em>in conjunction with the issuance of the First Tranche Notes, the Company issued warrants&#160;to purchase up to <ix:nonFraction id="c125342023" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,349,305</ix:nonFraction> shares of the Company&#8217;s Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The First Tranche Notes are convertible at the option of the holder at any time after issuance into Common Stock, at a per share conversion price equal to&#160;the lower of (a) $<ix:nonFraction id="c125342024" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.4168</ix:nonFraction>, (the &#8220;Fixed Conversion Price&#8221;) or (b) a price equal to <ix:nonFraction id="c125342025" contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" format="ixt:num-dot-decimal" decimals="2">92</ix:nonFraction>% of the lowest VWAP during the <em style="font: inherit;">seven</em> trading day period immediately preceding the effective conversion date (the &#8220;Alternate Conversion Price&#8221;, and together with the Fixed Conversion Price, the &#8220;Conversion Price&#8221;). If the Conversion Price is less than $<ix:nonFraction id="c125342027" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.38</ix:nonFraction> (the &#8220;Floor Price&#8221;), then in addition to the issuance of Common Stock upon conversion the Company will pay cash as a true-up which is determined by the product of (i) the difference between (y) the Floor Price less (z) the Conversion Price then in effect, multiplied by (ii) the conversion amount that is being paid in Common Stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The terms of the First Tranche&#160;Notes do <em style="font: inherit;">not</em> allow any conversion of the First Tranche Notes if it results in Anson owning more than <em style="font: inherit;">4.99%</em> of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation"). This limitation can be adjusted up to <em style="font: inherit;">9.99%</em> with prior notice, effective <em style="font: inherit;">61</em> days after such notice. Anson&#160;must ensure compliance with this limitation when submitting a notice of conversion, and the Company will rely on Anson's&#160;representation of compliance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company issues or grants options for Common Stock at a price lower than the current Conversion Price, the Conversion Price will be adjusted to match this lower price, (the&#160;&#8220;Base Conversion Price&#8221;). The Company must notify Anson of any such issuance, and Anson&#160;is entitled to convert shares based on the new Base Conversion Price.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company offers purchase rights to holders of Common Stock, Anson will be entitled to acquire those rights as if they had fully converted the Note, subject to the Beneficial Ownership Limitation. If exercising these rights would exceed the Beneficial Ownership Limitation, the rights will be held in abeyance until they can be exercised without exceeding the limit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The First Tranche Notes contain mandatory redemption features, whereby if at any time the First Tranche Notes are outstanding, the Company will be required to: (A) use up to <em style="font: inherit;">30%</em> of the gross proceeds from any Subsequent Financings (as defined in the Purchase Agreement) in cash, to redeem all or a portion of the Note for an amount equal to the outstanding principal, plus all accrued but unpaid interest, plus all liquidated damages (the &#8220;Redemption&#8239;Obligations&#8221;), multiplied by <em style="font: inherit;">1.05</em> (the &#8220;Mandatory Redemption Amount&#8221;)&#894; (B) redeem all of the Redemption Obligations at the Mandatory Redemption Amount in the event of a Change of Control Transaction (as defined in the First Tranche Notes)&#894; (C) redeem the Redemption Obligations for the Mandatory Redemption Amount in the event a registration statement is <em style="font: inherit;">not</em> available for each of the offer and resale of the shares issuable upon conversion of the First Tranche Notes (the &#8220;Conversion Shares&#8221;)&#894; and (D) redeem the Redemption Obligations for the Mandatory Redemption Amount if the Shareholder Approval is <em style="font: inherit;">not</em> obtained within <em style="font: inherit;">180</em> days following the date of issuance of the First Tranche Notes.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The First Tranche Notes contain certain covenants, and events of default and triggering events, respectively, which would require repayment of the obligations outstanding pursuant to such instruments. The obligations of the Company pursuant to the First Tranche Notes are (i) secured by all assets of the Company and all subsidiaries of the Company pursuant to the Security Agreement and Patent Security Agreement, dated <em style="font: inherit;"> August 14, 2024, </em>by and among the Company, the subsidiaries of the Company, and the Investors, and (ii) guaranteed jointly and severally by the subsidiaries of the Company pursuant to the Subsidiary Guarantee, dated <em style="font: inherit;"> August 14, 2024, </em>by and among the Company, the subsidiaries of the Company, and the Investors.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to the Purchase Agreement, on <em style="font: inherit;"> October 10, 2024 (</em>the &#8220;Second Closing Date&#8221;), the Company sold a total of $<ix:nonFraction id="c125342039" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">5.435</ix:nonFraction> million in Notes (the &#8220;Second Tranche Notes&#8221;, and collectively with the First Tranche Notes, the ("Anson Notes")) subject to an original issue discount of <ix:nonFraction id="c125342040" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="Pure" name="nrxp:DebtInstrumentOriginalIssuanceDiscount" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>% or $<ix:nonFraction id="c125342041" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" format="ixt:num-dot-decimal" decimals="INF">435,000</ix:nonFraction> less other cash issuance cost of $<ix:nonFraction id="c125342042" contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="nrxp:DebtIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">375,000</ix:nonFraction>, with an aggregate purchase price of approximately $<ix:nonFraction id="c125342043" contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" format="ixt:num-dot-decimal" decimals="-6">5.0</ix:nonFraction> million, and Warrants to purchase up to <ix:nonFraction id="c125342044" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,846,128</ix:nonFraction> shares of Common Stock. The Second Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $<ix:nonFraction id="c125342045" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.7664</ix:nonFraction> or (b) a price equal to <ix:nonFraction id="c125342046" contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" format="ixt:num-dot-decimal" decimals="2">92</ix:nonFraction>% of the lowest VWAP during the <em style="font: inherit;">seven</em> trading day period immediately preceding the effective date set forth in a Notice of Conversion delivered by an Investor to the Company. The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of common stock below the then effective Conversion Price. $<ix:nonFraction id="c125342048" contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-StreetervileComplaintMember" unitRef="USD" name="us-gaap:PaymentsForLegalSettlements" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.05</ix:nonFraction> million of the note proceeds were used to repay the Streeterville note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the above Second Tranche Notes&#8221;, the Company engaged Placement Agent. Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of <ix:nonFraction id="c125342049" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="Pure" name="nrxp:PlacementAgentFeePercentOfGrossProceeds" scale="-2" format="ixt:num-dot-decimal" decimals="2">7</ix:nonFraction>%&#160;of the gross proceeds the Company received&#160;in the Second Closing and incurred certain additional other issuance costs and reimbursement for legal counsel disbursements and placement agent, for aggregate issuance costs of approximately&#160;$<ix:nonFraction id="c125342050" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsGross" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction>&#160;million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Due to these embedded features within the Anson Notes, the Company elected to account for the First and Second Tranche Notes at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the consolidated statements of operations. Additionally the portion of changes in the fair value related to changes in credit risk are recorded to other comprehensive income in the consolidated statements of operations. To determine the initial carrying value of the Notes and the warrants issued to Anson under the First and Second Tranche Notes (see Note <em style="font: inherit;">9</em>), the Company allocated the proceeds using the fair value method. After allocation, the initial carrying value of the First Tranche Notes and the warrants issued to Anson were $<ix:nonFraction id="c125342052" contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.9</ix:nonFraction> million and $<ix:nonFraction id="c125342053" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million, respectively, and the initial carrying value of the Second Tranche Notes and the warrants issued to Anson were $<ix:nonFraction id="c125342054" contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.1</ix:nonFraction> million and $<ix:nonFraction id="c125342055" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.9</ix:nonFraction> million, respectively&#160;Refer to Note <em style="font: inherit;">11</em> for the reconciliation of the fair values for the periods presented.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the&#160;year ended <em style="font: inherit;"> December 31, 2024,&#160;</em>Anson converted $<ix:nonFraction id="c125342057" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.2</ix:nonFraction> million of principal and interest of the First Tranche Note into common stock, resulting in the issuances of <ix:nonFraction id="c125342058" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,676,796</ix:nonFraction> shares of Common Stock and loss on redemption&#160;of $<ix:nonFraction id="c125342059" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million (see Note 9).&#160;As of <em style="font: inherit;"> December 31, 2024, </em>the principal and accrued interest balance of the Anson Notes&#160;was $<ix:nonFraction id="c125342061" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-4">6.75</ix:nonFraction> million and $<ix:nonFraction id="c125342062" contextRef="i_2023-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively. During the&#160;year ended <em style="font: inherit;"> December 31, 2024, </em>the Company&#160;recorded a loss from the change in fair value of the First Tranche Notes of $<ix:nonFraction id="c125342063" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueAdjustment" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.4</ix:nonFraction> million, which was recognized in other (income) expense on the consolidated statements of operations as a result of the Company&#8217;s election of the fair value option.&#160;At <em style="font: inherit;"> December 31, 2024&#160;</em>the effective interest rate of the First and the Second Tranche Note was <ix:nonFraction id="c125342064" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">82</ix:nonFraction>% and <ix:nonFraction id="c125342065" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonSecondTrancheNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">53</ix:nonFraction>%, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From <em style="font: inherit;"> January 2, 2025 </em>to <em style="font: inherit;"> January 3, 2025, </em>the Company received conversion notices from Anson resulting in the conversion of the remaining principal of the First Tranche Note of $<ix:nonFraction id="c125342066" contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million of principal and interest in full from the First Tranche Note into <ix:nonFraction id="c125342067" contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,004,055</ix:nonFraction> shares of Common Stock (see Note <em style="font: inherit;">15</em>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Anson Notes as of <em style="font: inherit;"> December 31, 2024 (</em>in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="C3E25792-F6E3-49EC-9178-E2150EE9D837">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Par value of the Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341483" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">10,870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Initial original issue discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341484" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" format="ixt:num-dot-decimal" decimals="-4">870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341485" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt" scale="3" format="ixt:num-dot-decimal" decimals="-4">4,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carrying value of the Anson Notes before current period change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341486" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:num-dot-decimal" decimals="-4">5,810</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Fair value allocated to Common Stock liability classified warrants</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">(<ix:nonFraction id="c125341487" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,966</ix:nonFraction></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341488" contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,413</ix:nonFraction></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total carrying value of Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341489" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,257</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341490" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341491" contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,011</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2867431" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Sarah Herzog Memorial Hospital License Agreement</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is required to make certain payments related to the development of NRX-<em style="font: inherit;">101</em> (the "<i>Licensed Product</i>") in order to maintain the license agreement with the Sarah Herzog Memorial Hospital Ezrat Nashim (&#8220;<i>SHMH</i>&#8221;) (the "<i>SHMH License Agreement</i>"), including:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="nrxp:ScheduleOfMilestonePaymentsTableTextBlock" id="c2867432" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase I Clinical Trials of Licensed Product (completed)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341492" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase II Clinical Trials of Licensed Product (completed)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341493" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">250,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase III Clinical Trials of Licensed Product</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341494" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">250,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in U.S.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341495" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInUsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341496" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInEuropeMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual Revenues Reach $100,000,000</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341497" contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-AnnualRevenueThresholdMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">750,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The milestone payments due above <em style="font: inherit;"> may </em>be reduced by <ix:nonFraction id="c125342073" contextRef="i_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="Pure" name="nrxp:LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% in certain circumstances, and by the application of certain sub-license fees. As of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the total cumulative payments made under the <i>SHMH License Agreement</i> were $<ix:nonFraction id="c125342075" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementCumulativePayments" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million, with <ix:nonFraction id="c125342076" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> payments made during the year ended <em style="font: inherit;"> December 31, 2024, </em>and $<ix:nonFraction id="c125342077" contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.2</ix:nonFraction> million and $<ix:nonFraction id="c125342078" contextRef="d_2022-01-01_2022-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMilestonePayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.2</ix:nonFraction> million payments made during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Royalties</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A royalty in an amount equal to: (a) <ix:nonFraction id="c125342080" contextRef="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByLicensedPatentsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="Pure" name="nrxp:RoyaltyPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">1</ix:nonFraction>% of revenues from the sale of any product incorporating a Licensed Product when at least <em style="font: inherit;">one</em> Licensed Patent remains in force, if such product is <em style="font: inherit;">not</em> covered by a Valid Claim (as defined below) in the country or region in which the sale occurs, or (b) <ix:nonFraction id="c125342083" contextRef="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByValidClaimsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="Pure" name="nrxp:RoyaltyPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">2.5</ix:nonFraction>% of revenues from the sale of any Licensed Product that is covered by at least <em style="font: inherit;">one</em> Valid Claim in the country or region in which such product is manufactured or sold. A &#8220;Valid Claim&#8221; means any issued claim in the Licensed Patents that remains in force and that has <em style="font: inherit;">not</em> been finally invalidated or held to be unenforceable. The royalty rates above <em style="font: inherit;"> may </em>be doubled if we commence a legal challenge to the validity, enforceability or scope of any of the Licensed Patents during the term of the SHMH License Agreement and do <em style="font: inherit;">not</em> prevail in such proceeding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of <ix:nonFraction id="c125342087" contextRef="i_2024-12-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="Pure" name="nrxp:RoyaltyPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">8.5</ix:nonFraction>% of the payments received by us from sub-licensees in connection with such sales. During the&#160;years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> <ix:nonFraction id="c125342089" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="us-gaap:PaymentsForRoyalties" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> royalty payments were made.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Annual Maintenance Fee</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A fixed amount of $<ix:nonFraction id="c125342090" contextRef="d_2021-04-16_2021-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:PaymentForLicenseAgreementMaintenanceFee" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000</ix:nonFraction> was paid on <em style="font: inherit;"> April 16, 2021 </em>and, thereafter, a fixed amount of $<ix:nonFraction id="c125342091" contextRef="i_2022-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:LicenseAgreementMaintenanceFee" scale="0" format="ixt:num-dot-decimal" decimals="INF">150,000</ix:nonFraction> is due on the anniversary of such date during the term of the SHMH License Agreement. The Company paid $<ix:nonFraction id="c125342092" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember" unitRef="USD" name="nrxp:PaymentForLicenseAgreementMaintenanceFee" scale="0" format="ixt:num-dot-decimal" decimals="INF">150,000</ix:nonFraction> in annual maintenance fees in each of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> expensed through Research and Development expenses in the accompanying Consolidated Statement of Operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Exclusive License Agreement </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has entered into a License Agreement with Apkarian Technologies to in-license US Patent <em style="font: inherit;">8,653,120</em> that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-<em style="font: inherit;">101</em> to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. For the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company has recorded <ix:nonFraction id="c125342097" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#160;expenses relating to the licensure of the patent.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Operating Lease</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company leases office space on a&#160;month-to-month basis. The rent expense for the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> was $<ix:nonFraction id="c125342099" contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and $<ix:nonFraction id="c125342100" contextRef="d_2023-01-01_2023-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From time to time the Company is involved in litigation, claims, and other proceedings arising in the ordinary course of business. Litigation and other disputes are inherently unpredictable and subject to substantial uncertainties and unfavorable resolutions could occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company was a defendant in litigation filed by Streeterville in the Third Judicial District Court of Salt Lake County, Utah. See Note <em style="font: inherit;">7,</em> Debt, for additional information. The Complaint&#160;sought, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing Common Stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but <em style="font: inherit;">no</em> less than $<ix:nonFraction id="c125342103" contextRef="d_2024-04-24_2024-04-24_LitigationCaseAxis-StreetervileComplaintMember" unitRef="USD" name="us-gaap:LossContingencyDamagesSoughtValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,537,027</ix:nonFraction>, or the amounts currently outstanding under the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 29, 2024, </em>in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company&#160;announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin the planned Spin-Off of <ix:nonFraction id="c125342106" contextRef="d_2024-07-29_2024-07-29_LitigationCaseAxis-StreetervileComplaintMember" unitRef="Pure" name="nrxp:StockholdersEquityNoteSpinoffTransactionPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">49</ix:nonFraction>% of shares in HOPE to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#8217;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a&#160;national exchange. The arbitrator also denied Streeterville&#8217;s petition to enjoin the Company&#160;from selling additional shares of Common Stock to finance ongoing operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> August 12, 2024, </em>the Company signed a settlement agreement with Streeterville&#160;to retire its remaining debt for a settlement amount of $<ix:nonFraction id="c125342107" contextRef="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction>&#160;million and to settle outstanding litigation. This settlement amount was substantially less than the amounts claimed by Streeterville in its Compliant&#160;(see Note <em style="font: inherit;">7</em>). As of <em style="font: inherit;"> September 30, 2024, </em>the fair value of the Streeterville Note&#160;was adjusted to the settlement amount which was repaid in <em style="font: inherit;"> October 2024. </em>Such adjustment is included within the change in fair value of convertible notes payable on the consolidated statement of operations, therefore <ix:nonFraction id="c125342109" contextRef="d_2024-01-01_2024-12-31_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> gain or loss on the settlement was recorded.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> July 17, 2023, </em>NeuroRx&#160;and GEM entered into a settlement and release agreement (the &#8220;Settlement Agreement&#8221;) pursuant to which the parties agreed to dismiss the arbitration proceeding with prejudice.&#160;Pursuant to the Settlement Agreement on <em style="font: inherit;"> August 31, 2023, </em>the Company issued&#160;<ix:nonFraction id="c125342110" contextRef="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">67,568</ix:nonFraction>&#160;shares of Common Stock, the fair value of which was approximately $<ix:nonFraction id="c125342111" contextRef="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million based on the quoted trading price on the grant date, to GEM in full satisfaction of the Settlement Agreement which was approximately $<ix:nonFraction id="c125342112" contextRef="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction>&#160;million and was expensed as &#8220;Settlement expense&#8221; in fiscal <em style="font: inherit;">2023.</em> The shares are registered under a prospectus supplement to the Company&#8217;s registration statement on Form S-<em style="font: inherit;">3</em> and are subject to a restriction that they cannot be sold or traded for a period of <em style="font: inherit;">six</em> months from the effective date of the Settlement Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is currently involved in and <em style="font: inherit;"> may </em>from time to time become involved in various legal actions incidental to our business. As of the date of this report, the Company, other than as set forth above, is <em style="font: inherit;">not</em> involved in any legal proceedings that it believes could have a material adverse effect on its financial position or results of operations. However, the outcome of any current or future legal proceeding is inherently difficult to predict and any dispute resolved unfavorably could have a material adverse effect on the Company&#8217;s business, financial position, and operating results.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2867433" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Common Stock Reverse Stock Split</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 21, 2024, </em>the Board approved a reverse stock split ratio of <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c125342119" contextRef="d_2024-03-21_2024-03-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction>. On <em style="font: inherit;"> March 28, 2024, </em>the Company filed an amendment to its certificate of incorporation in the State of Delaware (the &#8220;<i>Amendment</i>&#8221;), which provided that&#160;every <span style="-sec-ix-hidden:c125342120">ten</span> shares of its issued and outstanding Common Stock would&#160;automatically be combined into <em style="font: inherit;">one</em> issued and outstanding share of Common Stock, without any change in the par value per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Effective <em style="font: inherit;"> April 1, 2024, </em>every <ix:nonFraction id="c125342122" contextRef="d_2024-04-01_2024-04-01_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction> issued and outstanding shares of the Company&#8217;s Common Stock were converted automatically into <em style="font: inherit;">one</em> share of the Company&#8217;s Common Stock, without any change in the par value per share. The Reverse Stock Split reduced the number of shares of Common Stock issued and outstanding from approximately <ix:nonFraction id="c125342124" contextRef="i_2024-03-28" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">95.7</ix:nonFraction> million to approximately <ix:nonFraction id="c125342125" contextRef="i_2024-04-01" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.6</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><em style="font: inherit;">No</em> fractional shares were issued in connection with the Reverse Stock Split. Shareholders who otherwise would have been entitled to receive a fractional share instead became entitled to receive <em style="font: inherit;">one</em> whole share of Common Stock in lieu of such fractional share. As a result of the Reverse Stock Split, <ix:nonFraction id="c125342128" contextRef="d_2024-04-01_2024-04-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:num-dot-decimal" decimals="INF">73,040</ix:nonFraction> additional shares of common stock were issued in lieu of fractional shares.&#160;All share and per share amounts in the accompanying consolidated financial statements and footnotes have been retrospectively adjusted for the reverse split.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the terms of the Company&#8217;s Second Amended and Restated Certificate of Incorporation, the Company has <span style="-sec-ix-hidden:c125342129">authorized&#8239;50,000,000&#8239;shares</span> of preferred stock with a par value of <span style="-sec-ix-hidden:c125342130">$0.001.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Series A Convertible Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 30, 2023, </em>the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;) with the Delaware Secretary of State (the &#8220;Certificate of Designation&#8221;) authorizing up to <ix:nonFraction id="c125342131" contextRef="i_2023-08-30_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,000,000</ix:nonFraction> shares of Series A Preferred Stock.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> August 2023, </em>the Company sold and issued <ix:nonFraction id="c125342132" contextRef="d_2023-08-01_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction> shares of Series A Preferred Stock. Each share of Series A Preferred Stock was sold with <span style="-sec-ix-hidden:c125342133">one</span> warrant (a &#8220;Unit"), see investor warrant section below for terms, for an aggregate cash purchase price of $<ix:nonFraction id="c125342134" contextRef="d_2023-08-01_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction> million or $<ix:nonFraction id="c125342135" contextRef="i_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.40</ix:nonFraction> per Unit.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> March 2024, </em>holders of the Company&#8217;s Series A Preferred elected to convert <ix:nonFraction id="c125342136" contextRef="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction> shares of Series A Preferred into <ix:nonFraction id="c125342137" contextRef="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">300,000</ix:nonFraction> shares of Common Stock. As of <em style="font: inherit;"> December 31, 2024, </em><ix:nonFraction id="c125342138" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series A Preferred remained issued or outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Dividend Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The holders of Series A Preferred Stock are <em style="font: inherit;">not</em> entitled to receive any dividends in respect to the Series&#8239;A Preferred Stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Voting Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The holders of Series A Preferred Stock have <em style="font: inherit;">no</em> voting rights other than for an affirmative vote in order for the Company to (a) disproportionally alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that disproportionally adversely affects any rights of the Holders, (c) increase or decrease the number of authorized shares of Series A Preferred Stock or (d) enter into any agreement with respect to any of the foregoing.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Conversion Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each share of Series A Preferred Stock shall be convertible into a number of shares of Common Stock equal to the number of shares of Series A Preferred Stock being converted. Notwithstanding the foregoing, <em style="font: inherit;">no</em> share of Series&#8239;A Preferred Stock shall be convertible during the <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>)&#8239;month period following the issuance date;&#8239;provided, however, if the Common Stock trades at or above $<ix:nonFraction id="c125342146" contextRef="i_2024-12-31_RangeAxis-MinimumMember_StatementClassOfStockAxis-CommonStockMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.20</ix:nonFraction> per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events), as reported on Bloomberg, L.P. on any trading day, holder <em style="font: inherit;"> may </em>convert the Series&#8239;A Preferred Stock prior to the <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>)&#8239;month anniversary of the issuance date. <em style="font: inherit;">No</em> fractional shares will be issued upon conversion. Conversion is subject to certain limitations, including the holder <em style="font: inherit;">not</em> owning more than <ix:nonFraction id="c125342151" contextRef="i_2024-12-31_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:InvestmentOwnedPercentOfNetAssets" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.9</ix:nonFraction>% of the outstanding shares of Common Stock.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Liquidation Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon any liquidation, dissolution or winding up of the Company (a &#8220;Liquidation&#8221;), whether voluntary or involuntary, each holder of Series A Preferred Stock shall be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive if such shares had been converted to Common Stock immediately prior to such Liquidation, subject to certain rights and limitations.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Common Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the terms of the Company&#8217;s Second Amended and Restated Certificate of Incorporation, the Company has authorized&#160;<ix:nonFraction id="c125342152" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>&#160;shares of common stock with a par value of&#160;$<ix:nonFraction id="c125342153" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 8, 2023, </em>NRx Pharmaceuticals entered into a securities purchase agreement with the <em style="font: inherit;"> March </em>Investors, providing for the issuance and sale of&#160;<ix:nonFraction id="c125342154" contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">386,667</ix:nonFraction>&#160;shares of Common Stock and the <em style="font: inherit;"> March </em>Investor Warrants to purchase up to&#160;<ix:nonFraction id="c125342155" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">386,667</ix:nonFraction>&#160;shares of Common Stock in a registered direct offering priced at-the-market under Nasdaq rules for a purchase price of $<ix:nonFraction id="c125342156" contextRef="i_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.50</ix:nonFraction>&#160;per share. The <em style="font: inherit;"> March </em>Investor Warrants have an exercise price of $<ix:nonFraction id="c125342157" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.50</ix:nonFraction> per share, are exercisable beginning on <em style="font: inherit;"> September 8, 2023 </em>and will expire <span style="-sec-ix-hidden:c125342158">5</span> years from the <em style="font: inherit;"> March </em>Initial Exercise Date.&#160;The <em style="font: inherit;"> March </em>Investors agreed <em style="font: inherit;">not</em> to transfer the Common Stock for&#160;<em style="font: inherit;">six</em> months&#160;following the date of issuance. The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> March </em>Offering were approximately $<ix:nonFraction id="c125342161" contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.5</ix:nonFraction> million net of offering costs of approximately $<ix:nonFraction id="c125342162" contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million. The Company used the net proceeds from such offering for working capital and general corporate purposes. The closing of the sale of these securities occurred on <em style="font: inherit;"> March 9, 2023. </em>The securities were issued pursuant to the Company&#8217;s registration statement on Form S-<em style="font: inherit;">3</em> filed with the SEC on <em style="font: inherit;"> June 9, 2022 (</em>File <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">265492</em>) which became effective on <em style="font: inherit;"> June 21, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> February 8, 2023, </em>the Company entered into a letter agreement with H.C. Wainwright &amp; Co., LLC. Although they did <em style="font: inherit;">not</em> act as the placement agent with respect to the <em style="font: inherit;"> March 2023 </em>Offering, H.C. Wainwright &amp; Co., LLC was paid a cash fee equal to <ix:nonFraction id="c125342168" contextRef="d_2023-02-08_2023-02-08_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="Pure" name="nrxp:LetterAgreementPercentageOfCashFeePaid" scale="-2" format="ixt:num-dot-decimal" decimals="2">3.0</ix:nonFraction>% of the amount raised, or approximately $<ix:nonFraction id="c125342169" contextRef="d_2023-02-08_2023-02-08_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.1</ix:nonFraction> million, pursuant to the letter agreement, which was charged against the proceeds in additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">6,</em> <em style="font: inherit;">2023,</em> the Company entered into a securities purchase agreement with the <em style="font: inherit;"> June </em>Investors, providing for the issuance and sale of <ix:nonFraction id="c125342172" contextRef="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">967,000</ix:nonFraction> shares of the Company&#8217;s Common Stock and the <em style="font: inherit;"> June </em>Investor Warrants to purchase up to <ix:nonFraction id="c125342173" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">967,000</ix:nonFraction> shares of Common Stock. The Common Stock was issued in a registered direct offering for a purchase price of $<ix:nonFraction id="c125342174" contextRef="i_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.50</ix:nonFraction> per share and the <em style="font: inherit;"> June </em>Investor Warrants were offered pursuant to a private placement under Section&#160;<em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>)&#160;of the Securities Act. The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> June </em>Offering were approximately $<ix:nonFraction id="c125342177" contextRef="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction> million. The Company used the net proceeds from the <em style="font: inherit;"> June </em>Offering for working capital and general corporate purposes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">H.C. Wainwright &amp; Co. LLC acted as the exclusive placement agent (the &#8220;Placement Agent&#8221;) for the <em style="font: inherit;"> June 2023 </em>Offering. The Placement Agent was paid a cash fee equal to <ix:nonFraction id="c125342178" contextRef="i_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="Pure" name="nrxp:PlacementAgentFeePercentOfGrossProceeds" scale="-2" format="ixt:num-dot-decimal" decimals="3">6.5</ix:nonFraction>% of the gross proceeds received by the Company from the sale of the securities at the closing of the <em style="font: inherit;"> June </em>Offering or approximately $<ix:nonFraction id="c125342179" contextRef="d_2023-06-06_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million which was charged against the proceeds in additional paid-in capital. The Company used the net proceeds from such offering for working capital and general corporate purposes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with the Note issued to Streeterville, on <em style="font: inherit;"> May 15, 2023 </em>the Company issued <ix:nonFraction id="c125342180" contextRef="d_2023-05-15_2023-05-15_DebtInstrumentAxis-StreetervilleCapitalLLCMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,868</ix:nonFraction> Common Stock to Streeterville in repayment of interest on the Note. Additionally on <em style="font: inherit;"> August 4, 2023 </em>and <em style="font: inherit;"> August 30, 2023, </em>the Company issued <ix:nonFraction id="c125342181" contextRef="d_2023-08-04_2023-08-04_DebtInstrumentAxis-StreetervilleCapitalLLCMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">131,266</ix:nonFraction> and <ix:nonFraction id="c125342182" contextRef="d_2023-08-30_2023-08-30_DebtInstrumentAxis-StreetervilleCapitalLLCMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:num-dot-decimal" decimals="INF">154,289</ix:nonFraction> respectively to Streeterville for repayment of principal and interest under the Note. Refer to Note <em style="font: inherit;">7</em> for further details.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> July 17, 2023, </em>the Company and GEM entered into a settlement agreement where the Company issued <ix:nonFraction id="c125342184" contextRef="d_2023-07-17_2023-07-17_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">67,568</ix:nonFraction> shares of Common Stock to GEM in full satisfaction of its obligation. Refer to Note <em style="font: inherit;">8</em> for further details.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> January 2, 2024, </em>the Company issued <ix:nonFraction id="c125342188" contextRef="d_2024-01-02_2024-01-02_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtToCommonStockMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">143,648</ix:nonFraction> shares of Common Stock as payment for the $<ix:nonFraction id="c125342189" contextRef="d_2024-01-02_2024-01-02_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtToCommonStockMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million minimum payment to Streeterville related to principal and interest payments on the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From <em style="font: inherit;"> February 20, 2024 </em>to <em style="font: inherit;"> July 29, 2024, </em>the Company announced that it entered into multiple purchase agreements (the &#8220;<i>ATM Purchase Agreements</i>&#8221;) subject to standard closing conditions where accredited investors purchased <ix:nonFraction id="c125342190" contextRef="d_2024-02-20_2024-07-29_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">385,515</ix:nonFraction> shares of unregistered Common Stock at a range of &#160;$<ix:nonFraction id="c125342191" contextRef="i_2024-07-29_RangeAxis-MinimumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.42</ix:nonFraction>&#160;&#8211; $<ix:nonFraction id="c125342192" contextRef="i_2024-07-29_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.10</ix:nonFraction>&#160;per share.&#160;On <em style="font: inherit;"> April 15, 2024, </em>the Company increased the maximum aggregate offering amount of the shares of Common Stock issuable under that certain At the Market Offering Agreement, dated <em style="font: inherit;"> August 14, 2023 (</em>the &#8220;<i>Offering Agreemen</i>t&#8221;), with H.C. Wainwright &amp; Co., and filed a prospectus supplement (the &#8220;<i>Current Prospectus Supplement</i>&#8221;) under the Offering Agreement for an aggregate of $<ix:nonFraction id="c125342193" contextRef="d_2023-08-14_2023-08-14_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.9</ix:nonFraction> million. Through <em style="font: inherit;"> December 31, 2024, </em>the aggregate net cash proceeds to the Company from the ATM Purchases Agreements were approximately $<ix:nonFraction id="c125342194" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.6</ix:nonFraction> million.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> February 27, 2024, </em>the Company entered into an underwriting agreement (the &#8220;<i><em style="font: inherit;"> February </em>Underwriting Agreement</i>&#8221;) with EF Hutton LLC (the &#8220;<i>Representative</i>&#8221;), as the representative of the several underwriters named therein (the &#8220;<i><em style="font: inherit;"> February </em>Underwriters</i>&#8221;), relating to an underwritten public offering (the &#8220;<i><em style="font: inherit;"> February 2024 </em>Public Offering</i>&#8221;) of <ix:nonFraction id="c125342195" contextRef="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction> shares (the &#8220;<i><em style="font: inherit;"> February </em>Shares</i>&#8221;) of the Company&#8217;s Common Stock. The public offering price for each share of Common Stock was $<ix:nonFraction id="c125342196" contextRef="i_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction> and the <em style="font: inherit;"> February </em>Underwriters purchased the shares of Common Stock pursuant to the <em style="font: inherit;"> February </em>Underwriting Agreement at a price for each share of Common Stock of $<ix:nonFraction id="c125342197" contextRef="i_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.76</ix:nonFraction>. Pursuant to the <em style="font: inherit;"> February </em>Underwriting Agreement, the Company also granted the Representative a <em style="font: inherit;">45</em>-day option to purchase up to an additional <ix:nonFraction id="c125342199" contextRef="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">75,000</ix:nonFraction> shares (the &#8220;<i><em style="font: inherit;"> February </em>Option Shares</i>&#8221;) of the Common Stock on the same terms as the <em style="font: inherit;"> February </em>Shares sold in the <em style="font: inherit;"> February 2024 </em>Public Offering (the &#8220;<i><em style="font: inherit;"> February </em>Over-Allotment Option</i>&#8221;). On <em style="font: inherit;"> February 28, 2024, </em>the <em style="font: inherit;"> February 2024 </em>Public Offering closed (the &#8220;<i><em style="font: inherit;"> February </em>Closing Date</i>&#8221;). The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> February 2024 </em>Offering proceeds were approximately $<ix:nonFraction id="c125342200" contextRef="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million after offering costs of approximately $<ix:nonFraction id="c125342201" contextRef="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million. On <em style="font: inherit;"> March 5, 2024, </em>the <em style="font: inherit;"> February </em>Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the <em style="font: inherit;"> February </em>Underwriting Agreement, dated <em style="font: inherit;"> February 27, 2024, </em>by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional <ix:nonFraction id="c125342202" contextRef="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">75,000</ix:nonFraction> shares of the Company&#8217;s Common Stock, at a public offering price of $<ix:nonFraction id="c125342203" contextRef="i_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction> per share (the &#8220;<i><em style="font: inherit;"> February </em>Overallotment Exercise</i>&#8221;). The <em style="font: inherit;"> February </em>Overallotment Exercise closed on <em style="font: inherit;"> March 6, 2024. </em>The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> February </em>Overallotment Exercise were approximately $<ix:nonFraction id="c125342204" contextRef="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction>&#160;million. The Company accrued additional offering costs of approximately $<ix:nonFraction id="c125342205" contextRef="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February </em><em style="font: inherit;">29,</em> <em style="font: inherit;">2024,</em> the Company entered into a securities purchase agreement with an investor providing for the issuance and sale of <ix:nonFraction id="c125342208" contextRef="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">270,000</ix:nonFraction> shares of Common Stock and warrants to purchase up to <ix:nonFraction id="c125342209" contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">270,000</ix:nonFraction> shares of Common Stock (the &#8220;<i><em style="font: inherit;"> February </em>Warrants</i>&#8221;) at a price of $<ix:nonFraction id="c125342210" contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.80</ix:nonFraction> per share of Common Stock and accompanying warrant, which represents a <ix:nonFraction id="c125342211" contextRef="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Pure" name="nrxp:PrivatePlacementPremiumPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">26.7</ix:nonFraction>% premium to the offering price in <em style="font: inherit;"> February 2024 </em>Public Offering. The Common Stock and the <em style="font: inherit;"> February </em>Warrants were offered pursuant to a private placement (the &#8220;<i><em style="font: inherit;"> February 2024 </em>Private Placement</i>&#8221;) under Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended (the &#8220;<i>Securities Act</i>&#8221;). The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> February 2024 </em>Private Placement were approximately $<ix:nonFraction id="c125342215" contextRef="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;">April&#8239;18,</em> <em style="font: inherit;">2024,</em> the Company entered into an underwriting agreement (the &#8220;<i><em style="font: inherit;"> April </em>Underwriting Agreement</i>&#8221;) with the Representative, as the representative of the several underwriters named therein (the &#8220;<i><em style="font: inherit;"> April </em>Underwriters</i>&#8221;), relating to an underwritten public offering (the &#8220;<i><em style="font: inherit;"> April 2024 </em>Public Offerin</i>g&#8221;) of <ix:nonFraction id="c125342218" contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">607,000</ix:nonFraction> shares (the &#8220;<i><em style="font: inherit;"> April </em>Shares</i>&#8221;) of&#160;Common Stock. The public offering price for each share of Common Stock was $<ix:nonFraction id="c125342219" contextRef="i_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.30</ix:nonFraction>. Pursuant to the <em style="font: inherit;"> April </em>Underwriting Agreement, the Company also granted the Representative a <em style="font: inherit;">45</em>-day option to purchase up to an additional <ix:nonFraction id="c125342221" contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,050</ix:nonFraction> shares (the &#8220;<i><em style="font: inherit;"> April </em>Option Shares</i>&#8221;) of the Common Stock on the same terms as the <em style="font: inherit;"> April </em>Shares sold in the <em style="font: inherit;"> April 2024 </em>Public Offering (the &#8220;<i><em style="font: inherit;"> April </em>Over-Allotment Option</i>&#8221;). On <em style="font: inherit;">April&#8239;19,</em> <em style="font: inherit;">2024,</em> the Offering closed (the &#8220;<i><em style="font: inherit;"> April </em>Closing Date</i>&#8221;). Net proceeds from the <em style="font: inherit;"> April 2024 </em>Public Offering were approximately $<ix:nonFraction id="c125342224" contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-April2024OfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.6</ix:nonFraction> million after offering costs of approximately $<ix:nonFraction id="c125342225" contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-April2024OfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million. On <em style="font: inherit;"> May 23, 2024, </em>the <em style="font: inherit;"> April </em>Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the <em style="font: inherit;"> April </em>Underwriting Agreement, dated <em style="font: inherit;"> April 18, 2024, </em>by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional <ix:nonFraction id="c125342226" contextRef="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,050</ix:nonFraction> shares of the Company&#8217;s Common Stock, at the public offering price of $<ix:nonFraction id="c125342227" contextRef="i_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.30</ix:nonFraction>&#160;per share (the &#8220;<i><em style="font: inherit;"> April </em>Overallotment Exercise</i>&#8221;). The <em style="font: inherit;"> April </em>Over-Allotment Exercise was exercised in full and closed on <em style="font: inherit;"> May 23, 2024.&#160;</em>The net&#160;cash proceeds to the Company from the <em style="font: inherit;"> April </em>Overallotment Exercise were approximately $<ix:nonFraction id="c125342228" contextRef="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction>&#160;million which include&#160;offering costs of less than $<ix:nonFraction id="c125342229" contextRef="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">23</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 28, 2024, </em>the Company issued <ix:nonFraction id="c125342232" contextRef="d_2024-08-28_2024-08-28" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">20,000</ix:nonFraction> shares of Common Stock in relation to consulting services performed by a <em style="font: inherit;">third</em> party. The fair value of the Common Stock on the date of issuance was less than $<ix:nonFraction id="c125342234" contextRef="d_2024-08-28_2024-08-28" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the&#160;year ended <em style="font: inherit;"> December 31, 2024,&#160;</em>Anson converted $<ix:nonFraction id="c125342235" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.2</ix:nonFraction> million of principal and interest of the First Tranche Note into common stock, resulting in the issuances of <ix:nonFraction id="c125342236" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,676,796</ix:nonFraction> shares of Common Stock valued at $<ix:nonFraction id="c125342237" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.5</ix:nonFraction> million based on the market price of our common stock at the date of common stock issuance resulting in a loss on redemption&#160;of $<ix:nonFraction id="c125342238" contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million (see Note <em style="font: inherit;">7</em>).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Common Stock Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Substitute Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Merger in <em style="font: inherit;">2021,</em> each warrant to purchase shares of Common Stock of NRx that was outstanding and unexercised immediately prior to the effective time (whether vested or unvested) was assumed by Big Rock Partners Acquisition Corp. (<i>"BRPA"</i>) and converted into a warrant, based on the exchange ratio (of&#160;<ix:nonFraction id="c125342241" contextRef="i_2021-05-24_BusinessAcquisitionAxis-NeuroRxMember_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember" unitRef="Pure" name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.316</ix:nonFraction>), that will continue to be governed by substantially the same terms and conditions, including vesting, as were applicable to the former warrant (the &#8220;<i>Substitute Warrants</i>&#8221;). There were <ix:nonFraction id="c125342242" contextRef="i_2021-05-24_BusinessAcquisitionAxis-NeuroRxMember_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,792,970</ix:nonFraction> warrants outstanding and unexercised at the effective time. As these Substitute Warrants meet the definition of a derivative as contemplated in FASB ASC Topic <em style="font: inherit;">815,</em> based on provisions in the warrant agreement related to the Earnout Shares Milestone and the Earnout Cash Milestone and the contingent right to receive additional shares for these provisions, the Substitute Warrants were recorded as derivative liabilities on the consolidated balance sheet and measured at fair value at inception (on the date of the Merger) and at each reporting date in accordance with FASB ASC Topic <em style="font: inherit;">820,</em> with changes in fair value recognized in the statements of operations in the period of change.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognized a gain on the change in fair value of the Substitute Warrants for each of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> of <span style="-sec-ix-hidden:c125342246">nil</span> and less than $<ix:nonFraction id="c125342247" contextRef="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively. Refer to Note <em style="font: inherit;">11</em> for further discussion of fair value measurement of the warrant liabilities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Assumed Public Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to the Merger, the Company had&#160;<ix:nonFraction id="c125342249" contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,450,000</ix:nonFraction>&#160;warrants outstanding (the &#8220;<i>Public Warrants</i>&#8221;) to purchase up to <ix:nonFraction id="c125342250" contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">345,000</ix:nonFraction> shares of Common Stock. Each Public Warrant entitles the holder to purchase&#160;<span style="-sec-ix-hidden:c125342251">one</span>-<em style="font: inherit;">tenth</em>&#160;share of Common Stock at an exercise price of $<ix:nonFraction id="c125342253" contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">115</ix:nonFraction>&#160;per share. The Public Warrants became exercisable at the effective time of the Merger and expire&#160;<em style="font: inherit;">five</em> years&#160;after the effective time on or earlier upon their redemption or liquidation of the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> <ix:nonFraction id="c125342256" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="nrxp:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#160;Public Warrants were exercised. The outstanding balance of these warrants remains in equity. At <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> there were <ix:nonFraction id="c125342258" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,448,856</ix:nonFraction> Public Warrants outstanding to purchase up to <ix:nonFraction id="c125342259" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">344,886</ix:nonFraction> shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Assumed Private Placement Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Prior to the Merger, the Company had outstanding&#160;<ix:nonFraction id="c125342260" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">136,250</ix:nonFraction>&#160;Private Placement Warrants (the &#8220;<i>Private Placement Warrants</i>&#8221;) to purchase up to <ix:nonFraction id="c125342261" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,625</ix:nonFraction> shares of Common Stock.&#160;The Private Placement Warrants are <em style="font: inherit;">not</em> indexed to the Company&#8217;s common shares in the manner contemplated by FASB ASC Topic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>-<em style="font: inherit;">15</em> because the holder of the instrument is <em style="font: inherit;">not</em> an input into the pricing of a fixed-for-fixed option on equity shares. The Company classifies the Private Placement Warrants as derivative liabilities in its consolidated balance sheets as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The Company measures the fair value of the Private Placement Warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company&#8217;s statements of operations for the current period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognized a gain on the change in fair value of the Private Placement Warrants for each of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> of less than $<ix:nonFraction id="c125342269" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively. Refer to Note <em style="font: inherit;">11</em> for discussion of the fair value measurement of the Company&#8217;s warrant liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">24</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Investor Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 8, 2023, </em>in conjunction with the issuance and sale of&#160;<ix:nonFraction id="c125342273" contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">386,667</ix:nonFraction>&#160;shares of the Company&#8217;s Common Stock, the Company issued <ix:nonFraction id="c125342274" contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">386,667</ix:nonFraction> <em style="font: inherit;"> March </em>Investor Warrants which were classified in stockholder&#8217;s equity. The measurement of fair value of the <em style="font: inherit;"> March </em>Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342275" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.20</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342276" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.50</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342277">five</span> and a half years, volatility of <ix:nonFraction id="c125342278" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">123.6</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342279" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.34</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342280" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The <em style="font: inherit;"> March </em>Investor Warrants had an original exercise price of $<ix:nonFraction id="c125342281" contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.50</ix:nonFraction> per share, are initially exercisable beginning&#160;<em style="font: inherit;">six</em> months&#160;following the <em style="font: inherit;"> March </em>Initial Exercise Date and will expire&#160;<span style="-sec-ix-hidden:c125342283">five</span> and a half years&#160;from the <em style="font: inherit;"> March </em>Initial Exercise Date.&#160; The grant date fair value of these <em style="font: inherit;"> March </em>Investor Warrants was estimated to be $<ix:nonFraction id="c125342284" contextRef="d_2023-03-08_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.4</ix:nonFraction> million on <em style="font: inherit;"> March 8, 2023 </em>and is reflected within additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As discussed above, on <em style="font: inherit;"> June 6, 2023, </em>in conjunction with the issuance and sale of&#160;<ix:nonFraction id="c125342285" contextRef="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">967,000</ix:nonFraction> shares of the Company&#8217;s Common Stock, the Company issued <ix:nonFraction id="c125342286" contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember" unitRef="Share" name="nrxp:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">967,000</ix:nonFraction> <em style="font: inherit;"> June </em>Investor Warrants which were classified in stockholder&#8217;s equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The measurement of fair value of the <em style="font: inherit;"> June </em>Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342287" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.30</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342288" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.53</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342289">five</span> and a half years, volatility of <ix:nonFraction id="c125342290" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">175.1</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342291" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.85</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342292" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The grant date fair value of these <em style="font: inherit;"> June </em>Investor Warrants was estimated to be $<ix:nonFraction id="c125342293" contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.1</ix:nonFraction> million on <em style="font: inherit;"> June 6, 2023, </em>and is reflected within additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company issued <ix:nonFraction id="c125342294" contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember" unitRef="Share" name="nrxp:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">19,340</ix:nonFraction> warrants to the Placement Agent with an exercise price of $<ix:nonFraction id="c125342295" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.13</ix:nonFraction> (the <em style="font: inherit;"> &#8220;June </em>Placement Agent Warrants&#8221;). As these <em style="font: inherit;"> June </em>Placement Agent Warrants were issued for services provided in facilitating the <em style="font: inherit;"> June </em>Offering, the Company recorded the fair value of such <em style="font: inherit;"> June </em>Placement Agent Warrants of approximately $<ix:nonFraction id="c125342296" contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million as a cost of capital on the issuance date. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342297" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.30</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342298" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.13</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342299">five</span> and a half years, volatility of <ix:nonFraction id="c125342300" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">175.1</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342301" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.85</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342302" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with the <em style="font: inherit;"> June 2023 </em>Offering, the Company also entered into a warrant amendment agreement (the &#8220;Warrant Amendment Agreement&#8221;) with certain investors to amend certain existing warrants to purchase up to <ix:nonFraction id="c125342303" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">962,278</ix:nonFraction> shares of Common Stock that were previously issued in <em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2021</em> and <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">2022</em> to such investors, with an exercise price of $<ix:nonFraction id="c125342306" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">30.70</ix:nonFraction> and $<ix:nonFraction id="c125342307" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">120.00</ix:nonFraction> per share, respectively (the &#8220;Amended Warrants&#8221;) as follows: (i)&#160;lower the exercise price of the Amended Warrants to $<ix:nonFraction id="c125342308" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.525</ix:nonFraction> per share, and (ii)&#160;provide that the Amended Warrants, as amended, will <em style="font: inherit;">not</em> be exercisable until <em style="font: inherit;">six</em> months following the closing date of the <em style="font: inherit;"> June </em>Offering, and (iii)&#160;extend the original expiration date of the Amended Warrants so that they will terminate <span style="-sec-ix-hidden:c125342311">five</span> and <em style="font: inherit;">one</em> half years from the closing of the <em style="font: inherit;"> June </em>Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recorded the incremental change in fair value of such Amended Warrants of $<ix:nonFraction id="c125342313" contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million as a cost of capital to issue the <em style="font: inherit;"> June </em>Investor Warrants. The measurement of fair value for the Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342314" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.30</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342315" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.525</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342316">five</span> and a half years, volatility of <ix:nonFraction id="c125342317" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">175.1</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342318" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.85</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342319" contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As discussed above, on <em style="font: inherit;">August&#8239;28,</em> <em style="font: inherit;">2023,</em> in conjunction with the issuance and sale of <ix:nonFraction id="c125342322" contextRef="d_2023-08-28_2023-08-28_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,000,000</ix:nonFraction> shares of the Company&#8217;s Series&#8239;A Convertible Preferred Stock, the Company issued <ix:nonFraction id="c125342323" contextRef="d_2023-08-28_2023-08-28_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" unitRef="Share" name="nrxp:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">300,000</ix:nonFraction> <em style="font: inherit;"> August </em>Investor Warrants which were classified in stockholder&#8217;s equity. Each Investor Warrants had an exercise price of $<ix:nonFraction id="c125342324" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction> and term of <span style="-sec-ix-hidden:c125342325">five</span> years. The measurement of fair value of the <em style="font: inherit;"> August </em>Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342326" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342327" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342328">five</span> years, volatility of <ix:nonFraction id="c125342329" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">175.1</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342330" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.38</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342331" contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The grant date fair value of these <em style="font: inherit;"> August </em>Investor Warrants was estimated to be $<ix:nonFraction id="c125342332" contextRef="d_2023-08-28_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction> million on <em style="font: inherit;"> August 28, 2023 </em>and is reflected within additional paid-in capital.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> October 24, 2023, </em>in connection with the Securities Purchase Agreement dated <em style="font: inherit;"> March 8, 2023, </em>the Company entered into a warrant amendment agreement (the <em style="font: inherit;"> &#8220;October </em>Warrant Amendment Agreement&#8221;) with certain Investors to amend the existing Investor Warrants to purchase up to <ix:nonFraction id="c125342333" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">386,667</ix:nonFraction> shares of Common Stock that were previously issued in <em style="font: inherit;"> March 2023 </em>adjusted from the original exercise price of $<ix:nonFraction id="c125342334" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.50</ix:nonFraction> to $<ix:nonFraction id="c125342335" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.525</ix:nonFraction> per share (the <em style="font: inherit;"> &#8220;October </em>Amended Warrants&#8221;).&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recorded the incremental change in fair value of such <em style="font: inherit;"> October </em>Amended Warrants of approximately $<ix:nonFraction id="c125342336" contextRef="d_2023-10-24_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">9.0</ix:nonFraction> thousand as a deemed dividend and an adjustment to arrive at net income available to common stockholders on the statement of operations. As the Company is in an accumulated deficit position, in the absence of retained earnings, the Company recorded the reduction to additional paid-in capital (i.e., a net <em style="font: inherit;">zero</em> impact to additional paid-in capital). The measurement of fair value for the <em style="font: inherit;"> October </em>Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of amendment (i.e., share price of $<ix:nonFraction id="c125342338" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.80</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342339" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.525</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342340">five</span> years, volatility of <ix:nonFraction id="c125342341" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">159.4</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342342" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.85</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342343" contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">25</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> February 28, 2024, </em>in conjunction with the sale of&#160;<ix:nonFraction id="c125342346" contextRef="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">270,000</ix:nonFraction>&#160;shares of the Company&#8217;s Common Stock, the Company issued&#160;<em style="font: inherit;"> February </em>Warrants to purchase up to <ix:nonFraction id="c125342347" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">270,000</ix:nonFraction> shares of Common Stock which were classified in stockholder&#8217;s equity. The <em style="font: inherit;"> February </em>Warrants have an exercise price of $<ix:nonFraction id="c125342348" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.80</ix:nonFraction> per share, are initially exercisable beginning <em style="font: inherit;">six</em> months following the date of issuance, and will expire <span style="-sec-ix-hidden:c125342350">five</span>&#160;years from the date of issuance. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342351" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.59</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342352" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.80</ix:nonFraction>, term of <ix:nonFraction id="c125342353" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342354" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">178.10</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342355" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.26</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342356" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The allocated fair value of the <em style="font: inherit;"> February </em>Warrants on the grant date was $<ix:nonFraction id="c125342357" contextRef="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million and is recorded within&#160;additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> February 28, 2024, </em>the Company issued to the Representative the Underwriter&#8217;s Warrant to purchase up to <ix:nonFraction id="c125342358" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction> shares of Common Stock (the &#8220;<i><em style="font: inherit;"> February </em>Underwriter Warrant Shares</i>&#8221;). The Underwriter&#8217;s Warrant is exercisable <em style="font: inherit;">six</em> months following the date of the Underwriting Agreement and terminates on the <span style="-sec-ix-hidden:c125342360">five</span>-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342361" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.05</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342362" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.30</ix:nonFraction>, term of <ix:nonFraction id="c125342363" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342364" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">178.10</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342365" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.26</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342366" contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The allocated fair value of the Underwriter's Warrants on the grant date was $<ix:nonFraction id="c125342367" contextRef="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 5, 2024 </em>the Company issued Underwriter&#8217;s Warrant to purchase up to <ix:nonFraction id="c125342368" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,750</ix:nonFraction> shares of Common Stock in relation to the exercise of the <em style="font: inherit;"> February </em>Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342369" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.05</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342370" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.30</ix:nonFraction>, term of <ix:nonFraction id="c125342371" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342372" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">178.10</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342373" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.12</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342374" contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $<ix:nonFraction id="c125342375" contextRef="d_2024-03-05_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> April 19, 2024, </em>the Company issued to the Representative the <em style="font: inherit;"> April </em>Underwriter&#8217;s Warrant to purchase up to <ix:nonFraction id="c125342376" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">30,350</ix:nonFraction> shares of Common Stock (the &#8220;<i><em style="font: inherit;"> April </em>Underwriter Warrant Shares</i>&#8221;). The <em style="font: inherit;"> April </em>Underwriter&#8217;s Warrant is exercisable <em style="font: inherit;">six</em> months following the date of the Underwriting Agreement and terminates on the <span style="-sec-ix-hidden:c125342378">five</span>-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342379" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.04</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342380" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.63</ix:nonFraction>, term of <ix:nonFraction id="c125342381" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342382" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">178.10</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342383" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.66</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342384" contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The allocated fair value of the <em style="font: inherit;"> April </em>Underwriter's Warrant&#160;on the grant date was less than $<ix:nonFraction id="c125342385" contextRef="d_2024-04-19_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> May 23, 2024 </em>the Company issued Underwriter&#8217;s Warrant to purchase up to <ix:nonFraction id="c125342386" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,553</ix:nonFraction> shares of Common Stock in relation to the exercise of the <em style="font: inherit;"> April </em>Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342387" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.62</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342388" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.63</ix:nonFraction>, term of <ix:nonFraction id="c125342389" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342390" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">178.10</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342391" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.52</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342392" contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $<ix:nonFraction id="c125342393" contextRef="d_2024-05-23_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">26</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Alvogen Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In conjunction with the amended Alvogen licensing agreement discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> February 7, 2024, </em>the Company issued warrants to purchase up to <ix:nonFraction id="c125342397" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">419,598</ix:nonFraction> shares of Common Stock. The warrants have an exercise price of $<ix:nonFraction id="c125342398" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction> per share, are exercisable immediately following the date of issuance, will expire <span style="-sec-ix-hidden:c125342399">three</span>&#160;years from the date of issuance, and <em style="font: inherit;"> may </em>also be exercised on a cashless basis if there is <em style="font: inherit;">no</em> effective registration statement available for the resale of the shares of Common Stock underlying the warrants. The warrants are subject to a beneficial ownership limitation of <ix:nonFraction id="c125342401" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember" unitRef="Pure" name="nrxp:ClassOfWarrantOrRightBeneficialOwnershipLimitation" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>% post-exercise, with the exception that the beneficial ownership limitation <em style="font: inherit;"> may </em>be waived up to a maximum of <ix:nonFraction id="c125342402" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_RangeAxis-MaximumMember" unitRef="Pure" name="nrxp:ClassOfWarrantOrRightBeneficialOwnershipLimitation" scale="-2" format="ixt:num-dot-decimal" decimals="4">9.99</ix:nonFraction>% at the election of the holder, with <em style="font: inherit;">not</em> less than <em style="font: inherit;">61</em> days prior notice. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342405" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.10</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342406" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction>, term of <ix:nonFraction id="c125342407" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342408" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">138.0</ix:nonFraction>%, risk-free rate of <ix:nonFraction id="c125342409" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.2</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342410" contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction>%). The fair value of the warrants on the grant date was $<ix:nonFraction id="c125342411" contextRef="d_2024-02-07_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million and was recorded within additional paid-in capital as of <em style="font: inherit;"> March 31, 2024.&#160;</em>Upon termination of the Alvogen Agreement on <em style="font: inherit;"> June 21, 2024, </em>the offsetting&#160;amount recorded within additional paid-in capital as an unfunded stock subscription receivable was expensed to research and development.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Anson Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Anson&#160;Warrants, originally issued in the Purchase Agreement, are recognized as derivative liabilities in accordance with ASC <em style="font: inherit;">815.</em> The Company concluded liability classification was appropriate&#160;as certain settlement features included in the Anson Warrants are <em style="font: inherit;">not</em> indexed to the Company's own stock, and therefore preclude&#160;equity classification. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercise or expiration, and any change in fair value is recognized in the Company&#8217;s consolidated statements of operations. The Anson Warrants were initially measured at fair value using a Black-Scholes model and have subsequently been measured based on the listed market price of such warrants. Warrant liabilities are classified as current liabilities on the Company's consolidated balance sheets. On <em style="font: inherit;"> August 14, 2024, </em>in conjunction with the issuance of the First Tranche Notes, the Company issued warrants&#160;to purchase up to <ix:nonFraction id="c125342414" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,349,305</ix:nonFraction> shares of the Company&#8217;s Common Stock which were classified as a liability. The warrants have an exercise price of $<ix:nonFraction id="c125342415" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.4168</ix:nonFraction> per share, subject to adjustment or other settlement provisions, and have a contractual term of <span style="-sec-ix-hidden:c125342416">five</span> years expiring on <em style="font: inherit;"> August 14, 2029.&#160;</em>The measurement of fair value of the Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342417" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.86</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342418" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.42</ix:nonFraction>, term of <span style="-sec-ix-hidden:c125342419">five</span> years, volatility of <ix:nonFraction id="c125342420" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">122</ix:nonFraction>%, and risk-free rate of <ix:nonFraction id="c125342421" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.67</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342422" contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The grant date fair value of these Investor Warrants was estimated to be $<ix:nonFraction id="c125342423" contextRef="d_2024-08-14_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million on <em style="font: inherit;"> August 14, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> October 10, 2024, </em>in conjunction with the issuance of the Second Tranche Notes, the Company issued warrants&#160;to purchase up to <ix:nonFraction id="c125342424" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,846,128</ix:nonFraction> shares of the Company&#8217;s Common Stock which were classified as a liability. The warrants have an exercise price of $<ix:nonFraction id="c125342425" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.7664</ix:nonFraction> per share, subject to adjustment or other settlement provisions, and have a contractual term of <span style="-sec-ix-hidden:c125342426">five</span> years expiring on <em style="font: inherit;"> October 10, 2029.&#160;</em>The measurement of fair value of the Investor Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<ix:nonFraction id="c125342427" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.38</ix:nonFraction>, exercise price of $<ix:nonFraction id="c125342428" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.76</ix:nonFraction>, term of <ix:nonFraction id="c125342429" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt-sec:numwordsen" decimals="INF">five</ix:nonFraction> years, volatility of <ix:nonFraction id="c125342430" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">105</ix:nonFraction>%, and risk-free rate of <ix:nonFraction id="c125342431" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.91</ix:nonFraction>%, and expected dividend rate of <ix:nonFraction id="c125342432" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%). The grant date fair value of these Second Trench Investor Warrants was estimated to be $<ix:nonFraction id="c125342433" contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.9</ix:nonFraction> million on <em style="font: inherit;"> October 10, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">27</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the fair value of the Anson Warrants was&#160;$<ix:nonFraction id="c125342436" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction> million. The Company recognized a loss on the change in fair value of The Anson&#160;Warrant for the year ended <em style="font: inherit;"> December 31, 2024 </em>of approximately $<ix:nonFraction id="c125342437" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.7</ix:nonFraction> million. Refer to Note <em style="font: inherit;">11</em> for discussion of the fair value measurement of the Company&#8217;s warrant liabilities. Refer to Note <em style="font: inherit;">11</em> for further discussion of fair value measurement of the warrant liabilities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table provides the activity for all warrants for the respective periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2867434" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Aggregate </b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><b>Intrinsic</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><em style="font: inherit;">Total </em></b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Term</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341506" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,648,492</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm" id="c125341507" format="ixt-sec:duryear">3.59</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341508" contextRef="i_2022-12-31" unitRef="USDPerShare" name="nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">64.90</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341509" contextRef="i_2022-12-31" unitRef="USD" name="nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341510" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="nrxp:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,673,007</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonNumeric contextRef="i_2023-12-31" name="nrxp:ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" id="c125341511" format="ixt-sec:duryear">4.38</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341512" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="nrxp:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341513" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="nrxp:ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341514" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,321,499</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm" id="c125341515" format="ixt-sec:duryear">3.91</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341516" contextRef="i_2023-12-31" unitRef="USDPerShare" name="nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">23.01</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341517" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341518" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="nrxp:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,948,484</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2024-12-31" name="nrxp:ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" id="c125341519" format="ixt-sec:duryear">4.71</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341520" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="nrxp:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.04</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341521" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="nrxp:ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c125341522" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="nrxp:ClassOfWarrantOrRightExpiredDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">96,417</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341526" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,173,766</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm" id="c125341527" format="ixt-sec:duryear">3.77</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341528" contextRef="i_2024-12-31" unitRef="USDPerShare" name="nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341529" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">80</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2867435" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em> Stock-Based Compensation </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2016</em> Omnibus Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to the Merger, NRx maintained its <em style="font: inherit;">2016</em> Omnibus Incentive Plan (the &#8220;<i><em style="font: inherit;">2016</em> Plan</i>&#8221;), under which NeuroRx granted incentive stock options, restricted stock awards, other stock-based awards, or other cash-based awards to employees, directors, and non-employee consultants. The maximum aggregate shares of Common Stock that were subject to awards and issuable under the <em style="font: inherit;">2016</em> Plan was&#160;<ix:nonFraction id="c125342445" contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">347,200</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, based on the Exchange Ratio (of&#160;<span style="-sec-ix-hidden:c125342446">0.316:1</span>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate&#160;<ix:nonFraction id="c125342447" contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">289,542</ix:nonFraction>&#160;shares of the Company&#8217;s Common Stock at an average exercise price of $<ix:nonFraction id="c125342448" contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">51.00</ix:nonFraction>&#160;per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2021</em> Omnibus Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of&#160;<em style="font: inherit;"> December 31, 2024, </em><ix:nonFraction id="c125342450" contextRef="i_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">955,281</ix:nonFraction>&#160;shares of Common Stock are authorized for issuance pursuant to awards under the Company&#8217;s <em style="font: inherit;">2021</em> Omnibus Incentive Plan (the &#8220;<i><em style="font: inherit;">2021</em> Plan</i>&#8221;). As of <em style="font: inherit;"> January 1, 2024, </em><ix:nonFraction id="c125342453" contextRef="d_2024-01-01_2024-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">83,920</ix:nonFraction>&#160;shares were added to the <em style="font: inherit;">2021</em> Plan under an evergreen feature that automatically increases the reserve with additional shares of Common Stock for future issuance under the Incentive Plan each calendar year, beginning <em style="font: inherit;"> January 1, 2022 </em>and ending on and including <em style="font: inherit;"> January 1, 2031, </em>equal to the lesser of (A) <ix:nonFraction id="c125342455" contextRef="i_2022-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember" unitRef="Pure" name="nrxp:SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" scale="-2" format="ixt:num-dot-decimal" decimals="2">1</ix:nonFraction>% of the shares of Common Stock outstanding on the final day of the immediately preceding calendar year or (B) a smaller number of shares determined by the Board. On <em style="font: inherit;"> December 28, 2023 </em>the <em style="font: inherit;">first</em> amendment to the <em style="font: inherit;">2021</em> Omnibus Plan was executed which increased the maximum number of shares (i) available for issuance under the Plan, by an additional <ix:nonFraction id="c125342458" contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">200,000</ix:nonFraction> shares, and (ii) that <em style="font: inherit;"> may </em>be delivered pursuant to the exercise of Incentive Stock Options granted under the Plan to be equal to <em style="font: inherit;">100%</em> of the Share Pool. As of <em style="font: inherit;"> December 31, 2024, </em>an aggregate <ix:nonFraction id="c125342460" contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">575,099</ix:nonFraction>&#160;shares have been awarded net of forfeitures, and <ix:nonFraction id="c125342461" contextRef="i_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">380,182</ix:nonFraction>&#160;shares remain available for issuance under the <em style="font: inherit;">2021</em> Plan. The <em style="font: inherit;">2021</em> Plan permits the granting of incentive stock options, restricted stock awards, other stock-based awards or other cash-based awards to employees, directors, and non-employee consultants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">28</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Option Awards</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company&#8217;s stock options for employees has been determined utilizing the &#8220;simplified&#8221; method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is <ix:nonFraction id="c125342466" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt-sec:numwordsen" decimals="-3">zero</ix:nonFraction> based on the fact that the Company has never paid cash dividends and does <em style="font: inherit;">not</em> expect to pay any cash dividends in the foreseeable future. Additionally, certain options granted contain terms that require all unvested options to immediately vest a) upon the approval of an NDA by the FDA for <em style="font: inherit;">NRX&#8209;101,</em> or b) immediately preceding a change in control of the Company, whichever occurs first.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company issued <ix:nonFraction id="c125342469" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and <ix:nonFraction id="c125342470" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction> stock options during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following assumptions were used for the year ended <em style="font: inherit;"> December 31, 2023:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2867436" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">Exercise price</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c125341530" contextRef="i_2023-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction></td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c125341532" contextRef="i_2023-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">11.80</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate of interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341533" contextRef="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.83</ix:nonFraction>%</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341535" contextRef="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.79</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c125341536" format="ixt-sec:duryear">0.5</ix:nonNumeric></td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c125341538" format="ixt-sec:duryear">7.0</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"><ix:nonFraction id="c125341540" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">150.3</ix:nonFraction>%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"><ix:nonFraction id="c125341543" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table summarizes the Company&#8217;s employee and non-employee stock option activity under the <em style="font: inherit;">2021</em> Plan for the following periods:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2867437" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted average<br/> exercise price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted average remaining contractual life (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate intrinsic value (in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341545" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">264,983</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341546" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c125341547" format="ixt-sec:duryear">7.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341548" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">75</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341549" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341550" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Expire</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341553" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">143,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341554" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341557" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">121,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341558" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.36</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">7.0</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341560" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options vested and exercisable as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341561" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">113,993</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341562" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">6.9</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341564" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation expense related to stock options was approximately $<ix:nonFraction id="c125342473" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> and $<ix:nonFraction id="c125342474" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The weighted average grant date fair value per share for employee stock and non-employee option grants during the year ended <em style="font: inherit;"> December 31, 2023 </em>was $<ix:nonFraction id="c125342476" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.50</ix:nonFraction>, respectively. There were <span style="-sec-ix-hidden:c125342477">no</span> option grants during the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At <em style="font: inherit;"> December 31, 2024, </em>the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was less than $<ix:nonFraction id="c125342478" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c125342479" format="ixt-sec:duryear">1.2</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Restricted Stock Awards</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Company&#8217;s Restricted Stock Activity:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="c2867438" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Awards</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023 (unvested)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341565" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">124,166</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341566" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341567" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonFraction id="c125341568" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" xsi:nil="true"></ix:nonFraction></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341569" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341570" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.64</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341571" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,333</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341572" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024 (unvested)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341573" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341574" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">29</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 12, 2022, </em>the Board granted an award of&#160;<ix:nonFraction id="c125342482" contextRef="d_2022-07-12_2022-07-12_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000</ix:nonFraction>&#160;restricted shares of the Company (&#8220;Restricted Stock&#8221;) as an inducement to the newly appointed CEO, pursuant to a separate Restricted Stock Award Agreement (the &#8220;RSA&#8221;). The Restricted Stock will vest in approximately equal installments over&#160;<em style="font: inherit;">three</em>&#160;(<ix:nonNumeric contextRef="d_2022-07-12_2022-07-12_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c125342484" format="ixt-sec:duryear">3</ix:nonNumeric>) years from the grant date, subject to continued service through the applicable vesting date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> December 28, 2023, </em>the Company granted <ix:nonFraction id="c125342485" contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,500</ix:nonFraction> RSAs to a consultant for services provided. The RSAs will vest after <span style="-sec-ix-hidden:c125342486">six</span> months from the grant date. The shares were valued on the grant date based on the quoted price of $<ix:nonFraction id="c125342487" contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.60</ix:nonFraction> or approximately $<ix:nonFraction id="c125342488" contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="nrxp:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million which will be amortized over the vesting term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation expense related to RSAs was approximately $<ix:nonFraction id="c125342489" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction>&#160;and $<ix:nonFraction id="c125342490" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> October 2024, </em>the Company's CEO announced his resignation and as a result, all unvested RSAs were forfeited. Accordingly, the Company does <span style="-sec-ix-hidden:c125342492">not</span> expect to recognize any further stock-based compensation expense for the balance of unvested RSAs as of <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table summarizes the Company&#8217;s recognition of stock-based compensation for the following periods (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2867439" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341575" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341576" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">572</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341577" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-5">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341578" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">185</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341579" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341580" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development related stock-based compensation expenses carried a negative balance for <em style="font: inherit;">2023</em> due to reversals of unvested stock options related to <em style="font: inherit;">2023</em> terminations in accordance with our policy.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueDisclosuresTextBlock" id="c2867440" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em> Fair Value Measurements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of stock options and warrants issued for services, and warrants issued with the Convertible Notes are estimated based on the Black-Scholes model during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The fair value of the Convertible Notes were estimated utilizing a Monte Carlo simulation during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value on a Recurring Basis</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company follows the guidance in ASC <em style="font: inherit;">820</em> for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the money market account represents a Level <em style="font: inherit;">1</em> measurement. The estimated fair value of the warrant liabilities and convertible note payable represent Level <em style="font: inherit;">3</em> measurements. The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="c2867441" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money Market Account</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341583" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">487</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341584" contextRef="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,874</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrant liabilities (Note 9)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341586" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,639</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341587" contextRef="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Convertible notes payable (Note 7)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341589" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,257</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341590" contextRef="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">30</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Convertible Note Payable - Streeterville</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The significant inputs used in the Monte Carlo simulation to measure the Streeterville convertible note liability that was categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="c1E714A33-C918-4E4B-B5A1-8FB31108B538" escape="true" continuedAt="c7DFFAB09-AB9A-468F-B76C-0E6A7752CBB4">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341593" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.60</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Time to expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341594" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.34</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Note market interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341595" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">9.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341596" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">85.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volume volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341597" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputVolumeVolatilityMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">590</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341598" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">5.35</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability of default</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341599" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">10.7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:-9pt;">During the year ended <em style="font: inherit;"> December 31, 2024, </em>the Streeterville Note was repaid in full and the outstanding balance was $<ix:nonFraction id="c125342506" contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> as of <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth a summary of the changes in the fair value of the Convertible Note categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="BD42D56E-BFFC-46CF-A82F-85A3AC5A7A1D" escape="true" continuedAt="B18C65DD-3C7C-4F46-AE81-09A2BD1E1560">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341600" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341601" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">7,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341602" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" scale="3" format="ixt:num-dot-decimal" decimals="-5" sign="-">400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341603" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,761</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341604" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341605" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleDebtCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341606" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="B18C65DD-3C7C-4F46-AE81-09A2BD1E1560" continuedAt="D2F4609C-E8A0-4176-8385-F1FF9B1728AC">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341607" contextRef="i_2022-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,525</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341608" contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,288</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341609" contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,786</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341610" contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341611" contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341612" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341613" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleDebtCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341614" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Convertible Notes Payable - Anson</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The significant inputs used in the Monte Carlo simulation to measure the Anson Convertible Notes that are categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="c7DFFAB09-AB9A-468F-B76C-0E6A7752CBB4" continuedAt="c4F2ECAB5-0429-4365-AAAE-3C68A8A19C27">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">$<ix:nonFraction id="c125341615" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Time to expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341618" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.87</ix:nonFraction></td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#8211;</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341620" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.03</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341621" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputCostOfDebtMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">11.80</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341624" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">120.7</ix:nonFraction>%</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341626" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">135.0</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341627" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.20</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability of credit default prior to maturity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c125341630" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember" unitRef="Pure" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">31</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth a summary of the changes in the fair value of the Anson Notes categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="D2F4609C-E8A0-4176-8385-F1FF9B1728AC" continuedAt="c06B6C2DE-B5CF-4C82-93C0-EDB825A4168E">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Notes at issuance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341633" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,034</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c125341634">(4,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341635" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,413</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341636" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,257</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341637" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:ConvertibleDebtCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341638" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember" unitRef="USD" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,011</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Warrant Liabilities</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company utilizes a Black-Scholes model approach to value the Private Placement Warrants and Substitute Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liabilities is determined using Level <em style="font: inherit;">3</em> inputs. There were <em style="font: inherit;">no</em> transfers between levels within the fair value hierarchy during the periods presented. Inherent in a Black Scholes options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility. For any lookback period which exceeded the trading history, the volatility was weighed between the actual and comparable public companies. The risk-free interest rate is based on the U.S. Treasury <em style="font: inherit;">zero</em>-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="c4F2ECAB5-0429-4365-AAAE-3C68A8A19C27">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341639" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341640" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.60</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341641" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.08</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341642" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">115.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341643" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.69</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341644" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341645" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">111</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341646" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">150.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341647" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341648" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341649" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341650" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341651" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.76</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341652" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A reconciliation of warrant liabilities is included below (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="c06B6C2DE-B5CF-4C82-93C0-EDB825A4168E">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341653" contextRef="i_2022-12-31_FairValueByLiabilityClassAxis-WarrantsMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain upon re-measurement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341654" contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341655" contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Initial recognition of issuance of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341656" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember" unitRef="USD" name="nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,965</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Loss upon re-measurement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341657" contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,657</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341658" contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,639</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c2867449" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">12.</em> Segment Reporting</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company operates as a <span style="-sec-ix-hidden:c125342722"><span style="-sec-ix-hidden:c125342723">single</span></span> operating and reportable segment, consistent with the manner in which the Chief Executive Officer, designated as the Chief Operating Decision Maker (CODM) of the Company, evaluates the Company&#8217;s performance and allocates resources. The Company&#8217;s operations solely consist of the development of novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#8220;PTSD&#8221;) and now schizophrenia.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">32</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company did <span style="-sec-ix-hidden:c125342519"><span style="-sec-ix-hidden:c125342724">not</span></span> generate any revenue during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The CODM evaluates performance based on operating expenses and monitors key expense categories related to the Company&#8217;s research and development activities, as well as general and administrative functions. As the Company is currently in the pre-revenue phase, the associated expenses above are drivers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The CODM does <em style="font: inherit;">not</em> separately evaluate performance by geographic region or product line, as the Company has <em style="font: inherit;">not</em> yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company&#8217;s operations are conducted solely within the United States of America.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Significant Segment Information</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">All of the Company&#8217;s assets relate to this single operating segment, see the accompanying balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">All of the Company&#8217;s operating expenses, which consists of research and development and general and administrative expenses, relate to this single operating segment, see the accompanying statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table reconciles the loss from operations to total loss:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="c2867450" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Years Ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Expense Category</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341659" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">18,502</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341660" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">27,837</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341661" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341662" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341663" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">230</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341664" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">120</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341665" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:num-dot-decimal" decimals="-3">849</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341666" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:LossOnContractTerminationForDefault" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value of convertible notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341667" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,654</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341668" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="nrxp:FairValueAdjustmentOfConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341669" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,657</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341670" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-4">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on convertible note redemptions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341671" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,278</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341672" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="nrxp:GainLossOnConvertibleDebtRedemption" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341673" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">25,126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341674" contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">30,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Long-lived assets consist of property, plant, and equipment, net which are included in other assets in the balance sheet as they are <em style="font: inherit;">not</em> material. Long-lived assets by year are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="c2867451" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers, cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341675" contextRef="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341676" contextRef="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341677" contextRef="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341678" contextRef="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341679" contextRef="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341680" contextRef="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">33</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160; &#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2867452" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">13.</em> Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company maintains a full valuation allowance on its net deferred tax asset due to the uncertainty of future taxable income. The Company did <span style="-sec-ix-hidden:c125342527"><span style="-sec-ix-hidden:c125342725">not</span></span> recognize an income tax benefit in the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> due to the uncertainty of future taxable income. In the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the difference between the statutory tax rate and the Company&#8217;s effective tax rate was due primarily to the valuation allowance recorded to offset any potential tax benefit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A reconciliation of the statutory U.S. federal income tax rate to the Company&#8217;s effective tax rate consist of the following:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2867453" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the Years Ended December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341681" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341682" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341683" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.05</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341684" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Settlement warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341685" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationSettlementWarrants" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341686" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationSettlementWarrants" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">0.02</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341687" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">2.23</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341688" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.21</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on Conversion of Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341689" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.06</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341690" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341691" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">0.17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341692" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.74</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341693" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="4">18.73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341694" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="4">9.45</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">R&amp;D credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341695" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" scale="-2" format="ixt:fixed-zero" decimals="0" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341696" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">1.66</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341697" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationConvertibleDebt" scale="-2" format="ixt:num-dot-decimal" decimals="4">2.19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341698" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="nrxp:EffectiveIncomeTaxRateReconciliationConvertibleDebt" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.89</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341699" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341700" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">0.11</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341701" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c125341702" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The components of income tax provision (benefit) are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="c2867454" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341703" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341704" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341705" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,715</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341706" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,278</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341707" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341708" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341709" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341710" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State and Local</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341711" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c125341712" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125341713" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341714" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,428</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341715" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,758</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341716" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341717" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341718" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that give rise to deferred tax assets and liabilities are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2867455" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets (liabilities):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341722" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,753</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341723" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-4">35,860</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341724" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,830</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341725" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,822</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">174 capitalization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341726" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,186</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341727" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,169</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341728" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,034</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341729" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-5">1,400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Bonus and severance accrual</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341730" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">119</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341731" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">167</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341732" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">741</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341733" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">488</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125341734" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341735" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341736" contextRef="i_2024-12-31" unitRef="USD" name="nrxp:DeferredTaxAssetsLiabilitiesGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">49,665</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125341737" contextRef="i_2023-12-31" unitRef="USD" name="nrxp:DeferredTaxAssetsLiabilitiesGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,904</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341738" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">49,665</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c125341739" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,904</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets, net of allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341740" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c125341741" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> the Company had federal net operating losses of approximately $<ix:nonFraction id="c125342533" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">187.1</ix:nonFraction> million and $<ix:nonFraction id="c125342534" contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">168.5</ix:nonFraction> million, respectively, and state net operating loss carryforwards of approximately $<ix:nonFraction id="c125342535" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">10.2</ix:nonFraction> million and $<ix:nonFraction id="c125342536" contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">10.4</ix:nonFraction> million, respectively. The federal and state net operating loss carryforwards generated in the tax years prior to <em style="font: inherit;">2018</em> will begin to expire, if <em style="font: inherit;">not</em> utilized, by <span style="-sec-ix-hidden:c125342539">2035.</span> Certain Net Operating Losses in these jurisdictions are <em style="font: inherit;">not</em> subject to expiration.&#160; Utilization of the net operating loss carryforwards <em style="font: inherit;"> may </em>be subject to an annual limitation according to Section&#160;<em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986</em> as amended, and similar provisions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">34</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">ASC <em style="font: inherit;">740</em> requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. After consideration of all of the evidence, the Company has recorded a valuation allowance of $<ix:nonFraction id="c125342548" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-3">49.665</ix:nonFraction> million against its deferred tax assets at <em style="font: inherit;"> December 31, 2024 </em>because management has determined that it is more likely than <em style="font: inherit;">not</em> that the Company will <em style="font: inherit;">not</em> recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of products or generation of revenue from product sales since inception.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes interest accrued to unrecognized tax benefits and penalties as income tax expense. The Company accrued total penalties and interest of $<ix:nonFraction id="c125342551" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023</em> and in total, as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023</em> has recognized penalties and interest of $<ix:nonFraction id="c125342558" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which they operate. In the normal course of business, the Company is subject to examination by federal and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024,</em> open years related to all jurisdictions are <em style="font: inherit;">2023,</em> <em style="font: inherit;">2022,</em> and <em style="font: inherit;">2021.</em>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has <em style="font: inherit;">no</em> open tax audits with any taxing authority as of <em style="font: inherit;"> December 31, 2024.</em></p>
  </ix:nonNumeric>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c2867456" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">14.</em> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Glytech Agreement</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company licenses patents that are owned by Glytech, LLC (&#8220;<i>Glytech</i>&#8221;), pursuant to a license agreement (the &#8220;<i>Glytech Agreement</i>&#8221;). Glytech is owned by Daniel Javitt, a co-founder and former director of the Company. The Glytech Agreement requires that the Company pay Glytech for ongoing scientific support and also reimburse Glytech for expenses of obtaining and maintaining patents that are licensed to the Company. During both the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> September 30, 2024&#160;</em>and&#160;<em style="font: inherit;">2023,</em> the Company paid Glytech <span style="-sec-ix-hidden:c125342568">zero</span>&#160;and&#160;$<ix:nonFraction id="c125342569" contextRef="d_2023-07-01_2023-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million, respectively,&#160;for continuing technology support services and reimbursed expenses. During the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company paid Glytech $<ix:nonFraction id="c125342571" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million and $<ix:nonFraction id="c125342572" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million, respectively, for continuing technology support services and reimbursed expenses. These support services are ongoing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Fourth Amendment to the Glytech Agreement, effective as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em> includes an equity value-triggered transfer of Excluded Technology from Glytech to NRx Pharmaceuticals. The Excluded Technology is defined in the Glytech Agreement as any technology, and any know-how related thereto, covered in the licensed patents that do <em style="font: inherit;">not</em> recite either D-cycloserine or lurasidone individually or jointly. This definition would cover pharmaceutical formulations, including some that NRx Pharmaceuticals considers &#8220;pipeline&#8221; or &#8220;future product&#8221; opportunities, that contain a combination of pharmaceutical components different from those contained in NRX-<em style="font: inherit;">100</em> and NRX-<em style="font: inherit;">101.</em> On <em style="font: inherit;"> November 6, 2022 </em>the Glytech Agreement was amended whereby Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology to NRx Pharmaceuticals for <em style="font: inherit;">no</em> additional consideration at any time upon receipt of written notice from the Company if, on or prior to <em style="font: inherit;"> March 31, 2024, (</em>i) the value of the Glytech equity holdings in NRx Pharmaceuticals (the &#8220;Glytech Equity&#8221;) has an aggregate liquidity value of at least $<ix:nonFraction id="c125342579" contextRef="i_2022-11-06_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MinimumMember_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember" unitRef="USD" name="us-gaap:InvestmentOwnedAtFairValue" scale="6" format="ixt:num-dot-decimal" decimals="-7">50</ix:nonFraction> million for <em style="font: inherit;">twenty</em> (<em style="font: inherit;">20</em>) consecutive trading days immediately preceding any given date and (ii) there are <em style="font: inherit;">no</em> legal or contractual restrictions on selling all of the securities represented by the Glytech Equity then applicable to Glytech (or reasonably foreseeable to be applicable to Glytech within the following <em style="font: inherit;">twenty</em> trading days).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Consulting Agreement with Dr. Jonathan Javitt</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major shareholder in the Company and a member of the Board of Directors. Therefore, his services are deemed to be a related party transaction. He served the Company on a full-time basis as CEO under an employment agreement with the Company until <em style="font: inherit;"> March 8, 2022 </em>and currently serves under a Consulting Agreement with the Company as Chief Scientist thereafter and received compensation of $<ix:nonFraction id="c125342584" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and $<ix:nonFraction id="c125342585" contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 29, 2023, </em>the Consulting Agreement dated <em style="font: inherit;"> March 8, 2022 (</em>the &#8220;Javitt Consulting Agreement&#8221;) between the Company and Dr. Jonathan Javitt was amended to extend the term of the Agreement until <em style="font: inherit;"> March 8, 2024 </em>with automatic annual renewals thereafter unless <em style="font: inherit;">one</em> party or the other provides notice of non-renewal. The amendment also provided for payment at the rate of $<ix:nonFraction id="c125342588" contextRef="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="nrxp:ConsultingAgreementAnnualPayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million per year, payable monthly (i.e., less than $<ix:nonFraction id="c125342589" contextRef="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="nrxp:ConsultingAgreementMonthlyPayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million per month), and a performance-based annual bonus with a minimum target of $<ix:nonFraction id="c125342590" contextRef="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="nrxp:ConsultingAgreementPerformanceBonusTargetValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million, at the discretion of the Board and upon satisfactory performance of the services. The annual discretionary bonus for <em style="font: inherit;">2023,</em> if any, <em style="font: inherit;"> may </em>be approved by the board in <em style="font: inherit;">2024</em> and is payable in <em style="font: inherit;"> March 2024, </em>will be pro-rated from the start of the extension period and is subject to Dr. Javitt&#8217;s continued engagement by the Company. The annual discretionary bonus for <em style="font: inherit;">2024,</em> if any, <em style="font: inherit;"> may </em>be approved by the board in <em style="font: inherit;">2025</em> and is payable in <em style="font: inherit;"> March 2025, </em>will be pro-rated from the start of the extension period and is subject to Dr. Javitt&#8217;s continued engagement by the Company. As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2024,</em> the annual discretionary bonus of $<ix:nonFraction id="c125342596" contextRef="i_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="us-gaap:AccruedBonusesCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million and $<ix:nonFraction id="c125342597" contextRef="i_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="us-gaap:AccruedBonusesCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million&#160;is accrued and included within accrued and other current liabilities on the consolidated balance sheets, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">35</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Javitt Amendment also provides, subject to the approval of the Board of Directors, for a grant of <ix:nonFraction id="c125342600" contextRef="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000</ix:nonFraction> shares of restricted stock of the Company under the Company&#8217;s <em style="font: inherit;">2021</em> Omnibus Incentive Plan. The restrictions are performance based, and half of the restricted shares (<ix:nonFraction id="c125342602" contextRef="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApplicationDateMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction>) shall have the restrictions removed on the New Drug Application Date (as defined below) and the remaining half (<ix:nonFraction id="c125342603" contextRef="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApprovalDateMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,000</ix:nonFraction>) will have the restrictions removed on the New Drug Approval Date (as defined below). As of <em style="font: inherit;"> December 31, 2024, </em>the Board of Directors has <em style="font: inherit;">not</em> approved the grant of restricted stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The term &#8220;New Drug Application Date&#8221; means the date upon which the FDA files the Company&#8217;s new drug application for the Antidepressant Drug Regimen (as defined below) for review. The term &#8220;New Drug Approval Date&#8221; means date upon which the FDA has both approved the Company&#8217;s Antidepressant Drug Regimen and listed the Company&#8217;s Antidepressant Drug Regimen in the FDA&#8217;s &#8220;Orange Book&#8221;. The term &#8220;Antidepressant Drug Regimen&#8221; means NRX-<em style="font: inherit;">101,</em> a proprietary fixed-dose combination capsule of d-cycloserine and Lurasidone, administered for sequential weeks of daily oral treatment following patient stabilization using a single infusion of NRX-<em style="font: inherit;">100</em> (ketamine) or another standard of care therapy.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Consulting Agreement with Zachary Javitt</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company&#8217;s CEO who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of $<ix:nonFraction id="c125342607" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. These services are ongoing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Included in accounts payable were less than $<ix:nonFraction id="c125342609" contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million and less than <span style="-sec-ix-hidden:c125342610">$0.1</span> million due to the above related parties as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2867457" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">15.</em> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Terminated <em style="font: inherit;"> January 2025 </em>Financing</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company was a party to definitive stock purchase agreements with an Arizona-based investment firm, Smith and Sauer, through their affiliate, JGS Holdings, LLC (&#8220;JGS Holdings&#8221;) whereby JGS Holdings committed to invest $<ix:nonFraction id="c125342613" contextRef="d_2025-03-13_2025-03-13_ConsolidatedEntitiesAxis-HopeTherapeuticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PurchaseAgreementMember" unitRef="USD" name="nrxp:SaleOfStockConsiderationCommitmentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction> million in NRx&#8217;s common stock, with an additional commitment of $<ix:nonFraction id="c125342614" contextRef="d_2025-03-13_2025-03-13_ConsolidatedEntitiesAxis-HopeTherapeuticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PurchaseAgreementMember" unitRef="USD" name="nrxp:SaleOfStockConsiderationAdditionalCommitmentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">25.0</ix:nonFraction> million to be invested directly in HOPE.&#160;JGS Holdings defaulted under the terms of the agreements, despite several extensions of the closing date.&#160;The Company formally terminated the stock purchase agreement on <em style="font: inherit;"> March 13, 2025.&#160; </em>Although <em style="font: inherit;">no</em> assurances can be given, management is currently negotiating with an alternative strategic investor to replace the investment contemplated with JGS Holdings, and, together with alternative sources of equity and debt capital, management believes it will able to fund its previously announced acquisitions on terms more favorable to our shareholders.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">36</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NRX PHARMACEUTICALS, INC.
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      </div>
     </div>
     <div class="hf-row">
      <div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <em style="font: inherit;"> DECEMBER 31, 2024 </em>AND
       <em style="font: inherit;">2023</em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><a id="notesend" title="notesend" href="#"></a><b><i><span style="text-decoration: underline; "><em style="font: inherit;"> January </em>Financings</span></i></b></p>
   <div>
     &#160;
   </div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Issuance of Senior Secured Promissory Notes and Common Stock Purchase Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On or about <em style="font: inherit;"> January 28, 2025, </em>the Company sold certain institutional investors (the &#8220;Investors&#8221;) a total of (a) $<ix:nonFraction id="c125342618" contextRef="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">5.435</ix:nonFraction> million in Notes (the &#8220;<i>Third Tranche Notes</i>&#8221;), with an aggregate purchase price of approximately $<ix:nonFraction id="c125342619" contextRef="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">5.0</ix:nonFraction> million, and (b) Warrants to purchase up to <ix:nonFraction id="c125342620" contextRef="i_2025-01-28_ClassOfWarrantOrRightAxis-ThirdTrancheNotesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" format="ixt:num-dot-decimal" decimals="-6">862,699</ix:nonFraction> shares of Common Stock (the &#8220;<i>Third Closing</i>&#8221;). The Third Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $<ix:nonFraction id="c125342621" contextRef="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.78</ix:nonFraction> (the &#8220;<i>Fixed Conversion Price</i>&#8221;) or (b) a price equal to <ix:nonFraction id="c125342622" contextRef="d_2025-01-28_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" format="ixt:num-dot-decimal" decimals="2">92</ix:nonFraction>% of the lowest VWAP during the <span style="-sec-ix-hidden:c125342623">seven</span> trading day period immediately preceding the effective date set forth in a Notice of Conversion (as defined in the Notes) (each, a &#8220;<i>Conversion Date</i>&#8221;) delivered by an Investor to the Company (the &#8220;<i>Alternate Conversion Price</i>&#8221;, and together with the Fixed Conversion Price, the &#8220;<i>Conversion Price</i>&#8221;). The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of Common Stock (or Common Stock Equivalents) below the then effective Conversion Price. The Company plans to use a portion of the proceeds from the sale of the Third Tranche Notes for general working capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Entry into Securities Purchase Agreement for Registered Direct Offering</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> January 27, 2025, </em>the Company entered into a securities purchase agreement (the &#8220;<i>RD Purchase Agreement</i>&#8221;) with the Investors for the sale by the Company of <ix:nonFraction id="c125342624" contextRef="d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,215,278</ix:nonFraction> shares (the &#8220;<i>RD Shares</i>&#8221;) of Common Stock to the Investors, at a purchase price of $<ix:nonFraction id="c125342625" contextRef="i_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.88</ix:nonFraction> per share, in a registered direct offering (the &#8220;<i>Registered Direct Offering</i>&#8221;). Concurrently with the sale of the RD Shares, pursuant to the RD Purchase Agreement the Company also sold to the investors unregistered Common Stock purchase warrants (the &#8220;<i>RD Warrants</i>&#8221;) to purchase up to an aggregate of <ix:nonFraction id="c125342626" contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,215,278</ix:nonFraction> shares of Common Stock (the &#8220;<i>RD Warrant Shares</i>&#8221;), in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $<ix:nonFraction id="c125342627" contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.88</ix:nonFraction> per share of Common Stock, subject to adjustments as provided under the terms of the RD Warrants. The closing of the sales of these securities under the RD Purchase Agreement occurred on or about <em style="font: inherit;"> January 29, 2025 (</em>the &#8220;<i>RD Closing Date</i>&#8221;). The RD Warrants are exercisable for <span style="-sec-ix-hidden:c125342628">five</span> years from the RD Closing Date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The gross proceeds to the Company from the offerings were approximately $<ix:nonFraction id="c125342629" contextRef="d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,500,000</ix:nonFraction>, before deducting offering expenses, and excluding the proceeds, if any, from the exercise of the RD Warrants. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Entry into Waiver and Consent Agreement</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On or about <em style="font: inherit;"> January 27, 2025, </em>the Company and the Investors entered into a Consent and Waiver Agreement (the &#8220;CWA&#8221;), relating to certain rights and prohibitions arising under the Purchase Agreement and the Notes. In the CWA, each of the Investors provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the Purchase Agreement and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and the Investors dated <em style="font: inherit;"> August 14, 2024, </em>until <em style="font: inherit;"> March 31, 2025. </em>As consideration for entering into the CWA, in the event that the VWAP of the Common Stock is less than the per share purchase price of the Common Stock sold to the Investors in the Registered Direct Offering on the Trading Day (as defined in the RD Purchase Agreement) immediately prior to the date that the Investors submit their <em style="font: inherit;">first</em> conversion notice to convert any portion of the Notes issued or to be issued in the Second Closing (as defined in the Purchase Agreement) or the Third Closing (as defined in the Purchase Agreement), respectively, into shares of Common Stock, the Company agreed to issue to the Investors: (i) that number of shares of Common Stock equal to (a) the quotient of (I) aggregate purchase price to be paid for all securities in the Registered Direct Offering, divided by (II) the price per share of Common Stock after giving effect to the VWAP-Based Adjustment (as defined below), minus (b) the number of shares of Common Stock issued, or to be issued, to the Investors at or upon the consummation of the Registered Direct Offering (the &#8220;Consideration Shares&#8221;), and (ii) Common Stock purchase warrants to purchase shares of Common Stock equal to <ix:nonFraction id="c125342631" contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="nrxp:ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" scale="-2" format="ixt:num-dot-decimal" decimals="0">100</ix:nonFraction>% of the aggregate number of Consideration Shares to be issued, with an exercise price equal to the dollar value of the VWAP-Based Adjustment (the &#8220;Consideration Warrants&#8221;). For purposes of the CWA, the &#8220;VWAP Based-Adjustment&#8221; means that amount, in dollars, equal to the greater of either (a) the VWAP of the Common Stock on the Trading Day immediately prior to the date that the Investors submit their <em style="font: inherit;">first</em> conversion notice to convert any portion of the Notes issued and to be issued in the Second Closing or Third Closing into shares of the Company&#8217;s Common Stock, or (b) <ix:nonFraction id="c125342633" contextRef="d_2025-01-27_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="nrxp:ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" scale="-2" format="ixt:num-dot-decimal" decimals="1">80</ix:nonFraction>% of the closing price of the Common Stock on the Trading Day immediately prior to the closing of the Registered Direct Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anson Conversion Notices</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From <em style="font: inherit;"> January 2, 2025 </em>to <em style="font: inherit;"> January 3, 2025, </em>the Company received conversion notices from Anson resulting in the conversion of the remaining principal of the First Tranche Note of $<ix:nonFraction id="c125342634" contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million of principal and interest in full from the First Tranche Note into <ix:nonFraction id="c125342635" contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,004,055</ix:nonFraction> shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">37</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="width: 100%;">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: calc(100% - 1px); display: inline-block;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9" title="item9" href="#"></a>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9a" title="item9a" href="#"></a>Item 9A. Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(a)</b>&#160;<b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we were required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of December 31, 2024 under the supervision, and with the participation, of our management, including our Chief Executive Officer (who serves as our principal executive officer) and our Chief Financial Officer (who serves as our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2024 in providing reasonable assurance of achieving the desired control objectives. &#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Management</i></b>&#8217;<b><i>s Report on Internal Control over Financial Reporting</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting refers to the process designed by, or under the supervision of, our principal executive officer and principal financial officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of our assets that could have a material effect on the financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making the assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in <i>Internal Control - Integrated Framework (2013)</i>. Based on the results of this assessment, management (including our Chief Executive Officer and our Chief Financial Officer) has concluded that, as of December 31, 2024, our internal control over financial reporting was effective.</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(b)</b>&#160;<b>Changes in Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the year ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company continues to review its disclosure controls and procedures, including its internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that the Company&#8217;s systems evolve with its business.</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c2867458" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9b" title="item9b" href="#"></a>Item <em style="font: inherit;">9B.</em> Other Information</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="-sec-ix-hidden:c125342638"><span style="-sec-ix-hidden:c125342736"><span style="-sec-ix-hidden:c125342737"><span style="-sec-ix-hidden:c125342738">None.</span></span></span></span></p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item9c" title="item9c" href="#"></a>Item 9C.</b>&#160;<b> Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 89
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#160;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="part3" title="part3" href="#"></a>PART III</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item10" title="item10" href="#"></a>Item 10. Directors, Executive Officers, and Corporate Governance</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item11" title="item11" href="#"></a>Item 11. Executive Compensation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference. Please refer to the proxy for more information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item12" title="item12" href="#"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item13" title="item13" href="#"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item14" title="item14" href="#"></a>Item 14. Principal Accountant Fees and Services </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 90
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="part4" title="part4" href="#"></a>Part IV.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item15" title="item15" href="#"></a>Item 15. Exhibits, Financial Statement Schedules</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">15(a)(1) Financial Statements. The following consolidated financial statements, related notes, report of independent registered public accounting firm and supplementary data are set forth in Item 8. Financial Statements and Supplementary Data in this annual report:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Reports of Independent Registered Public Accounting Firms on the Consolidated Financial Statements</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Consolidated Balance Sheets</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Consolidated Statement of Operations and Comprehensive Loss</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Consolidated Statements of Stockholders&#8217;&#160;Equity (Deficit)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Consolidated Statements of Cash Flows</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Notes to Consolidated Financial Statements</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">15(a)(2) Financial Statement Schedules. Schedules are omitted because they are not required or because the information is provided elsewhere in the financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;">&#160;</td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 24%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporate by Reference Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit Number</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="vertical-align: bottom; width: 5%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filing </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Filed </b><br/> <b>Herewith</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;">&#160;</td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/tm2323641d2_ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">At The Market Offering Agreement, dated August 14, 2023, by and between the Company and H.C. Wainwright &amp; Co., LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">08/14/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/tm247473d1_ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Underwriting Agreement, dated February 27, 2024, by and between NRx Pharmaceuticals, Inc. and EF Hutton LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">02/28/2024</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Second Amended and Restated Certificate of Incorporation</span></a></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Second Amended and Restated By-Laws</span></a></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/tm2317653d12_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Designation of Series A Convertible Preferred Stock</span></a></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/01/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495417011010/brpa_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Warrant Agreement, dated as of November 20, 2017, by and between BRPA and Continental Stock Transfer &amp; Trust Company</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/22/2017</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495417011010/brpa_ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Unit Purchase Option, dated November 20, 2017, with EarlyBirdCapital, Inc. and its designees</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/22/2017</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923032019/tm239495d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Common Stock Purchase Warrant, dated March 9, 2023 by and between NRX Pharmaceuticals, Inc. and Purchasers</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/14/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923068973/tm2317653d6_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Investor Warrant</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/07/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923068973/tm2317653d6_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Warrant Amendment Agreement</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/07/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/tm2317653d12_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Investor Warrant</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/01/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.7</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/tm247473d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Underwriter&#8217;s Warrant</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/28/2024</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.8</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex4d8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Capital Stock</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.8</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.9</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex4d9.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.9</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.10</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713629.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Senior Secured Convertible Promissory Note to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement</span></a></p> </td>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.12&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713630.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement</span></a></p> </td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;">4.13</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/ex_771257.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant to be issued pursuant to that certain Securities Purchase Agreement, dated January 27, 2025.</a></td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; text-align: center;">4.3</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; text-align: center;">1/29/2025</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%;">4.14</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 44%;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/ex_771258.htm" style="-sec-extract:exhibit;">Form of Consideration Warrant to be issued pursuant to that certain Consent and Waiver Agreement, dated January 27, 2025.</a></td>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 9%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; text-align: center;">4.4</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; text-align: center;">1/29/2025</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 9%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 91
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000095014221002728/eh210179827_ex1001.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Securities Purchase Agreement, dated as of August</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">19, 2021, by and among the Company and the Selling Securityholders.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/24/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000095014221002728/eh210179827_ex1002.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Preferred Investment Options, dated as of August</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">23, 2021, by and among the Company and the Selling Securityholders.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/24/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000095014221002728/eh210179827_ex1003.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Registration Rights Agreement, dated as of August</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">19, 2021, by and among the Company and the Selling Securityholders.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/24/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000095014221002728/eh210179827_ex1004.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Lock-Up Agreement, dated as of August</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">19, 2021, by and among the Company, Jonathan Javitt and Daniel Javitt.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/24/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.5</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495417011010/brpa_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Stock Escrow Agreement, dated November&#160;</span><span style="text-decoration: underline; ">20, 2017, between BRPA, Big Rock Partners Sponsor, LLC and Continental Stock Transfer</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">&amp; Trust Company</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/22/2017</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.6</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495417011010/brpa_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement among BRPA and Big Rock Partners Sponsor, LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/22/2017</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.7</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495418013053/brpa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement, dated November&#160;</span><span style="text-decoration: underline; ">17, 2018, among BRPA, Big Rock Partners Sponsor, LLC and BRAC Lending Group LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/20/2018</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.8</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495418013053/brpa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Stock Escrow Agent Letter, dated November&#160;</span><span style="text-decoration: underline; ">17, 2018</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/20/2018</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.9</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495418013053/brpa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Assignment Agreement, dated November&#160;</span><span style="text-decoration: underline; ">17, 2018</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/20/2018</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.10</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex106.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to the Stock Escrow Agreement, dated May&#160;</span><span style="text-decoration: underline; ">24, 2021, among BRPA, Continental Stock Transfer</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">&amp; Trust Company, and the stockholder parties thereto</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.6</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.11</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex107.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lock-up Agreement, dated May&#160;</span><span style="text-decoration: underline; ">24, 2021, by and between BRPA and the stockholder parties identified therein</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.7</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.12</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex108.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement, dated May&#160;</span><span style="text-decoration: underline; ">24, 2021, by and among NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., certain equityholders of the Registrant named therein and certain equityholders of NeuroRx named therein</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.8</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.13</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex109.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Sponsor Agreement, dated May&#160;</span><span style="text-decoration: underline; ">24, 2021, by and among BRPA, the Big Rock Partners Sponsor, LLC, and BRAC Lending Group LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.9</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.14</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521168481/d56937ds4a.htm#rom56937_103" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">NRx Pharmaceuticals,&#160;</span><span style="text-decoration: underline; ">Inc. 2021 Omnibus Incentive Plan</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.22</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.15</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000165495421002748/brpa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Subscription Agreement</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/15/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.16</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1024.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Development and License Agreement, dated as of May&#160;</span><span style="text-decoration: underline; ">2, 2016, between Glytech LLC and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.24</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.17</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1025.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Development and License Agreement, dated as of October&#160;</span><span style="text-decoration: underline; ">19, 2016, between Glytech LLC and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.25</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.18</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1026.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Second Amendment to Amended and Restated Development and License Agreement, dated as of June&#160;</span><span style="text-decoration: underline; ">13, 2018, between Glytech LLC and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.26</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.19</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1027.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Third Amendment to Amended and Restated Development and License Agreement, dated as of April&#160;</span><span style="text-decoration: underline; ">16, 2019, between Glytech LLC and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.27</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.20</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1028.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Fourth Amendment to Amended and Restated Development and License Agreement, dated as of December</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">31, 2020, between Glytech LLC and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.28</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 92
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.21</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1029.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exclusive License Agreement, dated as of April&#160;</span><span style="text-decoration: underline; ">16, 2019, by and between NeuroRx and Sarah Herzog Memorial Hospital Ezrat Nashim</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.29</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.22</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1030.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">License and Option Agreement, dated as of September&#160;</span><span style="text-decoration: underline; ">1, 2020, between The Research Foundation For The State University of New York and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.30</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.23</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1031.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Binding Collaboration Agreement, dated as of September&#160;</span><span style="text-decoration: underline; ">18, 2020, between Relief Therapeutics Holding Aktiengesellschaft and its wholly owned subsidiary Therametrics Discovery Aktiengesellschaft and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.31</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.24</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1032.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exclusive Distribution Agreement, dated as of September&#160;</span><span style="text-decoration: underline; ">25, 2020, between NeuroRx and Cardinal Health 105,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.32</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.25</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1033.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Employment Agreement, dated May&#160;</span><span style="text-decoration: underline; ">20, 2015, between NeuroRx and Jonathan C. Javitt</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.33</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.27</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1035.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to &#8220;</span><span style="text-decoration: underline; ">Work for Hire</span><span style="text-decoration: underline; ">&#8221;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Agreement, dated as of October</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">23, 2016, between NeuroRx and 20REBes Consulting LLC </span><span style="text-decoration: underline; ">&#8212;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Robert Besthof</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.35</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.29</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1037.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Feasibility Study and Material Transfer Agreement, dated as of January&#160;</span><span style="text-decoration: underline; ">6, 2021, by and between NeuroRx and TFF Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.37</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.30</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1038.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Manufacturing Supply Agreement, dated as of August&#160;</span><span style="text-decoration: underline; ">25, 2020, by and among NeuroRx, Nephron SC,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Nephron Pharmaceutical Corporation</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.38</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.31</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1039.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment #1 to Manufacturing Supply Agreement, dated as of September&#160;</span><span style="text-decoration: underline; ">2, 2020, by and among NeuroRx, Nephron SC,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Nephron Pharmaceutical Corporation</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.39</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.32</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1040.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment #2 to Manufacturing Supply Agreement, dated as of November&#160;</span><span style="text-decoration: underline; ">5, 2020, by and among NeuroRx, Nephron SC,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Nephron Pharmaceutical Corporation</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.40</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.33</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1041.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment #3 to Manufacturing Supply Agreement, dated as of February&#160;</span><span style="text-decoration: underline; ">5, 2021, by and among NeuroRx, Nephron SC,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Nephron Pharmaceutical Corporation</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.41</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.34</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1042.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Share Subscription Facility Agreement, dated as of October&#160;</span><span style="text-decoration: underline; ">18, 2019, among NeuroRx, GEM Global Yield LLC SCS and GEM Yield Bahamas Limited</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.42</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.35</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1043.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Common Stock Purchase Warrant dated March 28, 2021</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.43</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.36</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521157866/d56937dex1044.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Clinical Trial Participation Agreement, dated as of December&#160;</span><span style="text-decoration: underline; ">17, 2020, by and between Quantum Leap Health Care Collaborative and NeuroRx</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">S-4</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.44</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/21/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.38</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000119312521177240/d57577dex1034.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Voting Agreement by and between Jonathan Javitt and Daniel Javitt</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.34</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/28/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.39</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837021015962/nrxp-20210930xex10d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Statement of Work, dated July&#160;</span><span style="text-decoration: underline; ">26, 2021, between Pilltracker Ltd. and NeuroRx,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/15/2021</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.40</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022000738/nrxp-20220202xex10d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Securities Purchase Agreement, dated as of January</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">30, 2022, by and among the Company and the Purchasers.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2/03/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 93
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.41</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022000738/nrxp-20220202xex10d2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Preferred Investment Options, dated as of February</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">2, 2022, by and among the Company and the holders.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2/03/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.42</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022000738/nrxp-20220202xex10d3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Registration Rights Agreement, dated as of January</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">30, 2022, by and among the Company and the Purchasers.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2/03/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.43</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022000738/nrxp-20220202xex10d4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Placement Agent Preferred Investment Option, dated as of February</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">2, 2022 by and among the Company and H.C. Wainwright</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">&amp; Co., LLC.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2/03/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.44</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/eh220233089_ex1001.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consulting Agreement, dated March&#160;</span><span style="text-decoration: underline; ">8, 2022, by and between the Company and Dr.</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Jonathan Javitt</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/09/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.46</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022013673/nrxp-20220630xex10d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Employment Agreement, dated June&#160;</span><span style="text-decoration: underline; ">13, 2022, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Seth Van Voorhees</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/15/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.47</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022017772/nrxp-20220930xex10d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Employment Agreement, dated July&#160;</span><span style="text-decoration: underline; ">12, 2022, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Stephen Willard</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/14/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.48</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/tm2230161d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Share Purchase Agreement, dated November&#160;</span><span style="text-decoration: underline; ">4, 2022, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Streeterville Capital, LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/09/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.49</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/tm2230161d1_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Note, dated November</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">4, 2022, by and between NRX Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Streeterville Capital, LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/09/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.50</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/tm2230161d1_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Guarantee, dated November</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">4, 2022, by and between NeuroRx,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Streeterville Capital, LLC</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/09/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.51</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923054557/tm2314196d1_ex10-54.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Settlement Agreement by and between Relief Therapeutics Holding AG, Relief Therapeutics International SA, NeuroRx,&#160;</span><span style="text-decoration: underline; ">Inc. and NRX Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., dated November</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">12, 2022.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K/A</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.54</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/01/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.52</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923054557/tm2314196d1_ex10-55.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Asset Purchase Agreement by and between Relief Therapeutics Holding AG, Relief Therapeutics International SA, NeuroRx,&#160;</span><span style="text-decoration: underline; ">Inc. and NRX Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., dated November</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">12, 2022.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K/A</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.55</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/01/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.53</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923032019/tm239495d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Share Purchase Agreement, dated March&#160;</span><span style="text-decoration: underline; ">8, 2023, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Purchasers</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/14/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.54+</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837022004899/nrxp-20211231xex10d46.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Pill Tracker Supplemental Task Order, dated November 15, 2021.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.46</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/31/2022</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.55</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex10d55.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Consulting Agreement, dated March&#160;</span><span style="text-decoration: underline; ">29, 2023, by and between the Company and Dr.</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Jonathan Javitt.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.55</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.56+</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923067850/tm2317653d4_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Development and License Agreement, dated as of June&#160;</span><span style="text-decoration: underline; ">2, 2023, by and among the Company and Alvogen.*</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6/05/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.57</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923068973/tm2317653d6_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Securities Purchase Agreement</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6/07/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.58</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923068973/tm2317653d6_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lock-Up Agreement</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6/07/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.59</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837023014873/nrxp-20230630xex10d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Convertible Promissory Note, dated June&#160;</span><span style="text-decoration: underline; ">30, 2023, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Streetervillle Capital LLC.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.60</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex10d60.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Confidential Settlement Agreement and Release, dated July&#160;</span><span style="text-decoration: underline; ">17, 2023, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., NeuroRx,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., GEM Yield Bahamas Limited and GEM Global Yield LLC SCS</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.60</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.61</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/tm2317653d12_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Securities Purchase Agreement</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">9/01/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 94
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.62</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/tm2317653d13_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Client Agreement, dated August&#160;</span><span style="text-decoration: underline; ">31, 2023, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and LS Associates, a division of LifeSci Advisors, LLC Associates.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">9/14/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.63</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/tm2333890d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">12/29/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.64</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex10d64.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to Exclusive, Global Development, Supply, Marketing&#160;</span><span style="text-decoration: underline; ">&amp; License Agreement, dated February</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">7, 2024, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., Alvogen Pharma US,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc., Alvogen,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Lotus Pharmaceutical Co. Ltd.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.64</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.65</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/tm246184d2_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment #3 to Convertible Promissory Note, dated February&#160;</span><span style="text-decoration: underline; ">9, 2024, by and between NRx Pharmaceuticals,</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Inc. and Streetervillle Capital LLC.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.66</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex10d66.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form&#160;</span><span style="text-decoration: underline; ">of Securities Purchase Agreement, dated February</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">29, 2024</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.66</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.67&#160;&#160;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713631.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement, dated August 12, 2024, between NRx Pharmaceuticals, Inc. and the other parties signatory thereto</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.68&#160;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713632.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Security Agreement to be entered into by and among NRx Pharmaceuticals, Inc. and the other parties signatory thereto</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.69&#160;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713633.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Patent Security Agreement, to be entered into by and among&#160;</span><span style="text-decoration: underline; ">NRx Pharmaceuticals, Inc. and the other parties signatory thereto</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.70&#160;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713634.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Registration Rights Agreement to be entered into by and among NRx Pharmaceuticals, Inc. and the parties signatory thereto</span></a><span style="text-decoration: underline; ">&#160;</span></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.71&#160;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_713635.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Subsidiary Guarantee to be entered into by and among NRx Pharmaceuticals, Inc. and the purchasers signatory thereto</span></a><span style="text-decoration: underline; ">&#160;</span></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.5</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.72</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/ex_714090.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Settlement Agreement and Release of Claims, dated August 12, 2024, between the Company and Streeterville Capital, LLC.</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.6</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8/14/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.73</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/ex_750345.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement between Michael Abrams and NRx Pharmaceuticals, Inc., dated November 18, 2024</span></a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">11/20/2024</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.74</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925000801/ex_764005.htm" style="-sec-extract:exhibit;">Term Sheet, dated as of January 5, 2025, between the Company and JGS Holdings LLC</a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">1/10/2025</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.75+</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/ex_771259.htm" style="-sec-extract:exhibit;">Securities Purchase Agreement, dated January 27, 2025, by and among the Company and the purchaser signatories thereto.</a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.2</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">1/29/2025</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.76</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/ex_771260.htm" style="-sec-extract:exhibit;">Consent and Waiver Agreement, dated January 27, 2025, by and among the Company and the signatories thereto.</a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.3</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">1/29/2025</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.77</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925002610/ex_773641.htm" style="-sec-extract:exhibit;">Form of Amended and Restated Securities Purchase Agreement, dated as of January 28, 2025, by and among the Company and the Investor.</a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2/3/2025</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.78</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000143774925002610/ex_773940.htm" style="-sec-extract:exhibit;">Form of Second Amended and Restated Securities Purchase Agreement, dated as of February 3, 2025, by and among the Company and the Investor.</a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10.2</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2/3/2025</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14.1</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465924054115/tm2412573d1_ex14-1.htm" style="-sec-extract:exhibit;">NRx Pharmaceuticals, Inc. Code of Conduct</a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">10-K/A</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">14.1</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">4/29/2024</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">16.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000110465923120777/tm2331382d1_ex16-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter from KPMG LLP to the Securities and Exchange Commission dated November 21, 2023</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8-K/A</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">16.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/22/2023</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19.1</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_790359.htm" style="-sec-extract:exhibit;">NRx Pharmaceuticals, Inc. Securities Trading Policy </a></td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">X</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">23.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_789047.htm" style="-sec-extract:exhibit;">Consent of Independent Registered Accounting Firm</a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">X</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">24.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (included on the Signatures page of this Annual Report on Form 10-K).</a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">X</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">31.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_790360.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">X</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">31.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_790361.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">X</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">32.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_790362.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">X</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">32.2</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_790363.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">X</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">97.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1719406/000155837024004396/nrxp-20231231xex97d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">NRx Pharmaceuticals, Inc. Compensation Recovery Policy</span></a></p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">97.1</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/29/2024</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221;&#160;of this Annual Report on Form 10-K.</p> </td>
     <td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">104</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">+ Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulations S-K. &#160;The Company will furnish supplementally an unredacted copy of such exhibit to the Securities and Exchange Commission or its staff upon request.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8224; This certification is being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: left; font-size: 10pt; font-family: Times New Roman;">
    Page 95
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Times New Roman; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 14, 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:21.9%;">&#160;</td>
     <td style="vertical-align:top;width:4.7%;">&#160;</td>
     <td colspan="2" style="vertical-align:top;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NRX PHARMACEUTICALS, INC.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:21.9%;">&#160;</td>
     <td style="vertical-align:top;width:4.7%;">&#160;</td>
     <td colspan="2" style="vertical-align:top;width:23.7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:21.9%;">&#160;</td>
     <td style="vertical-align:top;width:4.7%;">&#160;</td>
     <td style="vertical-align:top;width:3%;">&#160;</td>
     <td style="vertical-align:top;width:20.7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:21.9%;">&#160;</td>
     <td style="vertical-align:top;width:4.7%;">&#160;</td>
     <td style="vertical-align:top;width:3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:20.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ Jonathan Javitt</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:21.9%;">&#160;</td>
     <td style="vertical-align:top;width:4.7%;">&#160;</td>
     <td style="vertical-align:top;width:3%;">&#160;</td>
     <td style="vertical-align:top;width:20.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jonathan Javitt</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:21.9%;">&#160;</td>
     <td style="vertical-align:top;width:4.7%;">&#160;</td>
     <td style="vertical-align:top;width:3%;">&#160;</td>
     <td style="vertical-align:top;width:20.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Chairman and Interim Chief Executive Officer (Principal Executive Officer) </i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><a id="poa" title="poa" href="#"></a>Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 5pt;"><b>Signature</b></p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;">&#160;</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">/s/ Jonathan Javitt</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chairman and Interim Chief Executive Officer</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 14, 2025</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Jonathan Javitt</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Executive Officer)</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;">&#160;</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">/s/ Michael Abrams</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 14, 2025</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Michael Abrams</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;">&#160;</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">/s/ Patrick J. Flynn</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 14, 2025</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Patrick J. Flynn</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;">&#160;</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">/s/ Chaim Hurvitz</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 14, 2025</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Chaim Hurvitz</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;">&#160;</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">/s/ Dennis McBride</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 14, 2025</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Dennis McBride</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:13.7%;">&#160;</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">/s/ Michael Taylor</p> </td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 14, 2025</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 13.7%; padding: 0pt 0pt 0pt 5pt;">Michael Taylor</td>
     <td style="vertical-align:top;width:1.8%;">&#160;</td>
     <td style="vertical-align:top;width:19.6%;">&#160;</td>
     <td style="vertical-align:top;width:1.4%;">&#160;</td>
     <td style="vertical-align:top;width:13.8%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: left; font-size: 10pt; font-family: Times New Roman;">
      Page 96
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>ex_790359.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html><head>
	<title>ex_790359.htm</title>

	<!-- Generated by ThunderDome Portal - 3/14/2025 2:24:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 19.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NRX PHARMACEUTICALS, INC. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES TRADING POLICY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MAY 2021</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Purpose</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To describe the standards concerning the handling of non-public information relating to NRx Pharmaceuticals, Inc. and its subsidiaries, including NeuroRx, Inc. (collectively, the &#8220;Company&#8221;) and the buying and selling of securities of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Persons Affected and Prohibited Transactions</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The general prohibitions of this Policy apply to all directors, officers and employees of the Company, while the restrictions regarding blackout periods and pre- clearance apply only to directors, executive officers<sup style="vertical-align:top;line-height:120%;">1</sup> and certain designated officers and employees. If you are unsure whether you are subject to any particular restrictions, please contact the Company&#8217;s General Counsel or his or her designee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The same restrictions described in this Policy also apply to your spouse, minor children and anyone else living in your household, partnerships in which you are a general partner, trusts of which you are a trustee, estates of which you are an executor and investment funds or other similar vehicles with which you are affiliated (collectively &#8220;<u>Related Parties</u>&#8221;). <b><u>You will be responsible for compliance with this Policy by your</u> <u>Related Parties</u>.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For purposes of this Policy, references to &#8220;<u>trading</u>&#8221; or to &#8220;<u>transactions in</u> <u>securities of the Company</u>&#8221; include purchases or sales of Company stock, options, puts and calls or other derivative securities based on securities of the Company, gifts of Company securities, loans of Company securities, hedging transactions involving or referencing Company securities, contributions of Company securities to a trust, sales of Company stock acquired upon the exercise of stock options, broker-assisted cashless exercises of stock options, market sales to raise cash to fund the exercise of stock options and trades in Company stock made under an employee benefit plan, such as a 401(k) plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Policy Statement</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>If you possess material nonpublic information (as further discussed below) relating to the Company, neither you nor any Related Party:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>may effect transactions in securities of the Company (other than pursuant to a pre-arranged trading plan that complies with Rule 10b5-1 (</b>&#8220;<b><u>Rule</u> <u>10b5-1</u></b>&#8221;<b>) under the Securities Exchange Act of 1934, as amended (the </b>&#8220;<u><b>Exchange Act</b></u>&#8221;<b>), as described below) or engage in any other action that take advantage of that information;</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>may pass that information on to any person outside the Company, except as permitted under applicable Company policies and procedures;</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>suggest or otherwise recommend that any person effect a transaction in securities of the Company or engage in any other action that takes advantage of that information; or</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>assist anyone engaged in any of the foregoing activities.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>_______________________</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">1 </sup>Executive officers for purposes of this Policy are all executive officers of the Company identified in its public filings and any other officer of the Company or any subsidiary that is subject to Section 16(b) of the Securities Exchange Act of 1934</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy will continue to apply after termination of employment to the extent that you are in possession of material nonpublic information at the time of termination. In such case, no transaction in securities of the Company may take place until the information becomes public or ceases to be material.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy also applies to information, obtained in the course of employment with, or by serving as a director of, the Company, relating to any other company, including any entity with which we may be negotiating a major transaction or business combination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Neither you nor any Related Party may effect transactions in the securities of any such other company while in possession of material nonpublic information concerning such company that was obtained in the course of employment with the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are no exception. Even the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Material Information</i>. &#8220;<u>Material information</u>&#8221; is any information that a reasonable investor would consider important in a decision to effect a transaction in securities of the Company. In short, any information that could reasonably affect the price of such securities. Either positive or negative information may be material. Common examples of information that will frequently be regarded as material are:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a pending or proposed merger, joint venture, acquisition or tender offer;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the offering of additional securities;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in senior management or other key employees;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">significant legal or regulatory exposure due to a pending or threatened lawsuit or investigation;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">impending bankruptcy or other financial liquidity problems; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in legislation affecting our business.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>20-20 Hindsight</i>. Remember, if your transaction in securities of the Company becomes the subject of scrutiny, it will be viewed after-the-fact with the benefit of hindsight. As a result, before engaging in any transaction you should carefully consider how regulators and others might view your transaction in hindsight.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Tipping Information to Others</i>. Whether the information is proprietary information about the Company or other information that could have an impact on the price of the Company&#8217;s securities, you must not pass the information on to others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Penalties will apply whether or not you derive, or even intend to derive, any profit or other benefit from another&#8217;s actions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>When Information is Public</i>. You may not trade on the basis of material information that has <u>not</u> been broadly disclosed to the marketplace, such as through a press release or a filing with the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;), and the marketplace has had time to absorb the information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Confidentiality Obligations</i>. The restrictions set forth in this Policy are designed to avoid misuse of material nonpublic information in violation of the securities laws. These restrictions are in addition to, and in no way alter, the general obligations that each director, officer and employee of the Company has to maintain the confidentiality of all confidential or proprietary information concerning the Company and its business, as well as any other confidential information, that may be learned in the course of service or employment with the Company. No such information is to be disclosed to any other person in the Company, unless that person has a clear need to know that information, and no such information may be disclosed to any third parties, except as required or otherwise contemplated by your function or position.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You should take precautions to prevent the unauthorized disclosure or other misuse of such information by maintaining files securely, avoiding discussions of such information in public and taking extra care when distributing such information electronically.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Additional Prohibited Transactions</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Because we believe it is improper and inappropriate for any person to engage in short-term or speculative transactions involving the Company&#8217;s securities, directors, officers and employees of the Company, and their Related Parties, are prohibited from engaging in any of the following activities with respect to securities of the Company:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b><i>Purchases of securities of the Company on margin</i></b>. You may not purchase securities of the Company on margin or pledge, or otherwise grant a security interest in, securities of the Company in margin accounts</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b><i>Short sales </i></b>(<i>i.e.</i>, selling stock you do not own and borrowing the shares to make delivery). The SEC effectively prohibits directors and officers from selling Company securities short. This Policy is simply expanding this prohibition to cover all employees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b><i>Buying or selling puts, calls, options or other derivatives in respect of securities of the Company</i></b>. This prohibition extends to any instrument whose value is derived from the value of any securities (<i>e.g., </i>common stock) of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prohibition does not apply to the Company&#8217;s warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Directors, executive officers and other employees, and their designees, are prohibited from purchasing any financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds) or otherwise engaging in transactions that are designed to or have the effect of hedging or offsetting any decrease in the market value of the Company&#8217;s equity securities whether they are (1) granted to you by the Company as part of your compensation; or (2) otherwise held, directly or indirectly, by you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Although the Company is not prohibiting standing or limit orders, you should use extreme caution if you engage in standing or limit orders (other than as established in connection with a Rule 10b5-1 plan as described below) since you might become aware of material non-public information after establishing an order. This could lead to inadvertent trading while in possession of material non-public information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Blackout Periods </u><u>&#8211;</u><u> For Directors, Executive Officers and Certain Other Personnel with</u> <u>Access to Material Nonpublic Information</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the time that the Company is seeking a target for its initial business combination, the Company will not institute blackout periods in connection with the Company&#8217;s announcement of quarterly financial results.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Nevertheless, the Company may from time to time establish blackout periods, during which the following persons and their Related Parties are <b><u>prohibited</u> </b>from effecting transactions in securities of the Company (except as otherwise expressly provided below):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">directors and their secretaries and other assistants;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">executive officers and their secretaries and other assistants; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">employees in the accounting, finance and legal departments; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other person designated by the General Counsel or his or her designee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You should be aware that the blackout periods described above may be imposed, modified or terminated by the Company at any time. Those subject to blackout period requirements will receive notice of any prohibition on trading prior to the start of such blackout period. Persons subject to the blackout period restrictions who terminate their employment with the Company during a blackout period will remain subject to the restrictions until the end of such period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The prohibition described in this Policy shall not apply to gifts of Company securities and contributions of Company securities to a trust so long as the requirements of this Policy below are complied with. We do, however, recommend that gifts and contributions be made, whenever possible, outside of a blackout period. The prohibition shall also not apply with respect to a public offering of Company securities specifically authorized by the Company&#8217;s board of directors or duly authorized board committee. In addition, the General Counsel or his or her designee may, on a case-by- case basis, authorize effecting a transaction in Company securities during a blackout period if the person who wishes to effect such a transaction (i) has, at least two business days prior to the anticipated transaction date, notified the Company in writing of the circumstances and the amount and nature of the proposed transaction and (ii) has certified to the Company that he or she is not in possession of material nonpublic information concerning the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Pre-Clearance of Securities Transactions</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To provide assistance in preventing inadvertent violations of the law (which could result for example, from failure by directors and officers subject to reporting obligations under Section 16 of the Exchange Act) and avoiding even the appearance of an improper transaction (which could result, for example, where an officer engages in a trade while unaware of a pending major development), we are implementing the following procedure:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>All transactions in securities of the Company by the following persons and their Related Parties must be pre-cleared with the Company</b>&#8217;<b>s General Counsel or his or her designee:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>directors and their secretaries and other assistants;</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>executive officers, any other officer who has an obligation to file reports under Section 16 of the Exchange Act, and their secretaries and other assistants;</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>employees in the accounting, finance and legal departments; and</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>any other person designated by the General Counsel or his or her designee.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Persons subject to these restrictions should contact the General Counsel or his or her designee <u>at least two business days (or such shorter period as the General Counsel or his or her designee may determine) in advance</u> and may not effect any transaction subject to the pre-clearance request unless given clearance to do so, which clearance, if granted, will be valid only for three business days following the approval date. If a transaction for which clearance has been granted is not effected (i.e., the trade is not placed) within such three business day period, the transaction must again be pre-cleared.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To the extent that a material event or development affecting the Company remains nonpublic, persons subject to pre-clearance will not be given permission to effect transactions in securities of the Company. Such persons may not be informed of the reason why they may not trade. Any person that is made aware of the reason for an event-specific prohibition on trading should in no event disclose the reason for the prohibition to third parties and should avoid disclosing the existence of the prohibition, if possible. Caution should be exercised when telling a broker or other person who suggested a trade that the trade cannot be effected at the time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Note that the pre-clearance procedures may delay the disposition of any security after it is purchased.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>10b5-1 Plans</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The SEC has adopted a safe harbor rule, Rule 10b5-1, which provides a defense against insider trading liability for trades that are effected pursuant to a pre- arranged trading plan that meets specified conditions. The trading plan must be properly documented and all of the procedural conditions of the Rule must be satisfied to avoid liability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Rule 10b5-1 plans allow transactions for the account of an insider to occur during blackout periods or while the insider has material nonpublic information provided the insider has previously given instructions or other control to effect pre-planned transactions in securities of the Company to a third party. The insider must establish the plan at a time when he or she is not in possession of material nonpublic information and the insider may not exercise any subsequent influence over how, when or whether to effect transactions. In addition to other specified conditions, a Rule 10b5-1 plan would specify in writing in advance the amount and price of the securities to be sold and the date for the sale (or a formula for determining the amount, price and date) or would otherwise not permit the insider to exercise any subsequent influence over how, when or whether to effect the sales. After adopting a valid Rule 10b5-1 plan, the insider will have an affirmative defense that a sale under the plan was not made &#8220;on the basis of&#8221; material nonpublic information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company will treat the creation, modification or termination of a pre- planned trading program or arrangement established to meet the requirements of Rule 10b5-1 as a transaction subject to the blackout period rules set forth in this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Transactions effected pursuant to a properly established Rule 10b5-1 plan however will <u>not</u> be subject to the blackout periods under this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company will treat the creation, modification or termination of a pre- planned trading program or arrangement established to meet the requirements of Rule 10b5-1 as a transaction subject to pre-clearance under this Policy at the time the plan is established, modified or terminated. Persons subject to the pre-clearance policy should coordinate any such plans or arrangements with the Company&#8217;s General Counsel or his or her designee. Even though each transaction effected under a Rule 10b5-1 plan does not need to be pre-cleared, it nonetheless must be made in accordance with Rule 144 and must be reported on a Form 4 under Section 16 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Assistance</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any person who has any questions about this Policy or about specific transactions may contact the Company&#8217;s General Counsel or his or her designee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Remember, however, that the ultimate responsibility for adhering to this Policy and avoiding improper transactions rests with you. In this regard, it is imperative that you use your best judgment and to ask before acting if you are unsure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Confirmation</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Please sign the attached confirmation page, indicating that you have received, have read and understand this policy, and return the signed confirmation page to the Company</b>&#8217;<b>s Corporate Counsel.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>CONFIRMATION</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[To be signed by all employees, directors, officers, agents and contractors of NeuroRx]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I HEREBY ACKNOWLEDGE THAT I HAVE RECEIVED, HAVE READ AND UNDERSTAND THE FOREGOING SECURITIES TRADING POLICY OF NRX PHARMACEUTICALS, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date:</td>
			<td style="width: 15%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Signature:</td>
			<td style="width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</td>
			<td style="width: 55%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i><u>Return signed confirmation to: [****]@nrxpharma.com</u></i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex_789047.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_789047.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2025 4:23:59 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-265492) and Form S-1 (File No. 333-283220) of our report dated March 14, 2025 on the consolidated financial statements of NRX Pharmaceuticals, Inc. as of and for the years ended December 31, 2024 and 2023, which report is included in the Annual Report on Form 10-K of NRX Pharmaceuticals, Inc. for the year ended December 31, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Salberg &amp; Company, P.A.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_____________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SALBERG &amp; COMPANY, P.A.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Boca Raton, Florida</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 14, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_790360.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_790360.htm</title>

	<!-- Generated by ThunderDome Portal - 3/14/2025 2:18:11 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO RULE 13a-14(a) AND 15d-14(a),</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Jonathan Javitt, Interim Chief Executive Officer of NRx Pharmaceuticals, Inc., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Annual Report on Form 10-K of NRx Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Registrant as of, and for, the periods presented in this Annual Report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;">Date: March 14, 2025</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:25.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Jonathan Javitt</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:25.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan Javitt</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:25.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interim Chief Executive Officer (Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_790361.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_790361.htm</title>

	<!-- Generated by ThunderDome Portal - 3/14/2025 2:15:39 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO RULE 13a-14(a) AND 15d-14(a),</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Michael Abrams, Chief Financial Officer of NRx Pharmaceuticals, Inc., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Annual Report on Form 10-K of NRx Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Registrant as of, and for, the periods presented in this Annual Report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;">Date: March 14, 2025</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:25.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Michael Abrams</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:25.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Abrams</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:25.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer (Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex_790362.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_790362.htm</title>

	<!-- Generated by ThunderDome Portal - 3/14/2025 2:14:42 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO 18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the &#8220;Report&#8221;) by NRx Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;), I, Jonathan Javitt, as Interim Chief Executive Officer of the Registrant, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:24.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 14, 2025</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Jonathan Javitt</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:24.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan Javitt</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interim Chief Executive Officer (Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex_790363.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_790363.htm</title>

	<!-- Generated by ThunderDome Portal - 3/14/2025 2:13:19 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO 18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the &#8220;Report&#8221;) by NRx Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;), I, Michael Abrams, as Chief Financial Officer of the Registrant, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:24.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 14, 2025</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Michael Abrams</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:24.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Abrams</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer (Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nrxp-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:16PM UTC 2025-03-14--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:nrxp="http://www.nrxpharma.com/20241231" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nrxpharma.com/20241231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-1-organization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995551 - Disclosure - Note 1 - Organization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-going-concern" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995552 - Disclosure - Note 2 - Going Concern</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995553 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-prepaid-expenses-and-other-current-assets" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995554 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accrued-and-other-current-liabilities" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995555 - Disclosure - Note 5 - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-alvogen-licensing-agreement-" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995556 - Disclosure - Note 6 - Alvogen Licensing Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-debt" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995557 - Disclosure - Note 7 - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-and-contingencies" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995558 - Disclosure - Note 8 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equity" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995559 - Disclosure - Note 9 - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995560 - Disclosure - Note 10 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-fair-value-measurements" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995561 - Disclosure - Note 11 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segment-reporting" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995562 - Disclosure - Note 12 - Segment Reporting</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995563 - Disclosure - Note 13 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-related-party-transactions" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995564 - Disclosure - Note 14 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-subsequent-events" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995565 - Disclosure - Note 15 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995567 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995568 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-prepaid-expenses-and-other-current-assets-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995569 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accrued-and-other-current-liabilities-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995570 - Disclosure - Note 5 - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-debt-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995571 - Disclosure - Note 7 - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-and-contingencies-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995572 - Disclosure - Note 8 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equity-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995573 - Disclosure - Note 9 - Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995574 - Disclosure - Note 10 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-fair-value-measurements-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995575 - Disclosure - Note 11 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segment-reporting-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995576 - Disclosure - Note 12 - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-tables" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995577 - Disclosure - Note 13 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-going-concern-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995578 - Disclosure - Note 2 - Going Concern (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995580 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995581 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995582 - Disclosure - Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-alvogen-licensing-agreement-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995583 - Disclosure - Note 6 - Alvogen Licensing Agreement (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-debt-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995584 - Disclosure - Note 7 - Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-debt-schedule-of-convertible-debt-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995585 - Disclosure - Note 7 - Debt - Schedule of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-and-contingencies-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995586 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995587 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equity-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995588 - Disclosure - Note 9 - Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equity-schedule-of-warrants-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995589 - Disclosure - Note 9 - Equity - Schedule of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995590 - Disclosure - Note 10 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995591 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-schedule-of-stock-options-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995592 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995593 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995594 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-fair-value-measurements-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995595 - Disclosure - Note 11 - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995596 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995597 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995598 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segment-reporting-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995599 - Disclosure - Note 12 - Segment Reporting (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995600 - Disclosure - Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segment-reporting-longlived-assets-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995601 - Disclosure - Note 12 - Segment Reporting - Long-lived Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995602 - Disclosure - Note 13 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995603 - Disclosure - Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995604 - Disclosure - Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995605 - Disclosure - Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-related-party-transactions-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995606 - Disclosure - Note 14 - Related Party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-subsequent-events-details-textual" roleURI="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995607 - Disclosure - Note 15 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nrxp_APICIncreaseForCostRecognitionContractTermination" name="APICIncreaseForCostRecognitionContractTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ATMOfferingMember" name="ATMOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_AccruedClinicalSiteCostsCurrent" name="AccruedClinicalSiteCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" name="AccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" name="AccruedResearchAndDevelopmentLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" name="AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AlvogenAndLotusWarrantsMember" name="AlvogenAndLotusWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AlvogenLicensingAgreementMember" name="AlvogenLicensingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnnualRevenueThresholdMember" name="AnnualRevenueThresholdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonConvertibleNotesMember" name="AnsonConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonFirstTrancheNotesMember" name="AnsonFirstTrancheNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonMember" name="AnsonMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonSecondTrancheNotesMember" name="AnsonSecondTrancheNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonWarrantsMember" name="AnsonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonWarrantsTrancheOneMember" name="AnsonWarrantsTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AnsonWarrantsTrancheTwoMember" name="AnsonWarrantsTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_April2024OfferingMember" name="April2024OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AprilOverallotmentAgreementMember" name="AprilOverallotmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AprilUnderwriterAgreementMember" name="AprilUnderwriterAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AprilUnderwriterOverallotmentWarrantsMember" name="AprilUnderwriterOverallotmentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AprilUnderwriterWarrantsMember" name="AprilUnderwriterWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_AugustInvestorWarrantsMember" name="AugustInvestorWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" name="ClassOfWarrantOrRightBeneficialOwnershipLimitation" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" name="ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightExercisesInPeriod" name="ClassOfWarrantOrRightExercisesInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" name="ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightIssuedInPeriod" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" name="ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" name="ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" name="ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" name="ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" name="ClassOfWarrantOrRightWeightedAverageRemainingTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" name="ClassOfWarrantsOrRightsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" name="ClassOfWarrantsOrRightsWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="nrxp_CommonStockAndWarrantIssuanceMember" name="CommonStockAndWarrantIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConsiderationWarrantsMember" name="ConsiderationWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConsultationAgreementWithDrJonathanJavittMember" name="ConsultationAgreementWithDrJonathanJavittMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConsultationAgreementWithZacharyJavittMember" name="ConsultationAgreementWithZacharyJavittMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ConsultingAgreementAnnualPayment" name="ConsultingAgreementAnnualPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ConsultingAgreementMonthlyPayment" name="ConsultingAgreementMonthlyPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ConsultingAgreementPerformanceBonusTargetValue" name="ConsultingAgreementPerformanceBonusTargetValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_ContractCosts" name="ContractCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConversionOfDebtToCommonStockMember" name="ConversionOfDebtToCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" name="ConversionOfPrincipalAndInterestIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" name="ConversionOfSeriesAPreferredStockToCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" name="ConversionOfSeriesAPreferredStockToPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_DebtInstrumentConditionalDefaultInterestRate" name="DebtInstrumentConditionalDefaultInterestRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" name="DebtInstrumentConversionsAndRepaymentsOfDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" name="DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_DebtInstrumentFaceAmountIndividualTranches" name="DebtInstrumentFaceAmountIndividualTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentInterestRateInEventOfDefault" name="DebtInstrumentInterestRateInEventOfDefault" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentNumberOfTranches" name="DebtInstrumentNumberOfTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentOriginalIssuanceDiscount" name="DebtInstrumentOriginalIssuanceDiscount" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentPrepaymentPercentage" name="DebtInstrumentPrepaymentPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentRedemptionAmount" name="DebtInstrumentRedemptionAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DebtInstrumentRedemptionConversionPricePercentage" name="DebtInstrumentRedemptionConversionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_DebtIssuanceCosts" name="DebtIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_DeferredTaxAssetsLiabilitiesGross" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="nrxp_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" name="EffectiveIncomeTaxRateReconciliationConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" name="EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" name="EffectiveIncomeTaxRateReconciliationSettlementWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" name="EndOfPhaseIClinicalTrialsOfLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" name="EndOfPhaseIIClinicalTrialsOfLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" name="EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_FairValueAdjustmentOfConvertibleDebt" name="FairValueAdjustmentOfConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_FebruaryOverallotmentOptionMember" name="FebruaryOverallotmentOptionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_FebruaryUnderwriterWarrantsMember" name="FebruaryUnderwriterWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_FebruaryUnderwritingAgreementMember" name="FebruaryUnderwritingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_FebruaryWarrantsMember" name="FebruaryWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" name="FirstCommercialSaleOfLicensedProductInEuropeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" name="FirstCommercialSaleOfLicensedProductInUsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_GainLossOnConvertibleDebtRedemption" name="GainLossOnConvertibleDebtRedemption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_GlytechLicenseAgreementMember" name="GlytechLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_HCWainwrightCoLLCMember" name="HCWainwrightCoLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_HopeTherapeuticsIncMember" name="HopeTherapeuticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_InterestRepaymentMember" name="InterestRepaymentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_June2023PurchaseAgreementMember" name="June2023PurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_JuneInvestorWarrantsMember" name="JuneInvestorWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_JunePlacementAgentWarrantsMember" name="JunePlacementAgentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_LeaseContractualTermOfficeSpaceRentalMember" name="LeaseContractualTermOfficeSpaceRentalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LetterAgreementPercentageOfCashFeePaid" name="LetterAgreementPercentageOfCashFeePaid" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LicenseAgreementAcceleratingPayment" name="LicenseAgreementAcceleratingPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LicenseAgreementCumulativePayments" name="LicenseAgreementCumulativePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LicenseAgreementInitialPayment" name="LicenseAgreementInitialPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_LicenseAgreementMaintenanceFee" name="LicenseAgreementMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_LicenseAgreementMilestonePayment" name="LicenseAgreementMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" name="LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_LitigationSettlementPaymentInstallmentOne" name="LitigationSettlementPaymentInstallmentOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LitigationSettlementPaymentInstallmentTwo" name="LitigationSettlementPaymentInstallmentTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_LongtermDebtTotal" name="LongtermDebtTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="nrxp_March2023PurchaseAgreementMember" name="March2023PurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_MarchInvestorWarrantsMember" name="MarchInvestorWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_MeasurementInputCostOfDebtMember" name="MeasurementInputCostOfDebtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_MeasurementInputMarketRateMember" name="MeasurementInputMarketRateMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_MeasurementInputProbabilityOfDefaultMember" name="MeasurementInputProbabilityOfDefaultMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_MeasurementInputVolumeVolatilityMember" name="MeasurementInputVolumeVolatilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_NRXPharmaceuticalsIncMember" name="NRXPharmaceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_NeuroRxMember" name="NeuroRxMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_NoncashLitigationExpense" name="NoncashLitigationExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_NondesignatedPreferredStockMember" name="NondesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_OctoberAmendedWarrantsMember" name="OctoberAmendedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_PatentLicenseMember" name="PatentLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_PaymentForLicenseAgreementMaintenanceFee" name="PaymentForLicenseAgreementMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_PlacementAgentFeePercentOfGrossProceeds" name="PlacementAgentFeePercentOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="nrxp_PreferredStockAndWarrantsMember" name="PreferredStockAndWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_PrepaidClinicalDevelopmentExpense" name="PrepaidClinicalDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_PrincipalRepaymentMember" name="PrincipalRepaymentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_PrivatePlacementPremiumPercentage" name="PrivatePlacementPremiumPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ProceedsFromInsuranceLoans" name="ProceedsFromInsuranceLoans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ProductsCoveredByLicensedPatentsMember" name="ProductsCoveredByLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ProductsCoveredByValidClaimsMember" name="ProductsCoveredByValidClaimsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_RDPurchaseAgreementMember" name="RDPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_RDPurchaseAgreementWarrantsMember" name="RDPurchaseAgreementWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" name="ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_RepaymentsOfInsuranceLoans" name="RepaymentsOfInsuranceLoans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" name="SaleOfStockConsiderationAdditionalCommitmentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_SaleOfStockConsiderationCommitmentAmount" name="SaleOfStockConsiderationCommitmentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" name="SarahHerzogMemorialHospitalLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" name="ScheduleOfMilestonePaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ShareSubscriptionFacilityAgreementGEMMember" name="ShareSubscriptionFacilityAgreementGEMMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_StockIssuedAsOfferingCosts" name="StockIssuedAsOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_StockSubscriptionsReceivableWriteOff" name="StockSubscriptionsReceivableWriteOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" name="StockholdersEquityNoteSpinoffTransactionPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_StreetervileComplaintMember" name="StreetervileComplaintMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_StreetervilleCapitalLLCMember" name="StreetervilleCapitalLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_StreetervilleConvertibleNoteAmendment2Member" name="StreetervilleConvertibleNoteAmendment2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_StreetervilleConvertibleNoteAmendment3Member" name="StreetervilleConvertibleNoteAmendment3Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_StreetervilleConvertibleNoteMember" name="StreetervilleConvertibleNoteMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_SubstituteWarrantsMember" name="SubstituteWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_The2016OmnibusIncentivePlanMember" name="The2016OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_The2021OmnibusIncentivePlanMember" name="The2021OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ThirdTrancheNotesMember" name="ThirdTrancheNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_ThirdTrancheNotesWarrantsMember" name="ThirdTrancheNotesWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_UnderwriterOverallotmentWarrantsMember" name="UnderwriterOverallotmentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_UnrestrictedUponNewDrugApplicationDateMember" name="UnrestrictedUponNewDrugApplicationDateMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_UnrestrictedUponNewDrugApprovalDateMember" name="UnrestrictedUponNewDrugApprovalDateMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_WarrantAmendmentAgreementMember" name="WarrantAmendmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" name="WarrantAmendmentJuneInvestorWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_WarrantsMember" name="WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" name="statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" name="statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" name="statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" name="statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-10-stockbased-compensation-tables" name="statement-statement-note-10-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" name="statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" name="statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" name="statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-11-fair-value-measurements-tables" name="statement-statement-note-11-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" name="statement-statement-note-12-segment-reporting-longlived-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" name="statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-12-segment-reporting-tables" name="statement-statement-note-12-segment-reporting-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" name="statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" name="statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-13-income-taxes-tables" name="statement-statement-note-13-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" name="statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" name="statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" name="statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" name="statement-statement-note-5-accrued-and-other-current-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" name="statement-statement-note-7-debt-schedule-of-convertible-debt-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-7-debt-tables" name="statement-statement-note-7-debt-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" name="statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-8-commitments-and-contingencies-tables" name="statement-statement-note-8-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" name="statement-statement-note-9-equity-schedule-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-note-9-equity-tables" name="statement-statement-note-9-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="nrxp_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nrxp-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:16PM UTC 2025-03-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="nrxp-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedClinicalSiteCostsCurrent" xlink:label="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ContractCosts" xlink:label="nrxp_ContractCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtIssuanceCosts" xlink:label="nrxp_DebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoncashLitigationExpense" xlink:label="nrxp_NoncashLitigationExpense" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromInsuranceLoans" xlink:label="nrxp_ProceedsFromInsuranceLoans" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RepaymentsOfInsuranceLoans" xlink:label="nrxp_RepaymentsOfInsuranceLoans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrxp_NoncashLitigationExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrxp_DebtIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrxp_ContractCosts" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nrxp_RepaymentsOfInsuranceLoans" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nrxp_ProceedsFromInsuranceLoans" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-longlived-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidClinicalDevelopmentExpense" xlink:label="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:label="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nrxp-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:16PM UTC 2025-03-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-1-organization" xlink:href="nrxp-20241231.xsd#statement-note-1-organization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-1-organization" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information" xlink:href="nrxp-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="nrxp-20241231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NondesignatedPreferredStockMember" xlink:label="nrxp_NondesignatedPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_NondesignatedPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_CommonStockAndWarrantIssuanceMember" xlink:label="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern" xlink:href="nrxp-20241231.xsd#statement-note-2-going-concern" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nrxp_AnsonMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-" xlink:href="nrxp-20241231.xsd#statement-note-6-alvogen-licensing-agreement-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenLicensingAgreementMember" xlink:label="nrxp_AlvogenLicensingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_AlvogenLicensingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt" xlink:href="nrxp-20241231.xsd#statement-note-7-debt" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsMember" xlink:label="nrxp_AnsonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_InterestRepaymentMember" xlink:label="nrxp_InterestRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrincipalRepaymentMember" xlink:label="nrxp_PrincipalRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_PrincipalRepaymentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_InterestRepaymentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ExclusiveLicenseAgreementMember" xlink:label="nrxp_ExclusiveLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PatentLicenseMember" xlink:label="nrxp_PatentLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByLicensedPatentsMember" xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByValidClaimsMember" xlink:label="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_ExclusiveLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="nrxp_PatentLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity" xlink:href="nrxp-20241231.xsd#statement-note-9-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_April2024OfferingMember" xlink:label="nrxp_April2024OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilOverallotmentAgreementMember" xlink:label="nrxp_AprilOverallotmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterAgreementMember" xlink:label="nrxp_AprilUnderwriterAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterWarrantsMember" xlink:label="nrxp_AprilUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AugustInvestorWarrantsMember" xlink:label="nrxp_AugustInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfDebtToCommonStockMember" xlink:label="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryOverallotmentOptionMember" xlink:label="nrxp_FebruaryOverallotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwriterWarrantsMember" xlink:label="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwritingAgreementMember" xlink:label="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryWarrantsMember" xlink:label="nrxp_FebruaryWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HCWainwrightCoLLCMember" xlink:label="nrxp_HCWainwrightCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_June2023PurchaseAgreementMember" xlink:label="nrxp_June2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JuneInvestorWarrantsMember" xlink:label="nrxp_JuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JunePlacementAgentWarrantsMember" xlink:label="nrxp_JunePlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_March2023PurchaseAgreementMember" xlink:label="nrxp_March2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MarchInvestorWarrantsMember" xlink:label="nrxp_MarchInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_OctoberAmendedWarrantsMember" xlink:label="nrxp_OctoberAmendedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PreferredStockAndWarrantsMember" xlink:label="nrxp_PreferredStockAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementWarrantsMember" xlink:label="nrxp_PrivatePlacementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PublicWarrantsMember" xlink:label="nrxp_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReverseStockSplitMember" xlink:label="nrxp_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleCapitalLLCMember" xlink:label="nrxp_StreetervilleCapitalLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SubstituteWarrantsMember" xlink:label="nrxp_SubstituteWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentAgreementMember" xlink:label="nrxp_WarrantAmendmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="nrxp_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_PreferredStockAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_March2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_MarchInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nrxp_HCWainwrightCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_June2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_JuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleCapitalLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_FebruaryOverallotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_FebruaryWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_AprilUnderwriterAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_AprilOverallotmentAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_April2024OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_SubstituteWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_PublicWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_PrivatePlacementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_JunePlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_WarrantAmendmentAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AugustInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_OctoberAmendedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AprilUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2016OmnibusIncentivePlanMember" xlink:label="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2021OmnibusIncentivePlanMember" xlink:label="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions" xlink:href="nrxp-20241231.xsd#statement-note-14-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GlytechLicenseAgreementMember" xlink:label="nrxp_GlytechLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrxp_GlytechLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events" xlink:href="nrxp-20241231.xsd#statement-note-15-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsiderationWarrantsMember" xlink:label="nrxp_ConsiderationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HopeTherapeuticsIncMember" xlink:label="nrxp_HopeTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PurchaseAgreementMember" xlink:label="nrxp_PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementMember" xlink:label="nrxp_RDPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementWarrantsMember" xlink:label="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesMember" xlink:label="nrxp_ThirdTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesWarrantsMember" xlink:label="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_PurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="nrxp_HopeTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_ThirdTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_RDPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_ConsiderationWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies" xlink:href="nrxp-20241231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables" xlink:href="nrxp-20241231.xsd#statement-note-7-debt-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:label="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables" xlink:href="nrxp-20241231.xsd#statement-note-9-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-2-going-concern-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:label="nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentNumberOfTranches" xlink:label="nrxp_DebtInstrumentNumberOfTranches" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nrxp_AnsonMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentNumberOfTranches" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-6-alvogen-licensing-agreement-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenLicensingAgreementMember" xlink:label="nrxp_AlvogenLicensingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementAcceleratingPayment" xlink:label="nrxp_LicenseAgreementAcceleratingPayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementInitialPayment" xlink:label="nrxp_LicenseAgreementInitialPayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockSubscriptionsReceivableWriteOff" xlink:label="nrxp_StockSubscriptionsReceivableWriteOff" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_AlvogenLicensingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementInitialPayment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementAcceleratingPayment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockSubscriptionsReceivableWriteOff" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-7-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsMember" xlink:label="nrxp_AnsonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:label="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:label="nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:label="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:label="nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentNumberOfTranches" xlink:label="nrxp_DebtInstrumentNumberOfTranches" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:label="nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentPrepaymentPercentage" xlink:label="nrxp_DebtInstrumentPrepaymentPercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentRedemptionAmount" xlink:label="nrxp_DebtInstrumentRedemptionAmount" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:label="nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtIssuanceCosts" xlink:label="nrxp_DebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_InterestRepaymentMember" xlink:label="nrxp_InterestRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LitigationSettlementPaymentInstallmentOne" xlink:label="nrxp_LitigationSettlementPaymentInstallmentOne" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:label="nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrincipalRepaymentMember" xlink:label="nrxp_PrincipalRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium" xlink:label="us-gaap_RedemptionPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_PrincipalRepaymentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_InterestRepaymentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentPrepaymentPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentRedemptionAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfDebt" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedemptionPremium" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LitigationSettlementPaymentInstallmentOne" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentNumberOfTranches" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ExclusiveLicenseAgreementMember" xlink:label="nrxp_ExclusiveLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementCumulativePayments" xlink:label="nrxp_LicenseAgreementCumulativePayments" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMaintenanceFee" xlink:label="nrxp_LicenseAgreementMaintenanceFee" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMilestonePayment" xlink:label="nrxp_LicenseAgreementMilestonePayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:label="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PatentLicenseMember" xlink:label="nrxp_PatentLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:label="nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByLicensedPatentsMember" xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByValidClaimsMember" xlink:label="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RoyaltyPercentage" xlink:label="nrxp_RoyaltyPercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_ExclusiveLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="nrxp_PatentLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementCumulativePayments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementMilestonePayment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_RoyaltyPercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForRoyalties" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementMaintenanceFee" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-9-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_April2024OfferingMember" xlink:label="nrxp_April2024OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilOverallotmentAgreementMember" xlink:label="nrxp_AprilOverallotmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterAgreementMember" xlink:label="nrxp_AprilUnderwriterAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterWarrantsMember" xlink:label="nrxp_AprilUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AugustInvestorWarrantsMember" xlink:label="nrxp_AugustInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:label="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfDebtToCommonStockMember" xlink:label="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryOverallotmentOptionMember" xlink:label="nrxp_FebruaryOverallotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwriterWarrantsMember" xlink:label="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwritingAgreementMember" xlink:label="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryWarrantsMember" xlink:label="nrxp_FebruaryWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HCWainwrightCoLLCMember" xlink:label="nrxp_HCWainwrightCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_June2023PurchaseAgreementMember" xlink:label="nrxp_June2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JuneInvestorWarrantsMember" xlink:label="nrxp_JuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JunePlacementAgentWarrantsMember" xlink:label="nrxp_JunePlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:label="nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_March2023PurchaseAgreementMember" xlink:label="nrxp_March2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MarchInvestorWarrantsMember" xlink:label="nrxp_MarchInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_OctoberAmendedWarrantsMember" xlink:label="nrxp_OctoberAmendedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PreferredStockAndWarrantsMember" xlink:label="nrxp_PreferredStockAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementPremiumPercentage" xlink:label="nrxp_PrivatePlacementPremiumPercentage" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementWarrantsMember" xlink:label="nrxp_PrivatePlacementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PublicWarrantsMember" xlink:label="nrxp_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReverseStockSplitMember" xlink:label="nrxp_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleCapitalLLCMember" xlink:label="nrxp_StreetervilleCapitalLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SubstituteWarrantsMember" xlink:label="nrxp_SubstituteWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentAgreementMember" xlink:label="nrxp_WarrantAmendmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="nrxp_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_PreferredStockAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_March2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_MarchInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nrxp_HCWainwrightCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_June2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_JuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleCapitalLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_FebruaryOverallotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_FebruaryWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_AprilUnderwriterAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_AprilOverallotmentAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_April2024OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_SubstituteWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_PublicWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_PrivatePlacementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_JunePlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_WarrantAmendmentAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AugustInvestorWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_OctoberAmendedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AprilUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PrivatePlacementPremiumPercentage" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:type="arc"/>
    <link:definitionArc order="43" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="44" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="45" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2016OmnibusIncentivePlanMember" xlink:label="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2021OmnibusIncentivePlanMember" xlink:label="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-14-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementAnnualPayment" xlink:label="nrxp_ConsultingAgreementAnnualPayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementMonthlyPayment" xlink:label="nrxp_ConsultingAgreementMonthlyPayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:label="nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GlytechLicenseAgreementMember" xlink:label="nrxp_GlytechLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrxp_GlytechLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ConsultingAgreementAnnualPayment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ConsultingAgreementMonthlyPayment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-15-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:label="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:label="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsiderationWarrantsMember" xlink:label="nrxp_ConsiderationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HopeTherapeuticsIncMember" xlink:label="nrxp_HopeTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PurchaseAgreementMember" xlink:label="nrxp_PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementMember" xlink:label="nrxp_RDPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementWarrantsMember" xlink:label="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:label="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:label="nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesMember" xlink:label="nrxp_ThirdTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesWarrantsMember" xlink:label="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_PurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="nrxp_HopeTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_ThirdTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_RDPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrxp_ConsiderationWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnnualRevenueThresholdMember" xlink:label="nrxp_AnnualRevenueThresholdMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMilestonePayment" xlink:label="nrxp_LicenseAgreementMilestonePayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrxp_AnnualRevenueThresholdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementMilestonePayment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantsMember" xlink:label="nrxp_WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nrxp_WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="nrxp-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedClinicalSiteCostsCurrent" xlink:label="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NondesignatedPreferredStockMember" xlink:label="nrxp_NondesignatedPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_NondesignatedPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LoansPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ContractCosts" xlink:label="nrxp_ContractCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtIssuanceCosts" xlink:label="nrxp_DebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoncashLitigationExpense" xlink:label="nrxp_NoncashLitigationExpense" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromInsuranceLoans" xlink:label="nrxp_ProceedsFromInsuranceLoans" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RepaymentsOfInsuranceLoans" xlink:label="nrxp_RepaymentsOfInsuranceLoans" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockIssuedAsOfferingCosts" xlink:label="nrxp_StockIssuedAsOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_DebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_ContractCosts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_NoncashLitigationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nrxp_RepaymentsOfInsuranceLoans" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nrxp_ProceedsFromInsuranceLoans" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nrxp_StockIssuedAsOfferingCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:label="nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:label="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_CommonStockAndWarrantIssuanceMember" xlink:label="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:label="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nrxp_AnsonMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details" xlink:href="nrxp-20241231.xsd#statement-note-7-debt-schedule-of-convertible-debt-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:label="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LongtermDebtTotal" xlink:label="nrxp_LongtermDebtTotal" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LongtermDebtTotal" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputCostOfDebtMember" xlink:label="nrxp_MeasurementInputCostOfDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputMarketRateMember" xlink:label="nrxp_MeasurementInputMarketRateMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:label="nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputVolumeVolatilityMember" xlink:label="nrxp_MeasurementInputVolumeVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantsMember" xlink:label="nrxp_WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="nrxp_WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="nrxp_MeasurementInputMarketRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="nrxp_MeasurementInputCostOfDebtMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="nrxp_MeasurementInputVolumeVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-longlived-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidClinicalDevelopmentExpense" xlink:label="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:label="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details" xlink:href="nrxp-20241231.xsd#statement-note-9-equity-schedule-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:label="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:label="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:label="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nrxp-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:16PM UTC 2025-03-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DocumentAndEntityInformation" xlink:label="nrxp_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DocumentAndEntityInformation" xlink:to="nrxp_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="nrxp_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible note payable, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-significant-accounting-policies-policies" xlink:label="nrxp_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-significant-accounting-policies-policies" xlink:to="nrxp_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:label="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:to="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free rate of interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:label="nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PaymentForLicenseAgreementMaintenanceFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_PaymentForLicenseAgreementMaintenanceFee</link:label>
    <link:label xlink:label="nrxp_PaymentForLicenseAgreementMaintenanceFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for License Agreement, Maintenance Fee</link:label>
    <link:label xlink:label="nrxp_PaymentForLicenseAgreementMaintenanceFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash paid for license agreement maintenance fee during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:to="nrxp_PaymentForLicenseAgreementMaintenanceFee-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" xlink:label="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Accrued and Other Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" xlink:to="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-7-debt-tables" xlink:label="nrxp_statement-statement-note-7-debt-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-7-debt-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-7-debt-tables" xlink:to="nrxp_statement-statement-note-7-debt-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HopeTherapeuticsIncMember" xlink:label="nrxp_HopeTherapeuticsIncMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_HopeTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hope Therapeutics, Inc. [Member]</link:label>
    <link:label xlink:label="nrxp_HopeTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to Hope Therapeutics, Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_HopeTherapeuticsIncMember" xlink:to="nrxp_HopeTherapeuticsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-8-commitments-and-contingencies-tables" xlink:label="nrxp_statement-statement-note-8-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-8-commitments-and-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-8-commitments-and-contingencies-tables" xlink:to="nrxp_statement-statement-note-8-commitments-and-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-9-equity-tables" xlink:label="nrxp_statement-statement-note-9-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-9-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-9-equity-tables" xlink:to="nrxp_statement-statement-note-9-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-tables" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-tables" xlink:to="nrxp_statement-statement-note-10-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-tables" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-tables" xlink:to="nrxp_statement-statement-note-11-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-12-segment-reporting-tables" xlink:label="nrxp_statement-statement-note-12-segment-reporting-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-12-segment-reporting-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Segment Reporting</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-12-segment-reporting-tables" xlink:to="nrxp_statement-statement-note-12-segment-reporting-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerRefundLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refund liability (see Note 6)</link:label>
    <link:label xlink:label="us-gaap_CustomerRefundLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRefundLiabilityCurrent" xlink:to="us-gaap_CustomerRefundLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsiderationWarrantsMember" xlink:label="nrxp_ConsiderationWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConsiderationWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_ConsiderationWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to consideration warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConsiderationWarrantsMember" xlink:to="nrxp_ConsiderationWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-tables" xlink:label="nrxp_statement-statement-note-13-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-13-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-13-income-taxes-tables" xlink:to="nrxp_statement-statement-note-13-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:label="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:to="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent</link:label>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">R&amp;D credit</link:label>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax (credit) expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:label="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:to="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:label="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price, Percentage of Closing Price</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to percentage of closing price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:to="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:label="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:to="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" xlink:label="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Debt - Schedule of Convertible Debt (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" xlink:to="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:label="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:to="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" xlink:label="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Equity - Schedule of Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" xlink:to="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:to="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:to="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:to="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:to="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:to="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:to="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:to="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:label="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:to="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" xlink:label="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Segment Reporting - Long-lived Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" xlink:to="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:to="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LitigationSettlementAmountAwardedToOtherParty</link:label>
    <link:label xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:to="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatements" xlink:label="nrxp_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NotesToFinancialStatements" xlink:to="nrxp_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="nrxp_RisksAndUncertaintiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label xlink:label="nrxp_RisksAndUncertaintiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of the entity's policy regarding risks and uncertainties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:to="nrxp_RisksAndUncertaintiesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="nrxp_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_CommonStockAndWarrantIssuanceMember" xlink:label="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_CommonStockAndWarrantIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock and Warrant Issuance [Member]</link:label>
    <link:label xlink:label="nrxp_CommonStockAndWarrantIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to common stock and warrant issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_CommonStockAndWarrantIssuanceMember" xlink:to="nrxp_CommonStockAndWarrantIssuanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Block]</link:label>
    <link:label xlink:label="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure regarding prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationSettlementExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement (income) expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ATMOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Offering [Member]</link:label>
    <link:label xlink:label="nrxp_ATMOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to ATM offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ATMOfferingMember" xlink:to="nrxp_ATMOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (unvested) (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (unvested) (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantsMember" xlink:label="nrxp_WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_WarrantsMember" xlink:to="nrxp_WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</link:label>
    <link:label xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options vested and exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementAcceleratingPayment" xlink:label="nrxp_LicenseAgreementAcceleratingPayment" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LicenseAgreementAcceleratingPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LicenseAgreementAcceleratingPayment</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementAcceleratingPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Accelerating Payment</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementAcceleratingPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the accelerating payment of a license agreement during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LicenseAgreementAcceleratingPayment" xlink:to="nrxp_LicenseAgreementAcceleratingPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementInitialPayment" xlink:label="nrxp_LicenseAgreementInitialPayment" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LicenseAgreementInitialPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LicenseAgreementInitialPayment</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementInitialPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Initial Payment</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementInitialPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the initial payment of a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LicenseAgreementInitialPayment" xlink:to="nrxp_LicenseAgreementInitialPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance loan payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMilestonePayment" xlink:label="nrxp_LicenseAgreementMilestonePayment" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LicenseAgreementMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the milestone payment for a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LicenseAgreementMilestonePayment" xlink:to="nrxp_LicenseAgreementMilestonePayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible note payable - current portion</link:label>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible note payable and accrued interest &#8211; short term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentRedemptionAmount" xlink:label="nrxp_DebtInstrumentRedemptionAmount" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentRedemptionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentRedemptionAmount</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentRedemptionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Amount</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentRedemptionAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the redemption amount of a debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentRedemptionAmount" xlink:to="nrxp_DebtInstrumentRedemptionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AlvogenAndLotusWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen and Lotus Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_AlvogenAndLotusWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Alvogen and Lotus warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AlvogenAndLotusWarrantsMember" xlink:to="nrxp_AlvogenAndLotusWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenLicensingAgreementMember" xlink:label="nrxp_AlvogenLicensingAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AlvogenLicensingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Licensing Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_AlvogenLicensingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Alvogen licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AlvogenLicensingAgreementMember" xlink:to="nrxp_AlvogenLicensingAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentPrepaymentPercentage" xlink:label="nrxp_DebtInstrumentPrepaymentPercentage" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentPrepaymentPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentPrepaymentPercentage</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentPrepaymentPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Percentage</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentPrepaymentPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the prepayment percentage on a debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentPrepaymentPercentage" xlink:to="nrxp_DebtInstrumentPrepaymentPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible note payable - current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LongtermDebtTotal" xlink:label="nrxp_LongtermDebtTotal" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LongtermDebtTotal-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of the Note before current period change in fair value</link:label>
    <link:label xlink:label="nrxp_LongtermDebtTotal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LongtermDebtTotal</link:label>
    <link:label xlink:label="nrxp_LongtermDebtTotal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LongtermDebtTotal" xlink:to="nrxp_LongtermDebtTotal-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Conversion of Note</link:label>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to loss on conversion of debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/Expire, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:label="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage of Equity Issuable</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum amount of equity issuable issuable by converting a a debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:to="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:label="nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentConditionalDefaultInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentConditionalDefaultInterestRate</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentConditionalDefaultInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conditional Default Interest Rate</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentConditionalDefaultInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the interest rate of debt instrument in the event of a default.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:to="nrxp_DebtInstrumentConditionalDefaultInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:label="nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentRedemptionConversionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentRedemptionConversionPricePercentage</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentRedemptionConversionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Conversion Price, Percentage</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentRedemptionConversionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:to="nrxp_DebtInstrumentRedemptionConversionPricePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption" xlink:type="locator"/>
    <link:label xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_GainLossOnConvertibleDebtRedemption</link:label>
    <link:label xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Convertible Debt Redemption</link:label>
    <link:label xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on convertible note redemptions</link:label>
    <link:label xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gain (loss) on convertible debt redemption.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_GainLossOnConvertibleDebtRedemption" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyExchangeRateRemeasurement1</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Exchange Rate, Remeasurement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:to="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementAnnualPayment" xlink:label="nrxp_ConsultingAgreementAnnualPayment" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConsultingAgreementAnnualPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ConsultingAgreementAnnualPayment</link:label>
    <link:label xlink:label="nrxp_ConsultingAgreementAnnualPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement, Annual Payment</link:label>
    <link:label xlink:label="nrxp_ConsultingAgreementAnnualPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the annual payment of a consulting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConsultingAgreementAnnualPayment" xlink:to="nrxp_ConsultingAgreementAnnualPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:label="nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConsultingAgreementPerformanceBonusTargetValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ConsultingAgreementPerformanceBonusTargetValue</link:label>
    <link:label xlink:label="nrxp_ConsultingAgreementPerformanceBonusTargetValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement, Performance Bonus, Target Value</link:label>
    <link:label xlink:label="nrxp_ConsultingAgreementPerformanceBonusTargetValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the target performance value of a bonus on a consulting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:to="nrxp_ConsultingAgreementPerformanceBonusTargetValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementMonthlyPayment" xlink:label="nrxp_ConsultingAgreementMonthlyPayment" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConsultingAgreementMonthlyPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ConsultingAgreementMonthlyPayment</link:label>
    <link:label xlink:label="nrxp_ConsultingAgreementMonthlyPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement, Monthly Payment</link:label>
    <link:label xlink:label="nrxp_ConsultingAgreementMonthlyPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the monthly payment of a consulting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConsultingAgreementMonthlyPayment" xlink:to="nrxp_ConsultingAgreementMonthlyPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrestricted Upon New Drug Approval Date [member]</link:label>
    <link:label xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to unrestricted upon New Drug Approval Date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:to="nrxp_UnrestrictedUponNewDrugApprovalDateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrestricted Upon New Drug Application Date [Member]</link:label>
    <link:label xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to unrestricted upon New Drug Application Date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:to="nrxp_UnrestrictedUponNewDrugApplicationDateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StreetervileComplaintMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Streetervile Complaint [Member]</link:label>
    <link:label xlink:label="nrxp_StreetervileComplaintMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Streeterville Complaint.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StreetervileComplaintMember" xlink:to="nrxp_StreetervileComplaintMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtIssuanceCosts" xlink:label="nrxp_DebtIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense for debt issuance costs due to fair value election on Anson Notes</link:label>
    <link:label xlink:label="nrxp_DebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label xlink:label="nrxp_DebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow related to the issuance of debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtIssuanceCosts" xlink:to="nrxp_DebtIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedBonusesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedBonusesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedBonusesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares</link:label>
    <link:label xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares</link:label>
    <link:label xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the annual percentage increase in authorized shares for a share based compensation arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:to="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Expire (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NeuroRxMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuro Rx [Member]</link:label>
    <link:label xlink:label="nrxp_NeuroRxMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Neuro Rx.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NeuroRxMember" xlink:to="nrxp_NeuroRxMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentNumberOfTranches" xlink:label="nrxp_DebtInstrumentNumberOfTranches" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentNumberOfTranches-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentNumberOfTranches</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentNumberOfTranches-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentNumberOfTranches-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of tranches to be received as part of a purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentNumberOfTranches" xlink:to="nrxp_DebtInstrumentNumberOfTranches-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByLicensedPatentsMember" xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Covered By Licensed Patents [Member]</link:label>
    <link:label xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to products covered by licensed patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:to="nrxp_ProductsCoveredByLicensedPatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarah Herzog Memorial Hospital License Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Sarah Herzog Memorial Hospital License Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ExclusiveLicenseAgreementMember" xlink:label="nrxp_ExclusiveLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ExclusiveLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_ExclusiveLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to an exclusive license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ExclusiveLicenseAgreementMember" xlink:to="nrxp_ExclusiveLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByValidClaimsMember" xlink:label="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ProductsCoveredByValidClaimsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Covered by Valid Claims [Member]</link:label>
    <link:label xlink:label="nrxp_ProductsCoveredByValidClaimsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to products covered by valid claims.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ProductsCoveredByValidClaimsMember" xlink:to="nrxp_ProductsCoveredByValidClaimsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:label="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements, Milestone Payments, Conditional Reduction Percentage</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the conditional reduction percentage for milestone payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:to="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of computer equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:label="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of AOCI upon settlement of Streeterville Note</link:label>
    <link:label xlink:label="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of reclassification adjustments of other comprehensive income (loss) upon settlement of convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:to="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMaintenanceFee" xlink:label="nrxp_LicenseAgreementMaintenanceFee" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LicenseAgreementMaintenanceFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LicenseAgreementMaintenanceFee</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementMaintenanceFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Maintenance Fee</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementMaintenanceFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maintenance fee on a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LicenseAgreementMaintenanceFee" xlink:to="nrxp_LicenseAgreementMaintenanceFee-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for settlement of accrued liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RoyaltyPercentage" xlink:label="nrxp_RoyaltyPercentage" xlink:type="locator"/>
    <link:label xlink:label="nrxp_RoyaltyPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_RoyaltyPercentage</link:label>
    <link:label xlink:label="nrxp_RoyaltyPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Percentage</link:label>
    <link:label xlink:label="nrxp_RoyaltyPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of revenue that a royalty is paid on.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_RoyaltyPercentage" xlink:to="nrxp_RoyaltyPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_InterestRepaymentMember" xlink:label="nrxp_InterestRepaymentMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_InterestRepaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Repayment [Member]</link:label>
    <link:label xlink:label="nrxp_InterestRepaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest repayment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_InterestRepaymentMember" xlink:to="nrxp_InterestRepaymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:label="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ScheduleOfMilestonePaymentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Milestone Payments [Table Text Block]</link:label>
    <link:label xlink:label="nrxp_ScheduleOfMilestonePaymentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of milestone payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="nrxp_ScheduleOfMilestonePaymentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrincipalRepaymentMember" xlink:label="nrxp_PrincipalRepaymentMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PrincipalRepaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Repayment [Member]</link:label>
    <link:label xlink:label="nrxp_PrincipalRepaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents principal repayment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PrincipalRepaymentMember" xlink:to="nrxp_PrincipalRepaymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">End of Phase II Clinical Trials of Licensed Product [Member]</link:label>
    <link:label xlink:label="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to End of Phase II Clinical Trials of Licensed Product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:to="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">End of Phase I Clinical Trials of Licensed Product [Member]</link:label>
    <link:label xlink:label="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to End of Phase I Clinical Trials of Licensed Product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:to="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series A Preferred Stock to Preferred Stock [Member]</link:label>
    <link:label xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the conversion of Series A convertible preferred stock to preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReverseStockSplitMember" xlink:label="nrxp_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="nrxp_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to a reverse stock split.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ReverseStockSplitMember" xlink:to="nrxp_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_PlacementAgentFeePercentOfGrossProceeds</link:label>
    <link:label xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement Agent Fee, Percent of Gross Proceeds</link:label>
    <link:label xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fee paid to the placement agent expressed as a percentage of gross proceeds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:to="nrxp_PlacementAgentFeePercentOfGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInUsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Commercial Sale of Licensed Product in U.S. [Member]</link:label>
    <link:label xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInUsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to First Commercial Sale of Licensed Product in U.S.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:to="nrxp_FirstCommercialSaleOfLicensedProductInUsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">End of Phase III Clinical Trials of Licensed Product [Member]</link:label>
    <link:label xlink:label="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to End of Phase III Clinical Trials of Licensed Product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:to="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnnualRevenueThresholdMember" xlink:label="nrxp_AnnualRevenueThresholdMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnnualRevenueThresholdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Revenue Threshold [Member]</link:label>
    <link:label xlink:label="nrxp_AnnualRevenueThresholdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to when annual revenues pass a certain threshold.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnnualRevenueThresholdMember" xlink:to="nrxp_AnnualRevenueThresholdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Commercial Sale of Licensed Product in Europe [Member]</link:label>
    <link:label xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to First Commercial Sale of Licensed Product in Europe.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:to="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryOverallotmentOptionMember" xlink:label="nrxp_FebruaryOverallotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FebruaryOverallotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February Overallotment Option [Member]</link:label>
    <link:label xlink:label="nrxp_FebruaryOverallotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the February Over-allotment Option.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FebruaryOverallotmentOptionMember" xlink:to="nrxp_FebruaryOverallotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwritingAgreementMember" xlink:label="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FebruaryUnderwritingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February Underwriting Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_FebruaryUnderwritingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the February Underwriting Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FebruaryUnderwritingAgreementMember" xlink:to="nrxp_FebruaryUnderwritingAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PublicWarrantsMember" xlink:label="nrxp_PublicWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PublicWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_PublicWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to public warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PublicWarrantsMember" xlink:to="nrxp_PublicWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StreetervilleConvertibleNoteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Streeterville Convertible Note [Member]</link:label>
    <link:label xlink:label="nrxp_StreetervilleConvertibleNoteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Streeterville Convertible Note.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StreetervilleConvertibleNoteMember" xlink:to="nrxp_StreetervilleConvertibleNoteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SubstituteWarrantsMember" xlink:label="nrxp_SubstituteWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SubstituteWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substitute Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_SubstituteWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to substitute warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SubstituteWarrantsMember" xlink:to="nrxp_SubstituteWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term, Office Space, Rental [Member]</link:label>
    <link:label xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the type lease arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:to="nrxp_LeaseContractualTermOfficeSpaceRentalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementPremiumPercentage" xlink:label="nrxp_PrivatePlacementPremiumPercentage" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PrivatePlacementPremiumPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_PrivatePlacementPremiumPercentage</link:label>
    <link:label xlink:label="nrxp_PrivatePlacementPremiumPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement, Premium Percentage</link:label>
    <link:label xlink:label="nrxp_PrivatePlacementPremiumPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the premium percentage on a private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PrivatePlacementPremiumPercentage" xlink:to="nrxp_PrivatePlacementPremiumPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PatentLicenseMember" xlink:label="nrxp_PatentLicenseMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PatentLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent License [Member]</link:label>
    <link:label xlink:label="nrxp_PatentLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the type of expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PatentLicenseMember" xlink:to="nrxp_PatentLicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonWarrantsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson Warrants Tranche One [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonWarrantsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Anson Warrants issued in Tranche One.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonWarrantsTrancheOneMember" xlink:to="nrxp_AnsonWarrantsTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryWarrantsMember" xlink:label="nrxp_FebruaryWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FebruaryWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_FebruaryWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to February warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FebruaryWarrantsMember" xlink:to="nrxp_FebruaryWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the weighted average exercise price for warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:to="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:label="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual term (Year)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the weighted average remaining term for warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:to="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDamagesSoughtValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyDamagesSoughtValue</link:label>
    <link:label xlink:label="us-gaap_LossContingencyDamagesSoughtValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period (in shares)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of warrants or rights issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:label="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the aggregate intrinsic value of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:to="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwriterWarrantsMember" xlink:label="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FebruaryUnderwriterWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February Underwriter Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_FebruaryUnderwriterWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the February underwriter warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FebruaryUnderwriterWarrantsMember" xlink:to="nrxp_FebruaryUnderwriterWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Subscription Facility Agreement - GEM [Member]</link:label>
    <link:label xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Share Subscription Facility Agreement - GEM.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementWarrantsMember" xlink:label="nrxp_PrivatePlacementWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PrivatePlacementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_PrivatePlacementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to private placement warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PrivatePlacementWarrantsMember" xlink:to="nrxp_PrivatePlacementWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:label="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Beneficial Ownership Limitation</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the beneficial ownership limitation on warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:to="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter Overallotment Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the underwriter over-allotment warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:to="nrxp_UnderwriterOverallotmentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilOverallotmentAgreementMember" xlink:label="nrxp_AprilOverallotmentAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AprilOverallotmentAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Overallotment Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_AprilOverallotmentAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the April Over-Allotment Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AprilOverallotmentAgreementMember" xlink:to="nrxp_AprilOverallotmentAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterAgreementMember" xlink:label="nrxp_AprilUnderwriterAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AprilUnderwriterAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Underwriter Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_AprilUnderwriterAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the April Underwriter Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AprilUnderwriterAgreementMember" xlink:to="nrxp_AprilUnderwriterAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightExpiredDuringPeriod</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of warrants or rights expired during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:to="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_OctoberAmendedWarrantsMember" xlink:label="nrxp_OctoberAmendedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_OctoberAmendedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October Amended Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_OctoberAmendedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the October Amended Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_OctoberAmendedWarrantsMember" xlink:to="nrxp_OctoberAmendedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Principal and Interest Into Common Stock [Member]</link:label>
    <link:label xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the conversion of principal and interest into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:label="nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentOriginalIssuanceDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentOriginalIssuanceDiscount</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentOriginalIssuanceDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Original Issuance Discount</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentOriginalIssuanceDiscount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of original issuance discount expressed as a percentage.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:to="nrxp_DebtInstrumentOriginalIssuanceDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:label="nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentInterestRateInEventOfDefault-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentInterestRateInEventOfDefault</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentInterestRateInEventOfDefault-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate in Event of Default</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentInterestRateInEventOfDefault-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual interest rate for funds borrowed, under the debt agreement, in the event of default.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:to="nrxp_DebtInstrumentInterestRateInEventOfDefault-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:label="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Securities Called by Warrants or Rights, Percentage of Principal Divided by VWAP</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of securities into which the class of warrant or right may be converted expressed as a percentage of the principal amount of the notes divided by the WVAP of the Company's common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:to="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterWarrantsMember" xlink:label="nrxp_AprilUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AprilUnderwriterWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Underwriter Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_AprilUnderwriterWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the April Underwriter Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AprilUnderwriterWarrantsMember" xlink:to="nrxp_AprilUnderwriterWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Anson Investment Master Fund LP and Anson East Master Fund LP.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonMember" xlink:to="nrxp_AnsonMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:label="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Percent of Offering Called by Warrants or Rights</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of offering called by warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:to="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonFirstTrancheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson First Tranche Notes [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonFirstTrancheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Anson First Tranche Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonFirstTrancheNotesMember" xlink:to="nrxp_AnsonFirstTrancheNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative fair value adjustments through earnings</link:label>
    <link:label xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible note payable</link:label>
    <link:label xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value adjustment of convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsMember" xlink:label="nrxp_AnsonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Anson Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonWarrantsMember" xlink:to="nrxp_AnsonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson Convertible Notes [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Anson Convertible Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonConvertibleNotesMember" xlink:to="nrxp_AnsonConvertibleNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:label="nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentFaceAmountIndividualTranches-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentFaceAmountIndividualTranches</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentFaceAmountIndividualTranches-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Individual Tranches</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentFaceAmountIndividualTranches-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Face (par) amount of debt instrument's individual tranches at time of issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:to="nrxp_DebtInstrumentFaceAmountIndividualTranches-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued and other current liabilities</link:label>
    <link:label xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses incurred but not yet paid nor invoiced within one operating cycle, and liabilities classified as other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonSecondTrancheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson Second Tranche Notes [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonSecondTrancheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Anson Second Tranche Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonSecondTrancheNotesMember" xlink:to="nrxp_AnsonSecondTrancheNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AnsonWarrantsTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anson Warrants Tranche Two [Member]</link:label>
    <link:label xlink:label="nrxp_AnsonWarrantsTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Anson Warrants Tranche Two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AnsonWarrantsTrancheTwoMember" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockIssuedAsOfferingCosts" xlink:label="nrxp_StockIssuedAsOfferingCosts" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StockIssuedAsOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock warrants as offering costs</link:label>
    <link:label xlink:label="nrxp_StockIssuedAsOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value of stock issued in noncash financing activities for offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StockIssuedAsOfferingCosts" xlink:to="nrxp_StockIssuedAsOfferingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AugustInvestorWarrantsMember" xlink:label="nrxp_AugustInvestorWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AugustInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August Investor Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_AugustInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents August Investor Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AugustInvestorWarrantsMember" xlink:to="nrxp_AugustInvestorWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial recognition of issuance of warrants</link:label>
    <link:label xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The initial recognition of the fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:to="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Streeterville Convertible Note Amendment 3 [Member]</link:label>
    <link:label xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Amendment 3 of the Streeterville Convertible Note.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JunePlacementAgentWarrantsMember" xlink:label="nrxp_JunePlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_JunePlacementAgentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June Placement Agent Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_JunePlacementAgentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents June Placement Agent Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_JunePlacementAgentWarrantsMember" xlink:to="nrxp_JunePlacementAgentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentAgreementMember" xlink:label="nrxp_WarrantAmendmentAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_WarrantAmendmentAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Amendment Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_WarrantAmendmentAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Warrant Amendment Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_WarrantAmendmentAgreementMember" xlink:to="nrxp_WarrantAmendmentAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Streeterville Convertible Note Amendment 2 [Member]</link:label>
    <link:label xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Amendment 2 of the Streeterville Convertible Note.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentNet</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Amendment, June Investor Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Warrant Amendment Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:to="nrxp_WarrantAmendmentJuneInvestorWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computers, cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HCWainwrightCoLLCMember" xlink:label="nrxp_HCWainwrightCoLLCMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_HCWainwrightCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC. [Member]</link:label>
    <link:label xlink:label="nrxp_HCWainwrightCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_HCWainwrightCoLLCMember" xlink:to="nrxp_HCWainwrightCoLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightExercisesInPeriod</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:to="nrxp_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:type="locator"/>
    <link:label xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversions and repayments of principal and interest (shares)</link:label>
    <link:label xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of conversion to shares of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:to="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionAmountsOfTransaction</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_March2023PurchaseAgreementMember" xlink:label="nrxp_March2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_March2023PurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2023 Purchase Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_March2023PurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the securities purchase agreement with the March Investors entered into on March 8, 2023.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_March2023PurchaseAgreementMember" xlink:to="nrxp_March2023PurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:label="nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LetterAgreementPercentageOfCashFeePaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LetterAgreementPercentageOfCashFeePaid</link:label>
    <link:label xlink:label="nrxp_LetterAgreementPercentageOfCashFeePaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter Agreement, Percentage of Cash Fee Paid</link:label>
    <link:label xlink:label="nrxp_LetterAgreementPercentageOfCashFeePaid-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of cash fee paid under the letter agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:to="nrxp_LetterAgreementPercentageOfCashFeePaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Underwriter Overallotment Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the April underwriter overallotment warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:to="nrxp_AprilUnderwriterOverallotmentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentRedemptionPricePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_June2023PurchaseAgreementMember" xlink:label="nrxp_June2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_June2023PurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2023 Purchase Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_June2023PurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the securities purchase agreement entered into on June 6, 2023.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_June2023PurchaseAgreementMember" xlink:to="nrxp_June2023PurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustment through accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustment through earnings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:label="nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SaleOfStockConsiderationCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_SaleOfStockConsiderationCommitmentAmount</link:label>
    <link:label xlink:label="nrxp_SaleOfStockConsiderationCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock Consideration, Commitment Amount</link:label>
    <link:label xlink:label="nrxp_SaleOfStockConsiderationCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash committed for the stock transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:to="nrxp_SaleOfStockConsiderationCommitmentAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:label="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount</link:label>
    <link:label xlink:label="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock Consideration, Additional Commitment Amount</link:label>
    <link:label xlink:label="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional commitment amount for the stock transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:to="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentPeriodicPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentPeriodicPayment</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentPeriodicPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputCostOfDebtMember" xlink:label="nrxp_MeasurementInputCostOfDebtMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_MeasurementInputCostOfDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Cost of Debt [Member]</link:label>
    <link:label xlink:label="nrxp_MeasurementInputCostOfDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement input using the cost of debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_MeasurementInputCostOfDebtMember" xlink:to="nrxp_MeasurementInputCostOfDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementCumulativePayments" xlink:label="nrxp_LicenseAgreementCumulativePayments" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LicenseAgreementCumulativePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LicenseAgreementCumulativePayments</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementCumulativePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Cumulative Payments</link:label>
    <link:label xlink:label="nrxp_LicenseAgreementCumulativePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cumulative amount paid for the licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LicenseAgreementCumulativePayments" xlink:to="nrxp_LicenseAgreementCumulativePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of shares related to reverse stock split (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateEffectivePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value of the Note</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossRelatedToLitigationSettlement</link:label>
    <link:label xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Litigation Settlement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentOwnedPercentOfNetAssets</link:label>
    <link:label xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Owned, Net Assets, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversions and repayments of principal and interest (cash)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByLiabilityClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:label xlink:label="ecd_TradingArrByIndTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued as repayment of principal and interest for convertible note (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued as repayment of principal and interest for convertible note</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series A preferred stock into common stock</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A preferred stock into common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A preferred stock into common stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant measurement input</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:label="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversions and repayments of principal and interest (shares and cash)</link:label>
    <link:label xlink:label="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of noncash and cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:to="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock issuances, net (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued in exchange for services</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued in exchange for services (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashUninsuredAmount</link:label>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock issuances, net</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increases (decreases) in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in exchange for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock as principal and interest repayment for convertible notes</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionOriginalDebtAmount1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesFairValueAdjustment</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockAmountConverted1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A preferred stock into common stock</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockAmountConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockAmountConverted1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock and warrants issued, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesConverted1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A preferred stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium" xlink:label="us-gaap_RedemptionPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RedemptionPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RedemptionPremium</link:label>
    <link:label xlink:label="us-gaap_RedemptionPremium-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption Premium</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedemptionPremium" xlink:to="us-gaap_RedemptionPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Account</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, 500,000,000 shares authorized; 14,591,505 and 8,391,956 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentOwnedAtFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentOwnedAtFairValue</link:label>
    <link:label xlink:label="us-gaap_InvestmentOwnedAtFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Owned, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForRoyalties</link:label>
    <link:label xlink:label="us-gaap_PaymentsForRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForLegalSettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForLegalSettlements</link:label>
    <link:label xlink:label="us-gaap_PaymentsForLegalSettlements-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredChargesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other prepaid expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementBasisAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonus and severance accrual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockSubscriptionsReceivableWriteOff" xlink:label="nrxp_StockSubscriptionsReceivableWriteOff" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StockSubscriptionsReceivableWriteOff-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_StockSubscriptionsReceivableWriteOff</link:label>
    <link:label xlink:label="nrxp_StockSubscriptionsReceivableWriteOff-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Subscriptions Receivable, Write Off</link:label>
    <link:label xlink:label="nrxp_StockSubscriptionsReceivableWriteOff-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Write off amount of stock subscriptions receivable during a period of time.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StockSubscriptionsReceivableWriteOff" xlink:to="nrxp_StockSubscriptionsReceivableWriteOff-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total other expenses, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:label="nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LitigationSettlementPaymentInstallmentTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LitigationSettlementPaymentInstallmentTwo</link:label>
    <link:label xlink:label="nrxp_LitigationSettlementPaymentInstallmentTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payment Installment Two</link:label>
    <link:label xlink:label="nrxp_LitigationSettlementPaymentInstallmentTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payment installment two for litigation settlement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:to="nrxp_LitigationSettlementPaymentInstallmentTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LitigationSettlementPaymentInstallmentOne" xlink:label="nrxp_LitigationSettlementPaymentInstallmentOne" xlink:type="locator"/>
    <link:label xlink:label="nrxp_LitigationSettlementPaymentInstallmentOne-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_LitigationSettlementPaymentInstallmentOne</link:label>
    <link:label xlink:label="nrxp_LitigationSettlementPaymentInstallmentOne-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payment Installment One</link:label>
    <link:label xlink:label="nrxp_LitigationSettlementPaymentInstallmentOne-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payment installment one for litigation settlement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_LitigationSettlementPaymentInstallmentOne" xlink:to="nrxp_LitigationSettlementPaymentInstallmentOne-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 8)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other (income) expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expense and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidatedEntitiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidatedEntitiesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation, liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in Valuation Allowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentForeignTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromInsuranceLoans" xlink:label="nrxp_ProceedsFromInsuranceLoans" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ProceedsFromInsuranceLoans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of insurance loan</link:label>
    <link:label xlink:label="nrxp_ProceedsFromInsuranceLoans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from insurance loans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ProceedsFromInsuranceLoans" xlink:to="nrxp_ProceedsFromInsuranceLoans-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of the Anson Notes before current period change in fair value</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfDebtToCommonStockMember" xlink:label="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConversionOfDebtToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Debt to Common Stock [Member]</link:label>
    <link:label xlink:label="nrxp_ConversionOfDebtToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the conversion of debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConversionOfDebtToCommonStockMember" xlink:to="nrxp_ConversionOfDebtToCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from liability classified warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total carrying value of Note</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfDebtIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expense for debt issuance costs due to fair value election on Anson Notes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_DeferredTaxAssetsLiabilitiesGross</link:label>
    <link:label xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets (Liabilities), Gross</link:label>
    <link:label xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax assets (liabilities) attributable to deductible temporary differences and carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:to="nrxp_DeferredTaxAssetsLiabilitiesGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:label="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:label xlink:label="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">174 capitalization</link:label>
    <link:label xlink:label="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax asset attributable to taxable temporary differences from research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:to="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfConvertibleDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible note</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized original issue discount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentCarryingAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Anson convertible notes, net of OID</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="nrxp_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_SeriesAConvertiblePreferredStockMember" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note</link:label>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoncashLitigationExpense" xlink:label="nrxp_NoncashLitigationExpense" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NoncashLitigationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash settlement expense</link:label>
    <link:label xlink:label="nrxp_NoncashLitigationExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The non-cash litigation expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NoncashLitigationExpense" xlink:to="nrxp_NoncashLitigationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series A Preferred Stock to Common Stock [Member]</link:label>
    <link:label xlink:label="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The unique name of a noncash or part noncash stock conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="locator"/>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement warrants</link:label>
    <link:label xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to settlement warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedClinicalSiteCostsCurrent" xlink:label="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AccruedClinicalSiteCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued clinical site costs</link:label>
    <link:label xlink:label="nrxp_AccruedClinicalSiteCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued clinical site costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AccruedClinicalSiteCostsCurrent" xlink:to="nrxp_AccruedClinicalSiteCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleCapitalLLCMember" xlink:label="nrxp_StreetervilleCapitalLLCMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StreetervilleCapitalLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Streeterville Capital, LLC [Member]</link:label>
    <link:label xlink:label="nrxp_StreetervilleCapitalLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StreetervilleCapitalLLCMember" xlink:to="nrxp_StreetervilleCapitalLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ContractCosts" xlink:label="nrxp_ContractCosts" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ContractCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant issuance costs related to Alvogen termination</link:label>
    <link:label xlink:label="nrxp_ContractCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The costs related to the contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ContractCosts" xlink:to="nrxp_ContractCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RepaymentsOfInsuranceLoans" xlink:label="nrxp_RepaymentsOfInsuranceLoans" xlink:type="locator"/>
    <link:label xlink:label="nrxp_RepaymentsOfInsuranceLoans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_RepaymentsOfInsuranceLoans</link:label>
    <link:label xlink:label="nrxp_RepaymentsOfInsuranceLoans-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of insurance loan</link:label>
    <link:label xlink:label="nrxp_RepaymentsOfInsuranceLoans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The repayment of insurance loans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_RepaymentsOfInsuranceLoans" xlink:to="nrxp_RepaymentsOfInsuranceLoans-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_April2024OfferingMember" xlink:label="nrxp_April2024OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_April2024OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2024 Offering [Member]</link:label>
    <link:label xlink:label="nrxp_April2024OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_April2024OfferingMember" xlink:to="nrxp_April2024OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_StockholdersEquityNoteSpinoffTransactionPercentage</link:label>
    <link:label xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note Spinoff Transaction, Percentage</link:label>
    <link:label xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of shares related to the spinoff.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:to="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued research and development expense</link:label>
    <link:label xlink:label="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:to="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidClinicalDevelopmentExpense" xlink:label="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PrepaidClinicalDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid clinical development costs</link:label>
    <link:label xlink:label="nrxp_PrepaidClinicalDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PrepaidClinicalDevelopmentExpense" xlink:to="nrxp_PrepaidClinicalDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2021OmnibusIncentivePlanMember" xlink:label="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_The2021OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Omnibus Incentive Plan [Member]</link:label>
    <link:label xlink:label="nrxp_The2021OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plan name for share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_The2021OmnibusIncentivePlanMember" xlink:to="nrxp_The2021OmnibusIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwardsExpirationDate</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2016OmnibusIncentivePlanMember" xlink:label="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_The2016OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2016 Omnibus Incentive Plan [Member]</link:label>
    <link:label xlink:label="nrxp_The2016OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plan name for share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_The2016OmnibusIncentivePlanMember" xlink:to="nrxp_The2016OmnibusIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultation Agreement with Zachary Javitt [Member]</link:label>
    <link:label xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of related party transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:to="nrxp_ConsultationAgreementWithZacharyJavittMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultation Agreement with Dr. Jonathan Javitt [Member]</link:label>
    <link:label xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of related party transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:to="nrxp_ConsultationAgreementWithDrJonathanJavittMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NondesignatedPreferredStockMember" xlink:label="nrxp_NondesignatedPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NondesignatedPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nondesignated Preferred Stock [Member]</link:label>
    <link:label xlink:label="nrxp_NondesignatedPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Nondesignated Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NondesignatedPreferredStockMember" xlink:to="nrxp_NondesignatedPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_NRXPharmaceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NRX Pharmaceuticals, Inc [Member]</link:label>
    <link:label xlink:label="nrxp_NRXPharmaceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_NRXPharmaceuticalsIncMember" xlink:to="nrxp_NRXPharmaceuticalsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance costs</link:label>
    <link:label xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The proceeds from issuance of common stock and warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:label="nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:type="locator"/>
    <link:label xlink:label="nrxp_APICIncreaseForCostRecognitionContractTermination-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract cost related to Alvogen termination (see Note 6)</link:label>
    <link:label xlink:label="nrxp_APICIncreaseForCostRecognitionContractTermination-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The contract costs related to the Alvogen termination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:to="nrxp_APICIncreaseForCostRecognitionContractTermination-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GlytechLicenseAgreementMember" xlink:label="nrxp_GlytechLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_GlytechLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glytech License Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_GlytechLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of related party transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_GlytechLicenseAgreementMember" xlink:to="nrxp_GlytechLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount</link:label>
    <link:label xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend - warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:label="nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_MeasurementInputProbabilityOfDefaultMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability of Default [Member]</link:label>
    <link:label xlink:label="nrxp_MeasurementInputProbabilityOfDefaultMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement input using the probability of default.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:to="nrxp_MeasurementInputProbabilityOfDefaultMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputVolumeVolatilityMember" xlink:label="nrxp_MeasurementInputVolumeVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_MeasurementInputVolumeVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Volume Volatility [Member]</link:label>
    <link:label xlink:label="nrxp_MeasurementInputVolumeVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement input using volume volatility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_MeasurementInputVolumeVolatilityMember" xlink:to="nrxp_MeasurementInputVolumeVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputMarketRateMember" xlink:label="nrxp_MeasurementInputMarketRateMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_MeasurementInputMarketRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Market Rate [Member[</link:label>
    <link:label xlink:label="nrxp_MeasurementInputMarketRateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement input using the market rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_MeasurementInputMarketRateMember" xlink:to="nrxp_MeasurementInputMarketRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:label="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued, aggregate intrinsic value</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the aggregate intrinsic value of warrants or rights issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:to="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued, weighted average remaining contractual term (Year)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for warrants or rights issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:to="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:to="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossOnContractTerminationForDefault-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible note default penalty</link:label>
    <link:label xlink:label="us-gaap_LossOnContractTerminationForDefault-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination for Default</link:label>
    <link:label xlink:label="us-gaap_LossOnContractTerminationForDefault-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Convertible note default penalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossOnContractTerminationForDefault" xlink:to="us-gaap_LossOnContractTerminationForDefault-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementMember" xlink:label="nrxp_RDPurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_RDPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RD Purchase Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_RDPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the RD Purchase Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_RDPurchaseAgreementMember" xlink:to="nrxp_RDPurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible notes payable (Note 7)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementWarrantsMember" xlink:label="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_RDPurchaseAgreementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RD Purchase Agreement, Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_RDPurchaseAgreementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RD Purchase Agreement, warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_RDPurchaseAgreementWarrantsMember" xlink:to="nrxp_RDPurchaseAgreementWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesWarrantsMember" xlink:label="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ThirdTrancheNotesWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Tranche Notes, Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_ThirdTrancheNotesWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to Third Tranche Notes, Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ThirdTrancheNotesWarrantsMember" xlink:to="nrxp_ThirdTrancheNotesWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesMember" xlink:label="nrxp_ThirdTrancheNotesMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ThirdTrancheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Tranche Notes [Member]</link:label>
    <link:label xlink:label="nrxp_ThirdTrancheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the Third Tranche Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ThirdTrancheNotesMember" xlink:to="nrxp_ThirdTrancheNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PurchaseAgreementMember" xlink:label="nrxp_PurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label xlink:label="nrxp_PurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Purchase Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PurchaseAgreementMember" xlink:to="nrxp_PurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredClassAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesAPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PreferredStockAndWarrantsMember" xlink:label="nrxp_PreferredStockAndWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_PreferredStockAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock and Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_PreferredStockAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to preferred stock and warrants issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_PreferredStockAndWarrantsMember" xlink:to="nrxp_PreferredStockAndWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:label="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:type="locator"/>
    <link:label xlink:label="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for deferred offering cost settlement</link:label>
    <link:label xlink:label="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) for recognition of deferred offering cost settlement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:to="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrant Issued with Preferred Stock [Member]</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:to="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock and warrants issued, net (in shares)</link:label>
    <link:label xlink:label="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of preferred stock and warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:to="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">nrxp_ClassOfWarrantOrRightIssuedInPeriod</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Issued in Period (in shares)</link:label>
    <link:label xlink:label="nrxp_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="nrxp_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative fair value adjustments through accumulated other comprehensive loss</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible note attributed to credit risk</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible note attributed to credit risk</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MarchInvestorWarrantsMember" xlink:label="nrxp_MarchInvestorWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_MarchInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Investor Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_MarchInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to March Investor Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_MarchInvestorWarrantsMember" xlink:to="nrxp_MarchInvestorWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JuneInvestorWarrantsMember" xlink:label="nrxp_JuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="nrxp_JuneInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June Investor Warrants [Member]</link:label>
    <link:label xlink:label="nrxp_JuneInvestorWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to June Investor Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_JuneInvestorWarrantsMember" xlink:to="nrxp_JuneInvestorWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingSegmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible note payable, net of current portion</link:label>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible note payable and accrued interest &#8211; long term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nrxp-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:16PM UTC 2025-03-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-1-organization" xlink:href="nrxp-20241231.xsd#statement-note-1-organization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-1-organization" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information" xlink:href="nrxp-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="nrxp-20241231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NondesignatedPreferredStockMember" xlink:label="nrxp_NondesignatedPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_NondesignatedPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_CommonStockAndWarrantIssuanceMember" xlink:label="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern" xlink:href="nrxp-20241231.xsd#statement-note-2-going-concern" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="nrxp_AnsonMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-" xlink:href="nrxp-20241231.xsd#statement-note-6-alvogen-licensing-agreement-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenLicensingAgreementMember" xlink:label="nrxp_AlvogenLicensingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_AlvogenLicensingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt" xlink:href="nrxp-20241231.xsd#statement-note-7-debt" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsMember" xlink:label="nrxp_AnsonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_InterestRepaymentMember" xlink:label="nrxp_InterestRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrincipalRepaymentMember" xlink:label="nrxp_PrincipalRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_PrincipalRepaymentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_InterestRepaymentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ExclusiveLicenseAgreementMember" xlink:label="nrxp_ExclusiveLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PatentLicenseMember" xlink:label="nrxp_PatentLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByLicensedPatentsMember" xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByValidClaimsMember" xlink:label="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_ExclusiveLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="nrxp_PatentLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity" xlink:href="nrxp-20241231.xsd#statement-note-9-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_April2024OfferingMember" xlink:label="nrxp_April2024OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilOverallotmentAgreementMember" xlink:label="nrxp_AprilOverallotmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterAgreementMember" xlink:label="nrxp_AprilUnderwriterAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterWarrantsMember" xlink:label="nrxp_AprilUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AugustInvestorWarrantsMember" xlink:label="nrxp_AugustInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfDebtToCommonStockMember" xlink:label="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryOverallotmentOptionMember" xlink:label="nrxp_FebruaryOverallotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwriterWarrantsMember" xlink:label="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwritingAgreementMember" xlink:label="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryWarrantsMember" xlink:label="nrxp_FebruaryWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HCWainwrightCoLLCMember" xlink:label="nrxp_HCWainwrightCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_June2023PurchaseAgreementMember" xlink:label="nrxp_June2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JuneInvestorWarrantsMember" xlink:label="nrxp_JuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JunePlacementAgentWarrantsMember" xlink:label="nrxp_JunePlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_March2023PurchaseAgreementMember" xlink:label="nrxp_March2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MarchInvestorWarrantsMember" xlink:label="nrxp_MarchInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_OctoberAmendedWarrantsMember" xlink:label="nrxp_OctoberAmendedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PreferredStockAndWarrantsMember" xlink:label="nrxp_PreferredStockAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementWarrantsMember" xlink:label="nrxp_PrivatePlacementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PublicWarrantsMember" xlink:label="nrxp_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReverseStockSplitMember" xlink:label="nrxp_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleCapitalLLCMember" xlink:label="nrxp_StreetervilleCapitalLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SubstituteWarrantsMember" xlink:label="nrxp_SubstituteWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentAgreementMember" xlink:label="nrxp_WarrantAmendmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="nrxp_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_PreferredStockAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_March2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_MarchInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="nrxp_HCWainwrightCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_June2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_JuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleCapitalLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_FebruaryOverallotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_FebruaryWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_AprilUnderwriterAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_AprilOverallotmentAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_April2024OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_SubstituteWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_PublicWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_PrivatePlacementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_JunePlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_WarrantAmendmentAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AugustInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_OctoberAmendedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AprilUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2016OmnibusIncentivePlanMember" xlink:label="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2021OmnibusIncentivePlanMember" xlink:label="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions" xlink:href="nrxp-20241231.xsd#statement-note-14-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GlytechLicenseAgreementMember" xlink:label="nrxp_GlytechLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="nrxp_GlytechLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events" xlink:href="nrxp-20241231.xsd#statement-note-15-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsiderationWarrantsMember" xlink:label="nrxp_ConsiderationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HopeTherapeuticsIncMember" xlink:label="nrxp_HopeTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NotesToFinancialStatementsAbstract" xlink:label="nrxp_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PurchaseAgreementMember" xlink:label="nrxp_PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementMember" xlink:label="nrxp_RDPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementWarrantsMember" xlink:label="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesMember" xlink:label="nrxp_ThirdTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesWarrantsMember" xlink:label="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_PurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="nrxp_HopeTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_ThirdTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_RDPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_ConsiderationWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_TradingArrByIndTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies" xlink:href="nrxp-20241231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-significant-accounting-policies-policies" xlink:label="nrxp_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrxp_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:label="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" xlink:label="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables" xlink:href="nrxp-20241231.xsd#statement-note-7-debt-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-7-debt-tables" xlink:label="nrxp_statement-statement-note-7-debt-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-7-debt-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:label="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-8-commitments-and-contingencies-tables" xlink:label="nrxp_statement-statement-note-8-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-8-commitments-and-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="nrxp_ScheduleOfMilestonePaymentsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables" xlink:href="nrxp-20241231.xsd#statement-note-9-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-9-equity-tables" xlink:label="nrxp_statement-statement-note-9-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-9-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-tables" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-tables" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-12-segment-reporting-tables" xlink:label="nrxp_statement-statement-note-12-segment-reporting-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-12-segment-reporting-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-tables" xlink:label="nrxp_statement-statement-note-13-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-13-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-2-going-concern-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentFaceAmountIndividualTranches" xlink:label="nrxp_DebtInstrumentFaceAmountIndividualTranches-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentNumberOfTranches" xlink:label="nrxp_DebtInstrumentNumberOfTranches-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="nrxp_AnsonMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentNumberOfTranches-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentFaceAmountIndividualTranches-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-6-alvogen-licensing-agreement-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenLicensingAgreementMember" xlink:label="nrxp_AlvogenLicensingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementAcceleratingPayment" xlink:label="nrxp_LicenseAgreementAcceleratingPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementInitialPayment" xlink:label="nrxp_LicenseAgreementInitialPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockSubscriptionsReceivableWriteOff" xlink:label="nrxp_StockSubscriptionsReceivableWriteOff-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="us-gaap_CustomerRefundLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_AlvogenLicensingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementInitialPayment-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementAcceleratingPayment-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CustomerRefundLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockSubscriptionsReceivableWriteOff-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-7-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonSecondTrancheNotesMember" xlink:label="nrxp_AnsonSecondTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsMember" xlink:label="nrxp_AnsonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap" xlink:label="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConditionalDefaultInterestRate" xlink:label="nrxp_DebtInstrumentConditionalDefaultInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable" xlink:label="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentInterestRateInEventOfDefault" xlink:label="nrxp_DebtInstrumentInterestRateInEventOfDefault-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentNumberOfTranches" xlink:label="nrxp_DebtInstrumentNumberOfTranches-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentOriginalIssuanceDiscount" xlink:label="nrxp_DebtInstrumentOriginalIssuanceDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentPrepaymentPercentage" xlink:label="nrxp_DebtInstrumentPrepaymentPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentRedemptionAmount" xlink:label="nrxp_DebtInstrumentRedemptionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentRedemptionConversionPricePercentage" xlink:label="nrxp_DebtInstrumentRedemptionConversionPricePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtIssuanceCosts" xlink:label="nrxp_DebtIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_InterestRepaymentMember" xlink:label="nrxp_InterestRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LitigationSettlementPaymentInstallmentOne" xlink:label="nrxp_LitigationSettlementPaymentInstallmentOne-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LitigationSettlementPaymentInstallmentTwo" xlink:label="nrxp_LitigationSettlementPaymentInstallmentTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrincipalRepaymentMember" xlink:label="nrxp_PrincipalRepaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:label="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedemptionPremium" xlink:label="us-gaap_RedemptionPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment2Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteAmendment3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_PrincipalRepaymentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_InterestRepaymentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonSecondTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentPrepaymentPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentRedemptionAmount-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentRedemptionConversionPricePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentConditionalDefaultInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedemptionPremium-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnContractTerminationForDefault-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LitigationSettlementPaymentInstallmentOne-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LitigationSettlementPaymentInstallmentTwo-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentNumberOfTranches-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PlacementAgentFeePercentOfGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentOriginalIssuanceDiscount-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentInterestRateInEventOfDefault-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ExclusiveLicenseAgreementMember" xlink:label="nrxp_ExclusiveLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:label="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementCumulativePayments" xlink:label="nrxp_LicenseAgreementCumulativePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMaintenanceFee" xlink:label="nrxp_LicenseAgreementMaintenanceFee-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMilestonePayment" xlink:label="nrxp_LicenseAgreementMilestonePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage" xlink:label="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PatentLicenseMember" xlink:label="nrxp_PatentLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PaymentForLicenseAgreementMaintenanceFee" xlink:label="nrxp_PaymentForLicenseAgreementMaintenanceFee-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByLicensedPatentsMember" xlink:label="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProductsCoveredByValidClaimsMember" xlink:label="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RoyaltyPercentage" xlink:label="nrxp_RoyaltyPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockholdersEquityNoteSpinoffTransactionPercentage" xlink:label="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervileComplaintMember" xlink:label="nrxp_StreetervileComplaintMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_ProductsCoveredByLicensedPatentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_ProductsCoveredByValidClaimsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_ExclusiveLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="nrxp_PatentLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="nrxp_LeaseContractualTermOfficeSpaceRentalMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="nrxp_StreetervileComplaintMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementCumulativePayments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementMilestonePayment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_RoyaltyPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForRoyalties-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PaymentForLicenseAgreementMaintenanceFee-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementMaintenanceFee-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockholdersEquityNoteSpinoffTransactionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-9-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AlvogenAndLotusWarrantsMember" xlink:label="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheOneMember" xlink:label="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonWarrantsTrancheTwoMember" xlink:label="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_April2024OfferingMember" xlink:label="nrxp_April2024OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilOverallotmentAgreementMember" xlink:label="nrxp_AprilOverallotmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterAgreementMember" xlink:label="nrxp_AprilUnderwriterAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AprilUnderwriterWarrantsMember" xlink:label="nrxp_AprilUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AugustInvestorWarrantsMember" xlink:label="nrxp_AugustInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation" xlink:label="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExercisesInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:label="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfDebtToCommonStockMember" xlink:label="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryOverallotmentOptionMember" xlink:label="nrxp_FebruaryOverallotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwriterWarrantsMember" xlink:label="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryUnderwritingAgreementMember" xlink:label="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FebruaryWarrantsMember" xlink:label="nrxp_FebruaryWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HCWainwrightCoLLCMember" xlink:label="nrxp_HCWainwrightCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_June2023PurchaseAgreementMember" xlink:label="nrxp_June2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JuneInvestorWarrantsMember" xlink:label="nrxp_JuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_JunePlacementAgentWarrantsMember" xlink:label="nrxp_JunePlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LetterAgreementPercentageOfCashFeePaid" xlink:label="nrxp_LetterAgreementPercentageOfCashFeePaid-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_March2023PurchaseAgreementMember" xlink:label="nrxp_March2023PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MarchInvestorWarrantsMember" xlink:label="nrxp_MarchInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_OctoberAmendedWarrantsMember" xlink:label="nrxp_OctoberAmendedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PlacementAgentFeePercentOfGrossProceeds" xlink:label="nrxp_PlacementAgentFeePercentOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PreferredStockAndWarrantsMember" xlink:label="nrxp_PreferredStockAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementPremiumPercentage" xlink:label="nrxp_PrivatePlacementPremiumPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrivatePlacementWarrantsMember" xlink:label="nrxp_PrivatePlacementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PublicWarrantsMember" xlink:label="nrxp_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReverseStockSplitMember" xlink:label="nrxp_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleCapitalLLCMember" xlink:label="nrxp_StreetervilleCapitalLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SubstituteWarrantsMember" xlink:label="nrxp_SubstituteWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnderwriterOverallotmentWarrantsMember" xlink:label="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentAgreementMember" xlink:label="nrxp_WarrantAmendmentAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:label="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="nrxp_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_PreferredStockAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_March2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_MarchInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="nrxp_HCWainwrightCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_June2023PurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_JuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleCapitalLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfDebtToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_FebruaryUnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_FebruaryOverallotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_FebruaryWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_AprilUnderwriterAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_AprilOverallotmentAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_April2024OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_SubstituteWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_PublicWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_PrivatePlacementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_JunePlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_WarrantAmendmentAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_WarrantAmendmentJuneInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AugustInvestorWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_OctoberAmendedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_FebruaryUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_UnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AprilUnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AprilUnderwriterOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AlvogenAndLotusWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_AnsonWarrantsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LetterAgreementPercentageOfCashFeePaid-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PlacementAgentFeePercentOfGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PrivatePlacementPremiumPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation-2" xlink:type="arc"/>
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExercisesInPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NeuroRxMember" xlink:label="nrxp_NeuroRxMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares" xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:label="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2016OmnibusIncentivePlanMember" xlink:label="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_The2021OmnibusIncentivePlanMember" xlink:label="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="nrxp_The2016OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="nrxp_NeuroRxMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="nrxp_The2021OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateRemeasurement1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-14-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:label="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:label="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementAnnualPayment" xlink:label="nrxp_ConsultingAgreementAnnualPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementMonthlyPayment" xlink:label="nrxp_ConsultingAgreementMonthlyPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsultingAgreementPerformanceBonusTargetValue" xlink:label="nrxp_ConsultingAgreementPerformanceBonusTargetValue-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GlytechLicenseAgreementMember" xlink:label="nrxp_GlytechLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NRXPharmaceuticalsIncMember" xlink:label="nrxp_NRXPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:label="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="nrxp_GlytechLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="nrxp_NRXPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="nrxp_ConsultationAgreementWithDrJonathanJavittMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="nrxp_ConsultationAgreementWithZacharyJavittMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="nrxp_UnrestrictedUponNewDrugApplicationDateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="nrxp_UnrestrictedUponNewDrugApprovalDateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ConsultingAgreementAnnualPayment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ConsultingAgreementMonthlyPayment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ConsultingAgreementPerformanceBonusTargetValue-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedBonusesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual" xlink:href="nrxp-20241231.xsd#statement-note-15-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonFirstTrancheNotesMember" xlink:label="nrxp_AnsonFirstTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice" xlink:label="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights" xlink:label="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConsiderationWarrantsMember" xlink:label="nrxp_ConsiderationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_HopeTherapeuticsIncMember" xlink:label="nrxp_HopeTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoteToFinancialStatementDetailsTextual" xlink:label="nrxp_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PurchaseAgreementMember" xlink:label="nrxp_PurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementMember" xlink:label="nrxp_RDPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RDPurchaseAgreementWarrantsMember" xlink:label="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount" xlink:label="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SaleOfStockConsiderationCommitmentAmount" xlink:label="nrxp_SaleOfStockConsiderationCommitmentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesMember" xlink:label="nrxp_ThirdTrancheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ThirdTrancheNotesWarrantsMember" xlink:label="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_PurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="nrxp_HopeTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_ThirdTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_ThirdTrancheNotesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_RDPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_RDPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="nrxp_ConsiderationWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonFirstTrancheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SaleOfStockConsiderationCommitmentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:href="nrxp-20241231.xsd#statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnnualRevenueThresholdMember" xlink:label="nrxp_AnnualRevenueThresholdMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:label="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:label="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LicenseAgreementMilestonePayment" xlink:label="nrxp_LicenseAgreementMilestonePayment" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:label="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:label="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_FirstCommercialSaleOfLicensedProductInUsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="nrxp_AnnualRevenueThresholdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LicenseAgreementMilestonePayment" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:label="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantsMember" xlink:label="nrxp_WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="nrxp_WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="nrxp-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedClinicalSiteCostsCurrent" xlink:label="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NondesignatedPreferredStockMember" xlink:label="nrxp_NondesignatedPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_SeriesAConvertiblePreferredStockMember" xlink:label="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_NondesignatedPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nrxp_AccruedClinicalSiteCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LoansPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-n10" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ContractCosts" xlink:label="nrxp_ContractCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:label="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:label="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtIssuanceCosts" xlink:label="nrxp_DebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-n8" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_NoncashLitigationExpense" xlink:label="nrxp_NoncashLitigationExpense" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromInsuranceLoans" xlink:label="nrxp_ProceedsFromInsuranceLoans" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_RepaymentsOfInsuranceLoans" xlink:label="nrxp_RepaymentsOfInsuranceLoans-n8" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockIssuedAsOfferingCosts" xlink:label="nrxp_StockIssuedAsOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_DebtIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_ContractCosts" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nrxp_NoncashLitigationExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nrxp_RepaymentsOfInsuranceLoans-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nrxp_ProceedsFromInsuranceLoans" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nrxp_StockIssuedAsOfferingCosts" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" xlink:href="nrxp-20241231.xsd#statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity" xlink:type="extended">
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:label="nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ATMOfferingMember" xlink:label="nrxp_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:label="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_CommonStockAndWarrantIssuanceMember" xlink:label="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:label="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:label="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_CommonStockAndWarrantIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="nrxp_ShareSubscriptionFacilityAgreementGEMMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="nrxp_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredClassAMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-n8" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_APICIncreaseForCostRecognitionContractTermination" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-1" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-1" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:href="nrxp-20241231.xsd#statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonMember" xlink:label="nrxp_AnsonMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:label="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="nrxp_AnsonMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details" xlink:href="nrxp-20241231.xsd#statement-note-7-debt-schedule-of-convertible-debt-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt" xlink:label="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt-n9" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_LongtermDebtTotal" xlink:label="nrxp_LongtermDebtTotal-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" xlink:label="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnContractTerminationForDefault" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_LongtermDebtTotal-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-1" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AnsonConvertibleNotesMember" xlink:label="nrxp_AnsonConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputCostOfDebtMember" xlink:label="nrxp_MeasurementInputCostOfDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputMarketRateMember" xlink:label="nrxp_MeasurementInputMarketRateMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:label="nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_MeasurementInputVolumeVolatilityMember" xlink:label="nrxp_MeasurementInputVolumeVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_StreetervilleConvertibleNoteMember" xlink:label="nrxp_StreetervilleConvertibleNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_WarrantsMember" xlink:label="nrxp_WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="nrxp_StreetervilleConvertibleNoteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="nrxp_AnsonConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="nrxp_WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="nrxp_MeasurementInputMarketRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="nrxp_MeasurementInputCostOfDebtMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="nrxp_MeasurementInputVolumeVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="nrxp_MeasurementInputProbabilityOfDefaultMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:label="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_GainLossOnConvertibleDebtRedemption" xlink:label="nrxp_GainLossOnConvertibleDebtRedemption-n8" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:label="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTerminationForDefault" xlink:label="us-gaap_LossOnContractTerminationForDefault-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnContractTerminationForDefault-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_FairValueAdjustmentOfConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_GainLossOnConvertibleDebtRedemption-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details" xlink:href="nrxp-20241231.xsd#statement-note-12-segment-reporting-longlived-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" xlink:label="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent-n8" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:href="nrxp-20241231.xsd#statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_PrepaidClinicalDevelopmentExpense" xlink:label="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:label="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_PrepaidClinicalDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:href="nrxp-20241231.xsd#statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:label="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:href="nrxp-20241231.xsd#statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:label="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="nrxp-20241231.xsd#statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:label="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_DeferredTaxAssetsLiabilitiesGross" xlink:label="nrxp_DeferredTaxAssetsLiabilitiesGross-3" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_DeferredTaxAssetsLiabilitiesGross-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:href="nrxp-20241231.xsd#statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:label="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details" xlink:href="nrxp-20241231.xsd#statement-note-9-equity-schedule-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue" xlink:label="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm" xlink:label="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm" xlink:label="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue" xlink:label="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue-1" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice" xlink:label="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="nrxp-20241231.xsd#nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" xlink:label="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrxp_statement-statement-note-9-equity-schedule-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedDuringPeriod-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantOrRightExpiredDuringPeriod-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>map01.jpg
<TEXT>
begin 644 map01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M#FQ./^H!<_\ QVD_X>1_M79_Y)Q8?^"*Y_\ CU?5FG:7-9Z7:&SL].C.I3Q
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MO>V.^2J3@U8R)K2%=!\R)5<NH(<#[PK% QGJ>]=->7$&EZ1*[#9! ARJG)
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M=_R+G@?_ *_[G_T"*OU1\(?\BEI?_7I%_P"@"ORN_P""IW_(N>!_^O\ N?\
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M&#Q7/?M9?"BV^)WP#\2Z=8W*G7M,>.\ALXH659WA!,K)GGE<X&?X:ZF/Q1)
M+@I9Z8ANR&G(M5'G,&W GWSS]:]6T:S6.QTUXA&XN/WY?'^L9N6__57A<199
M6J8&>%Q$K\ZL>UP]FJP68T\=06L&F?F;\"?V\?'G[/OPXN_#&ARV,MA<,QA^
MT1[GM&?.[9SZ^N>:]&_X)D?#Z]\4?$_7/'%]#->06D;6JR-'O^TW$YS(Q![!
M<D_6D_:V_8#UJQ^/5D?!MBT^B>+[IMNQ,QZ5+G,H?'1!RP)[<5],>$/AC;?
MCX:Z9X=LKN:'2X8^# F'OIS_ *R5VXY/IV&!7X=PGPQF&)S54,8WR4+VO^%C
M^B>-^+\GH9)*MEB7M<6O>MNN]S._;)_9L@_:LT.S\-AK*V\36"2W&CZ@[JJ*
M$.#"^/X6!&!VQ6+H?[%GAF__ &3YOAU836\FI+.\QOCM#MJ4>5,V>\9/R #^
M'GK7I/CFVB?P79NL*X=D4ONS(H"\89<$=>:N_#2Z2\\-FR$2;+?$2J.",D$8
M],8)K]TQ\,1B<FE@JTKTKVL?S%E<</@LYAF^'C;$1MJ?G_\ LT?L>:Q\3OCQ
M<:#XALKG3]+\,7'_ !/7=< ;6^6%?5GP,8[<U^CCVMK:1"V@1$MD5%C$,)10
MBC"KP.P&.:W_  PL<MM<7 AB26XE_>2K&%:<#[I8CKA2!S2>*+2%H$D9(Q*#
M@<#)%? \/\,4,II25-W;;=_+HC] XZXUQ'$%2%2M[J@K)7Z]=#GTL;::4#RX
M]Q/R[AT/J,]ZY[XW_LJ>'_V@],TBW\4&1ETJY6:VFA^679G+0LW=& KIS IW
M<$<\8ZU'<23231QF8D*#A2>*]>O0H5Z;IUX\R[,^*RW-*^#JK$X:;C-=4,UO
M2_\ A%;"*#25MT6TC6.WAAB51$JX&T>F ,59TRX,VG1VDB[!+C.XY,1ZDY^M
M5C@R9+ MCIGKBGB W#,WRC'& #CU_K74I0C!1BK);>7D8U,4ZE1U92N[_>WN
MSI-2D@M]+9&8?NU^4#D\?XUFZ:DR^";F*,*UQ&WR _Q#H,>W%9[V_P P8,3C
MJ3R:M:?=LL0@22.#<IC9CSOP !QVI\_,]#2%2,TXI[F!=:9>ZN4$ZQ1 #!4'
M(/K6=;:O8Z!:RJL7F+ ^"$;//?-=9?6,NG/@NKKMW CTK,L;"PFC<QPPE)CE
MRO//?-:45&*M4NU?Y'C5,*XM\IB:5\4/.OPMU"$@9L(R]5^M;NJWB:>J*RM)
M;SG+!.&CS_$OH?4=#7$ZGX3N9;V\DLX@T$+;\YYP/:MB.YEU&VMR[&0,N%!.
M,'I7H9M0PT80JX56OHU<B%><%=%^>YN=.6-XYA<VTK?NY.S^JGT;VK3:P@U2
M%689& 5?H2,9K/T:SEMX)8+R!UBN1B3!ROLX]".N:T=,B-M&UNYR\3>7GMQP
M/TQ^=>/.BUJ=*I*5)S6W8DCL(DM%BP=B@X/I[U6TN9H-5A9"<[PO'<9K0)X.
MXC'?VK(GF^R72.A7"N"I]>:PNDTS"ZBT=GXCM4DMC.<?)A7]U)Z?@>1[UR'Q
M+T)M6\+1WH!DN+;.\]R1PWYX)_"M?6/$%V=.G&0=Z=,4FG:U%<*]E/M\N]4R
MVS]FR,L,^H.>*]3#8GV<XU([H]9585*?+U/&VX)P<^AHK0\1Z2=(U>>#JB-E
M#V(/3_/M6?7Z?AZRJTU-=3PZBY96"BBBMR HHHH &Z&BANAHI]/N!;GRC_P5
M._Y%SP/_ -?]S_Z!%7ZH^$/^12TO_KTB_P#0!7Y7?\%3O^1<\#_]?]S_ .@1
M5^J/A#_D4M+_ .O2+_T 5^=Y[_ODS]=S'_DF\!_V_P#FC\_O^"\'_)4?A!]+
MO_T?;5[#<?\ 'Q)_O'^=>/?\%X/^2H_"#Z7?_H^VKV&X_P"/B3_>/\Z]/A+X
M:GR,>./^2?ROTJ?^EC*.I/3\*LVOE6NF7M[+"]T+,)^Z5MOWF W-CD*O4X["
MM.2SL4734N+.9)-7NVM+:>PF$]J_R;O,#'G Z$'FOH*^:4J53V<WJ?E\,/.<
M>:)AXS7:_"SQ4_\ :$.FS3HBYW6S,<A6_N9KE0L.F6VJW,T8N1IT)<()-BL=
MX0'/ISDU<EM[))KU))+:SGTTPMYMI(;F*8RD[$7'(DXR1GI7'FN(P]1>QJ.V
MFC-\+&I%\\3TGQ-KTFD6=O(\4@;[04P#M$Q;*@9] S#KZUQ/Q)URY$L&AW5O
M!%+I>)',;B1'+Y(*GTQU]Q6CH/C.TU&6+3KN>XOX;^SN;X7,L6V"W6,@31L#
MSD $'L#CUKF+I-&NFGO8;R6"UEN5BCM_LKF<F7)CVKU*D#@^U?.Y7"C1Q+G-
MZ+K^1Z6+O*DHQ12.IW'V(6_FR-#D83/&>U=SX+T8:+I$<CN?M$J/.PZ%.,)Q
M]37*_P#"0:+\/+C59IYX]3OM*MW,=O+"8K=YP 0K2,0JXR,[B.>F:Z+PC\:O
M"GCJ6$VM_#'),\5NR(\=PD;'G#-&YVKN&,M@<=>:>=9YA926%I22OY[E9;E&
M*<'B.1M+K9G8:5J9MO#D$*-MF'WO;@#^E0W-[-*A:1_,* GFJ9\6Z$;VSL([
MR5KF5KE,K;L0OE/M<L1P%4\$U%H_BC3/$TDD-G-</(+;[4BRVS1"6(MM#KNZ
MJ3TKYJ:GNSEKQJ7;>Q)I&IMJB,Q0H%/8YW5G>*=:N+?Q1INF6K:1;_:+.2Z:
MXOG*CAL;1R.?:ME52UC.T"-0"1M%9][X4MM:\2VFJ7:65S!;64D MYHO,8.S
MY5L'V_G44FNICAE:_,+>:B=)U;PU9F*RGFUEYHKB:'=Y?R1EU9.3P>*74]:;
MP_I4$D5NMS?7]U'8VD4A*QF5LEF8]=J@9_"E\0Z)=7^H^'[W3?[.2;0YY',$
MV8XW1H]@5=HXQUQ2ZKHTFO\ AZU!ELK35[&[6_MY(F:2 .F0 V>0&!.2*V]T
MZ*<86;)O#^J7,WB=M)U./3VN%MOMMO<69;RKF,-M92#SD&L#PY\1KZ[TK2]1
MNK71);37+QK+[/;.?MEL=[*'*YZ?+D^QK>T#3+A/%4VKZI+8BX:W%G!#:EGC
M@C+;BY8]22?P%8OA;X8P>#K?P]<6TNGQ:SI;R?:YPA,=U#(S9'KN"D8-7&4$
M;T734M#:U7Q06U77].>W@,>AVD31.,DS%HRQ#>W%8/A'49M/L-%-]::=%:>)
M6"026K,'MYF4LJN#]X$ ].E:E]I,.GZUXCG2XC^SZS;Q6T6X$F$JA7<W;GK^
M-8NDZ7<0VNA)J=QI[VNALC11V@8O<R*I168G@!03T[TU52BX*UF8SJ4[LT->
M\3Q^!-8TZS2S2>*X/G:C*6YLX&;RT8?5O7TJVVF0BX:W.5>!R<=NO:L+6_"E
MGXCU75I[W5+L#5G$,8MG*Q0P*N(PZXY(;D@<<UI6]TUJNF&6XAN+N*W6*YDB
MSMD8#&X9]0!7-4G%12BSDJU:5O=-KS%N(V7H&4KR>#D8J.0;5:?C*JHF4<A,
M# <>J^OH34P1)/F'(/.1WJ*XS:!9%?;(G*$?J,>A]*(R6US:A."=B:(B5>Q!
MX/-<WXIBGL\1PRC+_,HP,H >:V?M8C8>7$J1W$8EA (P21\RCGL0:PO$>F;]
M1MKAW(D"$,,]:NG"/M+R.3%4^7WC7T.XGNU<7&64*,%AC-1S6DMM:S1* 5CN
M87@4#_5[F.2/PINE:X1;+&Z[V7[I!ZU/9SR70GE/209C!&"I0Y'Z9K&#;DVR
ML&^9I(C^*/A*&2:TGBV!>(W(/ #<9_ _S->;7$+6MP\;J=T9*M]<XKU\Z6NL
MV,Z.K-%LSD>A]*\P\36KV]]ESD@F-VQ]XKQGZD5]WPWCI2C[.1>*A>/.D9M%
M%%?6=#SUL%%%%  W0T4-T-%/I]P+<^4?^"IW_(N>!_\ K_N?_0(J_5'PA_R*
M6E_]>D7_ * *_*[_ (*G?\BYX'_Z_P"Y_P#0(J_5'PA_R*6E_P#7I%_Z *_.
M\]_WR9^NYC_R3> _[?\ S1^?W_!>#_DJ/P@^EW_Z/MJ]AG_X^7_WC_.O'O\
M@O!_R5'X0?2[_P#1]M7L-S_Q\2?[Q_G7I\)?#4^1CQQ_R3^5^E3_ -++V@ZP
MVEPSPK--:_:-I$L*AFC*G."I^\I[BK>G7NEV-W')]IN#.FIC4W=+=8XG)C\M
MD$8/ *D\^M8>:,<8[5]!B,LHUY<TUJ?F-/%3@K(V]:U33-8>[MV\Q+:\A\F2
M2.((W^LW ;,^@ ]ZAU;4+'7+6:QE@CL[-+I;JU$,"8B=01\Z# 8$'')K*)QD
M]_K4MG837TGE6\3RMT 49_.B>78=Q?M/0B.(J=#>M;[1-]K$[3Q016ES87*P
MVRQBXCGQN( /RD'D'G..:\X_:+^/O@O]D_PGIEQ=:K#>W?VV&YLH[6S5+F\\
MD$",IG_:Y<G Z8KM-9T9=,6V^66.25<313+@QL.#CV/45^?O_!0>TAN/V\K#
M2/%%S/:^&K=-.A>4':8[.3#22#ZDMG']T>E88#(L%B,0E?1)MKO8^XX-R]9G
MC'2Q7PQ5].OD+\7?VR= _:?\6 ZKJ6O^%[>:8L#)%'-8AR<&658\-G'&[!P!
MQ76_%_X$ZW^R&?"OC'P]XH@U6QUD"6SOK,[ 'V@E",D.C _3&:[G_@JC\!?@
M/\-OV;]"O_ ::#9^(VN(HK :=="9[^ K\YD 8G '.3CFO#/#4VO?$?X!?"WP
MY'/<WL\UY>6FFVA)(*-*%1@.WS%AGL%K\K\3.$\J64?V]E\)4ZO,HZMW;N?T
M1PCCY5*=*G27+AESJ4916R7?<_2']G--/\;_  ZT#Q$[7.W7-+N5DA Q&#<-
MF0!NH =6 SVP:V/!6@ZKH^LR7>J.5@L],CTNR20)YKHK9Z(2,!0!DX/M3O G
M@L_#CP%X?\.6)5H-&LHK5Y1C+.H <_BV3^-=)C:>@S]W(%3@*M3ZM!5=[(_F
M#.<33^NUE0^#F?+Z7Z%5I_.;9M81CKE>34OVD G ?ZXQ3Y)!&?F('N333<QX
M^\,5JCQF]1KS8B8A'R >GKBEMCPQZ?-D?D*7[3&$)WK@=>:BCE9@%0<8(+,.
M.#U_'-5I8M+W6BP<8ZA>]1M,CR8))ST*CI0+0$ NQD8=R:>\B(G.U0.N>*2W
M)3Y9(F,-K<:6L1C5I$.<CG</3]:P?$5E':VT;1Q*,-AL"M6WNHK:X5"WS._R
M$#*D#O\ CFBXT(62-;3EI!O+@D=<U=6/9%XNBI+FB<F"<#)YQU[B@\DGN:Z+
M_A&[9A@*RYX!W=*R+2Q4ZH() =N2IYY'O7(U8\>="2(X=2G@7"2,!^=7;741
M>+%',Q+9.3[4^W\-'[:PDSY'8YYJ[;Z);V[@A>1W)JXILZ*=.I<>;<1,(LCR
MI#N1C_RQE]?8$=:R_$=RT5VJ% K+G=N3(S['TK;G4>0WTI+9Y?*PES<*H9@J
MY!V@'WK9N\=3U%-2IZLR] @CNHBSB-7SP I!/X5>-LMLZR\E8B"P&>5[C]:D
M=74$D^<I."I4;F'L0/O4Y"VP$"29#PKJN01Z$=F]JI*SYHBIIJS@[D^CJYG:
MVDN9$1!C<"<8(R&Z],5Q7Q-1CJDB,JA5C62+"[<XX;\>AKJ)/,@MWD6*13:X
M*LR$ H3RN?8]/K63\2+675K6"^:/9ARA8=-K#_$5[.35U3KQ<S>OS.FU8\^H
MI70HQ!ZJ2#[TE?I,9)I,\-(****IV&D#=#10>AHHNK:>0EN?*/\ P5._Y%SP
M/_U_W/\ Z!%7ZH^$/^12TO\ Z](O_0!7Y7?\%3O^1<\#_P#7_<_^@15^J/A#
M_D4M+_Z](O\ T 5^>9[_ +Y,_7<Q_P"2;P'_ &_^:/S^_P""\'_)4?A!]+O_
M -'VU>PW'_'Q)_O'^=>/?\%X/^2H_"#Z7?\ Z/MJ]AN/^/B3_>/\Z]/A+X:G
MR,>./^2?ROTJ?^EC****^P/R@,X(STK;\.6Z7&C7@DG%N5GBSN4LA')V2;>=
MAXR1[5B5+9WTVGR^9!(\3XQE3C(]*YL70=:DX)V9I1FHRNSJ+WQ6^BZ':O8V
MX@D0SMAXS-!<;9  J,REBI!)QVKY9_X+ _LVWOQ!\&0_$VRMO,O_  S<2Z=J
M<4<."U@&'ER8')"$\GT:OHC_ (2C4D!_TVX.>N6-,N]<O=3@FAG=]12[0PS6
MTV9$ND;AHV4]003Q7E8'"8C+\1'&0E?EZ=T?49%Q"\OQD<13757]#\?_ (5_
M#'6/C+\0]&\*Z%;O>:IK5PEM;*,E4R?F8GLJKEC["OTW_93_ &7I/ VO?\)'
MJ-M>:5'X36WT/0(;B##VT DVS7C@\!Y&WL/0'/>NH_9"_89\(_LS_$#Q3XJT
M!KN_EOIUCTR:ZA,;:5;LP+VZYY8Y)!;T %>[QZG>B*,N\C$C(8MG<,G%>/QY
MF]+-JM*G'^%#6W>7=^A^A<3<>RE3E2P*]R22;ZZ[HR;/Q#+JGC*\LG0&U"W/
MR&((UN8WPAX P&'O\V<U:>%8A+*96"8R #TJ[)J=S,S"4DHX^8[N35=HOE&,
M%"/P(]Z^0G)2LD?DU249NZT80PQLNX#<3@Y/)J3:/04T3C@$8[<=J?\ B"*@
MYVI";%R.!U':F(,W#_0C]:E! SGH*CASN+$<D8_/G_/UIK1%QV;'**KZK:/>
M6ZJB>858'&[%6114Z,B2ON0:=:)!;H /*(Z@-G&>O-2Z[J;"%I7.8X(^2OWC
M[T_O]16<\EMK:75HLFX#,<N."OH/Y_I730UTEL:TJC5-PB9&F?$&+4M72W,9
M6)^%=CSN[#'I6EJD;PW\5PBGCARH_G7*>$O"DEWXB;S$*PVCDG((!(/ KOY
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MV?E,L'43O;3_ (8^0/\ @J=_R+O@?_K_ +G_ - BK]4?"'_(I:7_ ->D7_H
MK\KO^"IPV^'? X.,_;KD<=ODBXK]4?"'_(I:7_UZ1?\ H KY'/?][D?J>8_\
MDW@/^W_S1^?W_!>#_DJ/P@^EW_Z/MJ]AN/\ CXD_WC_.O'O^"\'_ "5'X0?2
M[_\ 1]M7L-Q_Q\2?[Q_G7J<)?#4^1CQQ_P D_E?I4_\ 2QE%%%?8'Y0%%%%
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MEBW9S"LJRYRP&2.!VSR>@K94I[GV%*E5:4HJZ9T.G)+"61E^4#/-2W;K*HC
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M?^T[\-?@C8VWA/1+K0M%LM.WPP6(O=HC4MN^8J&!;).<MGIFN%_X*"?%N_\
M ?P%6;1IY;:?7;E=/61'/F0+M+2<]B0, ^YKRW]FK_@E:WQ^_9R7QO-XF^PW
MNI1RSV%JL*R(ZKD RN><DCMT'K7YYC(UH5Y4I?$EJ?&YQQ#C%C_JF7T%.I%7
M;;VCY'W)X ^(MOXHLH[BTF#2NNX$,&#KZJRY5A[@X_&NBO\ 79;RR*/&G#9+
M*V/KQ7Y_?\$L/B7J6D_$[6_!5[,US8V]K+<PC<7%M+$P5PI_NL.W3(!K[9UC
M71=Q^7'N5#]YB>36,*[<#U\AX@^OX)5I*SU37FC7EO$>V;EAN'&1[UG^)[+$
M27"]OD;\:7PO.;M&LRPR5RA)XSZ&M&YMQ=))!,%5@,,!T'O2U:N>S)1J4T<J
ML9;H"5SCBM32]9ATZ,0A)'+-C=V%:T%G';6PC5<A>,[<GZUFR:);VLZEI)&8
MG(QTJ4FCFC1E'8UP<C/K399%BC+-T%.!!QR#QVJ#4$\RU.#[UH==]!UM<K<[
MCM "G'-/,0*$ !<X)K U"[DAD01NRKG<<=ZL#Q4P'^I4_P# JA-)F4<1%/4O
M36R;6&P!\9&WUJEG:P!X^M7+744O+992R1N>V:J7VK(9/+D5D'WMZ '>OK5M
M)ZFE6<6N:.YJ!EDML@85E.*P;^,[0Z$C8,8]:DN==S/$L080IPP/\5)K&Z."
M-D.89/NL.H]C63L]CGG.,MNAXA^V^+FY^&&C2IO:&/42)\#Y0QC/ED^P^<#W
M-;OPA^*GPETC]DV73M433UU06LB7=M+#NNKB<Y^93C/)Z'/%=?XZ\$67C[P#
M?Z+J%U:6L.L1E+9Y9 &\V/#*ZCOM;&<>M?$.L^'+S0?$<VF7-NZWL,OD&-?F
M+OT&WU!XQCCFOY\X_KXO)<Y>/ITHU(UX<J4NG0_I;PRIX7.\@A@JU1TI49\V
MCM?U/6_V.K>1[_Q5/M*V:6D:D9^42&4^7]3UY^M>R#.!FO,O@UX@T[P-)'X)
M1@-8D?[5=R#F*XGV?Z@'J"B\#U.:]-!)&>@/:OZ&\"'0APU&C"HI3C)N2_E;
M>Q^;^+?M)9[*O*%H2BN5]TEN#=#10W0T5^U]#\O70^4?^"IW_(N>!_\ K_N?
M_0(J_5'PA_R*6E_]>D7_ * *_*[_ (*G?\BYX'_Z_P"Y_P#0(J_5'PA_R*6E
M_P#7I%_Z *_.\]_WR9^NYC_R3> _[?\ S1^?W_!>#_DJ/P@^EW_Z/MJ]AN/^
M/B3_ 'C_ #KQ[_@O!_R5'X0?2[_]'VU>PW'_ !\2?[Q_G7I\)?#4^1CQQ_R3
M^5^E3_TL91117V!^4!1110 4444 %%%% !1111IU$PH!R<#KG\J.I]AS^5;F
MG7(L_P"S!-9VTVFF&6XO6V9EC D55D!_NC//L:YL9BO80YYF]*DYRM$\E_:E
M^%,GQJ^ FLZ5:1B35;+;JFGJO61XAN:/_@29KXD\"_M2_$'X:_#R\\*:'XHU
M'3="OPWFVJ!?W8?AP"1E,].*_4""2RN9]%N'0++?+"SRVS;?)9Y2B,%QCL.I
MYKY?^/7_  35NO'OQ\TC6] 2/2_!GBNZ>75275FTIUEV2$ ?>$AR5 X4L:_-
M^(U"O55>@]7HS\\XSX6Q\Z\<9EUU)^Z[;M,9_P $L_@O<Z7X8\0>/[R)DCU4
MC2].+#ET5LRR ^F["Y[D&OL?P]IZ&U,CHI=CQN'05G^"KS3/#7A*+2=!T&==
M'T2V,%A#'D!EB8( ^1@;N6X))P:W]+U!-7TJ.Z41('9T948LH*G!P2 1]",U
MY*PSA%,^RR/AYY=@J=%ZM+7U9 NF>5K'FJH2,IC XYJQ<*"0_P!U@V,^M5;K
M5&5CM*J@Z9JCJ/B.0PA4V%L_>K+F2T/152,+W->:"7S"\;_-TQVJG=VTD(#2
M'):L^UUZ:)R78R[NW843ZX\[<CCTS@4<R(E7C+4T+&;R;D9Z'U-:+%9DV<$$
M=17-C5O]BE_M:53E1@?0TU,(XB*T+&MZ=Y4P*M\JKR/>LMB HQ6SID?]M6[M
M(Q^4XXJ+6-#CT^U\Q9&^4XP:B2,*E._O+8R@.1[=*L6Y^U0^02%<'=$2>A[K
M]#_/%08XH;.#P1Q][N#24C.E42E8!R2.A'!SVIE[XC_L2U&]MZ')6+;N+8Z\
M>@[GH*U+627Q%J^IVCK&L=G+9QQND8#J'A9G)/N17SC^V)X\NIM6TW0M-\RW
MAU"(2S_O=S3J7*QQ[EXV'&X@=SS7A<4YW#)<#+&2CS;)+NV?8\*<(U,YS!82
M$N6.[?9+4].^)7Q(TSQY=6NFZ*]F9X])U"!W%W"YCFD1-JA<YS\IZ<UY!^RS
M\1O!-GXZTW4/B KQWN@QA;&Z9=R2D?=64?WD_A/IUZ5J_$C]AG6/@G\*H/&\
M.MP3WNF^7=RVXBVB/IDJ>^,_C7D?Q#TJ*\$'B.P3;I^ML=X"\6ER!F6(]NIW
M#V-?@O%O$N;3Q='%XN@H3II-1?O)Q>SMZG]*<*\.Y5'"5<'A:[E";MS+1J2W
M5WW1W7Q!\2Z;\7OVP+2]\)6[16M]J4/E,$VF4J07EV]@1D_@:]RU8*=6N H
M42L!CIUQBO,OV-?AC-HT]KXNNM/EN[K4IGL-"M]PC\U@I,L^X]%500/7->LW
M/B"U/A_1-1U6WEDN;J,M/Y#*A1?.*#Y .2..N,XZU^Z^!U*IA,+7S3'1Y7B'
MS<J5DNVGF?E?BQ7H5<51RW"/F6'CRWWO\_)?B9>=P./_ -=*>#6UXJUBSLC+
M'=QR7%PFH7L-K%!B/_1X2O4@'.,@ 8Y)K/U>QCM)XF@,OD3PI-&)!M9%8 A6
M'8C-?T!@\RI8GW8/7<_'JV&E2>I\C_\ !4\8\.^!_P#K_N?_ $"*OU1\(?\
M(I:7_P!>D7_H K\KO^"I_'A_P1_U_P!S_P"@1U^J/A#_ )%+2_\ KTB_] %?
M&Y[_ +Y(_5<Q_P"2;P'_ &_^:/S^_P""\'_)4?A!]+O_ -'VU>PW'_'Q)_O'
M^=>/?\%X/^2H_"#Z7?\ Z/MJ]AN/^/B3_>/\Z]/A+X:GR,>./^2?ROTJ?^EC
M****^P/R@**** "BBB@ HHHH ****$ =JT].\43:7:"..* LJ-%O9<EHV(+(
M1W4D"LRBHJ4H5%RS5T5"33NC9M?%%O!>6+MI=F(K$QI$J%EVHARH.#\VTDX)
MZ9KM/A[9Z3-H_DQ1K.\XEQ/<%R=PE\TKC.%!)'0\XKS+T[>]=-X%\1264;P$
MEE4[\=\'K7S6>Y="&']M3CL=>'QK@_?9V.H-9:8MT9=*VK=.1(L4S!"2=Q(!
M^Z<X.5QS5*'5K"VM6AMA-;1[F8IY6\EFY+%B<DGU-7]1NSJ]DJAEDC*X!(XQ
M_C7/:A8?89E3?O#+D<?I7P,ZLOD5BL757O6NB>YELIS\UW>#V$  _G5=A8J0
M?-O'!..$4?UJ 'GCH?>DEZ#_ 'JQ]KY'#];;VB6F-B&)*WYSZ%12*UBR@^5J
M+?\ ;5/\*@;OT/X4#@?_ %J/:=D2L6U]E?<6-UBO(M[UO9IE_P *%N;1?^7*
M0GWN#_A5?BDI<[8/%RZ)?<;FB;)[9S# T2!N0LY)_4$4W5[J&4BWFN)X&4Y^
M:,.#]2,?RIWA9A]FDY/#"J/B,C^U9,'.0 >U:>TMN=7UK]WJD1O8VZGC4;5?
MK&_^%(;"'G_B86G_ 'P_^%5P<4FX^M0IQZHYOK%.WPFK9:?:-JQO()W%Y*(Q
M,+>]ECAGV J-R@<_+D'ZUX!^W!\*O[,\.Z+X@LK5[6TT[-C,IG\Q41V+HRMG
MD D@>E>Z:3K#:!/+=K@?9XF<%NB]RQ_6O(-?\6:O\6]4O8-+T@:E!,3))$UF
MMVSKGAF5@4&?0 8QWZU^>>)F9X!Y:LOKW=2H[Q45=Z=3]:\-5B8XN.84$E".
MDKNR:?0\2\7?M+^,_'O@2#P[J6MO=:7"%'E[%!E"] Q&"V..]>D_ KX>IK>E
MR^'-6MY9O#FGV)U37P@^>.>4CR$5C]UU49/^\:P]>\':-I1;7;[3-+\-_P!E
M2\W%P?LUC.XZ))"!R589_=@;L$8-;OP>_:,\*#PZ?#]CK&C^(-2NI9+F\GM+
MB6"YOIV(+,(Y !(!C 0'H.*^3\/_  VSC-,3#,L;&<Z-MY+[*Z'W?&7B-DN!
MP[R["RA2K-WY4U\3Z_(]BN_$]I=:996,>G_9[+2\&S2"=HY+4@8!5QT&WC'U
MJG//I$]O#$=*F2.W@%LH2]=3)'O,F'/5L,2>?6LZVNDO;:.:-MZ2#*MC&13Z
M_L:CD^#A3C3C!))6MY'\[5<=6J3=2;U9LZCXDLM2G5SIKP,MQ)=+)#=,DJR2
M#$@##^%@ ,>U4-8U5]8O!*XV[$6-!G.U0, 9/)/N:JT5U4,#1HWE3C9G/.M.
M:M)GRC_P5/S_ ,(]X'S_ ,_US_Z!%7ZH^$/^12TO_KTB_P#0!7Y7_P#!5'_D
M7O!'_7_<_P#HN*OU0\(?\BEI?_7I%_Z *^&SS_>Y'ZSF'_)-8#_M_P#-'Y_?
M\%X/^2H_"#Z7?_H^VKV&X_X^)/\ >/\ .O'O^"\'_)4?A!]+O_T?;5[#<?\
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M^@15^J'A#_D4M+_Z](O_ $ 5^5W_  5._P"1<\#_ /7_ '/_ *!%7ZH^$/\
MD4M+_P"O2+_T 5^=9[_O<C]=S'_DF\!_V_\ FC\_O^"\!_XNE\(/I=?^C[:O
M8;C_ (^'_P!X_P Z\E_X+QV+#QU\)+L@^7')<QD]N98&_P#9:]8>83MYB\JX
MWBO4X4:M47H8<:IOAW+)=O:+_P FN)1117V!^4A1110 4444 %%%% !1110
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M&_\ 15[#_P '-[_\8HHH]M4_F?WA];G_ "Q_\ A_\B'_  PS^T;_ -%7L/\
MP<WO_P 8H_X89_:-_P"BKV'_ (.;W_XQ111[:I_,_O#ZW/\ EC_X!#_Y$/\
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M,G':,?\ P"'_ ,B,D_8P_:7ED+M\8+=F;J3KE\2?_(-)_P ,6_M+?]%?MO\
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*6E)W84444$'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nrxgraph1.jpg
<TEXT>
begin 644 nrxgraph1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
M   *    &@    !'<F5E;G-H;W0 _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ S0%/ P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHI,@9
M_D,D_D!G_/O2;ER!G!/(!R#^O^>W6@!U%-+*O4X^M('5AE64],<\4 /KY-_;
MG_:'UG]D_P#9!_:*_:4\/:#IWBO6O@M\*_%'Q TKPYJT]S:Z5K5WH=B;JWL=
M0N;,&Z@M;B5=D\UN#+'"7=1E:^L3T/..#SZ>]?-G[7?[/&F?M9?LR_&S]FC6
M?$=_X.TCXV?#_7OA[J'B;2+"SU34M"L]=A-O)?V&FW\MO975Q!"Q9+>ZFBA8
M':[@ 4 ?SO:'_P %_/CMHWA?XXMXT^'/[)7Q-\3^!_V#]2_;2\*:[^S#\8/$
M/Q,\"^$;C3;S0+*3X6?':;[,;GP?XFNFUY'TZVM;XW5TUAJ"/%"D1D3]6_A9
M_P %?/V6/B'\/?B-XJN_^%MZ)XL^#GPZ^%OQ#^(/PYN?@A\38?&E]H?Q<MH(
M_!^O?#CPE-H9U_QWX9\0:\T^BZ+JVFVVSS(EEOS:6K-=GN_'_P#P39^!OBG]
MA[XC_L4>"]*\,_"32_B;\#M,^"?B7XG> _AOX4TCQ1J4&G:+IVCCQ7J>G:=!
MI5MK6K2G3$O9H+[49X7GGD+2,>6^8OCY_P $;-(^,VI?%C7-"_:;^)GPTUWX
MH_L]_LT_L^ROX?\ #FEW&F6NC_LV^+)?%6G-XAL8-4TF^\3^%?B(6?2?&?@Y
M]:T:UDTPS6UGK.R=2 #TS_A];^PW)X*\.^*;7Q'\2[SQ)XD^*?BWX+6GP>B^
M&.MQ?&.V^)'@+1HO$7C'P[J/@N]ELUL[S0=!N;;5;D?VI,L\$\,%BMYJ$@M!
MU_Q3_P""O'[%OP<M?AO+XT\7?$*.?XB_#2U^,]Q8Z?\ "3QW=ZQ\,_A!<:A;
MZ,?B;\9M%DTBTU+X7^%;?5;@65W<>)+6WNXIH[B6.RDLH7N!\&Q_\&__ (1L
M/A)XO^%MI\>O"6JZ?XQ^/WB3]H/6?#OC/]E+X5^)?A%_;?BKP9IOA&]T72OA
M]_;MGX@\)V>@3:9'K7A#6_!7Q&\-ZYI=RBV>OWGBNV$AFH>*?^#>#X9:AIOP
M:C\.?M)^,IO$/P_^ EK^SAX\\3_%[X4_#SX]:C\1/A_:^-;OQQ::GH%OX^N&
MTWX=^+]+U#4]0TCPYJ<<7BS1M,\,M;:+<:#?&PA= #])OVV/VXM1_9IT#]CK
MQ+\/]"\-?$/1?VI/VI_@E\"AJUUJ=Y#IMEX,^+EO>WD?C70[C3X6^WW"V$%K
M>::D@^QO'=*9VVL"/T8C+'=N8G!Q@J5(/WCD]&.&"_*2HVX!W;J^!_VD/V$_
M"'[1'A+]DKP6_C36? ^C?LE?'7X._&KPU'I6@:#>#Q/-\&;&>QT?PMJEJ#IM
MCHVG:NDR&\GTBSMA9E5CL;&VC8QU][0[@N'SN'+9"*<L2S9"#8&RQ!VLP("M
MG+&@":BBB@ HHHH **** "BBB@ HHHH **** "D(R.I&.<CV_.EIK9(  !^9
M<@G'&<D^^!SCV_$ 'X]?\%7_ /@H-\3OV&+C]E71?AL_[/VBW'[1/Q:U7X=:
MSX]_:4\0:]X9^&O@'3],\,WGB(ZUJ6JZ#=6DUNDIL_L):YD\B-YX')7#!O@S
MX1?\%YOB=K^B? _4_''P0\,^*;+QI^UK\2?V:O$7BW]G6T\;_$[PW\4M+\%^
M!;SQ=I?C?]G"T:"SU'Q7;ZA>PIHMW)J+2Z/#*LTL.HLN'3]FOVK?V'OAU^UM
M\1OV7?'_ ,0M6NS!^R_\4-0^)NE>$)-#T+7O#OCB^O\ P[?>'I-'\4VVNVMY
M'#I\<%Y]JBNK*(7<<T>U7PW%OXM_L5^ /BA\4/V4OB99ZK=> 4_9/\>:_P".
M_"7A#PAH6A:?X>UZY\0>&M0\.3:;J-O%:1)I5M;K?R7D3Z5''NN(@\NYG#@
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M_B=X.@:X\4?#WPGXODO7GO\ Q-HJ++]I2XTBSTZ5X98+6^NID*'Y-_X*"?\
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M\)5] KT'T'\J / O^%J_$C_HWSQ]_P"%#X!_^7M'_"U/B..G[/?CX?\ <P>
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MO?\ @G#XHO+[]H#7?A;\2_"'BBS\$?!+P!H5QJW@+Q_H'BCXI>%;/Q1I6K_
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MM0@THZY/XBTS3)M0\.GQ'K5U#H_A30O[6M;_ ,5:P_V72K&Z9':.?_@ENO\
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MT7KXT_\ @\T+_P"9ZC_A1VO?]%Z^-/\ X/-"_P#F>KZ!HH ^??\ A1^N\_\
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M<YS7L7B/QAX6\(P0W/B?Q#HGA^WGD$<,^M:G9Z7#(^&.$EO)8D9OE.%!)..
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MZS\*?!>KZ]K=WXA\%?9='M[=_%BKHMO?:G!+:6L$UO"'< _?4   8&   ,#
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M3;QC+'@*2!D^@QN.<<@8.?UH ^>/VJO^2)^*O^N^@?\ I_T^G>&?^3B?'O\
MV3;P?_Z73U\U_P#!2O\ ; _9E_94^!DMQ^T7\:O 7PB3QCJ6D6/A:#Q=K*6N
MH>(+JTU>RN;M-(TJWCN-3OX[.%#)>S6]I)':Q+)+*1'$[5ZK\"/BK\./C9\3
M=:^*'PD\;>&_B)\/?%WPH\'ZEX:\8^$M7LM;T#6;/^TKJ%I;'4+&::"5H98W
MBN8=PEM9-L<ZI(VT 'YK_P#!8'Q-^VO\![SX;_';X+_ME^/?@=\"-9^(/@;X
M;_%31O"G[,>@_'33/A'X;U"RURXUSXOZW'9P:AX[U*TGO+33-(CL].TZ;3-+
MN=0@O-0VVL<QKTS_ ((W_'KXZ?'?PA^TQ??%7X[^+_VHO '@SXVZ=X>^!7[1
M7B/X&2_ /3?B5X$F\!:)J.M'P_X,O=,TC5KR/P]XLN-4T74/$$]C'8:E<Q1M
MI),*2A:__!=&3XIW'[)6@>'/A=\0?^$2D\6?%'3M#\6^#-)^.OA[]F[Q[\9O
M#UUX5\4I;_#SX>_%GQ1>:=HVCZXGB%M#\37^CW6IZ2_B?0M"U+1[:_2:<%^C
M_P""0'@W]L/P[\*/BCX@_:LTGQ;X(T[QKXL\#ZA\&OA9\0/BCX>^+OB_P'H&
M@_"CPCX6\<WK>*?"<^IZ'I'AWQ]X]T/5/%GAGP=8ZKK3>'K2XN_MEV+J_:UA
M /V#,(.2))%R0<JV. 0V,?=.<88D%BI(!'! (%7&"^ 00"Q('J,'C!& >-W!
M^;)-344 ?/GCH ?'_P" J_P_V#\7RHYPI%CX1)8 DC<<#)QTX&*^@EZ#Z#^5
M?/WCK_DX#X"_]@'XP?\ I#X1KZ!7H/H/Y4 +1110 UP2   ?F!P?4?,#]00"
M/I7X^?\ !8#19M#^$7PV^.EC!(;KX(_%#POXJNIK48G731J]I<3*L@&Y(QJ-
MIITS'.U3&&X8+7["-T/MS_G\*^5?VU_AA_PN']ESXX> 8X$GO=9^'_B'^RHW
M4LO]KV5E+>:8VW#9;[7!$%P,@G(QUKCQT7/"U;+WH6DGU33B]/OUT[]CW.&<
M3##9[E_M7:EB:D\!5D_AA2Q].6$J5'H_X<:W.NEXH^B/"FN6GB;P]HGB73VW
M6'B'1],UVPP0<6>LV4&IP!F4E68)=CYEX(Z]JZ.O@G_@F)\3[KXN_L*?LW>+
M]2E:36XOAY:>%?$".X>2VUSP7>WGAB_M9BK$+-"VF(&0X900"!T'WMD9(].O
MXUTTY\].G*][PA?UY5?^OP6QYF,PTL'C<9@Y+7"XK$8=.UN94:LJ:G;^\H\V
MEU9GSO\ $X9^-/[.ASR-9^(W'KGP<<_EQ7T..GXM_,U\\?$__DM/[.?_ &&O
MB-_ZAIKZ&7I_P)OT8BK.81CSMSUP. 202>I'9>V>G/-?G_\ %[]O71?@]X\^
M,7@K6_A)X]DM_A3\([#XFZ=XBFN-(LM/^(VH:EXOT;P;;^$_"-L;B:]5X-5U
M_3(KW6=2AM;59IIX+>WG6UDF;] 2H.<DX(VD XX]B,,#]"/SKYI^+O[*'PJ^
M-FK>+=8\<PZ]=7'C+X67?PBU2.QURYT^*#PU=>(M.\5)>Z<($+VGB&QUK2[*
MYT_50[M:B(H(6$LQ< C_ &=/V@]2^-&E?$&U\7^!)/AEX]^$_C.?P1X_\+2>
M(+/Q-IEAJ*Z1I^NV=[I7B2UM=/M]1L+O2]3MI9'DMK9[2:.XAD#!%D9?@#XA
MT7Q+XE_:"U?P]J^F:]I<_P 7H4BU+1KZWU*PEEMO '@N"ZB2\M7>W,MM,K)/
M$)#)"P*R*&&*W_@5^SSX3^ WAW7M&T37?&7C#5?%WB2Z\7>,_&OQ"UR+Q#XR
M\7>(+FSM--6]UG5+:QTRVVVFEV-IIEG:Z?86%I!90B(0,7D9\_X)VEM:^,_V
MAH+:WAMHHOB[;^7';1I!$AD^'W@MI#'%$J1QF1\O)L1?,8DR;LG(!]%KT&/0
M?RI:0=!]!2T %%%% !3)&5%);&WOD@ #(!))P!C/<C)P*5R55F !(!(#-M4G
MMN;#%5SU(5B!DA6. ?#_ (M?$+5M)ETWP'X$B@O_ (E^+C+%H\4^6L_"^D1
M+J/CC7U1B4T;1E??;H^U-4U%K?2XV29I-H!\P_MM? KX6?M^>!_%?[%WQ%\.
M1>*/A?K4>G:G\8M9BD\B[\*Q6LZZCHFC^%=419&TSXB7LT*WEM=!)3H&G1M<
MW,3R7MM$WQ3_ ,$J/^"+'[!/[&7PX\0^*_A3\.=;UGQQ\0=9\3Z7KWCKQYXH
MO]9\66>D^&/&.N:1I>B>']2TQM*_L+3XK>RMI;Q;(+/J%[&+BXE "Q+^S'@+
MX?Z/\./"9\.Z8\][<$76I:WKMZI.J>(?$.H@RZOK^IS,SO)?:C=-)+L)*6T(
M@M8@8(8B>'_9>P?A!I#8 (\2_$@ @ 8!^(WBC=P, [BH8D@DG/..* (?^%&^
M)O#B3-\-OC-X^\.%V:6+2O%<EG\1?#T,B +%'#:Z['%JMO#M"HZ)J[G:BLA5
MUW/"FO\ [27A&VD.M>"O!'Q4@@"XNO!&MW/@W7KE 6#ROHOB5+O3#/T(@@U2
M&)B&"R %6KZ1*@]0"<$ D D9ZXR#_@>],\M0,<],'A<$9S]S&P9[D*"?6@#\
MA?\ @HO_ ,%>/@G_ ,$[?V<M;^,7QM^&OQA@U:ZO+;PIX7^'<GAM+"^\7>)]
M8@F$>FZ;XL674/"J6]E%%-=WLTE\)S:1O-;6TQ1DKY5_X(P?\%N?@'^WU\#;
M_P *^#OAA\6/"OQ2^#<=KIGB7X>6NB-XQ>[T[6;Z]N-+U_2O$&F+:Z/#I\SR
M?8YUUBYTV6WN@%)9 Q7]/O\ @H7^P3^S[_P43_9S\2_L_P#[1>AZKJ/@^XDB
M\1Z1JWAS5/[#\4^$_$NC1RS:?KWA[5?LMZD5Y&-]O-:W%I<V=[:2S6MW;S12
M;1\H_P#!&/\ X)=_LP?\$YOV?C<_ ;3_ !9>^*?C'%:ZU\0_&OCG6HM8\0ZP
MVD7NH6FDZ7 MKIVDV&EZ/81KYD=G::?&\ER[SSSRLP"@'Z$-XW^/WBA)%\,?
M"C0? D+L4@U7XG^*$OKEHCE1<'PSX/6[EWKD,(GU;;G =QR +\(/B3XHMS%\
M1?CCXIDAEYFTGX::=I_P^L5!8,8&U-%U/7)[8C*G-S;3N"6$B[E(^C?+3T[$
M$= 0W7<HPK9R?O G)SUI=HQM_AQ@#@  =,8 (P, <] .^20#\I/V_/\ @DY^
MQ7^VI^S]XA^'_P <?A[J^JMH5M=^*?#_ ([TSQ9K<7Q'T/Q#I6FW7V>_L?%&
MJ3ZI(\<P'EWUC/;O97D):)HD)WU+_P $V/\ @EU^QE^Q%^S)X?\ AY\&?A78
M7ECX_P!-T3QMXV\0^/XK+Q?XM\3>(=2TFU9I[[5[^R#6UI9K+)%I^G6,=M;6
M<3NBAF)=OTA^)'/@'QDI&<^&=:&3UYTZZ],=.WU-8_P8.?A'\,.!SX!\)?\
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MQPGV@B+]TS'JLNUEQG&,T <5^TO_ ,D%^+'_ &)&M?\ HJ.O4?"7_(K>&?\
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M2K+&@*9W)D9'7^ ]>TG6?VB_B2NDZA;7SZ=\/_"=GJ"P,'-K>+?S[H)"&(#
M9)5E5@>H](<TI<KZ:_?;^M_D.49Q@I\ON-M<UK[6OZ6]?U/Q-_X+WW7[02^&
M?AYX/\33_L07_P"Q[\8OB;\//A:__#3FA?%'2KWX;_$S4[3Q'J?_  LG7?BW
MX+U[2K3X?:):6VFR:7X?U&U:TO[J_P!3319;L1ZHR-W7_!O[_8'ASX6_M6?!
MGPU9?LSWFG?!?X_Z7X9_X6-^RC>^./%OPS^)\FI_#?PSK,?B&?XG^/M9U_5_
M&_BK1TE'A75;>'4YK;P?!I%GH<.4,:I]?_\ !17]L#]C3PC\._VA_P!F?XZ?
M%OPUX1\9/^RW\0OBGK3:[X#U3XAZ-\,O#%Q9S^%O!WQ \2Z=8Z+J6F+JR>,M
M2TZ3P)X7GD/B7Q5J]LB:+8730[XZ7_!'3XR? 'XB?L8_#SX>_!7Q'>:WK_[/
M6C^%?A!\<8==^$6K_ KQG_PMW2/">E7NL^(_%WPQ\0Z=I6MZ!J'CJ*ZA\56=
MU?1WJ:O9WOG?:IIBSFQ'Z-_$/X9^$OB=I>C:3XOTY]1L]#\8>%?'.GQQ7<]F
M\'B;P9J<.M>'KQI8#YTRV.H6\<\ELS8F11$P,>Z,^.^ /V/O@M\,_B_KGQK\
M,:5KD7BS6;SQ?J%EIFI>)M4U+P?X-U3XAZA%J_Q U7P#X5NF;2_"NI^/-4A6
M^\2SV(;[1*]RMN+=+R[2?ZK"K@':/N@9*X.,="",CZ&@A1SM'&3T'?D]<=2,
MGGD\F@#Y^\= ?\- _ 0X&1H/Q@P<#=_QX>$1][KCV)Q[5]!+T'T'\J^6?B[K
M&K:/\<?@'=:1X6U7Q7<MH_Q>B-EI=]I-A-'"=,\(N\KRZU?:?:28;Y0+>X>7
MG"*S8!]AT;Q;XMU%-0;4_AKX@\/"SL%NK,7VN>#+Q]3N\G_B6PKI>OW26DK@
M +/J+6L"%@7=!S0!Z-17D=IXZ\>SW-O#<?!OQ;9PSW%O#-=R>(_ 4T-E%,^R
M6\:.W\2S7,T=NI\UH4BDE91A4W  W]9\9>,--U*YL]/^%_B3Q!:6[+%'JUGK
M_@:SM+LE=S3K;ZCXBM-0M@#E6^V6UO%QN0D8- 'IO6FE5P0<X)SUQR.1C'IC
MI[<Y%>=WGB[Q9;Z1INH6OPU\1:AJ-XTBWF@0:WX.CO\ 20A_=R7EY/KZ:1=0
MS@[HWTZ]N67 $@&20ND>+?%FH1:H]_\ #7Q%H3V-D;BQ@OM:\'W3:K= <6=M
M+IVO7:6\KY)\^^:"S"QLIF$CI&QW\]_/U#^ONU7XZGQ)^W#8+X-^+?[#/[0%
MN%A'P]_:+M/AGXFO2AVP>#OV@/#NH^ G%U*,E;5/&*^$9,N0B3.C$X&*_1>'
M<$(P00$&#@M\HV$,0,,P93E@.0!7YZ_MRR_$GQ_^R?\ &O2K#X.>*K#7]"\'
MM\1/#=[/XA\"7BV7BCX8WME\1/#\\2:=XDNKF9QJOANW2)+-7GWNJ[8]ZY]_
M^'_QPUWX@^ _ _CWPC\+/$OB#PYXX\$>$O&>BZUI_B/P';6=_9^)_#VFZU"D
M,.I^)+::#R&OC:2_:(XV,T$KQJV]LY[3LM%J[+S6IK4G4G1IMKW*-X<V[?-+
MF2?6\>;W=[*UK),M_$\?\7K_ &<_^PS\1_\ U#<_UKZ('3\6_F:^7/'.I:I?
M?%[]F:>^\/7NC7%SJ7Q+EO+2ZNK*\DTR:/P=B*VFGL+BXM96GW.P>VFDC^55
MWD#CZB7.#GU;H<Y&2 ?;( ) XR2>]:&5K:?GKOJ.KYB_;$\6>+O!7[-?QG\0
M^!O%6G>!O%FG^"=1?P_XSU:._;3?"U_*J0KKEXVFZ;J][':Z8LAN9YX=-NQ:
MJ%G:)UCE"_3M0SV\%S&\-Q#%-%(ACDCFC26.1&!#))&X9'0@D%&!!!((Y- '
MYS_\$ZOBEX@^(?PC\;6NL>)]=^)6H_#_ ,>WGA9_BE<>-4^('A3XDSC1=*U"
M76_ /BD^'_#GVC1+6>\FT^ZM&L9OL6L1W%L+N5%"I[K^SKJ>O:MKWQ_O_$7A
MT^%M4N/B_&+C1&U>TUJ2V@C\ >"X[6=]0L8H[:47T $XM@K20;MCG(KZ6LM,
MT_2K:.QTRQLM/LXB?)M+&U@L[6)F;>?+M[=(XH\L=QV(,L23SDU\Z_#C5K'0
MO$7[2>L:E<):Z;I?Q0%YJ%P_RQ6UM9_#3P?-=S,O0".!#([<=B>G"E*$82G-
MV4;=?-7NEOVUTWOW"*J5*U&E3I2KUZ\O94X4T[7NK6BM7)Z12M=O979])*L2
MLZK&B[E&<(H5@>-I &&  (P<XYX'9YVDG/#;?F;&25!)P2/F(![$X^G-?SI_
ML[_\%MO@U\7_ -M[4_@)%+\4M/\ !VM:Q=^&O ?BO7;KP2W@C6-<66ZM[..*
MSTW2H?%5M:ZO-!Y&B"]NW\F4>;>&6%T%?M[XS^,5GI>K?\(5X)TB\^(OQ%:%
M)O\ A%]"FCM[31[>4 QZEXR\2SK-I?A32VX*"]9M5O4S_9EA=]:\K*LZR[.:
M5>ME^)ABHTING)4VGRRA925KWWOKK?U/N.._#?C'PVQF6X+C#)LPR;$9OEE'
M-LM6/PE3"1KX:M%2@XRD[2]G/]S525^=KFTE&3^?O^"E?[9%U^P)^Q+\>?VL
M+7P9)\0=2^$WA:/5-*\)+<M:6VHZQJ>I66BZ5_:M];KY]IH]M>ZA%?:I-&GV
MA+&"9(,RE&K^6W_@W_\ ^"UGQO\ ^"G/[6'B?]FG]I+X=>$K;1X(_'?[0OAN
MY^&NEWFF^'O^$DAU"UNVTSQ[8WMS?)>Z)I[3>9X<8O'')JC6\5RDS*H'];U[
M^SYI?Q4M-0F_:5&B_%JVU>RO+27X;7>G+-\'-#T^_MVBNK"#PMJ+SIXIO65F
MAN?$GBGS]1NGRVGV>EVV(4^:O^"=7[$'[(G[)UE\8-3_ &<?@1\-?A+J_B3X
MK^.]&UW5O!^AQVFJZAH&E:LK:1H\FHSRSWL>C608R6EE;2QZ:A 2*$!54>L?
M$<LFKI;<MVEWM^:_X)^G@1 P^0;B,D@9R3C))/))*C).=Q52<E00OE1[F;8N
MY@%9]HW,HZ*S?>8#L"2!V%.4KCY2,  >V.@Y-+D>H_,4"$* D' ##HVT$C@C
M@]1P2/H2.A-1F,#))W'MN&['"C"[B=H.T$A< D9()))<9H@<%U!]^/P^OM2>
M;$Q WJ<]L@]>A_3 ^M#^[;\_UV 3Y3@L"<8 '\/R\CY1A>">,@D>M(X1A]U<
M'(.54Y&1N4CN&PI(.02%.,BH[B58U9V=0J DX;!500-V=KJ% /S,PPHZXKR;
M6_C#X1L;UM)TNYN?%OB#YDCT#PA83Z]J"N" XN9+60:=9H#PTVH364:')W;0
MY7.4U:7O1C:+:E+1*W>_X_U;2EAZU>RITY.\HQO*3C%<S24I2O:"5[N3T6[=
MBS\8?&&E^!/A]XI\3ZQXC\(^%M-TW2+RXN-:\:ZFFD^&[=5MIE5=1OGDC,*.
M601%9-^Y0%#<)7S_ /L(_$K0/B3^SEX"U;P]XV^'_C>RL]/GL3J'P\UU-=TJ
M+.J:A+):WTAD,T%XH92D4\<:F*1&"')9OB?_ (*M_LL_M&?MR?LQ7?@;P3IW
MA?P$=%UNS\4+X2\5>*Y9+[QQ;Z:DP_LG69-)@GT;18MSI=0B2?6T^U11"40*
M@D'S+_P1/_X)[?M$_LL> O'OBSQ;X^T3X?1_$R;2I=)\$>&AI/C+3X;?1Y;J
M&75M7+QKI=OJ%Q*QM[8V$WF/$C/--F9HD^2KY]FE+BBAE5+)L15RZI@U5J9B
M_P"$IIQ]V+:Y>:5[+J][='_06 \*_#^OX"YOXAXSQ4R#+N/\)Q'#*J7A_4PV
M(K9C7I-)1K4:]+VOM8581JU%4I4_905-\[BE*<?Z0H]A56'!P1R!O7  *KT(
M &!M3 '/'7+F"N6W*".F&&00>0"#G(SU'(!YQD\^*_V#\;K"'9;>/_ VK2X/
MDKJO@#4+$2^K37.D^*RL;,>#Y-LJC.0IP<LBO/C]:9-UH?PIU9$)RMGXC\7:
M%+*"2?W<=[HVK11D8QAKN8$_-N4,$3ZIU5"<E&G)QYDVVVW=V348ZZ]E?3>V
MQ^#+ QE?V6/P4E&4HJ/MG"7+RP45)5J<91DW)N/-=WC9KWM=?XQ)I<_P_P!>
MM=?\0>*O#&DW<#PZCJ_@^%;C6K>UF1HKB*VW:?J6U9HF9)&6TD94.5*D U3^
M!=OH%A\./#UAX5\1>+/$OAW3[.WL=#U/QLFS6GTJTMXH+&U#-8:;))9VMK%"
MEL[6P+1A2Q))K\;O^"RW[:/[6O[+WP(\/7GPU\'Z?X'D\:>(SH&N_$&WU"V\
M;VWAW3OL;S)%#'<:7ID&FSZI./(34=5@N;:W)\N AG7&9_P1B_;Q^-'QV^ W
MBJ7]H;3/$6M67@;7-/\ #_A;XCZ/X%U62UUK3S8[9M/U,Z!9S6(NM(2"!9;J
M,I&Z./-V3LRU\LN,,"N*5PQ[/,(XF=".(;J85JA:3T4:KU:TN[=OB>I^[0^C
MIQC4\!I>.]/%9#5R"&?T\C>$AG^"GGE6<I*@JL,J2YTU53YX>TYXP3G.FK,_
MH'$:)G:@"L,8  !'<%<8().>5YZ]:4JI0DJ& P%&T$#;R,#H,$#&/ND#'(KR
MW2?C#\--7:.&S\:Z#]I<'9;7EZFF72D#C?9:E]ENDX[&#*DXY(S7H]O?6]W&
MCVMS#=*<LTD$BRJ!WYB,@X&1]<CK7UD)\S;4Z/+S-:2YGI;272+VNM7JE;5W
M_G^="O!TW4P]:DY0<U4J0<::LVN6_P ,I:7DELG:^IXU^T+H7CKQ7\)_%GA/
MX?:-H^MZ_P")],N=""Z[K1T.QLX+V,K-=O=1VMU),83M+6J1@S[=@920:[SP
M#_PDL?A#0;;Q;I-EHVOV=A:66HZ?IVI_VQ8PR6MM' C6^HM:VANEE5-P/E*T
M7W6)(.<KXD?$[PE\*O#=WXI\8WTVGZ'9X6[O+:QN;L6JL"=TJVPDD0 <EBL?
M^\I&:U?"WB[1_&/A[3O$^D7,ITC48$N+6XNX#9%[<J'222.=@85V<JP:1"IR
MZ X*PL1AW5=+V\.=)/ETVT5M//=W]-=3H>7YBL%3S&I@L13R^I4=&&8JDY86
M==<K5"$M5*K*+YE!*[B[^9V2*JH0@5 !QA4YR<D@# (/<>O/7%,F91N;"G P
M?[V6 P& 'S YZ$GN,5Y3K'QD\!:7=G2X-9D\0:R7\L:)X1L;KQ'J3.">&@TJ
MWO4@R 07NYH8UY8F+:67$;Q%\7_$P;_A'? ^D^#+&5@O]H_$'4#=ZIY)Z31>
M%_#=W<['8?-''J6K6)1@OFQ?P57M8>T48Q=2[M4Y'I"'1NS>MW:^G:[M9I9?
MBDH3KQ>'IOD47B)1P\I3E*%U*#O-Q<&Y-Q@U%:IIWM\$_P#!5?\ :6^#WP7^
M%.C>&/B+\1_#'@S7/%NHVLVDZ9J=IXRU36+VTL;N.2>^L]+\%7MC<)!;E3YM
MUJ,PA14(13(R"O>/V3/BGX%^,?B&7X@_#OQ1H?C+POK/PD\*-:Z[X=DU%]-E
MN8]7NH[RV2+5I)M6@FMW6/SX=5D^UHSD#* FOS=_X*N?\$JO%?[7$/A+XOQ_
M&Z'3_'_@FS_L"^C\1^&4B\+7>@:KJ,$:_P!F6'A^[AOM-N[2:17\RXEU W!Q
M]HF4D$_8?_!.']D;3_V*+/5?@;9^)[CQA?:?X'T;6]>\02VQL8;W6]7UFYGO
M18V+/+]GT^W46\5DH=@(_,Z,3GY#+\;Q16XHQN&QF58:GD%.C3^J8UU_]HJ2
M]Z]Z2F[VM9-J[776[_H7B;A3P)P7@'PEQ%D''6<9CXQXW.\70XCX1>7R63X'
M 4YI1G3Q56E3E!4X.DZ=?VLUBG4J>ZN11C^47_!6;P/^Q8?VT?'OCOXU?M&?
M'SP=X<\'? ?X'?&S]M;X$?#'X767C#X?_%CP'\#_ (JC4_V;_ _BKQQ<^7?>
M$O%WC[XA:C'I6@>$-(%U+XQAMCY@MHHFF/W)_P $4-:\"^.-._;2^*-SXG^-
MNM?M-_$C]I2VU?\ :H\.?'WX<Z5\)O''P^UBW^'^@P?"/P79>"="O=4TJV\*
M:7\*#H;Z!JUOJ%U/KD4D]Q=2+,@C'RA_P54_9L_X2W]M_P +?%6S_8L_;?\
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M7PY%,R+')KFC6UT;K365YT29+BT+1,\8DVLR[@#C/'2K_P - _ 4[1G^P/C
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M+Q'B.+,KS/#YW&GP]1PDH8G+5"TL352LXJ6U^:491G=N-K(_HGA;Q*\&,J\
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M?AW1[>*Y;49O$%U=69MND_:'_P""CWBCX-ZW\:M"\/\ [/.N^*8?A'XN\/\
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M2^;'G&X9P3CG. 0">G0$X)Z ]>AI/-3)&[D9'0XR,@C.,$@C:P!R&PIPQ H
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M Y!!&001P00001P1TH K&)F4;@P .1'NW#*OO4EN22KA9 0<L5VD8 %6Z**
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MC!RN"%W%3D !@OS%3A@I!( 894S1@,Q;Y5P6< E &SR7 *X &6.<(""Q (R
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M."&VD,5/S $$@9% $E(>1CGGTZ^__P"OMVI:* *[0JQ#%!N7(4C&5')(1N&
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MTOX8Z+INA:1X6TSQ_?Z'XF^)G@4ZK+I?CF:/Q7IGQ/\ !7BR37;B"[\+P2^
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nrxgraph2.jpg
<TEXT>
begin 644 nrxgraph2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** /R,_;]_;P^-7[+/QH\$^#/AUX9\%ZWX-/PAN?B[X]N?$?@?Q3XENH=)
MTWXN>"O >KK<^*-#^(WA*S^'6@:?X<\1ZIK4GB>Z\)_$:Y;5;&QTZW\,W0NF
M4]#XD_X*E^"]*\>_$SX;>&/A/XB^(WBGP?J_@72/!<'@WQAX1N-.^(EUXV^/
M=E^SJUC%KFH7%CHWAO5] \>W\ U:PU"^NH(++SHI[^VU*TO;&W^^_'?P'^"7
MQ1\1^&/&'Q*^$/PS^('BOP5N_P"$0\2^,_ _AKQ-KOA@/=0WSKH.JZSIMY>Z
M4K7MO;WC)930J;J"&X(,L2.N58?LU?L[Z7XBUGQ?IGP*^$.G^*_$.MZ?XEU[
MQ)9?#KPE;:YK/B'2O$ECXRTS7-3U6'24O;W5M/\ %VF:;XHLM0N)I+JV\0V%
MGK,,J:C;Q7">U3Q>3_5\-3KX"K4K48252I"I[.-:;KPG[[A.,Y+V49PYFU)*
MHXQY7&$X^+4PN;_6<34HX^G"A6G%TZ<X>TE1@J,X/DYX2C%NI*$^5)Q;IJ4F
M^><)? WB_P#X*L^&OAQJWBS3OB'\!OB%X;M=(/Q?T7PGJ\'B/P9KEGXZ\=?
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M#H%AXYO+Z27QO9>(F))^@I/@1\%I/B-/\8A\)_AS%\7KBWN;5_BI'X)\-?\
M"PQ%=Z-:^'IP/%[Z8^MG?H5E9:.PDO'1],M+;3W5[.)( I8C)(U.:G@JLZ53
M"5(RHSG4YJ>*=:$Z<E5]MS<D(1=-R@K\CO)5'*440P^=SIJ-3&TJ=6GBX25:
M$*;C4PJHRA43I>QMSSG)5+3T4U:+IJ,7+XZU/]M7QC\7_P!ESQ]\>?V0O =M
MXSN-)^(UCX)\ W7B:&'6+/X@:#IEUX9C^(/C+P/X4MO%G@>Y\:7GAR2]\8:%
MH/@Z3QIX1N_%'B3P9?0PZO;6LMOY_E7P9_X*:S^/-6$E]X+TKQ;\*+V^_96\
M-^%OC=X7O+?P3!XFUK]HS79/"<^M:O\ "KQ5XAU[Q/X"T;P_XAM=4@N-+U#7
M]=NM.ETB[TR?5]1N)[*ZF^Z/!G[*/P%\'? 'PM^S(_P[\.>,?@WX4L(K*U\)
M>/\ 1=&\6:?J<ZZI<Z[<:OK=EJ&F_P!EZAK-]KM[>ZW>7HT^'?J=W/<Q10EP
MHUM6_9?_ &;=>LY-.UOX!?!O5M/F\(Z#X EL=0^&O@^[M)/ WA;4K?6?#/@]
M[:?1WA;PSX=U>TM=4T/1"AT[2M0MX;RQMX+B-)!*Q.3Q6(I/!59TY8B;P]5O
M]]##<U%1E.2JP<ZTJ=.=H)PH4YU:K<*O-3]A;PV;RE0JK&4H5%AX+$4DFZ,\
M3RU6U"+I24*,9U(IR?/6J1I4K2I<M3VWYJ>)?^"J>J>,-=^'_A[X&_"#6[]K
MSXG?!;0/'&M:SXB\#_9_[/\ B;\2?''A;2_"/AC29=:BU77M5\9:+\/=9NM/
M\2Z1;W.F^'KC4M,-\DT$.I7%EZKJG_!1ZW\<_L??M2_M+_ _P6T;_ +P1:7>
MES_$!5O- U+XE?\ "#Z/XN\5>"-5TK0M7TS5Q-\-K[7;#PMXM5-2TTS:]%J%
MI87:BRFD'VI:_LN_LUV.L>#O$-E\ /@S::]\/(+*U\!:S:_#/P;!JG@NVT[6
MIO$FGP>%K^+1TNM!BL/$-S<ZW9II<MJMKJUQ/J$ 2ZFDE:O\.?V9/@[\-?A3
MXD^"MAX4L?$WP[\9^(OB!XG\9:!XWL=)\26/BS4_B;XEU/Q3XN7Q#87&FPZ5
MJEE?ZAJUQ ME<Z<UNFG16MFZR) &:IXK).6#IY?5C*E7H249U92]I1]JIXE5
M).;4Y2A3C3IIJ,81K35I2@JDIAA<YYIJKCZ4E4H5XN4*:CR5?9<F'=.*A%TU
M&=252HTYRFZ4'S1C/V<?SNO/^"EOB[X,V7QITOXSZ+\-OBWKGPC@\!Z[:^(O
M@E=7'@+3_%.A>+OA9XB^*6N^'_\ A"O%WB[XD:A8?$#P1I/ABZ:_TFP\8Z[I
M]YI6KZ#K^KW/A"QNI%3ZL^!G[<OA#X[_ !I\1? O0? ?BO1O&/@K3O$>N^.1
MJUWHCP>%?#L3^$KCX<:U?I8WMS-)!\6-%\5C6?#$4:B6U@T368-0"2VR[O87
M_9,_9<D\#6/PQD_9S^![_#G3-7F\0:?X$;X6^"F\(V6NW%JUC<:S;>'CHO\
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M:75E'.=1M;&ZMKR>SV>?';7-O,R".:-FP?%O[)'@OQWXDUCQAXP_9T^#VO\
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M[O+R[FCMK6TM;:-IKBYN;B9DA@MX(4>6::5TCBC1G=E521,S*HRS*H) !8@
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M45E_V/9_\]-2_P#!UK'_ ,GT?V/9_P#/34O_  =:Q_\ )]8FQJ45E_V/9_\
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M3S)]1U&RTFT6.%!).\;ZCJ-C:R3K$8+>2ZA-Q)$CAJ^6OVAOVN-4^&6L>*/
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M_7+6_BU?^OD__2F=5'^%2_Z]P_\ 244_[0LO^?J'_OL4?VA9?\_4/_?8JV2
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MI0<,7AL/B*\\TH_0/V.7_H(WWY67_P A4?8Y?^@C??E9?_(5? _A7]ICQ_\
M /Q!H_PL_;0&BVUCJ]XFC_#[]J7PS;_8OA3X\N' 6RT7XA6/F3'X4>/YP &C
MU&4^#];G8'1]6@D(M&^_$OK*2..6.\M9(I8TEBD2XB:.6*10\<D;JY5XY$(9
M'4E64AE)!!J,VR7&Y/.BZ_LL1A,7&53+\SP=3ZQEV8T8-1E5PF)48\S@VHU\
M-6A1QF#J/V&-PV'KJ5*.^49W@LXA65#VV'QF$E&GF&68VG]7S++:TTW&EC,,
MY2Y5-*4L/B:,ZV"QE)>WP.)Q.'E&K*/['+_T$;[\K+_Y"H^QR_\ 01OORLO_
M )"J;[7:?\_-O_W^C_\ BJ/M=I_S\V__ '^C_P#BJ\@]<A^QR_\ 01OORLO_
M )"H^QR_]!&^_*R_^0JF^UVG_/S;_P#?Z/\ ^*H^UVG_ #\V_P#W^C_^*H A
M^QR_]!&^_*R_^0J/L<O_ $$;[\K+_P"0JF^UVG_/S;_]_H__ (JC[7:?\_-O
M_P!_H_\ XJ@"'['+_P!!&^_*R_\ D*C['+_T$;[\K+_Y"J87=J3@7-N2> !-
M'DGT^]7RS\9OVOOAM\+->B^'/ARTUCXR?'+4HB=#^"WPQ2WUGQ7([_+%>>*K
M]I4T/P!X?1OWEYK_ (MOM.MX;5)I[6"_>$P-WY=E>89OB5A,MPE7%U^652<:
M:2A1HPLZF(Q-:;C1PN&HI\U?%8BI2P]"%YU:D()R7GYEFN7Y1AGB\RQ='"4.
M>-*$JC;G6K3TI8?#48*5;%8JM+W:&%PU.KB*\VH4J4YM1?U!]CE_Z"-]^5E_
M\A4?8Y?^@C??E9?_ "%7Y^P?L_\ QQ_:*8:]^UC\5+WX?^&7;[5H'[/?[/?C
M75/#.EZ%)]ZSNO'_ ,5=,DT_Q/XX\06(PYL]%?1O"5M>[GA@U5(K><6Q\.OV
MP/@&3-\'OBUH?[3/@"U)=/A=\?M1@T'XDV=G'MVV'A;XU:-:-;:I<)!"EO91
M^/M!F#32R37^O@-O3WGPYEC_ -DI\5Y++-H?Q,/46)HY5*;T6&PV?RIO 5<1
M!W5:M76$RE*TL-FV*C*Z\!<2YFO]KJ\)9W#*)_P\13>&K9M""U>)Q7#T:BS"
MEAIQ:=&CAWB\WOS1Q.4X24;/[W^QR_\ 01OORLO_ )"H^QR_]!&^_*R_^0J^
M./ O[=/PEU;Q!:?#_P"+^G>)_P!FKXKW$D=JG@7XUV4'A^SU>[<I$#X+\?V]
MQ=> O&EC<7!>/3Y])UY;^]1//_LN"-TW?9:7UE+''-'>6LD,R+)#*EQ$\<L;
M#*R1NKE71@05=25(.02*\3,LGS3)ZD*>98*OA'5CSX>I.*EA\72Z5L'BJ;GA
ML;AY;PQ&%K5J,UK"HUJ>YE>=95G5*=7*\=0Q:HR]GB*<)..)PE7K0QN$J*&*
MP6(CM/#XNC1KP>DZ<7H1_8Y?^@C??E9?_(5'V.7_ *"-]^5E_P#(53?:[3_G
MYM_^_P!'_P#%4?:[3_GYM_\ O]'_ /%5YIZ9#]CE_P"@C??E9?\ R%1]CE_Z
M"-]^5E_\A5-]KM/^?FW_ ._T?_Q5'VNT_P"?FW_[_1__ !5 $/V.7_H(WWY6
M7_R%1]CE_P"@C??E9?\ R%4WVNT_Y^;?_O\ 1_\ Q5'VNT_Y^;?_ +_1_P#Q
M5 $/V.7_ *"-]^5E_P#(5'V.7_H(WWY67_R%4WVNT_Y^;?\ [_1__%4?:[3_
M )^;?_O]'_\ %4 0_8Y?^@C??E9?_(5'V.7_ *"-]^5E_P#(53?:[3_GYM_^
M_P!'_P#%4?:[3_GYM_\ O]'_ /%4 0_8Y?\ H(WWY67_ ,A4?8Y?^@C??E9?
M_(53?:[3_GYM_P#O]'_\51]KM/\ GYM_^_T?_P 50!)$AC0(TLDQ&<R2[-YR
M>_EI&G'080<=<GFBG(Z2*&1U=3T9&#*<=<$$@_G10!^,_P#P60\93>$/AG\/
M[H>,OC]X.6&]\3:Q9WOP1\,^'([<WFF:4EK>6_C'XH>))H;/P3I>J:+JVH:4
M-,1+^ZU^&YNI-/TV?4=,M)8/U#D^'?A/XB?!O3?AQX_TC2?%?A77?!.@Z/KV
MF1WKW>DZG!%IE@?,L=4L&LI98!/!'=:=JEBUI+\D%Y:F!MFWU"YMK:]MYK2\
MMX+NUN(VBN+:YBCGMYXG&'CFAE5XY8V'#(ZLK#@@BN1\?>*H/ASX \5>,(]&
MN]5MO!OAK4]:30]'B1;F[@T>QDN%L;.,*(X5,<(0$)Y=O$"^PK'M/H2QDJN%
MP&$I4W3K86M6G&M&<5*I.M.FZ?+RPA*FZ4HNTI3FVY<RE&UCSXX14L5CL75J
M*=+$T:,)490DXTXT83C4;O.<:BJQDKQC3A9146IWN><>%_V7?@#X+\:^&?B-
MX9^&/A[2_'7@WP]>>$O"_BF+[=)J^C>%[Y]1DF\/VEQ/>2_\2E'UC57M;*59
M(;)]2OWLU@>[G:3W2:TM;A@T]M;SLHVJTT,<K*I.2 75B!GG XSS7Q'\+?VW
MO#/Q1\8_ 7P1IWA>"TUWXT>%_&OB/4M-'C7P_>:MX#3P;H]OK@GO])407FLZ
M+X@T_4O#U[H.IV"17=_I7BG0]=ATI]%.H7]E]N3W45N5602DL"1Y<,LHP#CD
MQHP!]B<]ZQQ<,73J16,=1U.1\GM:GM)>SC5JP=GS2M'VL:ME=)N\U=24GMA*
MF$J0D\(J:I\ZY_9T_9KGE2IS3:Y8WE[*=.[LVE:#LXN*B_LW3O\ GPLO_ 6#
M_P"-T?V;IW_/A9?^ L'_ ,;IO]I6_P#=N?\ P$N?_C5']I6_]VY_\!+G_P"-
M5RG4._LW3O\ GPLO_ 6#_P"-T?V;IW_/A9?^ L'_ ,;IO]I6_P#=N?\ P$N?
M_C5']I6_]VY_\!+G_P"-4 8_B/P5X/\ %^A:IX8\4^%] \0^'=;M);#5]%UC
M2;'4-,U&SF7;);W=G<P20S1GJ Z$HX5T*NJL/@"X^%?Q@_8OFDU?X%Z+J?QX
M_9G2>2ZUO]GW4;A-1^*7PILG)>YOO@5XAU60OXI\/6X+3-\,?$EY]IMHX4M_
M"VK1B=[:']%_[2M_[MS_ . ES_\ &J/[2M_[MS_X"7/_ ,:KW,ISW$Y7"MA)
MTJ.8Y3BY1ECLGQRG/!8F4$XPKPY)PK8/'4HMQH9A@JE#&48RG2565"I6HU?#
MS?(<+FDZ.+A5K9=F^$C*. SG N$,=A8RDI2H3YX3HXW 59)2Q&78VE7P5:2C
M5=&.(IT:U+ROX._%KX1?'KP?;^-_A?J^C^(M'>5[/4+?[$MEK?A[5H&:.\T'
MQ1H-Y##JOA[7;"9)(;S2]5M;:ZB=&(1XBDC>K?V;IW_/A9?^ L'_ ,;KXU^,
M'[,<.L>,9OCC^SSXIF^!G[0R0HFH>(['1;F\\!?%2RMQF/PW\9O!<2PV?B>Q
MF51!:>)K<6WB[0"8[K3]2E%K#:BU\'/VM[?Q!XL@^"OQZ\(W/P,_:'2&9[3P
M;JD\M]X2^)=G9ETN/$GP<\8&"&T\7Z.^P3S:3(+7Q/HZ310:CIA(,[=V+R+#
M8W#5LTX9JUL;A*%.5?'Y3B'"6=Y-2BKU*M:%*,(9GEE)7OF^"I0C2C'FS+!Y
M8ZE"-;S\)GV*P.)H95Q12H8/&8BI&A@,WPRG#(\ZJRLH4J,ZLZD\KS.J]LHQ
MU6<JLFXY9C<T5.O*C]@?V;IW_/A9?^ L'_QNC^S=._Y\++_P%@_^-TW^T;<=
M5N?_  $N?_C5<_XJ\>^#_ OA[5?%WC37].\)^%]#MFN]8\0^(9UTC1]-MU*K
MYEW?WWDVT6]V2.)&D\R:5TAB1Y71&^8ITZE6I"E2A.K5JSC3ITZ<93J5*DY*
M,(0A%.4YSDU&,8IRE)I)-L^IJ5*=&G.K5J0I4J4)5*E6I*,*=.G!.4YSG)J,
M(0BG*4I-1BDVVDCHO[-T[_GPLO\ P%@_^-UXU\9_C;\%?@!H$.O_ !0U[1]#
M%_+]DT'0K;3SK'B[Q7J+<1:5X2\)Z5;W>O>(]2F?"):Z78W#*S RF-,L/F*X
M_:4^-?[2!;3/V/O"$?AKX>7+R07/[4OQ>\/:M;^%I+8/LDO/A+\-[B"SUWXA
MW6%D%EJ^MC1/"HE,4S'5+=9HJ]7^"W[*_P +_A)KD_Q$UJ\\4_&#XX:I#LU[
MXV?%(S^(?&EP7&9;+PY$]NNC^!?#Z$^5::!X2L-,M8K2.W@NY;][=)S]8LAP
M&2_O.*L35I8F-G'AO+:E*6<R>CY,TQ,XUL+D$=XSIXFGC,VIS24\HA3G&NOD
MO]8,?G?[OA/#4JV%EI+B;,X5HY+&/\^5X:$J.+XAEJG"IAJN#RBI%MPSB=6G
M+#OQ]-,_:@_:Q!:2RU3]C3X"W>Y1!':Z/=_M/?$/37)5O.F\N_T#X+:3>(#A
M(AKWC.2!B&?2UN!Y7U?\'/V>?@Y\!?#C>&?A?X'TC0+6YD-SK&J2QMJGB7Q+
MJ#X,^J>*/$VIM=ZYXAU.X<>;->:I?7,C2$E=@.*]:_M*W_NW/_@)<_\ QJC^
MTK?^[<_^ ES_ /&JX,RXBQ>-PSRW"4</D^2\\9K*<M4Z="K.G_#K9A7J3J8S
M-<5%MRA7S'$8AT'.4,)'#4'&C'ORWAS"8+$K,L76Q&<YUR3@\WS-TZF(HPJ)
M*I0RZA3A3P>4X6:48SP^78?#JNH0GC)XJNI5Y._LW3O^?"R_\!8/_C=']FZ=
M_P ^%E_X"P?_ !NF_P!I6_\ =N?_  $N?_C5']I6_P#=N?\ P$N?_C5?/GT)
MS'C/X:_#WXB^'[SPKX\\$^%?%_AS4(I8;S1?$6A:;JNG3),ACD/V>\MY4CD*
M,5$T029.J.I (^,;C]B[Q7\)))M5_8^^,>J_"R%93=-\&OB7:W'Q4^!.J$-Y
MAL+32]6NAXR\ 1W!2*W%]X/\1+!I]J'2VT23=M'WK_:5O_=N?_ 2Y_\ C5']
MI6_]VY_\!+G_ .-5[66<09ME-.>'PN*Y\#5GSU\LQE&CC\JQ$]N>OEN-IU\%
M4JI:0KNBJ])^]1JTYI27B9GP[E&;U(8G%X5PQ]*#IX?-,%6KY?FV'@W?DH9G
M@:F'QM.DW9SH*N\/5MRUJ52#<7\$1?M;:_\ "6X@T?\ ;!^ .K?"&$-';_\
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nrxpic.jpg
<TEXT>
begin 644 nrxpic.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M+CPA%Y5AXWM8?&O]D3> O";^9\0X_%LM_P#V3MU-[U+[4EO/'/BO^QI^S?\
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M_P!85?FE^VC_ ,%1?A!^Q)\7OA)\"O%7P6_:=^-OQ0^-GA_5O$7@/PG^S?\
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MRRIPI^T6D^2*YUI*Y^=G[07["G[!/[4WB;X:>,_CS^SOJGCSQ7\(-(TCP_\
M#_7V\/\ Q\\-:GI'A_0-0?5=%T"_N?!\GA]_$^A:9J4UU>V>C>*_[;TV&XO]
M3D6U!U34?M7D/Q!_X)-?\$K/BE\1?'/Q7\<_L@R:QXZ^)$WB"[\8ZI;Z5^TC
MH>GZGJ?BAYY==URV\,^']3TKPMHGB2_NKJXOSXET'1=,U^VU2:35;34K?46-
MU7ZXT44\TS2C&$:.98ZE&G"5.G&GB\13C"$Y*<X04:J483G%3E&*2E)*33:N
M%7+.&J\ISK9'3K2J3A4J2JRP%252=.#IPG-SRIN4X0;A"4FW&#<4TFT>._#N
M'X;?"?X?^!?A9\/_  UXP\/^ _AKX.\,> /!.@KX(^*6I+HGA'P;HECX=\-Z
M0NHZQHFH:OJ"Z;HVFV5D+W5;^^U*Z$/GWUY<W4DLS_$ _P"";?\ P3F'[.,?
M[)(_9Q\4?\,]1?$X?&1?AX9/VH#&?B0-/;2O^$CD\3G6CXSF_P"):QLCH\OB
M)]!-OMC.ED*N/U!HK&EC,91E*5'%XBE*=6%><J5:K3E.M3<W3K2<9IRJTW4J
MN%1MS@ZDW%KFES;U<+D=>,85LJG6A"E.A"-6O@ZD84*JIJI1C&>6-1I5%2I*
M=-)0FJ=-2B^2-OE#Q=\%_P!F_P =?'_X3_M1^*OAOXNU7X[? [0_%?ASX6^.
MSX>^-UD_A?1O&^D:QH7B>S'AO3K>T\(ZS_:>DZ_J]H+GQ#H&K7=B+V2;3I[.
MX2&6.K^TI\"OV9?VOO!_A?P%^T7\,?%OQ&\)>#/B!H7Q2\-:/+X?^.'AA-.\
M=^&]-US2-&UPW?@N'PYJ%\+33?$FMVKZ5J-W=Z+>1WSF]TZY>&W>'ZYHI1Q6
M*A.A4CB:\:F&A[/#SC5J1GAX<TY\E"2GS4H<]2K/E@XKFJ3E:\I.3EA\EG"O
M3GEE25/%3]IB82Q&$E#$5.6$.>O%Y8XU9\E*E#FJ*4N6G"-[0BE\B^,/@1^S
M#\0/CSX-_::\9_"KQ)XA^-G@'P#XC^%_A;Q=J'A;XT/9V/@+Q;!KMKXC\-WG
M@Z.TC\"ZY::K;>)M=MYY]>\-:G?+!J4T4-U%&L2Q_$=M_P $:_\ @D99W^I:
MI:?L;7EK?:GJVG:W)/;C]J>$V&HZ5J46JV3^'XX_$*Q>%[5;R&/[1IOAN/2M
M-O;0-IU[:7&G.]JW[+45M1S+,L.N6AF&-H1Y(4N6CBL127LZ<I3A3M"HER0G
M4J3A#X8RJ2DDG*3>%;+N',2W+$9)"O)U)U7*M/ U6ZM2,(5*C<\JD_:5(4J<
M)S^*4:<(R;4(I?(WA3X%?LR^"/VC/BA^UIX7^&/BW2_V@_C/X:T#P?\ $KXA
M?\(_\<+V7Q)X<\+Z;X:TG0]-_P"$:U"&[\':.+/3_!_AJW>ZT#P]I5[>_P!E
M0RW]S=32W,DWC=M^P/\ \$_[;]GSQ1^RN?V<M3O?@-XQ\?ZG\4]<\":QH7Q_
MUS=\0]7CMX;[Q=I/B?69K_QEX;U@V]K';6MQX;\0Z2NG6KW-MIR6L%Y=QS_H
M[141QV.BXN.,Q47'ZNHN->LG%82/+A5%JI=?5HN4</;^#%VI\JO?26#R&2DI
M92Y*3Q#DI5L$U)XR2EBW)/*W=XJ48RQ%[^WDDZO,TF?FA\"?^">'_!._]F;Q
MU\/_ (F? O\ 9IU/X>>//AAI_B[3/!_B?3-'_:%O]2M[7QUIYTGQ.VN-KEUJ
MD7C*]O\ 3&.GV^I^,XM?U+2+,+;Z-=Z?$JJ/ICX_?#/]GW]J/X7Z]\&?C[\,
MM9^)7PU\226,^J>&]8^'_P 4;,?:],NH[S3M1TW5]%T;3->T+5;*XC#6NK:'
MJFG:E CSP1W2P7-Q'+]+T4JF-QM6O3Q-7&8FKB:3BZ6(J5ZTZ]-QFZD73JRF
MZD&JDIU(\LE:<G)>\VVZ>$R*C0J86CE,J6&JIJKAZ=;!PH55*$:4E4HQRM4Y
MJ5.$*;YHN\(Q@_=BDORUUW_@F9_P31\3_ OP)^S=K_[*L^J?"'X8ZGXDUCP!
MHEUH7[0K>(_"FH>,;XZGXJETGXD+=K\3((?$-^(;K5[-O&#V5]+9:8;BW<:5
MIHM?H/\ 9A_9U_9,_8R\&ZAX!_9E^"E]\*?#>LW\6J:XFE> OBSK.M^(+^WB
M>"TN?$7BWQ3IFN^+/$#6$$DT.G+K.MWT>G1W%REBENMS<"3['HJJF89A6I2H
M5L=BZM"=25:=&IB:\Z4ZTI.<JLJ<ZCA*I*;E.4VG)RDY-MW;BE@>'Z%6&(H9
M.J->G2C1A6I5,%3JPHQBH1HPJ0RM3C2C!*$::DH**44DDD?F[^U)^P!_P3[_
M &T?&&E?$#]I7]G#5?B+XWT;2;/0;/Q3#HO[07@?6Y-&T^XOKJQTS4K_ .'=
MQX2GUJRLY]2OGMH-9:_2 3E(PL<<2IT^N_L7_L)>(_V;;;]D/5?V:K-OV=;&
M^35['X;Z?\-OBKHMM8:^DES+_P )18^(M&TS3_&%EXOD:\O%N/%UKXAB\37,
M-Y>07&JRP74\<GWW1368YBJ="DL?C%2PLXU,-36)KJGAYQ^&="'M.6C.-Y<L
MJ:BU?1[W'@.'G4Q%5Y,G5Q<)4\54=3 NIB:<K<T,1/\ LOFK0E9<T:CE%V5T
M[(_*OP)_P3F_8#_9\:X\;?LX?LS7WP]^*6@?";XA?#;P?X@TG1?CW+>W&G>-
MM*OK>_M_$+Z_<ZAI_BK5-0FGAM/^$I\9Q:UX@L;!(+&VUFUTZVA@B_+W_@ES
M_P $9?V=/#O[-GP^U+_@H/\ L:FY_:<\(>/O&^HP1ZG;?$37X&\+7&K6]QX7
M@\6V/PMUF_\ AEXZB5([F:TL_%$/B=[*QFAL9TMT4V4/]2U%=D,_S>G0Q%%8
M[$N6)J4)U,4\1B7BU'#QQ"5&%?VZ:HU/K5652FU)2DXM->_S\53(>%ZF(PU=
MY/)0PM/$4Z>%C5R]8-RQ$L+*5:=#^R&G7I_5*4:52+BX1NFI6@X?S9_M*?\
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M7>LRV.G-?WKV5O UW<&3\R/^"G7[&7B[]LW]N[_@GCXOD^".L?%+]F/X9O\
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MROY-?VL/!W[=OQ:^''QS\*?'/PS^V#XZ^*P\??"(?#GP3\-_A=XSUK]GG7/
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M^)[)[/2;C4O['\1^'M<L[36-"U&&: VE[;W-INC<-+;M<6[0S2_"U[_P2O\
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M^#_P]M=/FF\>^,HO$.OZ9_93>>=:M;ZUMKNZFAN-*:!;-))(/M/N=M_P5:^
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MO_*\!0^;X"7_ (133MFEV_V7Q"/.O=WBEO,@^S?17[-W[,O@/]EW0?B)X=\
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MS6S2:2:_UCX,3C'^S.(+SC&4/^%S KG3J2IOEOPUIRSBTW+E6J:<DFS]-O\
MA<?PY_Z#\W_@A\1__*BC_A<?PY_Z#\W_ ((?$?\ \J*\(_8M_:8UG]I_X=^(
MO%7B/2O!&A^(/#GB>QT+4]'\!^*9_&FE:6^J>"_"GC*#3[KQ-;VC>&=7O[.'
MQ.MNM_X4U_7]/U+3(]-U;4(O"FN:CJ7@KP[]BUP5\NXTP]6=&KG?#4:E-I22
MX5S.2U2DFI1XS:::=TTVFFFK]?1P^/X7Q-&G7I97GDJ=1<T6\_P,7H[-.,N&
M$XM-2335T]'MKYC_ ,+C^'/_ $'YO_!#XC_^5%'_  N/X<_]!^;_ ,$/B/\
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M])YQGF791*O4H4<1A:E98>&.E75*.)H.I*G&#JP4G)1DN#P^.QSHXKVSP]+
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M-/UL? 7PI\3_ !1X+T"Z\/>$VUFQ^)/C'5/$6H6*:#K_ (@UNRT67P;XYO\
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MWO\ <W_"X_AS_P!!^;_P0^(__E11_P +C^'/_0?F_P#!#XC_ /E17Y[>-O\
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M/^&O%?CFRT33[;Q5XCT#PK-J<_AS2-:UR&W34-1L-%DUC43I]O=3RI;K<E$
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MNKV7-9RLN9I-)NVMDVVE?9-MI=6>577_ "6_0_\ LE7BG_U+O!U>JUY5=?\
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M]1RIR4FK0DT_:/X]\3?MO^,O!EWXP\+^)O@GX<M?B'\*_"7Q(^*?Q9\/:?\
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MDHIM2G"G*F_1?CI_P4!M_AU%\0-5^'][JVN^(K3XL:-'\.E^!7BK3]0\!?\
M"'^#+;Q%X6\>W%K_ &K;ZYXGOM3U6#6["S\&2'2HO'DAT+PKX5N+#Q,TEWK%
M/2?BY^USH(^,CQZO\5]?T-_B7\0+[X??$3Q!^Q]\9+S5_$4G@W]G3]E&?X?^
M [/X.V]EIVM^$? ?CKXBZM\=8_$?CB+2/#WAN_\ $?@K6[70M9\+ZSXGM+V?
MO/A]^WYK_C6;PC%<VGP'T<WOB+7M+G_XNAK=Z?C+::;^U/\ &?\ 9KMX/V:%
M@\*>=X\UK[+\*=*\>,MU"-'G?XC^!O#^H:IX;T/66\?V?C6B?\%'/B[XTL/@
M[JTVA_!7X0V'C'XP^!/#^L>(O%OQ5\'>(/ FE:%\0_V<?VIOB'-X$^(MWX4U
M?Q-K?@GQE\//%GP@\&37YUI_ &H^*-2\0Z)X9FTWPC#+K9D[UA\2Y5[Y9@H*
MG[2-2*EATE:<I1C%.G4E4E#V:C'V:E%IMUU)ZT_/>(PRC0MFN.G[7V<J<N7$
M-N\*<92E)5(1I0J>UYY>U<9)Z8>4(WC4],E^(?\ P4+OM!A\3S6]EX4U36+7
M]K;49/A[:_ C5?%+^#[GX(>*]4L?@MX<?Q#%XCB;7Q\8+6Q(AU6.V1/'?ANY
MT;4/APVF7<DNMZERFH?'/]M+37UX^!_AYX\M?$[VW[17Q#E\+^,_@Y\9_$_@
MC6)="L=9L_A!X)T+QE=VVKR:#K'B[Q%_9^HPZ!I^JZ#X7L?"7A#5(=/TRQUW
MXA>%'N?4/A'^WOXG^)WBGX;Z5-X%\!:-_P )AXL\(>"+SP)!X]O=3^*NL6?B
MGX<V_CV7X[?#O0&\/V2^)/@%ITDEWIUKXDNK:P;5='T?Q-XDFU'1[[PW)X4U
M+]-ZXL16EA)QAB<MP<924YQA%4^7DG*IRQER*3DH*48PE*3G[BDI\SFWVX>A
M'&0<\-FF-FH.$)3DZBESQA2<I1YW#D=1QE*<8Q4/WDHN#A&FH_B+\3_C5^WS
MJ'P7^*VF+'XQT'6(OA?\>Y_A1XS^%7[,7Q\\5>,OB9XRLO _@R/P)X-UW1]1
M^'7PW\5?"'78O%?BCQ5;^'/&(\$^']$\0+H^@ZKIGB(2>$?%\6O?7/[0OC3]
MHCP7\<[NZ^'9\<7'@"_^#WPYL?*TGX3>+?B?X<T'6+[XYMHGQ.\;V5CX6L9Y
M=3\=^$OA?KEOKVB^#WNOMNNQZ7'>V>A^*+/2-6T.Z_0&BN:684FZ=L%AXQA[
M7F@HPM/VCI-<S]E=N/LOM<T5SS5.-.#4%U1RZJHU5+'XF<I^QY9N=2]-TE53
MM:K\,O:ZJ/+)\D'4E5FG-_F7\1?B%^V+JOP4^"_B'P#X;\53?$,_'_XH:#X@
MN-.\ 7_A+6?$OP-T+X9_M&V?AGX@ZU\-O&VRT\)^+M9@TKP#XE\)>$OB)=^&
MO"6O_&8^!]&UH^$-"\50Z+IGC7Q,^*7[;L^G_&'PA\']-\<V'@;2_@OXVM/A
M7J_B3X3_ !UO_C;K%C8?LJMXY\'_ ! 3Q!K'PGM/#DWQGUWXXB#P#>^#-?\
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M$90G6G6O4G.,JCDYQC)MJ#E*4N915DM(^FNA1116!T'E5U_R6_0_^R5>*?\
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M?#&\T*\U2R34?$>O>"M1^(OPMO;F#Q+):1-IWA36435]0ECMK?6_"/&W@O\
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MN_B0^E:CXOM+#K?B+X3_ &^9-3UZ[^&D?QWM-7DC^*%MX>?5OB-^SQ-\.8?
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MKC*)YBKX6<*\J&4.NZ4U!WH4Y*I5FU5<7/DJSM'XJDG&2A/D2NI1D?HUX_\
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M_@H]^QLJ>)WUSXSZ'X2/A3QOXL\!WL/B>WO["XO]5\&;CK-_H\%O;WDNH:&
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M*T_0_P!GGXT^$KJU\/>)UM_B%9:=XR_X0_XR_&>*Q\">&1I_BK2M%\02>)/
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M))_%GAS4_#MI>:;8_$,>*U\%S>%_!EK:#&O/VT?C[I\_B#P=-_PHZ3Q?X/\
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M+-Y!I'[5?[<.N^$?B1K.C^%K?7OB9X97]H_PK)\-O#7[/GQ2U3P#X;UGX:_
M[QWXN\%>)-+^)CF&+QIX@NOCUHGA#X2I\-9+O2/%GB+0?$[30>$[+6-,N==E
M]/\ B9\6/V]/!_Q'\=>%?".F>&?$^D>$/"NKVGAW6=1^"OQHO=/\=3K\ KKQ
MO'\2H;KP%X"\3>$XKK3?C-YO@JU^&=A\3F\6ZMX?\/3:'8^$]:\6^+/"NN7W
M7[+,(58WKX+VT*,6I2J3NXX6=HRE*4>6<E*LK.5XSM&M&[I1JPXU4RV=*35#
M'.C.O.\8PI\JGBH)RC&*ES4XM4;N,%&5/WJ,DHU71GZWJ?[)OQ UKP%\"_
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M#6G#XQ>(_!7Q9O\ ]D[XE)XG\<2> ?AW\(?$6B>#_$'P6NX;'Q1X6\ OXO\
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MZ_Y+?H?_ &2KQ3_ZEW@ZO5:^8X<_WGBK_LI\1_ZJ<G/>SO\ @</_ /8AH?\
MJPS(*\K^(7_(W? K_LJFK_\ JD?C'7JE>5_$+_D;O@5_V535_P#U2/QCHXN_
MY%6$_P"RGX)_];/( X<_Y&&(_P"Q#Q5_ZS&<'JE>>_%3X::#\7O ^I^ /$US
MJEIHNK7_ (:U&ZFT::R@U 2^%O%&C>++"*.34+#4[3R+C4=#M+>^22RD:6QE
MN8H7MYWCN8?0J\4_:+\!>-?BA\%O'O@+X>>)Y?!_B[Q)IME::;K4&LW?AN1K
M>#6--O=9T3_A)=/T7Q)?^&8_%.AVNI>%YO$ECX=\07GA^'6'UBUT/5I[*/3[
MCZRAI6HM5%1:JT[57JJ7OK]XTM6H?$_0^<KI.A63INLG2J)T59.JN1_NTWI>
MI\.NFNI\Y_&3]F[]F;5)O$6F_$OXNWO@J[UKQ-\0OC=J=I?^/O 'AR[M;?QY
MH/A7X2>(=6B@U_0I)8/!VGSOX;TVPO[B.5+3Q3K=E9WVK7CZE8::=6Y_8/\
M 5S>:;-_PM7XUP6'A/3/%NF_#'18-4^&Z6'PH/BOX[?"?]HA;[PE=-\,'UW6
M+OPW\0O@I\/U\-Q_$C6?'NG0>'=-N]$U6PU>+4KR63YGT7_@G?X_>]-[XL\1
MZ-KT#7WP-@L]/\1_$KQ+XNN_#GA/X9?MF:#^T!K_ (3T?7=+^%GPWMI-'N?
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M?NU%'B[ 1E.4&I_6L>W&,?BC_N/O.:]FG4D_:)4^524)5(R]/HKS#[/\9_\
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MW=O#/#-;7$4B/&,-@D'A_P#A2WP^_P"?+Q'_ .' ^(/_ ,U%?(XC"<1X3/\
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MM[)Y7O[5$MA"97('L7P]UOQK\*-1\6:?H_P*_:C\:6>LZQ>:F^J^-_B%\/\
MQ1;!HD<0CP[_ &QXYM[_ $W3[P "*PG@@:!BIFCB!S1[6=T_<6MK>QI]+*]G
M![N6^WNWU38.$;K6>^O[VKY6^UMI9VMNV^Z^F#I'Q9R?^*Z\(\'K_P *[O\
MGW_Y'ZC^R?BS_P!#SX1_\-W?_P#S>UYB?CM\2Q?PZ>/V6?C$[/IR7LVH+JGP
MT&E6UP]M/.NG/<2>-XYYKH2Q):N;:VFBCFGC9W$0:09MO^T)\5Y;R2WD_9#^
M-T$$<J)]L?6?A)Y,D<B,XDB3_A8?FL4^6.52BJDC$!V522_:R_N?^":72W_3
MO6]NF]WW#V:[S_\ !E7R_O\ E_6M_8/[)^+/_0\^$?\ PW=__P#-[6%=W/Q-
ML[B2VE\;>%R\9 )3X=W94Y&>,_$$'OSD"N8M/C/\4KB>R6;]FKXC65I=>*)-
M#FN[C7? KM9:.)XH8O%,]G;^(IKLZ<R2-+);+%]O548QP2J&=?0M>YU6Z_WE
MZ_[H_P \<4_:2[0T_P"G5+LO[FNWI=L%3CU=3I_R]J^7]]]O\]W?F_[3^)7_
M $.OAG_PW5W_ //"I\>H_$EY(T/C7PT [JI(^'5UD;F X'_"PNO/%6:E@_U\
M/_76/_T-:'4E;:'1?PJ75I?R?UKKJ-4XW2O4W2UJU7V_OKMW_6_8_#K6]1\2
M_#[P)XCUAK5]6\0>#?#&MZH]C;26=DVHZKHEC?WK6=I+<WLMK:M<SRFWMI;R
M[D@B*1/<SLIE?LJ\X^#G_)(OA7_V3CP/_P"HQI=>CT54E4J):)3FDNR4FD%)
MMTZ;;NW"#;>[;BFV_4*_)[PE\$+[XM:[\=O%4VG^,O%E]8_&GX]Z79R2?M"_
M$_P):)J6@_$.6P\*^%K/1]$OY],T[08M#%V9+^UMXA:26]E:0V$J/-/%^L-?
M(W[*T\%KHW[0ES<RI!;6_P"T_P#M!SW$TC!8X8(?'.J22RNQX5(XU9V8\!02
M:Z*%2I2H8B=*<Z<^>A'FIRE"7*_:MKFBT[-I-J]FTNR.:O3IU<1AX5:<*D/9
MXB7+4C&<>:+HI/EDFKI2:3M=7=MV?*4/P,T6*71!K'@/Q+H]OK]U;VVDW4W[
M<GC:6/5HY.)[O1UCUTMJ$,.UV2-&6XE  6(,&5=JZ_9<\21P1R6GP5\=W,L8
ME>YB/[:/Q*07"1V\[I'ILC:@%:6YG2WBB:]%G$HE=Y9(U3->I> Q+-^S%\#;
ME+>XADD\/W(272OAW#XXC.F/IFJ21_;)GAB?PI:3H8IY-6AV".8B%=X;=7W=
MIW_(/L?^O.U[8_Y8)V[?3MTJ?KN,_P"@O%?^%%7_ .3\E]Q?U/"?] N&_P#!
M%+R_N>2/S!U3]E;Q,L,#Z%\'O&LTLHN#+%K/[9?Q1M/(6.2W^S!GL[Z]W37$
M4LVY(U>.*2V<--AX3)O^'/V1KN\UNUM?%'P]\9:-H,VMS6MQJNF?M=_%W5;Z
MST%-->:+5CILEU:)/>3:JJ60TZ*ZPMHYNWN$=3;G[;\3^.O%6@2W26/PP\2^
M(8()91'>Z=J7AR&WFM8EB;[6?MNJV\D"$M-^[N$BD"PE]I1U-<D/C]HIBD==
M OIWCNY[8QVVO>#7S%$%*7F9?$4!6WG!D6/>JR>9#(C(/D9SZ[C-_K>)_P#"
MBK_\G_PP?4\)_P! N&_\$4O_ )$\[_X8>^"G_04^,O\ X?;XL_\ S64?\,/?
M!3_H*?&7_P /M\6?_FLKV?2?B7KFJC3)4^%_C&*RU*>U5=22[\+7MC#:7<QB
M74#-9:].9K6--MQ*;=)7$#;U5@.?6J?UW&?]!>*_\**O_P GY+[@^IX3_H%P
MW_@BE_\ (^2^X_/CQQ^QUX*TV\TFR\"Q_$S7-3N9K"2[L-<_:'^+NE6BZ-_;
MNEVNOZA'>1>)+IVOM-T6XO;K3[+RUCO;N.*"22,'?7EFJ_L\V^CW.O-=_#OQ
M.=!T'4;RVN_$A_;=^(-G8V=HDRMIIUB"^U:WNM+U*\L9K6XFLIHBD,MPD:7,
ML;)*WZ6W?_([:/\ ]@#5_P#TLTZOF[P3-#?3_M</#&MQ;P_$RYBAFL/#T/BJ
M]?4-/\!>%(;D+X<DA\K6[S3[^#RH;)FD:>2$0EHV0 +Z[C/^@O$_^#ZO_P F
M"P>$U_V7#:/3]Q2[)[\A\Y0_LS7.I6"ZAH'PM\::S:WEA:W6FWMK^VE\1I;"
M2XFM UQ;SW$.J2*T=O>AHH[BS^TQSVQ28E)2\*3+^ROK\UC>-'\'?'=MJEN[
M1VT5]^V;\3O[.OS'<6R^=%<V5]=W,-O/;2S3PB>TCF62V:":&(R1L?O'X/;Q
MX//F_:/-_MO7/,^U>'O^$4N=YU"8GS_#PXTJ7/W[4?*C= !P/5*/KN,_Z"\3
MV_WBK_\ )^0?4\)_T"X;_P $4O\ Y$_-SX>_LA/K&LWMO\2O WC3P9H26 FT
M[4?#W[6GQ?\ %-_-J'G!7L[NPDO-*C@A\G=)'<Q7,^X! \<;LT:^Q?\ ##WP
M4_Z"GQE_\/M\6?\ YK*^P:*/KN,_Z"\3_P"#ZO\ \GY(/J>$_P"@7#?^"*7_
M ,CY(^/O^&'O@I_T%/C+_P"'V^+/_P UE>"?M/?LR_#[X2? WQS\0_!'B'XP
M:;XJ\,Q:)?:+?S?&WXIWD=I=_P#"1Z1#YK6ESXJ>VN%\N1U:&XCDAD5BDJ/&
M61OT\KY)_;I_Y-7^*_\ V#]$_P#4GT6NC"8S%RQ>$C+%8B498K#QE&5>JXRC
M*M33C).33BUHTU9K1Z&&+PN%AA<3*.&P\91P]9QE&C33BU3DTTU&Z::336J:
M36J1];4445YQZ 4444 %%%% 'S]^T7XX\5>!?"GAF[\(ZE#I.HZUXUM=#N;Z
M6PL]1:/3V\->*=9E6&"^CFMEEDN=&M4,KQ2%(FE" ,P9?D\_'+XT?]#\OI_R
M*WA3)]2!_90)'T'&>:^A?VM_^1.\!8Z_\++MO_4"^(''X^O;K7\_OQ4\6?M)
M:1^V]X/D\,>&-?USX3Z?'X=\*QW!TAI_#6F:/XZ3P(?'>HM<V\UN\]_9W%K<
MRP7=YYZZ9)'<B%/+$BGZSPZX%R_CG%<4K'XJK1JY5B*]7#RJ9_FV54'A\+D.
M2XJ.#H4L'F.#P\J]?&8RI-2<)U6JDW+GC"%-^'Q[QSB>!,MX4K87+HXREF\J
M&%Q"H</Y5F^)A7QF=YQAI8[$5<9EV,Q$,-A<)@81<(SC2YHPBO9RJ2J+]?O^
M%Y?&C_H?>P_YE;PIWZ'_ )!/0]OYT?\ "\_C1_T/O_EK>%/_ )45^>>M?%?X
MY:%KWB?3;'X<ZCXDMI/$VI6^BW[Z+-!8Z1IVE:C(6M8IK:<G5[34O#:Z;>V.
MIOY+?VUJ-[9A&%CMI3\;OCI+.$L?@9)<00I:7-U+<3:I9&6*2TCGN+*R6:,E
MKT2LT$;R!8%8#S&ZU]BO![*'"%2*JRISBI1F^-\\@K.,):JKGL)*\FX135Y.
M,FERM-_.OQ=Q$95(3HPC4I3=.<%P)E%5J:G*-KTLAFF[14W;:,XQ?O\ -&/Z
M%_\ "\_C1_T/O_EK>%/_ )44?\+S^-'_ $/O_EK>%/\ Y45\E?"#Q_XY\=V^
MM2>-OAY?> )K!=$>PAO&DD&H#4;![F^1'?&9=-N4^SS! %P\9R26Q[+D=?3/
MZ=:\G%>''#V"Q%3#5J.8NK2Y>;V7%G$5>'O1C-6J4LZG"6C5[2>MT];GMX'C
M[-<PPU+%X?\ LQ4JJDXJOPEP_AZJY9R@^>C7R6G5A[T7;FBKJS5TSU#_ (7G
M\:/^A]_\M;PI_P#*BC_A>?QH_P"A]_\ +6\*?_*BO+Z*Y_\ 4+AG_GQFW_B3
M<3__ #X\OS[LZ_\ 7'/.^3_^(SPS_P#.@TOBA^UG\5/A;X%U_P <ZOXVEN[;
M18(3%8P>&?"<<^H7UW<1VME912-HSK$9YY5WRLCB*)9) DA4(WQ=J'_!5+]H
M[30IN?#,NU]*M=:6>V3PCJ5HFF7UJEY:7<UUI_A:XMXT:WDCDECDECF@#;9H
MXGRH]S^,7PYA^*_PZ\1>!I;S^SIM5BMI]/ORGF)9ZGI]U%>64TL8(+P>9$8I
MU7YC%*Y3Y@M?%1_9A_:"T_PA=>%_^$^\ OX>@TZ5/L:V6H+*L=MI$.FI)%<"
MW$HFCL;0) '=H4FFFF*>8^\<&+X#R93A]6P^:N+2NO\ 67B:]T]=99Q;:RMU
MO?N=%#B_-Y-*?]D<SDE%+AGAG6[C96_LA:-MIZ^A[;)_P4\_:GL(;%-2\$W_
M -LN;%KUTM-/\-/B"W,,=W>26B>%KBZL+19)XF7[<498IHGWR1NLK0-_P5+_
M &EUFO8!X*U=YM/B2XO(X]+\/2M!;R2B&*X;R_!S!H)9& BFCW12 AT8H=U>
M!^&O@3\?OB%X:\(>.HO'7@I%\1^%=)UBVDO[74/[4DL-<M=/U:VBU9X8C'-=
MPP):6\K)^[(@.-Q=F?LD_9R_:*2XO;O_ (3CX="]OY-1>>]CMM:M[D+J33O-
M%#);B+R$B>ZNWMC&%>(W,@W%5B"<G^H>"6CPN:7O)-?ZS<2634E'E_Y'-_\
MA]4=%?BK-J%>M0K+*J56C5J4JM-\,\,WIU:<W"I"5LJDDXSC*+Y6TK:-[GI:
M_P#!4K]IEX%NHO!.L36KE!%=6^E>'KBWF,@+(89H?![QRJP# -&S NK(#N!
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ML]?U6X\/6NG&[\%>'99],T[7I;B3^S-(7SGFM]0MX[1+,RLT2EH_M#^\W?\
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M+HHW&&V">9)L3&[:S;5 S@"O.PLN;'825K7Q>%TWVK4UY=CHQ,5'!8J*=_\
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M^=CMM+_GS!7MHY0ZM*W7^K?/=_L'0\?\@?3>G3[%;?E_JZ7^P-#_ .@1IO\
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M73+K[-\(/']]#>1:9"D<-I/)'>".Z1%&Z:(R$;G)/[ZU_/G%::XTXQO!4_\
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MH.GZ7>RB)EN9M#\*S7GCF,K#O62 #0;CS"%:Y 22(FK:=\9="\&ZA+IOPO\
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M%XB:R NO$OCN<0608:3--<6>B:!:RW=@\>Z]O97:5K<]=KH U2Z   #*  ,
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MN>L?^$W+_P#-51_PHKXA_P#1<]8_\)N7_P":JOIZBC^SX?\ 0=GO_B1\0?\
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M;4YY)25GJG;JUL[K56:LU?0\H_X59+_T47Q_^?@C_P"8BC_A5DG_ $47Q_\
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M[+>NCI^UC^U<#ZCQ=\+\_G_PJ&OK*BCZW7[T^G_+BATM;_EWY(/JE#M4Z?\
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M;(</AZ-&$JF'S!Y%Q%/"5<UQ>*=2O3PN9/,)0GE^&Q>%Q>3QPCP&/QL/Z/\
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MH,,<6A1V,-IX=\(:7J6JW3[;NSM]3GNM"M[^]CBW"]U6(VTLC-)(#^C.B?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nrxtable1.jpg
<TEXT>
begin 644 nrxtable1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M:VPN4MD97,K%OZ,7/& "3P< 9/!'7)  /3WST.#7\XDG_!/O_@J=\'_VG/\
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M_#75?@]\,=4N/$WP7U=/VC/ 7C7XL>!/B5IGA?X=Z9X2L/%/@OQ[\%-+%_\
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MZ?4>M1'>?K^K 6BBDR/4?F*L!:*3(]1^=+D>O7I0 4444 >+_M&_$'5_A)\
MOC7\5/#]O8W>N_#7X3?$3Q[HMIJ:32:;=:MX1\):KK^GVVH);RP7#V5Q=6$4
M-RD$T4K12.$D5L&OYK_ 7_!6[_@I3\+_ -E']CW_ (*)?M3>"OV1/&'['7[3
M7BCX4^'/&6B_!NT^)_ACXT_"&Q^+VKRZ!H'BF4^+-6U/PKXCL]+U=(X]8TZU
M=I/)N%:VD*J"?Z6OC[\.K_XP? _XP_"C3-2M-(O_ (F_"[Q]\/[+5;V&6XM-
M+N_&/A;5/#]OJ5U! 5GFM[&74%N9HH2LLB1E$(8YK^=[X;?\$6?VX?$W[._[
M*'[#G[5O[6'[/^O_ +%'[+OB;X9^*9?!?P5^$/C30_BC\5U^$>IOKGA'PQXK
M\:>+/$ESI^F:'<ZLXN-9N-'TM+NZ2***- .@!^E?Q$_X+#?L>_"KXX6WP+\9
MR_&K2[F3XI>&/@C/\5F^!WQ!/P)L?BQXQ^R+X=\"7GQ9GTJ'P[_:^I27UI%'
M/:O=::LUPD/VXR!P.FC_ ."L/['<W@4^.T\5^,!"/VM(OV)&\)2>!-?3X@1_
MM$3:JNEQ^#YO!IA.L16Q##5/[9,1TX:)MU9I5M'5Z_(S]HC_ ((2?M6?'OX[
M^.OB-X@_:5^$?BG09_VO_ 7[3?PJ\2_$+3OC/J_Q%\$^"O!OB;1M9L_V?['0
M+#QA'\*O#GA'2[339X+'Q)HWA>XUV_>6*.],2F69<'X(?LB7O[0/_!?'XN?M
M#^#?!GQ>\+?L@?!BXM/CAXLTKXD?#S6O W@?QC^WV/"=[\'W\2_#K_A(K:TN
M?%-IIG@E4\0WVOV-O_94VHM!/92,\HGD /WX_:O_ &@O$?PGOO@'\,OAO;:3
M??%[]I'XQ:5\,_!(UV"XN=$T+0](TV[\9?$[QEJUM;2V]Q<VWAGP+HVIM9P1
M.HGUS4-)MW8)*U>-Z1_P50_9>U?QUJ/@ZW7XOVVB:%\:=2_9U\1_&+5?A%XM
MTWX(>'?C58Z\?#$'@+7?B3<VHTBQU/6->^R:;I%XJ2Z+/J&JZ5ITVHVU]J-O
M;FW^W!\/_$]K\4_V(?VG?#>C:KXGL_V:?COK">/O#^B65QJ6KK\-?CKX-O/A
M3XE\4:?I]K'+<W[>"M2U'0/$.I01Q2SC0H-8N5 -N&'YT?L__L??M;?'?X=?
M'7X(?$#5/AS\.?V7?$?_  4;^,_Q@U2#4_"'C2Q^/VH>$O!_[0MI\3M!T7PO
M)=%/!=UX:\?Z]H.EZG;>.KF,:A:^';R\LK&PU"5K74(@#]*['_@IE^S3??$6
MT\#1R_$I/#6H_%6[^!>E?':X^&?B2V_9ZU;XS66H3Z-<?#C3_BO+;KHLFM+K
MUI>>'XKZ2*+0+K7[:;1K75YM11;9\+0?^"G_ ,"O'2^*!\//"?QT\5V&GZ)\
M7+[P+XUM/@WXL;X;_%C5_@S8ZK/XR\.^!/&5O#-97NIVEQI%[:VT&J+H[:L]
MM=#27NWMW"_.-K_P3=_:(?PAX=_97U/XK?"-_P!CGPK^TO\ \-$:;JEEX:\6
M1?M"7FC6_P 5+_XR:7\);X27?_""0VUEXNU#['-X^AGDU:\T"S@M6T2.]EGN
MASWPW_X)<_&SPQ^T;:_%*Y\<_!3X=Z#;:O\ %^^\<^(_@1IOQ-\$^(_VC=-^
M)&B>(M'T31?B]\'I]>;X':)<^';C6[/6=7\3>%-,FU?6]2TB*>S.DF[O3(UN
MK]P/T+_8A_:<U/\ :X_9+^$7[1^I>"M7^'VI_$KP3%XFO/"NN:5?Z4;&YD6X
MD*Z8FJ.;N^T&=4C;3M3D$:ZA:[KE$A$BJ/F3]D+_ (*?_#/XO? OP%XN^+FO
MZ5H_Q('P:\7_ !N^.,W@W1=7NOAO\%O!?AC7O$=G#J?Q!\2/+>V/@ZYUW2M"
M:Z\/^']2O9/$.NB&XN].TZ2PV7!T?V8/^"<&A>!_A-^S[I'[1%EX<\:_&?\
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MHD6HP$6M["9?TAR/4?F* %HI,CU'YBC(]1^8H 6BDR/4?F*,CU'YB@!:***
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MYI;[4KE+FPF:Z-I;1I]'7?AC_@KRNI? F+P/XUTG2%T?PCKL/Q8\0_$OXS^
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M^X_J!,GBO@&8GH?^0?8\<?Q_Z9A6VY.TG[HSFG--XL4$F0CN/]!L._7/^G$
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M (4E\&S9^(?@DMJ?A5\/3;I/X:\:F=8#X1T?REG,?B((90FTR%$12WW44<
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M?AWXF:7I/A^VN-0<Q22:7%9:C/<:AI]JDT[A9+J2(P(^>(U_]L;XM:3^S?\
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MAKI[5G$!(<FTE;J^NPHMRU:T5[V3OI;U^?Y'Z9_\- ?!/_HI7A+Z_P!HQXZ
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MX3]H;X7?$FR^"_CVYF_:$\>WD<.EVK-;3>&OAZ$E_P")SIORL4\/HV=Q&3N
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M3?3=6 74XH]*-P4_6;]KK_DU7]I13T/P'^+('X^!==! QR#R .F#R,=:\P^
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MU>0CQ!XBUVQTZ*":WM/L$\2Z59WR:A)<W-L7C\MP6^A/^$*_:A_Z+_\ "O\
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M<PV^I17L,=S-(RW*6XZ?]D?XJ?"S]H[QC\2_#^L?!CX>>%IM!^W:SX1\/?\
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M*K-/ASX*2VG^%?Q6EE@3PUI2I(T>L^ EC9U%N-S(CNJOD$AB#@&O21X*_:B
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MCX$>.=&TS5(-<TW3?$7[,6J7]M8:S;)+';:K:*WQ\5K?4((YYDANHF26-99
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#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>salberglogo.jpg
<TEXT>
begin 644 salberglogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M3]H'XD?''4? NN:7>-8QW-Y\9/%WQ N-#UZVU!]*W:;"[>-;^^_M&73 VG0
M7$MEFSCCK]U/VR_CAHO_  1HU+3_ -A?]@ZP\.:%^T9H_@;PQJW[5_[:NJ^&
M=$U_XO>(?%GC/0XM:A\!?#*[UZSU2T^'WA*TT74+/4Y;>PMI)[2UU+2+&V\O
M7[/6_$6J_J&9\#>'V%Q&5Y3EW!.3YKGN;86KC*&'CC<7A\NP^"PRH+%9EC,<
MI8BI3P$*V(H4,/*EA*^(Q=:M"%.@H^VJ4OSO+.,^.<31S/-<QXPS7+,CRG$T
M\)6K3PM"MF.(Q5=U'A\OPN"DZ-.6-G2H5:M=5<13H8:%.K*I5;=*%7[OL_\
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M^UM^W+X=/A:+2+$>'Y= C_:=^*FBIHL^E&!K.XTM=&@@T@65Q#+;C2X8=/\
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MHOQ(\93ZK-JVFW.O67Q&N_"NO^,)->O!'<:G9'Q%--K[ZY>!);R '4KH!Y)
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MTVPT?5=1\.WUS;R16VLV.F^(+'4]"OKO3YF2Y@M=8TZ_TV:2-4O+2X@+PO\
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MQW\D1MM2%];P);I_1L.@^@Z]?QKX^^$O[$WP=^&OQ'N/CKXHN/%'QX_:,NK
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MQVEM:V=M>6UO:6J05M?_ &/?CS\0]"E\(_$__@H1^T=>^%+R VNKVWPH\*?
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M*^&O#]BN9;R_B_M*\\0W@C4BPT/0M6U:X:.UL)Y$\O\ '?@>;X)W_P#P1/\
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M,52J4,=0X9P/-"D\%'-YTL5CHUZE6I&ER4L9>GA6I.6'P-*5*DI.LZ<O+O\
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MSS]GOX884NHI5AC"_OX2D:%B51$4DDD*J(HY))PJJH'). H&20!7YY?MW_\
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MJD5)1;M=J^S=E]Q\I?\ #(?@S_HK?[5O_B5_Q\_^;NC_ (9#\&?]%;_:M_\
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M'*,$(5RK!6(W!6*G:Q&1D!L$CN..^0?VSFO_ $'XK_P;+^NGY]V']DY9_P!
M.&_\%Q_KHON/R@\%>)_V+OB%\76^!_A/]J/]J[4?'LNN>,_"VC-+^T#^UKIO
M@GQAXL^'/VD_$+PEX!^)NIZM9_#GQ[XJ\$"SOCXH\/>$/%.LZKI0TW5VGM=N
MBZL;+ZS_ .&1/!><?\+;_:MSUQ_PU?\ 'W...1_Q7?.,C..F1FOR;_9C^/GP
MA\+?L0?L8_ ^QT#0OB5^UOX7;X_Z3X2\"6$'A_7OB%\"/VA?@M\._C_J7CWX
MD>,/"%]=+K_AR33];M=4\&7VI3V4=YK>I?%30[:%;RQ\6)-/\H?##7_'&H?
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M\7?!?BA[[QQ)H?@F'2[2^GNO%<&F7_U+IOQTFO\ XO?"[X87'QAN[[Q5<_\
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M([OQ!H>D>%-2L/[/O-/A\(B>UT_0[RS%E/;1:=:S6ZVSHJI^Q'P:_P"#A/\
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K3G.SM=<\]?>=W&C2C)3C2IQFHN*E&$5)1?+>*DDFHODA=7L^2/\ *K?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>totalcareumbrella.jpg
<TEXT>
begin 644 totalcareumbrella.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
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M( 2XT>,L?N[AS7UC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !P!["EHHH *]?\ @Q\%_$_QK\8:5X9T>ZTOPYI-W<LFL^.O%,SZ;X/\-V4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BD9E16=V5$52S,Q"JJJ,LS,< * "220 !D\5\*_M!_P#!3']A7]F
M7EO\7OVDOASI>O62R>;X.\-ZJ?'7C7SHF"-:OX5\&1:YK%I=9.?*U"VL_ERY
M(3YJ /NNBOY2OV@O^#HOX5:*;W2_V8OV>O%OCZ[3=':>+?BYJMIX%\/EP&7[
M1'X9T"3Q!X@OK?=MDBBN=1T&XFB^646<C?)^&_[07_!<_P#X*/?'\WUE_P +
MI'P9\-7AE4>'/@9I0\"M%;RY!MSXK>YU7QRZA>!(OB6*7J-V"10!_H*_&#]H
MWX!_L_:1+KOQN^,?PW^%FFQ1&82^-_%^B:!<7"!2P6QL+Z\BU#49G Q%;V%K
M<SS.0D4;NRJ?Q1_:"_X.2OV%?A:;W3?A!I7Q&_:-UZW,D<$WA?2#X'\$S2+D
M*9/%?C2*TU(P,RD&;3?">JD HRQNK$K_  ;^(O$GB/QAJ]SX@\7>(==\5:]>
M2237>M^)=8U'7M7N996WR23ZEJMS=WDK2-\SEYB6;DY-8M ']#/[0/\ P<F?
MMR_$_P"W:;\'-$^&_P"SMH%QYL4-UHND+\0/&ZV[Y"[_ !#XQ@ET*WN-A*M-
M8>$;>9&VR6\T#KN/XG?&/]H[X_?M"ZJ^M?'+XS?$GXJW[2M*@\:^+=7UFPM7
M;(_T#1YKD:/IRA24"V%A;J(P(P-BJ!XO10 @ 4 *  .    !Z #@4M%% !11
M10 4444 %%%% !1110 5+#!/<S1V]M!-<W$SK'#;V\4D\\TC'"QQ0Q*\DKL>
M%1%9B>@-15^E?_!':VMKS_@IM^Q]!=V\%U WQ+NV:&YACGA9H_!_B9XV,<JN
MA:-PKHQ7*.H92& ( /SBOM+U32S$NJ:7J>EF?=Y U/3KS3S/L^_Y(O((3+LR
M-_E[MN1NQFJ-?VU?MQ:G\6O#O[*G_!3C3O\ @HYJOP&E\#:]X@UFR_X)Y^'(
M_P#A6U[\6H]276/$ \*WVCVW@\+K,#6'G>#IQ_:,G]O:;9VWB Z_]ETN:YCN
MOB?P]_P1]_9.^,7P#^+.L_#7X3?\%"OA%XH\#? +Q#\6O 7Q^_:-T;P'X6^%
M_P 2_$/AS1AJAT ^ K)9/%&E6&MRL);"&:PTN_&A17NH)J+W-BEMJ0!_+:G[
MQ_+C^>0LJB-/F<LYPBA%RQ9B0%4#+$@ $UU'B_P/XT^'NL'P[X^\(>)_!'B
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M?_A7^BGQ)X[_ + U3Q=\3;+5AX+\/".;^V_%)L9YQH.EF&87VIFVMS%()"C
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MPK^R]\7_ !GXV$#D[3-XK\8^#[K3H;A5"E9M(\+:5)&^X>;(AK\5OB[\&/\
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MC]MK_HSG]JK_ ,1X^+W_ ,Q]'_##'[;7_1G/[57_ (CQ\7O_ )CZ /U]N?\
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M_P#A"E'@S[4DXN4TY]-\4>0ZF-KV96!7K/ O_!53X(WGPY_:+^"7[1/[&?\
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MWPQ^(7A'Q;X5E\[1O%/@SQ7:6M['#.3'9K?64\4"W#Z=82-=/;QW-C>?/?\
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M?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\ \HZ /]$"BO\ ._\
M^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\ H[CXN?\ @?H?_P HZ /]$"BO
M\[__ (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\ \HZ /]$"
MBO\ ._\ ^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\ H[CXN?\ @?H?_P H
MZ /]$"BO\[__ (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\
M\HZ /]$"BO\ ._\ ^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\ H[CXN?\
M@?H?_P HZ /]$"BO\[__ (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+
MG_@?H?\ \HZ /]$"BO\ ._\ ^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\
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M (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\ \HZ /]$"BO\
M._\ ^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\ H[CXN?\ @?H?_P HZ /]
M$"BO\[__ (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\ \HZ
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M?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\ \HZ /]$"BO\ ._\
M^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\ H[CXN?\ @?H?_P HZ /]$"BO
M\[__ (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\ \HZ /]$"
MBO\ ._\ ^'H'_!0K_H[CXN?^!^A__*.C_AZ!_P %"O\ H[CXN?\ @?H?_P H
MZ /]$"BO\[__ (>@?\%"O^CN/BY_X'Z'_P#*.C_AZ!_P4*_Z.X^+G_@?H?\
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M)0!X;17N7_#,/[2O_1O?QN_\-7XW_P#E)1_PS#^TK_T;W\;O_#5^-_\ Y24
M>&T5[E_PS#^TK_T;W\;O_#5^-_\ Y24?\,P_M*_]&]_&[_PU?C?_ .4E 'AM
M%>Y?\,P_M*_]&]_&[_PU?C?_ .4E'_#,/[2O_1O?QN_\-7XW_P#E)0!X;17N
M7_#,/[2O_1O?QN_\-7XW_P#E)1_PS#^TK_T;W\;O_#5^-_\ Y24 >&T5[E_P
MS#^TK_T;W\;O_#5^-_\ Y24?\,P_M*_]&]_&[_PU?C?_ .4E 'AM%>Y?\,P_
MM*_]&]_&[_PU?C?_ .4E'_#,/[2O_1O?QN_\-7XW_P#E)0!X;17N7_#,/[2O
M_1O?QN_\-7XW_P#E)1_PS#^TK_T;W\;O_#5^-_\ Y24 >&T5[E_PS#^TK_T;
MW\;O_#5^-_\ Y24?\,P_M*_]&]_&[_PU?C?_ .4E 'AM%>Y?\,P_M*_]&]_&
M[_PU?C?_ .4E'_#,/[2O_1O?QN_\-7XW_P#E)0!X;17N7_#,/[2O_1O?QN_\
M-7XW_P#E)1_PS#^TK_T;W\;O_#5^-_\ Y24 >&T5[E_PS#^TK_T;W\;O_#5^
M-_\ Y24?\,P_M*_]&]_&[_PU?C?_ .4E 'AM%>Y?\,P_M*_]&]_&[_PU?C?_
M .4E'_#,/[2O_1O?QN_\-7XW_P#E)0!X;17N7_#,/[2O_1O?QN_\-7XW_P#E
M)1_PS#^TK_T;W\;O_#5^-_\ Y24 >&T5[E_PS#^TK_T;W\;O_#5^-_\ Y24?
M\,P_M*_]&]_&[_PU?C?_ .4E 'AM%>Y?\,P_M*_]&]_&[_PU?C?_ .4E'_#,
M/[2O_1O?QN_\-7XW_P#E)0!X;17N7_#,/[2O_1O?QN_\-7XW_P#E)1_PS#^T
MK_T;W\;O_#5^-_\ Y24 >&T5[E_PS#^TK_T;W\;O_#5^-_\ Y24?\,P_M*_]
M&]_&[_PU?C?_ .4E 'AM%>Y?\,P_M*_]&]_&[_PU?C?_ .4E'_#,/[2O_1O?
MQN_\-7XW_P#E)0!X;17N7_#,/[2O_1O?QN_\-7XW_P#E)1_PS#^TK_T;W\;O
M_#5^-_\ Y24 >&T5[E_PS#^TK_T;W\;O_#5^-_\ Y24?\,P_M*_]&]_&[_PU
M?C?_ .4E 'AM%>Y?\,P_M*_]&]_&[_PU?C?_ .4E'_#,/[2O_1O?QN_\-7XW
M_P#E)0!X;17N7_#,/[2O_1O?QN_\-7XW_P#E)1_PS#^TK_T;W\;O_#5^-_\
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M6/\ PPY]Y?\ 5-^?X>MO8_LSP:_Z23\&?_$SX3\O^JF\_P N^G]%U%?SH_\
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M^EX6R2IQ/G>6Y+3K/#5,QE4C&LJ,L0Z?L\-5Q+M1C.FZEU2<;*<;7YM4K/\
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MOCCC';/\^I_PWI\%.,_$+Q3WS_Q+O$W!/X'KW_SD_P"(!9A_T.Y_^&2MY?\
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M ,-':+_T7:W_ /#E2?\ RX_SV[4?\-':+_T7:W_\.5)[?]1CW_0UA_KUG/\
MT0?$?_A/BO\ YWGG_P#$5^&/^@_*O_#WEWE_T\\U_29_1117\Z__  T=HO\
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M-O FEV5AX"MS)\8K+P]X3N&UC3=?L;6/6=5\7PS2?9)+=-3N;E+:VMK(6JI
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MAF6]TB"/7IKHS0BVBTIKN2<RQB)7WKG]E/B'^V)\)/%%I^U>_C/XE_\ "S-
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MG[. [?\ ";^//T\/Z%_B?SKZ$_X(8_\ )@OAK_LIGQ+_ /3Q!7SU_P %^?\
MDGO[.'_8[^/?_4?T&N#P>_Y.%PK_ -?<7_ZJ<:?YS?M/O^1+]*3_ +*S%?\
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MHT.H>='!'_:-Y;$7;+;$>:R*WC!(&<GH,GZ#O7]-K07?@K7?VS_A3\!?AOX
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MZ/?_ "<3&?\ 9%9W_P"K[A(_@+]HA_R:?@[_ +.'A/\ UF^(SQJE )( !))
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M\$G5U@,Z:5/XF+:G]C%I*T-E:SQ2N(9$(4?$/(G-0G2S&E*I6I8?#JIAZ/\
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MP/\ !GQ.T.2(S1ZO\-_'6D^,/"?C"V,84NTUKI6K2:K9"+;)_:&G6FUAT/\
MH'E^;XK)/#GA3&X+!QS#%2RGA/"4<'*HZ3KRQT,OPCA":4K56JS5%27(ZO(I
MM0NS_'+B#A'*N-OI&^*F29UG,^'\LCQ7XK9MB\WA0CB8X&&25>(,U5:O1E.#
MEA(SPD7C'3;K1PJJRHQE54(O\A-2\,>)=&TK0=<UCP]KFE:)XJM[V[\,:QJ6
MDW]CI7B.UTZ[:PU"YT'4+JWBM-8M["^1[*]FT^:XCM;M6MIVCF4H,.OZ4;W]
MDGX=-X[_ &(O@'\39+;QQX-\"?!_]JSQ?X-LX9;ZZLOB796/CNX\5_#IFM=
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MLZB-)TN[U#SIXIC'>ZB?LL(MHKA_,#,Z)&K./VR^-O[-?P@3P_\ M@^$]?\
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M_P"#B"OGK_@OS_R3W]G#_L=_'O\ ZC^@U^&^#_\ R</A;_K]B_\ U58X_?\
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M3_\ G0?SJ?\ "AOB5_T 9?\ OI__ (S1_P *&^)7_0!E_P"^G_\ C-?T5_\
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M#_7\*/\ A$=#QC[%#T_YYKZ >G_U^G/%'_$R'%'_ $(LA^[,--O^HWU_ ?\
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M?P[4_;YM_P!#;%?^ 8;R_P"G'K_6R^H<+_\ 1)Y5_P"#LR\O^HWU_K;\4?\
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MP*L 0?\ 0V['(KY,.@Z.3DZ=:DGJ?)3)^IVU_!&5?24\0O#?^T^$\@622RK
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M/_A(>(O_ )6T?\*Z^(?_ $('CG_PD/$7_P K:1^@_P!K97_T,LO_ /"S#_\
MRSS7WG'45V/_  KKXA_]"!XY_P#"0\1?_*VC_A77Q#_Z$#QS_P"$AXB_^5M
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M/'/_ (2'B+_Y6T!_:V5_]#++_P#PLP__ ,L\U]YQU%=C_P *Z^(?_0@>.?\
MPD/$7_RMH_X5U\0_^A \<_\ A(>(O_E;0']K97_T,LO_ /"S#_\ RSS7WG'4
M5MZMX9\2Z#'%+KOASQ!H<4[F."76=$U/2XII ,E(I+^UMTD<#DHC,P'.,5B4
M'72K4:]-5:%6G6I2;4:E*<:E.33LTIP<HMIZ.ST>C/[6O^"&'_)@OAK_ +*9
M\2__ $\05]0?MO\ _(!^'_\ V&M:_P#3?:U\O_\ !##_ ),%\-?]E,^)?_IX
M@KZ@_;?_ .0#\/\ _L-:U_Z;[6OT?PP_Y+3AW_'B?_5;BS_F _:-[_24_P"R
MQQO_ *VN7'YVT445_9)_@D%%%% 'N?AK]G?XB^*_#FD^*]+/AJ/1]:C>2PDU
M#7XK*9A'-+;LLD+V[".020O\F]CMVL<9P+K_ +-?Q!C9D?5/ *LF0P/C&T!4
MCJ#_ */7V1^S]8)JOPR\%Q74K7-C8:0]S]@DYMQ>3:KJ"(70Y$BK$GFE#A6>
M1=P;;7?7'B/XAP>.X?#=K\(X;GP,US;HWQ#3QMX:MH;:R?3[6:>9O",ELNNM
M<P:C)<:>MI!NBE@M#?"[19H;9OYFSKQ<XJR_.,UP-"&5.C@\RQV%H^TP=:4_
M8X?$U*--SDL7%2FX03DU&*;;:45:W^EO!7T2?"WB#@_A3/L=B.*XXW.N&LBS
M;%QH9O@J=!8K,<KPF,Q"HPEE%64**JUIJG"4Y2C!I.<FKGYZG]G'QX,9U?X?
MC.<9\96?;K_R[TP_LZ^.5!)UKX>@+USXSL^/_)>OU9-O"W6)/3[B?_$_A49L
M[8]84_[Y7_"O,_XC1Q=_S[RC_P (:WE_U&^OW^A].OH9>$?7$\8_^'O >7_4
MD?G]_DC\IS^SSXU!P==^'8.,X/C2R''/_3O['CK3#^S[XQ')\0_#@ \9/C6R
M'//'_'OGMZ8]^17ZLG3[-NMO%_WR.3^7\L52OK*VMK.ZN8-)DU.>WMYIH=/M
M&LXKJ^E1&9+6WEO[FRL8YIV CC>\N[:V5F!FGC3<P7_$:.+_ /GWD_\ X0UO
M+_J-7G]_I8_XDR\(O^@GC'_P^8#R_P"I'Z_>?EB?@!XN!(/B3X;#'7/C>Q '
MXFW _7CO6Q)^R]\3X[%=2\[P;+926TMW!<0^*+>6*ZMXHS(\EM(EL8YQM!P4
M<@GC-?6?B7QC\;++0'U+0_V5D\5:A-<>&H8O"S?&CP#HFIBUU:34%\2W6HWN
MH6<N@0_\(K%;:>_V6SU/47UPZD$TYU^QSFM74+?_ (1'Q'>^';"W$>@^*O"N
MMZO'IC2>9'X=US3(;>6[?30/W4,&I6]V\5]%;A();FVBN44/)(S:T?&3BZI5
MIP<,HM*<(O\ V&LG9RBG_P QKZ-V\[^1SXOZ&_A)0PU>M#$\8<U*C5J+FSK
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M,[XAXHXFCDV GC7A<UK_ %CEK8:BJ7UC$5E1YI8BM1C:;I5$FFTN7WFKQO\
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MU6G3^W/)_?TZ?IE)\9OA;$,R>-='4>YNC_*V-9\GQZ^#L1Q)X_T-#Z,;P?\
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M>=?A[79/_F0V>O5/O\LY?3H\2HWMPCP.]+I>PX@O]G>V=O5WT6FY^_*_M)?
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M\)48-:_X2Y;1;P>)-9&E?V?Y1T\^&Q,AT%K8K_I?F'3S&=2_M("Z_M?^T/)
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M?[+M#M;@\ 9;G'*BO?&(+,5!"DDJ#C(!/ ..,@=<<>E>"_$/=_PGF@X"$?\
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M'3S/N_P#XSAEU./X?_ 7P_IMSJVCM.EYXCO]0CA\*^'GM!;R36ZM- +!KB*
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MY&1D X.>0#C(!'=_!3XS^!OV@/A]X-^*GPU\0:9XL\ >/=#76_#FNZ>D"^9
MR2B2.40_/::EIUY!-I^IV$Q$UE?6]S:7"+)$PK@OBV2?B7\-#D9-EXW)]_\
MBC;_ #^9[?A7H8&I"K5HS@VU[:$=59W4H/HWI:2ZGD9K3G2P>+A.U_JM=WBV
MUK1J:6:BTU;:WS/S"7H/H/Y4M(O0?0?RI:_T#/\  ".R]%^04444#"ONW]A_
M_D*?$7_KP\-_^E&LU\)5]V_L/_\ (4^(O_7AX;_]*-9KX/Q-_P"2&S[_ *]X
M'_U9X(_>/HR?\GRX#_[",\_]9C.CQ[]KK_DN&H_]@/P[_P"D;5_CH?&*WDG^
M-'Q92-E#M\4/'WE@N(][#Q7JWRJ[%4#$CY=S*3_#D@9_V+_VNQGXX:B/^H'X
M=[D?\N;=QS^5?Y;WQ ^('[,WQ!^*/Q.T?X]_!J[\&ZS!\0_'-DGQ)^%#P>%=
M5/D>*M6@CN]8T86VH>"]>=U0-<&[T70KNX;<SZSYLAG/\!>&F!AC>,?$*,L3
M2P\J>.H<BK\\:=3FQF873K1A.%)KE2C[2RDY:27*T_\ 4BAF-?+LVSRI2R_$
MX^G+$R]K]4E0EB*"C4J.,XX:M5I3Q,'S24XX=SK0Y5RTI\ZY?A[X>>*]7TZ_
M72;[4;K2[MS$OF3L8'E"C]R+D3[(;A4S^Y><K*B\PW4:XS^FWPB^+U[HVE1>
M"/B3ID&O^"M33:D=QEK.*6< )J&F7 C>31=2!*LLT&()V4F2*Z21Y#Y7-^QG
MX:\4Z6NI_ SXT>!OC'X?9#+:^$/$ES;?#WXCV2G<PM["PUO49?#>K7H)"QV_
MA+QK>7-Q.6QHQ9_+/.>$='^(_P ,]0G\,W6F2:Q96TGE:GX#\96\VG:]91!@
MK_V=-?0Q7$;* #$2@@G8)B&Y&,_U'P]0QN7SA"<7.,DDG"4:T7!V2A4IIM5J
M<E\-2E+F35W"R=OB^*Y95GE"3A#EJ0ES*G5IU<!B:%5)<M2E5JTZ57!UXZ<M
M/%1ITV[*-96N?:$GPET]=1L=?\(WW]J6<SQ1Z;>-%$+G84/EZ'KMKF5"Z1-)
M%97)\RWFMFDMXV>RDD@M?TT\.>$?!?["/@_2[6T.GV'[07Q(TVUU?5+C5(HI
M6^#GAW7[42V?A72&#27=KJE[#=&\UB[BDAU2WL;M/#,,Z1VU]-=?+W["S^%X
M?B#?_$/4$OKGP3\*O#E_X^\1> -<MV6_FU33;BSM?#6@3)+N273[[Q3>Z6;B
M>,R1K813@+:W$D42>5?M#?'B]^(7BW6O&FL6]UJVH:MXKBNM2DAFF\]H;@W5
MQ+;F%2(IG\U@$B9ML&TQK%*R_+Z7$..P=&OA<'AX*DYIUL5;6"YFE",)6<^5
MJ+E43UTA%I[+Y[A;*<;B:>+Q>+KSQ5"CR8?"N5H5:DH14Y.O!I)3I.4/8RC>
M#E5J3IZ.+?Z4^"/VE?!/P6U3PEKWQ2DT[XKZ3;S7=]IGB^=,^*_ FJW%N19Z
M%HT]G=R_VQX/U;4R]D\VHM)KGA_[490+VQ\]J]T\*_%N7P)\8OB!X!\77)TG
MX/?&+PYHOQ$TGX?>"+V:V\,6'B-9RGB31[Z_.G3-I-U!8WMA<:I;>'HDCOIY
M;JY$JDR[OQ\^%NF6_P :-%UG2_%OAF32CH82]B&NWNK:)H6N2BXA_LB;PYK%
MK;/-#JD4$.397D;6DQ)PT9E\M6?$CQ7\=?!'Q+L#I6AZUXF-O:0-IJQ6^H^*
M0T%S;RV[K"\*$AYK8R&=7M&VQ)&H0 EF]V>*RK+LM6*Q->$*-6.'C)\TG*C6
MC*492E&5DH72=U*^E]4B,GX+SGB3/:N6X+ XZIC*5+%2E"6'G*CBJ*E1K4_8
M5J<9I3BIMMQA;EE;2<JC?[M?"B^_LSQ5^UCX;^#+:98:CXA^%.CZI>>'+_7]
M3\<:8--\.W-TFK:?IVJWD]S?"632/$=M<3(^Q["ZL;F*%$$6P=A)\%_BMX7^
M$O[//PU\+M+XM+6>M:YK_A_3-5TJ32];UC7?$,VOZQ'=M+A8K,6.I/:ZK>:G
M+&&MHYE?RTMWS\/_ +)W@[XO>)?%7B?XO^(U_P"%7:!XIT"Z\.^(!XIL-8T/
M2+VPU"VA,5MIT-I =0U*^#PI+#IVGPNT^Y!,A@8FOVP_9:^'_A/4_#'B'PQX
M<O\ XB_$K5KHM>6UK;^!=3\+Z:+831"2TC\0:K<K</IR.L37,(MX/M,4;_NR
MID5OP'Q#XSR_)8XV.)S+ TZ]7!5<1ELJN)P^'QN-JT:TITHT,/-UJ\X3I1B\
M/RT,3).T8QDK*7^A7A;X/T,FRNEG^:85Q^JQP5.METL)B,;AL/*OEU/!5YXS
M&2Y*>$E0K5:U?$_6,1A742BU*GI5A\@_M)Z#XU\*IXABLVLH]9\=P6]A;67A
M?49M0T?PGHZ6XCC\/Z9J"VUG8RI:Q$PE+$MI,#Y*3Y2,CY,\0?LA:[\1OV?_
M  7XC\5>&[#1?$UKXLO?"?PVOA:+_;?BO2[P/>W/B"0)%/<WWAS0[Y6TR*6]
MD_X^)9YM&DDDM[QG_J:L_#?@7PC\+K>;QA\/[>]U32!++!J_BS2I=1T?0EVQ
MF:"RL[BT9[YD$:>3#%:$33A?+AV 25^=?CWXK:/XEUKQ)K6D:#XXU$66D0VV
MH:IJ^CO'=/:V5\IMK;PYI\4>[0-/PXBC2VF-R8%(E^SQ9BK^3?#?Q8SOCGB/
M,<'CHXV.'Q.'?LLJIX'&PIY?32M_PH8_'4:/+BITJ49T\/@Z*;C4C4E*#;@O
MU3$1RRAP_##95P_2PN'R?,&\?G=2=*4LQ=-.C2IX2%%*-*BZ=9QY<37G*-I<
MT9JI]8C^ _@K]GCQ1\-->U6V\4-<R>+;&9XH]+T^:TEN--L(Y90UYJ>MPO-8
M>%-*N)%27S(9+C6K_#8MH"5W\SXO-W;7$":+86.MZ^)C%;:IJ%M)/X5\.N07
M2;1-$NQ;QZE=%G4)K&N3+&UQNF@@<8C'Z;_M,Z?XBO\ X>Q>)=&\)2^']"T7
M5H=-EN[?33::9J-EKD<M]9_:3,]E!?:I!(IC$U_>731.TNV *0#^1/CG4-8D
M^UW%M?7"O;ZA-:7HT69(VMI'5I+93?G_ (E^FN4BD6)=)LU8,L@ENG7<']?/
M^ Y8G-YU:M"E2RZC!8F7LXRQ>=X^*BO]FA7K4JE#+Z<IRDG!4I1G%2=2E5]I
MS'=D_'?!F(P\I8IPJ5&_8K)<!46$PKKQO3A5S'%J<*V,YN6,U@L+)0C&7++$
M.JDW\W?&K2?!_AW4)]5^+_B/5O%OC*Z06LNCR23ZEJNZ,R2G3T@@6UO+6U#E
MU-E:KX:TX +'<7E[&K$_G;X[^)VG7.HQ:?HFBZ3I5M;29TW3)Q:Z]J5KEMJF
MT\.:8EMX2T"4C)>:^,^IEB3)>3RJS-]?^-?#^JZW#=:>+/[!IDD\USJ4.GZ=
M)J>KWLCQ+'+_ &CX@E:Y:7SAO+P?;-@+$QB-MN/,M(^!FMRQ^5X+^'7B&8SL
MR+?/IRVT<YDYF"WFL#2]/FWHJF2-;N[D(7*KG+-]_D'B%@<APD<JAA\)PWAJ
M"5/ZKA94\7F=5))QEB<76G##X><FDW1A5JJE?W)045%?"\?YCQ)F^%C_ &53
MP>595).G0<_8Y/EB@W%-4</5C'%XZI'EC4A5K8/$8OVEG3Q<YI2?S6/&'Q0>
MVO;C1]4M?!PN+:9+W7I)K:UULP;&5HY-;ND^V6D77-M8L( "T8O$V[1_I#>!
MRQ\#^!R\GG.?!?A(O-NW^<Y\/::7EWGE_-8E]YY?=N/)K^">+]A[XF^*(KC4
M?$*>&O#&DVUI<7<][XGO;J_%G9Q M-)'"[Z'I*K&OS>1_;AV ?<D4@'^][PA
M MKX0\(6J2)*MMX3\,VRRQ@".58-#L(EEC 9@(Y%0/&%=U", '888_%^*?$&
M#S[#9#5PD8Q=*KF3J*6(5?$OVD, XSK<JY8J7+)P<9S4O>::V/XLX]IXFEC,
M/'%9I5S6NY5YU<1+#XR%#G:HIJEBL:U5QD[*/M:G)#E2I[IH_9G]D;_DB.@?
M]A3Q#_Z=KBOIBOF?]D;_ )(CH'_84\0_^G:XKZ8K]6X5_P"29R#_ +%&7_\
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M?0Y1=:GJ'C/6K>TU,0Z1:VMRL.FQ:6EO->G6IX+V.5-*.CK9M_:UO(/6=?\
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MJNN:H;14+W6J&;6-2N+2VEN6GD:UM8(5^0)%'N"FOQ&^,GQ=\.?$;Q/+/>>
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M#7A'7]>OO$5I?R67A*[\5_%1;]#J=QX4UZW\2ZB&U"TLS>&QG\*ZA;>(KO\
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M#\HEZ#Z#^5+2+T'T'\J6O[]/\!H[+T7Y!1110,*^[?V'_P#D*?$7_KP\-_\
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ML](FOKFTT*W2'Q9J\<4=OH6G-#%,5CC13)+':NQ4;IB1@_ZUW[77_)<-1_[
M?AW_ -(VK_(L\2>%?B%\2/CS\4_#'P^TB\GGN?BKX^C==,4Q%5E\8ZOE[_5"
MH6V3+A=J.AD&T)#(S*M?P!X;5:L.,^/Z=*59NKF&'7LJ*E*564<7F'*G%-1?
M*Y.W,FU=V6Z?^H]&EA7F6?XC$_5J<<-B)2^LXEPA'#1G.KSR51KFI\_*D^64
M5+E2D]%:M)K=W8V_V/5M:M]%@8+NT?3MOVDC&%%Q:6)"0*!DXO)9)P<X&"S5
M^N7_  2PMO$OAWXB:WXXD\'W^A?"O4O OB#PMXI^*GB-GTG3_#=CJ_V.X36+
M0O);P_V:]QIL6GZK<&65IM+O+Z"VEFN62VD^=-#^"?[,?[&NG6OBW]J'64^)
M7Q5:&._T'X%^%KB&>_-T%$]I+XJFF^T6^@:;Y@42W>NI/=RJ6-AX?W[)5Z*T
M^(?[17[;LI6\;3/@]^SIX3>.].A:"EQHOP_\*Z?&WDV]Q.X!O_%?B*= +:VO
M]1;4]:U&Z+6NC06D1DMH_P"C<)"\WAL7*=7$5(<CP6'J*K.C%VN\76ES4Z'*
MG=PA%R=N63C=H^;S#,)N@\7ET%ALLHU(N6<9A1EAZ.)E!QFHY9@8\F)QKG:U
M.K5ER._N>T=F?IGXS\"^#_'WB'7;CX8?&'X8ZU''9F1#IWQ#\.VE_J7[M//>
MW?7;RUDM8N0(T<P2C?(9Q^ZKRSPM^QCXE\7:SKNG^#[GPMX@OK.2.P>#2O$^
M@ZS>6VJI"]U=0W.GZ;JUU.)98$6X789D4YW^4S[(?SY\0?$_PGI%K>^!O@<)
M-)\*Z-/_ &?XI^*<L$-QX@UC4A\HTSPO$&>*[\273$I EK+<:?X;C?[0US<W
MT8OX_ICX<Z;9_!SX<:5KTT<>G_$?QM'<_P#"-61O&GN?"VAL8Y+W5KN]9Q->
MZO*QBGUS6)2'O-1>VT2U9+*WU&O1PF1X'$SE2IXJ\:49.MB?9QG%3NDJ=)J4
M'5_>)PYGR1G).,%)0J2CYV-XPS3 4H5ZV$Y:F*J1IX7!RYH5Y048RG6Q,>:<
M<+&-/][*G[]2%+EG5C!U:$:LGQ"_9>\4^%XO%>G^(;34K?6--LW6]MI?/MIX
M;J.Z5!+#9)&()OW12(EHPD@99(9""J5G_L_>$9O&'PK\=> KZW\W4-%UV273
MG?*SK#=Z3/<2;UD)(YT;>ZHJHDCAT7& /O+X=_%"^^*_@67PE\0;U_$'C+0/
M#YU'3O$VK/%=:M=^'+DR0II&I7,L4]Q>:EI=G]GU07=W&\ZV6H0I<*7M&->8
M_ G1K#1OBCI=O%&R67BJRUFYN$!*KY@T+Q)%:N0APSKY4^U0S MOX!)SLLK^
MHU*=2K:4*$FJCB]*B:2T=MFY6EK?XEK9)<F-X@>8Y5BITHN->454I2DG*--P
M=YV4O[L9.#M9^[)=#Q3X2_"*WTOQEX!L]7LI6A\::"VKZ:<LA'B'P?K$UK>6
M<7R,MM+=Q++:Q2NR&24P!E:-6-?M'KO[&&D?%[P+HGAFVC237]+T^36?@QXK
MB!$EUHFH,=4U?X8ZE=!HWFAM+]I-?\$&9S)83S:IHB20V\N+7Y)_:)\!CPI\
M$O /Q/T%1!>?#;XR^);4R1NT9@T_5[F>ZMBY0*[+#=:'?2*"X8F\'49!^X/V
M+OVG]*^(6@^*O!DEW%9>(?!#67Q T")L$MX4U>>-_$0MT4"25/!GBR6:^DBC
MS(?#^K:C$FV)!M^/Q.69?G+Q6-PE2AA\[X>SBI7RG'.$93P]6=+V%:C66]3!
M8G#U(RQ--SY9T<17C[DN6I'\_P ?Q)Q9E#P69Y?3Q6+R[,<#7P>=8"$I)5Z%
M/$-X>OA[74,?AIPIO"R49/VD$I\T)2C+\O#HGCCX">,&T/Q)8R>4+N=)[":-
MELM0\DB.XFL \8$&I1QD->6+P@7,4L<_D?,\2>\W'POU#QQX?;XJ_!+4]4NC
MIEJ\WB#2?#\GF>)_#<*EOM+VNERN!KNB(S;K[0KOS##&^^SF2&:,7'ZX_M<?
M WPC^T/\*&^+GAG30NL6"26/Q"TVQAAFU/0M:L6:UF\36"G*2W>G7DG_ !,2
M0L.HV=Y;ZCF.UUN::+^>;PW\4OBA^S%\8X[2WGFL=9@E@O(EM)I8M*\9:3O8
MVFIZ3*5^6[N+?S@T.SS_ +0+BTDB:Y6]L)^JMQG5ED5?'Y1;+<?@<14P^;9=
M457FP&:X:,57I5(TTZD:=:,8UJ57#KGJX6I0Q="-6,O95?T/PTQ7#?$.=/AS
MQ"P-'$4\QP<997GE)J"K8/%5'*ABXJ3E3K45*3IXFCB(U_J6)52$XN$JBA[I
MX!_;'^+'P2OXM,FU9[#3=6E>%9=-C35? 7B9XSY=S'J/@[6WCL8-4C&Y=3TG
M=HFOV?SBWN+51'%)Z3XW^+/P>^+>F-KFN>&4^'&NNQC/C;P(USJ'@.XU!N1'
MJ"21C4_!>HL^TG2?%=G /F<0:W<QA))/4_%'PZ^#/[;O@Z3Q;X"30_ /QJU.
M)%UGPG?11V/@CXJ:A' 9!93VD4D5MX=\=.0YTVZL&AAU65'ET.>WO$DTBV_)
MS7;_ .(_[-'BV\M/$>C>*'TS27>RU.*,QQ?$#PG9HS1R)-%/#-I?Q%\(JQ8-
M!J5E?%80T5Q$DL<MY7X=3^DO4S.KF658)T<=G&!C*69<.XBM1EC*V'7-"&/R
MV;G3P^9X2M)6IXC"U:5YQEAZM&&-C.B?<<4?12P?#^<8?%K#_5:5>49Y?GN!
ME/#TJU*5I4G4J0<W"W-[^&KNO0II2E2;B[1]C\6Z_P#%;X>6,FJZ7:VGQ2\$
MG-S+<Z3%#=7<-JOS)+=Z9.)[6[41X\FY\J52#F*X9<[N(L?VK&\<:=+H6C:I
M:R@1F&?P-XO<7NG[R #!%H/BQM4L;0EF*HNE76FHO^LMT5@ G?\ A3Q?X+\8
M:6/''PK\41>$]4!:YGU?P5:?VAX(U.9\,T'C7X:7L[W'A:[G?*W=QH<_]G3;
MGDB>('8WSY\8HO@QXQO(3\5_"5O\(_'\AC;3?BMX&D:X^'GB29C\MQJZVBVE
MQX?GG;AX]0L[&+=(RC4+G'G3_CS\<L7B\[KK#X+%25*I+VU#"4Z_]J8!Q:4X
MXG*:GL<7.-)-WAE\IU*2?M,3@'!*<OW[A7P'S;#X'#8?'57A)XR$/J.(Q_L8
MY-FJFKT?JV9N53*<1.M*\*=/$RHUJE2\:$Y3O"/E/Q,^'5IXUM;R\L?AQIFA
M^(G69H=-\/ZT-"N;QU7F33;#6G.DWGRL2MMI-PL[N%C:1RP(_O2\%QM%X+\&
M0NKH\7@_PM$Z2<2(\>@Z>CK( 2!(K*0X!(# X.*_@+\37/C#X?VTBSZNFM^'
MY83+!J23C6-'O;55;9<+*([A8PR;2&NK6>, LW]I(=HB_OU\&OYO@SP;+P?,
M\(>%I,C !WZ#I[9 !8 '/ #$ 8P2,&GQUQ;#BO+LAK0JJLJ%3,/WB5-_Q88%
M<LJD*=*4IQ]E[\*E*,J;M%N3;M^9^+O"&><'8K+<!G>&GA*KGC%"A4^MTY1<
M(X64G'#8FK5C1I2A4I^RE15*%:*YO9I*+E^S?[(W_)$= _["GB'_ -.UQ7TQ
M7S/^R-_R1'0/^PIXA_\ 3M<5],5^W\*_\DSD'_8HR_\ ]1:9>4?\BK+O^P+#
M?^F8!1117OGHA7XI>'[:6]\7:/9P3M:S77B.QMXKE "]O)-J<<:3("""T3,'
M7((RHR".*_:VOQ#M-2TW1M:AUC6;N6PT?2M374M5OH#.L]GIME=_:;VZA:V2
M6Y$L%M')+&;>.2<.H,2,^U3_ "/])M-\1>#:C>[X@S1*RN[O'<*)675WV778
M_H;P0<8Y%XG2FTH+),&YMR44HK!\0N3<GI%6O>3T2UZ'V]XC\6>#_!MO'I.I
M:DFHZG%:L]SI5A#=:[JUR/+997FLK;[3<P+.Y4"YO3 F#Y<;L&V5\?\ Q-^'
MGBCXW0Z;K'Q!L_$G_"/6UU>6^F^!M(@MO#8OK&WG1K63Q#J-S*SV%I.KA))8
MK._U&>,R"RM851F;)\5?MI_L]?#ZTE;P#H^M^+=1F)G*6&E-X?MYKA22)M;U
MS7(UU/4+EGR[2O:7SJ/F4!PNW\Y_BU^W5\?O&5[?+H/B0?#K19BXBTSPG'$E
M\(QT-UX@O8)M3N)F&#)+;?8$SDI!$HVU_?669)F4JG/1P[H2=_\ :,:_9M+2
M\:=*$7.+:U<GIM9K=?Y_YWQ1E,J:H5<53KTHV<<%E=JT.:-G"=>O+DISM96@
MN5-N[C-VM^D#_!OP;X6DLM5U;4M%\)Z-H.F2'1_!VDZ78Z=X>TR.YA,%U)-=
MZD]I#J,EW%)-#?ZC+:76IWJ-ONY6#E4^"/'G[4'P;^ ^J>(=3CUBU^(GB2_M
MKFQL/#'@K6-.O[2*'>DL=AJ&IZ<D>BZ!I0N DEYYR:AJMT(E5=/F5%Q^8?CO
M6=?\7ZA<:IXIUG5_$VI7#L\FH>(-0O-7O&<G.XSZA+<.F"S?*A55S@  8'BN
MJV!^<A< Y'"X'?&,8!QSGCOGGH?KL+PZTHO%XV5:+:<Z-*FJ<%:SY5.3E-QW
M;NE*3WDD]?C:_%$*LDL%E\:$ES.->O6E6J*Z2YG3BHTU*RTBI<D-K.Q[/\3/
MV]?VG?&D]Y#8_$?4/A_X?D>5;+PQ\.H;;PO9Z?9LQ\NT.J6,":_>LJ[1-=7.
MIF6X9=Y2(;8E\!U7]JC]I6\CMXKG]H#XT21VNQH$7XE>+H40Q;51F$&J1&5T
M$:!6G:1B$ 8D "N8O]-)W$#GOP3Z'L../PZ_6N*O=,8Y^4@XQC!]6'8=_P#@
M0]QS7O0P6"II1AA</%=/W5-M^K:;;\VVVV[MGGPS''593<\9B6W9O]]42T[1
M4N56=FDEIWT1]4^"_P#@I#^UWX)5H1\2+?QE'YZ7 ;Q]X<TCQ)>H4D21T751
M#8:LJ7!5?/)OFD<C>)(Y?WAU?C/_ ,%'?VJ?C]X7/@&ZU[0OA[X1NX'M]:T;
MX6Z/<>&;GQ%#,"+BVUSQ!-J&I>(;C3KC<PN-+M-3L["YC=H[N"YC.P_$;:4=
MQRI]NI^GJ,_7_"O0/!&A1RWP,BY^8=0<#E>,GCG&>!UXQP*S65Y<JL*_U'#.
MK"7-&?LHW4M/>22Y>96TDXMKN=[S?,(T)TOKN(]G-6G!U)-R752DWSN'62YN
M625FNAP2_#^]FC$RQ.%"!0JJ0JJ,<8"C '8#C&/6HX/#;V\HCEB.Y&^7<F<$
M=1R.1W))R",YR,5]VV?AZS33PHB3(7@@'C('<=S],YKR36_#T*ZB=J[1ELD+
MGGM@8ZYZ<Y .<<U]#A9\WNV5K72MM;LO)J^FE^AYT,4YMQ:LM+>::6]]UI?T
MOO>QY+IFB*@4"-54#'RKM&."< ,!UY/0G/8FO0]-T=@5PAR<=1G'!]QUZYXY
M[< C?L-&"[01GISCGL3V ZCID=>N1QWFEZ)N*D GTR,Y)S@#CT/&3_.NN?PM
MOHM+^;6WY_UKJZR@W=W;>N[U[_H[>12T32]I4%!U(.1].<YSV]>YR:]3TO3,
M%"5Z@#./NGGKR?49R3_@_2M"PRC80022"#QC'3CC/;KVZ5Z'I^E8"\$]!C!P
M!C(XP#ST.<DC@<Y->1B(J,[JVM]%OIU?JFC-5%*5UM>R6UK^7]>N@W3[$X7
M(XST/.#SWQGVQS7?:39-\H"DYX[\G(('7D<8R,=,^U.T_3$$0&"#U'7)YS@#
MCCTS^6*[_1--&4.UOO#CGWP,XR!GKCMT.:\ZI&WRLHV6ZT_'TV->=P_1=&FE
M\OR9ZG\(+%D\5:3*00%:X.".?^/2?OP>#W[^]?U$^$O^15\,_P#8OZ-_Z;K:
MOYM?AK8"WU>QD*$?++@]B3!)\W3.?T //M_25X2_Y%7PS_V+^C?^FZVK^9>+
M_P#D\^9_]FSX5_\ 6HXT_K\3^H?#J2GX3X=K_HX/$*T_[)SA+_/Y'\2/_!5
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M[3I*PW5J2T4L:N4=F5D!+G&]05/0] %Z#"D5^"G[.?[;7A+]FWX?#X>_LR_
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MS19)?AKXI47<4,D-D+A";#$KW%K;7]Y*Z [KC4II#@S;C5^"G[._[<.C>/O
M[:U^R_\ M!VVG6WCVTU26[NOAGXJCBT^"]34H+V2::2P4):A[KS7+G;'O8Y
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MM":]X?N83;7.DZK\*/%>I6%S8D$?9+JRN=+EBN( "=L$P$MNWSV,]K+B6O\
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M_P"F8!1117OGHA7X5:Q8V^IPZMIMXC/::BE_8W2*[1L]O=>;!,BR(0Z,T;L
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MPT_^::C_ (E(\/\ _H?\9?\ A9D?E_U(?)_?Y!_Q,1Q?_P!"?AG_ ,)LU_\
MGOZ_TM?B3_AG;XS_ /0CW7_@W\.__+BC_AG;XS_]"/=?^#?P[_\ +BOMO_AL
M']DG_HZ3]G3_ ,/;\-/_ )IJ/^&P?V2?^CI/V=/_  ]OPT_^::C_ (E(\/\
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M([_HX-/_ ,1'@C_Z'#\"O^(<[5?^CNM/_P##&W/_ ,]JC_B'.U7_ *.ZT_\
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M*_\ Y>5!_P -@_LD_P#1TG[.G_A[?AI_\TU'_#8/[)/_ $=)^SI_X>WX:?\
MS34?ZL\.?]"#)?\ PV8+_P"4>2^X/[*RS_H78'_PDH>7_3OR1/\ \,K_  (_
MZ$?_ ,N/Q7_\O*/^&5_@1_T(_P#Y<?BO_P"7E0?\-@_LD_\ 1TG[.G_A[?AI
M_P#--1_PV#^R3_T=)^SI_P"'M^&G_P TU'^K/#G_ $(,E_\ #9@O_E'DON#^
MRLL_Z%V!_P#"2AY?]._)$_\ PRO\"/\ H1__ "X_%?\ \O*/^&5_@1_T(_\
MY<?BO_Y>5!_PV#^R3_T=)^SI_P"'M^&G_P TU'_#8/[)/_1TG[.G_A[?AI_\
MTU'^K/#G_0@R7_PV8+_Y1Y+[@_LK+/\ H78'_P )*'E_T[\D3_\ #*_P(_Z$
M?_RX_%?_ ,O*/^&5_@1_T(__ )<?BO\ ^7E0?\-@_LD_]'2?LZ?^'M^&G_S3
M4?\ #8/[)/\ T=)^SI_X>WX:?_--1_JSPY_T(,E_\-F"_P#E'DON#^RLL_Z%
MV!_\)*'E_P!._)$__#*_P(_Z$?\ \N/Q7_\ +RC_ (97^!'_ $(__EQ^*_\
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M_LS_ /1=/C?_ -^O!'_S/4 ?QW>3%_SRC_[X7_"CR8O^>4?_ 'PO^%?V(_\
M$./^S/\ ]%T^-_\ WZ\$?_,]1_Q#C_LS_P#1=/C?_P!^O!'_ ,SU '\=WDQ?
M\\H_^^%_PH\F+_GE'_WPO^%?V(_\0X_[,_\ T73XW_\ ?KP1_P#,]1_Q#C_L
MS_\ 1=/C?_WZ\$?_ #/4 ?QW>3%_SRC_ .^%_P */)B_YY1_]\+_ (5_8C_Q
M#C_LS_\ 1=/C?_WZ\$?_ #/4?\0X_P"S/_T73XW_ /?KP1_\SU '\=WDQ?\
M/*/_ +X7_"CR8O\ GE'_ -\+_A7]B/\ Q#C_ +,__1=/C?\ ]^O!'_S/4?\
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M'_S/4?\ $./^S/\ ]%T^-_\ WZ\$?_,]0!_'=Y,7_/*/_OA?\*/)B_YY1_\
M?"_X5_8C_P 0X_[,_P#T73XW_P#?KP1_\SU'_$./^S/_ -%T^-__ 'Z\$?\
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MO!'_ ,SU '\=WDQ?\\H_^^%_PH\F+_GE'_WPO^%?V(_\0X_[,_\ T73XW_\
M?KP1_P#,]1_Q#C_LS_\ 1=/C?_WZ\$?_ #/4 ?QW>3%_SRC_ .^%_P */)B_
MYY1_]\+_ (5_8C_Q#C_LS_\ 1=/C?_WZ\$?_ #/4?\0X_P"S/_T73XW_ /?K
MP1_\SU '\=WDQ?\ /*/_ +X7_"CR8O\ GE'_ -\+_A7]B/\ Q#C_ +,__1=/
MC?\ ]^O!'_S/4?\ $./^S/\ ]%T^-_\ WZ\$?_,]0!_'=Y,7_/*/_OA?\*/)
MB_YY1_\ ?"_X5_8C_P 0X_[,_P#T73XW_P#?KP1_\SU'_$./^S/_ -%T^-__
M 'Z\$?\ S/4 ?QW>3%_SRC_[X7_"CR8O^>4?_?"_X5_8C_Q#C_LS_P#1=/C?
M_P!^O!'_ ,SU'_$./^S/_P!%T^-__?KP1_\ ,]0!_'=Y,7_/*/\ [X7_  H\
MF+_GE'_WPO\ A7]B/_$./^S/_P!%T^-__?KP1_\ ,]1_Q#C_ +,__1=/C?\
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HK^RU"*-X_!.R22QNHKJ-'V^'PVQWB"OM(;:3@@X- ']"]%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034830371856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001719406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NRX Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2844431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1201 Orange Street, Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">254-6134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,915,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Salberg & Company, P.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boca Raton, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase one share of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRXPW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRXP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034835025952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="nump">$ 4,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,302<span></span>
</td>
<td class="nump">6,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">7,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">10,149<span></span>
</td>
<td class="nump">4,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_AccruedClinicalSiteCostsCurrent', window );">Accrued clinical site costs</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable and accrued interest &#8211; short term</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Insurance loan payable</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">5,639<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,863<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note payable and accrued interest &#8211; long term</a></td>
<td class="nump">5,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,874<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000,000 shares authorized; 14,591,505 and 8,391,956 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">255,035<span></span>
</td>
<td class="nump">241,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(278,273)<span></span>
</td>
<td class="num">(253,147)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(23,223)<span></span>
</td>
<td class="num">(11,733)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">7,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_NondesignatedPreferredStockMember', window );">Nondesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_AccruedClinicalSiteCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued clinical site costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_AccruedClinicalSiteCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced within one operating cycle, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_NondesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_NondesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828279488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">14,591,505<span></span>
</td>
<td class="nump">8,391,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">14,591,505<span></span>
</td>
<td class="nump">8,391,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_NondesignatedPreferredStockMember', window );">Nondesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_NondesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_NondesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034835041584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,199<span></span>
</td>
<td class="nump">$ 13,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,505<span></span>
</td>
<td class="nump">14,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement (income) expense</a></td>
<td class="num">(1,202)<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,502<span></span>
</td>
<td class="nump">27,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,502)<span></span>
</td>
<td class="num">(27,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Convertible note default penalty</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Change in fair value of convertible note payable</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Loss on convertible note redemptions</a></td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">6,624<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,126)<span></span>
</td>
<td class="num">(30,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount', window );">Deemed dividend - warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(25,126)<span></span>
</td>
<td class="num">(30,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,126)<span></span>
</td>
<td class="num">(30,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax', window );">Change in fair value of convertible note attributed to credit risk</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (25,126)<span></span>
</td>
<td class="num">$ (30,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (3.98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted (in shares)</a></td>
<td class="nump">10,644,461<span></span>
</td>
<td class="nump">7,576,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_FairValueAdjustmentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value adjustment of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_FairValueAdjustmentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_GainLossOnConvertibleDebtRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on convertible debt redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_GainLossOnConvertibleDebtRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTerminationForDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the loss on termination of a contract for default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482291/912-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482269/912-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTerminationForDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) from increase (decrease) in instrument-specific credit risk, realized upon derecognition of financial liability measured under fair value option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)(4)<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-12B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034820330928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock and Warrant Issuance [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
<th class="th">
<div>Common Stock and Warrant Issuance [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Common Stock and Warrant Issuance [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Common Stock and Warrant Issuance [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Common Stock and Warrant Issuance [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th"><div>Common Stock and Warrant Issuance [Member]</div></th>
<th class="th">
<div>ATM Offering [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
<th class="th">
<div>ATM Offering [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>ATM Offering [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>ATM Offering [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>ATM Offering [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th"><div>ATM Offering [Member]</div></th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th">
<div>Share Subscription Facility Agreement - GEM [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
<th class="th">
<div>Share Subscription Facility Agreement - GEM [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share Subscription Facility Agreement - GEM [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share Subscription Facility Agreement - GEM [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Share Subscription Facility Agreement - GEM [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th"><div>Share Subscription Facility Agreement - GEM [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,644,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 230,399<span></span>
</td>
<td class="num">$ (222,997)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuances, net (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,353,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuances, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8,121<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Preferred stock and warrants issued, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Preferred stock and warrants issued, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax', window );">Change in fair value of convertible note attributed to credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued as repayment of principal and interest for convertible note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">326,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Shares issued as repayment of principal and interest for convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost', window );">Adjustment for deferred offering cost settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">8,391,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">241,406<span></span>
</td>
<td class="num">(253,147)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuances, net (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,273,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">385,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuances, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3,256<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,257<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax', window );">Change in fair value of convertible note attributed to credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued as repayment of principal and interest for convertible note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,820,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Shares issued as repayment of principal and interest for convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">5,859<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,126)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Series A preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of shares related to reverse stock split (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_APICIncreaseForCostRecognitionContractTermination', window );">Contract cost related to Alvogen termination (see Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued in exchange for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt', window );">Reclassification of AOCI upon settlement of Streeterville Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,591,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 255,035<span></span>
</td>
<td class="num">$ (278,273)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (23,223)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_APICIncreaseForCostRecognitionContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contract costs related to the Alvogen termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_APICIncreaseForCostRecognitionContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of deferred offering cost settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification adjustments of other comprehensive income (loss) upon settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock and warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) from increase (decrease) in instrument-specific credit risk, realized upon derecognition of financial liability measured under fair value option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)(4)<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034820408288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_CommonStockAndWarrantIssuanceMember', window );">Common Stock and Warrant Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">$ 2,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember', window );">ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_CommonStockAndWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_CommonStockAndWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034820179680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,126)<span></span>
</td>
<td class="num">$ (30,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued in exchange for services</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Change in fair value of convertible note payable</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Loss on convertible note redemptions</a></td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtIssuanceCosts', window );">Expense for debt issuance costs due to fair value election on Anson Notes</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ContractCosts', window );">Warrant issuance costs related to Alvogen termination</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Convertible note default penalty</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_NoncashLitigationExpense', window );">Non-cash settlement expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increases (decreases) in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">3,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(5,217)<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">10,005<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,637)<span></span>
</td>
<td class="num">(21,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of computer equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible note</a></td>
<td class="num">(7,850)<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_RepaymentsOfInsuranceLoans', window );">Repayment of insurance loan</a></td>
<td class="num">(725)<span></span>
</td>
<td class="num">(943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Expense for debt issuance costs due to fair value election on Anson Notes</a></td>
<td class="num">(896)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ProceedsFromInsuranceLoans', window );">Proceeds from issuance of insurance loan</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Anson convertible notes, net of OID</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Proceeds from liability classified warrants</a></td>
<td class="nump">3,966<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">8,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,485<span></span>
</td>
<td class="nump">6,201<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,152)<span></span>
</td>
<td class="num">(15,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="nump">20,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">4,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_StockIssuedAsOfferingCosts', window );">Issuance of common stock warrants as offering costs</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for settlement of accrued liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember', window );">Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of common stock as principal and interest repayment for convertible notes</a></td>
<td class="nump">4,585<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember', window );">Conversion of Series A Preferred Stock to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series A preferred stock into common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ContractCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs related to the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ContractCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow related to the issuance of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_FairValueAdjustmentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value adjustment of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_FairValueAdjustmentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_GainLossOnConvertibleDebtRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on convertible debt redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_GainLossOnConvertibleDebtRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_NoncashLitigationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-cash litigation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_NoncashLitigationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ProceedsFromInsuranceLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from insurance loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ProceedsFromInsuranceLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds from issuance of common stock and warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_RepaymentsOfInsuranceLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The repayment of insurance loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_RepaymentsOfInsuranceLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_StockIssuedAsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_StockIssuedAsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTerminationForDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the loss on termination of a contract for default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482291/912-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482269/912-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTerminationForDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034939161744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="item9b" title="item9b"></a>Item <em style="font: inherit;">9B.</em> Other Information</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="-sec-ix-hidden:c125342638"><span style="-sec-ix-hidden:c125342736"><span style="-sec-ix-hidden:c125342737"><span style="-sec-ix-hidden:c125342738">None.</span></span></span></span></p>
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034817832432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="item1c" title="item1c"></a>Item <em style="font: inherit;">1C.</em> Cybersecurity </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   The Company maintains a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The underlying processes and controls of NRx&#8217;s cyber risk management program incorporate recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework (&#8220;CSF&#8221;). NRx has an annual assessment performed by a third-party specialist of the Company&#8217;s cyber risk management program against the NIST CSF. The annual risk assessment identifies, quantifies, and categorizes material cyber risks. In addition, the Company, in conjunction with the third-party cyber risk management specialists develop a risk mitigation plan to address such risks and, where necessary, remediate potential vulnerabilities identified through the annual assessment process.
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">In addition, NRx maintains policies over areas such as access and account management to help govern the processes put in place by management designed to protect NRx&#8217;s IT assets, data, and services from threats and vulnerabilities. NRx employs additional key practices within the cybersecurity risk management program including, but <em style="font: inherit;">not</em> limited to maintenance of an IT assets inventory, identity access management controls including restricted access of privileged accounts, and critical data backups to reduce cybersecurity risk. &#160; &#160; &#160; &#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">Cybersecurity partners to the Company, including consultants, are a key part of NRx&#8217;s cybersecurity risk management strategy and infrastructure. The cybersecurity partners provide services including, but <em style="font: inherit;">not</em> limited to cybersecurity strategy, cyber risk advisory, assessment, and remediation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">NRx&#8217;s management team, in conjunction with cybersecurity service providers are responsible for oversight and administration of NRx&#8217;s cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. The Company&#8217;s management team has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes via engagement of strategic third-party partners. The Company also relies on threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by NRx for strategic cyber risk management, advisory and decision making.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Audit Committee of the Board of Directors oversees NRx&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx&#8217;s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   NRx faces risks from cybersecurity threats that could have a material adverse effect on its business, financial condition, results of operations, cash flows or reputation. NRx acknowledges that the risk of cyber incident is prevalent in the current threat landscape and that a future cyber incident may occur in the normal course of its business. However, prior cybersecurity incidents have not had a material adverse effect on NRx&#8217;s business, financial condition, results of operations, or cash flows. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, investors, and additional stakeholders, which could subject the Company to additional liability and reputational harm. In response to such risks, the Company has implemented initiatives such as a cybersecurity risk assessment process and development of an incident response plan. See Item 1A. "Risk Factors" for more information on cybersecurity risks.
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The Company maintains a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The underlying processes and controls of NRx&#8217;s cyber risk management program incorporate recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework (&#8220;CSF&#8221;). NRx has an annual assessment performed by a third-party specialist of the Company&#8217;s cyber risk management program against the NIST CSF. The annual risk assessment identifies, quantifies, and categorizes material cyber risks. In addition, the Company, in conjunction with the third-party cyber risk management specialists develop a risk mitigation plan to address such risks and, where necessary, remediate potential vulnerabilities identified through the annual assessment process.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">NRx faces risks from cybersecurity threats that could have a material adverse effect on its business, financial condition, results of operations, cash flows or reputation. NRx acknowledges that the risk of cyber incident is prevalent in the current threat landscape and that a future cyber incident may occur in the normal course of its business. However, prior cybersecurity incidents have not had a material adverse effect on NRx&#8217;s business, financial condition, results of operations, or cash flows. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, investors, and additional stakeholders, which could subject the Company to additional liability and reputational harm. In response to such risks, the Company has implemented initiatives such as a cybersecurity risk assessment process and development of an incident response plan. See Item 1A. "Risk Factors" for more information on cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee of the Board of Directors oversees NRx&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx&#8217;s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">NRx&#8217;s management team, in conjunction with cybersecurity service providers are responsible for oversight and administration of NRx&#8217;s cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. The Company&#8217;s management team has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes via engagement of strategic third-party partners. The Company also relies on threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by NRx for strategic cyber risk management, advisory and decision making.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828354704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a href="#" id="notes" title="notes"></a><em style="font: inherit;">1.</em> Organization</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Business</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRX&#8221; or the &#8220;Company&#8221;) is a clinical-stage bio-pharmaceutical company which develops and intends to distribute, through its wholly-owned operating subsidiaries, NeuroRx, Inc., (&#8220;NeuroRx&#8221;) and HOPE Therapeutics, Inc. (&#8220;HOPE&#8221;), and collectively with NRX and NeuroRx, the (&#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#8220;PTSD&#8221;) and now schizophrenia. All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate (&#8220;NMDA&#8221;) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. NeuroRx is organized as a traditional research and development (&#8220;R&amp;D&#8221;) company, whereas HOPE is organized as a specialty pharmaceutical company intended to distribute ketamine and other therapeutic options to clinics that serve patients with suicidal depression and PTSD.&#160;The Company has <em style="font: inherit;">two</em> lead drug candidates that are expected to be submitted by year end for Food and&#160;Drug Administration (&#8220;FDA&#8221;)&#160;approval with anticipated FDA decision dates under the Prescription Drug User Fee Act ("PDUFA") by the end of <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">2025:</em> NRX-<em style="font: inherit;">101,</em> an oral fixed dose combination of D-cycloserine and lurasidone and NRX-<em style="font: inherit;">100,</em> a preservative-free formulation of ketamine for intravenous infusion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operations</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s drug development activities have expanded from its original focus on development of NRX-<em style="font: inherit;">101,</em> a fixed dose combination of D-cycloserine (&#8220;DCS&#8221;) and lurasidone for the treatment of suicidal bipolar depression to encompass the development of NRX-<em style="font: inherit;">101</em> for the treatment of chronic pain and PTSD and to the development of intravenous ketamine (NRX-<em style="font: inherit;">100/HTX</em>-<em style="font: inherit;">100</em>) for the treatment of suicidal depression. These additional indications have been added as the Company has gained access to clinical trials data funded by governmental entities in France and potentially in the United States which has the potential to afford the Company potential safety and efficacy data on key indications at low cost.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45035024404576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em> Going Concern</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal&#160;year and has a working capital deficit at <em style="font: inherit;"> December 31, 2024. </em>The Company has no revenues and expects to continue to incur operating losses into <em style="font: inherit;">2025.</em> Although the Company projects operating revenue&#160;to be derived from the operation of clinical facilities through its HOPE subsidiary and sales of its pharmaceutical products in <em style="font: inherit;">2025,</em> these projections are subject to completion of anticipated clinical acquisitions in the <em style="font: inherit;">first</em> case and regulatory approvals in the latter case. In the absence of these projected developments, the Company&#8217;s ability to support its ongoing capital needs is dependent on its ability to continue to raise equity and/or debt financing, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be available on favorable terms, or at all, in order to continue operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the Company had $1.4 million in cash and cash equivalents. On <em style="font: inherit;"> August 12, 2024, </em>the Company entered into that certain Securities Purchase Agreement dated <em style="font: inherit;"> August 12, 2024 (</em>the &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to sell Senior Secured Convertible Promissory Notes (the &#8220;Anson&#160;Notes&#8221;) in the aggregate principal amount of up to approximately $16.3 million in three tranches of $5.435 million, and warrants to purchase that amount of shares of the Company&#8217;s common stock, $0.001 par value (&#8220;Common Stock&#8221;) equal to <em style="font: inherit;">50%</em> of the principal amount of the Notes in the respective tranche divided by the volume weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Purchase Agreement (the &#8220;Anson&#160;Warrants&#8221;).&#160; The Company consummated the sale of the <em style="font: inherit;">first</em> tranche of $5.435 million ($4.5&#160;million in net proceeds)&#160;in Notes and Warrants (the &#8220;First Closing&#8221;) on <em style="font: inherit;"> August 14, 2024 (</em>the &#8220;First Closing Date&#8221;), and the <em style="font: inherit;">second</em> tranche of $5.435&#160;million in Notes and Warrants (the &#8220;Second Closing&#8221;) on <em style="font: inherit;"> October 10, 2024 (</em>the &#8220;Second Closing Date&#8221;), for aggregate gross proceeds of approximately $10.87 million, before deducting fees, costs, and other expenses including the use of proceeds to repay $5.55 million of the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has&#160;secured operating capital that it anticipates as sufficient to fund its drug development operations through [&#9679;] and to finance submission of FDA New Drug Applications for NRX-<em style="font: inherit;">100</em> and NRX-<em style="font: inherit;">101.</em> The Company <em style="font: inherit;"> may </em>pursue additional equity or debt financing or refinancing opportunities in <em style="font: inherit;">2025</em> and <em style="font: inherit;">2026</em> to fund ongoing clinical activities, to meet obligations under its current debt arrangements and for general corporate purposes. Such arrangements <em style="font: inherit;"> may </em>take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures or other agreements. The sale of equity could result in additional dilution to the Company&#8217;s existing shareholders. The Company cannot make any assurances that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company&#8217;s business and operations and could also lead to a reduction in the Company&#8217;s operations. The Company will continue to carefully monitor the impact of its continuing operations on the Company&#8217;s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company&#8217;s ability to continue as a going concern for a period of at least <em style="font: inherit;">twelve</em> months from the date of issuance of these consolidated financial statements. The accompanying consolidated financial statements do <em style="font: inherit;">not</em> include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the company be unable to continue as a going concern.&#160;</p>
   <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828610800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em> Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Presentation and Principles of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of NRX Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the fair value of convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results <em style="font: inherit;"> may </em>differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain Risks and Uncertainties</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on <em style="font: inherit;">third</em> party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ASC <em style="font: inherit;">820,</em> <i>Fair Value Measurements</i>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accounting guidance classifies fair value measurements in <em style="font: inherit;">one</em> of the following <em style="font: inherit;">three</em> categories for disclosure purposes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">1:</em> Quoted prices in active markets for identical assets or liabilities.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">2:</em> Inputs other than Level <em style="font: inherit;">1</em> prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3:</em> Unobservable inputs which are supported by little or <em style="font: inherit;">no</em> market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note <em style="font: inherit;">11</em>)</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are <em style="font: inherit;">not</em> exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, exceed federally insured limits. As of <em style="font: inherit;"> December 31, 2024 </em>the Company&#8217;s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $1.2 million. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. &#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company considers all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less at the time of initial purchase to be cash equivalents, including balances held in the Company&#8217;s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time <em style="font: inherit;"> may </em>exceed the U.S. federally insured limits. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company&#8217;s cash flow requirements, and to attain a market rate of return.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue Recognition</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for revenue under FASB ASC Topic <em style="font: inherit;">606,</em> <i>Revenue for Contract with Customers</i> (&#8220;<i>ASC <em style="font: inherit;">606</em></i>&#8221;) or other accounting standards for revenue <em style="font: inherit;">not</em> derived from customers. Arrangements <em style="font: inherit;"> may </em>include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which <em style="font: inherit;"> may </em>include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company enters into contractual arrangements that <em style="font: inherit;"> may </em>include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC <em style="font: inherit;">606,</em> the Company evaluates the promised good or services to determine which promises, or group of promises, represent performance obligations. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which <em style="font: inherit;"> may </em>include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement (the &#8220;<i>License Agreement</i>&#8221;) with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, &#8220;<i>Alvogen</i>&#8221;) (as further discussed in Note <em style="font: inherit;">6</em> below) was accounted for in accordance with ASC <em style="font: inherit;">606.</em> In accordance with ASC <em style="font: inherit;">606,</em> the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC <em style="font: inherit;">606,</em> it performs the following <em style="font: inherit;">five</em> steps:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">i. identify the contract(s) with a customer&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">ii. identify the performance obligations in the contract&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">iii. determine the transaction price&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">iv. allocate the transaction price to the performance obligations within the contract&#894; and</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">v. recognize revenue when (or as) the entity satisfies a performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company only applies the <em style="font: inherit;">five</em>-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At contract inception, once the contract is determined to be within the scope of ASC <em style="font: inherit;">606,</em> the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements typically consist of a license to intellectual property and research services. The Company <em style="font: inherit;"> may </em>provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are <em style="font: inherit;">not</em> individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration <em style="font: inherit;"> may </em>be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur when the uncertainty associated with the variable consideration is subsequently resolved.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s revenue arrangements <em style="font: inherit;"> may </em>include the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i>: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company <em style="font: inherit;">first</em> estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would <em style="font: inherit;">not</em> occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research Services</i>: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note <em style="font: inherit;">6</em> below), the Company would have been&#160;reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company would have recognized revenue for the reimbursed costs when the First Milestone Payment contingencies had&#160;been achieved and the Company had&#160;an enforceable claim to the reimbursed costs.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research and Development Costs</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development expense&#160;consists primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Non-cancellable Contracts</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company <em style="font: inherit;"> may </em>record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs <em style="font: inherit;"> may </em>be recorded as a deferred cost asset.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Convertible Notes Payable and Fair Value Election</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As permitted under FASB ASC Topic <em style="font: inherit;">825,</em> Financial Instruments (&#8220;<i>ASC <em style="font: inherit;">825</em></i>&#8221;), the Company elected to account for its promissory notes, which meet&#160;the required criteria, at fair value at inception. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying consolidated statements of operations and comprehensive loss.&#160;As a result of electing the fair value option, direct costs and fees related to the promissory notes are expensed as incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg&#8217;s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At <em style="font: inherit;"> September 30, 2024, </em>the Streeterville Note valuation&#160;was adjusted to the post settlement amount agreed upon. Interest expense is included within the change in fair value of the notes payable and accrued interest is included within the fair value of the convertible notes payable on the balance sheet. See Note <em style="font: inherit;">7</em> for Streeterville and Anson convertible notes. Management believes those assumptions are reasonable but if these assumptions change, it could materially affect the fair value.</p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock-Based Compensation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company&#8217;s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations and comprehensive loss based upon the underlying individual&#8217;s role at the Company.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC Topic <em style="font: inherit;">480,</em> <i>Distinguishing Liabilities from Equity</i> (&#8220;<i>ASC <em style="font: inherit;">480</em></i>&#8221;) and FASB ASC Topic <em style="font: inherit;">815,</em> <i>Derivatives and Hedging</i> (&#8220;<i>ASC <em style="font: inherit;">815</em></i>&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own Common Stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company generally determines&#160;fair value of the Common Stock&#160;Warrants (as defined below) using a Black Scholes valuation methodology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which <em style="font: inherit;"> may </em>result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In accordance with ASC <em style="font: inherit;">480,</em> the Company&#8217;s Series A Preferred Stock was classified as permanent equity as it was <em style="font: inherit;">not</em> mandatorily redeemable upon an event that is considered outside of the Company&#8217;s control. Further, in accordance with ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40,</em> <i>Derivatives and Hedging </i>&#8211;<i> Contracts in an Entity</i>&#8217;<i>s Own Equity</i>, the Series A Preferred Stock did <em style="font: inherit;">not</em> meet any of the criteria that would preclude equity classification. The Company concluded that the Series A Preferred Stock was more akin to an equity-type instrument than a debt-type instrument, therefore the conversion features associated with the convertible preferred stock were deemed to be clearly and closely related to the host instrument and were <em style="font: inherit;">not</em> bifurcated as a derivative under ASC <em style="font: inherit;">815.</em></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><em style="font: inherit;"></em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Segment Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who reviews financial information presented for purposes of making operating decisions, assessing financial performance, and allocating resources.&#160;The Company operates as a single operating and reportable segment, consistent with the manner in which the CODM evaluates performance and allocates resources, see Note&#160;<em style="font: inherit;">12</em> for further information.</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Income taxes are recorded in accordance with FASB ASC Topic <em style="font: inherit;">740,</em> <i>Income Taxes</i> (&#8220;<i>ASC <em style="font: inherit;">740</em></i>&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than <em style="font: inherit;">not</em> that some or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740.</em> When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than <em style="font: inherit;">not</em> be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than <em style="font: inherit;">not</em> be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Loss Per Share</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company applies the <em style="font: inherit;">two</em>-class method when computing net income or loss per share attributable to common stockholders. In determining net income or loss attributable to common stockholders, the <em style="font: inherit;">two</em>-class method requires income or loss allocable to participating securities for the period to be allocated between common and participating securities based on their respective rights to share in the earnings as if all of the income or loss allocable for the period had been distributed. In periods of net loss, there is <em style="font: inherit;">no</em> allocation required under the <em style="font: inherit;">two</em>-class method as the participating securities do <em style="font: inherit;">not</em> have an obligation to fund the losses of the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">264,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,173,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,321,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,920,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recent Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;"> November 2023, </em>the FASB&#160;issued Accounting Standard Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2023&#8209;07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>)-<i>Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>)</i>, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>&#160;should be applied on a retrospective basis.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>&#160;is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted. The Company has adopted the reportable segment disclosure requirements. See Note <em style="font: inherit;">12.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>-Income Taxes (Topic <em style="font: inherit;">740</em>): I<i>mprovements to Income Tax Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>)</i>, which is intended to enhance the transparency and decision usefulness of income tax disclosures, primarily by amending disclosure requirements for the effective tax rate reconciliation and income taxes paid.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;should be applied on a prospective basis, and retrospective application is permitted.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827871584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em></b> <b>Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prepaid expenses and other current assets consisted of the following at the dates indicated (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expense and other current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,078</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid clinical development costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">824</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other prepaid expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">208</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total prepaid expense and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,859</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure regarding prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827974896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em> Accrued and Other Current Liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accrued and other current liabilities consisted of the following at the dates indicated (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued and other current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Refund liability (see Note 6)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,732</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Employee costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">577</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">835</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued research and development expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">655</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,112</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other accrued expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">470</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accrued and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034832257760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Alvogen Licensing Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em> Alvogen Licensing Agreement</b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">2023,</em> the Company entered into a License Agreement with Alvogen. Under the License Agreement, the Company granted Alvogen certain license rights&#160;to develop, manufacture, and commercialize the Company&#8217;s candidate therapeutic product, NRX-<em style="font: inherit;">101,</em> for the treatment of bipolar depression with suicidality.&#160;In exchange for the license granted and the participation of the Company in certain development, regulatory and commercial activities, Alvogen was obligated to pay the Company specified regulatory and commercial milestones, the <em style="font: inherit;">first</em> of which was $9&#160;million upon the later of a positive data read-out from the Company&#8217;s ongoing Phase <em style="font: inherit;">2b/3</em> clinical trial and completion of the Type B meeting with the FDA (the &#8220;<i>First Milestone Payment</i>&#8221;). In <em style="font: inherit;"> February 2024, </em>the parties executed an amendment accelerating payment of up to $5 million related to the First Milestone Payment, with the remaining $4 million due upon the original agreement&#8217;s terms (see below for advances received through <em style="font: inherit;"> December 31, 2024). </em>As compensation for advancing the milestone, Alvogen received warrants to purchase up to 419,598 shares of the Company's Common Stock, at a strike price of $4.00 with a <span style="-sec-ix-hidden:c125341895">three</span> year term (See Note <em style="font: inherit;">9</em>). The grant date fair value of the warrants was approximately $1.3 million, which the Company planned to account for as&#160;consideration paid to a customer (see below). The <em style="font: inherit;">second</em> portion of the <em style="font: inherit;">first</em> milestone was to be $4 million and, as before, triggered by a positive response to the Company's planned end of phase <em style="font: inherit;">2</em> meeting with FDA.&#160;If the <em style="font: inherit;">first</em> milestone was <em style="font: inherit;">not</em> achieved by <em style="font: inherit;"> September 3, 2024, </em>the Company would have been obligated to repay any amount received against the $5 million advance of the First Milestone Payment to Alvogen. As there was significant uncertainty relative to approval of any drug candidate in development, the Company concluded that it was <em style="font: inherit;">not</em> probable that a significant reversal of revenue would <em style="font: inherit;">not</em> occur if the Company were to include the First Milestone Payment, or any advances thereof, in the transaction price prior to receiving FDA approval. Accordingly, the transaction price was fully constrained and advances from Alvogen were recorded as a refund liability until such time as the refund right expired. Further, the Company accounted for the warrants issued to Alvogen within additional paid-in capital consistent with the accounting for unfunded stock subscription agreements until such time as the uncertainty around the First Milestone was resolved. &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Termination</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Under the License Agreement, as amended, Alvogen was granted early termination rights. On <em style="font: inherit;"> June 21, 2024, </em>the Company received a notice of termination from Alvogen effective immediately.&#160;Following the termination of the License Agreement by Alvogen, the amounts advanced pursuant to the amendment&#160;became due and payable to Alvogen. Accordingly, the refund liability has <em style="font: inherit;">not</em> been reclassified to deferred revenue or recorded as revenue as of <em style="font: inherit;"> December 31, 2024 </em>and will remain permanent as refund liability until settled.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination.&#160;As of <em style="font: inherit;"> December 31, 2024, </em>the refund liability due to Alvogen was $4.7&#160;million, which represents all payments made by Alvogen through <em style="font: inherit;"> December 31, 2024, </em>and is included as a component of accrued expense&#160;and other current liabilities on the consolidated balance sheet (refer to Note <em style="font: inherit;">5</em>).&#160;Following the early termination by Alvogen, the Company does <em style="font: inherit;">not</em> anticipate recognizing any revenue under the License Agreement. Additionally, in <em style="font: inherit;"> June 2024&#160;</em>the Company wrote-off the unfunded stock subscription receivable of $1.3 million related to the warrants previously classified in additional paid-in capital&#160;to research and development expense following the termination.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827866960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em> Debt </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Streeterville Convertible Note</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> November 4, 2022, </em>the Company issued an 9% redeemable promissory note (as amended, the &#8220;<i>Streeterville</i>&#160;<i>Note</i>&#8221;) to Streeterville Capital, LLC, a Utah limited liability company (&#8220;<i>Streeterville</i>&#8221;), for an aggregate principal amount of $11.0 million. The Streeterville Note originally matured&#160;18 months from the date of issuance subject to certain acceleration provisions. The Streeterville Note carried&#160;an original issue discount of $1.0 million which was deducted from the principal balance of the Streeterville Note. The net proceeds from the issuance of the Streeterville Note was $10.0 million after transaction costs including the original issue discount, legal and other fees are included.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The initial terms of the Streeterville Note included the following provisions, certain of which were subsequently modified, as described below. The Company had&#160;the option to prepay the Streeterville Note during the term by paying an amount equal to 110% of the principal, interest, and fees owed as of the prepayment date. The noteholder had&#160;the right to redeem up to $1.0 million of the outstanding balance of the Streeterville Note per month starting <em style="font: inherit;">six</em> months after the issuance date (the &#8220;<i>Maximum Monthly Redemption Amount</i>&#8221;). Payments could&#160;be made by the Company at their option in: (i) in cash with a 10% premium (the &#8220;<i>Redemption Premium</i>&#8221;) for the amount redeemed, (ii) by paying the redemption amount in the form of shares of Common Stock with the number of redemption shares being equal to the portion of the applicable redemption amount divided by the Redemption Conversion Price (as defined below), or (iii) a combination of cash and shares of Common Stock. The &#8220;<i>Redemption Conversion Price</i>&#8221; on any given redemption date equaled&#160;85% multiplied by the average of the <em style="font: inherit;">two</em> lowest daily volume weighted average prices per share of the Common Stock during the <em style="font: inherit;">ten</em> trading days immediately preceding the date that the noteholder delivered&#160;notice electing to redeem a portion of the Streeterville Note. Beginning <em style="font: inherit;"> May 1, 2023, </em>in the event (a) the daily dollar trading volume of the Common Stock of the Company on any given trading day was at least <em style="font: inherit;">fifty</em> percent (<em style="font: inherit;">50%</em>) greater than the lower of (i) the median daily dollar trading volume over the previous <em style="font: inherit;">ten</em> (<em style="font: inherit;">10</em>) trading days or (ii) the daily dollar trading volume on the trading day immediately preceding the date of measurement or (b) if the closing trade price on any given trading day was at least <em style="font: inherit;">thirty</em> percent (<em style="font: inherit;">30%</em>) greater than the Nasdaq Minimum Price, then the lender would be entitled to redeem over the following <em style="font: inherit;">ten</em> (<em style="font: inherit;">10</em>) trading days an amount of indebtedness then outstanding under the Streeterville Note equal to twice the monthly redemption amount of $1.0 million solely by payment by stock, if permitted under the agreement, subject to the Maximum Percentage (as defined in the Streeterville Note) and other ownership limitations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Streeterville Note contained&#160;certain Trigger Events (as defined in the Streeterville Note) that generally, if uncured within <em style="font: inherit;">five</em> trading days, could result in an event of default in accordance with the terms of the Streeterville Note (such event, an &#8220;<i>Event of Default</i>&#8221;). Upon an Event of a Default, the Lender could consider the Streeterville Note immediately due and payable. Upon an Event of Default, the interest rate could&#160;also be increased to the lesser of 18% per annum or the maximum rate permitted under applicable law (see below).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Due to these embedded features within the Streeterville Note, the Company elected to account for the Streeterville Note at fair value at inception. Subsequent changes in fair value were recorded as a component of other income (loss) in the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><span style="text-decoration: underline; ">Streeterville</span></i><i><span style="text-decoration: underline; ">Convertible Note Amendments</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 30, 2023, </em>the Company entered into an Amendment to the Note (the &#8220;<i>First Amendment</i>&#8221;), pursuant to which the Maximum Percentage was set at 9.99% of the number of shares of Common Stock outstanding on a given date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 7, 2023, </em>the Company entered into Amendment <em style="font: inherit;">#2</em> to the Streeterville Note with Streeterville (the &#8220;<i>Second Amendment</i>&#8221;). Pursuant to the Second Amendment, the Company agreed to amend the redemption provisions of the Streeterville Note to provide that the Company would pay to Streeterville an amount in cash equal to $1.8 million on or before <em style="font: inherit;"> July 10, 2023, </em>which amount was paid on <em style="font: inherit;"> July 10, 2023. </em>In addition, the Company agreed that, beginning on or before <em style="font: inherit;"> July 31, 2023, </em>and on or before the last day of each month until <em style="font: inherit;"> December 31, 2023, </em>the Company would pay Streeterville an amount equal to $0.4 million in cash, less any amount satisfied by the delivery of Redemption Conversion Shares (as defined below). Notwithstanding the foregoing, Streeterville could also submit a request for redemption of up to an aggregate of $1.0 million per month in accordance with the terms of the Second Amendment. However, the portion of each payment that was <em style="font: inherit;">not</em> satisfied by the delivery of Redemption Conversion Shares was the maximum amount of cash the Company would have been&#160;required to pay in accordance with the Second Amendment during the period from <em style="font: inherit;"> July 31, 2023 </em>and on or before the last day of each month until <em style="font: inherit;"> December 31, 2023. </em>The redemption of the Maximum Monthly Redemption Amount in excess of the Minimum Amount would be satisfied by the delivery of additional Redemption Conversion Shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> February 9, 2024, </em>the Company entered into Amendment <em style="font: inherit;">#3</em> to the Streeterville Note (the &#8220;<i>Third Amendment</i>&#8221;), with Streeterville. In accordance with the Third Amendment, the Company and Streeterville agreed to amend the redemption provisions of the Streeterville Note to provide that the Company would pay to Streeterville an amount in cash equal to $1.1 million on <em style="font: inherit;"> February 12, 2024, </em>which the amount was paid on <em style="font: inherit;"> February 12, 2024. </em>In addition, beginning on or before <em style="font: inherit;"> February </em><em style="font: inherit;">29,</em> <em style="font: inherit;">2024,</em> and on or before the last day of each month until <em style="font: inherit;"> July 31, 2024, </em>the Company was obligated to pay Streeterville an amount equal to $0.4 million in cash, less any amount satisfied by the delivery of Redemption Conversion Shares. During the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of this amended payment period, Streeterville could <em style="font: inherit;">not</em> request to redeem amounts greater than $0.4 million per month.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">After <em style="font: inherit;"> April&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024,</em> and for the remainder of the payment period through <em style="font: inherit;"> July 31, 2024, </em>Streeterville could redeem any Redemption Amount (as defined in the Streeterville Note), including an amount in excess of the Minimum Payment, subject to the Maximum Monthly Redemption Amount. During the period through <em style="font: inherit;"> July 31, 2024, </em>the Company was&#160;permitted to pay the Redemption Amounts by delivery of the Redemption Conversion Shares (as defined below) without regard to the existence of any Equity Conditions Failure, to the extent Streeterville submits&#160;redemption notices during such month pursuant to the terms of the Streeterville Note, and only for the Redemption Amounts covered by such notices. Moreover, the Redemption Premium would continue to apply to the Redemption Amounts. To the extent there was an outstanding balance under the Streeterville Note after <em style="font: inherit;"> July 31, 2024, </em>the Company would be required to pay such outstanding balance in full in cash by <em style="font: inherit;"> August 31, 2024. </em>As a result of the alleged Event of Default mentioned below, the Company did <em style="font: inherit;">not</em> pay any&#160;Redemption Amounts during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024,</em> prior to the settlement, also as described below.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the Minimum Payment Period (defined in the Streeterville Note, as amended), the Company was&#160;permitted to pay the Redemption Amounts in the form of shares of Common Stock of the Company (the &#8220;<i>Redemption Conversion Shares</i>&#8221;) calculated on the basis of the Redemption Conversion Price (as defined in the Streeterville Note) without regard to the existence of an Equity Conditions Failure. Moreover, the Redemption Premium (as defined in the Streeterville Note) would continue to apply to the Redemption Amounts.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Both the Second Amendment and the Third Amendment (considered cumulatively with the Second Amendment) were deemed to be debt modifications and did&#160;<em style="font: inherit;">not</em> give rise to a debt extinguishment&#160;in accordance with FASB ASC Topic <em style="font: inherit;">470,</em> <i>Debt</i>, which was accounted for prospectively. The modification did <em style="font: inherit;">not</em> result in recognition of a gain or loss in the consolidated statements of operations as the modifications were <em style="font: inherit;">not</em> considered debt extinguishments, but impacted interest expense recognized in subsequent periods, prior to the settlement of the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Convertible Note Fair Value Measurements</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company estimated&#160;the fair value of the Streeterville Note using a Monte Carlo simulation model, which used&#160;as inputs the fair value of its Common Stock and estimated&#160;for the equity volatility and volume volatility of its Common Stock, the time to expiration of the Streeterville Note, the risk-free interest rate for a period that approximated&#160;the time to expiration, and probability of default. Therefore, the Company estimated&#160;its expected future volatility based on the actual volatility of its Common Stock and historical volatility of its Common Stock utilizing a lookback period consistent with the time to expiration. The time to expiration was&#160;based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning <em style="font: inherit;">six</em> months from the issuance date. The risk-free interest rate was&#160;determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default was estimated using either Bloomberg's Default Risk function, which uses&#160;its financial information to calculate a default risk specific to the Company, or&#160;management's estimates which included, the Company's current cash runway,&#160;current efforts to raise financing,&#160;and current economic environment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The discount to the principal amount was included in the carrying value of the Streeterville Note. During <em style="font: inherit;">2022,</em> the Company recorded a debt discount of approximately $1.0 million upon issuance of the Streeterville Note for the original issue discount of $1.0 million. As a result of electing the fair value option, any direct costs and fees related to the Streeterville Note were expensed as incurred. For the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company recorded a gain from the change in fair value of the Streeterville Note&#160;of $1.8 million and $2.7 million, respectively, which was recognized in other (income) expense on the consolidated statements of operations as a result of the Company&#8217;s election of the fair value option.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2024, </em>the Company made cash principal repayments on the Note of approximately $7.4 million, made cash interest payments on the Note of approximately $0.5 million, including $0.2 million of redemption premiums, issued shares of Common Stock as principal repayment of $0.3 million, and issued shares of Common Stock as interest repayment of $0.1 million, and incurred a default penalty&#160;of $0.8&#160;million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company made cash principal repayments on the Note of approximately $2.3 million, made cash interest payments on the Note of approximately $0.9 million, including $0.1 million of redemption premiums, issued shares of Common Stock as principal repayment of $0.7 million, and issued shares of Common Stock as interest repayment of $0.2 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Note carried a remaining principle balance of $0 and $8.3 million, respectively. Refer to Note <em style="font: inherit;">11</em> for the reconciliation of the fair values for the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Alleged Default</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> April 24, 2024, </em>the Company received written notice from counsel for Streeterville that an alleged event of default occurred with respect to the Streeterville Note issued by the Company in favor of Streeterville (the &#8220;<i>Notice</i>&#8221;). The Notice alleged that, among other things, (i) the announcement of the plan to partially spin-off of HOPE (the &#8220;<i>Spin-Off</i>&#8221;), constituted a &#8220;Fundamental Transaction&#8221; (as defined in the Streeterville Note) for which the Company failed to obtain Streeterville&#8217;s prior written consent before undertaking such transaction; and (ii) the Company failed to pay the Minimum Payment, as defined in the Streeterville Note, by <em style="font: inherit;"> April 8, 2024, </em>following a Redemption Notice issued on <em style="font: inherit;"> April 3, 2024 </em>by Streeterville to the Company, each of which resulted in the failure to cure a Trigger Event and subsequent Event of Default of the Streeterville Note, resulting in the acceleration of all of the outstanding amounts due thereunder.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Streeterville also filed a complaint (the &#8220;<i>Complaint</i>&#8221;) naming the Company as a defendant in the Third Judicial District Court of Salt Lake County, Utah. The Complaint was seeking, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing Common Stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but <em style="font: inherit;">no</em> less than $6.5 million, or the amounts currently outstanding under the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 29, 2024, </em>in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company&#160;announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin Spin-Off of 49% of shares in HOPE&#160;to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#8217;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a&#160;national exchange. The arbitrator also denied Streeterville&#8217;s petition to enjoin the Company&#160;from selling additional shares of Common Stock to finance ongoing operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Streeterville Settlement</span></i><span style="text-decoration: underline; ">&#160;</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 12, 2024, </em>the Company and Streeterville entered into a Settlement and Release of Claims (the &#8220;Settlement Agreement&#8221;), whereby the Company and Streeterville agreed to settle all disputes between the parties and release the Company from all obligations arising from the Notes at certain Securities Purchase Agreement, dated <em style="font: inherit;"> November 4, 2022 (</em>&#8220;Streeterville Notes&#8221;), between the Company and Streeterville, and that certain Convertible Promissory Note, dated <em style="font: inherit;"> November 4, 2022, </em>issued to Streeterville by the Company, in exchange for a payment of $2.5 million upon the initial closing of the sale of the Anson Notes, and within <em style="font: inherit;">60</em> days thereafter, a <em style="font: inherit;">second</em> payment of $3.05 million. The Company made the $2.5 million payment upon the Anson Notes closing on&#160;<em style="font: inherit;"> August 15, 2024. </em>The Company made the final $3.05 million payment in <em style="font: inherit;"> October 10, 2024 </em>using proceeds from the Second Closing of Anson Convertible Promissory Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluated the terms of the Settlement Amendment in accordance with ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">50,</em> <i>Debt Modifications and Extinguishments</i>. Both the Settlement Amendment and the Third Amendment (considered cumulatively with the Settlement Amendment) were deemed to be debt modifications&#160;and did <em style="font: inherit;">not</em> give rise to a debt extinguishment in accordance with ASC <em style="font: inherit;">Topic&#8239;470,&#8239;</em><i>Debt</i>, which will be accounted for prospectively. The modifications did <em style="font: inherit;">not</em> result in recognition of a gain or loss in the consolidated statements of operations as the modifications were <em style="font: inherit;">not</em> considered debt extinguishments, but will impact interest expense and the determination of fair value&#160;in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Streeterville Note as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Par value of the Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized original issue discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares and cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carrying value of the Note before current period change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(952</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,451</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cumulative fair value adjustments through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">952</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cumulative fair value adjustments through accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total carrying value of Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anson Convertible Promissory Notes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 12, 2024, </em>the Company entered into the Purchase Agreement with Investors. The Company agreed to sell, in <span style="-sec-ix-hidden:c125342005">three</span> equal tranches, original issue discount Anson Notes&#160;in the aggregate principal amount of up to approximately $16.3 million&#160;for an aggregate purchase price of up to approximately $15.0 million&#160;and warrants to purchase that amount of shares equal to 50% of the principal amount of the Notes divided by the VWAP&#160;of the Company&#8217;s Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Anson Warrants.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the above offering, the Company engaged EF Hutton LLC as placement agent (the &#8220;Placement Agent&#8221;), Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of 7% of the gross proceeds the Company receives in the offering at closing.&#8239;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; "><em style="font: inherit;">2024</em> Senior Secured Convertible Promissory Notes</span></i><span style="text-decoration: underline; ">&#160;</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 14, 2024, </em>the Company entered into the <em style="font: inherit;">first</em> tranche Senior Secured Convertible Note Agreements (the &#8220;First Tranche Notes&#8221;) with Anson Investment Master Fund LP and Anson East Master Fund LP (collectively &#8220;Anson&#8221;) at various amounts for an aggregate of $5.435 million subject to an original issuance discount of 8% or $435,000, less other cash issuance costs of $521,000, resulting in net cash proceeds of $4.5&#160;million, prior to any allocation to the Anson Warrants. The First Tranche Notes bear interest at a rate of 6% per annum (or 10% during the occurrence of any Event of Default (as defined in the First Tranche Notes)) and have a term of 15 months from the issuance date, maturing on <em style="font: inherit;"> November 14, 2025&#160;(</em>the &#8220;First Tranche Maturity Date&#8221;) (see Note <em style="font: inherit;">9</em>).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 14, 2024, </em>in conjunction with the issuance of the First Tranche Notes, the Company issued warrants&#160;to purchase up to 1,349,305 shares of the Company&#8217;s Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The First Tranche Notes are convertible at the option of the holder at any time after issuance into Common Stock, at a per share conversion price equal to&#160;the lower of (a) $2.4168, (the &#8220;Fixed Conversion Price&#8221;) or (b) a price equal to 92% of the lowest VWAP during the <em style="font: inherit;">seven</em> trading day period immediately preceding the effective conversion date (the &#8220;Alternate Conversion Price&#8221;, and together with the Fixed Conversion Price, the &#8220;Conversion Price&#8221;). If the Conversion Price is less than $0.38 (the &#8220;Floor Price&#8221;), then in addition to the issuance of Common Stock upon conversion the Company will pay cash as a true-up which is determined by the product of (i) the difference between (y) the Floor Price less (z) the Conversion Price then in effect, multiplied by (ii) the conversion amount that is being paid in Common Stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The terms of the First Tranche&#160;Notes do <em style="font: inherit;">not</em> allow any conversion of the First Tranche Notes if it results in Anson owning more than <em style="font: inherit;">4.99%</em> of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation"). This limitation can be adjusted up to <em style="font: inherit;">9.99%</em> with prior notice, effective <em style="font: inherit;">61</em> days after such notice. Anson&#160;must ensure compliance with this limitation when submitting a notice of conversion, and the Company will rely on Anson's&#160;representation of compliance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company issues or grants options for Common Stock at a price lower than the current Conversion Price, the Conversion Price will be adjusted to match this lower price, (the&#160;&#8220;Base Conversion Price&#8221;). The Company must notify Anson of any such issuance, and Anson&#160;is entitled to convert shares based on the new Base Conversion Price.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company offers purchase rights to holders of Common Stock, Anson will be entitled to acquire those rights as if they had fully converted the Note, subject to the Beneficial Ownership Limitation. If exercising these rights would exceed the Beneficial Ownership Limitation, the rights will be held in abeyance until they can be exercised without exceeding the limit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The First Tranche Notes contain mandatory redemption features, whereby if at any time the First Tranche Notes are outstanding, the Company will be required to: (A) use up to <em style="font: inherit;">30%</em> of the gross proceeds from any Subsequent Financings (as defined in the Purchase Agreement) in cash, to redeem all or a portion of the Note for an amount equal to the outstanding principal, plus all accrued but unpaid interest, plus all liquidated damages (the &#8220;Redemption&#8239;Obligations&#8221;), multiplied by <em style="font: inherit;">1.05</em> (the &#8220;Mandatory Redemption Amount&#8221;)&#894; (B) redeem all of the Redemption Obligations at the Mandatory Redemption Amount in the event of a Change of Control Transaction (as defined in the First Tranche Notes)&#894; (C) redeem the Redemption Obligations for the Mandatory Redemption Amount in the event a registration statement is <em style="font: inherit;">not</em> available for each of the offer and resale of the shares issuable upon conversion of the First Tranche Notes (the &#8220;Conversion Shares&#8221;)&#894; and (D) redeem the Redemption Obligations for the Mandatory Redemption Amount if the Shareholder Approval is <em style="font: inherit;">not</em> obtained within <em style="font: inherit;">180</em> days following the date of issuance of the First Tranche Notes.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The First Tranche Notes contain certain covenants, and events of default and triggering events, respectively, which would require repayment of the obligations outstanding pursuant to such instruments. The obligations of the Company pursuant to the First Tranche Notes are (i) secured by all assets of the Company and all subsidiaries of the Company pursuant to the Security Agreement and Patent Security Agreement, dated <em style="font: inherit;"> August 14, 2024, </em>by and among the Company, the subsidiaries of the Company, and the Investors, and (ii) guaranteed jointly and severally by the subsidiaries of the Company pursuant to the Subsidiary Guarantee, dated <em style="font: inherit;"> August 14, 2024, </em>by and among the Company, the subsidiaries of the Company, and the Investors.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to the Purchase Agreement, on <em style="font: inherit;"> October 10, 2024 (</em>the &#8220;Second Closing Date&#8221;), the Company sold a total of $5.435 million in Notes (the &#8220;Second Tranche Notes&#8221;, and collectively with the First Tranche Notes, the ("Anson Notes")) subject to an original issue discount of 8% or $435,000 less other cash issuance cost of $375,000, with an aggregate purchase price of approximately $5.0 million, and Warrants to purchase up to 1,846,128 shares of Common Stock. The Second Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $1.7664 or (b) a price equal to 92% of the lowest VWAP during the <em style="font: inherit;">seven</em> trading day period immediately preceding the effective date set forth in a Notice of Conversion delivered by an Investor to the Company. The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of common stock below the then effective Conversion Price. $3.05 million of the note proceeds were used to repay the Streeterville note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the above Second Tranche Notes&#8221;, the Company engaged Placement Agent. Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of 7%&#160;of the gross proceeds the Company received&#160;in the Second Closing and incurred certain additional other issuance costs and reimbursement for legal counsel disbursements and placement agent, for aggregate issuance costs of approximately&#160;$0.4&#160;million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Due to these embedded features within the Anson Notes, the Company elected to account for the First and Second Tranche Notes at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the consolidated statements of operations. Additionally the portion of changes in the fair value related to changes in credit risk are recorded to other comprehensive income in the consolidated statements of operations. To determine the initial carrying value of the Notes and the warrants issued to Anson under the First and Second Tranche Notes (see Note <em style="font: inherit;">9</em>), the Company allocated the proceeds using the fair value method. After allocation, the initial carrying value of the First Tranche Notes and the warrants issued to Anson were $2.9 million and $2.1 million, respectively, and the initial carrying value of the Second Tranche Notes and the warrants issued to Anson were $3.1 million and $1.9 million, respectively&#160;Refer to Note <em style="font: inherit;">11</em> for the reconciliation of the fair values for the periods presented.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the&#160;year ended <em style="font: inherit;"> December 31, 2024,&#160;</em>Anson converted $4.2 million of principal and interest of the First Tranche Note into common stock, resulting in the issuances of 3,676,796 shares of Common Stock and loss on redemption&#160;of $1.3 million (see Note 9).&#160;As of <em style="font: inherit;"> December 31, 2024, </em>the principal and accrued interest balance of the Anson Notes&#160;was $6.75 million and $0.1 million, respectively. During the&#160;year ended <em style="font: inherit;"> December 31, 2024, </em>the Company&#160;recorded a loss from the change in fair value of the First Tranche Notes of $4.4 million, which was recognized in other (income) expense on the consolidated statements of operations as a result of the Company&#8217;s election of the fair value option.&#160;At <em style="font: inherit;"> December 31, 2024&#160;</em>the effective interest rate of the First and the Second Tranche Note was 82% and 53%, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From <em style="font: inherit;"> January 2, 2025 </em>to <em style="font: inherit;"> January 3, 2025, </em>the Company received conversion notices from Anson resulting in the conversion of the remaining principal of the First Tranche Note of $1.3 million of principal and interest in full from the First Tranche Note into 1,004,055 shares of Common Stock (see Note <em style="font: inherit;">15</em>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Anson Notes as of <em style="font: inherit;"> December 31, 2024 (</em>in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Par value of the Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Initial original issue discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carrying value of the Anson Notes before current period change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Fair value allocated to Common Stock liability classified warrants</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">(3,966</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,413</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total carrying value of Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827982992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Sarah Herzog Memorial Hospital License Agreement</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is required to make certain payments related to the development of NRX-<em style="font: inherit;">101</em> (the "<i>Licensed Product</i>") in order to maintain the license agreement with the Sarah Herzog Memorial Hospital Ezrat Nashim (&#8220;<i>SHMH</i>&#8221;) (the "<i>SHMH License Agreement</i>"), including:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase I Clinical Trials of Licensed Product (completed)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase II Clinical Trials of Licensed Product (completed)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase III Clinical Trials of Licensed Product</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in U.S.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual Revenues Reach $100,000,000</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">750,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The milestone payments due above <em style="font: inherit;"> may </em>be reduced by 25% in certain circumstances, and by the application of certain sub-license fees. As of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the total cumulative payments made under the <i>SHMH License Agreement</i> were $0.4 million, with no payments made during the year ended <em style="font: inherit;"> December 31, 2024, </em>and $0.2 million and $0.2 million payments made during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Royalties</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A royalty in an amount equal to: (a) 1% of revenues from the sale of any product incorporating a Licensed Product when at least <em style="font: inherit;">one</em> Licensed Patent remains in force, if such product is <em style="font: inherit;">not</em> covered by a Valid Claim (as defined below) in the country or region in which the sale occurs, or (b) 2.5% of revenues from the sale of any Licensed Product that is covered by at least <em style="font: inherit;">one</em> Valid Claim in the country or region in which such product is manufactured or sold. A &#8220;Valid Claim&#8221; means any issued claim in the Licensed Patents that remains in force and that has <em style="font: inherit;">not</em> been finally invalidated or held to be unenforceable. The royalty rates above <em style="font: inherit;"> may </em>be doubled if we commence a legal challenge to the validity, enforceability or scope of any of the Licensed Patents during the term of the SHMH License Agreement and do <em style="font: inherit;">not</em> prevail in such proceeding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of 8.5% of the payments received by us from sub-licensees in connection with such sales. During the&#160;years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> no royalty payments were made.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Annual Maintenance Fee</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A fixed amount of $100,000 was paid on <em style="font: inherit;"> April 16, 2021 </em>and, thereafter, a fixed amount of $150,000 is due on the anniversary of such date during the term of the SHMH License Agreement. The Company paid $150,000 in annual maintenance fees in each of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> expensed through Research and Development expenses in the accompanying Consolidated Statement of Operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Exclusive License Agreement </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has entered into a License Agreement with Apkarian Technologies to in-license US Patent <em style="font: inherit;">8,653,120</em> that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-<em style="font: inherit;">101</em> to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. For the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company has recorded no&#160;expenses relating to the licensure of the patent.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Operating Lease</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company leases office space on a&#160;month-to-month basis. The rent expense for the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> was $0.1 million and $0.1 million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From time to time the Company is involved in litigation, claims, and other proceedings arising in the ordinary course of business. Litigation and other disputes are inherently unpredictable and subject to substantial uncertainties and unfavorable resolutions could occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company was a defendant in litigation filed by Streeterville in the Third Judicial District Court of Salt Lake County, Utah. See Note <em style="font: inherit;">7,</em> Debt, for additional information. The Complaint&#160;sought, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing Common Stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but <em style="font: inherit;">no</em> less than $6,537,027, or the amounts currently outstanding under the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 29, 2024, </em>in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company&#160;announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin the planned Spin-Off of 49% of shares in HOPE to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#8217;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a&#160;national exchange. The arbitrator also denied Streeterville&#8217;s petition to enjoin the Company&#160;from selling additional shares of Common Stock to finance ongoing operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> August 12, 2024, </em>the Company signed a settlement agreement with Streeterville&#160;to retire its remaining debt for a settlement amount of $5.6&#160;million and to settle outstanding litigation. This settlement amount was substantially less than the amounts claimed by Streeterville in its Compliant&#160;(see Note <em style="font: inherit;">7</em>). As of <em style="font: inherit;"> September 30, 2024, </em>the fair value of the Streeterville Note&#160;was adjusted to the settlement amount which was repaid in <em style="font: inherit;"> October 2024. </em>Such adjustment is included within the change in fair value of convertible notes payable on the consolidated statement of operations, therefore no gain or loss on the settlement was recorded.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> July 17, 2023, </em>NeuroRx&#160;and GEM entered into a settlement and release agreement (the &#8220;Settlement Agreement&#8221;) pursuant to which the parties agreed to dismiss the arbitration proceeding with prejudice.&#160;Pursuant to the Settlement Agreement on <em style="font: inherit;"> August 31, 2023, </em>the Company issued&#160;67,568&#160;shares of Common Stock, the fair value of which was approximately $0.3 million based on the quoted trading price on the grant date, to GEM in full satisfaction of the Settlement Agreement which was approximately $0.3&#160;million and was expensed as &#8220;Settlement expense&#8221; in fiscal <em style="font: inherit;">2023.</em> The shares are registered under a prospectus supplement to the Company&#8217;s registration statement on Form S-<em style="font: inherit;">3</em> and are subject to a restriction that they cannot be sold or traded for a period of <em style="font: inherit;">six</em> months from the effective date of the Settlement Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is currently involved in and <em style="font: inherit;"> may </em>from time to time become involved in various legal actions incidental to our business. As of the date of this report, the Company, other than as set forth above, is <em style="font: inherit;">not</em> involved in any legal proceedings that it believes could have a material adverse effect on its financial position or results of operations. However, the outcome of any current or future legal proceeding is inherently difficult to predict and any dispute resolved unfavorably could have a material adverse effect on the Company&#8217;s business, financial position, and operating results.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034931527120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Common Stock Reverse Stock Split</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 21, 2024, </em>the Board approved a reverse stock split ratio of <em style="font: inherit;">1</em>-for-10. On <em style="font: inherit;"> March 28, 2024, </em>the Company filed an amendment to its certificate of incorporation in the State of Delaware (the &#8220;<i>Amendment</i>&#8221;), which provided that&#160;every <span style="-sec-ix-hidden:c125342120">ten</span> shares of its issued and outstanding Common Stock would&#160;automatically be combined into <em style="font: inherit;">one</em> issued and outstanding share of Common Stock, without any change in the par value per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Effective <em style="font: inherit;"> April 1, 2024, </em>every 10 issued and outstanding shares of the Company&#8217;s Common Stock were converted automatically into <em style="font: inherit;">one</em> share of the Company&#8217;s Common Stock, without any change in the par value per share. The Reverse Stock Split reduced the number of shares of Common Stock issued and outstanding from approximately 95.7 million to approximately 9.6 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><em style="font: inherit;">No</em> fractional shares were issued in connection with the Reverse Stock Split. Shareholders who otherwise would have been entitled to receive a fractional share instead became entitled to receive <em style="font: inherit;">one</em> whole share of Common Stock in lieu of such fractional share. As a result of the Reverse Stock Split, 73,040 additional shares of common stock were issued in lieu of fractional shares.&#160;All share and per share amounts in the accompanying consolidated financial statements and footnotes have been retrospectively adjusted for the reverse split.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the terms of the Company&#8217;s Second Amended and Restated Certificate of Incorporation, the Company has <span style="-sec-ix-hidden:c125342129">authorized&#8239;50,000,000&#8239;shares</span> of preferred stock with a par value of <span style="-sec-ix-hidden:c125342130">$0.001.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Series A Convertible Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 30, 2023, </em>the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;) with the Delaware Secretary of State (the &#8220;Certificate of Designation&#8221;) authorizing up to 12,000,000 shares of Series A Preferred Stock.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> August 2023, </em>the Company sold and issued 3,000,000 shares of Series A Preferred Stock. Each share of Series A Preferred Stock was sold with <span style="-sec-ix-hidden:c125342133">one</span> warrant (a &#8220;Unit"), see investor warrant section below for terms, for an aggregate cash purchase price of $1.2 million or $0.40 per Unit.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> March 2024, </em>holders of the Company&#8217;s Series A Preferred elected to convert 3,000,000 shares of Series A Preferred into 300,000 shares of Common Stock. As of <em style="font: inherit;"> December 31, 2024, </em>no shares of Series A Preferred remained issued or outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Dividend Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The holders of Series A Preferred Stock are <em style="font: inherit;">not</em> entitled to receive any dividends in respect to the Series&#8239;A Preferred Stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Voting Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The holders of Series A Preferred Stock have <em style="font: inherit;">no</em> voting rights other than for an affirmative vote in order for the Company to (a) disproportionally alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that disproportionally adversely affects any rights of the Holders, (c) increase or decrease the number of authorized shares of Series A Preferred Stock or (d) enter into any agreement with respect to any of the foregoing.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Conversion Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each share of Series A Preferred Stock shall be convertible into a number of shares of Common Stock equal to the number of shares of Series A Preferred Stock being converted. Notwithstanding the foregoing, <em style="font: inherit;">no</em> share of Series&#8239;A Preferred Stock shall be convertible during the <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>)&#8239;month period following the issuance date;&#8239;provided, however, if the Common Stock trades at or above $1.20 per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events), as reported on Bloomberg, L.P. on any trading day, holder <em style="font: inherit;"> may </em>convert the Series&#8239;A Preferred Stock prior to the <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>)&#8239;month anniversary of the issuance date. <em style="font: inherit;">No</em> fractional shares will be issued upon conversion. Conversion is subject to certain limitations, including the holder <em style="font: inherit;">not</em> owning more than 4.9% of the outstanding shares of Common Stock.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Liquidation Rights</i>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon any liquidation, dissolution or winding up of the Company (a &#8220;Liquidation&#8221;), whether voluntary or involuntary, each holder of Series A Preferred Stock shall be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive if such shares had been converted to Common Stock immediately prior to such Liquidation, subject to certain rights and limitations.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Common Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the terms of the Company&#8217;s Second Amended and Restated Certificate of Incorporation, the Company has authorized&#160;500,000,000&#160;shares of common stock with a par value of&#160;$0.001.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 8, 2023, </em>NRx Pharmaceuticals entered into a securities purchase agreement with the <em style="font: inherit;"> March </em>Investors, providing for the issuance and sale of&#160;386,667&#160;shares of Common Stock and the <em style="font: inherit;"> March </em>Investor Warrants to purchase up to&#160;386,667&#160;shares of Common Stock in a registered direct offering priced at-the-market under Nasdaq rules for a purchase price of $7.50&#160;per share. The <em style="font: inherit;"> March </em>Investor Warrants have an exercise price of $7.50 per share, are exercisable beginning on <em style="font: inherit;"> September 8, 2023 </em>and will expire <span style="-sec-ix-hidden:c125342158">5</span> years from the <em style="font: inherit;"> March </em>Initial Exercise Date.&#160;The <em style="font: inherit;"> March </em>Investors agreed <em style="font: inherit;">not</em> to transfer the Common Stock for&#160;<em style="font: inherit;">six</em> months&#160;following the date of issuance. The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> March </em>Offering were approximately $2.5 million net of offering costs of approximately $0.4 million. The Company used the net proceeds from such offering for working capital and general corporate purposes. The closing of the sale of these securities occurred on <em style="font: inherit;"> March 9, 2023. </em>The securities were issued pursuant to the Company&#8217;s registration statement on Form S-<em style="font: inherit;">3</em> filed with the SEC on <em style="font: inherit;"> June 9, 2022 (</em>File <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">265492</em>) which became effective on <em style="font: inherit;"> June 21, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> February 8, 2023, </em>the Company entered into a letter agreement with H.C. Wainwright &amp; Co., LLC. Although they did <em style="font: inherit;">not</em> act as the placement agent with respect to the <em style="font: inherit;"> March 2023 </em>Offering, H.C. Wainwright &amp; Co., LLC was paid a cash fee equal to 3.0% of the amount raised, or approximately $0.1 million, pursuant to the letter agreement, which was charged against the proceeds in additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">6,</em> <em style="font: inherit;">2023,</em> the Company entered into a securities purchase agreement with the <em style="font: inherit;"> June </em>Investors, providing for the issuance and sale of 967,000 shares of the Company&#8217;s Common Stock and the <em style="font: inherit;"> June </em>Investor Warrants to purchase up to 967,000 shares of Common Stock. The Common Stock was issued in a registered direct offering for a purchase price of $6.50 per share and the <em style="font: inherit;"> June </em>Investor Warrants were offered pursuant to a private placement under Section&#160;<em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>)&#160;of the Securities Act. The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> June </em>Offering were approximately $5.6 million. The Company used the net proceeds from the <em style="font: inherit;"> June </em>Offering for working capital and general corporate purposes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">H.C. Wainwright &amp; Co. LLC acted as the exclusive placement agent (the &#8220;Placement Agent&#8221;) for the <em style="font: inherit;"> June 2023 </em>Offering. The Placement Agent was paid a cash fee equal to 6.5% of the gross proceeds received by the Company from the sale of the securities at the closing of the <em style="font: inherit;"> June </em>Offering or approximately $0.6 million which was charged against the proceeds in additional paid-in capital. The Company used the net proceeds from such offering for working capital and general corporate purposes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with the Note issued to Streeterville, on <em style="font: inherit;"> May 15, 2023 </em>the Company issued 40,868 Common Stock to Streeterville in repayment of interest on the Note. Additionally on <em style="font: inherit;"> August 4, 2023 </em>and <em style="font: inherit;"> August 30, 2023, </em>the Company issued 131,266 and 154,289 respectively to Streeterville for repayment of principal and interest under the Note. Refer to Note <em style="font: inherit;">7</em> for further details.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> July 17, 2023, </em>the Company and GEM entered into a settlement agreement where the Company issued 67,568 shares of Common Stock to GEM in full satisfaction of its obligation. Refer to Note <em style="font: inherit;">8</em> for further details.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> January 2, 2024, </em>the Company issued 143,648 shares of Common Stock as payment for the $0.4 million minimum payment to Streeterville related to principal and interest payments on the Streeterville Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From <em style="font: inherit;"> February 20, 2024 </em>to <em style="font: inherit;"> July 29, 2024, </em>the Company announced that it entered into multiple purchase agreements (the &#8220;<i>ATM Purchase Agreements</i>&#8221;) subject to standard closing conditions where accredited investors purchased 385,515 shares of unregistered Common Stock at a range of &#160;$2.42&#160;&#8211; $7.10&#160;per share.&#160;On <em style="font: inherit;"> April 15, 2024, </em>the Company increased the maximum aggregate offering amount of the shares of Common Stock issuable under that certain At the Market Offering Agreement, dated <em style="font: inherit;"> August 14, 2023 (</em>the &#8220;<i>Offering Agreemen</i>t&#8221;), with H.C. Wainwright &amp; Co., and filed a prospectus supplement (the &#8220;<i>Current Prospectus Supplement</i>&#8221;) under the Offering Agreement for an aggregate of $4.9 million. Through <em style="font: inherit;"> December 31, 2024, </em>the aggregate net cash proceeds to the Company from the ATM Purchases Agreements were approximately $1.6 million.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> February 27, 2024, </em>the Company entered into an underwriting agreement (the &#8220;<i><em style="font: inherit;"> February </em>Underwriting Agreement</i>&#8221;) with EF Hutton LLC (the &#8220;<i>Representative</i>&#8221;), as the representative of the several underwriters named therein (the &#8220;<i><em style="font: inherit;"> February </em>Underwriters</i>&#8221;), relating to an underwritten public offering (the &#8220;<i><em style="font: inherit;"> February 2024 </em>Public Offering</i>&#8221;) of 500,000 shares (the &#8220;<i><em style="font: inherit;"> February </em>Shares</i>&#8221;) of the Company&#8217;s Common Stock. The public offering price for each share of Common Stock was $3.00 and the <em style="font: inherit;"> February </em>Underwriters purchased the shares of Common Stock pursuant to the <em style="font: inherit;"> February </em>Underwriting Agreement at a price for each share of Common Stock of $2.76. Pursuant to the <em style="font: inherit;"> February </em>Underwriting Agreement, the Company also granted the Representative a <em style="font: inherit;">45</em>-day option to purchase up to an additional 75,000 shares (the &#8220;<i><em style="font: inherit;"> February </em>Option Shares</i>&#8221;) of the Common Stock on the same terms as the <em style="font: inherit;"> February </em>Shares sold in the <em style="font: inherit;"> February 2024 </em>Public Offering (the &#8220;<i><em style="font: inherit;"> February </em>Over-Allotment Option</i>&#8221;). On <em style="font: inherit;"> February 28, 2024, </em>the <em style="font: inherit;"> February 2024 </em>Public Offering closed (the &#8220;<i><em style="font: inherit;"> February </em>Closing Date</i>&#8221;). The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> February 2024 </em>Offering proceeds were approximately $1.3 million after offering costs of approximately $0.4 million. On <em style="font: inherit;"> March 5, 2024, </em>the <em style="font: inherit;"> February </em>Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the <em style="font: inherit;"> February </em>Underwriting Agreement, dated <em style="font: inherit;"> February 27, 2024, </em>by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional 75,000 shares of the Company&#8217;s Common Stock, at a public offering price of $3.00 per share (the &#8220;<i><em style="font: inherit;"> February </em>Overallotment Exercise</i>&#8221;). The <em style="font: inherit;"> February </em>Overallotment Exercise closed on <em style="font: inherit;"> March 6, 2024. </em>The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> February </em>Overallotment Exercise were approximately $0.2&#160;million. The Company accrued additional offering costs of approximately $0.2 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February </em><em style="font: inherit;">29,</em> <em style="font: inherit;">2024,</em> the Company entered into a securities purchase agreement with an investor providing for the issuance and sale of 270,000 shares of Common Stock and warrants to purchase up to 270,000 shares of Common Stock (the &#8220;<i><em style="font: inherit;"> February </em>Warrants</i>&#8221;) at a price of $3.80 per share of Common Stock and accompanying warrant, which represents a 26.7% premium to the offering price in <em style="font: inherit;"> February 2024 </em>Public Offering. The Common Stock and the <em style="font: inherit;"> February </em>Warrants were offered pursuant to a private placement (the &#8220;<i><em style="font: inherit;"> February 2024 </em>Private Placement</i>&#8221;) under Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended (the &#8220;<i>Securities Act</i>&#8221;). The aggregate net cash proceeds to the Company from the <em style="font: inherit;"> February 2024 </em>Private Placement were approximately $1.0 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;">April&#8239;18,</em> <em style="font: inherit;">2024,</em> the Company entered into an underwriting agreement (the &#8220;<i><em style="font: inherit;"> April </em>Underwriting Agreement</i>&#8221;) with the Representative, as the representative of the several underwriters named therein (the &#8220;<i><em style="font: inherit;"> April </em>Underwriters</i>&#8221;), relating to an underwritten public offering (the &#8220;<i><em style="font: inherit;"> April 2024 </em>Public Offerin</i>g&#8221;) of 607,000 shares (the &#8220;<i><em style="font: inherit;"> April </em>Shares</i>&#8221;) of&#160;Common Stock. The public offering price for each share of Common Stock was $3.30. Pursuant to the <em style="font: inherit;"> April </em>Underwriting Agreement, the Company also granted the Representative a <em style="font: inherit;">45</em>-day option to purchase up to an additional 91,050 shares (the &#8220;<i><em style="font: inherit;"> April </em>Option Shares</i>&#8221;) of the Common Stock on the same terms as the <em style="font: inherit;"> April </em>Shares sold in the <em style="font: inherit;"> April 2024 </em>Public Offering (the &#8220;<i><em style="font: inherit;"> April </em>Over-Allotment Option</i>&#8221;). On <em style="font: inherit;">April&#8239;19,</em> <em style="font: inherit;">2024,</em> the Offering closed (the &#8220;<i><em style="font: inherit;"> April </em>Closing Date</i>&#8221;). Net proceeds from the <em style="font: inherit;"> April 2024 </em>Public Offering were approximately $1.6 million after offering costs of approximately $0.4 million. On <em style="font: inherit;"> May 23, 2024, </em>the <em style="font: inherit;"> April </em>Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the <em style="font: inherit;"> April </em>Underwriting Agreement, dated <em style="font: inherit;"> April 18, 2024, </em>by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional 91,050 shares of the Company&#8217;s Common Stock, at the public offering price of $3.30&#160;per share (the &#8220;<i><em style="font: inherit;"> April </em>Overallotment Exercise</i>&#8221;). The <em style="font: inherit;"> April </em>Over-Allotment Exercise was exercised in full and closed on <em style="font: inherit;"> May 23, 2024.&#160;</em>The net&#160;cash proceeds to the Company from the <em style="font: inherit;"> April </em>Overallotment Exercise were approximately $0.2&#160;million which include&#160;offering costs of less than $0.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> August 28, 2024, </em>the Company issued 20,000 shares of Common Stock in relation to consulting services performed by a <em style="font: inherit;">third</em> party. The fair value of the Common Stock on the date of issuance was less than $0.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the&#160;year ended <em style="font: inherit;"> December 31, 2024,&#160;</em>Anson converted $4.2 million of principal and interest of the First Tranche Note into common stock, resulting in the issuances of 3,676,796 shares of Common Stock valued at $5.5 million based on the market price of our common stock at the date of common stock issuance resulting in a loss on redemption&#160;of $1.3 million (see Note <em style="font: inherit;">7</em>).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Common Stock Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Substitute Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Merger in <em style="font: inherit;">2021,</em> each warrant to purchase shares of Common Stock of NRx that was outstanding and unexercised immediately prior to the effective time (whether vested or unvested) was assumed by Big Rock Partners Acquisition Corp. (<i>"BRPA"</i>) and converted into a warrant, based on the exchange ratio (of&#160;0.316), that will continue to be governed by substantially the same terms and conditions, including vesting, as were applicable to the former warrant (the &#8220;<i>Substitute Warrants</i>&#8221;). There were 3,792,970 warrants outstanding and unexercised at the effective time. As these Substitute Warrants meet the definition of a derivative as contemplated in FASB ASC Topic <em style="font: inherit;">815,</em> based on provisions in the warrant agreement related to the Earnout Shares Milestone and the Earnout Cash Milestone and the contingent right to receive additional shares for these provisions, the Substitute Warrants were recorded as derivative liabilities on the consolidated balance sheet and measured at fair value at inception (on the date of the Merger) and at each reporting date in accordance with FASB ASC Topic <em style="font: inherit;">820,</em> with changes in fair value recognized in the statements of operations in the period of change.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognized a gain on the change in fair value of the Substitute Warrants for each of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> of <span style="-sec-ix-hidden:c125342246">nil</span> and less than $0.1 million, respectively. Refer to Note <em style="font: inherit;">11</em> for further discussion of fair value measurement of the warrant liabilities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Assumed Public Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to the Merger, the Company had&#160;3,450,000&#160;warrants outstanding (the &#8220;<i>Public Warrants</i>&#8221;) to purchase up to 345,000 shares of Common Stock. Each Public Warrant entitles the holder to purchase&#160;<span style="-sec-ix-hidden:c125342251">one</span>-<em style="font: inherit;">tenth</em>&#160;share of Common Stock at an exercise price of $115&#160;per share. The Public Warrants became exercisable at the effective time of the Merger and expire&#160;<em style="font: inherit;">five</em> years&#160;after the effective time on or earlier upon their redemption or liquidation of the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> no&#160;Public Warrants were exercised. The outstanding balance of these warrants remains in equity. At <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> there were 3,448,856 Public Warrants outstanding to purchase up to 344,886 shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Assumed Private Placement Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Prior to the Merger, the Company had outstanding&#160;136,250&#160;Private Placement Warrants (the &#8220;<i>Private Placement Warrants</i>&#8221;) to purchase up to 13,625 shares of Common Stock.&#160;The Private Placement Warrants are <em style="font: inherit;">not</em> indexed to the Company&#8217;s common shares in the manner contemplated by FASB ASC Topic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>-<em style="font: inherit;">15</em> because the holder of the instrument is <em style="font: inherit;">not</em> an input into the pricing of a fixed-for-fixed option on equity shares. The Company classifies the Private Placement Warrants as derivative liabilities in its consolidated balance sheets as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The Company measures the fair value of the Private Placement Warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company&#8217;s statements of operations for the current period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognized a gain on the change in fair value of the Private Placement Warrants for each of the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> of less than $0.1 million, respectively. Refer to Note <em style="font: inherit;">11</em> for discussion of the fair value measurement of the Company&#8217;s warrant liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Investor Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 8, 2023, </em>in conjunction with the issuance and sale of&#160;386,667&#160;shares of the Company&#8217;s Common Stock, the Company issued 386,667 <em style="font: inherit;"> March </em>Investor Warrants which were classified in stockholder&#8217;s equity. The measurement of fair value of the <em style="font: inherit;"> March </em>Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $7.20, exercise price of $7.50, term of <span style="-sec-ix-hidden:c125342277">five</span> and a half years, volatility of 123.6%, risk-free rate of 4.34%, and expected dividend rate of 0%). The <em style="font: inherit;"> March </em>Investor Warrants had an original exercise price of $7.50 per share, are initially exercisable beginning&#160;<em style="font: inherit;">six</em> months&#160;following the <em style="font: inherit;"> March </em>Initial Exercise Date and will expire&#160;<span style="-sec-ix-hidden:c125342283">five</span> and a half years&#160;from the <em style="font: inherit;"> March </em>Initial Exercise Date.&#160; The grant date fair value of these <em style="font: inherit;"> March </em>Investor Warrants was estimated to be $2.4 million on <em style="font: inherit;"> March 8, 2023 </em>and is reflected within additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As discussed above, on <em style="font: inherit;"> June 6, 2023, </em>in conjunction with the issuance and sale of&#160;967,000 shares of the Company&#8217;s Common Stock, the Company issued 967,000 <em style="font: inherit;"> June </em>Investor Warrants which were classified in stockholder&#8217;s equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The measurement of fair value of the <em style="font: inherit;"> June </em>Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $5.30, exercise price of $6.53, term of <span style="-sec-ix-hidden:c125342289">five</span> and a half years, volatility of 175.1%, risk-free rate of 3.85%, and expected dividend rate of 0%). The grant date fair value of these <em style="font: inherit;"> June </em>Investor Warrants was estimated to be $3.1 million on <em style="font: inherit;"> June 6, 2023, </em>and is reflected within additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company issued 19,340 warrants to the Placement Agent with an exercise price of $8.13 (the <em style="font: inherit;"> &#8220;June </em>Placement Agent Warrants&#8221;). As these <em style="font: inherit;"> June </em>Placement Agent Warrants were issued for services provided in facilitating the <em style="font: inherit;"> June </em>Offering, the Company recorded the fair value of such <em style="font: inherit;"> June </em>Placement Agent Warrants of approximately $0.1 million as a cost of capital on the issuance date. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $5.30, exercise price of $8.13, term of <span style="-sec-ix-hidden:c125342299">five</span> and a half years, volatility of 175.1%, risk-free rate of 3.85%, and expected dividend rate of 0%).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with the <em style="font: inherit;"> June 2023 </em>Offering, the Company also entered into a warrant amendment agreement (the &#8220;Warrant Amendment Agreement&#8221;) with certain investors to amend certain existing warrants to purchase up to 962,278 shares of Common Stock that were previously issued in <em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2021</em> and <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">2022</em> to such investors, with an exercise price of $30.70 and $120.00 per share, respectively (the &#8220;Amended Warrants&#8221;) as follows: (i)&#160;lower the exercise price of the Amended Warrants to $6.525 per share, and (ii)&#160;provide that the Amended Warrants, as amended, will <em style="font: inherit;">not</em> be exercisable until <em style="font: inherit;">six</em> months following the closing date of the <em style="font: inherit;"> June </em>Offering, and (iii)&#160;extend the original expiration date of the Amended Warrants so that they will terminate <span style="-sec-ix-hidden:c125342311">five</span> and <em style="font: inherit;">one</em> half years from the closing of the <em style="font: inherit;"> June </em>Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recorded the incremental change in fair value of such Amended Warrants of $1.5 million as a cost of capital to issue the <em style="font: inherit;"> June </em>Investor Warrants. The measurement of fair value for the Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $5.30, exercise price of $6.525, term of <span style="-sec-ix-hidden:c125342316">five</span> and a half years, volatility of 175.1%, risk-free rate of 3.85%, and expected dividend rate of 0%).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As discussed above, on <em style="font: inherit;">August&#8239;28,</em> <em style="font: inherit;">2023,</em> in conjunction with the issuance and sale of 3,000,000 shares of the Company&#8217;s Series&#8239;A Convertible Preferred Stock, the Company issued 300,000 <em style="font: inherit;"> August </em>Investor Warrants which were classified in stockholder&#8217;s equity. Each Investor Warrants had an exercise price of $4.00 and term of <span style="-sec-ix-hidden:c125342325">five</span> years. The measurement of fair value of the <em style="font: inherit;"> August </em>Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.00, exercise price of $4.00, term of <span style="-sec-ix-hidden:c125342328">five</span> years, volatility of 175.1%, risk-free rate of 4.38%, and expected dividend rate of 0%). The grant date fair value of these <em style="font: inherit;"> August </em>Investor Warrants was estimated to be $0.8 million on <em style="font: inherit;"> August 28, 2023 </em>and is reflected within additional paid-in capital.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> October 24, 2023, </em>in connection with the Securities Purchase Agreement dated <em style="font: inherit;"> March 8, 2023, </em>the Company entered into a warrant amendment agreement (the <em style="font: inherit;"> &#8220;October </em>Warrant Amendment Agreement&#8221;) with certain Investors to amend the existing Investor Warrants to purchase up to 386,667 shares of Common Stock that were previously issued in <em style="font: inherit;"> March 2023 </em>adjusted from the original exercise price of $7.50 to $6.525 per share (the <em style="font: inherit;"> &#8220;October </em>Amended Warrants&#8221;).&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recorded the incremental change in fair value of such <em style="font: inherit;"> October </em>Amended Warrants of approximately $9.0 thousand as a deemed dividend and an adjustment to arrive at net income available to common stockholders on the statement of operations. As the Company is in an accumulated deficit position, in the absence of retained earnings, the Company recorded the reduction to additional paid-in capital (i.e., a net <em style="font: inherit;">zero</em> impact to additional paid-in capital). The measurement of fair value for the <em style="font: inherit;"> October </em>Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of amendment (i.e., share price of $2.80, exercise price of $6.525, term of <span style="-sec-ix-hidden:c125342340">five</span> years, volatility of 159.4%, risk-free rate of 4.85%, and expected dividend rate of 0%).&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> February 28, 2024, </em>in conjunction with the sale of&#160;270,000&#160;shares of the Company&#8217;s Common Stock, the Company issued&#160;<em style="font: inherit;"> February </em>Warrants to purchase up to 270,000 shares of Common Stock which were classified in stockholder&#8217;s equity. The <em style="font: inherit;"> February </em>Warrants have an exercise price of $3.80 per share, are initially exercisable beginning <em style="font: inherit;">six</em> months following the date of issuance, and will expire <span style="-sec-ix-hidden:c125342350">five</span>&#160;years from the date of issuance. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.59, exercise price of $3.80, term of 5 years, volatility of 178.10%, risk-free rate of 4.26%, and expected dividend rate of 0%). The allocated fair value of the <em style="font: inherit;"> February </em>Warrants on the grant date was $0.5 million and is recorded within&#160;additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> February 28, 2024, </em>the Company issued to the Representative the Underwriter&#8217;s Warrant to purchase up to 25,000 shares of Common Stock (the &#8220;<i><em style="font: inherit;"> February </em>Underwriter Warrant Shares</i>&#8221;). The Underwriter&#8217;s Warrant is exercisable <em style="font: inherit;">six</em> months following the date of the Underwriting Agreement and terminates on the <span style="-sec-ix-hidden:c125342360">five</span>-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.05, exercise price of $3.30, term of 5 years, volatility of 178.10%, risk-free rate of 4.26%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was $0.1 million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 5, 2024 </em>the Company issued Underwriter&#8217;s Warrant to purchase up to 3,750 shares of Common Stock in relation to the exercise of the <em style="font: inherit;"> February </em>Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.05, exercise price of $3.30, term of 5 years, volatility of 178.10%, risk-free rate of 4.12%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> April 19, 2024, </em>the Company issued to the Representative the <em style="font: inherit;"> April </em>Underwriter&#8217;s Warrant to purchase up to 30,350 shares of Common Stock (the &#8220;<i><em style="font: inherit;"> April </em>Underwriter Warrant Shares</i>&#8221;). The <em style="font: inherit;"> April </em>Underwriter&#8217;s Warrant is exercisable <em style="font: inherit;">six</em> months following the date of the Underwriting Agreement and terminates on the <span style="-sec-ix-hidden:c125342378">five</span>-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.04, exercise price of $3.63, term of 5 years, volatility of 178.10%, risk-free rate of 4.66%, and expected dividend rate of 0%). The allocated fair value of the <em style="font: inherit;"> April </em>Underwriter's Warrant&#160;on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> May 23, 2024 </em>the Company issued Underwriter&#8217;s Warrant to purchase up to 4,553 shares of Common Stock in relation to the exercise of the <em style="font: inherit;"> April </em>Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.62, exercise price of $3.63, term of 5 years, volatility of 178.10%, risk-free rate of 4.52%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Alvogen Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In conjunction with the amended Alvogen licensing agreement discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> February 7, 2024, </em>the Company issued warrants to purchase up to 419,598 shares of Common Stock. The warrants have an exercise price of $4.00 per share, are exercisable immediately following the date of issuance, will expire <span style="-sec-ix-hidden:c125342399">three</span>&#160;years from the date of issuance, and <em style="font: inherit;"> may </em>also be exercised on a cashless basis if there is <em style="font: inherit;">no</em> effective registration statement available for the resale of the shares of Common Stock underlying the warrants. The warrants are subject to a beneficial ownership limitation of 4.99% post-exercise, with the exception that the beneficial ownership limitation <em style="font: inherit;"> may </em>be waived up to a maximum of 9.99% at the election of the holder, with <em style="font: inherit;">not</em> less than <em style="font: inherit;">61</em> days prior notice. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $4.10, exercise price of $4.00, term of 3 years, volatility of 138.0%, risk-free rate of 4.2%, and expected dividend rate of 0.0%). The fair value of the warrants on the grant date was $1.3 million and was recorded within additional paid-in capital as of <em style="font: inherit;"> March 31, 2024.&#160;</em>Upon termination of the Alvogen Agreement on <em style="font: inherit;"> June 21, 2024, </em>the offsetting&#160;amount recorded within additional paid-in capital as an unfunded stock subscription receivable was expensed to research and development.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Anson Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Anson&#160;Warrants, originally issued in the Purchase Agreement, are recognized as derivative liabilities in accordance with ASC <em style="font: inherit;">815.</em> The Company concluded liability classification was appropriate&#160;as certain settlement features included in the Anson Warrants are <em style="font: inherit;">not</em> indexed to the Company's own stock, and therefore preclude&#160;equity classification. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercise or expiration, and any change in fair value is recognized in the Company&#8217;s consolidated statements of operations. The Anson Warrants were initially measured at fair value using a Black-Scholes model and have subsequently been measured based on the listed market price of such warrants. Warrant liabilities are classified as current liabilities on the Company's consolidated balance sheets. On <em style="font: inherit;"> August 14, 2024, </em>in conjunction with the issuance of the First Tranche Notes, the Company issued warrants&#160;to purchase up to 1,349,305 shares of the Company&#8217;s Common Stock which were classified as a liability. The warrants have an exercise price of $2.4168 per share, subject to adjustment or other settlement provisions, and have a contractual term of <span style="-sec-ix-hidden:c125342416">five</span> years expiring on <em style="font: inherit;"> August 14, 2029.&#160;</em>The measurement of fair value of the Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $1.86, exercise price of $2.42, term of <span style="-sec-ix-hidden:c125342419">five</span> years, volatility of 122%, and risk-free rate of 3.67%, and expected dividend rate of 0%). The grant date fair value of these Investor Warrants was estimated to be $2.1 million on <em style="font: inherit;"> August 14, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> October 10, 2024, </em>in conjunction with the issuance of the Second Tranche Notes, the Company issued warrants&#160;to purchase up to 1,846,128 shares of the Company&#8217;s Common Stock which were classified as a liability. The warrants have an exercise price of $1.7664 per share, subject to adjustment or other settlement provisions, and have a contractual term of <span style="-sec-ix-hidden:c125342426">five</span> years expiring on <em style="font: inherit;"> October 10, 2029.&#160;</em>The measurement of fair value of the Investor Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $1.38, exercise price of $1.76, term of five years, volatility of 105%, and risk-free rate of 3.91%, and expected dividend rate of 0%). The grant date fair value of these Second Trench Investor Warrants was estimated to be $1.9 million on <em style="font: inherit;"> October 10, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the fair value of the Anson Warrants was&#160;$5.6 million. The Company recognized a loss on the change in fair value of The Anson&#160;Warrant for the year ended <em style="font: inherit;"> December 31, 2024 </em>of approximately $1.7 million. Refer to Note <em style="font: inherit;">11</em> for discussion of the fair value measurement of the Company&#8217;s warrant liabilities. Refer to Note <em style="font: inherit;">11</em> for further discussion of fair value measurement of the warrant liabilities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table provides the activity for all warrants for the respective periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Aggregate </b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><b>Intrinsic</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><em style="font: inherit;">Total </em></b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Term</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,648,492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,673,007</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,321,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,948,484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(96,417</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,173,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034934631232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em> Stock-Based Compensation </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2016</em> Omnibus Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to the Merger, NRx maintained its <em style="font: inherit;">2016</em> Omnibus Incentive Plan (the &#8220;<i><em style="font: inherit;">2016</em> Plan</i>&#8221;), under which NeuroRx granted incentive stock options, restricted stock awards, other stock-based awards, or other cash-based awards to employees, directors, and non-employee consultants. The maximum aggregate shares of Common Stock that were subject to awards and issuable under the <em style="font: inherit;">2016</em> Plan was&#160;347,200.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, based on the Exchange Ratio (of&#160;<span style="-sec-ix-hidden:c125342446">0.316:1</span>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate&#160;289,542&#160;shares of the Company&#8217;s Common Stock at an average exercise price of $51.00&#160;per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2021</em> Omnibus Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of&#160;<em style="font: inherit;"> December 31, 2024, </em>955,281&#160;shares of Common Stock are authorized for issuance pursuant to awards under the Company&#8217;s <em style="font: inherit;">2021</em> Omnibus Incentive Plan (the &#8220;<i><em style="font: inherit;">2021</em> Plan</i>&#8221;). As of <em style="font: inherit;"> January 1, 2024, </em>83,920&#160;shares were added to the <em style="font: inherit;">2021</em> Plan under an evergreen feature that automatically increases the reserve with additional shares of Common Stock for future issuance under the Incentive Plan each calendar year, beginning <em style="font: inherit;"> January 1, 2022 </em>and ending on and including <em style="font: inherit;"> January 1, 2031, </em>equal to the lesser of (A) 1% of the shares of Common Stock outstanding on the final day of the immediately preceding calendar year or (B) a smaller number of shares determined by the Board. On <em style="font: inherit;"> December 28, 2023 </em>the <em style="font: inherit;">first</em> amendment to the <em style="font: inherit;">2021</em> Omnibus Plan was executed which increased the maximum number of shares (i) available for issuance under the Plan, by an additional 200,000 shares, and (ii) that <em style="font: inherit;"> may </em>be delivered pursuant to the exercise of Incentive Stock Options granted under the Plan to be equal to <em style="font: inherit;">100%</em> of the Share Pool. As of <em style="font: inherit;"> December 31, 2024, </em>an aggregate 575,099&#160;shares have been awarded net of forfeitures, and 380,182&#160;shares remain available for issuance under the <em style="font: inherit;">2021</em> Plan. The <em style="font: inherit;">2021</em> Plan permits the granting of incentive stock options, restricted stock awards, other stock-based awards or other cash-based awards to employees, directors, and non-employee consultants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Option Awards</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company&#8217;s stock options for employees has been determined utilizing the &#8220;simplified&#8221; method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does <em style="font: inherit;">not</em> expect to pay any cash dividends in the foreseeable future. Additionally, certain options granted contain terms that require all unvested options to immediately vest a) upon the approval of an NDA by the FDA for <em style="font: inherit;">NRX&#8209;101,</em> or b) immediately preceding a change in control of the Company, whichever occurs first.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company issued 0 and 90,000 stock options during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following assumptions were used for the year ended <em style="font: inherit;"> December 31, 2023:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">Exercise price</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.00</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$11.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate of interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.83%</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.79%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">150.3%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table summarizes the Company&#8217;s employee and non-employee stock option activity under the <em style="font: inherit;">2021</em> Plan for the following periods:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted average<br/> exercise price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted average remaining contractual life (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate intrinsic value (in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">264,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Expire</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(143,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">121,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">7.0</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options vested and exercisable as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">6.9</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation expense related to stock options was approximately $0.2 and $0.1 million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The weighted average grant date fair value per share for employee stock and non-employee option grants during the year ended <em style="font: inherit;"> December 31, 2023 </em>was $3.50, respectively. There were <span style="-sec-ix-hidden:c125342477">no</span> option grants during the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At <em style="font: inherit;"> December 31, 2024, </em>the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was less than $0.1 million, which the Company expects to recognize over a weighted-average period of approximately 1.2 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Restricted Stock Awards</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Company&#8217;s Restricted Stock Activity:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Awards</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023 (unvested)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(90,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(33,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024 (unvested)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> July 12, 2022, </em>the Board granted an award of&#160;100,000&#160;restricted shares of the Company (&#8220;Restricted Stock&#8221;) as an inducement to the newly appointed CEO, pursuant to a separate Restricted Stock Award Agreement (the &#8220;RSA&#8221;). The Restricted Stock will vest in approximately equal installments over&#160;<em style="font: inherit;">three</em>&#160;(3) years from the grant date, subject to continued service through the applicable vesting date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> December 28, 2023, </em>the Company granted 57,500 RSAs to a consultant for services provided. The RSAs will vest after <span style="-sec-ix-hidden:c125342486">six</span> months from the grant date. The shares were valued on the grant date based on the quoted price of $4.60 or approximately $0.3 million which will be amortized over the vesting term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation expense related to RSAs was approximately $0.3&#160;and $0.3 million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> October 2024, </em>the Company's CEO announced his resignation and as a result, all unvested RSAs were forfeited. Accordingly, the Company does <span style="-sec-ix-hidden:c125342492">not</span> expect to recognize any further stock-based compensation expense for the balance of unvested RSAs as of <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table summarizes the Company&#8217;s recognition of stock-based compensation for the following periods (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development related stock-based compensation expenses carried a negative balance for <em style="font: inherit;">2023</em> due to reversals of unvested stock options related to <em style="font: inherit;">2023</em> terminations in accordance with our policy.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034944684384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em> Fair Value Measurements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of stock options and warrants issued for services, and warrants issued with the Convertible Notes are estimated based on the Black-Scholes model during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The fair value of the Convertible Notes were estimated utilizing a Monte Carlo simulation during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value on a Recurring Basis</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company follows the guidance in ASC <em style="font: inherit;">820</em> for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the money market account represents a Level <em style="font: inherit;">1</em> measurement. The estimated fair value of the warrant liabilities and convertible note payable represent Level <em style="font: inherit;">3</em> measurements. The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money Market Account</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrant liabilities (Note 9)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Convertible notes payable (Note 7)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Convertible Note Payable - Streeterville</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The significant inputs used in the Monte Carlo simulation to measure the Streeterville convertible note liability that was categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Time to expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Note market interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volume volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability of default</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:-9pt;">During the year ended <em style="font: inherit;"> December 31, 2024, </em>the Streeterville Note was repaid in full and the outstanding balance was $0 as of <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth a summary of the changes in the fair value of the Convertible Note categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,850</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,786</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Convertible Notes Payable - Anson</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The significant inputs used in the Monte Carlo simulation to measure the Anson Convertible Notes that are categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Time to expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.87</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8211;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">11.80%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120.7%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">135.0%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.20%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability of credit default prior to maturity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table sets forth a summary of the changes in the fair value of the Anson Notes categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Notes at issuance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c125341634">(4,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,413</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Warrant Liabilities</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company utilizes a Black-Scholes model approach to value the Private Placement Warrants and Substitute Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liabilities is determined using Level <em style="font: inherit;">3</em> inputs. There were <em style="font: inherit;">no</em> transfers between levels within the fair value hierarchy during the periods presented. Inherent in a Black Scholes options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility. For any lookback period which exceeded the trading history, the volatility was weighed between the actual and comparable public companies. The risk-free interest rate is based on the U.S. Treasury <em style="font: inherit;">zero</em>-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level <em style="font: inherit;">3</em> of the fair value hierarchy are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">111</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">150.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A reconciliation of warrant liabilities is included below (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain upon re-measurement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Initial recognition of issuance of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,965</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Loss upon re-measurement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,657</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034931527376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">12.</em> Segment Reporting</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company operates as a <span style="-sec-ix-hidden:c125342722"><span style="-sec-ix-hidden:c125342723">single</span></span> operating and reportable segment, consistent with the manner in which the Chief Executive Officer, designated as the Chief Operating Decision Maker (CODM) of the Company, evaluates the Company&#8217;s performance and allocates resources. The Company&#8217;s operations solely consist of the development of novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#8220;PTSD&#8221;) and now schizophrenia.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company did <span style="-sec-ix-hidden:c125342519"><span style="-sec-ix-hidden:c125342724">not</span></span> generate any revenue during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em> The CODM evaluates performance based on operating expenses and monitors key expense categories related to the Company&#8217;s research and development activities, as well as general and administrative functions. As the Company is currently in the pre-revenue phase, the associated expenses above are drivers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The CODM does <em style="font: inherit;">not</em> separately evaluate performance by geographic region or product line, as the Company has <em style="font: inherit;">not</em> yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company&#8217;s operations are conducted solely within the United States of America.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Significant Segment Information</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">All of the Company&#8217;s assets relate to this single operating segment, see the accompanying balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">All of the Company&#8217;s operating expenses, which consists of research and development and general and administrative expenses, relate to this single operating segment, see the accompanying statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table reconciles the loss from operations to total loss:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Years Ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Expense Category</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18,502</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(27,837</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value of convertible notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,654</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,657</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on convertible note redemptions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(30,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Long-lived assets consist of property, plant, and equipment, net which are included in other assets in the balance sheet as they are <em style="font: inherit;">not</em> material. Long-lived assets by year are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers, cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034831588864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">13.</em> Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company maintains a full valuation allowance on its net deferred tax asset due to the uncertainty of future taxable income. The Company did <span style="-sec-ix-hidden:c125342527"><span style="-sec-ix-hidden:c125342725">not</span></span> recognize an income tax benefit in the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023</em> due to the uncertainty of future taxable income. In the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the difference between the statutory tax rate and the Company&#8217;s effective tax rate was due primarily to the valuation allowance recorded to offset any potential tax benefit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A reconciliation of the statutory U.S. federal income tax rate to the Company&#8217;s effective tax rate consist of the following:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the Years Ended December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Settlement warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on Conversion of Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">R&amp;D credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The components of income tax provision (benefit) are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State and Local</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,428</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,758</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,850</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that give rise to deferred tax assets and liabilities are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets (liabilities):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,753</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,830</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">174 capitalization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,186</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Bonus and severance accrual</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(49,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(44,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets, net of allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> the Company had federal net operating losses of approximately $187.1 million and $168.5 million, respectively, and state net operating loss carryforwards of approximately $10.2 million and $10.4 million, respectively. The federal and state net operating loss carryforwards generated in the tax years prior to <em style="font: inherit;">2018</em> will begin to expire, if <em style="font: inherit;">not</em> utilized, by <span style="-sec-ix-hidden:c125342539">2035.</span> Certain Net Operating Losses in these jurisdictions are <em style="font: inherit;">not</em> subject to expiration.&#160; Utilization of the net operating loss carryforwards <em style="font: inherit;"> may </em>be subject to an annual limitation according to Section&#160;<em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986</em> as amended, and similar provisions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>


   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">ASC <em style="font: inherit;">740</em> requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. After consideration of all of the evidence, the Company has recorded a valuation allowance of $49.665 million against its deferred tax assets at <em style="font: inherit;"> December 31, 2024 </em>because management has determined that it is more likely than <em style="font: inherit;">not</em> that the Company will <em style="font: inherit;">not</em> recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of products or generation of revenue from product sales since inception.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes interest accrued to unrecognized tax benefits and penalties as income tax expense. The Company accrued total penalties and interest of $0 during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023</em> and in total, as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023</em> has recognized penalties and interest of $0.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which they operate. In the normal course of business, the Company is subject to examination by federal and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2024,</em> open years related to all jurisdictions are <em style="font: inherit;">2023,</em> <em style="font: inherit;">2022,</em> and <em style="font: inherit;">2021.</em>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has <em style="font: inherit;">no</em> open tax audits with any taxing authority as of <em style="font: inherit;"> December 31, 2024.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827873376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">14.</em> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Glytech Agreement</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company licenses patents that are owned by Glytech, LLC (&#8220;<i>Glytech</i>&#8221;), pursuant to a license agreement (the &#8220;<i>Glytech Agreement</i>&#8221;). Glytech is owned by Daniel Javitt, a co-founder and former director of the Company. The Glytech Agreement requires that the Company pay Glytech for ongoing scientific support and also reimburse Glytech for expenses of obtaining and maintaining patents that are licensed to the Company. During both the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> September 30, 2024&#160;</em>and&#160;<em style="font: inherit;">2023,</em> the Company paid Glytech <span style="-sec-ix-hidden:c125342568">zero</span>&#160;and&#160;$0.1&#160;million, respectively,&#160;for continuing technology support services and reimbursed expenses. During the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> the Company paid Glytech $0.3 million and $0.3 million, respectively, for continuing technology support services and reimbursed expenses. These support services are ongoing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Fourth Amendment to the Glytech Agreement, effective as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em> includes an equity value-triggered transfer of Excluded Technology from Glytech to NRx Pharmaceuticals. The Excluded Technology is defined in the Glytech Agreement as any technology, and any know-how related thereto, covered in the licensed patents that do <em style="font: inherit;">not</em> recite either D-cycloserine or lurasidone individually or jointly. This definition would cover pharmaceutical formulations, including some that NRx Pharmaceuticals considers &#8220;pipeline&#8221; or &#8220;future product&#8221; opportunities, that contain a combination of pharmaceutical components different from those contained in NRX-<em style="font: inherit;">100</em> and NRX-<em style="font: inherit;">101.</em> On <em style="font: inherit;"> November 6, 2022 </em>the Glytech Agreement was amended whereby Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology to NRx Pharmaceuticals for <em style="font: inherit;">no</em> additional consideration at any time upon receipt of written notice from the Company if, on or prior to <em style="font: inherit;"> March 31, 2024, (</em>i) the value of the Glytech equity holdings in NRx Pharmaceuticals (the &#8220;Glytech Equity&#8221;) has an aggregate liquidity value of at least $50 million for <em style="font: inherit;">twenty</em> (<em style="font: inherit;">20</em>) consecutive trading days immediately preceding any given date and (ii) there are <em style="font: inherit;">no</em> legal or contractual restrictions on selling all of the securities represented by the Glytech Equity then applicable to Glytech (or reasonably foreseeable to be applicable to Glytech within the following <em style="font: inherit;">twenty</em> trading days).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Consulting Agreement with Dr. Jonathan Javitt</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major shareholder in the Company and a member of the Board of Directors. Therefore, his services are deemed to be a related party transaction. He served the Company on a full-time basis as CEO under an employment agreement with the Company until <em style="font: inherit;"> March 8, 2022 </em>and currently serves under a Consulting Agreement with the Company as Chief Scientist thereafter and received compensation of $0.1 million and $0.9 million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 29, 2023, </em>the Consulting Agreement dated <em style="font: inherit;"> March 8, 2022 (</em>the &#8220;Javitt Consulting Agreement&#8221;) between the Company and Dr. Jonathan Javitt was amended to extend the term of the Agreement until <em style="font: inherit;"> March 8, 2024 </em>with automatic annual renewals thereafter unless <em style="font: inherit;">one</em> party or the other provides notice of non-renewal. The amendment also provided for payment at the rate of $0.6 million per year, payable monthly (i.e., less than $0.1 million per month), and a performance-based annual bonus with a minimum target of $0.3 million, at the discretion of the Board and upon satisfactory performance of the services. The annual discretionary bonus for <em style="font: inherit;">2023,</em> if any, <em style="font: inherit;"> may </em>be approved by the board in <em style="font: inherit;">2024</em> and is payable in <em style="font: inherit;"> March 2024, </em>will be pro-rated from the start of the extension period and is subject to Dr. Javitt&#8217;s continued engagement by the Company. The annual discretionary bonus for <em style="font: inherit;">2024,</em> if any, <em style="font: inherit;"> may </em>be approved by the board in <em style="font: inherit;">2025</em> and is payable in <em style="font: inherit;"> March 2025, </em>will be pro-rated from the start of the extension period and is subject to Dr. Javitt&#8217;s continued engagement by the Company. As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2024,</em> the annual discretionary bonus of $0.3 million and $0.2 million&#160;is accrued and included within accrued and other current liabilities on the consolidated balance sheets, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Javitt Amendment also provides, subject to the approval of the Board of Directors, for a grant of 50,000 shares of restricted stock of the Company under the Company&#8217;s <em style="font: inherit;">2021</em> Omnibus Incentive Plan. The restrictions are performance based, and half of the restricted shares (25,000) shall have the restrictions removed on the New Drug Application Date (as defined below) and the remaining half (25,000) will have the restrictions removed on the New Drug Approval Date (as defined below). As of <em style="font: inherit;"> December 31, 2024, </em>the Board of Directors has <em style="font: inherit;">not</em> approved the grant of restricted stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The term &#8220;New Drug Application Date&#8221; means the date upon which the FDA files the Company&#8217;s new drug application for the Antidepressant Drug Regimen (as defined below) for review. The term &#8220;New Drug Approval Date&#8221; means date upon which the FDA has both approved the Company&#8217;s Antidepressant Drug Regimen and listed the Company&#8217;s Antidepressant Drug Regimen in the FDA&#8217;s &#8220;Orange Book&#8221;. The term &#8220;Antidepressant Drug Regimen&#8221; means NRX-<em style="font: inherit;">101,</em> a proprietary fixed-dose combination capsule of d-cycloserine and Lurasidone, administered for sequential weeks of daily oral treatment following patient stabilization using a single infusion of NRX-<em style="font: inherit;">100</em> (ketamine) or another standard of care therapy.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Consulting Agreement with Zachary Javitt</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company&#8217;s CEO who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of $0.1 million during the years ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. These services are ongoing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Included in accounts payable were less than $0.1 million and less than <span style="-sec-ix-hidden:c125342610">$0.1</span> million due to the above related parties as of <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034931408368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">15.</em> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Terminated <em style="font: inherit;"> January 2025 </em>Financing</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;">The Company was a party to definitive stock purchase agreements with an Arizona-based investment firm, Smith and Sauer, through their affiliate, JGS Holdings, LLC (&#8220;JGS Holdings&#8221;) whereby JGS Holdings committed to invest $2.0 million in NRx&#8217;s common stock, with an additional commitment of $25.0 million to be invested directly in HOPE.&#160;JGS Holdings defaulted under the terms of the agreements, despite several extensions of the closing date.&#160;The Company formally terminated the stock purchase agreement on <em style="font: inherit;"> March 13, 2025.&#160; </em>Although <em style="font: inherit;">no</em> assurances can be given, management is currently negotiating with an alternative strategic investor to replace the investment contemplated with JGS Holdings, and, together with alternative sources of equity and debt capital, management believes it will able to fund its previously announced acquisitions on terms more favorable to our shareholders.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><a href="#" id="notesend" title="notesend"></a><b><i><span style="text-decoration: underline; "><em style="font: inherit;"> January </em>Financings</span></i></b></p>
   <div>
     &#160;
   </div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Issuance of Senior Secured Promissory Notes and Common Stock Purchase Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On or about <em style="font: inherit;"> January 28, 2025, </em>the Company sold certain institutional investors (the &#8220;Investors&#8221;) a total of (a) $5.435 million in Notes (the &#8220;<i>Third Tranche Notes</i>&#8221;), with an aggregate purchase price of approximately $5.0 million, and (b) Warrants to purchase up to 862,699 shares of Common Stock (the &#8220;<i>Third Closing</i>&#8221;). The Third Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $3.78 (the &#8220;<i>Fixed Conversion Price</i>&#8221;) or (b) a price equal to 92% of the lowest VWAP during the <span style="-sec-ix-hidden:c125342623">seven</span> trading day period immediately preceding the effective date set forth in a Notice of Conversion (as defined in the Notes) (each, a &#8220;<i>Conversion Date</i>&#8221;) delivered by an Investor to the Company (the &#8220;<i>Alternate Conversion Price</i>&#8221;, and together with the Fixed Conversion Price, the &#8220;<i>Conversion Price</i>&#8221;). The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of Common Stock (or Common Stock Equivalents) below the then effective Conversion Price. The Company plans to use a portion of the proceeds from the sale of the Third Tranche Notes for general working capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Entry into Securities Purchase Agreement for Registered Direct Offering</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> January 27, 2025, </em>the Company entered into a securities purchase agreement (the &#8220;<i>RD Purchase Agreement</i>&#8221;) with the Investors for the sale by the Company of 1,215,278 shares (the &#8220;<i>RD Shares</i>&#8221;) of Common Stock to the Investors, at a purchase price of $2.88 per share, in a registered direct offering (the &#8220;<i>Registered Direct Offering</i>&#8221;). Concurrently with the sale of the RD Shares, pursuant to the RD Purchase Agreement the Company also sold to the investors unregistered Common Stock purchase warrants (the &#8220;<i>RD Warrants</i>&#8221;) to purchase up to an aggregate of 1,215,278 shares of Common Stock (the &#8220;<i>RD Warrant Shares</i>&#8221;), in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of Common Stock, subject to adjustments as provided under the terms of the RD Warrants. The closing of the sales of these securities under the RD Purchase Agreement occurred on or about <em style="font: inherit;"> January 29, 2025 (</em>the &#8220;<i>RD Closing Date</i>&#8221;). The RD Warrants are exercisable for <span style="-sec-ix-hidden:c125342628">five</span> years from the RD Closing Date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The gross proceeds to the Company from the offerings were approximately $3,500,000, before deducting offering expenses, and excluding the proceeds, if any, from the exercise of the RD Warrants. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Entry into Waiver and Consent Agreement</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On or about <em style="font: inherit;"> January 27, 2025, </em>the Company and the Investors entered into a Consent and Waiver Agreement (the &#8220;CWA&#8221;), relating to certain rights and prohibitions arising under the Purchase Agreement and the Notes. In the CWA, each of the Investors provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the Purchase Agreement and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and the Investors dated <em style="font: inherit;"> August 14, 2024, </em>until <em style="font: inherit;"> March 31, 2025. </em>As consideration for entering into the CWA, in the event that the VWAP of the Common Stock is less than the per share purchase price of the Common Stock sold to the Investors in the Registered Direct Offering on the Trading Day (as defined in the RD Purchase Agreement) immediately prior to the date that the Investors submit their <em style="font: inherit;">first</em> conversion notice to convert any portion of the Notes issued or to be issued in the Second Closing (as defined in the Purchase Agreement) or the Third Closing (as defined in the Purchase Agreement), respectively, into shares of Common Stock, the Company agreed to issue to the Investors: (i) that number of shares of Common Stock equal to (a) the quotient of (I) aggregate purchase price to be paid for all securities in the Registered Direct Offering, divided by (II) the price per share of Common Stock after giving effect to the VWAP-Based Adjustment (as defined below), minus (b) the number of shares of Common Stock issued, or to be issued, to the Investors at or upon the consummation of the Registered Direct Offering (the &#8220;Consideration Shares&#8221;), and (ii) Common Stock purchase warrants to purchase shares of Common Stock equal to 100% of the aggregate number of Consideration Shares to be issued, with an exercise price equal to the dollar value of the VWAP-Based Adjustment (the &#8220;Consideration Warrants&#8221;). For purposes of the CWA, the &#8220;VWAP Based-Adjustment&#8221; means that amount, in dollars, equal to the greater of either (a) the VWAP of the Common Stock on the Trading Day immediately prior to the date that the Investors submit their <em style="font: inherit;">first</em> conversion notice to convert any portion of the Notes issued and to be issued in the Second Closing or Third Closing into shares of the Company&#8217;s Common Stock, or (b) 80% of the closing price of the Common Stock on the Trading Day immediately prior to the closing of the Registered Direct Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anson Conversion Notices</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From <em style="font: inherit;"> January 2, 2025 </em>to <em style="font: inherit;"> January 3, 2025, </em>the Company received conversion notices from Anson resulting in the conversion of the remaining principal of the First Tranche Note of $1.3 million of principal and interest in full from the First Tranche Note into 1,004,055 shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034820241344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Presentation and Principles of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of NRX Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the fair value of convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results <em style="font: inherit;"> may </em>differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain Risks and Uncertainties</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on <em style="font: inherit;">third</em> party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ASC <em style="font: inherit;">820,</em> <i>Fair Value Measurements</i>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accounting guidance classifies fair value measurements in <em style="font: inherit;">one</em> of the following <em style="font: inherit;">three</em> categories for disclosure purposes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">1:</em> Quoted prices in active markets for identical assets or liabilities.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">2:</em> Inputs other than Level <em style="font: inherit;">1</em> prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3:</em> Unobservable inputs which are supported by little or <em style="font: inherit;">no</em> market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note <em style="font: inherit;">11</em>)</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are <em style="font: inherit;">not</em> exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, exceed federally insured limits. As of <em style="font: inherit;"> December 31, 2024 </em>the Company&#8217;s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $1.2 million. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. &#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company considers all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less at the time of initial purchase to be cash equivalents, including balances held in the Company&#8217;s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time <em style="font: inherit;"> may </em>exceed the U.S. federally insured limits. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company&#8217;s cash flow requirements, and to attain a market rate of return.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue Recognition</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for revenue under FASB ASC Topic <em style="font: inherit;">606,</em> <i>Revenue for Contract with Customers</i> (&#8220;<i>ASC <em style="font: inherit;">606</em></i>&#8221;) or other accounting standards for revenue <em style="font: inherit;">not</em> derived from customers. Arrangements <em style="font: inherit;"> may </em>include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which <em style="font: inherit;"> may </em>include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company enters into contractual arrangements that <em style="font: inherit;"> may </em>include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC <em style="font: inherit;">606,</em> the Company evaluates the promised good or services to determine which promises, or group of promises, represent performance obligations. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which <em style="font: inherit;"> may </em>include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement (the &#8220;<i>License Agreement</i>&#8221;) with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, &#8220;<i>Alvogen</i>&#8221;) (as further discussed in Note <em style="font: inherit;">6</em> below) was accounted for in accordance with ASC <em style="font: inherit;">606.</em> In accordance with ASC <em style="font: inherit;">606,</em> the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC <em style="font: inherit;">606,</em> it performs the following <em style="font: inherit;">five</em> steps:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">i. identify the contract(s) with a customer&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">ii. identify the performance obligations in the contract&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">iii. determine the transaction price&#894;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">iv. allocate the transaction price to the performance obligations within the contract&#894; and</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">v. recognize revenue when (or as) the entity satisfies a performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company only applies the <em style="font: inherit;">five</em>-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At contract inception, once the contract is determined to be within the scope of ASC <em style="font: inherit;">606,</em> the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements typically consist of a license to intellectual property and research services. The Company <em style="font: inherit;"> may </em>provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are <em style="font: inherit;">not</em> individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration <em style="font: inherit;"> may </em>be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur when the uncertainty associated with the variable consideration is subsequently resolved.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s revenue arrangements <em style="font: inherit;"> may </em>include the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestone Payments</i>: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company <em style="font: inherit;">first</em> estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would <em style="font: inherit;">not</em> occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research Services</i>: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note <em style="font: inherit;">6</em> below), the Company would have been&#160;reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company would have recognized revenue for the reimbursed costs when the First Milestone Payment contingencies had&#160;been achieved and the Company had&#160;an enforceable claim to the reimbursed costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research and Development Costs</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development expense&#160;consists primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Charges, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Non-cancellable Contracts</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company <em style="font: inherit;"> may </em>record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs <em style="font: inherit;"> may </em>be recorded as a deferred cost asset.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Convertible Notes Payable and Fair Value Election</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As permitted under FASB ASC Topic <em style="font: inherit;">825,</em> Financial Instruments (&#8220;<i>ASC <em style="font: inherit;">825</em></i>&#8221;), the Company elected to account for its promissory notes, which meet&#160;the required criteria, at fair value at inception. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying consolidated statements of operations and comprehensive loss.&#160;As a result of electing the fair value option, direct costs and fees related to the promissory notes are expensed as incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg&#8217;s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At <em style="font: inherit;"> September 30, 2024, </em>the Streeterville Note valuation&#160;was adjusted to the post settlement amount agreed upon. Interest expense is included within the change in fair value of the notes payable and accrued interest is included within the fair value of the convertible notes payable on the balance sheet. See Note <em style="font: inherit;">7</em> for Streeterville and Anson convertible notes. Management believes those assumptions are reasonable but if these assumptions change, it could materially affect the fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock-Based Compensation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company&#8217;s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations and comprehensive loss based upon the underlying individual&#8217;s role at the Company.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC Topic <em style="font: inherit;">480,</em> <i>Distinguishing Liabilities from Equity</i> (&#8220;<i>ASC <em style="font: inherit;">480</em></i>&#8221;) and FASB ASC Topic <em style="font: inherit;">815,</em> <i>Derivatives and Hedging</i> (&#8220;<i>ASC <em style="font: inherit;">815</em></i>&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own Common Stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company generally determines&#160;fair value of the Common Stock&#160;Warrants (as defined below) using a Black Scholes valuation methodology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which <em style="font: inherit;"> may </em>result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stockholders' Equity, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In accordance with ASC <em style="font: inherit;">480,</em> the Company&#8217;s Series A Preferred Stock was classified as permanent equity as it was <em style="font: inherit;">not</em> mandatorily redeemable upon an event that is considered outside of the Company&#8217;s control. Further, in accordance with ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40,</em> <i>Derivatives and Hedging </i>&#8211;<i> Contracts in an Entity</i>&#8217;<i>s Own Equity</i>, the Series A Preferred Stock did <em style="font: inherit;">not</em> meet any of the criteria that would preclude equity classification. The Company concluded that the Series A Preferred Stock was more akin to an equity-type instrument than a debt-type instrument, therefore the conversion features associated with the convertible preferred stock were deemed to be clearly and closely related to the host instrument and were <em style="font: inherit;">not</em> bifurcated as a derivative under ASC <em style="font: inherit;">815.</em></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Segment Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who reviews financial information presented for purposes of making operating decisions, assessing financial performance, and allocating resources.&#160;The Company operates as a single operating and reportable segment, consistent with the manner in which the CODM evaluates performance and allocates resources, see Note&#160;<em style="font: inherit;">12</em> for further information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Income taxes are recorded in accordance with FASB ASC Topic <em style="font: inherit;">740,</em> <i>Income Taxes</i> (&#8220;<i>ASC <em style="font: inherit;">740</em></i>&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than <em style="font: inherit;">not</em> that some or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740.</em> When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than <em style="font: inherit;">not</em> be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than <em style="font: inherit;">not</em> be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Loss Per Share</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company applies the <em style="font: inherit;">two</em>-class method when computing net income or loss per share attributable to common stockholders. In determining net income or loss attributable to common stockholders, the <em style="font: inherit;">two</em>-class method requires income or loss allocable to participating securities for the period to be allocated between common and participating securities based on their respective rights to share in the earnings as if all of the income or loss allocable for the period had been distributed. In periods of net loss, there is <em style="font: inherit;">no</em> allocation required under the <em style="font: inherit;">two</em>-class method as the participating securities do <em style="font: inherit;">not</em> have an obligation to fund the losses of the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">264,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,173,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,321,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,920,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recent Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;"> November 2023, </em>the FASB&#160;issued Accounting Standard Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2023&#8209;07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>)-<i>Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>)</i>, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>&#160;should be applied on a retrospective basis.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>&#160;is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted. The Company has adopted the reportable segment disclosure requirements. See Note <em style="font: inherit;">12.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>-Income Taxes (Topic <em style="font: inherit;">740</em>): I<i>mprovements to Income Tax Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>)</i>, which is intended to enhance the transparency and decision usefulness of income tax disclosures, primarily by amending disclosure requirements for the effective tax rate reconciliation and income taxes paid.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;should be applied on a prospective basis, and retrospective application is permitted.&#160;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's policy regarding risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034830233552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">264,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,173,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,321,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,920,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034831586128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expense and other current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,078</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid clinical development costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">824</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other prepaid expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">208</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total prepaid expense and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,859</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828615504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued and other current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Refund liability (see Note 6)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,732</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Employee costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">577</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">835</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued research and development expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">655</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,112</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other accrued expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">470</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accrued and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034825443840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Par value of the Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized original issue discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares and cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carrying value of the Note before current period change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(952</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,451</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cumulative fair value adjustments through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">952</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cumulative fair value adjustments through accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total carrying value of Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Par value of the Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Initial original issue discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carrying value of the Anson Notes before current period change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Fair value allocated to Common Stock liability classified warrants</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">(3,966</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,413</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total carrying value of Anson Notes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828445056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ScheduleOfMilestonePaymentsTableTextBlock', window );">Schedule of Milestone Payments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase I Clinical Trials of Licensed Product (completed)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase II Clinical Trials of Licensed Product (completed)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">End of Phase III Clinical Trials of Licensed Product</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in U.S.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First Commercial Sale of Licensed Product in Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual Revenues Reach $100,000,000</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">750,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ScheduleOfMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ScheduleOfMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827627280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Aggregate </b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><b>Intrinsic</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><em style="font: inherit;">Total </em></b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Term</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,648,492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,673,007</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,321,499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,948,484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(96,417</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,173,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034931431392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;">Exercise price</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.00</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$11.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate of interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.83%</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.79%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">150.3%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted average<br/> exercise price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted average remaining contractual life (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate intrinsic value (in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">264,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Expire</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(143,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">121,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">7.0</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options vested and exercisable as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">6.9</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Awards</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023 (unvested)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(90,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(33,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024 (unvested)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034931518736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money Market Account</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrant liabilities (Note 9)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Convertible notes payable (Note 7)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Time to expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Note market interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volume volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability of default</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Time to expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.87</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8211;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">11.80%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120.7%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">135.0%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.20%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability of credit default prior to maturity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock price on valuation date</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">111</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">150.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,850</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (cash)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,786</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Notes at issuance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversions and repayments of principal and interest (shares)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c125341634">(4,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value adjustment through earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,413</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of the Note as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable - current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,011</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain upon re-measurement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Initial recognition of issuance of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,965</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Loss upon re-measurement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,657</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034931452896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Years Ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Expense Category</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18,502</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(27,837</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible note default penalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value of convertible notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,654</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,657</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on convertible note redemptions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(30,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers, cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827546848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the Years Ended December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Settlement warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on Conversion of Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">R&amp;D credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State and Local</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,428</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,758</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,850</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets (liabilities):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,753</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,830</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">174 capitalization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,186</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Bonus and severance accrual</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(49,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(44,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets, net of allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034830284528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Going Concern (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 10, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 12, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nrxp_AnsonMember', window );">Anson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 10,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,870<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentNumberOfTranches', window );">Debt Instrument, Number of Tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentFaceAmountIndividualTranches', window );">Debt Instrument, Face Amount, Individual Tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonSecondTrancheNotesMember', window );">Anson Second Tranche Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">5,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervileComplaintMember', window );">Streetervile Complaint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="nump">$ 5,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentFaceAmountIndividualTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument's individual tranches at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentFaceAmountIndividualTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches to be received as part of a purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nrxp_AnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nrxp_AnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonSecondTrancheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonSecondTrancheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervileComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervileComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034820260048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034818119344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">121,833<span></span>
</td>
<td class="nump">264,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">7,173,766<span></span>
</td>
<td class="nump">3,321,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nrxp_AnsonMember', window );">Anson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,920,126<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nrxp_AnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nrxp_AnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827802320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">$ 1,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PrepaidClinicalDevelopmentExpense', window );">Prepaid clinical development costs</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expense</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other current receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expense and other current assets</a></td>
<td class="nump">$ 1,859<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_PrepaidClinicalDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_PrepaidClinicalDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034825668368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refund liability (see Note 6)</a></td>
<td class="nump">$ 4,715<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee costs</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_AccruedResearchAndDevelopmentLiabilityCurrent', window );">Accrued research and development expense</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expense</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 10,149<span></span>
</td>
<td class="nump">$ 4,714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced within one operating cycle, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_AccruedResearchAndDevelopmentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_AccruedResearchAndDevelopmentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034820215584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Alvogen Licensing Agreement (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 07, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Customer Refund Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_AlvogenLicensingAgreementMember', window );">Alvogen Licensing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementInitialPayment', window );">License Agreement, Initial Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementAcceleratingPayment', window );">License Agreement, Accelerating Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Customer Refund Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_StockSubscriptionsReceivableWriteOff', window );">Stock Subscriptions Receivable, Write Off</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_AlvogenLicensingAgreementMember', window );">Alvogen Licensing Agreement [Member] | Alvogen and Lotus Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementAcceleratingPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the accelerating payment of a license agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementAcceleratingPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the initial payment of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_StockSubscriptionsReceivableWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off amount of stock subscriptions receivable during a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_StockSubscriptionsReceivableWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrxp_AlvogenLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrxp_AlvogenLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034817022032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Debt (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th">
<div>Apr. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 09, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th">
<div>Nov. 04, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Loss on Contract Termination for Default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 849,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtIssuanceCosts', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,034,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Gain (Loss) on Convertible Debt Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,278,000)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsMember', window );">Anson Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap', window );">Class of Warrant or Right, Securities Called by Warrants or Rights, Percentage of Principal Divided by VWAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,349,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember', window );">Streetervile Complaint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,537,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_StockholdersEquityNoteSpinoffTransactionPercentage', window );">Stockholders Equity Note Spinoff Transaction, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LitigationSettlementPaymentInstallmentOne', window );">Litigation Settlement, Payment Installment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LitigationSettlementPaymentInstallmentTwo', window );">Litigation Settlement, Payment Installment Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,050,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,050,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember', window );">Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,585,000<span></span>
</td>
<td class="nump">982,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,020,000<span></span>
</td>
<td class="nump">11,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,000<span></span>
</td>
<td class="nump">497,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentPrepaymentPercentage', window );">Debt Instrument, Prepayment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentRedemptionConversionPricePercentage', window );">Debt Instrument, Redemption Conversion Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentConditionalDefaultInterestRate', window );">Debt Instrument, Conditional Default Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable', window );">Debt Instrument, Convertible, Maximum Percentage of Equity Issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Liabilities, Fair Value Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Loss on Contract Termination for Default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member] | Principal Repayment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member] | Interest Repayment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment2Member', window );">Streeterville Convertible Note Amendment 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment2Member', window );">Streeterville Convertible Note Amendment 2 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment3Member', window );">Streeterville Convertible Note Amendment 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentNumberOfTranches', window );">Debt Instrument, Number of Tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PlacementAgentFeePercentOfGrossProceeds', window );">Placement Agent Fee, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member] | Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,676,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Gain (Loss) on Convertible Debt Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Liabilities, Fair Value Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,750,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentOriginalIssuanceDiscount', window );">Debt Instrument, Original Issuance Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtIssuanceCosts', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentInterestRateInEventOfDefault', window );">Debt Instrument, Interest Rate in Event of Default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member] | Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,676,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Gain (Loss) on Convertible Debt Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member] | Conversion of Principal and Interest Into Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="nump">1,004,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonSecondTrancheNotesMember', window );">Anson Second Tranche Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PlacementAgentFeePercentOfGrossProceeds', window );">Placement Agent Fee, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentOriginalIssuanceDiscount', window );">Debt Instrument, Original Issuance Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtIssuanceCosts', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervileComplaintMember', window );">Streetervile Complaint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,050,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities into which the class of warrant or right may be converted expressed as a percentage of the principal amount of the notes divided by the WVAP of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentConditionalDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the interest rate of debt instrument in the event of a default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentConditionalDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of equity issuable issuable by converting a a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentInterestRateInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement, in the event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentInterestRateInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches to be received as part of a purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentOriginalIssuanceDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of original issuance discount expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentOriginalIssuanceDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentPrepaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the prepayment percentage on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentPrepaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption amount of a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentRedemptionConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentRedemptionConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow related to the issuance of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_GainLossOnConvertibleDebtRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on convertible debt redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_GainLossOnConvertibleDebtRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LitigationSettlementPaymentInstallmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment installment one for litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LitigationSettlementPaymentInstallmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LitigationSettlementPaymentInstallmentTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment installment two for litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LitigationSettlementPaymentInstallmentTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_PlacementAgentFeePercentOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee paid to the placement agent expressed as a percentage of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_PlacementAgentFeePercentOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_StockholdersEquityNoteSpinoffTransactionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of shares related to the spinoff.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_StockholdersEquityNoteSpinoffTransactionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTerminationForDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the loss on termination of a contract for default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482291/912-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482269/912-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTerminationForDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_PrincipalRepaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_PrincipalRepaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_InterestRepaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_InterestRepaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteAmendment3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonSecondTrancheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonSecondTrancheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervileComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervileComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034830350912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Debt - Schedule of Convertible Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 12, 2024</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Convertible note default penalty</a></td>
<td class="nump">$ 849<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Cumulative fair value adjustments through earnings</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax', window );">Cumulative fair value adjustments through accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable - current portion</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note payable, net of current portion</a></td>
<td class="nump">5,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par value of the Note</a></td>
<td class="nump">11,020<span></span>
</td>
<td class="nump">11,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized original issue discount</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Convertible note default penalty</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt', window );">Conversions and repayments of principal and interest (shares and cash)</a></td>
<td class="num">(12,324)<span></span>
</td>
<td class="num">(4,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LongtermDebtTotal', window );">Carrying value of the Note before current period change in fair value</a></td>
<td class="num">(952)<span></span>
</td>
<td class="nump">6,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Cumulative fair value adjustments through earnings</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax', window );">Cumulative fair value adjustments through accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total carrying value of Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable - current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note payable, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par value of the Note</a></td>
<td class="nump">10,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized original issue discount</a></td>
<td class="num">(870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt', window );">Conversions and repayments of principal and interest (shares and cash)</a></td>
<td class="num">(4,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Cumulative fair value adjustments through earnings</a></td>
<td class="nump">4,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax', window );">Cumulative fair value adjustments through accumulated other comprehensive loss</a></td>
<td class="num">(3,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total carrying value of Note</a></td>
<td class="nump">6,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable - current portion</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note payable, net of current portion</a></td>
<td class="nump">5,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of the Anson Notes before current period change in fair value</a></td>
<td class="nump">$ 5,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash and cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_FairValueAdjustmentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value adjustment of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_FairValueAdjustmentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LongtermDebtTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LongtermDebtTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTerminationForDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the loss on termination of a contract for default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482291/912-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482269/912-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTerminationForDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) from increase (decrease) in instrument-specific credit risk, realized upon derecognition of financial liability measured under fair value option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)(4)<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828868752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2024</div></th>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th"><div>Apr. 24, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 17, 2023</div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,199,000<span></span>
</td>
<td class="nump">$ 13,371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ShareSubscriptionFacilityAgreementGEMMember', window );">Share Subscription Facility Agreement - GEM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,568<span></span>
</td>
<td class="nump">67,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember', window );">Streetervile Complaint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,537,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_StockholdersEquityNoteSpinoffTransactionPercentage', window );">Stockholders Equity Note Spinoff Transaction, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember', window );">Streetervile Complaint [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) from Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nrxp_LeaseContractualTermOfficeSpaceRentalMember', window );">Lease Contractual Term, Office Space, Rental [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">Sarah Herzog Memorial Hospital License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage', window );">License Agreements, Milestone Payments, Conditional Reduction Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementCumulativePayments', window );">License Agreement, Cumulative Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">License Agreement, Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PaymentForLicenseAgreementMaintenanceFee', window );">Payment for License Agreement, Maintenance Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMaintenanceFee', window );">License Agreement, Maintenance Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">Sarah Herzog Memorial Hospital License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">Sarah Herzog Memorial Hospital License Agreement [Member] | Products Covered By Licensed Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">Sarah Herzog Memorial Hospital License Agreement [Member] | Products Covered by Valid Claims [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Patent License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementCumulativePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount paid for the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementCumulativePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maintenance fee on a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payment for a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the conditional reduction percentage for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_PaymentForLicenseAgreementMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for license agreement maintenance fee during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_PaymentForLicenseAgreementMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of revenue that a royalty is paid on.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_StockholdersEquityNoteSpinoffTransactionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of shares related to the spinoff.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_StockholdersEquityNoteSpinoffTransactionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ShareSubscriptionFacilityAgreementGEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_ShareSubscriptionFacilityAgreementGEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=nrxp_StreetervileComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nrxp_LeaseContractualTermOfficeSpaceRentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nrxp_LeaseContractualTermOfficeSpaceRentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_ProductsCoveredByLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_ProductsCoveredByLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_ProductsCoveredByValidClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_ProductsCoveredByValidClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrxp_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrxp_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=nrxp_PatentLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=nrxp_PatentLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034831530192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details) - Sarah Herzog Memorial Hospital License Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">End of Phase I Clinical Trials of Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">End of Phase II Clinical Trials of Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">End of Phase III Clinical Trials of Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">First Commercial Sale of Licensed Product in U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">First Commercial Sale of Licensed Product in Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember', window );">Annual Revenue Threshold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payment for a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_FirstCommercialSaleOfLicensedProductInUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_FirstCommercialSaleOfLicensedProductInUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrxp_AnnualRevenueThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrxp_AnnualRevenueThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034702789088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 28, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 19, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 18, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th">
<div>Mar. 06, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 07, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 17, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 28, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,591,505<span></span>
</td>
<td class="nump">8,391,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock Issued During Period, Shares, Reverse Stock Splits (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,027,000<span></span>
</td>
<td class="nump">$ 8,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Gain (Loss) on Convertible Debt Redemption | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,278,000)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,173,766<span></span>
</td>
<td class="nump">3,321,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,657,000<span></span>
</td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,948,484<span></span>
</td>
<td class="nump">1,673,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember', window );">Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,585,000<span></span>
</td>
<td class="nump">$ 982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleCapitalLLCMember', window );">Streeterville Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member] | Conversion of Debt to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PlacementAgentFeePercentOfGrossProceeds', window );">Placement Agent Fee, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member] | Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,676,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Gain (Loss) on Convertible Debt Redemption | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | NRX Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Investment Owned, Net Assets, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember', window );">Conversion of Series A Preferred Stock to Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember', window );">Class of Warrant or Right, Warrant Issued with Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedInPeriod', window );">Class of Warrant or Right Issued in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember', window );">March Investor Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember', window );">June Investor Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember', window );">February Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_SubstituteWarrantsMember', window );">Substitute Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_SubstituteWarrantsMember', window );">Substitute Warrants [Member] | Neuro Rx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1', window );">Foreign Currency Exchange Rate, Remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,792,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,886<span></span>
</td>
<td class="nump">344,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,448,856<span></span>
</td>
<td class="nump">3,448,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightExercisesInPeriod', window );">Class of Warrant or Right, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentAgreementMember', window );">Warrant Amendment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentAgreementMember', window );">Warrant Amendment Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentAgreementMember', window );">Warrant Amendment Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember', window );">Warrant Amendment, June Investor Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember', window );">August Investor Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember', window );">October Amended Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember', window );">February Underwriter Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember', window );">Underwriter Overallotment Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember', window );">April Underwriter Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember', window );">April Underwriter Overallotment Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation', window );">Class of Warrant or Right, Beneficial Ownership Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember', window );">Alvogen and Lotus Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation', window );">Class of Warrant or Right, Beneficial Ownership Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,349,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember', window );">Anson Warrants Tranche One [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Estimate of Fair Value Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember', window );">Anson Warrants Tranche Two [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_March2023PurchaseAgreementMember', window );">March 2023 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_March2023PurchaseAgreementMember', window );">March 2023 Purchase Agreement [Member] | H.C. Wainwright &amp; Co., LLC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_LetterAgreementPercentageOfCashFeePaid', window );">Letter Agreement, Percentage of Cash Fee Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_March2023PurchaseAgreementMember', window );">March 2023 Purchase Agreement [Member] | March Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_June2023PurchaseAgreementMember', window );">June 2023 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_June2023PurchaseAgreementMember', window );">June 2023 Purchase Agreement [Member] | H.C. Wainwright &amp; Co., LLC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PlacementAgentFeePercentOfGrossProceeds', window );">Placement Agent Fee, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_June2023PurchaseAgreementMember', window );">June 2023 Purchase Agreement [Member] | June Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ShareSubscriptionFacilityAgreementGEMMember', window );">Share Subscription Facility Agreement - GEM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember', window );">ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember', window );">ATM Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember', window );">ATM Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_FebruaryUnderwritingAgreementMember', window );">February Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_FebruaryOverallotmentOptionMember', window );">February Overallotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_PrivatePlacementPremiumPercentage', window );">Private Placement, Premium Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_AprilUnderwriterAgreementMember', window );">April Underwriter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_AprilOverallotmentAgreementMember', window );">April Overallotment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_April2024OfferingMember', window );">April 2024 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Conversion of Series A Preferred Stock to Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Preferred Stock and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=nrxp_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the beneficial ownership limitation on warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_GainLossOnConvertibleDebtRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on convertible debt redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_GainLossOnConvertibleDebtRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_LetterAgreementPercentageOfCashFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash fee paid under the letter agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_LetterAgreementPercentageOfCashFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_PlacementAgentFeePercentOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee paid to the placement agent expressed as a percentage of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_PlacementAgentFeePercentOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_PrivatePlacementPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the premium percentage on a private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_PrivatePlacementPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateRemeasurement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfDebtToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfDebtToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nrxp_NRXPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nrxp_NRXPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_MarchInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_JuneInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_SubstituteWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_SubstituteWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nrxp_NeuroRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nrxp_NeuroRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_JunePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_WarrantAmendmentJuneInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AugustInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_OctoberAmendedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_FebruaryUnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_UnderwriterOverallotmentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AprilUnderwriterOverallotmentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AlvogenAndLotusWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_AnsonWarrantsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_March2023PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_March2023PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nrxp_HCWainwrightCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nrxp_HCWainwrightCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_June2023PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_June2023PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ShareSubscriptionFacilityAgreementGEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_ShareSubscriptionFacilityAgreementGEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_FebruaryUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_FebruaryUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_FebruaryOverallotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_FebruaryOverallotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_AprilUnderwriterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_AprilUnderwriterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_AprilOverallotmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_AprilOverallotmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_April2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_April2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_PreferredStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_PreferredStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=nrxp_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=nrxp_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034826606176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equity - Schedule of Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">3,321,499<span></span>
</td>
<td class="nump">1,648,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm', window );">Outstanding, weighted average remaining contractual term (Year)</a></td>
<td class="text">3 years 9 months 7 days<span></span>
</td>
<td class="text">3 years 10 months 28 days<span></span>
</td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 23.01<span></span>
</td>
<td class="nump">$ 64.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Issued (in shares)</a></td>
<td class="nump">3,948,484<span></span>
</td>
<td class="nump">1,673,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm', window );">Issued, weighted average remaining contractual term (Year)</a></td>
<td class="text">4 years 8 months 15 days<span></span>
</td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice', window );">Issued, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue', window );">Issued, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightExpiredDuringPeriod', window );">Expired (in shares)</a></td>
<td class="num">(96,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">7,173,766<span></span>
</td>
<td class="nump">3,321,499<span></span>
</td>
<td class="nump">1,648,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="nump">$ 23.01<span></span>
</td>
<td class="nump">$ 64.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate intrinsic value of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average remaining term for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate intrinsic value of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828148784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 12, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,833<span></span>
</td>
<td class="nump">264,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.36<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrxp_The2016OmnibusIncentivePlanMember', window );">The 2016 Omnibus Incentive Plan [Member] | Neuro Rx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1', window );">Foreign Currency Exchange Rate, Remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrxp_The2021OmnibusIncentivePlanMember', window );">The 2021 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">83,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual percentage increase in authorized shares for a share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateRemeasurement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrxp_The2016OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrxp_The2016OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nrxp_NeuroRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nrxp_NeuroRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrxp_The2021OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrxp_The2021OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034816983168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">150.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">3.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years) (Year)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">4.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years) (Year)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827271312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Schedule of Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">264,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Expire (in shares)</a></td>
<td class="num">(143,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Expire, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">121,833<span></span>
</td>
<td class="nump">264,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.36<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable (in shares)</a></td>
<td class="nump">113,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827368960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance (unvested) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="nump">57,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance (unvested) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827653216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="num">$ (185)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034829691344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Fair Value Measurements (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45035034887984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">$ 5,639<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money Market Account</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">5,639<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes payable (Note 7)</a></td>
<td class="nump">$ 6,257<span></span>
</td>
<td class="nump">$ 9,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034831463584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Anson Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Anson Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.69<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">2.08<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputMarketRateMember', window );">Measurement Input, Market Rate [Member[ | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputMarketRateMember', window );">Measurement Input, Market Rate [Member[ | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">1.76<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputCostOfDebtMember', window );">Measurement Input Cost of Debt [Member] | Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Anson Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Anson Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">1.11<span></span>
</td>
<td class="nump">1.503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputVolumeVolatilityMember', window );">Measurement Input, Volume Volatility [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0.0437<span></span>
</td>
<td class="nump">0.0414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputProbabilityOfDefaultMember', window );">Measurement Input, Probability of Default [Member] | Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputProbabilityOfDefaultMember', window );">Measurement Input, Probability of Default [Member] | Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_AnsonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nrxp_AnsonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nrxp_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputMarketRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputMarketRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputCostOfDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputCostOfDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputVolumeVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputVolumeVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputProbabilityOfDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nrxp_MeasurementInputProbabilityOfDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034815324432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_StreetervilleConvertibleNoteMember', window );">Streeterville Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 9,161<span></span>
</td>
<td class="nump">$ 10,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Conversions and repayments of principal and interest (cash)</a></td>
<td class="num">(7,850)<span></span>
</td>
<td class="num">(2,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares', window );">Conversions and repayments of principal and interest (shares)</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(1,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustment through earnings</a></td>
<td class="num">(1,761)<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible note payable - current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible note payable, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Fair value adjustment through accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_AnsonConvertibleNotesMember', window );">Anson Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares', window );">Conversions and repayments of principal and interest (shares)</a></td>
<td class="num">(4,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustment through earnings</a></td>
<td class="nump">4,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">6,257<span></span>
</td>
<td class="nump">6,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible note payable - current portion</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible note payable, net of current portion</a></td>
<td class="nump">5,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustment through earnings</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">5,639<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition', window );">Initial recognition of issuance of warrants</a></td>
<td class="nump">$ 3,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of conversion to shares of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The initial recognition of the fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_StreetervilleConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nrxp_StreetervilleConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_AnsonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nrxp_AnsonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=nrxp_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=nrxp_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828616304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Reporting (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034702546032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">$ (18,502)<span></span>
</td>
<td class="num">$ (27,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Convertible note default penalty</a></td>
<td class="num">(849)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Change in fair value of convertible note payable</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Loss on convertible note redemptions</a></td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,126)<span></span>
</td>
<td class="num">(30,150)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,502)<span></span>
</td>
<td class="num">(27,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTerminationForDefault', window );">Convertible note default penalty</a></td>
<td class="num">(849)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_FairValueAdjustmentOfConvertibleDebt', window );">Change in fair value of convertible note payable</a></td>
<td class="num">(2,654)<span></span>
</td>
<td class="num">(2,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(1,657)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_GainLossOnConvertibleDebtRedemption', window );">Loss on convertible note redemptions</a></td>
<td class="num">(1,278)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,126)<span></span>
</td>
<td class="num">$ (30,150)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_FairValueAdjustmentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value adjustment of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_FairValueAdjustmentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_GainLossOnConvertibleDebtRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on convertible debt redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_GainLossOnConvertibleDebtRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTerminationForDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the loss on termination of a contract for default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482291/912-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482269/912-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTerminationForDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034827889952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Segment Reporting - Long-lived Assets (Details) - Operating Segments [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Computers, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total equipment</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Computers, cost</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034825883232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Dec. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 49,665<span></span>
</td>
<td class="nump">44,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income Tax Examination, Penalties and Interest Accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income Tax Examination, Penalties and Interest Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">187,100<span></span>
</td>
<td class="nump">168,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034828146304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants', window );">Settlement warrants</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="num">(0.02%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(2.23%)<span></span>
</td>
<td class="nump">3.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent', window );">Loss on Conversion of Note</a></td>
<td class="nump">1.06%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(0.17%)<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="nump">18.73%<span></span>
</td>
<td class="nump">9.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent', window );">R&amp;D credit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt', window );">Convertible Note</a></td>
<td class="nump">2.19%<span></span>
</td>
<td class="nump">1.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.11%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to loss on conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to settlement warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax (credit) expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034829612736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(4,715)<span></span>
</td>
<td class="num">(4,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Change in Valuation Allowance</a></td>
<td class="nump">4,758<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034830352608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 39,753<span></span>
</td>
<td class="nump">$ 35,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Common stock warrants</a></td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts', window );">174 capitalization</a></td>
<td class="nump">5,186<span></span>
</td>
<td class="nump">5,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Bonus and severance accrual</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation, assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_DeferredTaxAssetsLiabilitiesGross', window );">Deferred Tax Assets (Liabilities), Gross</a></td>
<td class="nump">49,665<span></span>
</td>
<td class="nump">44,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(49,665)<span></span>
</td>
<td class="num">(44,904)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax assets (liabilities) attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034830295888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Related Party Transactions (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,130<span></span>
</td>
<td class="nump">$ 4,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_GlytechLicenseAgreementMember', window );">Glytech License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_GlytechLicenseAgreementMember', window );">Glytech License Agreement [Member] | NRX Pharmaceuticals, Inc [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Owned, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithDrJonathanJavittMember', window );">Consultation Agreement with Dr. Jonathan Javitt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithZacharyJavittMember', window );">Consultation Agreement with Zachary Javitt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ConsultingAgreementAnnualPayment', window );">Consulting Agreement, Annual Payment</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ConsultingAgreementMonthlyPayment', window );">Consulting Agreement, Monthly Payment</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ConsultingAgreementPerformanceBonusTargetValue', window );">Consulting Agreement, Performance Bonus, Target Value</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued Bonuses, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithZacharyJavittMember', window );">Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithZacharyJavittMember', window );">Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member] | Unrestricted Upon New Drug Application Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithZacharyJavittMember', window );">Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member] | Unrestricted Upon New Drug Approval Date [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ConsultingAgreementAnnualPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual payment of a consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ConsultingAgreementAnnualPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ConsultingAgreementMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monthly payment of a consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ConsultingAgreementMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ConsultingAgreementPerformanceBonusTargetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the target performance value of a bonus on a consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ConsultingAgreementPerformanceBonusTargetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrxp_GlytechLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrxp_GlytechLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nrxp_NRXPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nrxp_NRXPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithDrJonathanJavittMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithDrJonathanJavittMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithZacharyJavittMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrxp_ConsultationAgreementWithZacharyJavittMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=nrxp_UnrestrictedUponNewDrugApplicationDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=nrxp_UnrestrictedUponNewDrugApplicationDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=nrxp_UnrestrictedUponNewDrugApprovalDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=nrxp_UnrestrictedUponNewDrugApprovalDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45034829275984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Subsequent Events (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 13, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 27, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 6,750,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember', window );">Anson First Tranche Notes [Member] | Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,676,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Third Tranche Notes, Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,699,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | RD Purchase Agreement, Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Consideration Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights', window );">Class of Warrant Or Right, Percent of Offering Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice', window );">Class of Warrant or Right, Exercise Price, Percentage of Closing Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Third Tranche Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Anson First Tranche Notes [Member] | Conversion of Principal and Interest Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Hope Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_SaleOfStockConsiderationCommitmentAmount', window );">Sale Of Stock Consideration, Commitment Amount</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount', window );">Sale Of Stock Consideration, Additional Commitment Amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_RDPurchaseAgreementMember', window );">RD Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pertains to percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of offering called by warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional commitment amount for the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrxp_SaleOfStockConsiderationCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash committed for the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrxp_SaleOfStockConsiderationCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_AnsonFirstTrancheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_ThirdTrancheNotesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_ThirdTrancheNotesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_RDPurchaseAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_RDPurchaseAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrxp_ConsiderationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrxp_ConsiderationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nrxp_ThirdTrancheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nrxp_ThirdTrancheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=nrxp_HopeTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=nrxp_HopeTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrxp_RDPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrxp_RDPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M MMK*'"K K=K@5<5> 69\E(*#@LJZ?12\%<B\D^#6OZ@@%E4P^6'2?Z]KZ2
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MW!PN"%:DH 74_3E3?7!UHM_:UU]IQO\!4$L#!!0    ( ."#;EIF(QVZ4@,
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M%D5UF3$*LFL,X/>U@)G9W)@_: ^@%_\#4$L#!!0    ( ."#;EK$BW6WG!,
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MW+T2>08HNP%*;$"Y=&* NAN@Q@94[DX,*.X&%.,#3FU2:3>@E'<?RKL!Y=B
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M-T*;ANR&I;D!05H'LYX+H?>&3=#?J>DK4$L#!!0    ( ."#;EIZZ9R>)PD
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MIA=4W#@H8@D6B;W01<5+^'6<R1)=6I :+PD;3,UXT HSF5YN&&%8*=M2!QE
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M[2'RUU(RWW$GA\6?^!'#-%R00?BP1]U*=-@S5S(&9Q/"'S\V-D2W9W9LQJ.
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M8\4T-<>"!^H6=<TX[%M6%3KA&*K1L-]C:IN0YNBHO.RJ+#%QF<.<:HBCT80
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ME_;/R;*9HG_5F[?H1E N.4<*-VPZ&KXZBYHT=AMGJC!3U\;QA [+@I]$)*_
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M$AQN2@LPOU"0)KS0 ?573!?_!5!+ P04    " #@@VY:F@ 8F)<%   8#0
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M;5#WY"?:AY@2E7T3K\KPDS0P]^?!U0"TVZ/OH'U?>U3]->I#:VO07,)5MD;
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M!?ZZL)<+^#YS,&J[$0;=GZ&#_P!02P,$%     @ X(-N6L!9!\=="0  J1H
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MFYJEJ&+I*CJ*^%[$ >N'71;UHL$1O'XM8M_A]8^(:)A5[(/,>!9+GK 'RZV
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MB?;3T;<[H.@?4U7 TWW I2[!2__PNOMY:L\*RKZFBFJVTZZE7K#WA:ZR^8M
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MT&(!RED\.>N/AG''6CJ/"@,OGW[]91)'IQ=F)P.@%>7\.0$ .!I%01ANJ*#
MBR,V=>A(<>$8;M*\[Y^ZGS]X6:%EL.U'VZOQ]CW!M)CQQ(DD;"ZUL7YWP2$9
MAJ\.G_S)!\5TS75FV&=0,.<2D<;SRMGDXEL4JUP]">%<4*KRI%WH<L\6R%G+
MI&$(38F&LHF"C!@'FI>HG+=I_2;GJ,GWZ5+EY ,'<T)\DD"A,I$'3J?:+83-
MX<]9+E,$N%\CG>!>ELM"TI'U^HE9B53.(;B4T!*8*((D*Z&[A-R#RA&2N;2
M+7WWQ^GN/#1.19$L;6N*<;5!/ *4#O%V=R"V@O[OJ-+9NULK;WE[HA6ZV!>E
MVQD W5N/&4?-3(@2K9P@7)FKZ(3OC1,()@XOC%-A#B7<0G3!"E0=E3D\[N+#
MJZ2E^78RU_ ^*@NX0L!I\B^<TSD#M0@TXG&)Y*CKVI?@'A"8K4R%,'Z2(@='
M%;I)@#I1VYG)!YD),.(? _2[T&J;WSEF'5]B.VPX2TN![&0K+@',S;)%,X[D
M3(&04EF4_7^2D>'9110B*;9#S%0X*70;SL)^B(S>YC>K=$/=D^ :44%3P,LT
M<QGIP><JQW3HBAB5ZAIH#7:0#,)3W.#M@4O.7RZ!M:T:=)10_3EA1U$43$)V
MUSI*U_G7.BP))LDK2 Z#T[-7&_)=D!T[JUZC3H\@<1J$F^>>"']8)X"C$6HZ
M"LVVZUQXQA?/"+!\EHMZ1I;?:4K9$=!_L^"XD9<4J$"99] 5M8_/>]F?;GB%
M 4WQ?K&@!8T!I" :I]5 KI"DR >T7UFRFI)IVS[ )*+ (*=]J20A9$MEH#$$
M/W7[UL[ZG[!X/.R?31)VQ*))D(1@^A37IZ.Z)AM?+<6&R'W_,;[/!16< 1Q%
M??TX&B9].(6]WKOGQPH.611'_4D"1>,@&;M :'?7&M8#"7FI;H?.NWL!HZ1_
M=D86 W(R9./@#-<-:'= 3SL#NJN!I2$?Y:ZIH)IL9Z2;@58KK1Y=K<8X=10&
ML5,+%VB%,L\)Z"<R=_T\4'P+<PVMTRG;GK]5?6LU7P1QMU^^J"?[\A\0+S4-
MV-3N:O!W< RRE!3WLTNWP3_+13?2DR*[,O$E4)USYPUDFTK3FJ'?'$-OB:'W
MQ-!7Q] -SSFU@GW9<+P9:2-8$(W'"(U1$(<>KY,&7WW0':,X4W2^AMPP& \W
M:<".DZ2?U(\<Q.'#A]W#7R1*R?ZH$%%1[*<PFDNII&+]Q?C59T8^_E]Q?'<_
MW1.^21.^R<^&+]Y</J56.05=4%#GVQ%!/U&?M4C5HI3-6X_99W'3US;P2!2I
M$#7;]?*<_<L9].Z 03_F]3=1(@+]E,<SC"&8MM#YZ#WJB"43JJZCTYA"&H=A
MK'4C 0:&7*W<BR:F993.R0AQ\UE9 .VUJSD1D3<9U^![81MW_PC-8&31FH9
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MV#NQ%,4])3M'B*TYI@82=^R]#^9YFJH&88G8SRR93O [#*:3A+V3?"8+::4
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M';Z@H%ZP:(0Y<GON2_I#FNR2?I30@">7,L-4Q^ZD*#(@6DBC8OMXV#>K=8W
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MN*0/);0L0/MS0\%M)WS [M-K^B]02P,$%     @ X(-N6NO>X78\!@  @@X
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M0$' A-BDU60_^H^ /,)AG(1O_I&;APP^WCB^>[GG8L->@"W$FA)8TT#0:AL
M;W3YF31W&\10J1?48X@%(( 0Z>J5WQ1#KYROMIODI$E1+4&XJN,Z^SQDTP\S
M[F^(N88]W?.VGX^R_T0SS&^^K6&_OPF-#^1LX'>H;B0 YC#>2W(J$G/^]O?M
M:[?H#9/"U['X +V>^66B@)OXQ+4&U@JQ$0;/-=)&H _1CWA3"C78PLHGYXA@
MUX8=$3S7@H[SUU93 M=&/@@@HUD8K\['+^E>*YX#+_X/G<UI,N/N\4LAS/_Q
M<*H!DOJ++);<!J:;KA%_[4 7DW19%(IVV &62<1["A-!>*E'GRW9!)OAQJ.F
MS:/)*!-6:UMXL;;Z "C1/&1WMX+0\FTLU!CND_:162ZX7% >C\C-K7S%)A9O
MI3A4JEB*<JVN&\=57%$P+7&#.5^V.N>&VU?A- H)NZ U:FO8U<_C'L'5J$/<
M42-VWVZ B04_CX':/'B$];/<LFE%&?>WB[##1)2B"\._>8U[MH'W+W%3AC1=
MO/.GQQV67L4'?'ZLQJ/]JMYDW'S ZH._LU%?UT6P&:+C:?7ZOZ9S8]S?27&G
MI=A]&\JZSQ;2T^A_:N'D737(JX71,_55H@:$<0U5XG[TS\D/N,#0VWGU]?IS
M; DU L9EZ@=NLR'W]'4&I=(EY=)TR7-/[>5[$+O'%MXP5G5)C0E.$ &W8-G(
M4.89HEH;>U,VE$BU5=L6!.1O3GPQS=9EJK=@IM 66 D<2!?_NK6@5,CI5-@%
M.Q'D8&>.B741S4EOQ(PX3$)4K:+^=O&]N8V*[ VPB)1-U'C2IUU-T\JXOY'D
M4P$/J=6WY.'9:O54PMB _\#%T4<X9]LDMP+6&5EDAQJ]P[?1U/ \#!_ZA-)T
M6HS[6RT^)&6! W;J!D?&&=JSA?,GFBQ^)<P55^SBC]8%;[6V_*\(?\ '<I)4
M,!N42#F>S[WI+6AJ' ?#NI)>;P9PI,4%0C!/32J XVDMRBR-:S3;M?QT:!)?
M\P\\*,8B#P(N5T7-V3%E"+2X>[2ZK2N^" W!R]\E<F_LM<F9JZT-P'GG<A-,
M8T-W$AC/:W]IG!#:K?-,TCVZXNJTJ0[V /YN_RHV(\V"E)U)TS<5QG69TNUR
MPYT.2M%PJ!^X*=T-I.S<P+'!%L\&QYA6C_IH!UT9A39<$>'@<?_NH'5'*F+@
M/*J%*'6:U-*X!3S@RSQK%M&4G$IE#EOS6H?@MCQ3:'&D.P'R?4%)Q#_.+%S3
MFKUOZUCWG'R[Q8M%[:66"=3T5Z[0RZ2=$V=>ZE$[&ZEOZVEGM:YNM;;5[($L
MH0DK/2)K+@\ZDAON:/'"?\=!TWU"/9Z,!^?'QVIR>C)X=7Y,US$[=9$#[.0-
MQI\,QJ=G83NNK1).G0W&9\>#L]-3=3PX!N635Z_4!7*[PA?1L<9D-!A/3B.]
M=J%]%8&0D UCCD>CP6@TZ@-TDZ;5:M+? /5%KSL_FRIM82FW_U/=I?UK[7:@
MMSK56S_=ZO"@/K+"^7*EW,878+KSDYK.!%(W#_[#SV,H.$''Q B=_YT+PG+%
M\Z< S*&KG1N/[:IJ)D=W[H*:Q[*HUSPR3$K6AX15O]A[43/2K@$^#OF)#F_T
MZLWH#+J'Y.P3\G8:*,U<UN-$-HX [:[C[R*<>G%Q]UW4=73VZ&]4;,K@9-7M
MKTZ&T%1F+[Z1@4+C%4?F+9::Z+V/E5>/_NY8=Y>6'K5^[K?4Y9Q_U$B1#@<J
MO_R+W\8?3E[(SP6;X?*KR\]).:?>T5S/,'4T/'MY('T*X4-E5_SCP:FM*KOD
MQX5.$!=I -[/+$S1?Z %XL])W_\/4$L#!!0    ( ."#;EKKV_,VQP(  .,%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;(U4VV[;, S]%<(#B@WP
MZEN:I&UB($D[; \=@KK;'H8]*#8="Y4M3Y*;[.]'R8G7 5FP%UL7\O <4N1L
M)]6SKA -[&O1Z+E7&=/>!('.*ZR9OI0M-G132E4S0UNU#72KD!7.J19!'(;C
MH&:\\=*9.UNK="8[(WB#:P6ZJVNF?BU1R-W<B[SCP2/?5L8>!.FL95O,T'QI
MUXIVP8!2\!H;S64#"LNYMXANEB-K[PR^<MSI5VNP2C92/MO-IV+NA980"LR-
M16#T>\$5"F&!B,;/ Z8WA+2.K]='] ]..VG9,(TK*;[QPE1S;^I!@27KA'F4
MNX]XT'-E\7(IM/O"[F ;>I!WVLCZX$P,:M[T?[8_Y.%_'.*#0^QX]X$<RSMF
M6#I3<@?*6A.:73BISIO(\<86)3.*;CGYF?2S- @)O(>LKPK($C*^;7C)<]88
M6.2Y[!K#FRVLI> Y1PUOG]A&H'XW"PPQL#A!?HBV[*/%_X@6Q? @&U-IN&\*
M+/X&"(CZP#\^\E_&9Q'O,+^$)/(A#N/1&;QDR$?B\)(S^=#0"SREK_<>G?:V
M'72C6Y;CW*,6T:A>T$LOWD3C\/8,M]' ;70./<VH(XM.H*W1@FI2<-'9-PT9
MYIWBQM;F?I^+CE(+I9(UK&3==H:Y]T].]TPU5$D-:U2054PA?'=2X0GW!I9"
MYL\_3JD^R^NT:BH,UAN*<RR._220&8H!LK64-$1QY$^3!.+QR+^>)O"(VBB>
M&^*OG2';,55HN'@SC:/XENQ'?C2>6%TU2>IMR$314]4P\:-)XD_&8TC\A)!'
MU]>4)TV&?54I1ASZ43P>\%:R>4%EN$T!42]1J2'TT28)0S\,0SA5P.!5X]6H
MMFZ\:' MT_?@<#I,L$7?N'_,^_'WP-264TH$EN0:7DZN/%#]2.DW1K:NC3?2
MT%!PRXJF,"IK0/>E))&'C0TPS/7T-U!+ P04    " #@@VY:8N%?BK0"   9
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R-5=MNVS ,_17"'8H-
MR.I+W,9-$P--VF%[Z!:TW?8P[$&QF5BH;'F2<MF^?I3L>%F7!GNQ1(D\/"1%
M>K21ZDD7B :VI:CTV"N,J8>^K[,"2Z;/9(T5W2RD*IDA42U]72MDN3,JA1\%
MP85?,EYYZ<B=S50ZDBLC>(4S!7I5EDS]G*"0F[$7>KN#>[XLC#WPTU'-EOB
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M:F= WY>*LME.7(#N1VGZ+U!+ P04    " #@@VY:42.8;Z$"  !)!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R=55%/VS 0_BNG#$U,8DV:MH!8
M&XD6T)#&5+6P/4Q[<)UK8^'8G>U0^/<[.R$4K503+XW/ON^[[\Z^ZW"CS;TM
M$!T\EE+9450XMSZ+8\L++)GMZ#4J.EEJ4S)'IEG%=FV0Y0%4RCA-DN.X9$)%
MV3#L34TVU)630N'4@*W*DIFG,4J]&47=Z'EC)E:%\QMQ-ERS%<[1W:VGAJRX
M9<E%B<H*K<#@<A2==\_&?>\?''X(W-BM-?A,%EK?>^,Z'T6)%X02N?,,C#X/
M.$$I/1')^--P1FU(#]Q>/[-?A=PIEP6S.-'RI\A=,8I.(\AQR2KI9GKS%9M\
M!IZ/:VG#+VQJWT$2 :^LTV4#)@6E4/67/39UV *<O@5(&T :=->!@LH+YE@V
M-'H#QGL3FU^$5 .:Q GE+V7N#)T*PKGLNW8(I_ 9)KHLA:-R.PM,Y60K)]0*
M%1=HX?"6+23:3\/845 /C7D38%P'2-\(T$WAAJ@*"Y<JQ_PU04QJ6\GIL^1Q
MNI?Q GD'>MTC2).TOX>OUY:@%_AZ>TI@H4YP5WXUNK\;[9OFS*X9QU%$76'1
M/&"4??S0/4Z^[-'6;[7U][%G<VK"O)((>@DW@@0ZK1"F[*F^J%]!-=SBHX.Q
MU/S^]ZX$]H;8G0#=E0\Y+>C!PS5,""0XDW!K!)/6'WT3G%H3<Y@:G5?<P2'7
MY5JBP_P3'$ W28Z2)('71.]A2@<[F?Z/Z@5^)8QUX96CX>0/<U:7]1^,4'#7
MF7<(.TC>@;VL#(W,+?2Y4A5A9OB JJ*7-D/&"SAH*A1<#N"DD;GKS<1;[4T*
M5F&(6>"Z4J[N]':WG9/G]7AX<:^'[ TS*Z$L2%P2-.F<#"(P]>"J#:?785@L
MM*/1$Y8%S7HTWH'.EYJZI3%\@/;?(_L+4$L#!!0    ( ."#;EK!.!PP_P(
M 'X&   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(U5VV[30!#]E9%!
MT$K&E[4;)R6)U$ 1?0"JMM 'Q,/&GMBKKKUA=]V$OV?63DQ!(?#BO<TY<XX]
M.YYNE'XP%:*%;2T;,_,J:]?G86CR"FMN K7&ADY62M?<TE*7H5EKY$4'JF7(
MHF@4UEPTWGS:[5WK^52U5HH&KS68MJZY_K% J38S+_;V&S>BK*S;".?3-2_Q
M%NWG];6F53BP%*+&Q@C5@,;5S+N(SQ>IB^\"O@C<F"=S<$Z62CVXQ54Q\R(G
M""7FUC%P&A[Q#4KIB$C&]QVG-Z1TP*?S/?N[SCMY67*#;Y2\%X6M9M[8@P)7
MO)7V1FW>X\[/F>/+E33=$S9];)9YD+?&JGH')@6U:/J1;W?OX0E@'/T%P'8
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MT'3KLY\Y7;-1&@&:7PKBJQN8!?J+^_Q?4$L#!!0    ( ."#;EK,'PEE80,
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MZOO6\MVT577;43.8"660&N($V$7_N<JRKNZD9Y4C 66#DC"Y\*WBRG>G+)>
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M/C?6]@_H]A/]YELI#5WV8=NOM[A$.BF@D_2&X0"Z9A,-,]H0L:DS\Q^+_O?
M487Q@@B6D_TS;!,K(>PE40;S->,KRZ0O+9-N6B81R$$&42\;!/ DM'5NK^ZP
M.Y'HM$UT>G:B6YPFN3=*(67<>E>R!;4275))G)?ADS;_1X9;9(;PS"'K5 =8
MW2OX3.,)#2)4#25?064J/J>6\4I3";6.0E'8XA%%-3:;02]+ T/LFJ*N; ,Y
M])=>%@?F&4404MGG;%-2 LI_7(X&O3!+S3,=N=;SWOSE%]\VH*@7Q(E)-)7C
M3/"MBZ-"*G>;7I;G<DM)#:G>PW38E/HP"2'),O*6PI(WK3NB;D:D24:]-!U
MDO1&07)$F4/SZ317#+/=K>Y;<>L!-Y%:'DF>2ZW^T1!1HUS948G"++9<NWFB
M_=I.8S=N"#E<=Z/<)R97)5=0X9)$ W](/4&Z\<B]:+&Q(\E":!IP['9-$R5*
M<X'.EX(:9O-B#+0SZO1?4$L#!!0    ( ."#;EJU5:KF604  -PC   9
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M NQY+FV?](YKN^&GD?P#4$L#!!0    ( ."#;EH:3Z8>4 ,  )\,   9
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MS@55)NK#%!2AJ3S3\7)-!,B^JS1C<UTW+MF-"W;X&78^1M><J;5$GUD"R3Z
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M    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;(V546^;,!#'OXJ%^M!*6R%
M2%J12&VR:7O8%C7M]NS )5@UF-DFZ;[]SH:B!$B5%[#Q_?_\[CB;^"#DJ\H
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MA)Q$"T:KAG%\0C;6S/QP&BSLP<*S8"];G8, S-/"[/D,]JH-UJ7>\7!4C57
M%'(XPHG"T_]ZK'%=UYMFCGKFZ"QS>R1Q1WX&,!HM'L3.">!8,W.G\>(>+SZ+
M]\"DVH9XT$.8 4Z['D+_]Y IZ'AT.ES'#3Z=8(]5ZJ %)^#VH'_JN^L'YCM2
M"40A5S;G.E9^WMX'[42RVK34+9.J09MAH:Y0X%J@ON=,'?UNHKMT?RDO_@%0
M2P,$%     @ X(-N6GI:"PU.!0  0B8  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&ULO9K[;]LV$,?_%<(KAA3PHH=?<>882*S'.JQMD#0KAF$_T/+9
M%BJ)+DGE >R/'_6P;#DR9[6W_6*+DNYS1]X7%'G@Y(GQ+V(-(,ES'"7BJK.6
M<G-I&")80TS%.=M HIXL&8^I5$V^,L2& UWD1G%DV*8Y-&(:)IWI)+]WRZ<3
MELHH3."6$Y'&,>4O-Q"QIZN.U=G>N M7:YG=,*:3#5W!/<B'S2U7+:.B+,(8
M$A&RA'!87G6NK4O?&F4&^1N_A_ D]JY)UI4Y8U^RQKO%5<?,(H(( IDAJ/I[
MA!E$4492<7PMH9W*9V:X?[VE>WGG56?F5,",19_#A5Q?=2XZ9 %+FD;RCCW]
M F6'!ADO8)'(?\E3^:[9(4$J)(M+8Q5!'";%/WTN!V+/0'&:#>S2P#XTZ!\Q
MZ)4&O5,-^J5!_U2#06DP.-5@6!H,3S48E09Y]HUB=//4.%32Z82S)\*SMQ4M
MN\CSFUNKC(1))L5[R=734-G)Z0<F@0S)3^0Z>F0K2,AO89 )+5F1ZQ4'4*J3
MY,P!2<-(D$_P+%,:O57O/]P[Y.S-6_*&&$2L*0=!PH0\)*$4775377]:LU30
M9"$FAE219OZ,H(SJIHC*/A*51=ZS1*X%<9,%+.KVANIAU4U[V\T;6PO\-4W.
M2<_L$MNT^PWQS/3F'LS/B3T^:N[HS1T(E'?KJ+E[@G=S=-3<.]U[K\'</V'H
M3+O)O):*7J6X7L[K'^'-<E$#)W>P3).%$AR=AU$H7[IDEG*N]-:D%RTSFZ\O
MQ88&<-51$[( _@B=Z8\_6$/SYZ9D8\*< C;(8=G$_SCMCZS!Q'C<3S"F1^^U
M1[/NSD=R5\MOO\IO7YO?[41"L]PRF0KRF7).$RG(G^\AG@/_JRG!6FC;!&/"
M'$R8BPGS,&$^$JRFF4&EF8%^3HBH$(0MMU(A3$T/V2*B2SZDF62R9_<0I#R4
MH?K2S&@4P8+,7W;:VEH(<J:^/<47Z6V3T+21M!4:)LS!A+D%;+@_+5GCP?BB
M/E-XF#Y])%A-0L-*0L-OE9#[##P(!9!;KA8W>^\<JF;!HHAR039*<+F"&@6D
MC:.M@#!A#B;,';[^KAUH!].=CP2K:6=4:6>DU4XEA^R;5>KA8RJ%5&VU$NZJ
M=2^/R=D?0'FC(K3TMHK A#F8,%<_B#WRHL:G:;'O84;A(\%J0KFHA')QTMJF
M:9.D6]QHJ6T%@@ES,&$N)LS#A/E(L)IHQI5HQEK1%&*!G52ZY)W:)H<T(K?T
M)3ZRX=$RVTIF_'HN-\V#38.#Z='%A'F8,/_U6(SWQZ*68LO<E5',MDF^#@*(
M@%.9S1.:3.O);5-=TO;[-WB=:U2?+BK-0Z7Y6+2Z+O;*:]9_4.W00UM+ I/F
ME+1ZP>-08"ZJ3P^5YF/1ZI*P=Y*PM9*XERSX0N[3N0AXN,D*\D*I(X#PD<XC
MZ)+/:I,+Y.-RV:@,^]7H6[W#T9_I(VB=<4R:BTKS4&D^%JVNC%UEU-*71D]9
M7I*_R3=6V/3.6T\JJ$545)J+2O-0:3X6K2ZQ77'6TE=G_\]*FSZ4UH+KGU31
M<E"]NJ@T#Y7F8]'J4MK5;*UO+MHB5]ST@;06TN#?*EL.JD,7E>:ATGPL6EU#
MNZ*MI:_:?F_E38]OK0Q]L,<K7 YJ'"XJS4.E^5BTNF!VE5KKNTJUC1I!+<^6
M-/T"W$'UZ:+2/%2:CT4K]&#LG611N^95?DA)D("EB2Q.>U1WJX-0U_GQGX/[
M-];EK#C.M,,4IZO>4[X*U98K@J5"FN<CE4I>'%@J&I)M\O,R<R;5UCV_7 -=
M ,]>4,^7C,EM(W-0'1N;_@-02P,$%     @ X(-N6K%[*U:^'   \_ ! !D
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M=X+[<S+?IHWIA_8D4,U$-0O5;%1S4,VMM,-)]6C8'W=Z8W52[:'#^J@6H)I
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MJ!93FIJ!=0-BVG+_"_+6R/JQ6T=?X]83Q[<?-M%!+52S4<U!-1?5/%3S42U
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M![0D*SLAH6'$BB6&541#6>:I"CPE\%3U(&$F$F8A8382YB!A+A+F(6$^$A:
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MY9&QKWKR,9U[@<X(<DBDAL#J8P]+R'.-I/+X5H-Z34SMV!X_H7\PQ:MB'K&
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M7[)^]\^>_=[_VB_RV?K=/WOV[G_U2];O_MG^NW_VU2]9O_MGG][]'S]GZJ=
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M)%:76$-B38FU)-:66$=B78GU)-:7V$!B0XF-)#:6V$1BD1S=AVHTKH/F==#
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M'5)M],+/X?SD[>7;W9_"F%YT0K5(B>S#B[+=!K2<#=^PZ1LV?L/F;]@ #IO
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M/Z<+C%3+4ZU M2+52E0K4ZU"M2K5:E2K4ZU!M2;56E1K4ZU#M2[5>E3K4VU
MM2'51E0;4VU"M4AI"H?W<[O :#F;][$._.T#Z>S9Y>G%LUM'[+2BY6R8ATWS
ML'$>+,]WB_=F@/'APR.+]P'/!DF^R,&56FHYJN6I5J!:D6HEJI6I5J%:E6HU
MJM6IUJ!:DVHMJK6IUJ%:EVH]JO6I-J#:D&HCJHVI-J%:I'2 PRLUY6S<A\W[
M6 ?^LTK]_'9L>ET;YF'3/&R<A\WS8(&^VZDW^XOODO<7"]/Y(C.8WMS/,G']
M]_OEZM.](]M/M_Y7YL\OUF@ZQDBU'-7R5"M0K4BU$M7*5*M0K4JU&M7J5&M0
MK4FU%M7:5.M0K4NU'M7Z5!M0;4BU$=7&5)M0+5)B__ :;<<8+6?S/M:!O_-D
MXY.=)[JM:_0K/]'&=-B<#AO489,Z6%3O%N3-@.*[Y '%ROWM]EW5\<OK[ZVF
M<XA4RU$M3[4"U8I4*U&M3+4*U:I4JU&M3K4&U9I4:U&M3;4.U;I4ZU&M3[4!
MU894&U%M3+4)U2(E]P]OR'8.T7(V[\,&?MC$#QOY83,_;.B'3?U@L;_;MC<#
MC._^?SG F/RJ#J[J=("1:GFJ%:A6I%J):F6J5:A6I5J-:G6J-:C6I%J+:FVJ
M=:C6I5J/:GVJ#:@V?-+>;AT7OGV3/3O9^BN[>W(XHB]@3+4)U2*E&1S>Q^W*
MHN5LJ(=-];"Q'C;7PP9[V&0/&^W!LGVWCV_F&-\ESS%N[@E99E9WF;B^GJ_F
M=[?3FTQK.K]^?$[?3]./\]7TYH<OC;V\7-[/KK]ZVPA=9J1:CFIYJA6H5J1:
MB6IEJE6H5J5:C6IUJC6HUJ1:BVIMJG6HUJ5:CVI]J@VH-GS2TO[%_(A>=4RU
M"=4B)>@/K]=V<]%R-LG#1GG8+ \;YF'3/&R<A\WS8(&^6Z\W$X_OCIYX?*K1
MAXW,T E'JN6HEJ=:@6I%JI6H5J9:A6I5JM6H5J=:@VI-JK6HUJ9:AVI=JO6H
MUJ?:@&K#)VWGN\S>G9T_Z]9TFY%J$ZI%2LH?WJWM-J/E;)"'3?*P41XVR\.&
M>=@T#QOGP?)\IUL__,_X+^7Z\>.D=OVZ6[<S_\K49]/E_>+S9Y5O/]X_U._N
M8\M^NM4DZ2;OE-=P:.>V7,YR><L5+%>T7,ER9<M5+%>U7,UR=<LU+->T7,MR
M;<MU+->U7,]R?<L-+#>TW,AR8\M-+!=IW>'@SHX]7 0"-X' 52!P%PA<!@*W
M@<!U(' ?"%<(]MK[9B?R\>.D]OZEJ$]OK]>W=V\]YN^'YZW]Y7Y.%R(ME[-<
MWG(%RQ4M5[)<V7(5RU4M5[-<W7(-RS4MU[)<VW(=RW4MU[-<WW(#RPW77/9L
MZZ3\XLW9WCFYO>K8<A/+15KJ']&[[28D]G#"!X[XP!D?..0#IWS@F ^<\^&"
M?J]WGV[U[N0ER7_GU'SO>S23#\[I]*3E<I;+6ZY@N:+E2I8K6ZYBN:KE:I:K
M6ZYAN:;E6I9K6ZYCN:[E>I;K6VY@N:'E1I8;6VYBN4BK#T<4>#M*B3W<! )7
M@<!=(' 9"-P& M>!P'T@7"'8*_";><K'C[_%P3F=GK1<SG)YRQ4L5[1<R7)E
MRU4L5[5<S7)URS4LU[1<RW)MRW4LU[5<SW)]RPTL-UQSV>U;S-.>E&)?P]AR
M$\M%6@<XHH7;Z4GLX;P/'/B!$S]PY ?._,"A'SCUP\7^7@O?;%4^?OR?.T;_
M.'N_FEUG>K/%AY13],17<7A+EUS.<GG+%2Q7M%S)<F7+52Q7M5S-<G7+-2S7
MM%S+<FW+=2S7M5S/<GW+#2PWM-S(<F/+32P7:>WAB/Y./5P$ C>!P%4@<!<(
M7 8"MX' =2!P'PA7"/;Z^V87\_'C;W&*3F<R+9>S7-YR!<L5+5>R7-ER%<M5
M+5>S7-UR#<LU+=>R7-MR'<MU+=>S7-]R \L-U]S>[><7S\[-Z2BFY2:6B[34
M/Z)WVV%,[.&$#QSQ@3,^<,@'3OG ,1\XY\,%_5[OWLQM/G[\GSHW_WS7^>#N
M9KJ:W\Q7?Z0<G=-]3LOE+)>W7,%R1<N5+%>V7,5R5<O5+%>W7,-R3<NU+->V
M7,=R7<OU+->WW,!R0\N-+#>VW,1RD58@CJCP=KD3>[@)!*X"@;M X#(0N T$
MK@.!^T"X0K!7X3<;GH\??XNC<SK*:;F<Y?*6*UBN:+F2Y<J6JUBN:KF:Y>J6
M:UBN:;F6Y=J6ZUBN:[F>Y?J6&UANN.:RYUM'Y]DW5Q?/;SJG^YR6FU@NTG+_
MB.9M-SJQAS,^<,@'3OG ,1\XYP,'?>"D#Q?U>\U[L];Y^/%_ZO"\,U_^(U-8
MS&8//[":/;R^5:8S7:4]Q(7.>5HN9[F\Y0J6*UJN9+FRY2J6JUJN9KFZY1J6
M:UJN9;FVY3J6ZUJN9[F^Y0:6&UIN9+FQY2:6B[0><423MW.@V,--(' 5"-P%
M I>!P&T@<!T(W ?"%8*])K\9!GW\^%N<H=-%4,OE+)>W7,%R1<N5+%>V7,5R
M5<O5+%>W7,-R3<NU+->V7,=R7<OU+->WW,!RPS67O=@Z0S]Y<W+V]OD=Z'0I
MU'(3RT5:\!]1O>U:*/9PR =.^< Q'SCG P=]X*0/'/7ALGZW>F>W9D.S_[G9
MT"]/;LG-?YM?SQZ[>^H9>O++.;BC4RYGN;SE"I8K6JYDN;+E*I:K6JYFN;KE
M&I9K6JYEN;;E.I;K6JYGN;[E!I8;6FYDN;'E)I:+M!IQ>)&W'BX"@9M X"H0
MN L$+@.!VT#@.A"X#X0K!'M%?FM!-/M-%D23KW)X/[<+HI3+6ZY@N:+E2I8K
M6ZYBN:KE:I:K6ZYAN:;E6I9K6ZYCN:[E>I;K6VY@N>&:VWX.^LG^Z3F]Y-AR
M$\M%6N0?4;KQ?*CU<+P'SO?  1\XX0-'?.",#QSRX5)^KW2?;I7NY/G0I]*=
MB8=6??UT@+Z8?>[8R<?@=@^4<CG+Y2U7L%S1<B7+E2U7L5S5<C7+U2W7L%S3
M<BW+M2W7L5S7<CW+]2TWL-S0<B/+C2TWL5RD]8$C&CG> [4>;@*!JT#@+A"X
M# 1N X'K0. ^$*X0[#7RK3W0;/(>Z$\WT^4R<_>W]3TLF;O%Y]/P'S*-^\<^
M_OC/NK/W]XOY:CY;9GZ:WMS,KC,__[&YZ67]%<O,=_/;S/+7Z<,K_?[E%F]7
M0RF7LUS><@7+%2U7LES9<A7+52U7LUS=<@W+-2W7LES;<AW+=2W7LUS?<@/+
M#=?<]F'YN\O3TZNWST[,[5(HY2:6B[1V<$0_QTNAUL,9'SCD Z=\X)@/G/.!
M@SYPTH>+^KU^OK44^O@8J>/Z>?[WV>+]?#E[>K+YYG/V*_GUW<W-=+',?'QH
M\Y_J^?>9?V7^G/GQJ:N_7-437];A55UR.<OE+5>P7-%R)<N5+5>Q7-5R-<O5
M+=>P7--R+<NU+=>Q7-=R/<OU+3>PW'#-76U5]<LW%Z?/OC.47G9LN8GE(JTG
M'-'4J8<3/G#$!\[XP"$?..4#QWS@G \<].&2?J^I;VV"9O_-3=#>;/$A\]UX
M-EU\Y73<KH%2+F>YO.4*EBM:KF2YLN4JEJM:KF:YNN4:EFM:KF6YMN4ZENM:
MKF>YON4&EANF1=M%YH_9XP'29>;#W>WJUY=.C$;V)8TM-[%<I)6!(^HXG@JU
M'H[_P/D?N  $;@"!*T#@#A"X!(1K 7MU?&LJ-)L\%?J:6\T?'],ROYU_N/^0
M<O>Y'0.E7,YR><L5+%>T7,ER9<M5+%>U7,UR=<LU+->T7,MR;<MU+->U7,]R
M?<L-+#>TW,AR8\M-+!=I%>&(DH['0*V'FT#@*A"X"P0N X';0. Z$+@/A"L$
M>R5]:PPTFSP&^K_M[A:['DJYG.7REBM8KFBYDN7*EJM8KFJYFN7JEFM8KFFY
MEN7:ENM8KFNYGN7ZEAM8;KCFWFW=W7)V\N;JV<TM=CN4<A/+15I-.**HX^U0
MZ^&$#QSQ@3,^<,@'3OG ,1\XY\,%_5Y1W]H.S29OA[[V-'WZ^RM.T^TL*.5R
MELM;KF"YHN5*EBM;KF*YJN5JEJM;KF&YIN5:EFM;KF.YKN5ZENM;;F"YH>5&
MEAM;;F*Y2*L(1Y1T/ MJ/=P$ E>!P%T@<!D(W 8"UX' ?2!<(=@KZ5NSH-GD
M6=#_;:?I=D>4<CG+Y2U7L%S1<B7+E2U7L5S5<C7+U2W7L%S3<BW+M2W7L5S7
M<CW+]2TWL-QPS6W/B&9/GS\%W6Z(4FYBN4AK"4?T=+PA:CT<\($3/G#$!\[X
MP"$?..4#QWRXG-_MZ:=;&Z*GR1NBSP[3?\A\FA4MW_XV6ZX>^OBS/=$7:W?R
M50ZNW93+62YON8+EBI8K6:YLN8KEJI:K6:YNN8;EFI9K6:YMN8[ENI;K6:YO
MN8'EAI8;66YLN8GE(JT='-[/K8>+0. F$+@*!.X"@<M X#80N X$[@/A"L%>
M/]^:!CU-G@:-Z[_?+U>/Q7R96=UEXOIZOIK?W4YO,JWI_#HSO\W\-/TX7TUO
M?OARTEY>+N]GUX]'Y2]7=;L22KF<Y?*6*UBN:+F2Y<J6JUBN:KF:Y>J6:UBN
M:;F6Y=J6ZUBN:[F>Y?J6&UANN.9V3L@O3A[_VC\EIQ<>6VYBN4CK $>T<+P5
M:CT<\H%3/G#,!\[YP$$?..D#1WVXK-]KX:=;+?S K=#44_+'&]!GT^7]XO-]
MZ>7;C_</7]1]O''EZ;Z7Y/-TNS%*N9SE\I8K6*YHN9+ERI:K6*YJN9KEZI9K
M6*YIN9;EVI;K6*YKN9[E^I8;6&YHN9'EQI:;6"[2>L0131YOC%H/-X' 52!P
M%PA<!@*W@<!U(' ?"%<(]IK\UL;H:?+&:.J3T9^U]I?[N5T/I5S.<GG+%2Q7
MM%S)<F7+52Q7M5S-<G7+-2S7M%S+<FW+=2S7M5S/<GW+#2PW7'./:X!?3M$O
MWIP].T&WVZ&4FU@NTE+_B-Z-MT.MAQ,^<,0'SOC (1\XY0/'?."<#Q?T>[U[
M:SOTX>-O<8*^]\VCR8?HB2_I\)(NN9SE\I8K6*YHN9+ERI:K6*YJN9KEZI9K
M6*YIN9;EVI;K6*YKN9[E^I8;6&YHN9'EQI:;6"[2JL0199YZN @$;@*!JT#@
M+A"X# 1N X'K0. ^$*X0[)7YK7G1TW]S7O25A^AV9)1R.<OE+5>P7-%R)<N5
M+5>Q7-5R-<O5+=>P7--R+<NU+=>Q7-=R/<OU+3>PW'#-9<^W#M$OWUR<7CP[
M1K=+HI2;6"[2<O^(YHV71*V',SYPR =.^< Q'SCG P=]X*0/%_5[S7MK2?3T
MP"71HX_1/\[>KV;7F=YLD?*(].17='A+MX.CE,M;KF"YHN5*EBM;KF*YJN5J
MEJM;KF&YIN5:EFM;KF.YKN5ZENM;;F"YH>5&EAM;;F*Y2&L21W1Y/#AJ/=P$
M E>!P%T@<!D(W 8"UX' ?2!<(=CK\EN#HZ?)@Z/J%-WNAU(N9[F\Y0J6*UJN
M9+FRY2J6JUJN9KFZY1J6:UJN9;FVY3J6ZUJN9[F^Y0:6&ZZYO5O1+Y^=H=O]
M4,I-+!=IJ7]$[\;[H=;#"1\XX@-G?."0#YSR@6,^<,Z'"_J]WKVU'WIZX'[H
MD6?HG^] ']S=3%?SF_GJCY1C=+LT2KF<Y?*6*UBN:+F2Y<J6JUBN:KF:Y>J6
M:UBN:;F6Y=J6ZUBN:[F>Y?J6&UAN:+F1Y<:6FU@NTLK$$74>+XU:#S>!P%4@
M<!<(7 8"MX' =2!P'PA7"/;J_-;2Z&GRTJ@Z1K?#H93+62YON8+EBI8K6:YL
MN8KEJI:K6:YNN8;EFI9K6:YMN8[ENI;K6:YON8'EAFMNYV;T[)NKB^RS@W2[
M'4JYB>4B+?>/:-YX.]1Z..,#AWS@E \<\X%S/G#0!T[Z<%&_V[S/MK9#S_1V
MZ,L'Z9WY\A^9PF+V^)6KV<-K764ZTU7*PUV27]O!?9UR.<OE+5>P7-%R)<N5
M+5>Q7-5R-<O5+=>P7--R+<NU+=>Q7-=R/<OU+3>PW-!R(\N-+3>Q7*1UBL-;
MO?5P$0C<! )7@<!=(' 9"-P& M>!P'T@7"'8:_5;BZ-GR8NCZ#P]^2J']W,[
M,TJYO.4*EBM:KF2YLN4JEJM:KF:YNN4:EFM:KF6YMN4ZENM:KF>YON4&EANN
MN>SVSNC)FY.SM\^>[D(O/+;<Q'*1%OQ'5&\\,VH]'/*!4SYPS ?.^<!!'SCI
M T=]N*S?J]ZG6]7[V\R,?GFZ2V[^V_QZ]MCCT\_3[>(HY7*6RUNN8+FBY4J6
M*UNN8KFJY6J6JUNN8;FFY5J6:UNN8[FNY7J6ZUMN8+FAY4:6&UMN8KE(JQ1'
ME'J\.&H]W 0"5X' 72!P&0C<!@+7@<!](%PAV"OU6XNC9]]D<33Y*H?W<[LX
M2KF\Y0J6*UJN9+FRY2J6JUJN9KFZY1J6:UJN9;FVY3J6ZUJN9[F^Y0:6&ZZY
MR^WC]&<GZ79NE'(3RT5:Y!]1NO'<J/5PO ?.]\ !'SCA T=\X(P/'/+A4GZO
M=&_-C3Y\G%2ZX_Z7^^4JX>#\Y8Z=B![>L267LUS><@7+%2U7LES9<A7+52U7
MLUS=<@W+-2W7LES;<AW+=2W7LUS?<@/+#2TWLMS8<A/+15H9.**.4P\7@<!-
M(' 5"-P% I>!P&T@<!T(W ?"%8*].KXU&'J6/!CZT\UTN<S<_6W=PS,/E?S3
M4?CCO2JSQ?OY<O;T.,7-YRR_?-(R\]W\-G-]=W,S72PS'V>+S/+7Z6+V?>9?
MF3]G?OS\-\N7"[U=&*5<SG)YRQ4L5[1<R7)ERU4L5[5<S7)URS4LU[1<RW)M
MRW4LUUUSV_=1G^\>_/;L)?N6&UAN:+F1Y<:6FU@NTCK"$2T=CXM:#\=[X'P/
M'/"!$SYPQ ?.^, A'R[E]UKZUKCHV:O&1;]^I\JGL=#OQK/IXON7Z[:="J5<
MSG)YRQ4L5[1<R7)ERU4L5[5<S7)URS4LU[1<RW)MRW4LUTW[X_DB\\?#G[PO
M'73T["OI6VY@N:'E1I8;6VYBN4CK $>T<#P+:CV<^H%C/W#N!P[^P,D?./H#
M9W^X\-]KX5NSH&?)LZ!Q_??[Y>KQ;O!E9G67B>OK^6I^=SN]R;2F\^O,_#;S
MT_3C?#6]^>'+:7IYN;R?73\>A[]<R^U"*.5RELM;KF"YHN5*EBM;KF*YJN5J
MEJM;KF&YIN5:EFM;KF.Y[IK;/@5_>_+XU[.C<+O]2;F!Y8:6&UEN;+F)Y2*M
M AQ1PO%&J/5PQ@<.^< I'SCF ^=\X* /G/3AHGZOA&]MA)XE;X2FWC_^\H-7
MNH^WHCS=R9)\I[E= Z5<SG)YRQ4L5[1<R7)ERU4L5[5<S7)URS4LU[1<RW)M
MRW4LU[5<SW)]RPTL-[3<R')CRTTL%VFUX8CBCM= K8>;0. J$+@+!"X#@=M
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MU[!<TW(MR[4MU[%<UW(]R_4M-[#<T'(CRXTM-[%<I#6'([H[WO^T'FX"@:M
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M<G7+-2S7M%S+<FW+=2S7M5S/<GW+#2PWM-S(<F/+32P7:0WBB Z/ET&MAYM
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M7%ZV8;FFY5J6:UNN8[FNY7J6ZUMN8+FAY4:6&UMN8KE(B_TCBC?U<,('COC
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MQI9++9=9;F*YJ>5FEIM;;F&YI>56EHNJL7]">-O=G]C#(SX:V,,M$#@& M=
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MN9'E$LN-+9=:+K/<Q')3R\TL-[?<PG)+RZTL%U7I<$*\V[V>V,,E$#@% K=
MX!@(7 .!<R!P#X0+@D*\?]GK>??ZKS@UIWL]+5>W7./ Y0_-G]\[,:?+.BW7
MMES'<EW+]2S7M]S <D/+C2R76&YLN=1RF>4FEIM:;F:YN>46EEM:;F6YJ!KY
M)T2WW>N)/3S>HX$]W *!8R!P#03.@< ]$"X(OH[NL]Q>S[,_O-?SX1/SC_>7
MSZXNU]?;R^WU^_)#\_)W<7244ZYNN8;EFI9K6:YMN8[ENI;K6:YON8'EAI8;
M62ZQW-ARJ>4RRTTL-[7<S')SRRTLM[3<RG)150_'][OU< @$+H' *1"X!0+'
M0. :")P#@7L@7! 4^CVW!O2L? TH.C0OO\KQ?6X7?%*N<>#.GN5.S<\>OWQU
M5CPYI]=M6:YMN8[ENI;K6:YON8'EAI8;62ZQW-ARJ>4RRTTL-[7<S')SRRTL
MM[3<RG)1-?=/*&^\X=-Z>,9' WNX!0+'0. :")P#@7L@7! 4ROL\5][E2RE/
M/CE/M_M_U9J[S>;V"[<_MME?U]+U=<6S6LK?S/&!;M>!4JYAN:;E6I9K6ZYC
MN:[E>I;K6VY@N:'E1I9++#>V7&JYS'(3RTTM-[/<W'(+RRTMM[)<5$7$"1F/
M5X1:#Y= X!0(W *!8R!P#03.@< ]$"X("AF?6Q%Z5KXB5!V@V[V@E*M;KG'@
MSO*+09\\?O+LQ8M[)^AV,2CEVI;K6*YKN9[E^I8;6&YHN9'E$LN-+9=:+K/<
MQ')3R\TL-[?<PG)+RZTL%U6#_X3TQHM!K8>'?#2PAUL@< P$KH' .1"X!\(%
M02&]<XM![^ZP^#-.T#\_K:6^_7U[L;D+]^H#]-+W<GR@2ZYNN8;EFI9K6:YM
MN8[ENI;K6:YON8'EAI8;62ZQW-ARJ>4RRTTL-[7<S')SRRTLM[3<RG)1U1 G
M5#SU< @$+H' *1"X!0+'0. :")P#@7L@7! 4*CZW(_3L+]D16GZ5X_O<[@BE
M7./ Y1_;\N3>T;G=#TJYMN4ZENM:KF>YON4&EAM:;F2YQ')CRZ66RRPWL=S4
M<C/+S2VWL-S2<BO+1=7(/R&Z\7Y0Z^'Q'@WLX18(' .!:R!P#@3N@7!!4(CN
MW'[0LV/W@XY^W^S6EY=7UQ\Z^]Y!^L/-;1> 4JYNN8;EFI9K6:YMN8[ENI;K
M6:YON8'EAI8;62ZQW-ARJ>4RRTTL-[7<S')SRRTLM[3<RG)1%0<GY#E> &H]
M7 *!4R!P"P2.@< U$#@' O= N" HY'EN >A9^0+0-Y?K_;YV]?.APVM7NX]'
MXX]JPYN['K_[O6SS]N:VW;>;?>W-;;EO+FH_O?\2[H>?V-=^V+ZK[7]9W[[3
M'Q^N>+LFE'+U Y<_ZG[V_'EAK6?#7K5IN9;EVI;K6*YKN9[E^I8;6&YHN9'E
M$LN-+9=:+K/<Q')3R\TL-[?<PG)+RZTL%U5M<$*=XRVAUJMC#Z= X!8(' .!
M:R!P#@3N@7!!4*CSW);0LXHMH1?_O-E_."??UZZO:G%Q<5OA5^_6E[5DO;VH
MW>;VF_5OV^OUY://_=[9[V]N _V_M;\]G.!V)RCEZ@<N_VG-LR=WO^Y%N-WV
M2;F6Y=J6ZUBN:[F>Y?J6&UAN:+F1Y1++C2V76BZSW,1R4\O-+#>WW,)R2\NM
M+!=5"7!"A.-MG]:K8P^G0. 6"!P#@6L@< X$[H%P05"(\-RVS[/R;9]'W\'R
M\$=!L[N#\4_+B,KO=;%K02E7MUS#<DW+M2S7MES'<EW+]2S7M]S <D/+C2R7
M6&YLN=1RF>4FEIM:;F:YN>46EEM:;F6YJ,J($T(>;Q"U'BZ!P"D0N 4"QT#@
M&@B< X%[(%P0?!WRY[D-HN?E&T31YS_+KW)TGU.N?N#.\K>Q/'W\XKQX@DXO
MV[1<RW)MRW4LU[5<SW)]RPTL-[3<R'*)Y<:62RV766YBN:GE9I:;6VYAN:7E
M5I:+JK%_?'A;#T_XJ&,/IT#@%@@< X%K(' .!.Z!<$%0"._<ZL_S\M6?Z 2]
M\9_-[NUV_UV'Z.7OZ/A(MVM"*=>P7--R+<NU+=>Q7-=R/<OU+3>PW-!R(\LE
MEAM;+K5<9KF)Y::6FUEN;KF%Y9:66UDNJDKBA);'RT2MATL@< H$;H' ,1"X
M!@+G0. >"!<$A98_S[5\^3)1=8ANMX12KG[@BH?H]SX+2B_;M%S+<FW+=2S7
MM5S/<GW+#2PWM-S(<HGEQI9++9=9;F*YJ>5FEIM;;F&YI>56EHNJL7]">./U
MG]:K8P^G0. 6"!P#@6L@< X$[H%P05 ([]SZS_/R]9_L$/W31J+)9O=KQ1FZ
MW11*N;KE&I9K6JYEN;;E.I;K6JYGN;[E!I8;6FYDN<1R8\NEELLL-['<U'(S
MR\TMM[#<TG(KRT552)R0\GB=J/5P"01.@< M$#@& M= X!P(W /A@J"0\KEU
MHK>O_XHS]-*K'-_GDJL?N/P1^O-[Y^?RDDW+M2S7MES'<EW+]2S7M]S <D/+
MC2R76&YLN=1RF>4FEIM:;F:YN>46EEM:;F6YJ!KY)T0W]?!TCSKV< H$;H'
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M&QZXL[-<@]\]Q/_UZWL);M=_4FYLN=1RF>4FEIM:;F:YN>46EEM:;F6YJ J
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ML5S7<CW+]2TWL-S0<B/+)98;6RZU7&:YB>6FEIM9;FZYA>66EEM9+JKRX(1
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M;"[N#L4?SG*[ZO,3]SQ_%'[VY.[7O;-PN\63<DW+M2S7MES'<EW+]2S7M]S
M<D/+C2R76&YLN=1RF>4FEIM:;F:YN>46EEM:;F6YJ&J $RH<;_&T'BZ!P"D0
MN 4"QT#@&@B< X%[(%P0%"H\M\7S>?D6S^_XI.?#NX2RNWM2/MW24OZ94+O@
MDW)URS4LU[1<RW)MRW4LU[5<SW)]RPTL-[3<R'*)Y<:62RV766YBN:GE9I:;
M6VYAN:7E5I:+JG X(=WQ&E#KX1((G *!6R!P# 2N@< Y$+@'P@5!(=US:T"?
MEZ\!10N$RJ]R?)]_Y,Z^^KCGXU<O[IV9V\V=E&M:KF6YMN4ZENM:KF>YON4&
MEAM:;F2YQ')CRZ66RRPWL=S4<C/+S2VWL-S2<BO+1=78/R&\\>9.Z^$2")P"
M@5L@< P$KH' .1"X!\(%02&\<YL[GY=O[CSYS+SP2=#R8W.[UY-R=<LU+->T
M7,MR;<MU+->U7,]R?<L-+#>TW,ARB>7&EDLMEUEN8KFIY6:6FUMN8;FEY5:6
MBZIV.*'>\0I0Z^$2")P"@5L@< P$KH' .1"X!\(%0:'><RM GY>O %7'YG;]
MYR?NJV/S\\?/SN\=F]N]GI1K6JYEN;;E.I;K6JYGN;[E!I8;6FYDN<1R8\NE
MELLL-['<U'(SR\TMM[#<TG(KRT75V#\AO/%>3^OA$@B< H%;(' ,!*Z!P#D0
MN ?"!<'7X?TBM]?S1?E>SS]P;/[;YNWUYN+C<UE*3\W+W\+154ZYNN4:EFM:
MKF6YMN4ZENM:KF>YON4&EAM:;F2YQ')CRZ66RRPWL=S4<C/+S2VWL-S2<BO+
M154Z'!_OUL,A$+@$ J= X!8(' .!:R!P#@3N@7!!4(CWW$;0%^4;0=&I>?E5
MCN_SCUS^T/S>4B%ZR8;EFI9K6:YMN8[ENI;K6:YON8'EAI8;62ZQW-ARJ>4R
MRTTL-[7<S')SRRTLM[3<RG)1-?)/B&Z\]=-ZN 0"IT#@%@@< X%K(' .!.Z!
M<$%0B.[S7'27;_T\^<3\X_WELZO+]?7V<GO]ON+0W.[[I%S=<@W+-2W7LES;
M<AW+=2W7LUS?<@/+#2TWLEQBN;'E4LMEEIM8;FJYF>7FEEM8;FFYE>6BJAY.
MZ'>\%-1ZN 0"IT#@%@@< X%K(' .!.Z!<$%0Z/?<4M 7Y4M!U:&YW?'YB2L\
MH>7\WJWF]+(-RS4MU[)<VW(=RW4MU[-<WW(#RPTM-[)<8KFQY5++99:;6&YJ
MN9GEYI9;6&YIN97EHFKLGQ#>>,.G]7 )!$Z!P"T0. 8"UT#@' C< ^&"H!#>
MN0V?MZ__E(/S=+O_5ZVYVVQNOW"]N7USU[5T?5WQJ);R-W-\GTNN;KF&Y9J6
M:UFN;;F.Y;J6ZUFN;[F!Y8:6&UDNL=S8<JGE,LM-+#>UW,QR<\LM++>TW,IR
M4141)V0\]7 (!"Z!P"D0N 4"QT#@&@B< X%[(%P0%#(^MR+T1?F*4'5^;O>"
M?N+.\HM!GSQ^\O3%RWLGZ'8O*.6:EFM9KFVYCN6ZENM9KF^Y@>6&EAM9+K'<
MV'*IY3++32PWM=S,<G/++2RWM-S*<E$U^$](;[P7U'JX! *G0. 6"!P#@6L@
M< X$[H%P05!([]Q>T!=_TE[0SP]KJ6]_WUYL[L*]^@#=K@BE7-UR#<LU+=>R
M7-MR'<MU+=>S7-]R \L-+3>R7&*YL>52RV66FUAN:KF9Y>:66UAN:;F5Y:*J
M(4ZH>+PBU'JX! *G0. 6"!P#@6L@< X$[H%P05"H^-R*T!=_R8K0\JL<W^<?
MN?S]YT_N'9W;]:"4:UJN9;FVY3J6ZUJN9[F^Y0:6&UIN9+G$<F/+I9;++#>Q
MW-1R,\O-+;>PW-)R*\M%U<@_(;KQ>E#KX1((G *!6R!P# 2N@< Y$+@'P@5!
M(;ISZT%?G+0>=/+OJXI3<+OQDW)URS4LU[1<RW)MRW4LU[5<SW)]RPTL-[3<
MR'*)Y<:62RV766YBN:GE9I:;6VYAN:7E5I:+JAPX(<CQQD_KX1((G *!6R!P
M# 2N@< Y$+@'P@5!(<AS&S]?E&_\?'.YWN]K5S\?FKQVM?MX&/ZH-KRYZ_&[
MW\LV;V]VV^OM9E][L[Z\W%S4?GK_)>(//[&O_;!]5]O_LKY]IS\^7/%V+RCE
MZI9K6*YIN9;EVI;K6*YKN9[E^I8;6&YHN9'E$LN-+9=:+K/<Q')3R\TL-[?<
MPG)+RZTL%U4-<4+%X_6AUL,E$#@% K= ?(Z!KQYZ]^K9B[/S5U_?>A!XT >>
M](%'?;A9_W6@O\QM!GU9OAFT)- ;_]GLWF[WFT^/-/_R/<4FO[BZO%SO]K7?
M;G/^0Y__6/MO[6^UOW^*]0=;O?QM'=WJE*M;KF&YIN5:EFM;KF.YKN5ZENM;
M;F"YH>5&EDLL-[9<:KG,<A/+32TWL]S<<@O++2VWLEQ4Y<3QK6X]' *!2R!P
M"@1N@?@< V?G^5A__/+%BV?W6MU>&D_ZP*,^W*POM'IN$>C+/[@(=++9_5K[
M8;E9[QX^("_WCX]NR=4MU[!<TW(MR[4MU[%<UW(]R_4M-[#<T'(CRR66&ULN
MM5QFN8GEII:;66YNN87EEI9;62ZJNN"$Z,;;0JV'2R!P"@1N@:B*@?__>>W]
M;=(]=(X:>/(''OV!9W^XX5^H\/-<A9=O!FVNM[O:;'UYLZG%Q3]O]M<?/L&9
M/QW_;^UO#^>W7?9)N;KE&I9K6JYEN;;E.I;K6JYGN;[E!I8;6FYDN<1R8\NE
MELLL-['<U'(SR\TMM[#<TG(KRT55$)R0WWC9I_5P"<3G%/CJ_H^73^Y^%<Z4
M\9@//.<##_K DS[PJ \WZPNUG=OC^?(/[?'\=FO;Q9V4JUNN8;FFY5J6:UNN
M8[FNY7J6ZUMN8+FAY4:62RPWMEQJN<QR$\M-+3>SW-QR"\LM+;>R7%3EP FM
MC?=[6@^70. 4"-P"\3D&\@M<SEX_]&<!/.@#3_K HS[<K"^T=FYUY^WKLM;^
MCJ>GW/9V8W^]_?7NN>)7/]=R9^'YQQF6/FNE_$T<7^:2JUNN8;FFY5J6:UNN
M8[FNY7J6ZUMN8+FAY4:62RPWMEQJN<QR$\M-+3>SW-QR"\LM+;>R7%3%PPEE
M3CT< H%+(' *!&Z!P#$0N 8"YT#@'@@7!(5\SZWL?/F'5G9^^ZC<[NBD7-UR
M#<LU+=>R7-MR'<MU+=>S7-]R \L-+3>R7&*YL>52RV66FUAN:KF9Y>:66UAN
M:;F5Y:(J!TX(<KS(TWJX!.)S"N1O2WG^XANWI> =G9^\[SH%Q^LWK8>G>+@Q
M7LCHW/K-ER>MWRR<@C^P?C.[>]K)IX>EE)^ VYV;E*M;KF&YIN5:EFM;KF.Y
MKN5ZENM;;F"YH>5&EDLL-[9<:KG,<A/+32TWL]S<<@O++2VWLEQ4A<,)P8UW
M;EH/ET#@% C< H%C(' -!,Z!P#T0+@@*Z9[;N?GR+]FY67Z5X_M<<G7+-2S7
MM%S+<FW+=2S7M5S/<GW+#2PWM-S(<HGEQI9++9=9;F*YJ>5FEIM;;F&YI>56
MEHNJ.CBAS_%Z3NOA$@B< H%;(#['P-E7'R1]_/3^4\3MA?&<#SSHPTWZ0GCG
M]FZ^_,-[-Q\^,R\\8[S\V-PNZ:1<W7(-RS4MU[)<VW(=RW4MU[-<WW(#RPTM
M-[)<8KFQY5++99:;6&YJN9GEYI9;6&YIN97EHJH=3LARO*33>K@$ J= X!8(
M' .!:R!P#@3N@7!!4*CWW)+.E^5+.M6QN5V_2;FZY1J6:UJN9;FVY3J6ZUJN
M9[F^Y0:6&UIN9+G$<F/+I9;++#>QW-1R,\O-+;>PW-)R*\M%51V<T.=X_:;U
M< D$3H' +1"?8Z!P;/[RQ?UC<[Q\TWIXT(>;]%^']ZO<\LU7Y<LW_\"Q^6^;
MM]>;BX\;?TI/S<O?PM%53KFZY1J6:UJN9;FVY3J6ZUJN9[F^Y0:6&UIN9+G$
M<F/+I9;++#>QW-1R,\O-+;>PW-)R*\M%53H<7^76PR$0N 0"IT#@%@@< X%K
M(' .!.Z!<$%0B/?<-LY7?W ;Y_>=FI=?Y?@^MSLY*=>P7--R+<NU+=>Q7-=R
M/<OU+3>PW-!R(\LEEAM;+K5<9KF)Y::6FUEN;KF%Y9:66UDNJNK@A#['.SFM
MATL@< H$;H'X' -?/1WFWHFYO2B>\8&'?+@I7XCN\UQTER_?//G$_./]Y;.K
MR_7U]G)[_;[BT-QNZJ1<W7(-RS4MU[)<VW(=RW4MU[-<WW(#RPTM-[)<8KFQ
MY5++99:;6&YJN9GEYI9;6&YIN97EHJH>3HARO*G3>K@$ J= X!8(' .!:R!P
M#@3N@7!!4.CWW#K/5W]HG>=W'YK;[9Z4JUNN8;FFY5J6:UNN8[FNY7J6ZUMN
M8+FAY4:62RPWMEQJN<QR$\M-+3>SW-QR"\LM+;>R7%35P0E]CK=[6@^70. 4
M"-P"\3D&"K>:/WG@X!SO]K0>'O3A)GTAO'.[/6]?_RD'Y^EV_Z]:<[?9W'[A
M>G/[YJYKZ=WVS_+S\](W<WR?2ZYNN8;EFI9K6:YMN8[ENI;K6:YON8'EAI8;
M62ZQW-ARJ>4RRTTL-[7<S')SRRTLM[3<RG)1%1$G]#GU< @$+H' *1"X!0+'
M0. :")P#@7L@7! 4,CZWX_/5']KQ^=WGYW;E)^7JEFM8KFFYEN7:ENM8KFNY
MGN7ZEAM8;FBYD>42RXTMEUHNL]S$<E/+S2PWM]S"<DO+K2P7575P0I_CE9_6
MPR40. 4"MT!\CH&S_&+0)X^?/'U]=O\$'>\%M1X>]>%F?2&]<WM!7_U)>T$_
M/ZREOOU]>[&Y"_?J W2[(I1R=<LU+->T7,MR;<MU+->U7,]R?<L-+#>TW,AR
MB>7&EDLMEUEN8KFIY6:6FUMN8;FEY5:6BZJ&."'0\8I0Z^$2")P"@5L@< P$
MKH' .1"X!\(%0:'B<RM"7_TE*T++KW)\G]L5H91K6*YIN9;EVI;K6*YKN9[E
M^I8;6&YHN9'E$LN-+9=:+K/<Q')3R\TL-[?<PG)+RZTL%U5U<$*?XQ6AUL,E
M$#@% K= ?(Z!_/WG3^X?G>/UH-;#0S[<E"]$=VX]Z*OR]:"#]>[M+[7S)^=/
M:\G-[<OU?E.+?^PV'RN[_"#<+OVD7-UR#<LU+=>R7-MR'<MU+=>S7-]R \L-
M+3>R7&*YL>52RV66FUAN:KF9Y>:66UAN:;F5Y:*J"$X(;;STTWJX! *G0. 6
M"!P#@6L@< X$[H%P05!H\MS2SU?E2S^SZZNW_ZIU]ON;NSM3;G;;=_^H)9O=
M]NKB42W[97U[T4>UX>;?'[]C7_MA^ZZV__#E'Q_N=+O\DW)URS4LU[1<RW)M
MRW4LU[5<SW)]RPTL-[3<R'*)Y<:62RV766YBN:GE9I:;6VYAN>6!RY](/GWU
MXL6+EU\?2Z[L=:-J_I]0X'BMI_7PC \\Y -/^<!C/O"<#SSH T_Z<*/^ZP)_
MG=O^^;I\^^>'RO[T8/*[O+ZXNKQ<[_:UWS:[CZG]8^V_M;_5_OZINQ_,[O)+
M')W=E*M;KF&YIN5:EFM;KF.YKN5ZENM;;F"YH>5&EDLL-[9<:KG,<A/+32TW
ML]S<<@O++0_<ZUQVOWS\O-C<]*)1-?&/;V[KX?D>>, 'GO"!1WS@&1]XR >>
M\H''?+@Y7VCNW-+.U^5+.Y/=U=O-YF)?^WEW]>N'L^WUN]O\OMK5LO7E[?__
M7&O\S\W=>J#;\GXXN.VZ3LK5+=>P7--R+<NU+=>Q7-=R/<OU+3>PW-!R(\LE
MEAM;+K5<9KF)Y::6FUEN;KF%Y98'+O_DBO/G3^Y^W8MNO(G3>GC$!Y[Q@8=\
MX"D?>,P'GO.!!WW@21]XU(>;]87H/L]%=_G2SF3]_NY&[_U=7G^Y[>1#>+^Y
MVM]^_9NQ;==P4JYNN8;EFI9K6:YMN8[ENI;K6:YON8'EAI8;62ZQW-ARJ>4R
MRTTL-[7<S')SRRTLMSQP^=A^]G!KXP6;UL,3/O"(#SSC P_YP%,^\)@//.<#
M#_K DS[<J"^T=F[!YNOR!9O?]U'+V^)N/W[SN#9?;]_]>W?W%)3:_UK_^MO_
MONWQQX]J_?[M;Y5^*K/\31P?YG;_)N4:EFM:KF6YMN4ZENM:KF>YON4&EAM:
M;F2YQ')CRZ66RRPWL=S4<C/+S2VWL-S2<BO+154\G)#O>/^F]7 )!$Z!P"T0
M. 8"UT#@' C< ^&"H)#ON36=MZ__G*/R4O?X(I=<W7(-RS4MU[)<VW(=RW4M
MU[-<WW(#RPTM-[)<8KFQY5++99:;6&YJN9GEYI9;6&YIN=6!R]]7_N1Q<3M+
MU9@_(;2IA^=[X $?>,(''O&!9WS@(1]XR@<>\^'F?"&T<XLT7Y<OTNQOKJ\W
MNR]'XX_N'G[R]O;%^A\?;@-_L][_4FMN-K5DO;UXN+CM#DW*U2W7L%S3<BW+
MM2W7L5S7<CW+]2TWL-S0<B/+)98;6RZU7&:YB>6FEIM9;FZYA>66EEL=N+,G
M7R7WDZ?WFQLOQ[0>GO"!1WS@&1]XR >>\H''?. Y'WC0AYOTA>;.;=!\7;Y!
M\[OO3?GXC9UWOV_VUU>[+SLWR^])L2LS*5>W7,-R3<NU+->V7,=R7<OU+->W
MW,!R0\N-+)=8;FRYU'*9Y2:6FUIN9KFYY1:66UIN9;FHBH83LAVOS+0>+H'
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M8+FAY4:62RPWMEQJN<QR$\M-+3>SW-QR"\LMJP;O\]K[VYGZT"'6RKZ3J&J
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M\H'X^$S'*;]]D9S@GP[_;+Y2\0502P,$%     @ X(-N6EY2:&@7!   9!
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MYJ#+O'?G$RTRUR_G0IONZX8K\]Y!:07,_D*8GEE,K('R!37^"5!+ P04
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MX*NAY5JO"X_Y(E-ZP8ZCBBY@"NJI>A XLSN6-"^!R9PS(F ^M&[<ZW&HXTW
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M*D1)HNE>S43QRC2 &5?83LPPPX8/0@?@_IQC$V@G^@7=7XCX+U!+ P04
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MC(9%J8R/@LM?F:PG%G_$@@((P6_@EC .GDBPI^".DF3/J51+)/*71]EWUON
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MD64;3'99B.;+]NT^' 2$X2L!81L0OC5@V 8,G="&F9.U8(;%D9([4-:;T.S
M[8V+)C6%L*>X,HI6"XHS\:TT"(,0/L *-W0Z!I98264*L8'3!1I6< WWN#<U
MXV=P H6 ^US6FHE41[XA!A;'3]ILLR9;^$HV2G0CA<DU?!$IIL\!?*+>\0^?
M^,_"7L0%)A<P')Q#&(0C>%@MX/3D[ BQ^=MAAL=AGM$;=ML[=+BC5W"7N$51
M(V1*EC GZ8KJEH[8Y#!WAXOJ'*Y%PNO4[OB5UDA/"O=L?VQWFV1CE\S>SVT<
M1/[V4&:?QS,%HT[!J%?!;5VN48',X'N%BKG":$OE: $T:),# H,7%'OSV:YU
MJ2N6X-2CMJ11;=&+W[\;3(+//><Q[M2,WZBF*7.VYM@K9_Q/.;T)_U>.?W"3
MJ38VKL%I2&0M3',INMFNAUZYUO%B?D:]M6F%?V&:QGS#U*80&CAF!!E<?"0!
MJFEVC6%DY?K%6AHJ4#?,Z?^ RCK0>B:I9[2&3=#]<>(_4$L#!!0    ( ."#
M;EJ2]:=N"00  .D/   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;*V7
M46^C.!#'OXK%K4Z[TJ5@$DC22R)MTUO=2M?=JMW=>SC=@T,F"5JP.=M)VF]_
M8Z"0@J%1U9<$FYGA-V/L/S,["OE3[0 T>4@3KN;.3NOLTG55M(.4J0N1 <<[
M&R%3IG$HMZ[*)+!U[I0FKN]YH9NRF#N+63YW*Q<SL==)S.%6$K5/4R8?KR 1
MQ[E#G:>)NWB[TV;"7<PRMH5[T-^S6XDCMXJRCE/@*A:<2-C,G8_T<DFGQB&W
M^!'#49U<$Y/*2HB?9O!Y/7<\0P0)1-J$8/AW@"4DB8F$'/^509WJF<;Q]/HI
M^J<\>4QFQ10L1?)WO-:[N3-QR!HV;)_H.W'\$\J$ A,O$HG*?\FQM/4<$NV5
M%FGIC 1IS(M_]E 6XL2!AAT.?NG@-QU&'0[#TF&8)UJ0Y6E=,\T6,RF.1!IK
MC&8N\MKDWIA-S,TRWFN)=V/TTXLO0@.A/AF0>]CB\FAR!YF0.N9;G+N#2/ H
M3F*6UUQLR%]"*?))BI1\S4#FTXIH0;X)S9+B[OMKT"Q.U <,\/W^FKQ_]X&\
M(S$GWW9BKQA?JYFK$=T N%&)>55@^AV82'@CN-XI\@=?P_IY !=SKA+WGQ*_
M\GLC7D-T08;T-^)[_L@"M#S??=B#,ZS689C'&W7$RRNW,74555UM92JB!'D4
MLT4/BP&=!)X_<P^G\!8S?SP9CBNS9Y"C"G+4"_F9:Y"@-"YF)%*P\14!PI,'
MCT8--HO)=&0'"RJPX#PP>,#S35G)@M9C_:'70&O;4-^SHX456MB+MA3\ +B?
M5@D0;C9;><80!&6)?K2AABV,P60T;;"VC3I(QQ7IN)]TQ_@6S$;=L%B2 TOV
M8+9\U,P@8X\,!S;R<;O(8=!\ 2Q&8Z_CU9Q4\)-7P1^9E Q/-3S"5GB.Z1BL
MVVK27O@P&#>XVT:#KK=C6F%/7][V>+*V:BQA#6G6>0Q,+2_J>-+@;1MUT%*O
M5@NOE_<+?E@DR&P]P3U+?0+JAPTLF]W0HT$7W(F4T5ZX4I%0N4HM4^2?&TA7
M(/^U\O9&,]]/ERIC$<P=_$!2( _@+'[]A8;>[S:Y>*MHSW/WZ]S]-]&/,DSX
MDH#8['H4A-8Z1_N%[@P-*2/TBHC-IDM%:*UO]$R!Z]$1VM:O05M);%:=6D)K
MG:/]0O<:-:%M5;/(B<6JB[:6/OJ"]KV!HE"+&%HTQ6K6J2JTUD3Z.E$\4U=H
M6^L&%F6QF'6^*[4BTGY)?*VV4(O.6=3%8M:%7*LA[9?#7GF96KYI;?)BL;/)
MBWO2-*4@MWDOJ;!:>ZZ+-J*:K?K5CWF7UIB_,GULWHS588HF^(;);8S]40(;
M#.E=C!%*%GUE,= BRUNSE=#8Z.67.^S%01H#O+\1N%[EP#R@ZNX7_P-02P,$
M%     @ X(-N6B,*QX"1 @  5 <  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3DN>&ULK55K;],P%/TK5IC0D+;EV0 CC;2U() 83.L&'Q ?W.0VL>;$F>VT
MX]]S[62A8UFU";XD?MQS[CE^7"<;(:]5":#);<5K-75*K9MCUU59"1551Z*!
M&F=60E948U<6KFHDT-R"*NX&GA>[%66UDR9V[%RFB6@U9S6<2Z+:JJ+RUREP
ML9DZOG,W<,&*4IL!-TT:6L "]%5S+K'G#BPYJZ!63-1$PFKJG/C'L]C$VX!O
M##9JJTV,DZ40UZ;S*9\ZGA$$'#)M&"C^UC #S@T1RKCI.9TAI0%NM^_8/UCO
MZ&5)%<P$_\YR74Z=-P[)845;KB_$YB/T?B:&+Q-<V2_9]+&>0[)6:5'U8%10
ML;K[T]M^';8 ?O0((.@!P5,!80\(K=%.F;4UIYJFB10;(DTTLIF&71N+1C>L
M-KNXT!)G&>)T^D5H('Y #LD""MP=32Z@$5*SNL"QSZ(N#CFN<TY.E *MR/X<
M-&5<O<+9KPU(:B-[K"(_SJ!:@OR)LU>+.=G?>T7V"*O)92E:1>M<):Y&U2:W
MF_4*3SN%P2,*YY =D= _(($71"/PV=/AX7VXBVLU+%@P+%A@^:)'^&:B:EH-
M4AV03"@]YF<G@;F6QZJA&4P=O'<*Y!J<].4+/_;>C;GKR":6S%S)=1J\3=SU
MB(-P<!#N='"296W5<JIQ5W- #1FCYDJ-60D?9#_T_Z3O%'8Q\;V8:%QB-$B,
M=DJ\%)IR C<M:\RY&E,6/<CJ>W\)BQZ(]R?CNB:#KLF3-I^\OY,VG/@QC3O)
MGGL0_A/9/=_QX#O^UT,?[SJGG8.=.9[KP-VJ>>:].:.R8+4B'%9([QV]1BFR
MJ^%=1XO&EL&ET%A4;;/$9P^D"<#YE<!2V'=,91T>TO0W4$L#!!0    ( ."#
M;EH34=%]8@,  $8+   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;*U6
MVV[;.!#]%4);% F01A?+LIW:!FRGB^VB:8,D;1^*?6"DL4V4(KTD%;M_WR&E
M*+[(2G:1%ULD9P[/F2&',UQ+]5,O 0S9Y%SHD;<T9G7A^SI=0D[UN5R!P)6Y
M5#DU.%0+7Z\4T,PYY=R/@B#Q<\J$-QZZN6LU'LK"<";@6A%=Y#E5OZ; Y7KD
MA=[CQ U;+(V=\,?#%5W +9BOJVN%([]&R5@.0C,IB(+YR)N$%[/0.3B+;PS6
M>NN;6"GW4OZT@X_9R LL(^"0&@M!\>\!9L"Y14(>_U:@7KVG==S^?D3_TXE'
M,?=4PTSR[RPSRY'7]T@&<UIP<R/7?T$EJ&OQ4LFU^R7KTC9)/)(6VLB\<D8&
M.1/E/]U4@=AR"(\Y1)5#M.\0'W'H5 X=)[1DYF1=4D/'0R771%EK1+,?+C;.
M&]4P8=-X:Q2N,O0SX\_2  D[Y!WY*%*9 [FC&]#DY!(,95R3.]B8@O)3-/AZ
M>TE.WIR2-X0)<K>4A:8BTT/?( T+YJ?5EM-RR^C(EF%$KJ0P2TT^B RR70 ?
M^=<BHD<1TZ@5\1+2<]()ST@41'$#H=G+W3LM=#IU3#L.+SZ"]Q1)\F&#]TT#
M.9F"@#DSITWA*M&Z#LU>NX=Q,/0?MOFW6>Q0C&N*<2O%+RM0U#"Q()^DUF1&
ME?J%-6%-5:;/+&MFE_&:X:&")L[M\'5$,:2=;E-&6OUM[;K0*YK"R,/BI$$]
M@#=^^T>8!.];\M.MQ7>?83<'I2!S&9IH#08U?Z.\*"5/.-8V*M)&W=V#3,2#
M).GNY:NT2K:MXD$0-^<LJ6DG+S]6%&N!HWM&KD%0;AC>6KR/>(T-8,@,F:2I
M*O:O5RDB.:"W?^#:+';(]VKRO=<D7]V;)O*]9\FW6>R0[]?D^^T'!JEKPU)'
M_^]",9VQ\A7Z<07Y/:A_FHBV8K[\B)>:7@EL1_Z@EC_XW\6B2?C@(/YAOQ<&
M^VEJ,$OZW>!(KL+@Z44+6NG>&JQ9[CA]DBGE+T]8.^Y_S=AKH>U&8>M=#U\U
M:17<=F4+@^@@:8UF\4'2_*V.) >U<(V:)JDLA"G?]7JV;@8GK@7:FY_:)M%U
M.D\P98=Y1=6""4TXS!$R..\A)U4V;>7 R)7K>^ZEP2[*?2ZQT05E#7!]+K'W
MJ09V@[IU'O\&4$L#!!0    ( ."#;EH2GY2&=@,  (P+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;)V6;8_B-A#'OXH5J=56:DGL ($K(-VR=^I)
MO;L5VX?7WF2 :!V;V@;VOGW'3C;+(L<]]0W$R<Q_?C-QQK,X*_UD]@"6/#="
MFF6RM_;P+DU-N8>&FY$Z@,0G6Z4;;G&I=ZDY:."5=VI$RK)LFC:\ELEJX>_=
MZ]5"':VH)=QK8HY-P_6W6Q#JO$QH\G)C4^_VUMU(5XL#W\$#V#\/]QI7::]2
MU0U(4RM)-&R7R7OZ;DUSY^ M_JKA;"ZNB4OE4:DGM_A4+9/,$8& TCH)CG\G
M6(,03@DY_NE$DSZF<[R\?E'_Z)/'9!ZY@;42?]>5W2^364(JV/*CL!MU_@VZ
MA"9.KU3"^%]R;FT+C%@>C55-YXSKII;M/W_N"G'A0*<##JQS8-<.XP&'O'/P
ME4M;,I_6';=\M=#J3+2S1C5WX6OCO3&;6KK7^& U/JW1SZZ^* N$YN07\DF6
MJ@'R!W\&@\L'W##540!16W>/;#@:;J!4LJQ%S?T[N+D#RVMA?EJD%EF<8EIV
M<6_;N&P@+F7DLY)V;\@'64'U5B#%)/I,V$LFMRRJ> ?EB.3T9\(R-@X K;_?
M/8_@Y'UA<Z\W'M#["!5H+HBQW!ZMTM^(Q@J&"A77N6%TE&4_A$J\_C^>;Y(9
M]\F,HU+W@%^,!&E);:$QH2Q: =KN,]<\3JL,PV>317JZ9!ZPH[/>[@WAI"><
M1 FQWU@!C4,\<ZVYM$'*23 ZS8LKRGBP&_1AT<).>^QI'-NJ\HG@AX=MV?B/
M*D0=U[AA(Y:'-\@TF&[.:+C814]=1"/^KHPA^/VOE3R!]AT=NX1K)2'Z(ESS
M;'I5\\XNN[0+<\YZSME_5-<U+>LZ6@@L[HPOF1;ALLZ"&8V+<1AWWN/.HQ&Q
M ^-);(#4DIRX.+9-E@L\:KDL@[6=ATCHK,BO:ANTR^;C29B89J_'1Q9EWOS(
MF\.O=P3)J]H&SX$L]EY;O!>;ZSTRG0[P71QO-,K7;E%;/^))-K1!.XGKZ(S.
MKS'#AG0V'\!DKY@LBOG5[D$'V=AW5"^N[38RC78K^GJHT?B9\F&[!3]XN:]J
M\$3K1.+049L6+[V8:QK0.S_N&6R71VG;P:"_VX^4[_T@=77_UHV:?EYZE6GG
MU,]<[VIIB( M2F:C CN_;D>_=F'5P4]/C\KB+.8O]S@N@W8&^'RK<%=U"Q>@
M'\!7_P)02P,$%     @ X(-N6CKTA'/1 @  X @  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C(N>&ULG9;;3N,P$(9?Q8JX &F7G-N VDBT9;5<L$(4V&N3
M3)H(Q\[:#NV^_=I."#VD8=6;QF///_YFXGHR63/^)G( B38EH6)JY5)6U[8M
MDAQ*+"Y9!52M9(R76"J3KVQ1<<"I$97$]AQG9)>XH%8\,7,//)ZP6I*"P@-'
MHBY+S/_.@+#UU'*MCXG'8I5+/6''DPJO8 GRN7K@RK*[*&E1 A4%HXA#-K5N
MW.NYZVB!\7@I8"VVQDBG\LK8FS;NTJGE:"(@D$@= JO'.\R!$!U)<?QI@UK=
MGEJX/?Z(_L,DKY)YQ0+FC/PN4IE/K<A"*62X)O*1K7]"FU"HXR6,"/.+UJVO
M8Z&D%I*5K5@1E 5MGGC3%F)+X(Z."+Q6X.T+@B,"OQ7X)M&&S*2UP!+'$\[6
MB&MO%4T/3&V,6F534/T:EY*KU4+I9/R+24"NC[ZC.YJP$M 3WH!0YE(=F+0F
M@%BVM81N-^H "4#G,Z"0%?("S5E9,0I4"G2^ (D+(BZ4_GFY0.=G%^@,%10]
MY:P6F*9B8DL%K;>VDQ9PU@!Z1P!=#]TS*G.!;FD*Z6X 6V7;I>Q]I#SS!B,N
M(+E$OOL->8X7] #-_U_N#^#XW1OP3;S@2+QYS;FJ7E]E&F%HA/K_^!X[$_M]
M&W7(8X<FZ&B"09H%9*!XTCZ<1CG:VNQ[,';#/:0^+V\<]6.%'59X:I'"@_WV
MBS3DL4,SZFA&)Q=I]"7.D,<.SKC#&9]:G/&7-$,>.S111Q.=7)RHYVSX>T"'
M/F[@'3D^5QW3U7"%<DQ7H&^B%TQJ;!K(#5$M#-,$^D"O#B""<1CMD1XZ>5%X
MI'JN\WDA.X.L3TQBTGM/.E]>!X,N#8^]U2M*X"O30@5*6$UE<X=VLUV;OC'-
M:6]^IMNWZ4&?89K>?X_YJJ "$<A42.=RK'AXTTX;0[+*=*17)E5_,\-<?8(
MUPYJ/6.J*[6&WJ#[J(G_ 5!+ P04    " #@@VY:E%5V]'$#   )"P  &0
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M8IK$#U2N6:D(AQ5JO*L1BF73=S4#+;9UZW(G-#9"]>,&>U60Q@"_KP2V+^W
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M^;R+KAA]_VF5!CE?XT"M:2ZHDF&<M%%UR5.<1)!O XI$0A'O&M5X7)O05"W
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MO1W"S"Z--FSN5L:+4F&IP.^U"<U!6VL0NXF8>V0Z-KPY (T90&DAE!:A:+H
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M[01Z^V2SFT!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U [T"]@T#O0+V#0.]
MO8- [T"]@T#O0+V#0.^8_*PDT#M0[R#0.U#O(- [4.\@T#M0[R#0.Z/>F4#O
MC'IG KTSZIT)],ZH=R;0.Z/>F4#OC'KG[]2[CI^'4J\]7VM\_G=2/9[O+=?'
M7Y9?)R<OU 7G=%M1G_\"4$L#!!0    ( ."#;EK2-&04[ $   <F   3
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MX(-N6L'X657O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ X(-N6IE<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #@@VY:K#ZG
MC6((  #].@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ X(-N6KHI;-;I!0  L1D  !@
M ("!IA   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ."#
M;EIF(QVZ4@,  )4.   8              " @<46  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " #@@VY:[239368%  ",%@  &
M        @(%-&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ X(-N6L2+=;><$P  E$ ! !@              ("!Z1\  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ."#;EKX0'OPL0(  &L'   8
M              " @;LS  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " #@@VY:T,XNAJ@(   M*@  &               @(&B-@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ X(-N6M9*&=IZ @
M7P<  !@              ("!@#\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( ."#;EIZZ9R>)PD  $4B   8              " @3!"
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #@@VY:[8\L
M3*\$   ]"@  &0              @(&-2P  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( ."#;EH%>NW3H@,  +X'   9
M  " @7-0  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MX(-N6J__U05F$0  B2\  !D              ("!3%0  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " #@@VY:ITC"QLT"  "<!@  &0
M            @('I90  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( ."#;EK!;943 @,  +@&   9              " @>UH  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ X(-N6M2@V1A/ P
M< <  !D              ("!)FP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " #@@VY:?=@DV*0,  #1)   &0              @(&L
M;P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ."#;EJ:
M !B8EP4  !@-   9              " @8=\  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ X(-N6L!9!\=="0  J1H  !D
M     ("!58(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ."#;EK?4(R03 4  /8,   9              "
M@9RE  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ X(-N
M6N7BH+76!   T0H  !D              ("!'ZL  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " #@@VY:EU;#[= 2  !:.@  &0
M        @($LL   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( ."#;EKKV_,VQP(  .,%   9              " @3/#  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ X(-N6F+A7XJT @  &08
M !D              ("!,<8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " #@@VY:ZL+H,LT"   O!@  &0              @($<R0
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ."#;EJJSS.A
MK ,  #0)   9              " @2#,  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ X(-N6E$CF&^A @  208  !D
M ("! ]   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #@
M@VY:P3@<,/\"  !^!@  &0              @(';T@  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ."#;EHM1]@X<00  ($+   9
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M970S-BYX;6Q02P$"% ,4    " #@@VY: 7::'B("  ! !   &0
M    @($![@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M ."#;EH:3Z8>4 ,  )\,   9              " @5KP  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ X(-N6BM?>'>. @  _@8  !D
M             ("!X?,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " #@@VY:[C-\?[X"  "@!P  &0              @(&F]@  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ."#;EIZ6@L-3@4
M $(F   9              " @9OY  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ X(-N6K%[*U:^'   \_ ! !D              ("!
M(/\  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #@@VY:
M&Y-^>"H&  "[*0  &0              @($5' $ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( ."#;EJZH;:5(@D  ,%A   9
M      " @78B 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ X(-N6N0DO?C: P  >Q0  !D              ("!SRL! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #@@VY:H7%N#W^U  "WO!
M&0              @('@+P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( ."#;EI>4FAH%P0  &00   9              " @9;E 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ X(-N6D WVZU.
M"0  9EH  !D              ("!Y.D! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " #@@VY:R#=77Q0#  !-"0  &0
M@(%I\P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ."#
M;EI=%4),Z ,  +X/   9              " @;3V 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ X(-N6@)$-)O$ P  :P\  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( ."#;EH.SO?^L@0  ,L4   9
M  " @7 - @!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
MX(-N6JU?41") @  ?08  !D              ("!61(" 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " #@@VY:DO6G;@D$  #I#P  &0
M            @($9%0( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( ."#;EHC"L> D0(  %0'   9              " @5D9 @!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ X(-N6A-1T7UB P
M1@L  !D              ("!(1P" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " #@@VY:$I^4AG8#  ","P  &0              @(&Z
M'P( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ."#;EHZ
M](1ST0(  . (   9              " @6<C @!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ X(-N6I15=O1Q P  "0L  !D
M     ("!;R8" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M" #@@VY:>)8^U'(&  #D,P  &0              @($7*@( >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ."#;EH>D!9S^0@  )E7   9
M              " @< P @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L!
M A0#%     @ X(-N6D MV%AI P  E1<   T              ( !\#D" 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #@@VY:EXJ[',     3 @  "P
M        @ &$/0( 7W)E;',O+G)E;'-02P$"% ,4    " #@@VY:Y:*4\"H%
M  "/*P  #P              @ %M/@( >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ X(-N6K5Q8'P6 @  JB8  !H              ( !Q$," 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ X(-N6M(T9!3L 0
M!R8  !,              ( !$D8" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $D 20#V$P  +T@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>436</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>128</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995551 - Disclosure - Note 1 - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-1-organization</Role>
      <ShortName>Note 1 - Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995552 - Disclosure - Note 2 - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern</Role>
      <ShortName>Note 2 - Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995554 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets</Role>
      <ShortName>Note 4 - Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 5 - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities</Role>
      <ShortName>Note 5 - Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995556 - Disclosure - Note 6 - Alvogen Licensing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-</Role>
      <ShortName>Note 6 - Alvogen Licensing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Note 7 - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-7-debt</Role>
      <ShortName>Note 7 - Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995558 - Disclosure - Note 8 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies</Role>
      <ShortName>Note 8 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995559 - Disclosure - Note 9 - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-9-equity</Role>
      <ShortName>Note 9 - Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995560 - Disclosure - Note 10 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation</Role>
      <ShortName>Note 10 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995561 - Disclosure - Note 11 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements</Role>
      <ShortName>Note 11 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995562 - Disclosure - Note 12 - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting</Role>
      <ShortName>Note 12 - Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Note 13 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes</Role>
      <ShortName>Note 13 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995564 - Disclosure - Note 14 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions</Role>
      <ShortName>Note 14 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Note 15 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events</Role>
      <ShortName>Note 15 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995568 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995569 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables</Role>
      <ShortName>Note 4 - Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995570 - Disclosure - Note 5 - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables</Role>
      <ShortName>Note 5 - Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995571 - Disclosure - Note 7 - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables</Role>
      <ShortName>Note 7 - Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-7-debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995572 - Disclosure - Note 8 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables</Role>
      <ShortName>Note 8 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 9 - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables</Role>
      <ShortName>Note 9 - Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-9-equity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995574 - Disclosure - Note 10 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables</Role>
      <ShortName>Note 10 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 11 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables</Role>
      <ShortName>Note 11 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995576 - Disclosure - Note 12 - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables</Role>
      <ShortName>Note 12 - Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Note 13 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables</Role>
      <ShortName>Note 13 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995578 - Disclosure - Note 2 - Going Concern (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual</Role>
      <ShortName>Note 2 - Going Concern (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995580 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995581 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details</Role>
      <ShortName>Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995582 - Disclosure - Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details</Role>
      <ShortName>Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 6 - Alvogen Licensing Agreement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual</Role>
      <ShortName>Note 6 - Alvogen Licensing Agreement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995584 - Disclosure - Note 7 - Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual</Role>
      <ShortName>Note 7 - Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Note 7 - Debt - Schedule of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details</Role>
      <ShortName>Note 7 - Debt - Schedule of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995586 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 8 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details</Role>
      <ShortName>Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995588 - Disclosure - Note 9 - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual</Role>
      <ShortName>Note 9 - Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995589 - Disclosure - Note 9 - Equity - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details</Role>
      <ShortName>Note 9 - Equity - Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995590 - Disclosure - Note 10 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual</Role>
      <ShortName>Note 10 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995591 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details</Role>
      <ShortName>Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995592 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details</Role>
      <ShortName>Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details</Role>
      <ShortName>Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995594 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details</Role>
      <ShortName>Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Note 11 - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual</Role>
      <ShortName>Note 11 - Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995596 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details</Role>
      <ShortName>Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details</Role>
      <ShortName>Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995598 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details</Role>
      <ShortName>Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995599 - Disclosure - Note 12 - Segment Reporting (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual</Role>
      <ShortName>Note 12 - Segment Reporting (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995600 - Disclosure - Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details</Role>
      <ShortName>Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995601 - Disclosure - Note 12 - Segment Reporting - Long-lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details</Role>
      <ShortName>Note 12 - Segment Reporting - Long-lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995602 - Disclosure - Note 13 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual</Role>
      <ShortName>Note 13 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details</Role>
      <ShortName>Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995604 - Disclosure - Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details</Role>
      <ShortName>Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995606 - Disclosure - Note 14 - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual</Role>
      <ShortName>Note 14 - Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="nrxp20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Note 15 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual</Role>
      <ShortName>Note 15 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nrxp-20241231.xsd</File>
    <File>nrxp-20241231_cal.xml</File>
    <File>nrxp-20241231_def.xml</File>
    <File>nrxp-20241231_lab.xml</File>
    <File>nrxp-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="nrxp20241231c_10k.htm">nrxp20241231c_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>map01.jpg</File>
    <File>nrxgraph1.jpg</File>
    <File>nrxgraph2.jpg</File>
    <File>nrxpic.jpg</File>
    <File>nrxtable1.jpg</File>
    <File>salberglogo.jpg</File>
    <File>totalcareumbrella.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="939">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nrxp20241231c_10k.htm": {
   "nsprefix": "nrxp",
   "nsuri": "http://www.nrxpharma.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "nrxp-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nrxp-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nrxp-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nrxp-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrxp-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "nrxp20241231c_10k.htm"
     ]
    }
   },
   "keyStandard": 319,
   "keyCustom": 76,
   "axisStandard": 37,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 84,
   "hidden": {
    "total": 96,
    "http://fasb.org/us-gaap/2024": 73,
    "http://www.nrxpharma.com/20241231": 7,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://xbrl.sec.gov/cyd/2024": 6
   },
   "contextCount": 436,
   "entityCount": 1,
   "segmentCount": 128,
   "elementCount": 656,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 939,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 11,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
     "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals",
     "longName": "005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals)",
     "shortName": "Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-1-organization",
     "longName": "995551 - Disclosure - Note 1 - Organization",
     "shortName": "Note 1 - Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
     "longName": "995552 - Disclosure - Note 2 - Going Concern",
     "shortName": "Note 2 - Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
     "longName": "995553 - Disclosure - Note 3 - Summary of Significant Accounting Policies",
     "shortName": "Note 3 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets",
     "longName": "995554 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets",
     "shortName": "Note 4 - Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities",
     "longName": "995555 - Disclosure - Note 5 - Accrued and Other Current Liabilities",
     "shortName": "Note 5 - Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
     "longName": "995556 - Disclosure - Note 6 - Alvogen Licensing Agreement",
     "shortName": "Note 6 - Alvogen Licensing Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
     "longName": "995557 - Disclosure - Note 7 - Debt",
     "shortName": "Note 7 - Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
     "longName": "995558 - Disclosure - Note 8 - Commitments and Contingencies",
     "shortName": "Note 8 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
     "longName": "995559 - Disclosure - Note 9 - Equity",
     "shortName": "Note 9 - Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
     "longName": "995560 - Disclosure - Note 10 - Stock-based Compensation",
     "shortName": "Note 10 - Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
     "longName": "995561 - Disclosure - Note 11 - Fair Value Measurements",
     "shortName": "Note 11 - Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting",
     "longName": "995562 - Disclosure - Note 12 - Segment Reporting",
     "shortName": "Note 12 - Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
     "longName": "995563 - Disclosure - Note 13 - Income Taxes",
     "shortName": "Note 13 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
     "longName": "995564 - Disclosure - Note 14 - Related Party Transactions",
     "shortName": "Note 14 - Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
     "longName": "995565 - Disclosure - Note 15 - Subsequent Events",
     "shortName": "Note 15 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies",
     "longName": "995567 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
     "longName": "995568 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
     "longName": "995569 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Note 4 - Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables",
     "longName": "995570 - Disclosure - Note 5 - Accrued and Other Current Liabilities (Tables)",
     "shortName": "Note 5 - Accrued and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables",
     "longName": "995571 - Disclosure - Note 7 - Debt (Tables)",
     "shortName": "Note 7 - Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables",
     "longName": "995572 - Disclosure - Note 8 - Commitments and Contingencies (Tables)",
     "shortName": "Note 8 - Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "nrxp:ScheduleOfMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "nrxp:ScheduleOfMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables",
     "longName": "995573 - Disclosure - Note 9 - Equity (Tables)",
     "shortName": "Note 9 - Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables",
     "longName": "995574 - Disclosure - Note 10 - Stock-based Compensation (Tables)",
     "shortName": "Note 10 - Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables",
     "longName": "995575 - Disclosure - Note 11 - Fair Value Measurements (Tables)",
     "shortName": "Note 11 - Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables",
     "longName": "995576 - Disclosure - Note 12 - Segment Reporting (Tables)",
     "shortName": "Note 12 - Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables",
     "longName": "995577 - Disclosure - Note 13 - Income Taxes (Tables)",
     "shortName": "Note 13 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
     "longName": "995578 - Disclosure - Note 2 - Going Concern (Details Textual)",
     "shortName": "Note 2 - Going Concern (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
     "longName": "995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
     "longName": "995580 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details",
     "longName": "995581 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "shortName": "Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
     "longName": "995582 - Disclosure - Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "shortName": "Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
     "longName": "995583 - Disclosure - Note 6 - Alvogen Licensing Agreement (Details Textual)",
     "shortName": "Note 6 - Alvogen Licensing Agreement (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember",
      "name": "nrxp:LicenseAgreementInitialPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
     "longName": "995584 - Disclosure - Note 7 - Debt (Details Textual)",
     "shortName": "Note 7 - Debt (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:LossOnContractTerminationForDefault",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-08-12_ClassOfWarrantOrRightAxis-AnsonWarrantsMember",
      "name": "nrxp:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
     "longName": "995585 - Disclosure - Note 7 - Debt - Schedule of Convertible Debt (Details)",
     "shortName": "Note 7 - Debt - Schedule of Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:LossOnContractTerminationForDefault",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember",
      "name": "nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
     "longName": "995586 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 8 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details",
     "longName": "995587 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)",
     "shortName": "Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember",
      "name": "nrxp:LicenseAgreementMilestonePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember",
      "name": "nrxp:LicenseAgreementMilestonePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "nrxp:ScheduleOfMilestonePaymentsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
     "longName": "995588 - Disclosure - Note 9 - Equity (Details Textual)",
     "shortName": "Note 9 - Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2024-04-01",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-04-01",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details",
     "longName": "995589 - Disclosure - Note 9 - Equity - Schedule of Warrants (Details)",
     "shortName": "Note 9 - Equity - Schedule of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
     "longName": "995590 - Disclosure - Note 10 - Stock-based Compensation (Details Textual)",
     "shortName": "Note 10 - Stock-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
     "longName": "995591 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)",
     "shortName": "Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "em",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "em",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details",
     "longName": "995592 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)",
     "shortName": "Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
     "longName": "995593 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)",
     "shortName": "Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details",
     "longName": "995594 - Disclosure - Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)",
     "shortName": "Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
     "longName": "995595 - Disclosure - Note 11 - Fair Value Measurements (Details Textual)",
     "shortName": "Note 11 - Fair Value Measurements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details",
     "longName": "995596 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)",
     "shortName": "Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
     "longName": "995597 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)",
     "shortName": "Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
     "longName": "995598 - Disclosure - Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)",
     "shortName": "Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual",
     "longName": "995599 - Disclosure - Note 12 - Segment Reporting (Details Textual)",
     "shortName": "Note 12 - Segment Reporting (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
     "longName": "995600 - Disclosure - Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)",
     "shortName": "Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
     "longName": "995601 - Disclosure - Note 12 - Segment Reporting - Long-lived Assets (Details)",
     "shortName": "Note 12 - Segment Reporting - Long-lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
     "longName": "995602 - Disclosure - Note 13 - Income Taxes (Details Textual)",
     "shortName": "Note 13 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details",
     "longName": "995603 - Disclosure - Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)",
     "shortName": "Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details",
     "longName": "995604 - Disclosure - Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)",
     "shortName": "Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "longName": "995605 - Disclosure - Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
     "longName": "995606 - Disclosure - Note 14 - Related Party Transactions (Details Textual)",
     "shortName": "Note 14 - Related Party Transactions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
     "longName": "995607 - Disclosure - Note 15 - Subsequent Events (Details Textual)",
     "shortName": "Note 15 - Subsequent Events (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-01-28_ClassOfWarrantOrRightAxis-ThirdTrancheNotesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20241231c_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "nrxp_APICIncreaseForCostRecognitionContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "APICIncreaseForCostRecognitionContractTermination",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract cost related to Alvogen termination (see Note 6)",
        "documentation": "The contract costs related to the Alvogen termination."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ATMOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ATMOfferingMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Offering [Member]",
        "documentation": "Relating to ATM offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "terseLabel": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r728"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccruedBonusesCurrent",
        "terseLabel": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "nrxp_AccruedClinicalSiteCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AccruedClinicalSiteCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical site costs",
        "documentation": "Represents accrued clinical site costs."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced within one operating cycle, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
       "parentTag": "nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "nrxp_AccruedResearchAndDevelopmentLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AccruedResearchAndDevelopmentLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
       "parentTag": "nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development expense",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r130",
      "r521"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r77",
      "r136",
      "r517",
      "r544",
      "r545"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r20",
      "r433",
      "r436",
      "r484",
      "r540",
      "r541",
      "r788",
      "r789",
      "r790",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r728",
      "r933"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r802",
      "r803",
      "r804",
      "r805",
      "r876",
      "r934"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment for deferred offering cost settlement",
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of deferred offering cost settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r341"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r93"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
        "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r93"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r381"
     ]
    },
    "nrxp_AlvogenAndLotusWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AlvogenAndLotusWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alvogen and Lotus Warrants [Member]",
        "documentation": "Relating to Alvogen and Lotus warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AlvogenLicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AlvogenLicensingAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alvogen Licensing Agreement [Member]",
        "documentation": "Relating to Alvogen licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnnualRevenueThresholdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnnualRevenueThresholdMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Revenue Threshold [Member]",
        "documentation": "Relating to when annual revenues pass a certain threshold."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonConvertibleNotesMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson Convertible Notes [Member]",
        "documentation": "Represents the Anson Convertible Notes."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonFirstTrancheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonFirstTrancheNotesMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson First Tranche Notes [Member]",
        "documentation": "Represents the Anson First Tranche Notes."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson [Member]",
        "documentation": "Represents Anson Investment Master Fund LP and Anson East Master Fund LP."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonSecondTrancheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonSecondTrancheNotesMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson Second Tranche Notes [Member]",
        "documentation": "Represents the Anson Second Tranche Notes."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson Warrants [Member]",
        "documentation": "Represents the Anson Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonWarrantsTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonWarrantsTrancheOneMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson Warrants Tranche One [Member]",
        "documentation": "Represents the Anson Warrants issued in Tranche One."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AnsonWarrantsTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AnsonWarrantsTrancheTwoMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anson Warrants Tranche Two [Member]",
        "documentation": "Represents Anson Warrants Tranche Two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "nrxp_April2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "April2024OfferingMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 Offering [Member]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AprilOverallotmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AprilOverallotmentAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Overallotment Agreement [Member]",
        "documentation": "Relating to the April Over-Allotment Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AprilUnderwriterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AprilUnderwriterAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Underwriter Agreement [Member]",
        "documentation": "Relating to the April Underwriter Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AprilUnderwriterOverallotmentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AprilUnderwriterOverallotmentWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Underwriter Overallotment Warrants [Member]",
        "documentation": "Represents the April underwriter overallotment warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_AprilUnderwriterWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AprilUnderwriterWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Underwriter Warrants [Member]",
        "documentation": "Relating to the April Underwriter Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r109",
      "r132",
      "r164",
      "r199",
      "r207",
      "r225",
      "r229",
      "r238",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r428",
      "r430",
      "r466",
      "r512",
      "r604",
      "r689",
      "r690",
      "r728",
      "r744",
      "r828",
      "r829",
      "r891"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r137",
      "r164",
      "r238",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r428",
      "r430",
      "r466",
      "r728",
      "r828",
      "r829",
      "r891"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r761"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r761"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r761"
     ]
    },
    "nrxp_AugustInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "AugustInvestorWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Investor Warrants [Member]",
        "documentation": "Represents August Investor Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r424",
      "r707",
      "r708"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r424",
      "r707",
      "r708"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r128",
      "r675"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Account",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r878"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r83",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r83"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashUninsuredAmount",
        "terseLabel": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133",
      "r134",
      "r135",
      "r164",
      "r189",
      "r190",
      "r193",
      "r195",
      "r201",
      "r202",
      "r238",
      "r263",
      "r266",
      "r267",
      "r268",
      "r272",
      "r273",
      "r305",
      "r306",
      "r309",
      "r312",
      "r318",
      "r466",
      "r551",
      "r552",
      "r553",
      "r554",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r592",
      "r613",
      "r633",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r780",
      "r797",
      "r806"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightBeneficialOwnershipLimitation",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation",
        "terseLabel": "Class of Warrant or Right, Beneficial Ownership Limitation",
        "documentation": "Represents the beneficial ownership limitation on warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice",
        "terseLabel": "Class of Warrant or Right, Exercise Price, Percentage of Closing Price",
        "documentation": "Pertains to percentage of closing price."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)",
        "documentation": "The number of warrants or rights exercised during period."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightExercisesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisesInPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightExercisesInPeriod",
        "terseLabel": "Class of Warrant or Right, Exercises in Period (in shares)",
        "documentation": "Number of warrants exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightExpiredDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightExpiredDuringPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expired (in shares)",
        "label": "nrxp_ClassOfWarrantOrRightExpiredDuringPeriod",
        "documentation": "Represents the number of warrants or rights expired during the period."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued, aggregate intrinsic value",
        "label": "nrxp_ClassOfWarrantOrRightIssuedAggregateIntrinsicValue",
        "documentation": "Represents the aggregate intrinsic value of warrants or rights issued."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in shares)",
        "label": "nrxp_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)",
        "documentation": "Represents the number of warrants or rights issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightIssuedInPeriod",
        "terseLabel": "Class of Warrant or Right Issued in Period (in shares)",
        "documentation": "The number of warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued, weighted average remaining contractual term (Year)",
        "label": "nrxp_ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm",
        "documentation": "Weighted average remaining contractual term for warrants or rights issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)",
        "periodStartLabel": "Outstanding, balance (in shares)",
        "periodEndLabel": "Outstanding, balance (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant Or Right, Percent of Offering Called by Warrants or Rights",
        "documentation": "Represents the percentage of offering called by warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap",
        "terseLabel": "Class of Warrant or Right, Securities Called by Warrants or Rights, Percentage of Principal Divided by VWAP",
        "documentation": "The number of securities into which the class of warrant or right may be converted expressed as a percentage of the principal amount of the notes divided by the WVAP of the Company's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Warrant Issued with Preferred Stock [Member]",
        "documentation": "Information pertaining to warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingTerm",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding, weighted average remaining contractual term (Year)",
        "label": "nrxp_ClassOfWarrantOrRightWeightedAverageRemainingTerm",
        "documentation": "Represents the weighted average remaining term for warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantsOrRightsAggregateIntrinsicValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding, aggregate intrinsic value",
        "label": "nrxp_ClassOfWarrantsOrRightsAggregateIntrinsicValue",
        "documentation": "Represents the aggregate intrinsic value of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ClassOfWarrantsOrRightsWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Represents the weighted average exercise price for warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r114",
      "r122"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r102",
      "r514",
      "r591"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r255",
      "r256",
      "r668",
      "r816",
      "r821"
     ]
    },
    "nrxp_CommonStockAndWarrantIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "CommonStockAndWarrantIssuanceMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Warrant Issuance [Member]",
        "documentation": "Relating to common stock and warrant issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r738",
      "r739",
      "r740",
      "r741",
      "r802",
      "r803",
      "r805",
      "r876",
      "r931",
      "r934"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r592"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, issued (in shares)",
        "terseLabel": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r71",
      "r592",
      "r610",
      "r934",
      "r935"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value, 500,000,000 shares authorized; 14,591,505 and 8,391,956 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r516",
      "r728"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r143",
      "r145",
      "r150",
      "r508",
      "r525",
      "r526"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r116"
     ]
    },
    "nrxp_ConsiderationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConsiderationWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration Warrants [Member]",
        "documentation": "Pertains to consideration warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r428",
      "r429",
      "r430",
      "r431",
      "r493",
      "r669",
      "r827",
      "r830",
      "r831"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r428",
      "r429",
      "r430",
      "r431",
      "r493",
      "r669",
      "r827",
      "r830",
      "r831"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r171",
      "r199",
      "r209",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r689",
      "r690",
      "r828",
      "r829"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r171",
      "r199",
      "r209",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r689",
      "r690",
      "r828",
      "r829"
     ]
    },
    "nrxp_ConsultationAgreementWithDrJonathanJavittMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConsultationAgreementWithDrJonathanJavittMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultation Agreement with Dr. Jonathan Javitt [Member]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConsultationAgreementWithZacharyJavittMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConsultationAgreementWithZacharyJavittMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultation Agreement with Zachary Javitt [Member]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConsultingAgreementAnnualPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConsultingAgreementAnnualPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ConsultingAgreementAnnualPayment",
        "terseLabel": "Consulting Agreement, Annual Payment",
        "documentation": "Represents the annual payment of a consulting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConsultingAgreementMonthlyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConsultingAgreementMonthlyPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ConsultingAgreementMonthlyPayment",
        "terseLabel": "Consulting Agreement, Monthly Payment",
        "documentation": "Represents the monthly payment of a consulting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConsultingAgreementPerformanceBonusTargetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConsultingAgreementPerformanceBonusTargetValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_ConsultingAgreementPerformanceBonusTargetValue",
        "terseLabel": "Consulting Agreement, Performance Bonus, Target Value",
        "documentation": "Represents the target performance value of a bonus on a consulting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ContractCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ContractCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issuance costs related to Alvogen termination",
        "documentation": "The costs related to the contract."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConversionOfDebtToCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConversionOfDebtToCommonStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Debt to Common Stock [Member]",
        "documentation": "Represents the conversion of debt."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConversionOfPrincipalAndInterestIntoCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConversionOfPrincipalAndInterestIntoCommonStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Principal and Interest Into Common Stock [Member]",
        "documentation": "Relating to the conversion of principal and interest into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConversionOfSeriesAPreferredStockToCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConversionOfSeriesAPreferredStockToCommonStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A Preferred Stock to Common Stock [Member]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ConversionOfSeriesAPreferredStockToPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ConversionOfSeriesAPreferredStockToPreferredStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A Preferred Stock to Preferred Stock [Member]",
        "documentation": "Relating to the conversion of Series A convertible preferred stock to preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of Series A preferred stock into common stock",
        "label": "us-gaap_ConversionOfStockAmountConverted1",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ConversionOfStockSharesConverted1",
        "terseLabel": "Conversion of Stock, Shares Converted (in shares)",
        "negatedLabel": "Conversion of Series A preferred stock (in shares)",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ConversionOfStockSharesIssued1",
        "terseLabel": "Conversion of Stock, Shares Issued (in shares)",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note payable - current portion",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable (Note 7)",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note payable, net of current portion",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible note payable, net of current portion",
        "label": "Convertible note payable and accrued interest \u2013 long term",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total carrying value of Note",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r900"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible note payable - current portion",
        "label": "Convertible note payable and accrued interest \u2013 short term",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r278",
      "r307",
      "r491",
      "r502",
      "r511",
      "r677",
      "r679"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r800",
      "r872"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CurrentForeignTaxExpenseBenefit",
        "terseLabel": "Current",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r800"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current",
        "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r800",
      "r872"
     ]
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
       "parentTag": "nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refund liability (see Note 6)",
        "terseLabel": "Customer Refund Liability, Current",
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r775"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r775"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r777"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r775"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r768"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r769"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r769"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r767"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r767"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r767"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r770"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r772"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r772"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r776"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r774"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r771"
     ]
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion Description [Axis]",
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock as principal and interest repayment for convertible notes",
        "terseLabel": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "us-gaap_DebtConversionNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Name [Domain]",
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtConversionOriginalDebtAmount1",
        "terseLabel": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r162",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r261",
      "r262",
      "r274",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r290",
      "r297",
      "r298",
      "r299",
      "r476"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r62",
      "r63",
      "r100",
      "r101",
      "r171",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r719",
      "r798",
      "r817",
      "r818",
      "r819",
      "r886",
      "r887"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentCarryingAmount",
        "terseLabel": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r300"
     ]
    },
    "nrxp_DebtInstrumentConditionalDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentConditionalDefaultInterestRate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentConditionalDefaultInterestRate",
        "terseLabel": "Debt Instrument, Conditional Default Interest Rate",
        "documentation": "Represents the interest rate of debt instrument in the event of a default."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentConversionsAndRepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentConversionsAndRepaymentsOfDebt",
        "negatedTerseLabel": "Conversions and repayments of principal and interest (shares and cash)",
        "documentation": "Amount of noncash and cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r277"
     ]
    },
    "nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable",
        "terseLabel": "Debt Instrument, Convertible, Maximum Percentage of Equity Issuable",
        "documentation": "Represents the maximum amount of equity issuable issuable by converting a a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
        "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentConvertibleThresholdTradingDays",
        "terseLabel": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Par value of the Note",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r476",
      "r477",
      "r698",
      "r699",
      "r719"
     ]
    },
    "nrxp_DebtInstrumentFaceAmountIndividualTranches": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentFaceAmountIndividualTranches",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentFaceAmountIndividualTranches",
        "terseLabel": "Debt Instrument, Face Amount, Individual Tranches",
        "documentation": "Face (par) amount of debt instrument's individual tranches at time of issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r302",
      "r476",
      "r477",
      "r719"
     ]
    },
    "nrxp_DebtInstrumentInterestRateInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentInterestRateInEventOfDefault",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentInterestRateInEventOfDefault",
        "terseLabel": "Debt Instrument, Interest Rate in Event of Default",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement, in the event of default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r276"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r171",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r719",
      "r798",
      "r817",
      "r818",
      "r819",
      "r886",
      "r887"
     ]
    },
    "nrxp_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentNumberOfTranches",
        "terseLabel": "Debt Instrument, Number of Tranches",
        "documentation": "The number of tranches to be received as part of a purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_DebtInstrumentOriginalIssuanceDiscount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentOriginalIssuanceDiscount",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentOriginalIssuanceDiscount",
        "terseLabel": "Debt Instrument, Original Issuance Discount",
        "documentation": "Amount of original issuance discount expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentPeriodicPayment",
        "terseLabel": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r57"
     ]
    },
    "nrxp_DebtInstrumentPrepaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentPrepaymentPercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentPrepaymentPercentage",
        "terseLabel": "Debt Instrument, Prepayment Percentage",
        "documentation": "Represents the prepayment percentage on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_DebtInstrumentRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentRedemptionAmount",
        "terseLabel": "Debt Instrument, Redemption Amount",
        "documentation": "Represents the redemption amount of a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_DebtInstrumentRedemptionConversionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtInstrumentRedemptionConversionPricePercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DebtInstrumentRedemptionConversionPricePercentage",
        "terseLabel": "Debt Instrument, Redemption Conversion Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentRedemptionPricePercentage",
        "terseLabel": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Month)",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentUnamortizedDiscount",
        "terseLabel": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized original issue discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r885",
      "r886",
      "r887"
     ]
    },
    "nrxp_DebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DebtIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense for debt issuance costs due to fair value election on Anson Notes",
        "terseLabel": "Debt Issuance Costs",
        "documentation": "The cash outflow related to the issuance of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r871",
      "r872"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFinanceCostsGross",
        "terseLabel": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r887"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r871"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred",
        "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r871",
      "r872"
     ]
    },
    "nrxp_DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "174 capitalization",
        "documentation": "Amount of deferred tax asset attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock warrants",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "nrxp_DeferredTaxAssetsLiabilitiesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_DeferredTaxAssetsLiabilitiesGross",
        "totalLabel": "Deferred Tax Assets (Liabilities), Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax assets (liabilities) attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Deferred tax assets, net of allowance",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_DeferredTaxAssetsOther",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus and severance accrual",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "nrxp_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "negatedLabel": "Depreciation, liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r54",
      "r55",
      "r170",
      "r185"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r342",
      "r373",
      "r374",
      "r376",
      "r710"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-1-organization",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r761"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r761",
      "r763"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r186",
      "r189",
      "r193",
      "r194",
      "r195",
      "r198",
      "r422",
      "r426",
      "r440",
      "r441",
      "r509",
      "r527",
      "r681"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r197"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r712"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
        "negatedLabel": "Federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r390",
      "r413",
      "r712"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r712",
      "r801",
      "r863"
     ]
    },
    "nrxp_EffectiveIncomeTaxRateReconciliationConvertibleDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationConvertibleDebt",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on Conversion of Note",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to loss on conversion of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r801",
      "r863"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r801",
      "r863",
      "r865"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationSettlementWarrants",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement warrants",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to settlement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r712",
      "r801",
      "r863"
     ]
    },
    "nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent",
        "negatedLabel": "R&amp;D credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax (credit) expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
       "parentTag": "nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee costs",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_EndOfPhaseIClinicalTrialsOfLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EndOfPhaseIClinicalTrialsOfLicensedProductMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "End of Phase I Clinical Trials of Licensed Product [Member]",
        "documentation": "Relating to End of Phase I Clinical Trials of Licensed Product."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_EndOfPhaseIIClinicalTrialsOfLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EndOfPhaseIIClinicalTrialsOfLicensedProductMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "End of Phase II Clinical Trials of Licensed Product [Member]",
        "documentation": "Relating to End of Phase II Clinical Trials of Licensed Product."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_EndOfPhaseIIIClinicalTrialsOfLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "EndOfPhaseIIIClinicalTrialsOfLicensedProductMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "End of Phase III Clinical Trials of Licensed Product [Member]",
        "documentation": "Relating to End of Phase III Clinical Trials of Licensed Product."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
      "http://www.nrxpharma.com/20241231/role/statement-note-1-organization",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables",
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r124",
      "r147",
      "r148",
      "r149",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r200",
      "r239",
      "r240",
      "r246",
      "r320",
      "r411",
      "r412",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r478",
      "r479",
      "r484",
      "r524",
      "r540",
      "r541",
      "r542",
      "r560",
      "r633"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r465",
      "r698",
      "r699"
     ]
    },
    "nrxp_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement [Member]",
        "documentation": "Relating to an exclusive license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_FairValueAdjustmentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FairValueAdjustmentOfConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cumulative fair value adjustments through earnings",
        "label": "Change in fair value of convertible note payable",
        "documentation": "Represents the fair value adjustment of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "terseLabel": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r715"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r456",
      "r457",
      "r459",
      "r497",
      "r498",
      "r499",
      "r698",
      "r699",
      "r704",
      "r705",
      "r706",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r698",
      "r699"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r447",
      "r713",
      "r880",
      "r883"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r507",
      "r713",
      "r716"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r332",
      "r337",
      "r444",
      "r457",
      "r497",
      "r704",
      "r705",
      "r706",
      "r713"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r444",
      "r445",
      "r446",
      "r447",
      "r457",
      "r499",
      "r698",
      "r699",
      "r704",
      "r705",
      "r706",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r453",
      "r458"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r447",
      "r713",
      "r880",
      "r883"
     ]
    },
    "nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversions and repayments of principal and interest (shares)",
        "documentation": "Amount of conversion to shares of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment through earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r458"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment through accumulated other comprehensive loss",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r458"
     ]
    },
    "nrxp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial recognition of issuance of warrants",
        "documentation": "The initial recognition of the fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversions and repayments of principal and interest (cash)",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r458"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r458"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r456",
      "r457",
      "r459",
      "r497",
      "r498",
      "r499",
      "r698",
      "r699",
      "r704",
      "r705",
      "r706",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r883"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "nrxp_FebruaryOverallotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FebruaryOverallotmentOptionMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Overallotment Option [Member]",
        "documentation": "Relating to the February Over-allotment Option."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_FebruaryUnderwriterWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FebruaryUnderwriterWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Underwriter Warrants [Member]",
        "documentation": "Relating to the February underwriter warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_FebruaryUnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FebruaryUnderwritingAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Underwriting Agreement [Member]",
        "documentation": "Relating to the February Underwriting Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_FebruaryWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FebruaryWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Warrants [Member]",
        "documentation": "Relating to February warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_FirstCommercialSaleOfLicensedProductInEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FirstCommercialSaleOfLicensedProductInEuropeMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Commercial Sale of Licensed Product in Europe [Member]",
        "documentation": "Relating to First Commercial Sale of Licensed Product in Europe."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_FirstCommercialSaleOfLicensedProductInUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "FirstCommercialSaleOfLicensedProductInUsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Commercial Sale of Licensed Product in U.S. [Member]",
        "documentation": "Relating to First Commercial Sale of Licensed Product in U.S."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateRemeasurement1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateRemeasurement1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ForeignCurrencyExchangeRateRemeasurement1",
        "terseLabel": "Foreign Currency Exchange Rate, Remeasurement",
        "documentation": "Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "nrxp_GainLossOnConvertibleDebtRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "GainLossOnConvertibleDebtRedemption",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_GainLossOnConvertibleDebtRedemption",
        "terseLabel": "Gain (Loss) on Convertible Debt Redemption",
        "negatedLabel": "Loss on convertible note redemptions",
        "documentation": "The amount of gain (loss) on convertible debt redemption."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GainLossRelatedToLitigationSettlement",
        "terseLabel": "Gain (Loss) from Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r822"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r615"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "nrxp_GlytechLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "GlytechLicenseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Glytech License Agreement [Member]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_HCWainwrightCoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "HCWainwrightCoLLCMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H.C. Wainwright &amp; Co., LLC. [Member]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_HopeTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "HopeTherapeuticsIncMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hope Therapeutics, Inc. [Member]",
        "documentation": "Pertains to Hope Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r761"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r253",
      "r254",
      "r449",
      "r453",
      "r458",
      "r537",
      "r539",
      "r618",
      "r672",
      "r714",
      "r902"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r449",
      "r453",
      "r458",
      "r537",
      "r539",
      "r618",
      "r672",
      "r714",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r390",
      "r391",
      "r400",
      "r407",
      "r712",
      "r868"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r390",
      "r391",
      "r400",
      "r407",
      "r712",
      "r868"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r386",
      "r390",
      "r397",
      "r398",
      "r399",
      "r401",
      "r405",
      "r414",
      "r416",
      "r417",
      "r418",
      "r556",
      "r712"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued",
        "terseLabel": "Income Tax Examination, Penalties and Interest Accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense",
        "terseLabel": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "terseLabel": "Income Tax Expense (Benefit)",
        "totalLabel": "Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r120",
      "r184",
      "r185",
      "r199",
      "r212",
      "r229",
      "r389",
      "r390",
      "r415",
      "r528",
      "r712"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in Valuation Allowance",
        "label": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r387",
      "r388",
      "r401",
      "r402",
      "r404",
      "r409",
      "r550"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r159",
      "r406",
      "r407"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increases (decreases) in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r294",
      "r303",
      "r700",
      "r701"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r792"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r157",
      "r158"
     ]
    },
    "nrxp_InterestRepaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "InterestRepaymentMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Repayment [Member]",
        "documentation": "Represents interest repayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r210",
      "r229",
      "r689",
      "r791"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InvestmentOwnedAtFairValue",
        "terseLabel": "Investment Owned, Fair Value",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r584",
      "r595",
      "r596",
      "r642",
      "r644",
      "r645",
      "r646",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r736",
      "r744",
      "r932"
     ]
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InvestmentOwnedPercentOfNetAssets",
        "terseLabel": "Investment Owned, Net Assets, Percentage",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r578",
      "r579",
      "r644",
      "r650",
      "r652",
      "r655",
      "r660",
      "r736",
      "r932"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in exchange for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "nrxp_June2023PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "June2023PurchaseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2023 Purchase Agreement [Member]",
        "documentation": "Represents the securities purchase agreement entered into on June 6, 2023."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_JuneInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "JuneInvestorWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Investor Warrants [Member]",
        "documentation": "Relating to June Investor Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_JunePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "JunePlacementAgentWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Placement Agent Warrants [Member]",
        "documentation": "Represents June Placement Agent Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r781"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r781"
     ]
    },
    "nrxp_LeaseContractualTermOfficeSpaceRentalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LeaseContractualTermOfficeSpaceRentalMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term, Office Space, Rental [Member]",
        "documentation": "Pertains to the type lease arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
      "http://www.nrxpharma.com/20241231/role/statement-note-1-organization",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables",
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LetterAgreementPercentageOfCashFeePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LetterAgreementPercentageOfCashFeePaid",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LetterAgreementPercentageOfCashFeePaid",
        "terseLabel": "Letter Agreement, Percentage of Cash Fee Paid",
        "documentation": "Percentage of cash fee paid under the letter agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r62",
      "r63",
      "r64",
      "r66",
      "r67",
      "r68",
      "r69",
      "r164",
      "r238",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r429",
      "r430",
      "r431",
      "r466",
      "r590",
      "r682",
      "r744",
      "r828",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r103",
      "r519",
      "r728",
      "r799",
      "r814",
      "r884"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r127",
      "r164",
      "r238",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r429",
      "r430",
      "r431",
      "r466",
      "r728",
      "r828",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesFairValueAdjustment",
        "terseLabel": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LicenseAgreementAcceleratingPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LicenseAgreementAcceleratingPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LicenseAgreementAcceleratingPayment",
        "terseLabel": "License Agreement, Accelerating Payment",
        "documentation": "Represents the accelerating payment of a license agreement during the period."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LicenseAgreementCumulativePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LicenseAgreementCumulativePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LicenseAgreementCumulativePayments",
        "terseLabel": "License Agreement, Cumulative Payments",
        "documentation": "The cumulative amount paid for the licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LicenseAgreementInitialPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LicenseAgreementInitialPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LicenseAgreementInitialPayment",
        "terseLabel": "License Agreement, Initial Payment",
        "documentation": "Represents the initial payment of a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LicenseAgreementMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LicenseAgreementMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LicenseAgreementMaintenanceFee",
        "terseLabel": "License Agreement, Maintenance Fee",
        "documentation": "Represents the maintenance fee on a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LicenseAgreementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LicenseAgreementMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment",
        "terseLabel": "License Agreement, Milestone Payment",
        "documentation": "Represents the milestone payment for a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LicenseAgreementsMilestonePaymentsConditionalReductionPercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage",
        "terseLabel": "License Agreements, Milestone Payments, Conditional Reduction Percentage",
        "documentation": "Represents the conditional reduction percentage for milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LitigationSettlementAmountAwardedToOtherParty",
        "terseLabel": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement (income) expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "nrxp_LitigationSettlementPaymentInstallmentOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LitigationSettlementPaymentInstallmentOne",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LitigationSettlementPaymentInstallmentOne",
        "terseLabel": "Litigation Settlement, Payment Installment One",
        "documentation": "Amount of payment installment one for litigation settlement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_LitigationSettlementPaymentInstallmentTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LitigationSettlementPaymentInstallmentTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_LitigationSettlementPaymentInstallmentTwo",
        "terseLabel": "Litigation Settlement, Payment Installment Two",
        "documentation": "Amount of payment installment two for litigation settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance loan payable",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Carrying value of the Anson Notes before current period change in fair value",
        "label": "us-gaap_LongTermDebt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r287",
      "r301",
      "r698",
      "r699",
      "r719",
      "r900"
     ]
    },
    "nrxp_LongtermDebtTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "LongtermDebtTotal",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Carrying value of the Note before current period change in fair value",
        "label": "nrxp_LongtermDebtTotal",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r42",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LossContingencyDamagesSoughtValue",
        "terseLabel": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_LossOnContractTerminationForDefault": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossOnContractTerminationForDefault",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note default penalty",
        "terseLabel": "Loss on Contract Termination for Default",
        "negatedLabel": "Convertible note default penalty",
        "documentation": "The amount of the loss on termination of a contract for default."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505"
     ]
    },
    "nrxp_March2023PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "March2023PurchaseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2023 Purchase Agreement [Member]",
        "documentation": "Represents the securities purchase agreement with the March Investors entered into on March 8, 2023."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_MarchInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "MarchInvestorWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March Investor Warrants [Member]",
        "documentation": "Relating to March Investor Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r339",
      "r382",
      "r447",
      "r503",
      "r536",
      "r538",
      "r546",
      "r581",
      "r582",
      "r643",
      "r647",
      "r648",
      "r649",
      "r658",
      "r670",
      "r671",
      "r695",
      "r702",
      "r709",
      "r715",
      "r716",
      "r717",
      "r718",
      "r730",
      "r832",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "nrxp_MeasurementInputCostOfDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "MeasurementInputCostOfDebtMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Cost of Debt [Member]",
        "documentation": "Measurement input using the cost of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "nrxp_MeasurementInputMarketRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "MeasurementInputMarketRateMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Market Rate [Member[",
        "documentation": "Measurement input using the market rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r879",
      "r880",
      "r881"
     ]
    },
    "nrxp_MeasurementInputProbabilityOfDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "MeasurementInputProbabilityOfDefaultMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Probability of Default [Member]",
        "documentation": "Measurement input using the probability of default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r715"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r715"
     ]
    },
    "nrxp_MeasurementInputVolumeVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "MeasurementInputVolumeVolatilityMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Volume Volatility [Member]",
        "documentation": "Measurement input using volume volatility."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r339",
      "r382",
      "r447",
      "r503",
      "r536",
      "r538",
      "r546",
      "r581",
      "r582",
      "r643",
      "r647",
      "r648",
      "r649",
      "r658",
      "r670",
      "r671",
      "r695",
      "r702",
      "r709",
      "r715",
      "r716",
      "r717",
      "r730",
      "r832",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "nrxp_NRXPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "NRXPharmaceuticalsIncMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NRX Pharmaceuticals, Inc [Member]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r85",
      "r104",
      "r125",
      "r142",
      "r144",
      "r149",
      "r164",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r191",
      "r238",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r422",
      "r426",
      "r441",
      "r466",
      "r523",
      "r612",
      "r631",
      "r632",
      "r742",
      "r828"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r177",
      "r178",
      "r179",
      "r180",
      "r186",
      "r187",
      "r192",
      "r195",
      "r426"
     ]
    },
    "nrxp_NeuroRxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "NeuroRxMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neuro Rx [Member]",
        "documentation": "Relating to Neuro Rx."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_NoncashLitigationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "NoncashLitigationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash settlement expense",
        "documentation": "The non-cash litigation expense."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_NondesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "NondesignatedPreferredStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nondesignated Preferred Stock [Member]",
        "documentation": "The Nondesignated Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonmonetaryTransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonmonetaryTransactionTypeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transaction Type [Axis]",
        "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_NonmonetaryTransactionTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonmonetaryTransactionTypeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transaction Type [Domain]",
        "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NonoperatingIncomeExpense",
        "negatedTotalLabel": "Total other expenses, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (income) expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "nrxp_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r808"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfReportableSegments",
        "terseLabel": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r694",
      "r808"
     ]
    },
    "nrxp_OctoberAmendedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "OctoberAmendedWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October Amended Warrants [Member]",
        "documentation": "Pertains to the October Amended Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r683",
      "r807",
      "r809",
      "r810",
      "r811",
      "r812"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwardsExpirationDate",
        "terseLabel": "Operating Loss Carryforwards, Expiration Date",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r689",
      "r690"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-1-organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r98",
      "r547",
      "r548"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
       "parentTag": "nrxp_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued expense",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cumulative fair value adjustments through accumulated other comprehensive loss",
        "label": "Change in fair value of convertible note attributed to credit risk",
        "negatedLabel": "Change in fair value of convertible note attributed to credit risk",
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) from increase (decrease) in instrument-specific credit risk, realized upon derecognition of financial liability measured under fair value option."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r139",
      "r140",
      "r141",
      "r467"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expense",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r815"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_PatentLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PatentLicenseMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent License [Member]",
        "documentation": "Pertains to the type of expense."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_PaymentForLicenseAgreementMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PaymentForLicenseAgreementMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_PaymentForLicenseAgreementMaintenanceFee",
        "terseLabel": "Payment for License Agreement, Maintenance Fee",
        "documentation": "The amount of cash paid for license agreement maintenance fee during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsForLegalSettlements",
        "terseLabel": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsForRoyalties",
        "terseLabel": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfDebtIssuanceCosts",
        "negatedLabel": "Expense for debt issuance costs due to fair value election on Anson Notes",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquireProductiveAssets",
        "negatedLabel": "Purchase of computer equipment",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r873",
      "r874",
      "r875"
     ]
    },
    "nrxp_PlacementAgentFeePercentOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PlacementAgentFeePercentOfGrossProceeds",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_PlacementAgentFeePercentOfGrossProceeds",
        "terseLabel": "Placement Agent Fee, Percent of Gross Proceeds",
        "documentation": "The fee paid to the placement agent expressed as a percentage of gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_PreferredClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredClassAMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Class A [Member]",
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_PreferredStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PreferredStockAndWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock and Warrants [Member]",
        "documentation": "Relating to preferred stock and warrants issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r738",
      "r739",
      "r740",
      "r741",
      "r931",
      "r934"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, authorized (in shares)",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r592"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issued (in shares)",
        "terseLabel": "Preferred Stock, Shares Issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, outstanding (in shares)",
        "terseLabel": "Preferred Stock, Shares Outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r592",
      "r610",
      "r934",
      "r935"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r515",
      "r728"
     ]
    },
    "nrxp_PrepaidClinicalDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PrepaidClinicalDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical development costs",
        "documentation": "Amount of asset related to consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expense and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "nrxp_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Text Block]",
        "documentation": "The entire disclosure regarding prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r696",
      "r815"
     ]
    },
    "nrxp_PrincipalRepaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PrincipalRepaymentMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Repayment [Member]",
        "documentation": "Represents principal repayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_PrivatePlacementPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PrivatePlacementPremiumPercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_PrivatePlacementPremiumPercentage",
        "terseLabel": "Private Placement, Premium Percentage",
        "documentation": "Represents the premium percentage on a private placement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants [Member]",
        "documentation": "Relating to private placement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Anson convertible notes, net of OID",
        "terseLabel": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromDebtNetOfIssuanceCosts",
        "terseLabel": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from liability classified warrants",
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r680"
     ]
    },
    "nrxp_ProceedsFromInsuranceLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ProceedsFromInsuranceLoans",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of insurance loan",
        "documentation": "The cash inflow from insurance loans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "nrxp_ProceedsFromIssuanceOfCommonStockAndWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and warrants, net of issuance costs",
        "documentation": "The proceeds from issuance of common stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfDebt",
        "terseLabel": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs",
        "terseLabel": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r551"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r506",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r674",
      "r703",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r825",
      "r826",
      "r835",
      "r901",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r506",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r674",
      "r703",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r825",
      "r826",
      "r835",
      "r901",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "nrxp_ProductsCoveredByLicensedPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ProductsCoveredByLicensedPatentsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products Covered By Licensed Patents [Member]",
        "documentation": "Relating to products covered by licensed patents."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ProductsCoveredByValidClaimsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ProductsCoveredByValidClaimsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products Covered by Valid Claims [Member]",
        "documentation": "Relating to products covered by valid claims."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r480"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers, cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r129",
      "r522"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentNet",
        "totalLabel": "Total equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r480",
      "r510",
      "r522",
      "r728"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r480"
     ]
    },
    "nrxp_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Relating to public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Represents Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_RDPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "RDPurchaseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RD Purchase Agreement [Member]",
        "documentation": "Pertains to the RD Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_RDPurchaseAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "RDPurchaseAgreementWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RD Purchase Agreement, Warrants [Member]",
        "documentation": "Represents RD Purchase Agreement, warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r331",
      "r339",
      "r368",
      "r369",
      "r370",
      "r382",
      "r447",
      "r500",
      "r501",
      "r503",
      "r536",
      "r538",
      "r546",
      "r581",
      "r582",
      "r643",
      "r647",
      "r648",
      "r649",
      "r658",
      "r670",
      "r671",
      "r695",
      "r702",
      "r709",
      "r715",
      "r716",
      "r717",
      "r718",
      "r730",
      "r736",
      "r820",
      "r832",
      "r880",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r331",
      "r339",
      "r368",
      "r369",
      "r370",
      "r382",
      "r447",
      "r500",
      "r501",
      "r503",
      "r536",
      "r538",
      "r546",
      "r581",
      "r582",
      "r643",
      "r647",
      "r648",
      "r649",
      "r658",
      "r670",
      "r671",
      "r695",
      "r702",
      "r709",
      "r715",
      "r716",
      "r717",
      "r718",
      "r730",
      "r736",
      "r820",
      "r832",
      "r880",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "nrxp_ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of AOCI upon settlement of Streeterville Note",
        "documentation": "Amount of reclassification adjustments of other comprehensive income (loss) upon settlement of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39"
     ]
    },
    "us-gaap_RedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RedemptionPremium",
        "terseLabel": "Redemption Premium",
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r338",
      "r488",
      "r489",
      "r513",
      "r520",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r611",
      "r641"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r488",
      "r489",
      "r490",
      "r491",
      "r513",
      "r520",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r611",
      "r641"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r488"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r890"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r338",
      "r488",
      "r489",
      "r513",
      "r520",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r611",
      "r641",
      "r890"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r557",
      "r558",
      "r559",
      "r616",
      "r617",
      "r618",
      "r638",
      "r640"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfConvertibleDebt",
        "negatedLabel": "Repayment of convertible note",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfDebt",
        "terseLabel": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "nrxp_RepaymentsOfInsuranceLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "RepaymentsOfInsuranceLoans",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_RepaymentsOfInsuranceLoans",
        "negatedLabel": "Repayment of insurance loan",
        "documentation": "The repayment of insurance loans."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r278",
      "r307",
      "r491",
      "r502",
      "r511",
      "r678",
      "r679"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "terseLabel": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r672",
      "r689",
      "r899"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r93",
      "r518",
      "r543",
      "r545",
      "r555",
      "r593",
      "r728"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r239",
      "r240",
      "r246",
      "r411",
      "r412",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r426",
      "r432",
      "r434",
      "r435",
      "r437",
      "r439",
      "r478",
      "r479",
      "r540",
      "r542",
      "r560",
      "r934"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r199",
      "r208",
      "r209",
      "r223",
      "r229",
      "r233",
      "r235",
      "r236",
      "r329",
      "r330",
      "r506"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r199",
      "r208",
      "r209",
      "r223",
      "r229",
      "r233",
      "r235",
      "r236",
      "r329",
      "r330",
      "r506"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r673"
     ]
    },
    "nrxp_ReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ReverseStockSplitMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split [Member]",
        "documentation": "Relating to a reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Policy Text Block]",
        "documentation": "The disclosure of the entity's policy regarding risks and uncertainties."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_RoyaltyPercentage",
        "terseLabel": "Royalty Percentage",
        "documentation": "Represents the percentage of revenue that a royalty is paid on."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SaleOfStockConsiderationAdditionalCommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_SaleOfStockConsiderationAdditionalCommitmentAmount",
        "terseLabel": "Sale Of Stock Consideration, Additional Commitment Amount",
        "documentation": "The additional commitment amount for the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_SaleOfStockConsiderationCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SaleOfStockConsiderationCommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_SaleOfStockConsiderationCommitmentAmount",
        "terseLabel": "Sale Of Stock Consideration, Commitment Amount",
        "documentation": "Cash committed for the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_SarahHerzogMemorialHospitalLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SarahHerzogMemorialHospitalLicenseAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sarah Herzog Memorial Hospital License Agreement [Member]",
        "documentation": "Relating to Sarah Herzog Memorial Hospital License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r712",
      "r863"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r878"
     ]
    },
    "nrxp_ScheduleOfMilestonePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ScheduleOfMilestonePaymentsTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Milestone Payments [Table Text Block]",
        "documentation": "Tabular disclosure of milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r95"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r213",
      "r214",
      "r215",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r236",
      "r684",
      "r687",
      "r688",
      "r689",
      "r691",
      "r693",
      "r694"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r232",
      "r235",
      "r685",
      "r686",
      "r692"
     ]
    },
    "nrxp_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r834"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "us-gaap_ShareBasedCompensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedTerseLabel": "Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited, weighted average grant date fair value (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average grant date fair value (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Balance (unvested) (in shares)",
        "periodEndLabel": "Balance (unvested) (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested, weighted average grant date fair value (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedTerseLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price (in dollars per share)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate of interest",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedLabel": "Forfeited/Expire (in shares)",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/Expire, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)",
        "periodStartLabel": "Outstanding, balance (in shares)",
        "periodEndLabel": "Outstanding, balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and exercisable, aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and exercisable (in shares)",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and exercisable, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r346",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharePrice",
        "terseLabel": "Share Price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ShareSubscriptionFacilityAgreementGEMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ShareSubscriptionFacilityAgreementGEMMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Subscription Facility Agreement - GEM [Member]",
        "documentation": "Relating to the Share Subscription Facility Agreement - GEM."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares",
        "documentation": "Represents the annual percentage increase in authorized shares for a share based compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "documentation": "The fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years) (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r161"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133",
      "r134",
      "r135",
      "r164",
      "r189",
      "r190",
      "r193",
      "r195",
      "r201",
      "r202",
      "r238",
      "r263",
      "r266",
      "r267",
      "r268",
      "r272",
      "r273",
      "r305",
      "r306",
      "r309",
      "r312",
      "r318",
      "r466",
      "r551",
      "r552",
      "r553",
      "r554",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r592",
      "r613",
      "r633",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r780",
      "r797",
      "r806"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r71",
      "r74",
      "r75",
      "r124",
      "r147",
      "r148",
      "r149",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r200",
      "r239",
      "r240",
      "r246",
      "r320",
      "r411",
      "r412",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r478",
      "r479",
      "r484",
      "r524",
      "r540",
      "r541",
      "r542",
      "r560",
      "r633"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-1-organization",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables",
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r200",
      "r479",
      "r506",
      "r549",
      "r571",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r614",
      "r615",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r633",
      "r737"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.nrxpharma.com/20241231/role/statement-note-1-organization",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-longlived-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-schedule-of-warrants-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables",
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r200",
      "r237",
      "r479",
      "r506",
      "r549",
      "r571",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r611",
      "r614",
      "r615",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r633",
      "r737"
     ]
    },
    "nrxp_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock and warrants issued, net (in shares)",
        "documentation": "Number of preferred stock and warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock and warrants issued, net",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for settlement of accrued liability",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "nrxp_StockIssuedAsOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StockIssuedAsOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock warrants as offering costs",
        "documentation": "The fair value of stock issued in noncash financing activities for offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)",
        "negatedLabel": "Conversion of Series A preferred stock into common stock (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r44",
      "r71",
      "r74",
      "r93",
      "r291"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued as repayment of principal and interest for convertible note (in shares)",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r44",
      "r70",
      "r71",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued in exchange for services (in shares)",
        "label": "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices",
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuances, net (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r70",
      "r71",
      "r93",
      "r551",
      "r633",
      "r663"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting of restricted stock awards (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r70",
      "r71",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares related to reverse stock split (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Reverse Stock Splits (in shares)",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation",
        "terseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r70",
      "r71",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A preferred stock into common stock",
        "negatedLabel": "Conversion of Series A preferred stock into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r71",
      "r74",
      "r75",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued as repayment of principal and interest for convertible note",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r71",
      "r74",
      "r75",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued in exchange for services",
        "label": "us-gaap_StockIssuedDuringPeriodValueIssuedForServices",
        "terseLabel": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuances, net",
        "terseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r70",
      "r71",
      "r93",
      "r560",
      "r633",
      "r663",
      "r743"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting of restricted stock awards",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r93"
     ]
    },
    "nrxp_StockSubscriptionsReceivableWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StockSubscriptionsReceivableWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_StockSubscriptionsReceivableWriteOff",
        "terseLabel": "Stock Subscriptions Receivable, Write Off",
        "documentation": "Write off amount of stock subscriptions receivable during a period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r75",
      "r87",
      "r594",
      "r610",
      "r634",
      "r635",
      "r728",
      "r744",
      "r799",
      "r814",
      "r884",
      "r934"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r163",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r438",
      "r636",
      "r639",
      "r667"
     ]
    },
    "nrxp_StockholdersEquityNoteSpinoffTransactionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StockholdersEquityNoteSpinoffTransactionPercentage",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "nrxp_StockholdersEquityNoteSpinoffTransactionPercentage",
        "terseLabel": "Stockholders Equity Note Spinoff Transaction, Percentage",
        "documentation": "Percent of shares related to the spinoff."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1",
        "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r637"
     ]
    },
    "nrxp_StreetervileComplaintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StreetervileComplaintMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern",
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streetervile Complaint [Member]",
        "documentation": "Relating to the Streeterville Complaint."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_StreetervilleCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StreetervilleCapitalLLCMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streeterville Capital, LLC [Member]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_StreetervilleConvertibleNoteAmendment2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StreetervilleConvertibleNoteAmendment2Member",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streeterville Convertible Note Amendment 2 [Member]",
        "documentation": "Represents Amendment 2 of the Streeterville Convertible Note."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_StreetervilleConvertibleNoteAmendment3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StreetervilleConvertibleNoteAmendment3Member",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streeterville Convertible Note Amendment 3 [Member]",
        "documentation": "Represents Amendment 3 of the Streeterville Convertible Note."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_StreetervilleConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "StreetervilleConvertibleNoteMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-schedule-of-convertible-debt-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streeterville Convertible Note [Member]",
        "documentation": "Represents the Streeterville Convertible Note."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r495"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r495"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r495"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r496"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity-parentheticals",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-2-going-concern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "nrxp_SubstituteWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "SubstituteWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substitute Warrants [Member]",
        "documentation": "Relating to substitute warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-12-segment-reporting-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-13-income-taxes-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-5-accrued-and-other-current-liabilities-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-tables",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_The2016OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "The2016OmnibusIncentivePlanMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2016 Omnibus Incentive Plan [Member]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_The2021OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "The2021OmnibusIncentivePlanMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Omnibus Incentive Plan [Member]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ThirdTrancheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ThirdTrancheNotesMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Tranche Notes [Member]",
        "documentation": "Pertains to the Third Tranche Notes."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_ThirdTrancheNotesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "ThirdTrancheNotesWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events",
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Tranche Notes, Warrants [Member]",
        "documentation": "Pertains to Third Tranche Notes, Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r889"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation",
      "http://www.nrxpharma.com/20241231/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "nrxp_UnderwriterOverallotmentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "UnderwriterOverallotmentWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Overallotment Warrants [Member]",
        "documentation": "Relating to the underwriter over-allotment warrants."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_UnrestrictedUponNewDrugApplicationDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "UnrestrictedUponNewDrugApplicationDateMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted Upon New Drug Application Date [Member]",
        "documentation": "Relating to unrestricted upon New Drug Application Date."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_UnrestrictedUponNewDrugApprovalDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "UnrestrictedUponNewDrugApprovalDateMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted Upon New Drug Approval Date [member]",
        "documentation": "Relating to unrestricted upon New Drug Approval Date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r113",
      "r115",
      "r117",
      "r118"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions",
      "http://www.nrxpharma.com/20241231/role/statement-note-14-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "nrxp_WarrantAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "WarrantAmendmentAgreementMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Amendment Agreement [Member]",
        "documentation": "Represents the Warrant Amendment Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_WarrantAmendmentJuneInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "WarrantAmendmentJuneInvestorWarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Amendment, June Investor Warrants [Member]",
        "documentation": "Information pertaining to the Warrant Amendment Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount",
        "negatedLabel": "Deemed dividend - warrants",
        "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r195"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-document-and-entity-information",
      "http://www.nrxpharma.com/20241231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r738",
      "r739",
      "r740",
      "r741"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-7-debt-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement input",
        "terseLabel": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-15-subsequent-events-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-6-alvogen-licensing-agreement-details-textual",
      "http://www.nrxpharma.com/20241231/role/statement-note-9-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ]
    },
    "nrxp_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
      "http://www.nrxpharma.com/20241231/role/statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Relating to warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.nrxpharma.com/20241231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-10-stockbased-compensation-schedule-of-restricted-stock-awards-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-10-stockbased-compensation-schedule-of-stock-options-valuation-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation - Schedule of Stock Options, Valuation Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-10-stockbased-compensation-schedule-of-stockbased-compensation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-10-stockbased-compensation-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-10-stockbased-compensation-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-11-fair-value-measurements-schedule-of-assets-and-liabilities-on-a-recurring-basis-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-11-fair-value-measurements-schedule-of-level-3-fair-value-changes-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-11-fair-value-measurements-schedule-of-significant-inputs-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-11-fair-value-measurements-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-11-fair-value-measurements-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-12-segment-reporting-longlived-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-12-segment-reporting-longlived-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Segment Reporting - Long-lived Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-12-segment-reporting-reconciliation-of-loss-from-operations-to-total-loss-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-12-segment-reporting-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-12-segment-reporting-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-benefit-components-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Schedule of Income Tax Expense (Benefit) Components (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-13-income-taxes-schedule-of-tax-rate-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Schedule of Tax Rate Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-13-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-13-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-schedule-of-prepaid-expense-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-5-accrued-and-other-current-liabilities-schedule-of-accrued-and-other-current-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-5-accrued-and-other-current-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-5-accrued-and-other-current-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Accrued and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-7-debt-schedule-of-convertible-debt-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-7-debt-schedule-of-convertible-debt-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Debt - Schedule of Convertible Debt (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-7-debt-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-7-debt-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Debt"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-8-commitments-and-contingencies-schedule-of-milestone-payments-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-8-commitments-and-contingencies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-8-commitments-and-contingencies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-9-equity-schedule-of-warrants-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-9-equity-schedule-of-warrants-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Equity - Schedule of Warrants (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-note-9-equity-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-note-9-equity-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Equity"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nrxpharma.com/20241231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)(4)",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-12B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482291/912-20-45-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482269/912-20-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-23"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001437749-25-007743-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-007743-xbrl.zip
M4$L#!!0    ( .&#;EIL_X3]YP(  &(*   -    97A?-S@Y,#0W+FAT;=U6
M46_3,!!^9K_BZ ,PJ6G:I&-;FT7J6%NF;25JBQA/R'4NC9%C1X[#*+^>2]J)
M=8,),0W0^M#6OL_^OO.=/SE(;2;#($46ASO/ BNLQ!"_?MH_.&QW]UL4#=SU
MY,XSBC]W'!BC0L,LQK!8P3PM58SF1&<(D3:627# =SN>Z[6]/>CV/+^W=PC1
M!3A.&&1H&?"4F0+M4:.TB7/0V,PJEN%1(]$F8]:)T2*W0JL&<*TL*D);E)BG
M6N&1THUP)W#7FH.%CE=0V)6LEROK%.(;]CKMW/;K8<(R(5>]EW.180$3O(*I
MSIAZV<]9' NU[+6%@E9'J'ZU:[ZUU6;MK:7]G]%\848P97NJRD#V+7ZU#I-B
MJ7I&+%/;SYA9"M6K\)3R(AQ>OCT]/IV#Y[<Z@;L( S</=W[!?U?[;RC8(GRA
M%D7>OX_C83ER*A&:.TF^T:J@".@$3JE-<J0O&DYQ*0K"4PM%Y4(*#@/.=:DL
ME0-&PF3_PX$\%8Z'%?9S65B1K+9)/R"D5#VZ_GQ38*O!I@A"<6UR3>Y =[>R
M!X,) 16O0C5B7?H-8&;)1C):7P"-1D0.,\>'5R,A$2:Z!;[O.][KO>ZAMPM,
MQ=>0SFW(@>]Y[=VJS71IB)0D6(AKC[I@AJ?0Z3:A-B2]EE'IUE*L(8E03'%!
MUE7<$)3 9'H)$9E5QCB65G FBR;U,6\!J^.5(C*L>L,5DJE!U=\QG"#';($&
M_$[-VJV1],=OPE4J2,Y&H2BJ$Y-EM6AS/@.E2A(R70.N3Z73=L[N5W13QZ]D
MM/YU*SX5CC^X4MO.*$*W<&'&))5G"2]8EO?AC<YRIE9-B%H#JI2XUP ?JN#3
M?9_'))X-SH^'T_%USN\NHL'DXW7.CT=[K#F#*;-:-6$DM:&;_YATVZ;S%]LU
M%E^ 2U841XWSP6SN1(/QT#F>#@=GU>/F1C0:C^;36W-IXAA]=7>2HY00C2?O
M+WZP$:)Z@_WDAU2XU9N,^K=^6WX'4$L#!!0    ( .&#;EH?MFCBV1P  +:[
M   -    97A?-SDP,S4Y+FAT;>T]:W,;M[6?DU^!Z\YMI3M+67*<-K$4S65D
MV=8TD342TS;3Z72PNR"):+E@]B&*]]??\P"PV.52DA]U')&9=F22N\ !<-XO
M'$VK679\-%4R/?[RBZ-*5YDZ5K?__LNW^U]]_>T>_'KTE+_\\@OX_;\& _%:
MY:J0E4I%O!2C:9VGJGAI9DI<F**2F1B(KYX>/'_Z;/_9U^+9BV?/7^Q_)2Y^
M%(/!\=%,55(D4UF4JOKN25V-!]\\L=_F<J:^>S(VQ4Q6@U15*JFTR9^(Q.25
MRN'I2F5J/C6Y^BXW3XZ_/'K*,!_%)EV*LEIF]'I>#4K]?^J%.-B?5X>"OAC+
MF<Z6+\0??ZU-=3C2,U6*<[40EV8F<_[R4,QEFNI\\D+LZUSL[QWH_% D=5&:
MXH60=64.<<ZYFV@FBXG.X>'YK:")*G5;#62F)_!EH2=3-_=[ 0-[@L^V5N7>
M^U/GE3]%@KZ)1*D*/5Z9%L:*CT]OISK6E3CX=N_@Z&E\?/04GX(_\^,O'[JJ
M3(T_HT7],8_+^>&:=81C=T8^;$8B^.GCC2RTS*L7.6)?=ABL.@'44\6AW1A\
M@?;S_/(?XN+-\/+'X<GI3Z.SD^$/5Y$X.S_9$[R[GQB<J].3GR[/1F>G5V)T
M.7QY=OY:7+S]X>SDY_N@6=GWA\#3FMV=PR=>\8_#GP4PF(/?_P)_J<M*CY>=
M%=;'%W4Q-Z4Z>EH_O@72KQKD!KSPU9\)BI$1J2J30L=*5%,%8,@\E45:H@!(
M5)$#;Z8?IO!]AA_,6.0F'\SK.-.)T#F+#I 9HE 9_ .?-^+\\E9<@,"9R435
ME4YD!DSE+$_V!(PC=%6*LHY+G6J '_F-SI.L1D$ ZZT+<WEKG]Y)3):A3+I1
MV3(B2/[XAV^>/=L_/#&SN<R7].G@<)?&Q9_C>HG#X,=290[D4H%0T17,A9_P
M.?O^WJ,[949C!2(T+\5P/(;= YT!]^.B,"2/X..HD'DI2=:7&X/K<.H34J(R
M,;=;@>MGC- E*%* TDLAY_-LB4@LLTRDNH -- 7@J!F/-9!$27NI9O/,+-4*
M/D5B,=49$U.ARJK0O,GP80)TA>@89S*Y-G4EYB!D3<KCS0LU$$FF)!Q,HBP,
M)F=  B#4+6 RDH,'YZBL_9;>J(*(S>Y+9>:'0 %J,%6H&[TX>+;_W[ 1P+[A
MG6.:%T:H)*A>P 7@#5(O^]>Y)\[&8FEJ(0LEZKRLX<]BJF"=A?\::/H7 )3V
M+E^";H?0U)DL6EL1B3FLLU2D8TI\O-D^).>#OQR65MO-X'N82V7"% */"/_
MA RM4H^/>M?@;0EJ>AN?'-L&;IJWT3<K38/#<#2%*.>F+E4D9AI@ $- 9VFA
M<CI?V'/0[87*X#PR?8/X">/16U-\:6JR-**3A/,HIWI>XN^ X\G4'[MLR(J?
M T9=P-*(-KJ/TB\*@('% +KU/9-;+ =825KD-_#L#'9$C,'J(20PA'>EAD,
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MDG99 [8=[,=?#P[$#J*Z$^BD;N&O3I#S0\Q^8B>YX;%=RZX1N*L&W--;D.0
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M%3C(N7+5&NU06.P2ST".@+F980[1'_;I/WA/)M>3PH!J.FC_M+*"-R\O>U?
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M5L2S6?5E4[B[GU$+$#)I7+M=L)0TX<>-\AS<FEBT,QQ6\"B)E^WA^LC4L#U
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M$EFB8$]/KP>DXP^!?\0F7<*RI]4L._Y_4$L#!!0    ( .&#;EJ-K<[X( @
M  TP   -    97A?-SDP,S8P+FAT;>U;;7/;-A+^W/R*/7>:V#.4]>*XS4FR
M9Q1;3M4FMD>6;WJ?;B 2%#$! 08 ]=)??[L@]6+)=ISFFLASZDRJ$%@ "^!Y
M\.R"3#MQJ3QM)YQ%IR]^:#OA)#_ET__\\L_:T<^U0ZQM5XO"%S]@_3\J%7C'
M%3?,\0B&,Q@DN8JX.=<IAVMM')-0@:-J_76U46L<0Z-9?].LU^'Z U0JI^V4
M.P9APHSE[F0O=W'ES5Y9JEC*3_9B;5+F*A%W/'1"JST(M7)<H;7CDF>)5OQ$
MZ;W3%^UJX7-[J*,96#>3OKER%2O^Y$VHUS+7 E\0LU3(61->?LJU:PU$RBU<
M\@GT=<I44=B"C$614*,FU(2"VF%=J!:$N;':-('E3K=HS.S.0&6_:QVVEDYX
M'_SCF!G!E&LJFI]L.3YU%2;%2#6-&"6NE3(S$JI)]K@@P]/N-!%#X>"H?EAO
M5X>G[6IV^N*!\5^M.?#J*1[<&?"E&MJL]=@87S?'$#>0FXU)GG7[@]Y%[ZPS
MZ%U=PM4%#'[MPMFOO>X%=/_HGMT.>O_J8C%:=/N?6X2_Q<'KV_[-;>=R (,K
MZ-^^[T+]B%7JK_?9 70NSZ%^'!5/P7?QKG,#G?.KZT'W'%8=O>F>^?4\JC7F
M:WK3Z;_M7'9O*E=_O._^&SIG ZIIU&J-;<#6EN+WS@B] '[3BKF$*?B-C85S
M ?1H5T0*9XG@,72G/,R=&'.XBF,1<@,ZALO^%*[QN$M9R+$R9-)2N_ P +1P
M(IX!=NF:WW!Y'!M*#D-M\-0^V:OA <NE+ ^_Q;/-6#A_+EV:B,@E=*S6?FJ!
M!Z? @Q]'A%HVI<,1Y0'UP\SMQS0_G'")87 Z\U9D%*UW^L;[Z2OO70/86(0
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M$CI#PU(;P$4B> Q70C$5"MSV;N)8A-R CN&Z?P^WN,NE+.2Y$R&3:-]3X7$
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M)I,X!CR&BK$\(R%#Z,EJV4Y691L%!LR(1EQIKCPND)MF>DA&@MPNZ5N7M0.
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MQQ.>#PX,]U\9=SJL,WJ\2@O[0J"%T_:SI$\7%D'_-CF;H-W4%RL+I?G7]+P
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M@K+1%%3..R71-DRS\89LX4PF.DGOU'KAN(GS#R(KZ4I32W2-,7*LW""F(9<
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ML%KDO.7"1X@+/%,",P9,]D8A>()Z$^EUL$A'6#7C3=B. 2[0!N4=?8;W&8%
M#^JOFRRS#W4$^J=1^Y@'>,HG]0DX@<F7#X;9ZH57J>;SN)'-!HKRM]%H7: *
M;N58"9+[WY2[,XICGH^]!"6BYC>D5\8,[ZBH*3.:\AM$N8^N3/T_)IUQ_V3T
MWG3;SXG4^$: 0DQ=BRTH!B*?LS*>OM-A(S<I,K@A4XAB0&,40X^,Q_CP@6-
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MP_ACI(;KWHR/L.O07^V^\/IVJXZ$>Y0CH,XKN&B6JX>'4Y!*(6')???EE<Q
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M\EQ]V\Y=8*3@L41B5",:)'.76#VA;.]57+6[R:/&F>/^7:$#&W-*V E.Y<K
M$&:GLV4B[V%-V< ZR?0FZSW&DJ);-_]F2SH_LIF-;EA?-)5A,L+-*8<U%7?'
M'CM_Q;G1CX3I#P6C4CIOY/2%B/VE8$W,T9V:Z'BUI>7KF/0X:5-1@\F+K3W]
M7JYOR6=L_OK4$XTO:'V>2:)IQB#_N%)O D,N(7F8>0R-N"K)YZ,RI-NX5LC
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M$QL-]9.YGB^PEARBA@RS!T37QM3$T*9Y]OA$J6&B5&,\%.J+6JQV62R@Z/X
MXF$&T?<"-)&UPX+3A\V8ROG?VZ>'.,8VW(*&^N-C#Z!)UP9AA-MJ74H##E%)
M1FL#WD=GIP8AB:FM:P]&Z),;#VRU^,MP[P#%O).N[KL,SQ=%BE] YVZ?+JC)
MUZ@?1<H4W>MW"\FL6F W?SS.'@O!F)(P?*I.$3P$>6]XQJ29[H*K-])3:)0C
ML^L5]8#(%$B.C_XG>0U@RW+^G1NDC>H?B$WJGQ ;V=_J3*3O-?Z?U9EDAC(
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M87='>9\ES" LZ 4R+K) 4D^6Y,1NGGK*AAC6-:<&,[<+ / >A:-C_EYM5NA
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M.4F1!![)\Q",#FOH=0T781PC/V5SVB8TR<#8@T"D2#>S2IQ[RH);*\/B;;(
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M+0]:N"IID3N^CU_\A4;F-JR!7N(N"COEE!-Q%730,M45MQ(JV2)__B@%@P)
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M@,UU*XD"C&F4/;#^H0<,1I(9NC2GBC2_2NN9VKHK1P%:WZ  O4%W[",'9"B
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M3\@/<"%04O2Q%Q#05G8UDB!0%$/-_A=02P,$%     @ X8-N6L7ZG%?WG
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MGMS3@ #0RSC^XS]8^'B, H,0/W,$/#V49OW&0,_!:<Q<'U<^%%+L9E/I.>W
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M!A'R>=7#\#@ZVQG1/C;ZI&QLS<[^TO';6>+/G_X4[GJNWD#+G"K@2;2PA-W
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M-QW>#T&ZN 32C202K=A4!*F&"W#(0$J;J['TN_!UB,K-0,Y!$-GQF"5)8U>
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MXKM&PAT^?1]J/I8*N<-RF,>S$^K:$B4*3X:]?78>E7L#W%EG;FZB[RQZT/Z
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M.Z?9(;P1D!<?!F;W407MCJX*PM/;A!CMD>?:'O7GGSWTE &'!<QO?ZI>7;)
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M%QMY#\DWW$\N89LRV8Z$@R]=731=N^QF\P']D":2%1Q8I_E:[]J'K(VN^,.
MC!=<OCV?)W%"<7;[]%=VT89LL;%,>>6B+,%&0SJVHY5(DJ9!TN=[Q1U4&:D=
MT@8SRWFF2QINHK29F;[N^YO&,D7E#J_N-3^&M=I2[U-/N8M:KXU<E7D1:[0Z
M6QO<G/N1^B@3EG#K)%XTMOCO*;>S5NW?;%[E!YW7_='9^D5;3%/X/7QVCOT
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M>X,:K4NJXH'"7Q;_PPO!M3/Y?U!+ P04    " #A@VY:!_#9^D9@  !4:
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MT@OR$;"H^/"?I_%*/3#ZU#"I/:-5T/1FC-*ZN49A;!><BJ#I+VZ'M;)H*I'
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MU"T1QE:RQL9]NAR>:X^5(E3'*3E1?CF7VC1U2B53W!7FK";(HZ^*B^\/[3C
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MML/<L5:D=,E4-6M^%[^0_GZ]\Y=O"W,X>5;0> %'DIL36P 1VSFO(R[[]1<
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M9XF%EZ4-./RJG[EWU(;H55@@_KV$;UCE29FBMZH'CX<ZT>1+8/XJ'2]*%!B
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M1C/!:;5?7<8L3"@K,G)1<=\#9[(/G+0_3D#V^Q*GZW0@9T_'])'E61#F$M"
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MJ[KXBBQ8F4;KA+TJOZ<C3%*OKQMAZRQ.Q*\!;*X>:HN8&6<1?O73\GH#E'0
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M3'&L F<Y15(CY"9=%_G5"\G"F)';+ [5'\E@YL"(UB3,2709/\412:.[0.+
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M*$3'RA E;<?#MLK%HF1O6ZKMF77W:Y<BB(_- 5:7/9O;J&N+D\?[L5N=22_
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M,[I]U]:OCFY;*@QN$KBCV82V+9&=-NI?T+"PSU@S1N0SUAQEK+6.YCD =Y7
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MZIY#%ZX"@];2(N\VHM7ZAVQA>7$;(FD=,=AV[#8@R3Y.<WN_V\@-ZXB[F R
MT/^*%KJA*0B(]V](\9IX(H!0?T$+5>,Q@HH26,6GSF8BZ )@%::@+BDH3FR2
M54N[#A0N5M&JA8D7"AFK; 5S?T%18I6LC+RO4+!8A:INWC^7<8EET?_W$U:L
M5D&VF="Y-H0O%^86T^8&'=[@)&[1#I$^CO&<XQB[NW;")8D*D=PUY81$<5((
M\>6>A$56Y@!?O81)P=FGTL56ZZ+JY3B;GYZ=6E]0;R_R+L8S<#&6;];Q4/.@
MT3OE5+"\+\[[XKPO[NQ]<9(C@+J[/YT+^#]-UAE9!W$T(95UDTV"-)K0?$FR
M"4>5B9$!8R1O*=^W?X$[\;XKC5ZZ]](])#F LIQ=!.LX#Y+X/R2ZK9ANFD8S
MP6G3DL$4'0QEZ0,='^LE=R^Y>\G=2^Y><O>2^_E*[G9O2^=R^L_"U,P7+VJ0
M3),X>(R34O]H)Z.W>[@[^;P+?5XV][(YS/)>N7+8;; 1;,0/A&G%=)\.' :2
MLFP\TLOD7B;W,KF7R;U,[F7R\Y7)[=V4SN7QOW)N>\S;B=N-<]U)TXK7>V'9
M"\OJRD)/),MCSC@BC!HDWX#F>''7B[M>W/7BKA=WO;A[ON*NP57H7)[]VX0/
M6<5Y&8E>FED%#\3I@J3M8[O-'NI. FY#EQ>-SUDTEE2B/2BHGV/.$3E-"==0
M2[912COM)GLIV$O!7@KV4K"7@KT4?'Y2<)<[T;DX_,N$E!G5[>1>R6QW JZ2
M "_)GK,D:S$BXG6! =&D:-=T;-NG['4+%6DX1,OG>;'8B\5>+/9BL1>+O5A\
M?F*QY6O2N:3\]L<)$P0_BHI3PJZZ+SG53G8&/\^=-&U(DI>OO7RM:B,BO$ L
M)]$=__\L#OE/Y8XOTX+9-,SC)TX>2%[J\JB!=(HKOEWIAI![DCW%(6DN5C=-
M2KK*Q.D[$M)%6F9JD"RF5?X&7.?HZ7U#:62-Y)??O"KP9\8_]AX\^'ILK4C3
MYR"+ZF2+8KS5-V:L6%6_:[TVW5_B=5FORWI=UNNR7I?UNNPWH<M:OSL=<W)?
MR]%%S (N@;NZQ?HEZ*ZI $&[JUYL\MU[U4+<FWS>3N9!G$V>1*,+OD:!2)2O
M8NG:F7R@SW-H\C$CR9M\O,D'TLNWJBXQ3>MI;9\KYHIFZ9TH(Y?%Z8(/X =F
MMOMGV1!I?T\^D'"9QG\6P&QTI^\>9E75@$H$7U/ZR/CA*ZB^2==%+@[8-.2S
MMKB B]C#JP8RG9CR18G-T')B\1W><.(-)]YPX@TGWG#B#2??@N'$^M4Y0KO)
M *+K"$TK_<NF[@T,[R;;\V22[=H]M30MZ)_DT*@ )<:;$[PY02%&'V_:V;PZ
M'D7)^6V/M =Z05-&DSCB_!?I!.ZNCQL4^XR+@,&VE]8\SC]15J><=5N);@_W
M*JM76;W*ZE56K[)ZE?5\5=8^[LP1ZJIVA"CWFM;[25PVF>5ZR$O;,B_JASC4
MKP!T>-7*JU8@_YB(S*"I.+)F\WT?YJNJ/=0'DG+>A=4_M/#$@59@US&!4]ED
M@#-$W^II0R4IS.=$A"21_6>ZXP?-B:W,#'[[1WHUTJN17HWT:J17([T:>;YJ
MI+V;<H3*HS49<83N2RL2HG.]^=UD087W3C ER<1YDP=QPE5.3E\1[#<V4($&
M/LV=)FU$D%>ISUFEEE1&G::,IK6"QJ)$!?M\=!+4:Z$"AMLBZCK.6/Z0!2D_
M6"!4:<;;(DM#13\OO1>W9F2P&+H)%@@3I:]O4L9O'''>7 <AF:Y$[Y>;-(J?
MXH@?+]O7GS)TR]G62?Y2B!69S>%DRF;8J%"<9X3D(JTH(4)X2/@1E,L_,F!X
M=[V897E-)^;_.AQ;_!__OA#?BV3K(,LW7X(5:3B[=,-ZI_&.K(LL7 :,3!=\
MQ<1'/*6G\39H-?<\T%B[^%IUI@G8DHN+XC^B9-)3D @9>II?!%FVX9),&2 G
M,;L8S76+BJY6V_30VR";9:7.%Y7TW)*LS"*488+/=(KH^%QLV/GZ@0/2>[AN
M0%2_'CX@[=)-#AT^1MH'/9-N,QH2$I5.8$'@%Y)SI9ZQ@@L!I$SHE:"!3QP,
MSXX:H;4_RG:#?H+CT,'UMM2TDFK9,,>T/I&T(&+EN-:49T&8_Q[GRXN"Y71%
MLJN7,"DB$?+.&.'_$S83*9S63_*>)_>>)^_^Z Q$JSS03G(Z)J@ :8F:WO"C
M\V1!149T7A'M]Z"FUC-4/CL[S-F/*V_@;PFR.;K%:&$CPJPV:+9ANSN ZJRV
MJ/:@];NPTW9TYW<TVXXPJS<0I+L*5&"08*NOV^_HHUAZC&*1GI_G%L7B[HZ'
M0>JL<*,[3&&X6YC1T9VH,*0P*R\0W$](P!F[+8'X?L:+#^X]!F+]"Q*LK;U
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M3L2O 6RN'FJ+F!EGD2!):%F+'% R$SS)%H%?^2V0/6=Q3C(H>?HI/1!WM":
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M8[R ZX.EF-8P^>+ 1<)6CJNSXPZ(&TO]+;<Q:\#%P5:ORW$4+E2*PU;DJ_<
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M1+D,YB&\Z+03VTNB#-)'IW+T@+YUU#ZZPZ';XK0- 42G)G0R]H$C.]&=E1T
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MI!MK/SJY\U=W!A4U[NDW]*'$&#$1_>>)$&(_Y&@\0C8HH)JX%HE%\S 1)FU
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MLSOV5(APO25K7/[[V+,@9U[./'WA,;S;UGT;FW:/]#+ 4*O5('\"'WT>TYI
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M]KQS&V\/R%)UZ+^2'7,00P$ ?LV'+D^D6RB>X_.!3K?+H?@9;P6*MA25$GT
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MF?O^AV8/X/\?0L/06VZ',AOO !TF:&;467D/V';D;5M<H/S._-X$1O?2\+O
M-*/?C7DH]FCZR =5A![>Y1$RP],S.2',/V><#FSV[?FNCBR^AC9THYV)^\Z6
M0[LV_?C;EX64YG?)2.7R]<[9.-.KA^IYX\;M.L-<[U[,$Y@ZTE%\ Q^;1^_U
M)@T6TJ88KN<^>&V(T\-!:T+VF0:&D_P1X@A@_GM21=F!>(Q_I!7Z?3B9KR#.
MJ"C>P'W-RX^2-;O30# @>L!K4N!..'A=T?@)M "X=;JJI>K!U.;4:MRYCZ"&
MP%OOSLF#LA8H6E/P]%Z9[&)FH-'UVN71!O;MW^FQ1N^BFW2W01^@ES6,^)J]
MJ?-[:),[&).2SD1'9I2:$Q8N Q]\0XVS.-LEN$09IIH=D8>L[I(9(G9<N+F(
MW%H8:H#S]1I#C21\R=J;WD>OMU&%;S'@G6:\YNT5*<M5SM512?^]6@,N]3UY
M2&-8FU1'PQ@#=[U' 3CX33KP(*2@BI3W:0!:]?;U3<]CQ%5ODD(+.@P;]0%7
M+QCGJ,!P,+. <Z &5=%KTVT7?7C .5ZG]4;'=8F,\2_IK[8[^(I>Z:+M-GMK
M,O@3.J:LTABM<4+MM0Q1,Z[:41%[ZT]84%:6\ 9*M0W\N_[5AXPR]&N>M SQ
M>&F^@WG)EF750_&4J*J*]&%7,:N#CL_J!8_W%ISI(O\*Q][>)&Z$\-WXV>J>
MGSLH,\>JMJ2U  @>(7QXWZS@%,@G9X2[:Z7=-GC]EB'V_Z_J:W:DRN+-VZ*H
M6'WZZUW9/D>OZ6:WZ0Z^U;HNP@SV*?U@^DE09S;SIT(5J &>$%70,WQ\<\L)
M&T^./0P7J,81[=M:36.3]\ 2.YG"-1NZI"7>3X1?#,$D:_]"[<*X)@@"VV;X
MDJFE H9?./67;CX666D2!&+%_K*/@2MKRQZFOHI.LH9 ./FR3"L' J-B2+F2
M MMF4Y(".E%VAM?1+J._XRGG<).4,I0DQELQC4;@A#&&1A R/^NM4FO)X&EP
M0C52J,$*S9!F2\6Q:@+!(]6XCGI6"CQ2P'?X&7=9V@SY.=@O,CM3:+%(+X:C
MJ@V=QXKI0)6 3H5);-9V$ (+6NY!B)6U6@D6Z;9<%*+GYV>H+>R%ASHAW]C#
MSXTTJH=(D3ZFH*KI3_(XW=*_=;<RIL2B"KT\I?$3_U<<Y>B!5YZ@Q@OSVS/]
M![T?B^"Z3&5#3Q6?D%PN0ZWV4Y3N>=[;6((.D2$]IC!,1W-)3.]%5TG@H;P]
MG="FH8\ #_3ABKU4M2J(Q\0P534;$O>[ JH1>;7WKM:+^.E*URC51W:W@OHM
M<SM]^<B6-&N6M$\T4YX=T0$TI8K*(+J<]N:'.M]L,_*&,4N$I5*91@]I1BU1
M7(Y'T4F/T_3Y3,[O6F\V"+#8FC!UN>5Y3+09YTW0+DB!T\><(Q&_G;_RJ#/^
M?K[!4;DKF!?GHT#@E,=K"IXT'%\)$]((Z82&.Z16XRBOL4$-.JC!A_D[X*;1
M0RG(EE270F+,;$/+F)XXY2ZK^B4!EGF^&RV=+SM&QR:>FMN+03R%A+(M99\J
MC?W3(;'7VH;AH5TEV3YE=CK:<*KVJNC''?TA2W=([QZBQ6+[^H#>R=>DV$ H
M\2>2[\K[J'C$U5!%#8,9+.F*$4BA-,<(2C9VFU6*K6F5'E:(H;5 '#$T3\*M
M*)V*4[CMT=XF643H 9#D:>+SU40R.W5$+TFOB7TM]9GDU5/VIF:V# ^RI(OV
M)P^E?O:QL+'Q3.FRIF1J1&S:+J:TV0G<JNEZ)]:+8!.-J(DQ+GMS.2QCEC E
MU]QA_&--9\+PI,X+]M50Y?H!N<5<0Q6TZ->P%[4_(,R-?T(NB!K+YA-?*)_P
M?;T;J'GI'$[X:BD<GW=8%X4C'KA2A"[WYE3KA-/ 8C!9W&49NOR&+E/M5"QY
MB#)VY?E2^&%6>$29&S/->!)K8#?U0X;6S/"R^',.D7)%"GFR/V])?HU?SHK=
MXW*[+0B]GT,U1''A9N7!.I=':2"NCYL^(@@P0105!+B@!AE>O?.WC69E9X>D
MFM=XWO7)WXG)#W#O4I=#8L;Q^=NBUR3G^J-.V6FCRW@L/TYL&Z72 'U;IY.(
MS=Y,G:3 JRGA@)]A#%=*R FGI$U_[&BI*S;34>_62)'?D3:L%46Q<&:V9&G,
M4-:U7,3C[1HOQW#"VB\-/K4)H]N<PBW!KJV8/2;,RI 9$<MI6V:*]8:;\:XJ
M,*8Z_#G-,&B-+$K'VKU(?*ZSU4:F=;VS^J!1"UM_$UDEQ7S/P+-+#Z4^C0'V
MB(SX$%5&VD@,JRO*G4+0ZY#<"S_23NSJ3^8\J+<NG 4-U8\KZ)4HV;$J5ET9
M1(0S7)?EHU997H*JA:[*>LE,9J1JYVHU-)Y.1S*[P5P_)R".RB=$=M4Z(R^H
MX"'-S6YNURY<A3'Q;B!RW//Y%@H-SEG,QE1L_^BW^B^AQW/ZNK0. M=\%;5!
MA=ZC*&M07X,._B8Z(B!$B5^F9IMN3]PZP++-1KS,XP)JI%[FRUWU1 HHOLI&
M#AZ#'L%JF9'NT?,2[>2!#G6[=HZ\#>-\:B++NWSHAB:HT]!1A;XD5EN-7N\X
ME_8X%W6<XTX[9K!&_!^(4<LJOK9+%G4L"7&9\:@,22C1F/]KB6S!2$>1/-)P
MYUIS=?9/*+*$A C*L,E=DT3YP^*U[_?E0WE;^2PZ&T@WKNC96=27"NE4=;E!
MFEII?'+GY00!.HKJNV%=%CZ(F$LRF>AQSIN W9 LC=_N\6OUB<[]^_*AK(HH
M%DG6Q->:(B68U=?Q) "O<ZA8HT0_BAR\_PR-=.K^X6AC3,D(4627H;_D&N\*
M<OLJ?M@:_$#'![$WD6OA9<#0[:O^<Y4ANN8/5 T) 2YPPVM.ICECM10A#PQ=
MK>^IE1(_#?O=Y$:8%QD\G#E 1<%#% SKYYE39*-68!U13]9H-F3I/T[E+3%5
M#1WV,:OJ%^/T&8HZ0PY64>?W;>E43^#A"9G=)[F!AHOZC3/;4!G<% 1:H)6G
MY!D7./GT=I7&8,[2^TD%?C/QD:4V4D<YR$%PK20:+%"-!OKTAAI$4(V)_@'H
MBD;SDW';T!W7=#^\H:RA>\NQ"["5%,6.&/#9])$L*J*GO^#B[^21SDZ*-,K^
M0LIM6D59#;Q+W!5'/.E.HO6 I0K,>704((0X1JA!"34X-=NPRUTWB)MR3[KY
MEE1E1XA7"6UY)796PK1=);3N+*D9(;]%)8=HM9H<G]I]X%8-WN9.LTZ3^;Z*
M<H1;4NLS+JB]*"M21(>GMBW&7Z(L34ZS*-VH6(O"458LQ:/9O5N)U%IB2"".
MA44+T0)M;JS#9T9OS#";@V4H%C&A53C!6\.M<[@[R\]IALN*Y+A^#2I['2EN
MF][4XSTA;,VIL^U,87OQ[Y@BJ=[;W#M7-'Q$1P=ZN4 MGDW$4;G?#Z?%U:2_
MA'_N6 D=BGM\*%H^]"*)(%9HTS*P+C$50@U:4PC$R8KY>U2LD;LGR_AON[3
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MV12?,' XV$#=XI%(UE 4') )(=TC8D%D&69<W*DD>6.RWM/_QD]XE8_(LM0
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MRHZ?S#7T\I3&3]R=U"S"2[<([&D$;:(W]-#XFZ#VD] &A>&\MGKKC&IM6O8
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MPFM<0-A@"=C#846@L )X&]A/=&JU^&+$CYP1.7Z$L  UQZ\;?@0^L,>E6N,
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M$(K*$M?5!WHQA'\.I"Z55XB8LSV8<KU-R]\O"HP;]7\;56INI^D)+*E9,:
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M%=4;^/L&7@.F/M,IVS PG?N'I0XF J A_/^3O"2R#'(J%;=X2[GX%-$3Y+'
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M;=!E?3!A=#M3K.W@<<0?B^;%&AT55IR/A2&6URDK8X+)WO;P+:ZB-,?)>51
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MCXO-&7X0N6F&/M$\D?I3^8K-CHKB#=+(GJ-LQ[9!1:5HF9<D9U712_2 UZ3
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M,O#=]46A0A*)"ZE:9+JT%T@R@.06<O6?-*G,<WN"$<+MS3:%V^72 '?'_6[
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MY<>G*'QNL3?,'<$C!!;=)7DE_.!#05#J%3N[+Q^A?&VE>B.:1MXYA&$=>N0
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MH[,O^>:+OOFB,C!GW7Q1K'P1DP>[*U "$L@T%4=7$&H4-PE,T!L[!G*+$^G
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M4GDA891QLDAD0ZW0RLW#D0\V&KAW&0=9-IMOO_(L?<"+I:@#FG2\?>J%08B
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ME>Z(W_?!AHW9Q;+M@+HD68L#^_WXA>_25'*'\GK*^%:V#!9T!5T&V?(&H?L
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MQJ_*#:RFU %Z<W4++R9S2L[DI:2G9I;.VM8M5'ZPT;J%FM3YNH7]UBT<4?G
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MTH0.DZXO4^]W"]U9OD3I)5E1W61)]4/\0A]'M0Y>\()U>L:,_B/*\[BZ8\W
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M/A'VHRUK3.N>+A8I52AR9.36:4V/8^CW>OBJOMXQ;"T<)MT0-:SOD"D)X'V
MWCT%YA%^EB^J9^4;Z@$QHQ1K+$'H81F$>1'$K&G)>Q'2=BCQT<X^VKE5M',7
MAD$?X'P^ <XF@N'&$J3D@^&TFLWU:2?J;XV=#[(JMI#S")$;C*!W7G%SAFSQ
M8Z^ :!94J6/HO$+CK&G9/<3;_5K!G)1VPD'&=IIWSY]7!-^ //+]1?$-.GJY
M=\\@&%?E%M?G@JN*/PNNCXQ%[^\593W7"ASDL5@6+(/<PRFMWK?[/*$'^6F'
M&X=-Z:!D,\ZV-N. <=]S1#;PI0.,S5:BW$=I#SI*&_@MNXS75EH^IIH%,A)8
MYQQ!B<;&,4:I?-@C]\B $S8N%(X=5E ![_JY_K,HTWMV3=FS,I/J:1DDQXH;
M2[+J)SY>G8))\JN;(#/M^$3"*HU 5_0(V"=TV<)?B3A'OLNQ"<XX\L>OGUB*
M[3#$WO 6OB9]CGR=+RR1F2DE_81,JKY_;+'6H\-W9/'6</Z&=["HD^;(-ZFL
M'-;NT^/7NR=&'O,WO'6O2=^PO@[7;7O079/H/@Z2+\$*":OP]_DJ'_[KPW\-
MA/]"[4P^$/A\ H&;;7B=1,9 SSU7H)0'% L,IJY$54O7$\ ,ZPH6ON*L#[*W
MX*1N:ZQQ;OO9AEE1=^IO[^<HS=!YK76Q5=X'X@_ ^-Y#X/YQ"/33^2U[B?',
M!_</P$;6>^C_&:Y[>?B!SP2P'6C@4P+,.@?-AIF&E" 2XX@=0)/G( Z2$$VR
M)4*Y0M@HX"&&PD#!E/BPSE[#.J=A2'=O=$E'XC"('^D9?TFR/&ONX*TRI3OB
M:KW?IDE453FOWE7[C8!2I?D=D$W/C0AE>)&PQ7V_.VGYD91JDSH@\)&>YQ2+
M6I5^*)5J,\U&UH8A*>@I3H]X9A,3MZ 7#S9-=[$J8O;9>07\69G_+RB?S9^"
M5SY#.D\QRVD4E57S@_@^P%22O S6. ]B'D?BT68ISS+$;1)=_7+RP2)ET^>L
M+(L@I/!TD 4Z)9NR/L82GI=!MJ27!/N#R8<O0<PDPVE^&:3I!B<+4<R(TERS
M7+$.A;-Y>40+HS'X \W22U8KG)=".0.44,F'"O-)^/:>5YAAG .2E#@*EPQG
MF&%:][?Y'4D6K+!*V<=S>SER20?-LL5)G1;QL0.;9)2/*RIFO5!-ZZ7>]UC,
M!62*41[XLGG#"$NG_;%F4&[#)8DCE&:5<4!.>..T@7(CD1)4I]OB3;P/W@ZT
M]35(D, .(,%(HQ27BD,EA+WMV'9"LW"L4:J/%5#192L8:9KB-55I6))[DJ&=
M20(B(2O,-)POFE-1$46[3ILU;?0*S7&(>0S!)]J)C:W+PX*,7>EX'XD,H7<V
MO\%)0(5VJO.3K-3^)7>6RE07HJM[H!,H\^A*.2./.86L*Q_7?3YQW?*3GL"M
M*<Z!(H]&%5^0SH5(BE:)CMO'N?AE*4 Z'B?GEI$/=!]BH/L0 Y-$KAY7D.#P
M6+]XU3TQKIP9<G"4C0@]!LZ3/(C-!I7)\1&Z(5V);)?# +#P]1!A/OR%H;TB
M!GYPP.X7/2>!*S>/,O?UU0,(.7)E+>G@U#)BSQ6!MRUTL+!,5ZZQ-AM2Q>_?
MWTTW'KRD;DI7LI_:@ 0/P^@A3<F>\-1J74D]]J[D%G5T6LG#K?I+!1KOVM)>
M5,J=/L:TJ(!1DW#!U&$)7AH_ D?)0?D=%M(*A\A!.7VO"D)2&^!(.2RCMTIK
M@2/HL-2N&F$%!TU9BA^9[""/>(%C=48R/"@BVF+N]/['&:O=2-9HVX-O$B15
MC<?]^3*):]T[%9.K-=]B(_NZ%:D^/;O7].Q]J8=I]-]%EE<1:355\ H]-^9H
MJ\SK@,Q/]$NP>WB6G+SC 45H5593:*(2,.U-QU%S^5NG@H8D U<PPU8N(Y\B
M25BMPDRC'.V$F'N4EC4])&S(AENE_6.0X1!(^-%8HU0W'B2_!VE9F(Q#/6B.
M42X^H83>:C$53:;1"B>8+0-FH]W&0'#X ,XRRDFU&?>^6LD&D(PV3'F.TK*;
M8XG>%Y)L18UDP:5>.L,P!ZP<$ .RPG5''Y?\YN&VKK0[*IXO2M'N$>5Y7*X(
M\08 S#"<4K>5%<I5S$S@."G)NR$I56:#(N:GV(%G&N6(WJH'*P:']L8QPZ;2
MDL!S1,/T)< Q<XT\D9I)<JN5BBY?Q:?8XK5V&E;DBO<R=_PD83;[(7$@N=3
M\\PFS^Y(VA+#VR=OQEE:/V_HD* N'6^'>NFYU##2%N(" _8^R6QG2-OLA>BJ
M&.$#"EFF!)[CL#(N[D7KFY2LIB3$Y4V6HI LDBI-;4[%#;ZZ:ID:T^UL49"&
M+"3\"KV@F*SEL@]HCD_K=2 %=JN97I%OR0,IDN@&!:S\ZA4*4Q1D=%L<"01[
M.8#IY94<,%VQP$X.@QT]W9;2<%*#MJJ$.IN7]&6S(L_R((GHZ2H2J+2>,4@N
MKW!<,,<9SI@SAG[&<G=);LYN'^Y>KK7,2.'3J\\PO;K'C,>!Q][XC$< GT19
M,7$%%#F[1$N(=67[*.&C9.%W)<-$"2&P";B_C!(+H3!*$$DM.DZE2>I!PS>^
MN'+NP"XK1=ME#Y?6<2L;LVL'SCVIJP= -YHK*TD3):"OU)5;3 LE93>@*WF2
M2FAI1I"YDB.IM;(48EYZ2),<S:&N'?;70[;D25,W\Z*4UD)3\./VES9I0>[4
M TL4E-!#DN1H]F'?WHG^DBM'N?34HTA<$=-@:I%RO+$KUCP5QGF+RTTM2!.9
M080U]+=Y+9Q^FA]"(1W"%24+=M;!DA)<.>"DW J0:8@'<$7'A"V5/B('7%E8
M'6.C@;IP>5I.:PV#;#F9Q^1;-_FK;Q]G/U&51Y//2.TU(W5G/"UKRYV\F3^@
MFQ?3#9G1936;WZ>8"G+KTG.[LWS3/^O*%;^';:L'=<S(MKKY<669)W4^5)_3
M 1O,8'>;907KW,U=#-Q!/C?:6FXTOVLU.U(/#O_F^&C0V [(N4])B%"4,<WK
M-J$7-UM"90G")H+DH[LF:;NHV<K9[S%ZB.Q,_E37D=()?T0'Q#^@=; I+\_9
M7(XG?W2WBZ[DF0%!Q2WZ*GIX4<&*>YK(1QN-&CZ<']EV0Y2RY1-Y0%1N"7&,
M3JVG= A= 2^8BB<?-U^I?'R;[$,DIF&.7ZH**I)NSH9>:[96 :7QI%S_ [V+
M4QQ2R6];SO_X![61E-FXJ(3];$VR(/Z4DF+-@MZHU%\6M:,K9K8O;,+!U20)
MDY\\R@90_GE\*-_30XW0#5HY8 Z.F"WCUZ_A,D@6Z(&J0M?T!.27\#!*A+4*
M)S41N+P^2W?45F)"T04/'-F\R845?IA\=Z"-GM4)_K.@^&=ABDN13]"#4FFN
M1:[V(%.Y(D^+,N6C1)_WL52G6^3M2[!"C48"Z'##M*]3%.*@0041#?'U9S2K
MMCP%KZQ>,X[>*@?R@:;I/3GY3[I7\,D7S[-TKC;2Q6DTL9>,Y0WLNWJL92SV
MI&WKT,J+"BD^P#)_VX975UO;6&/C*S"OD(?92M;=63!E9TSC*+.4[FT?IU:/
M&Y(^HO0%ARB;I9=Q@+EI[EK/\/6*VE;8:;(F;",KZM8$#F/P!]BK(00D4%:F
M1OM!0^"WRKIH\44;'C"L+]I H-X7!3QH"/PV6/S4^&QXP+"^J+HI5?]!PZZ_
M9H?*K3%ZOQV2:'_80>ID*,\WRMW]WA\B<WP"9M@2$'<D/9%I^&>!4T17?E2P
M18Z$8K!TGC6&:OXTL>M7888U#@[-PP[&+;AHU>))UC@^R/#'H0O5OQ#]S:EL
M#V!>_Z&#P(%].'0?!V$9ZZ3(;_-DP]76#KYCV)X4S+!UL.P"4%'$ IFIBB^R
MDC8/MF3K&FV9./KMZ?5_PR+Z))("9(HO===(YSZ @N=M:1IBEL9BO:[JC 3Q
M[NO>)G.2KJH(9<G24)OM7C4UT-[P)=7.IZ2:FE^8\";R?)6NP"0ONZ;A8'<E
M&4]Y#745:.U*&FQ[ /4BO%U9@";J0@Y\"?FZD  ^27>V75?0:H'#>66<PY:5
MV>AK5Q:A,=2.Y#5>[%I_*Y9>U\\42;,9^C; A9F\7+E[;2#<(KS%E8(*-F#O
MHY#;P(L1F(2Y[]J"XZB99QSQ@93<.X_E+4EZ[J\LG^.X"BH+]%#+SWE,M6--
M^RONYR[8"FGSK@C-,'U:-YN@!\W8ID2@ 8,01*TT!<?TXJXQE>0RN;)O>X!-
M.R>J/TW60B7%=L#J1V6[8@YH9?<'1^D[=K&T@*,&JGH <']WB8T*T)V J)\I
MXXJEJ=4.!F=.G<<.AL!QU H.'F/;P]X=+X"J];!Z$ /'"YY.+HPKXDH'RPY:
MULZ5^Z&CQ09-\>G!J^ (;%KY0ZXX#+J'LVU&DBLN@ZZ/1-4*FJZX"?I=H:(<
MLOYL_\-1ZQ1AU"]I 9>SE<.[1HNFW;J%\"^B;+98E[11#3C-S^Z[M*R."O\J
MRJ;UZJM<)Z/4JFS64G5%=H:9I+32"GNP0]F!2)'YAK;$C;7&^C,1CP@?<;U'
M5U0J<'=TG0HPKNPS=?:YV8G0*KFN;$$MZ)1Z"KCBW6^UR/C% ?HSVEH)'6F%
MDG)U\0-XMMN&E>I1-L$)_<6A0^TD0G,<XGR"J/B8;W;$MVLIIO2J ;0;TZ 7
MUHJ,TQIE>G][N=-D;TC*CJ2'0^/1AG#-W;NW%3':/:2#WB[3I\^[\Y3?Q(H[
MJ L"#O&=3V0:127/0<P$K=MD&W%3 ^<1Y7F\+9VQBYNK7PB-Y/?SBDZZC#58
M1'=6/E%3,?"T3IH2'3?<G<VG85BLBIAM0%XKWZ]K2F -2$#+KS[?TT47))9,
M]U@\[ZL!W 1AV9]XNDA1^?9/UY_YWTQC>E>MFVK&]DHLN"K86J[L<%7'S&./
M![^26[</-=L(2KZ8&K^>]GS#;:X:CS4Q1Y YMIIU<4_J<FT]GR:U/K"K/<,Y
MVB9=5NNP=HV6J6Q<(,R\UBR6;*\M*MF([CTJ+ >'GSS1OV54J&!&0_$:T7N*
MV09#[-K82O'"QB[\@88;(HD;ATK'V6W?5!WNZNV;3N?9JAIY72H!;!>3A"YB
MX8H1CO7EI=]0R;L9&4%;W3R(=XD$FWV*\6Q=':;' N#A6&;.[RD)<9GLEAY.
MU^D\1^E3\,K!PQ(U]NHL;^6M\IR;"L\6X5@[5,L/1-%0PS0?AU](J!8--ESU
M-Z?G%XJN@S2APKKXZA</-EMN-(AW)398B</9O"9Y",]O^$3SA8NS69%G>9 P
M]RZ/_--QEEJ2ZM-KI[GGWI-5E_@$;1FEX^U0?R)]9! .1'-\B6M8B>O'FNVX
MPA->ZUH^UQ>]YA6]%MJ42M$,:J?J^K&V"H"_-:K5U:J:L?,1A72HH/%$NX=:
MJ_ /I?HK%<%;LW[TD.'P6?V\5E!,A\\W#['6^4! Y!?TK?R5%H=O)@^'KT-\
M7W7 ? M2%D8TF]/O,4<X+U(]EE6>.R0TV(ZKLBD>U['FQN4_90B<EM=*QV>U
MVC//&X6!75AOB-:XK\3/& R7+6^KYF<,Z[(J:=2\JYKG#H:K[F\JY<>:Q^)(
M71-Q=S30EBVF!<66K#'%<X8C'*2;FCE.9,N0C3=*_1-]V6Q>\X,**!>.=;J-
M$<#L<2;]C"0\$N5U[@P@4G:);GR;*Q'R\C4#.&%<62]B5DG;N#IGU@QX6TG"
M>%U)G@ !HN*<=088>',BN1?)E5,&QO+1BI$%(;A2&TEAO8C]ILZM%2Z[3>N$
M'V'CS!6DNH?.I*&@,BX*$=G.'3)0C"!A2:Z46E-?0'I)"LX=1) #6A8-[ESQ
M#.@B @0]N[)@I#KF?F.UR8-PYJQ6T:Q40R^=.[,'V +66GDK8 $?6;AK?\?.
MT)&1>I^<DYGE>"@& CES"K=!2.1^=NX$;@2HCQ1FYT1%^=+J+*BVA^I9-DNQ
MPR <2F8:&/R!URSNX-:01%:!D1IX5>+VMT=70 V\\2#@%NFUL Q<UAV+U5RX
MXLS68("#.W #!KA9#R\Q'([$.%JA='P3P(*+X2#"=8O1@J@9H W'$*Y^#!]#
M]2H9<)S<43:ZR86 (^=$H=Z.,X?@Z+FL*VA&L\/!<UE]@"5NP;%R0(-H5_H3
M;O15UA&L5/3M8'5)4X?@F(VC@7;[XZQ#R$;M7#!4A12.IK(CPE*C%%WOGFZW
MDO?*#HAA R--U#H@8Z+V>$)R-/DPR8K5*D@WK*YVANF-Q'8$_6T0AJQ0.OM^
M:Q+CD.ER6;A$41$C-I:.P1&."]:7<)(=]+V(Q6W%>P#D=<F-D&&H9KE!7F#U
MS(_2XN@C?UB0EW<1PE5&'/W+(1&._N/?UY2"?--8:HOW:^TD/3DU=U2?CZMW
M-B3C"49T4:\\R4@B*)7^]M<=O/2PD POJ3IKUH@P6S:W1M/!D'#]ROIP42&I
M[%:[6A?Y5CC81:%2<:J\WZHN$B?P]?+L,:'R<=/\ $$JK8$W#@!!%ADG+& (
MG6:A)/!>O#W0)2EG#)IEMA8PO??)!E7&B,J[+N1!.MYP.<\C.Y2DFJ=@K"\,
MZ$ )O6UXC7 5-(YQIS"!93GE3"H<B 1L(E,(QLZ\2?F$Z,H!KH LCZ4W)B:Z
MDO%B>-T"!297HM<-HPL0ZER)>C>,K$!0<B5,WA"B8K.8*Y'SAI>GDB[MRM7%
MEP:D)E]7[I<A)Q<.R97;H\75@B_NKU33?,Z/5-+P< !4O]1SKVD\V:3'3)L\
M[P3KWPE6NX.^T(_5;/R%#N^ *'81WB94("[*"A#[V%"6K_^ UL&F3"Y@J1?-
M_6=5YD^27SND?)_?=4B" '7,A<S3JYS,(?2.)(L<I2OVX">2!W$356\&=4K"
M8YXBE+- I3A&)VM*T'T7/*M/;ZW&<09RP&H?D^;]16QQL'#&\@BX#S8"D[ID
MEJ62X*?'&)B'IM%#H/RR2)FLI<; =I*E;W!\4@N<R/R!%NF]"4)QF !O^"#0
MEGJL9<,MTOXU"5:$+N;_H.@*9R'X$S3,L]5?8G<2-H@$34,L+1F69CAK"E\O
M$]/G01'SB0?/](UMC9</L-6%PP<,C,Y.T[W$ZKWKY^-=%PAN1%74< 43N>U7
M)NZZX@@0KPXMA=\5!P$ &K USI7EXOU&@_8;#3AK$JJ)][!3AE^Z0EU'=FXW
M"?%15F5["-4Y7D5/+.]^2$NIO=^EOV"< 1Y+,/=*?R$U0X5$QP\&1DFY%LP
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MO&HHJ^(M*^PJ3U_*/,TR>3.(L[=)G/I(*3W>+C;@[N& F;;:I]=(J^';XBR
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MX1LO/^]=V!;@T6L^P?#V%(W_]?.>!S#]1(KOT_E/G\0X?^K;^D1QO8D):W$
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M'V&6(DT^?&GK>G^)&-R["/8N<Z%STIUE+NPO9C"<I$O(UA'\?\;D_N9;;.?
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M9JLNN#1HU8C.B>N:=:IQ=DBM44_DCRF[-J@#G@B#2#8Z!9_9'SX62K]@+[_
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ME3!><[\\E9]!M6Q^KN[8^LJ9IJK^8EE[JJK&ZYK25;N.W16GK&H<KSIMM>L
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M/7-+4%X[CU/33N/CCBV@=[N,6[H:RN0EUH!<E6]827!NSAVL@5JX$UA)A&[
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M5HO'F1,K_2HMBH.[&VA:G/=US&F3^*M@^*E4$-R!2%0A**Q:4*ID(*QZ?*H
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M 7&JH&!XOPA=(P-BH0X/U<V2C1LJ+^>6'47!UO/L_AJU?JOUVXI]MLV'=M"
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MN&SJ3\0Y"MXKELS&(LRTF2:.A_0(--G(Z1 2_;TM)A5]19,(%C,6Z(L(:2Q
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M;?F%<1<\RP)P1+S)P#_- YX C"415!QNILY#^<'1"9F%#<HZ-)7,F,8ZH(\
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MT'_0GN5%/,FY<=MUG<X:;3^[]]__=7%T=/C=FQ?7_*_!=_O]Z#&-SUV6:J8
M=$WF/C.^C1,ZWG#/%=JO)C':$"J/YY6)]M*^Z=,GY0UW6<NE1YETN;&=YE")
MO8?-*(N$MC)ZFV.\N(IT.KEIRF*>Q14:ZM8+G1K:M.D/^&7<A<[]J&=_]=J
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M'V3QD(.W 4#Y?4K!?> T=OZ9U?Z9RYU_9N>?^9K\,Y];S>7@]'4SFP5 XA<
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M2'ZJ>FO%)IE3:]GM3]97>2,A;*B3SDV5@D)I#8CBE2:?U-->1(_QLC#DO$%
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M%HR#9!BBV_7(22QXRH<>%7-@)YI<,V)4$MGI<CZ ''M'D5IV2',R 7)M.$6
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MW)#J"K1[K8XT:+&*:[XU-KSO%@KW+;VMZ(DNFDJ6N7(T,CY+4K"#>"=T4.S
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M9A%]6HG=V5@)[_S0M/RJZ] SL&-&H.&P2!9C96=2#0Y?<,B2J5-N$1L@>EO
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MGSRE,VN13*NL18MC 2C BK3X1TNQ_$>FVY2Z4[RO98UIB]6 ZU7&JHC._12
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M64K\)UGD8ISWR#BAME*L?N!>99/"B1;T%TJ%$,1+?E>LKMJ:F[Q4N\]O_N;
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M0 Q.,9G[##6!A \ZTS<=M+GB=G5H 7 F].XEDF\F[MD7(@G#& YBDN.ZE'U
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M!^]-*>B$G&0*]SEXZ<+)!J +V%M?STK5JI:H5DN7/E5!=.*RF0SB-Z:"*'0
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M*;9A +&W,H$71C-,-0Y4J?SM$3:$4D:GDBI^DZE0$HU+,E,9W)-=I>K=\'6
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M+SM=N/B>A+)[A_;2[AV%=K7&GSO97R]6+U*/3\%)ZR;<1,]!JD'J.R!4YR/
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MDT3VO#ZN&DT(V=S1-ZE&JD?)3=O56W;$7%[/!UNO-5'?B_Q@>,,@Q5-K #1
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M/@A*&Q4>MEZ<E/7R1 YR"^4Z<!J9;X3>I'W;,/C!Y9P%QMU+LQ.'I.^JO^D
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MFK1\BDG90#;:(*CNZ'E$E_(XV=OH"*M;9N[8EGMRS>)6P:VCJ?5+:Z%ZZXZ
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M=CJ2T.-,N^0]"B\<"ZBC">$&9V/X30ZD=Q FC;;I4#.:.G77E(RYZG-!$+C
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M$-/]9.X)FS(_'6 M9LO():L%89_LVG++'+EJQM/0^?]G[\V:&SF2+>'W[U?
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MQZWK?$PGB*48J,I5\\*[BZ\%T-2H2UCEYC[5OM(=2^BF$",7U<G4?^/3UHV
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M_N9S[K4)(DB@\IB'\OL&!%52"%\0.;H?9;?Z:W,7/+S^/A,AN)/@%U#E/O,
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M6JMX3[9\79-_?_;V&3L>J\^'&"5RT?',F.0#@019XL[5">3DF=LCRR-7C1]
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M%<U5.+IQEK18W3;[H>Y%,_9 B2EY6A([)E/S#RYRK/$OR M21IWKDT3@D.H
MH]3.W2AEA5F.K[8>"+8 /Z,0.C %'\\TIG=%"AI#]4]JBRR &:E3.GC*<K.)
MSN@>_44MD0^ N4[=&4DW_125TD<9<&E1X0N&(5S3NJQA!B[EC[8J'K*<5V&^
MGITQ"CR5!+T))4D+P)%J5#)@@,M4-TVS+:PYH64D?N_WWOG11P2"*6A)5A:K
M6U C^W!==:DNHTFYE@4 2\GEA@K;M-?RI@^OVZ;<*O>&-?L* E(Q(UG8;>D1
M?SZZV'EFF;>CC>K\HK<=25:_(#YD[\\6:-HVD72RE1^7:]@,K*/XTJ>SY!S@
M<&B<:'*AKE19.RLA&(*!O\HI*XZ[J?+)D3[DE@B9%FX;G$=H\SM4O7 ?HO!*
MP:4_1=R.JK60L>C=3,W77PYQVAV9179AT:"D($T*=3Q!VZ;(>FHW-P"R)C'A
M.JO&Q&5#@N=UGO^EOW@,#/]IKZ4_$13LK9B0NNR9&H4#=HR_XLF,1453 G<2
MM+*4H1YHDI2\=2JE:UH$G72HJNKLX]ZJ7[$3.L?FL&PQC@N'T['(EN4?9-#)
M#U1/EX1)4EC6B8WK7[*W$N:/VK0)2CW>0J;?K6H%BP.T3%HYCKB=-B?-<3Z5
MX\- ]8#YN7W/CQJ!5VZX/UC[^"3JF,HF)J>;-W@YEK+<XS;L F]RT2NZ#0ER
ML33;MGM$-QP5)+ '(Z^I'Q4A\E'@Q'0*.8HZ/3J*4I3<6P*^=HP5B5],I0.I
M'SH2@G-V!E%UC_*'$\MY^9YVQ_M>?71P@ D#B:_S+M'D/<A#L(+$IFS;">UR
M>NCH/*ON(G_RS!OJ/)])+M\_S#:_._+ZEZV ^PSV$K>B[J<9]5V^V>3Q"ZL]
M$L3HN]DMP^8T^NSYW/E=@HG&G.RC1\28)H2$CQ2DS,!MFY;80XBIHHEQ^II^
M)M@=)>G[O6Y_M#@/=6I)7;:1?<-1F3QY_C7_H@JR8G=-J/&$<@"/2B/,GM[C
M/L5HJQ.-ZW*6D5QK: P0>SX^J[375:;JL\]?KKI-&S>_^I28I=1911"8A^.N
M@X9/.?;D$L8%<-@G>0(A0OB,AOMS5]=XZ8(+AV2) V]\#^(@4EGHAIAU2F;^
MHP0OH)!O1;-U];I8O<;_Z/_^@];"?S@J>DYNN$][FGHMG/"Y<B3:TIKWX)OJ
M^H;*2GJ )DLJUX-,KUW3WX]CM.9.OQP/F]J@UPEM".BH6F,\BV/ 4%*QC?(G
MZ5E?OYZW9KP2/:(\C54$GU&6MD/^J5>U<Y=**4RMI@"NAJ'X@K8IL)OBS4PO
M/C[9:*E4G0_22GZ*;:"-$N= AK5*@>>SU5<.+<(5(8Z,T@'&U:),]#=EZ 3:
MJ;^B&$55>[=3"WF<V]W,$J.M:FG,T0\(#7@ 9<"A Q8RIMEL>$L,.R:> P:9
MN9#J^,BCP_RB,'DA_OTYB'^C"P^2(MG4F,F4_'O*8//^!1".L9_RI@&>BQD:
MR&5"5N0&"FN)&7@[])QL#E<#F*.EG'.8C5R!TN"' /Y;/CT@5NV<U>BVQ<M<
M6-(OEC]G^8JRH4 G>B#@4 11[S8Q^]#>SL0Y6AR3)(NX^)0OM2,0K6VSSH(U
M63A*O3WM]$Z^YU.*>-CMQ05Q3*3N\T+O[!%*$H482FF('LB>5VRZB!295B#T
M01<87<V#25*?V[X<:J80<A6H]U] -JE9J?@\PN&__V-H^D]'\\Z_O&!!W@<+
M\H<+%N2"!?DPL2"7@_4I'*P3.C>-IHOL!.MF*HXM%4 E)4&/%"/3Z!<6.)K;
M[;L0C@*S$*2+BYS-6<17"5'0]G(=JH'8/XAENZ:B%_7"--+XI"T.7GAAIB,B
M'L]Z<E)!T! R.9^I 7[YM\".X) O<6Q;*H!8SNVIP7E.Z8]-_"?ZF]@!1BJK
M[19U_BY:?I>%>,[#)8\RY?&05XL&HSP(\]*1VH=$#;]HQMW<4!H_?MXO,B.)
MQ"48_K UWE-:2ESV1D:DO'.P9PT=X^>J-L,9,=N[-*$A8]R"SKRQ0@UEYF5M
MJ 1F#&&;5;6/:XT@Z3?4GFV<X10*6L98H]J\[=N8(_HYNO[ZM#!($G:B/C)E
MFEDJF5ST<";4*O4 [N&T\4])MU@70F:,X3-F,WX3E7]@S^ST$.@8G',4;8?Y
M^>3VNO%3$%*,ZC[&OIO:\:._* >*0!BT3#$3_FF(..(,Z$*\'C>#I-L*3W\R
M+GX)::EREL1("_ Q9X\-& 4_^$GL7N^_?(IPOSDW!?R3R W>QJ427Y,2V&<>
MTW-S\]/:AV6^'CV'/O/FT6#XZGD"+.X$:&I260EHZK9F(4=Y>K4I&H/^=*3=
M<W_2CE"&56ULAQ9B<MJ[U25<'>*6#9D-)NRC?;SK!B:(R]8#W#MP:6A7+3KS
MHHGKI3*W[Y9@M>OY3<(64I':S$'=3MM/?<TX/^]"4M94)MY5O[+"U6M?#7NV
M^FMS1SAF]7@[QHLCQ\/H&UEGXX.<6AMG5W:1=]RSYVRNM\=TX":):9QF1N_D
MCWWL(<J)/W?'9ZLW>A-Z=M4.QK7E@CO>E'WK$E?<SQVY<8MN)LW3'I^M3RVH
M_FZ>9X!!B^K8&R?/0841>A[7L/1R7R18GB&B)HVFOLDT(V"P X2B!IJ&. #Q
M&=@?@F\#J+6X-@7J1[[([0&AQ0Q2VG6N\9%& T*3W87P3CYOFU,!%'@G%)E4
M<C*"S7RS+Q@?0RD+D%5FL%3D%P-%#M*4=]N =+OI1D<&>!VZYA"'MFHWP\$L
M]+9JM ]]W-WF@:!V%_A7-0K%VQ"=MX!+QU&KM@.X]>'KPO!HQX%D=<V=#.P(
M+\SMH]QXIP?53$OLV.V==Q+4;]>BN2&9G;K.Z$+XW9CG1VDQM+2=.,>?Y@$H
M<<ED_*1?07"WNLVG@H/?Y5.9/N$84AS'F8X.]"=I7S!M$.^Z!"J&:-%B0C2B
MD%Q U?OJ )@I(>,%;=P!N@>?F7Q8(M>EIEJB&Z'-/CX>'J7C[=.E0K Y")KK
M%,HV8=>@;ZEB-DQ3=<:113]VAUV9XKQO;BBR^V3]F]]F4.PXJM=M>8 =*F-5
MN>NY1Y9&_Y_J3,?=7,S=6KC@8>.IW $6=Y?Q,Y)/0IX^@[_G.Z+W96WB8PEW
M%SHM>#(9%H&_S4U<96R4V,'CX*<,%:U0.]:T-XRVST$:@M@80&:,EG:OV<)_
M@R>?H!VS XWO.XQZ(F#L5TQ: S1]Q^P]QB Y(C;M^N:84R)FB/D)T!E (#I"
M9B@7IQ7G3,<",(S2TA"IH4R:A^I1_Y!V#=&=C,$0O4]Q )C^3"3&GE)CT3S0
MTRN!<2LB%?%91I$,0"FV,^VG)[3?<ZXC0Y4QB@)&25BU=HPCXQ:(4=B@WW.!
MPC9TQZI7@%'T<!KNJ'$30 <'+H[&B^E34'XLU$I,N,W#%?N,-:E,V>$!D\UN
M*43RSB[@.=R%/$ZIF_K*=ZO\QF?35".I(H&LK>3TCC>G3O8)]NLHO7?L3IN;
M>.3XWU$R>Z.=5,<83E5'\GI$RI,[F,2OM3N)_(I]C4?-H[/E[\0R],.5_,S;
M,.U^J@!%3LW0Z:F6>)29Y?/GF!QRI1XPUJO[!OOL-.LAA0,0P&S9^ 5]+3X"
MK&%7WL9?T?80C[CK@2K3 MNQ+5NK'9SJ-=;[Q[U_.IST_+DJ!_&,GC7MNT8@
MPU^F$^STA/91?HYO$MVD$6'/#V8V9,<AND2;;.167Q^99ZI+C859>1)A\[BK
M.W47PB/,&B(I>S'7%#F2O.);-79WNY<7):_#M838>'(-"<C?+E'XE-V16N4
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MK5]Y"[951WJP<!FF!08W#@6';@@(3NKVN%!= [DL9&>64(DCN-S8-X7X#X?
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M^EJ8+0A]6/:EORN],,-LGZW>!I-+B:?"1!7JE29MZ-)ODH#UEU0FBE>GC1A
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M;^ILXP*JF\TY%WN<^31V__AH+JGM["PY_3K_Y!C&2)SR&^UU64L,3]"]V2#
M'F'.?9<KFNN@31KR7DSFQ9%:<FWS=2"#E==Z35B375)GNJOMH A79X_->B\
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MN=\[*OX:>_[0HAKCB:M8D\$%SON]=MHH%1%]98UFQ8J+AC>AW/>DR]A:[XA
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M^LGOGY-DW1XH]B3?306Z'6_5=&/S23HJE&_UF>+4MWU@HNZ/JOA(J$-J#4J
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MZ-&<0^\;':H6)BR>:7"6S4TG0"TSB II.,&IXO)A_0@OEFRP(:<@!F(/8Q(
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M$A6NJ.A=Y!O-2HP7X_JU7Q#E8!\?$B @QWNI)CHD:P8CQ][ _<ZA&=G/62,
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MH_L(M:#18&*,.D7>_NOUBP!]Z(CNWPE^T:ZQ3@L"1PPTLEKX;6Y+L!>5?A,
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M0U4Q=\PA=&5\%I7_Q6 HXG.4W#B1,6VO@"D4!)/+;?5B4Y#J0KR0BE.S7N/
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M)A0(O(F;+D2+6V\BT6=%\A^XF ?#J#0*()?>),4T#"ZG_!Q(D*AFP&,3@DA
M\YM@8S<XG3#XY\^7P2^@?C-0(B$SB-KL_L6ZI.4^N'^4IDW::Y3F@NX[K[^2
MVX3,]^/IDAQNXW2!(O_QP/F6X#C1*,9WS%R.6!$?NC<_@;)=[A!T&P.,XQ)N
MK*U8@$.,,TZ\;D Z$3SS(I(ZM3JEOEWV#I#G;\FAVCR-;E^"/OS1S9BJY80^
MUS<L'Z/XNL4.7G SPL4@4]CY+!JQ-\BA*H_]TM=\N@%*0XRXJ[BZULYPWEC
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MC]]]F;]#:0MI'(TY0[+@""-KXVU?=&_0'V)2NY=Q!)O.I8R@O">5YKWR%.&
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M0C_L+N3X"9SR;4;$/LSK*C!;?$+*S,!79BA'@^%@F8K?O6C9?*N^OP:%!I2
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MS+Z[1--_9[VGTG:DRH\;SS)NEB8.B8N(GLCX9E)6ICMCT0G3>-=^3W8. ;)
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MYN9:]C1";;(*F\_HBZCBMF2,FA*S49*8?5TSIC3ZK6%%4>"TA[P!=>0#A"/
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MNO2T8V2M1&7>"(CE=>)X>!VPVVX3\],>Z55ZE.Q?6!2Q$SCD\[VR.@0WS<>
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M-TT\O"4[\#6LS@.K69EXC016&RN!U0,%5AM5LW98+1FLEH6?K4!"7Q\_4PJ
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M/T,#)0IIXC)HPI]P;,858T:S S>^=W?Q\ZJY]QZ7BL^+VI Y9V+\S]!CDK?
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M3'@!.@\Z0V/KV[Y!4#PF:T]VY1X?%5$#YAZXAS=DV!8;S>\XSY\@,)\#^/A
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M+UY.D%?%#GO. $[X@I\160TF[&J*7UQ4YN*.;X!&LA_"?TW8"N:(&UUFBZ!
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MMP&P;AS!F9D&_B@>PJI 236KC+U66Y(%7 VZ?Q0(.Z)W!_T_<*:^:P>PP&G
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MF[G9.U]H3_4/DA$[-^-S>.<K(6Z! DO.V^D>YBU*G?"1<?+ !AML1',C%U&
M17A\&T'A9;7EPF&XJHG66162/;D- V4;*Y=PYI6-TP["2(TQ8JV*KG "[X*'
MH8G8/ZQ,-Z05Y%UG'GA"K1%U2D6^NS%7%Y(0EGY"N1!^@_@@:</EPH.58N^D
MQ"H]AO^9'\O/&:YL8P.#9\<G\SK2YB+?U8D3YK>G(DQ8O2%%B02U"^4A#US
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MZX8@BOU$3(V=[*\HT(C\2=LQ:,1PZ9<VGQ-58X.1UN$<YL4X[/<O@$. +?.
M'++P0QHOSA6O#PI>FX[I]$E!12X&9TVQ9]3Y'2LV3A2BOC,B0MIIMS6\(3YD
M.L5ABJ\X*.A%LQTFCD,CC)9#C_Q1/4"T#$R7 >ORDRE,G'_XN^O3<XRZ\7AL
M=_QOXLT1@M<SZ/PC\#?--X-8]DQ;@-2;:PY;5WI IE5/1+W8"=F'PR>&]9Y
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MSX(8BZ=E;S0+?OP,+S*!?V'*R.;-]0I>F[%*K@1/JY'0\=2K-M(FYU(Z\,G
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MO($">5V+35-!@KH5)^)!%#<75.3\C[#6%U\\]#+A_1TS8].L]+%\K+<ZZ48
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M%'Z?ZJ.U#I+GSN%UT3QWC9?G7CJ>+^!GV'"PL.'<R4U.IGA5C)''9**XX*$
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MH)MLZ (%]$RJH$'+ X^.#R:>/*59-H7Y\)$])+33.>+=E&P1XV.WL0VI7/H
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M"V9P@\1N(G^?N,!P<.PZS\$GZ8]@+B*Y^?SSUX_,>\!B%U$J#3D/)$_)C?Y
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M7[78YUW[C?HT1'V(^G: ^G",C *,6+^@6TPWK+<WU]%QS:F&=Y.>UW?-,3]
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M7ETF]-TL4"WI[H+8<K)Q'4&FZN82PZ(*LZ;H)F6/82:&11%F[@AFM@2=8R6
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MFQH8(IV#0?J>%DF5D01\/R*]1!G@01YA9%DJV#ED$WPSAS&R^*?O&0ZA0R^
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MX3?/(98:]X,<EGC. ;J^ #@N\ VH/</8[BZSU655#)1>^G.Z(<1 ^,QI^9/
M%=VGS0V:%\TEJ'^B1Y-.O#^/#F.I#2ZGY1L7!U/KM5^4VZ0G^'G6H(-C%6YK
M&;D3KHPL)>2I3U0&J.DI/5_Y_,4!>OMWQMV&=VZE@J/=$VZU'AG+QKJ>?>9S
MBZ\<\C.O6:EV&[9/J/?_N&"/;*0<Z5)9;Q^)[Q('O98<4DP55O'-"RE8*-J
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M$33*B34-@F?G4&M1_BM?GP'$ZI:DZ(!_&7TIH\]B8'U=6V]#53(A6UO2HJ8
MZ9Z>>Y?)/>9#_%F[8/W73UDUM0!M&X<3WRJ]#D^47+2YWG;F9UM,6JZ_IL7V
MUK><VH]C@=^3W^%!U62V.(5YFS'-)W4J_B"_Z8L=:"O9IC+!7.UQ$Q@]3L>*
M4XK:U8A%*@:O6#,NA6;6^X0\07]@\B#7_ ESZUB==.1$<_KYUGV]>;Q837:5
M*0*CP\'C0A")^WO=^&S*L19\*E($8WTV8Y^0M)N=S(-(A W,[@Q6;^MN6=E-
M[OC(7YMNUG+_0#\_U=Z:7!,\FWOT5[?B6'=DA +%=M2FRD#>O=/$SONV2KU*
M3GIE"M&W>6,\X@51VKZN:OU*S=/BJS_?>]Z[Y_LKO!U]+2U3Z)FGT36B'Y_7
MM+6I;FJBVSG+W#R;"Q\FC8@N"6I=06^I%^+W;CYEMTSC%I_C 3N8.%L84-W\
M2N9^:%K''\7*K&//3)D<*/,)0C9KH+.IA<D9J"P"G1B%3Q6^3Q$_F=QK0)<G
M^0YU_,7T&)L)3J)_[<^K2D>^Y-\WV,PT\QHGHT.^&BW # #5X@!"S\,AMF?5
MZT*/O[LT-XP74N!;=+26-L:"OB"Q5KB=;O*?J1/6NL;W-HR_[CR,BI%6NYF_
M$7GW#$LIK>9YDI]G;K7[P,WU3\76[L5RSPI_51J/Y135?"A:-[2IJ%HVLB.H
MJAGI?YU+NZX$*W6729,U+O<M/C>:&.)VWG6=FG&S5.X\\1C)7K?\<*E<B(V0
MFL69IU;?M[>L61!<MRD/$@Z3"4:>0 0C9WK<P/2E.'GKID]A;)?CZ:PK:)A7
MCN7X#WA]7=20#0]"^SJ00)BJJUN9()?,B@20QPX87:4.*-@4F[YE27.IOLJ<
M%^&46Y<]F"%-J)FI_M]ZL;"D?5P/*JU=JR6IZZGW(#_A6V2G-(?K.# 2"]*_
MA0[VO69$DU-N,O0^&A3\USNDL3O:Y%[<GH7>L^_JQ4*VL S75TV9U_3T4NN)
MM!584M2I+:.@88,"36)U2YS2GM*AY.)K%AXYJA[2@BY]KM'GM:M4BDA#Q_[D
M01I_UYJY>X]6+TL'1&UF?Z <Q'4;4?Y"S##J3<)9AMB/TPM0K%H03+#K%$8?
MP*7H%DLO?6EKDXO);*[=B&7A3G11(JN#N>J3>H*$I'&N&%ZVCX1^W-]]LJ%U
M*CQJ(^BO])][7,%(OI0%<(I-+K'T,:83E$5^Z1N(;S@$DU-+V_+KYZV(<Y@_
MIQ=1PMXA4WM*TO%]K0CAZ!<\2)*O<:KSI><D3;83-'7^0W]06*!ME$L =%?+
MXKXY8FCM4Z_3]4W;?)5*P8D^$\NS](F[C-ZSEI*<]I!,!Y);GDVXM8V]EM[V
M+X;K/VC?*F41GV\_':GCO2Z$Q$SOSK^^-(A1/[@1S%FG"+[X237+O*NO7UNN
M$3V/PX;P6VK\*UZ/9];Q];=C#2^%-> .M^-[89_OHV;4IVG#+;7(X)(SH\X+
M [-NTRG',\M7V^')JJ-=ZJL/JPKWI@ST?94!;G'5&K,5=;G9<[UIA#\6:WF0
MX[A;L,_Q-,0FAXZ;"7R';\HL*0"@_=15OFK.EP*#].34.HQ79(QB;C@1?'&=
M8?^$A,[QG=JB-.F^B?H:ZS9U9Y=T>LEV[$=S+>M2L?Z'ZZ9;98V]*[)9*OEB
M"0V2:H[=3J66F7)Z&N.50TGWHAABA*T :!U!E;7:K^6I0+RW425]CK:I%7;[
MM%'XPQ;&)$.R=HJ<VNU:.YCJY';W4W7CLR$_I-:DK$W(SP*=O!WV>PZ_"HM%
M"X"]PPR,?HCMQL'SI9J%/XSY\R?Y5!,C?"^Y"P%NNX_Z3_CES[+1MY$I.6 C
M0JCE:\6O&6]KVNMFXME7):'2_L&:_VWK8!\ !5GGN8-M%,E=V".$,-MKT78A
MDXN8,#V'<2S6A67Y*J/$P277_/78KX&H]++II5'_IUYS;=E7@9_!QHK$XK[Z
M%P?_*S#=[*$7AD6<6#>Q-)#TF<HTG(IND*QI;ZC4#G$BCCA[,P@JRW8VZV(Q
M:?9;NX[=MV10 ;MA^'5NOYNJU6>W;F>F"TE2J+%R\^=KEI';8R?BN1O#:I9V
ME?Z_5FC036N6$.8P^'L)-AN[N+>Y1P0%EE#9)+9Y,!TGM5HB!VYJ:I/8'L1_
M5\ZR'0"[A=F.0[3M+1^;#[/KRQV7:'%J>^45=@HNUYXB.;4X_^S/V<P%)7'4
M;/JB-HEAN?V.RC'1J!FDX;.P)Z:C7H3;VP:3=W88 G^[4-N_3N5%7BX2[WH2
M5^T3_)CF&]5\X_;S;ZSYM%!8MML:O:LS?7_HG'I4@["HU]PX0>;U.1?2UN6*
MDR^7)67>6UC:JWFNX9W_,26["'*RN8/N=RJ]#5JZXWPKK<X:.%?"-BF!1F_Z
M=>[E>A<]S8FQQHMA/^(:5S9Q+#D>A(JA-!ETA\?03!#B9!,CW%*LG7P/3+[%
M#N'Q%BC!QU8%Z5PAH/,5[PQ8L!2KRN-65.)155;57WV^(->#'^"4O4O2?4!)
MUD6P@)D/!&[%D_@N+7QO2Q;8HW%6J L";$L4E'WWL9W\NX)?8-GW#7,'82]S
MZ&/4L2;T>.^WD/;LI&V]ZASWPG,M,K2DR9/[W]-2_2_DU+IW,*ZG3I'LQDB>
M;C4?2"'.CPGJ;B%&;R8(ZA&N7U2^>(O%VZOW#8@\H>9IFEQ\0TT4>D*RS BE
M*=MD7I^(]G?/T\L_YT*4(TUDT"3/.KVIJI@S-0-9@#C3CU.M!TMH;QM )G*U
M&,L\R+L1V!I_PII*#6D_8@SVK-'P"L&1,]XSH7 4[6JS1OA#P^_CF_-VL-Y7
M&W**_R2<G7JABSI-*1EAR6!["XS;MJSJ1P"KOGLA"ZU9_RV$;FFAPRA!_^4[
M(-W<9,<VJ529MR= ^(7U@LH5, Z6J!V0?[7^S/.5EI:G4,HJX=@=_2)EFQ(=
M<?M<R7)[R76JJ.^L3+JE:&&&1UN"Q@V-V" J84#RE(/@$S>B>LM%HFNMP9!Q
M#BF^V-KV\PCT@?T-KUS\Y+IKZ?TYIDXQ_+$]_-><#2>%!_$C2;MRGND5ZRPB
MTTC1\,_C#A-1E)G6I4U\\ZT>6E]6K:Z'-..9-CR@E9&1XVVN2/T"[L,DOEZY
M*Q?[H"S?6K'+E:]\V=@>7Q@X!-@R1QF!F\6+LE&(.6%F$^#0PU< "T9R^@XT
MX]X:Y01;$F Y ^&O@"+CF!3=+>0[[+$I%0"50(K*A/7*.23I/L@J#0^.J Z9
M,FAL2PG#A9\CK=Y^DP03M1)K<*MQ+3=\;]GBV1(\?*'/2EY=ST\]GS^[JUD/
M<^>6BP.WD-N7E_"B^7>YRB)>0C_;FXG3"67+YJ+QE<YBZ!M_E;OG+N6Q\HBT
M,\!.S=DA(40[\NT>= G!O,R__KO8L1(A#@EQRR&5K[T\R$V8)*[;P 0.:+B-
MHGB0( K,BF6+,>.4[L)GXZ^-GQHOGVZ.11T)<C?^BD\D=81*EC15(5<O>JT9
M'RG!TUDS^?<+K,8WY_;DN4(<EM$ZL@VZJ<9 +&[WA,OW\0.X=%2Q+95?=ZSH
MYR$:5'KUO^M*AH!O34[FJ=UP9 _SX1V\/H66OB"V*A>]Q:RLO#X3TEZ9^+V4
MZ'7=ZZL4)Z3L;82W>7:?/V"4D2?C,;AL[ZJU6\B/F,6Q[K7IO?0(O7*U#T[+
M):?Z)1::JDJ/^*<+]OS^0QP^L-S0\]WM_.^TH@B%SU^Z,G-7K: /=5\]UY87
MMK0YD?&&ENQ<[#59LV[7BBD%#%RSO0%5*C0-+\<]O@!:,8MS%A?B30P8ZMP5
M6MSWMTNPXZ'^MH]YD'ZE8\V,[21=Q3OR/(APSY)\\1UN_YP5XTA_>M2=X9>O
M+"(CC;57!GB09.1!7 @\ 0L'Q1G3[[HN,$:H9"65=%@:6X,'.3K2CSK&@X00
MDC%6Y6";%6RNY'@C/_&G;&('Z"("UA,Z51M2M_E->:M=9\8A,MQ@+,HC>VN]
M9K37Y46YLZ2DC79&S95/N8$C#I]MBR<(FY4DE:IE80NB?CTGT58]2DFI"BKI
M6[36[I87YBL5*BIK/C/!9' _NJX;-[37%$D$WG_SP"?[/>P1'K"!@V=YD,T9
M!K)[@5\^[D?L!0#9!X7XSJ^;BC(0S)6M:#IB\\60N?6$[J7WE ;,#3HIIF>:
M>[^@!CG[^V%)3JP$%H<7.]OK.*24BP!L^:?KH_27LZY8L)1FH*DKO5M+%Q[.
MBX*_X/'CO2,X#I%3"Z.^#\ E1MBT9^^'.0XL-K<D?1,L>Z1P$.%QKO[-[=\=
M*^HY0SJ"KL5GS:+/9O:^&4Z[5]"06^RAYOR]:+9J[G%D3LL<Y<R]$NF$4S:R
M1V3&"6[3B88\2&#_B?J)FQMFPFI.F1XR9MIE-O<3//3*2+\[68[<=PC @3QW
MJ=\8T0N?=6#>F3 ]C5XR'P_?"45(7GF)P0*F;R(J9H9TF9YW6G# #Z2@ _V2
MO*RVMFE/.%UJ\E23]7+:Y.DT*_//;'-.-L5O.PW?M)V$"\ I<(?=9\GOX$=D
M;@&HGK>()(JDR:4 FOQKTWE<,_L""1UJ,\JV>QEJ(%(;TH@,];1O"ZX-<5XO
MS&U/W/I8L(<RF)=PMSW_4>(N<'W3,TG,!GU=TRY:07<J[3JZ)K_\3-'3/#TI
M<M?>Y"(Z;D34Z=O:1%]?C[331+<1_>46^N:9GUTAH_<],JW.EHW_B3%G:7 _
M\/WCP*9=*3J^A]*X]V[(BN:6G*X==J?#*3I@<22CZPQ#(.766-_BV-)4QXTE
M6P<Q-,&Y>8P':=8[5/G99^/BY[4AW$.F.Z#WM3OGES)7*)HEBW[+'.*\I2R6
MF,)S%K,:&+9,?Y!OVL2B*+/&/C%7)G:&+ED#*RF5G[ZWMKS^%'UU!R\=ZAP2
M,>.ME3@0KSMDOV=+>2S\1EN7J-S6@5QU3YL3?N'_ZO7,=Z'FVB556U$;-X9X
MK7OM?K\2.MB563*EY^-Y]T54U???@3+ZE3*O.R)N^)JGO>O1>H!523HN^6JR
MW%PDK7NLHHN42DC+1 1P\M1M\FQR)T*ZKT2:N5CWVUECA%F&W'[DJY'-O$6*
M(ML4/,"Z9+V8+81Q;"RX!J;[/UC$9908=C):G^C5E][<AZ6V;*>XEV@P_FAX
MF7[9R[4UW:QC\NS8R62GSJMAY=(Z @P'* _2K4Y9+/"5 E&,2S2I5);*@A?;
M!.RCPP319+I <GT8)3C<,01["I!#E\$%UA_:U]:L3[<O))P%=DSU&#Y=+V#Q
MT7#H7$\X.42J7^HQ2@MW(ZAN*O Y<;*Z22&$Z!M5XU'8=U-BP[5L25VG%AXZ
MY!Q5*;%F<\>Y:L+;,\(R6YLV(.0Z;RU@GZ ^5FHW"*%9%D<M\0,:WW/>&T\,
M^N!4>_1<?UGX_^#JS..A7-_XKV^G%&E"]F5.J>PD)M)D3AP),=GWF7"L8TG(
MR#"5?9U**&(28TRV9,TV,8-3DNQ9PLQ4]CQ/EIX8XS?G]]_O]\?]W[SNU\QU
M7]?U^;Q?]_-<8Z4W 3T%U[>,H-@='6+G)3H.=H\.7$--1+D.\E2XMP%DQP'2
M7T-Z:[(3RS-*:*E@X$IKQ3)6K$,OT/P6ITMQ/PC/0%C]3\&RN[L2(>,G>Z#>
M,)>&?+U;PO=^6I_V!/ZI^;PGL!6]6UC:!/KT4 $ZJRRY%)__?98U2S+JC^)X
M_&W)ABEX3$9CY'*,>J,X"ECWYCIF';S.4G+Q>_ 0?=K>P?%#+3Y#XU7#4HP/
MTJUGK,9AA)9:X_:9 8/A'"GF%Z[D(!#F+N:&#1<HI]^_*/?Y?49.0M[AB*16
M.C7>6=;@CO.'TQJ:0HHSSFE%/9G(:F1VE0UCLL-/DF;W+<.U@*S I\,QOJ09
M&>GL"3"BP/U[ D_34"S#0=1\;P\*"N']25S7\<B4F%_^]HO8N<G+[4@VPNX)
M_/5Y@*M5O"?PD9.U)Y"PS(<_,ER:SZJMT+T]@0_=<*#0G[S.X<"Y^L1CJ-]/
MJGO2$#]WZ'/;>P*6=F3M/8'G07X\J>M[ O-AO<2NR!?$ 5(&$?C"_6M/X+L7
M";*N1_\&01)/CIX"YWYP\C:5_1T["\02*;2!O#V!3^=U^3I23EQO?C_44&#E
MJ^I;E^R0>.+!%8[#IX9V(=MND_W'9;^3J59(O,&Y3OF'!]]+'17*=%4I"[?J
M_&C]V.]0[)./@:5#K^EZ'.M'N4U1]AP?'S_<ZS25YW=?I*D(5#NT1<XEC.X)
MO(+W8"0\\%^J[@[*,0V-E[[O3E_)Q4Z4 9C8JJ\^IHT_"=]O"QU[="#2@?O;
M'UM'[VGF:1([G7AJG[DZ\=8CGMF]/&7H1"5$FA-,W1Q(XZF CXDB<2K]<ZAC
M<1^PXE.807[ %,;JB7+*28C#(5QM%EQA=CFJXL7G12<C^*@LPQ;NT^6NGQ=V
M1/?-=YE^9+'/$Z1(D%KA:;OESY5QH7??!WB.TV7L,A0O+DNH79%0$HJ@J%5G
M2AAN\+33H8)SK,FG"LC6T[1GQ$ O<*,VI-#):N[FFSB;K/Z7;*/#QJ54>7'&
M,%7M\3?#'$]9BP8_(0G4\TGUWWF@X\,]@0,'@=Y[*-_2/.:>0".OF+4F0S@*
M)I.,3F,65<$H)EV4S]]_S;I\^>R&M\36 WX)#60X%'-Y>&-5G:%O) +DI04'
MM9V<41[9Q!5ZVS4VM(RO_?E^O'X 4FW_1NT-/;8<I[+[VALD,08F?LUA4^*.
M=\[UPWNV4<D$/_!_ZZY06!G^_A!6<*'QSEHRP8J=PH7'5&*A989A4%-4KNL&
MYL^.\<K5ZI6UYPT[DY@C715EXPI 9<!H#?+2A9:<W:5T)/5!=VDVZ90.PA,K
ML[;..IM-<9L8L\M3?CL*OHQH?T$XT!U"43L.2IR0C;@T>>O?>;+Y^4G",,,8
M3X"WODOO'JXP*TJ_'\XK#/FQ&J09$EI3';Q265GUO;6MK37_(L[-TLU_$I=>
M4)#Z],3]F4,VW_(#/)32]/QN.]B:*L PG[AHBBNN0W:LGGQL(?_^OUNR'Y/+
M)Y8F'99,D(W#B+)B3T0WY7UW^)&QGWJZ!EEX2FK*H_,VW&7HHLWN*VYT*=<L
MFT/CF\Y[ 40YI"D'EIKK&G6/*P507=IVGVZB$^Y0&>FH%1$YIWC7X2"D5,D$
MYLOT\FWQ@6*/&<*5IC;)K;%)78CTSF5[ %(F\1T8#AL//T;W(@L%MA!73U"Y
M9T#ZVX'T +"N<T_@&!?%$81B@*EN5^5THY,#<S'208@JH4D&*ZZVW#5 42)W
M:,BE?F<U9-9VW4'+"?/TQV\=GKA-WT_"E(Q3^FO7-[EN4JY%8MGDT; -%1^9
MGN TO(;]&\QIZPMVQ7GL -N<(QYW1A8&/EN'&?[D^UIUWPL]-O&4+IDO&DVZ
MCTJ<9!Q,EEUB"5?"LGT,3#.[3!%)-W.#5]>/(%QKF9YG-]2<DINHA\GTJ(X_
M/T5,[:(L1B+;3S+L1Y]F6PR'1JJKN^U:C>:X1.Q<^)[%WLQYZI [>>&0[_4K
M5R5JL/WPWH'[LQ(GH<Z=FX%DL3T!WX%C!#Q(SB+@ FA<X=&&V8EACEDO%H8G
ML[H>ZM\EB,ZAT^B'>:I<'=)6>"M0R)1\@!_ -H]^&PW1>R,[,X[."=*J))@6
ML&-J(%7KIZ&<=+E^]:T:(*\7)6*^<WZ!7-=[M^-H  8%:J^T%4E@8:8PIAM:
M%C]P_0U8EEAY_N$?YL'5RW#1CA.!&/4\3(Q?^RCB[V#'>?1RR1P/)I?\=J0S
MK-I&MCGC_,'VJ*Q$>2-)+)::;3EU0VVHUTO'H.T@UDG_9G_M4)<MXQM$.'JF
MXV18MW&'1^*W*HZD_H'47KL>X$J8FC/!T3#QP-W"(&LU]7U.%TBUO<,5]QB>
MKYYPNW*O4Q_?D-2J5M)A>@/U9X%<R0A=>?1&?U04SA,7'AL;'NKCXQ.*^/+M
MV_3@E.NDZ]2587?WZ>EK[XY( L8DC6&+17F;DHNO7SZ2\R9ZTR:FEF2#O_%S
M.5IL("#6.TSD2^'(T7/9;M-3;0\&Q+,<KQ8^3/XSGWL(\@/06VT0"[R_MF6^
M6QI)GQ0E^A$3I<CU"K-9/*7992/44$3HI':7T?DVH(K411?L!8]N?YB /HH<
M'/NY;B]Y<GE5-K*J*66EVB?-N?*Y(GU'.&Y@G+B/'E(S989N!O)Z:@Y"<-O0
M)$GB_N\%9M!3_2Z8!'31&/C8>I1Z8#P]V^(-%$5SQY^9V6%LZ]_?^!+%% UL
M46@8JRK%WV*F>[@*H\5U@'75OELK2R7L%:V+^N]?N[J;)'?Z/%%A WAND\0S
MSW-M\I+GG+<1-.] EHXEDFE#O<_LW9^KTG:MQ&ZJ4K\A%THO^!Z=96Z-A*>]
M_?J[.LHI.<Q@95A!XXSNOJ>LUT&. 1GE@,U;QV*W_992B;FFR37(VS*<=3,5
MUHO%'<'47?PP7W0RL;8><',P+S'2RB,_TD/=&CSZ,(:FZZ;T[E:%=W"TYB N
M(LOLV:$ZL2NK?U[/,'/ ?HCJ6IMHW2H%]%?,=MR@Y;=T$03L(.%V,D<Y]0=/
MO"P/4.J.D]RM5&I\ V4#+^9=0,'[1FH#;/7@.^LL7BVP@%^[2NHR4H2("CUU
M6_V>JP2WZ%#$]\0H,W9R)FKN.5G<2'/Y%T: ;W=#X8*$L^-Q:KQ_C13J_@;0
M/;/_\PCHD&B"T%50*">KECHQO0 8/2QQAV;>+KOR7@&4$LP7_^V>FF_HZ)"J
MM1K!L\[3(=Z6:IR@G+G7;5=T#Z1U?Y=D]"T;H%8.NQ:J109>B0#MUR<?=5E(
M*,L.O5LWE7UDGXU%[0F(%LC=?_NMH2Y$D.\U^E]]U@B1$LRC5YIZUJ:CL&T5
MMCD7C,O$RDP/<4X8VL^;^EVPRS%HZ8</[WI"4=V*LF#<4\4FEK:H/T9EL"S7
M_^0H]V*%,^[./W5N;[+8TFL;?>D%9KF']YF7N%@RYRH20]1_OZD?084&ZW+T
M4XWD"#9\&Q#:O9N+% 2I6X5\VDSDG>">!?R8*%&N-W@^G1)P[C(0N&XSOJ$M
M8EX#]79)-=T^KV\D/][=BK=T'(T,-KYD9M<X:-Q?RJT"S+K@P/6!)+@P4F'N
M8N@AWF>L$$$D )AEGZ&QK"ZR:A@#Z=NW*T+!&!LH+_;K%SS#&" G5&_B:&XF
MDD[Y<3F<LD_(TS3_5*6)Y=M.V>\TVIV)^VF.70XT+4/6;.5[E^"@DQ35D:ZQ
M3D[)L_>EL26/ ]%Z#(W6PTX2>=>IMLZ&TI]':AQ_/ [\R49&5)C)63S&BZ<J
M2NI\*&=_N6HL_=)@^OC/JT/D.IL<%1]GZE.O1<]PM4W57IF4M^^+%//4*@R)
MXT5TML+^KA:KF79V9K@9,)/H^36VU75\\Z(FW/SUCL.'\XZSN)%(F=655=Y@
M=%AH@&#AN>AQ7<8?,90<T?JY(KDGGF\:\]738U)*B@[//3R=A/>Y?,K.1,/G
MT=72*TY9?_N:73E2>E^$J#I;/YM(#UE+@PNC_-$'"=&#]* !&8)96]/N,Q9D
M/D=,)!]!>E=R_P#SDE>#];[XL0_L"62L$/93<!TB#> 9,K%L8GF20AFKT:JC
MX'_("8N<E\M$( X.T>/HWI<C88S".UT[=KLEH:$1LY+3SC/.O,$X6':7OBMB
MM/%AJ4E8&5<]*?0@WAC'M[:WUZ^ >(MH8L/73*\6LXXC3/.?[@ZL?D5IUK36
MS6:2]D<=A["A8M<L)Z$<0%W83NM=6'.0HY3\B,>=<-I3]MFZ*D,]?Z3UP0[%
M#*IKIK_)<C.:F3]MP\2W/05FO+,]56^<2"G&(@K5I'^E)7D6WJ@U<'?<=T%-
MXH2E.H/-9Y; S3$YA62F8Z8AHOP]$6-C*O$[>ON)C>EQ ?[:9V8[JM<OVQ.+
M=AX)BB@\/Z+D$2B;\Z4],_/UNY,F<NBHR%/7C15=E%*//%()4!"]]>'Y5RQ^
MN'/26RT0HP&,%:V5F52=G,6U>)2<SPP[V]@TFA.B5:)9AKYIVJ8_)^?B>_)4
M3ND)'$<;4AV(Y[IQUCX[;=T%2/>0FFR4+%3G,MAV6I+$(AWVSR>G<$U>]@6#
M4IV_QG466[1(N&@:UCS4!Q<>;>@Z93'H.C40]J?SBX?C@/;6H]UGJ,!",\P8
M08O\1YP>-/XW@%K19H4FTF%M3F4$%#B>^@]X,%F_ITJ7;9; ]WWAH24>%D47
M %@BTA9YH :*FRM[58<_NB?@A#O]JCG-=S?\+D'_/;YW7W*/=W.=\,-1VC/O
MU]M/7#> (=J1,S#8HY$L(S&F]ZN7+PH)LY\-#ZLV7(FDO:<8.I,]?\-2%$_[
M3LL\<>J<PUM*%0U1L^=T9?$M$CHZ5*2OKGBA;>[_PAAS8=8%B4>*QQU^S%$P
MA;)IA1;-/MCM-B-#X*^ZCA%T!D%-;_<<7C-2G<-64%JY$SOZ[N3DY/;R:I%I
MZ:\_1/_0A\D_>D!H"&RJQM=TS4CO:'-/=9S^A+RTM89:P4[E]Q26[M:MS* G
MX_JV=@J(];'DU6/1/,<] ?6!Y ]3W\^L?8UQVWV*PM'H/O0I;>-A(U&"R7T&
M<U:>=W1IC X+Z1#@6HT8*>&7-!&A?X%2]R(+8KW12:BC$+Z6G[ZI2A"1W4WN
M3R$&^_N8YVW!>4*:@!-;N0<VF<X[S-H3.!1U3[/-CK4&PY=PFL&:%*0#D.T.
MT8&2SJW)'A+P;X =%PWP\BH@+^:B866^#]<UN*.*/7O4+";:[U3N>#@BXY-^
MG#<K"O;M-]]>&YWO\CJ+7]M\Z=P6K('0WR4?59CC5J0NJ#UPIKW,T=6P]G33
M*"M_7VG_:O%3KO+QI;F%WQ-^:<],GO[SIM&K&2Z5U'.#.&HP!R!J$5);B=:G
M.!KCB<LMD8J26H7(.I&\P0]+AB!%7]XD$\]Z]3+K?--R;.9N%M4OM#R@*3<_
M,?&KY27*9B93_W;4=8/W5J'A(3]-D-877$[>OB)_/W"4J(<Q&B&&T)/&]P1D
M.F 0JHO>@*A\R)O 'MU$)4;Q8V$DS;5_!9F4\@;./X &">9ET!D^%.O@,-(
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M<:IB\^_2..BD*7OZ>@IQKI9X,)A+!),MQHWD\$NS+"=&L#BKHY9%3C,\,%;
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MK9-BD/;-$DRA/A;Y;I.B&*C= X,L&OX H]*"-U=-+,#JS J\X)61C=0X14S
M]JD4S['3P\A@3QIEM*HWZ5NMVR7;7YNP+A*;AKQ0@LK2;$/YL;_7)D#WQ[OR
M6G(IK'\CD?!+>KA5+'JHX6+%L;"O?3%45_=C5_%.,J@_\4U;,"B2,YM(%^F0
MQ'/8U%5!CF5H$E:.@ +7K$!J!N]T-T<;CBO2!;X4U7I2%UN^-[#IL.7SDCR8
M9,N'!0*"Y0%GG,_]:2+14[2E+R7[N&E/('0\D0GQI+I])CR.I&MV>NILU$Y\
M^#^,O7=4$^G;_Y]=5U$14!&0&ANB5 M%*<DJ"PALB/1.EF61$B%*D0 A644(
M",A*76D1*1$"Q$(1"(F0 !]%0 A%0 A)I$9DHA!'".&;_?WW>S[/.?O\,>?,
MF7-GSLP]UW6]7^\[]\S]PM)60:'H:@5JKV#(^Y<;PO[SE@.-8;I&^^?4FLAI
M'E4KRQ?]H9>ZOA,.<:,UANE)#X-N8O>^U"A0#8"JIKT1*CWAY>\=O%!PS#O
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MI^"N;Q%I!EP#V2Y1V4'&F-2.82:1W-5/1CSH82R:&5=FW-0(]-3S3JTK9,_
MD+("NGGF4L%DUN>\#49^Q=+K")F2Q6T(<)61GJ!RUU(GECJ%.T=R":6IQ\/R
MA=:LT[/0#"WXL.0DGDW83Y<-;;--YJ+V3 I@RLATSFZ<-A>A^Y7?2VST7C>
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M.C+U4*&QKFUETCB6[IZ0?DF2\S^3Z'^1%U29EI:4&N ?%F$_":EI="7QL4:
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M!"4@=-+L.A;-4CT%7\$?SK:Z,'JOANFU@>AR<?9QXX=N]C>WPDS0%ZIYY']
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MRA:B\:K*RS)_!PNOU'H,US_HBE!IE9AC*Y1+S:H-F\SZ7(A!)T7H4P&9E?-
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M<WD',P*;Y0Q7)4KEPMB53(DAL/Y\J8!^3.C49ARAO/SU"EMK\H.WNJ%.+QQ
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M"H;P@DQ(+'^=5P':HSA[+L4?VIE@EA;3VJ37L7=^7H_BFT':[S=ECS8D8Z9
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MNMB,#U><P=F06&47 *<.[FKJS _OUI$_8)D>XY9*\94@G+F!F]SAL]0\I,,
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M2^IX?#]_&S(IX$IR>5O*<GH\S[LK?#!=N+'*) DC\0:2\4(U"U"QD[2['+0
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M.-P@ZV*&\.:$SI\C))HVPAWN("&1@J8?:P2?5=@!2_B=6 IRQ'+G-F0W(=F
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ML>)V'JD+->+B&H^#X,))L@G>;5E0Y\.QQB/$J 3*'@EZ+/-*@%R7;RUT<JQ
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M:4Z$\,99R[6+&)STAZBP".S;E(7*2ZR=D&?K:B,Y*C.XT[C*#R(*"[-!Q_;
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MKYI]4J)H6%$.A3-Z12PL'6R)AZ54UQ7(L@MU> >;!V\F)P@S@]&@3F:%GR0
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M07)Q(#1R_E6_Q+<RQ#-$!]9CZV+'KX\.7OO/?$%I)C8@T<?GR)3-'0I\Z(G
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M$I6QD(] H8UVJ WT)AAM.A%D((;*9!6OY<F'#1O*U(]F.2#X _:P2!'O8S.
M6(TT8<^!%V9^WF$<>:#^_=@,HW9],6O3QD.H"BF_PA=:2:H\$$E&];($&DR<
M@C (6L:5$\) FTS>DJ6@C4-KE]C"?1CU. U9\;=0 M>!ZE#L@=E+DQ?J0;6U
M9U$J4.<2\D3QG%7 J-!^ZS4C +=CC\6:/?F2SE-K]2\)MGV$4_S>A :G4U/+
M;&LW7E9<L\Y.ZD'J/0SP[5PH+E'F].2N9]87U_[JJZ8?I>>5X;_"#WWVXW>P
MOOR5Y\1B*Z#]H[JCC" :?Y.6N$8\E.4V+#1Z&9"O1/Z0;P!JM/[S)DYBA/!S
M-B-V!_9RL[U3:$5S^9)++W@Z85[>Q5#AA%*O73W=^%B6Z]M*7HJ]^W!U"Z$]
MY4!F!?)LI@N3H7=[VF#YS$<SBV]OIUVE%,I[+4RM)/XL*[?+1<%UJA)*S-+:
MVOIC9LLZS\7(";I5?>NRZWP_V@S]\'__CI\[X:/$4/:#U\"7=GE6N@9$:8!B
M3T5J<_;S'HK-HRCE!:P2ZASD-"+J8'&<VPV%&L43!.<!@LPK:-0#&UV+%[1N
M2#^C":\5>E@)M*VE<,K0,R[+XUP_ 14_1_XTOH:#G@((UOHZ\2CA+B$25/W.
M1.]N5FI<9:02POE+NI+:O(Y% 6#/FR%9US.2"VO<3):/$#P 'S9"T6/AT-R,
M"VB6\VI6J2&1QGB;O6 Y0!\I;&X<>Z[>8C28\RSE.O/"31*Y24S15*V[2^5.
M1NZ=$KTBQ?=FAVQ7RZ;QKG*:P\]R,C5M;LYDZ9<8OOOX=E3O5?%GAV*!N)'E
M@0NYGY/.%#9_[S]PIO!79,6"R"IJ9]GO5K:A-[+PQBU.S?^^1?>*1T_B*T6=
M!'-115#P9,^.C&?MX/)$P3:L\N"?_Z7QSS\OR-F('\KTO<0QA^%MV.IUH5<1
MB?&W8\R./J<\(Z[6_KD['OVW9\(VK$9:CKAP/E>UW.,):,\KC09WH$#Y%6D=
M7.'JVUC_SZ:1<GF=WZN70WOH\J!9"K]K?U'ZS==#2TA2BOFUN@:ZQ=EBO_O>
M[Y,4&O($[^/[=A[:E[$+/\J/;\6I0A*\F<1I@$AJMB@=<_5K'%+JYL;]'8#7
M3[FT[M*/YJD-KF /8Z%[Z".S88U9L5] -7(\X<IC'A0:/Z(3<MGUR9F53?*K
M@A)_'0<'UTJ;88^*+#H#/S!<1L#T_>B<,Y9++UW0L"P,<4RO> __.ACA0655
M9\\39L#TM0=;+^HMFDU+A590TY.IRI8 -O<0W< _+$N$ L3B=9<"A8]?[M0:
MC810WY>C*YIJT:T<PC*OY1)3Q#>R&VPSGLC,6ZO";V3&98<^(/YG&[;K]J1?
M+9$Y#(WNC8]9Z96?8QP,N:6/B9OS!%Y"-$$#D\@Y@6M6"^$>A+N/Z H-0(DI
M*FL5^$P\K$]1G>O#AULW]>N[27KH6'YS0?GT$Z?R1.@G@T_XO3*SG!7)2."2
MQ&4TFWBXV8J_P)#"8WA92R]>BOJ4=MSC2F2X%>0"3'*L56<^9%LOHN1JR,P-
MAPB#I%4OGIM?"%?<;\1X)2("NXC9-)_C-*2&7C;GY])UZT$%4LFP\ JO*D!
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MU.RX>95@#"['H-3GT_%9O)"-=@J/2**K KW,S0GL+Z\!,FM+V;I?+8D[]=M
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M?3JADOZC9O6@Y%>:%\W%[RBI*.HOQD&"*4!N39MOE"?SE\7QE>T(8,9JJ#F
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MV%ZAY-;S9B*11O@%<*<)U7?1U1;6#;*<*(=%)Q<\% $NF[9'^+B??@;?@Y"
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M*UJ^CBPK1()WHXXWC)R")M8P8YU=MH#I"*F4&P#_S^"*9ATYR3?+/NI9)$6
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MW("I%"&U&X$8(W'QPX!0\1\=.8$O\'NS(5U=6P0P]!EQ"-= 'M]$.'E\J^2
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MV9]@<BSY1 @&GLX!"33./GQN!5/0.YG&F<=0\_WRV>?+PC/+HBYD*>QL\R-
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MVVOIVJC_JJI2B?NSH8X[W1,7O#9W2("#'']N$D _0:R#ZW_;X6@^1Q2UN;P
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MNT1Q7"8&B?AIS3\KG42?A%,5.QGQ=_?N8%NU[H)/VO]8XI4<XT]BRJE?=J!
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M)(=^SB+<756,;!ZA3Z0"NF>V0)8&E^$.3ZK&Z'-R+:S!+#]) 8OL[H&EQ51
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M]NXRSCW]M<ZPW1[XW%R4%V/ #B_%=V8ID,(J(,*A+2R!2SCG]^2'0<&I1KK
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MUH/!_F?$H+9F/P^V-%4D0O6+AV\@[G-4881!].2@/-;T/DT+./1R!1[<Y#/
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M[G!Q6.?*Y]\8B1_&78]CG:._EIAF2@A>(T4CT./F/=E5;6BB4J<J/1&XT,7
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M1 6LL":0U'RR3\3L;H&D+E !>U=MHS1X1NUFS\F,]_ELO()'M#4)1U0 P<F
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M=<$QI$/;%LJ%);A>;CB;YX'%PM0&5IAP@CQ>JWY(%W;C^AP#KQ7V7,O1LN%
MAF&PFJYB+:09$CO]:O@AL+;QJ1Y4$=33GK 4MV\-O=R.XDI[F^DZ70<"6J?W
M^7AR]N0<>2 L?83(X94QZ^B"R]5X#(]BJ3BWP*JNR;:ME[18)B]#"ZW+H@=8
M<F!VN=<7#B?<HE:^0V7WQ.MJ7K*NLJZ&Z\B-FD'#CR,VC0UQV/.X/Q<<KT>5
MM2@$T*/,'78DAEO) %2T7ZR_W;^ /_"$5MR]2V^V/&!QVZH4PB^"T]&:PCS1
MS[BUUC_&W\_ CET./N$3G\XO4!L@F"-R2J<6G+Q_Y>;,65Y?_BQJ;U(HZ,$A
MTAZNG6:K%;9^9#8JQ(K&NU\!76MYAMJ.Y+R>)_L^UW95#R[^]EGJTB^1ZHJ&
M%0Z<&XN7SU#^W K"H>B4Z#6!SR'</?;A@ F-V!Z#/(+!2W)"M4+6K[G#+2^M
M(#9!!"B\XU2[K^ I+;[")V%QI+5K$;RJP2B4*L ]^#BA=]0>LXB]^=:G&K*4
M _RT$2<L"U/9@TOCR2>S3HGZE!&@*L46T@:16RA0%>21( 077J\D>(9;&E==
MZCGE@^HH05WW0KN^1D55-S!9.Q)7!L<BGTW"H;.0)0H :5%<67+8\M@V JE5
MHG<HE79IC .@-/*(I>6YJ"(+6T\[%J18'/3]TA@AM^!-<"7Q-Y.$^_ADE2,V
M<OS6+]]33%8OH@,9.AI449\*X$1\3*PV67+ "TAO[Q%,P>00BMCFS[-,<"B5
M/1,@HYFEEKLA-IO$*;,,%X%<SH]5=,,'-Y#2K'(C,S^K_B6Z!R:S<?7.Z>4[
M<.1&GJ!*'"MV:S_?"!>6LOU)J3L2M3W5,]UNYX=$2F M-[NU-^D[)/8;>[2Q
M Z%*[S_-#*"@8[8_(FC<Y"B],9><F;X766L.&.BB;6+ZJJ;ARF?DD;OZ'0';
M5JUA."L#WNV>UP$9+BTW -SM>$A\\>5#%?%_*5NV.K6X=(?@R(Y-<+U;:_LO
M1$9#Y6/;/@E:X'LLH) OXB2E-=)\=U,&^ I-JH%GJ*;)S*XN>=LEI08*,(<J
M?/F^? '")[Z="SB\;<F2*WF%\Z0=6)@-.5)]3&KX[#3U-R!#%(. !.5FO]V1
MD.3+^1RJV_+P@>(R6N^B41KQ\'.)=4TA2_V!V!6F0=_I7KDG%5::K$182"16
M]UUUO8G\^0GDAM_+[X^'A]>0?M(O5YNE,CR,^IY2YW!#)0]+KAB;7?C4[H5P
MU7;'G62;L0Z"L^>K@>P8+%RI$FSD33_<D?#'!OG$H:9;B7)HN>_3"4QBE?2!
M?3#X3>ZDC?7N4> K*3("7WH]J(&P%]GPIL[67)_\8?G&H)IP5ZU +YZ(QD1A
MRR\,;V9]\'K;HQ8[!DW("DQNTU:KUK=R['N7?/(XI?+5SWBFO'>L*6ZB6#HA
M#OI3IA!5X/6(G)KJ!_%-?-3*6W3\J_I,JUL;%QBE7^6H%\I]N0B1JNA+5<PT
MSSU7:QKT!#=8<*K@5)6Z/=7^MOQ&5.#9X7S38-GXQ^AK&V"E;/$3BJELA0(3
M%4IS;:2JAB=ITCX@#?_CYMG_YZ<CMNP#M.53TTKP2U-:4:1]JD-T3E&"&B")
MBR9*&C^YQ9*WU<3>WI'@^EG.!A)^%9(U$OV'@Y^WU"[HEG44-^^>D,=&?MM]
ME&I:T.WLW9,I+#61'(P_0PXGF9N$=3F@.E&C)J7?#"J08Z;!8R[QM;GY%;W/
M[*=O%-7./UI4@DULI_>)PW1,I5XA]]VV=>2^ZG[#98-I[T'F.>P6G&_+.^<+
M(%N>,P;]@?:JJ>/US!&ZRF%RJYUDZUATSBPION!X?]@X%=_*.MHX##]!QD$X
MBHP&@@UQ'.H%R',4F">*<!TMTPJE0&_:-YC\)(AW!K5"@.P6UFEC>=)'A/+0
MNL]AL IY$-?3N>D696$%>-?Z9[MF*1\TI:5LHTL6IDSCK8':J#7+\%Z#>\_.
MG9;QVFO_]0/G7CNV/21Z"&]KA[C_M\\;G-7DW'Q*_6SVO?82;S/]W/)TID#;
M,;9T/\Q?2*H?T8 9;%+/F>C=<;=:&]F";;1#9K:0^]QQ\QR/N@\B+=WV6D%H
M.W'?9S 4>[,"-\ S)@&,*X)\]L,J@L_L$R>>3.),%WLW2/$4[,EX :9QW.2]
M%8'LQS\/7A(9@"0>4CIJ+[ >_4%9"81P&]D*J$#6:;"QD'"H?^ :<)\QG!XD
M4@>;BD&;03N9:H$RM.EPBWB*V ]+T/5/=B8A@;BGQ>C-L;P,]Z ,M.O^$/RZ
M^=$GGC<K,[VADKO(/1-:-@;I\WGY)AHFZGM[1AH&TU,<TU\W]#=7.MZ[GN),
MD[E$=M33)]3-]A2]R,AU'MA\4S2G92*/A_T.E\=LW4.;=B0@4PAIAY%<VBB#
M)_/H!9]2OFV>+)X##D:;H]D'PRAI<2(UT?L!/Z![GF21P)0@F.;^W?0!#N52
ME#PQK@YC'U$=-\-"YA#GP,0M_T!O4X#Q5BBW9IO=AM 8(O@096A^I:#C!E^<
M+C(6V75ZM61<)Q\;RFL($LDSKL#E@7ZH^4_V@(C-)4("I]080&HMSTNU=>H4
M,)_&[1U"Z5R?ERQPRI+<K4/N.M8W]SB@2WW_O2F'N>2,[),.=J->:M3,5]+M
M^JDF"E"C2-.)_LQS17/*MXK^+BG*-KN'<1VL6@$LXL-(XXU7P9S=:0D$_1+P
M^5L3BZ,9=DU#LS4@NAAMK++?<&Z >6YOTFWE<9X3[MWBU(FD:2_!/(.+9\L$
MG4$W9!5S/ZY[A2N9<MQ!?*A%$M-R*WQA2D>P"P$%K.*,I@]TD0DH)M ]U\1X
M.%O0+Y+VX-%)+<N'W>*O@]1"+Z^FKQDO",I#A4/+Z6/#YPAAO$7D$?=QZU(4
MYX5PUM)J)",]H_FW^S&Q38\SO3)LL-J)H8LOGU7U8TWPTX.Y]A:>'1C$_<G
MUU6\B</WQ^\.<"-J,C-1_=.[OD2?$#*_C8\WF7@"R-AM26PHEQU[$(5+4@=,
M$K@#].>3Q)EUGZ.TW'9(PDI$!.7+=[U:P6O,/L4.D6S7GW"=F=&Z.N9@Z9O^
M;;<_";[B/B=UJ1_VG.OV>_0(?F9:UF?RRUV^]Z'!.NKA#L7H-)Z=CO4'>I--
M< (+.DA74O$<OH\\ -*LF !_A<$05%5SIV6GT,E%'MZCHL=]=C>+V/-[?QAX
M8&2X>4Z9-29:L\&^'LN]HZ>?.:O^30$MFDQK6%RN6%Q9TZ'=Q!Z^6V-]MM':
MNEW&0G%;-VTCA7AP&UX/YJLD%3[<#A%DV07IM +4%"(0;QQ?Q@&6F=9E(*2-
M=09HH[=FATS:88,A"3!FTP7KSZG2^NK)2/J6=I).+CT8JPX+L,_/\*PK?B\=
M<&X!VNCQ_!FFQ-%+)M?0Y5A]Q6!%.,G(.M3VR@7%SL[-3_-WQCKMOL$;9RU)
MJ321(I@^S2UI2/$VZ4D.*33.P)>@-[]N1/_<3X.]B%GTSI56VMV3LWN9*> ?
MM@H."3[]^J_19YAL8=ZRZ)3'MODSEO8X^!DY4L6TIDXNY&JT/K'E?FV<-9?D
M.)FS-R[G5X'QW-1J*@[I.>@W'EKITTN>N(@IG>:;>$/[;SSGC)UZ4NZ#[SZB
MW7WM&23 NL+9Q;PX.<REJ/A=*5[3S'N".=)4DEGRYQ>RMY&PU'G6;F CR-HQ
M(B/;[$G5/ VS=F]L)#DDV><I"7"R.(ZS;^^??HN  YN/C9#[P>26]XC"2C"5
MMV)/LD32^7VVD9CRCW"3I[V'BHP2K)VMPB\E7?S#BD>+V9&8R=B1J)&ADL'Q
MV8X.:'Y :_1>#QWJQ;>F$:GW0<-%<Q\'6\,M0U163EG3<"FO\=,;B-R3-X6V
MPUD?\@ULW^GY(_D1O)$E-N VFY9@:'&88 \\QSUW I:+W1<PQE2*!UK0>BO7
M.7*]R_;=;9A&C&UBP1B>$NG'0!]K>6=GL+;A!>J4H_4#LPN.YLY>?;A<H.-N
MU!3XDGC3Q3;LXL9R9T*2TXT_7M(T?R-T3(*IJAJ"RP1WDNO;@ GSC$_7V2\Y
M/]AJD9.:_>L[SR;XK9^P3:AVZ.*[TI:$!6:RVJ/^)C^D5"S53$A5$YU23UAX
M*/P!1B:3,^;_+D/F!8S.^VB'W70R:G?\GNKFF*>?7H$\66A9/T!V#6VQM#(N
MSO$M'ZI(_DMSIC"E-(X-[ 4N;IP%8.TJXZ'-Q!_A;MSW]R'Q?+A;:.@+SG'4
MD?!?QG 1+8K>I963B/%&LRA[//7 E&CC+$-RTE45>SJE_PKD2X\X\NSJ _6!
M'S<]O2YZU(&SA0L1#U)8!X&#@'+^"YT%XUQQ1&NQYB6_?UDEBSCA[3%I3BTH
M+!WWQ#V0'TCG??ULSWSJR(?QK2Z).S8^NA.A),C=/M\??;PWF#=D\G&()';D
M L\@Q\25@QW&E8(CN2YNFDZ!VL8/DS:5;&?D6R;=[/KN4V@0@S'< SYOS7K+
MN+@<-8'JCMRUP7BT?,VS9+4M A,:@@F3JH$[C7>K.:KJN$U\.J?G9_6XQENZ
M5V=&O_YJL5ID%#R(X[NF-=A=?B-D_4N RROWUWNHIM\J9RA]Y)2D5N[BX.<V
MAU2MR\Z+*J2 2/6K = 0E>-SU]S#82:\O("##LU]/6=2V/PW=]#?I/S-3G)F
M[Z']UC@?XGR/>ZM*.KZ&_E)L7W(WC$56:"^1;V,#5]G**DK;<,'ZO>;"<7)\
M&%$J,&M#4<K[<H[OS3V/=R1^JXGK[KM%E]NH.!)]=;SD0J.D\=N.]:[WR:)(
MJQT) @QT2]T^#OX T&;4L]B^ )M#>^$!%E]C#!FQ39P'OUD'!^N>2)>,5,3:
M\_E7AH^5/CUT=O3:GO:)']+\:25OYQ3N6,:1G\TY5!R7D7.)2@EJSSM%]J9?
MM3]QV;"JV';1A6)Z()3J\W'+XB5/_RP)DU"Q?.M,3Z7?,2V!S,E4'9-,;;@+
MP3P(3 I-8U"^>8RT.G(&*:['+"@M399Q'(=GN$$<00\*62IWVAG]!U!+ P04
M    " #A@VY:7D_<ZF"V  !7N@  #0   &YR>'1A8FQE,2YJ<&>DNPL\D___
M-SXA(2V$(E8.J9PJIT\.VZ=4DB0IQ]BG5 [#$C+,5H00"Y_X1*P2*F8YE\.&
M#95*SIF8;>4LUU7,%3O\]_G^_O_[_[CO^_]_/.['?<_CFEV'7=[/]_OU>AZN
MQX/XBW@2MO74":<3,"DI*=A?DA^8F ,S/HX+O@:#N;C ]L-@L$V2<P=A&R2?
M%"2;IF2#.=ZX>C4\,@@;!1./P1S^_>[_T>O?F_R?WD-*W 93W@0C2.5*2^G"
M-BA+22M+B9DP! PF)?M?%\#^[Y?4!FD9V8URF^05%"47U&^%;9"2EMX@(RTK
M*R,C.9L@.0^34995V7WPR$95MTMRNA';#MW.?K))[VAUN]JY/D#?_/*-1'D%
M=8WM.S0-]ACNW;??PM+*^H_#-@['CI]P/.ETROW\!0]/+V^?@"M7KP4&!8=$
M1D7?C,'%QB7=24Y)O9N6GI/[]X.\_'\>%CPM>59:5O[\Q<N:VKKZAL;7;YHZ
M&,S.KNZW[][W#PP.#8]\&65QN+QOWZ>F9V;GP)^_EE?XJ]#OM7]Q2<&D_QOT
M_T]<RA)<&V1DI&7D_L4EM2'FWPN4961W']RH<L1-[E*$JNZAVYNV'<U^4MTN
MKV=^#E"[?*-/05W?@F, _@OM/\C^UX E_F\A^V_ _E]<+-AF:2G)XDDKPU P
MD?"*[-]2]W(BLA]I4Y)F[U]G[/II$Z@FF ZA VYL:-\(D\UR%BGH 0/\<Y#L
MNCZ.S5E=D.*-:W4T59%!LRZV"OX@:,YUJ:),'@>G1UMLD?E*J\EA]1XUB?Q^
M^>C=F%#3<Z,[+K[OI)=HV/VUP54.=@5PO'@?9F__Z_/DR*\T0X'JDDBA""#R
M'XEAB1D"1^$#T1Y1EXTAHW=LE;LQ@_MBA9[!\NP,B^&:,;3"S-J4)BV:^Y>Q
M< -JRHK+":WXPJ)3MIB>-Y2RYO2AJ[HPX#Z\7*0CAK5?)P8(,7P/88$8%HS5
M>0=J=*S2Z[!)> =NF#G',5&DA5OBP4EVYBC&^N@R.EVI,AB]I055->Z+BV^W
M67GPG;)Z]T=)PZN<KXS]R0IM"4< ,4RD$+.^#>\^5)>IUX[0BBHZXT?D7V\1
M4BRT1J,28ES[+7MO-?EUKE0U\OP,/0:CQN*-IH"5X:(8+-=$7=[7N\\@.?]L
M]9V_V1"/AX9VKRZ:3Z*3Q; :Q,(*H,BCWA$$K*,$&I JJ,>A=II)X4^!V$[T
MG0:1,<0 #2^V@NH5X,H*(G%$7:0/7JAO%;V(WXQ06$FXV<W(MP)],]X\R_'^
M2H@1?1'#7L$[$<EH*3%L,E<, \Z(8:DVJW>CT6.Y'2QLIAAVC8V0+"."0=::
M(VY>H@>@6'I>PQ9FF3[=Z7;QSX/ (-J.5Y^CO$;.)S+.#>9[U@\>Z^@WU%!V
MT0U_+X8-3Q+1!+B0(E+&GQ+F[Q)2"3M=N&*8#G[G$%[V)=X1^$K3 AS3#$%2
M!MZR3%A_&:L$:4YU##";LDHJ>P+TX]0?->Q#ED^-V7EE18= )2)YM!@FNP-Z
M('G?,(0*_8+<+=A$$Q:3%G@@^PSDS2%)X_*\79D7 %$)1Q&EZN,G<*S1B(F[
MF<U]I]><^6,YX2!3$UW(EV<Y5P1[$1[BC:%@#CF)K827!JCM35$V,7=$6A"*
MX:\(?$]NP6SV6'-,7BYTT7,]=K+] G%/WY7+&^1R3AA.Z9/N$/\2P[XT<^$+
MC2!#I& (6G<1#(&JYE+"%T2]#'HG'A[ $<,6=S_'13+><;3@<.0#;F1"F(Q2
M14)9W_=/Q0.^"8]>+FT^X!+G,SPOADF+-FT5#: ;Q+ ,@@8TPK\'4#O$L,VX
M2&;PNA'AO0U[40GT66<>"M'=*[A ]0VY@=>#HJ\TA5;;1<[?1&J/V+EP?1\R
MN]@.&:<2WQ^,CFV)@]^1K.@3>FTE>PO>D>>Z'?_GJ_YGD!\PS2G/(%BB9WV0
MS14XYW;_?5#&T]G&)B*CPB2NJXO?ZP\E1SY'=P=C@/5CKX=:T-L:"Q+J)XK4
M.A=;;N SP48^#NR^BPI&0'OA'45VE)1\R5(H"[-;+,L$?X!=)9@7/1SR%H$3
MY,S1CN20TP0&7*U%FQW?!CZ(=$#UV]SQ7;)./RB3PYU/"GPO;0<6G46;!G@4
M17XTV+V0"W1WTS;W$Z0PN7@%:'Z2) _E+'6M'L(9\<LA[Y<S-E32@JEEINE/
M=J=F>7MOIF?<_CE6ZS?_W:0N)'SD>_'Z$95GU0QIZ7EX%AOPQ-Z63"!-$5?!
M)2;;&8&>S&(SP)6)34)*@8'MO=OP>Z'L26S:A&8M](X[KR3G &91)A,"&?<A
MDD@Y8]'&[\0\8^UC?6;7 ZZ21R<>%1@O?*'W9_$BCP3MPR[4 TM=C4@%T*,>
MU/D<Q!+#D@0&/%<M'\%.*/\YWAP*YB[I=)>^XV 5!,Y04B#G!=YRDKUU(C/R
M1-:OTT/4IX4GR.?J4GUL\#6AZ(\55,@@M=LD@-/;/1YX"B MS ,5W-7,*C$L
M,):F,Z,9PUPBH=1#ER8A>1#M E&LBD X=XE94;%(T-9@KA55\N/VY')ZY1P1
MR2VCU++"\P6SG S5_W#D7P06NXYZE_!'#Y>D+M 9RN5Z,I<VX,\ \ R\(XCA
MW;F)D&^QYU <VM86E]H_JDXVIAA;D%-]F*_F:%I#H96$O="M.<VL$LQSA^<A
M!=:L;/6OTLN>743  _NEI UY&$3<$CB#<IW#(_Y*T ,B@.GRWU,'.8/6YP&Y
M9*0)JW/G,$HING?G;+%&,[!"S;1SFCX"3[;0;R[XQ;3V]/!@Q=F--+PP9@4*
MMKE.3C.]1=L_ F-='BQ%#+KN"AF&W(TSE_ %@YY6K #E/H&*4:D3NZ!$NWWP
M.]@ZC(DS@["7_KEN#*4:K#%A4IO$8*6FM+P+^\&*Y6:V(-PD^*,$YP>1.A*B
M>0YZWN8.MH1)JA4)8!>[P_2Z*^N?Z4@!TYEX.:XO61%=,QK;#[UBX3SFM+Q5
MS,L?*A6OWT'M[^:A($-4)U%9-%!L (UB>'"93LYB(/\[@%@\@BV]2 Q3\D')
MX3SYYX:0&R9F5/YNL$IBFD,%:R;^(Z'4,C$LX%B'=TGSAD-2R_D=9M!^PX48
MD-Y%4P%<;PEBN?GY7+7\M"6D#JZ92=],V(U#<>BD<+PRUGXD,PHM)S@*FJ5&
M+2G,%ZPFFX0NF493]O>>"UZ\7-M\]9"B;Y*&)Q O4MBQ?E 0"?*3@5]MQ89@
M0 C2N@%46NI8VHHC<QJS!-J3J'MY_ML\<YDQ9#E!!-<%[@*PF<X)NJS#V"HM
M1N.J2419YY[2R_E6SM,CW06N E5G[C9R+5N@NCJ90N>A%8]+VNA-#(AD<V]6
M/%7R,*?,HK:*=@A. O+D=EUG+S]+K7WX""Q1#%-%UQJNZ7?'TSJ1#NL:$E7=
M3] 7];)54=>&P<9DY(9>#GHTP&6DL@Z;;N/()+)4N^A;"?KH=YSXWDTXC'>?
M:"=N@.DFL(',8H6D!#VH+1@%Y)8]V9O'<$COZ.?%P0C9^.O":I&.Z!-Z6SW%
MG#O"1&S$.7-ZDXB!+D1>=Z;L1#9W70S;,5N@GLQ+,.J(\=_K6W3H_1(CM>.F
MZXO.JPF!;UJ."$OT8\Z.%4J9DQZ(D,3VOV@;<6;\&\)2VCZ\0;^ R*6GT:5$
M.D$TJP&1)L2;%,,ZB;)S_KOZ\6$O27!(L?MST%ICRO)BY 7(_25FXY%8GHON
M[DN;;Y9-Q%=X_Z#DN9B-=8ODA2"*_P)D,[';< Z=Q4J?%_#!ZVJX$GY(;2-H
M'%=QT1?7Z ]U<M!W[\_G9UP*,S9Y[/@LR-HCYN#1Q1C^:(G7_;9(;S&LOE&@
M.L(E=XMA:OBX$;N#/+CLS$VR&OT25D[4$[=3\\O0!Q8V W\8)+"Y:I_>/"]4
M#/84*<\N/Y_H,&@,P&.]6K(W;;.'Q9/;Z&/E[3ZD!2%O*0VQLR7L\2C4PX\%
MK),%?NLNUBE(;?Q)(#QSTA4Z;6> 8"KI&*$VX;B*O3LJQ+ .O=A+=L,JK8N"
M2.,T7>:';)W"<Y*^NB?J:2)VGH=.V3GR_-S/)S$EBAEXUP[]!&\&3KP!Z.T$
M*RBM=+:I-\E.@T=.L_%/C>1@-T%DOP'+UBT_M*V]!DU\^BR+#EKN,#&@W=;B
M(%@(OK2PNL4E<CT"9SB9GT:3,I.8.@9GA&$/[YPP@;*C>17$[7AC4.,68?L7
MP<&AL#HT'$<\W=0O\"V#R"X#?S4-K"AFHAWSCS:_?ITWU7LV?3LW7X.;+U!%
M\_- 1/<,89? <H@ QQ\<,K5S =">KBSS-G]+J'K2-<TG,%FD/5NL\@IT313$
M ^[.DNJ51]K-:7924^M-M!@3IN"5 @O^&K+B2M,C)63:M9-RK+@8P3;TY%(R
M_K!]-Q.A;I@I"*@08"$>0&V;D(;D@#%N#,DNLHJ4I+/_31_>38:PL:8/*W"*
MC9V,O]*0U%UL4%?ONK']^<6VJ-:C0>&+?<LM1R3<Y"3,LO#3X-RL+H/6F2*;
M-U ?AZXA:>3R9*2FX "4REO:"17T<D0O@I]"/SKQ6IS>+?Z8M3-O)L?/_;1%
MJ08UC><5)I0X:W>P'1&YO_#$231DV+WHL&Z']^R3>%MX4E-O.TE;X-Q/,Q"Q
MS%X*[*';+R%JATAEA*8F&F1K1)'3"S8W>6;494K[#^(/\GKET#/J6S$',Z7/
M]=6/R?^H[.?*_]785,7F_\NNUP5N$!Q<Y\"[2=NAZ7:D[K"%$,&G@V:=S? M
M7O/JFE%$57H(^:X(#L[/LK>8F'$?< '/Y%W 0@&*%1V\L&)_]*CE80H/\^[Q
M7>F9<5?^#%"T.+*0 +JVV>2E\<Q&(_D4T&^IHQE[5Y=]H;]^:3/>920L>A]A
M1W="V1PFT*0LFS+OKPD:WEY95SK:,>;=9^>U9EGW5CU6+W79BBZ+%<.N+&E+
MK(CC@MJZXH2S7)J=RU/"EQAZO2$3O@.ZUG->#+OCW$'?3-LF\ +)7;B"I7/-
M#;=\YOUWC;2X3B[)SC9%OLX3_9SW+!Y)*+U7X[ET<M=/>/C#V16=>N4) KU"
M*NAIKMX@X7*E[']^1[W1:8T[*W5\VUFY#%$??6LT\0X91K,4G >$K9D3S< (
MQYKIJC/34%#@LJ<PN@+GV.%312\?"Y''&FO KT9$7]IFO4^F[U3?28Z^1SMU
MBMZ&!CR6H'VN$BLXZLBWE\QX&F%P0D&8;7=I79LPX+\7<N?T[@BB;UQ$&D(!
M/-<.+40&JZ5IXVWN0]<,RS#7#II>;?]*5)9]P)GZF[GO7GLTW'^92"REDNA;
MJ*(#>#C$ $I.#U(L,L2P-+IB2P(@ZKG0FN*;X6*ZU(54'[)#85_X'9'RGFJL
MSC_K^_#IG<H:_:M;4PY3I^,YC0+E0#X'M%Y86M]+8)#KL8N7UE$2(UOMN-#,
MQ:80]N6W$V4)6Z$!!Z@$]",HSV&K<(X,'2.P/,/.*;)\MD#[4R67Y_VZ;[FN
MN>GDTW0+Z<=RLVBF*V1LO1 /5/"2&]OH.WK "N<WN=S\%.2F7M";)H<_@MH0
M2C#&=2]D<-@;_/'>Y%.I##IK[>_\X6Q'^XKQX K+#@<^;]=UFR")^:U$57^=
MD$7:NJI!;4=1F)/TRR> OXME1@:X,L2Z8ZR7LQ$0$KOQGS/5:M6;+5T7<Y4'
M4M(:/8(]^H;F?YKS[TIF6X4P1-81V4+S7&N)Y47?(>S['"BD"F37703[03.F
MB2T/204UVI$* #:M+NQ:+Y]8_=G8[A*B@[H%Y^A<-Q"8V,TLL$[^83FVFK=W
MZ?2IJP^O$S81WN;3Z^ "C6[N]")\DKT1[P\T+MP&+G,'>*D9%M0T!-R2*HU#
M=*$:OP!%2^VKH!F#"IVD4$SQ[L%E. -WIC5+F$GGGV=E'+'_^][/M&\P(224
M,'60F;+ D"9AGAY.:T-N AC/SX8Z2_'FP,F1OUZ_Z;,P@9\<"!=<!6V[?.KK
MZQI6-:PF=@"FF2_J'RG;I*U\='!JO"EOY)DYBP NP$?C/<'ADLGY:(@>]C0(
MK1EM-CK")&ZO1]_Q-QD@;,+%\"YDM> /RMVJ9Z=96Y6<K!Y<R8Q?* C/QKTP
MS4 ^>3GK$\7*K.>78,/#1%\1<($K!G3E[Q:6XZU+0FB&M<("@NV\/&\)/I/G
MJ9E715<BV$!6OSBN:7BW\EE^=4\D84)AL%Y;FFGSMW*G,>]HDM>;LTJO+_WN
M6T>)NMGUC=W$5+0V81/^SR'D3L%A83[>44*=6E OF'0^R1U(S30FH$)T5 #B
MHF(P:'ND#V]FT.<J.X[#=*_QDTKG;D[8O+D7HD[3;FFIJ7XU:(#Q.[H+WM^,
M@/;E+PPD@.H#;7T]X#X[R^>""\V01BG^YFLHD.N,'9WW@#Y>?>Y:<A'_QX#(
MJ">\R;B@?WXXOQB1OG;RZ6?3^O7@.HR??]AQ]5&@3G(S,:R-JFV6+L?HE1=$
M@7XIY*?XBS3 +#,,J015T[0$7D.BS5_F:J$>!DT&?-!B[NT_=S-?\_@BI4[S
MZ<QBA7W]YW[_Q<6O9I^LZ( +F[5;L)O#'D6[0Q1 DLH#R JB?DE<[],,?W&5
M0U4_OG[4/VA88A3,1(>"B?+8._E$(-$A["IWT6$A$K>VX]L0U4+Q#Q/?8UE\
M[Q^I]@!;)!\)UC(0=6'43B/R3L$V*.;Q6(@8IK'4$LE%W=;$,MDR$(F?.4#0
M#RK6[5MVT>"NML^N3$':3R]"-WF^M</11%6<^^E"S^$5$]U]"Y]RPI=.9X93
MO\(_T[^D\A\-BF$8TJ@91V,1\0)GY DEO!"< D[[[VD!JMZ4HF=/=$T=?WV_
MZI^"DL+FQ8W1)\?.#'Y3KGJ":?JNHJS[_'<N_ZBD^\@"<Z@5,&OS-X7>4&=]
M4,S; *93#-.B_?%Q<ES#LPG" K[MA.TC+8Z!6\I!.2;)9)&45!4];G040X5#
MQ'.MN4R;F13NTIF!9Z]&KT<1K\$APXW)D\0[[-H?V>O'O'&17?0=8M@U\A86
MI,A9)2&U<&/<I50[DWB.JWR(1BU.[\*P &%X=YFBNX3&A:L3MXY.S#85/QJY
MM+AH4/"ABGV?H$9L5\:*E 7;0+DV,4Q.<.$SWO9?+S-IR*0GH1L\BDJ#;23*
MI]SB1PU![AD2:0FB 4O*]V_T4<16NUUK/W$QS)NL7(=G.&K'@<ZR![5O!A9*
MO1M;B4:$70F^H+1(80 @GH0LP<)N@C(4#];AEMH04BVN$LGMOH74$QA(0@V5
M=@B".ZQ;/L4QVB+87:;1O0H^[) X^^Z[.KO#*#--ID^VE">4.F#VVT:K$-O=
M"-MPOASRK98 'CJ97.?717DI4 +(W:[I-MA$@ARNFWF3OE& X)H<_O%LQ"X^
M*OW^K&:D9?&+YUY>[3$OH40L7.)+0QOR^4<_T77P-I)5.B;XLQ80PY@NJIT
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M(S'4?KNM1^$W04E@!K]$F"K:"^UA.( Q#'J2#9U9 NYGSM&W5/T(+>PL;X_
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M<SML;)O?[#VTI&=K'FUXV([;3&5]4__WD<\!V#M("<3()-4=!$Q?GUC8&O%
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M-J WF3#&A2>FZ('NG*![OA"FZTEG.UB<MUO_'7>CEMU'VE_2-]E-[\\$2<_
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M0:W9B9V#IM]^4DRB;6]S2[[UQEM=KC[N+;MPJ[3DU/NYP@DU:)1'WXDK(\I
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M#)@N8;1=#89;=(#N3N26DHWH7ML"?Y._1#L+_#J\HJ(,OG:&5[YEJ)[<_3)
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M7H5F7QZT2(^-X%BX//D]^5NX_Q"! *[@1%2V5)M3:[^1.$:"2KPG*)IH>UO
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MS#_AG\5BE*Q\7@Q.6')"PD?'3K#G-5Z<>N1(FNNME)BLE1%UOH S?2Y@I<"
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MT)W6W$Z2IMW':ECR-[IEL1XCJ:^#4VAWM,/2JHG7E(^]+?QC7"^T.I3Q_N$
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MYX_?<GJVM!JW#MG.!69OBTBBW4=>&#%D0Y/_&/ISEET-BY_N1B4QCQ.\03D
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M'AKIY_5?-Z1&_KKSR#5<[6J^YS\ROVLH\QSXFB<YR3-*PJ\3'^^S11Y$K4*
M9&SVL# VR8D&Z/T,#G]0XA7/))B-FX,G;C+HO;/S89ON_]G0.$Z]+V\[9609
M(%(3'ZD:% ?PT.0A(^3 $@:&1 V.F9*:D3HAEG>+7?([RT:&<\>%O,"TT7F<
M8YF+K<KYR7'!T^8[WB:VRRTNC]G;Q<X\<Y;]7O@.L;, 0:1Y?@1OSW!(S1+C
MEHIAG%VW5-4;%O_7F1.T."D^&;"56-88E0LF1I\X0D/8#>38-8V9O?_DL_U:
M_MB:@SU^FA];/-7]LX0.^PP(:[A1&,@J)# (7: <S2&J3G>#S]#^EWQ#16<1
M.HU<R3X6M-J $IZ^O$E@LO-KHN*?O)5(MKAJVTAN;ZV[WQ]&^NLZLSK=&8T&
M>V1,%6.#PRR?OQ&(>T.>&MO7;5XJM9Y2S][_@^:2\\\T9R9#([%4:_AR;YBO
M9LB[QU_'-\LPUW<JM%XQP&83MHNWUX&/.,:P^#$C<",_JE-V>\@L=>X$-&4E
MK/HI+31_^*1="<NCV5RE4?\!\1FEXV= VM@T^TK-ZW.WW&4PU+M_%Q)Q :N0
MC29K@H&&QN#6\76<>$I@B5X_GT$!% N8T=J-6N&E(9C\GZ!/Z_*#A:>T(R58
MMV\K:3D?G?.GU;WF:-,])3?'K+K!',!)F(A\2-IL>QAGREN%;)MZ8)0$1P3#
ME. P,,HSF^_=MR"^6(1-G.!\9Q0.#V-)3(]L?: @/DP[,ZK4@YDV9MA[PPD]
M[-GQW8(K<Y/'7RBXL5A9T3]3[8V:BJY]C!D=Q-;-T9.6 J/E9C.Y>RVCD7Y]
M:_#'4 $_>#"\9^QK!8@V7P0R\UQ/F=B\#'L6L17E''EG%7+M!R5+H_G!U\FT
M?=HB0S2%]NGY]I M#S!,:&QM5].")IJD)#X$R+<^Z$I<(FV=DBJ'^/\/Q2P6
MMG7D8SV<WMS>"8S'2(I##TYYN8X=UUD<N+O^S^CZ[]PW+;A0;M?6_ZUOH,D4
M.2'BQ#H?@]A 1K!T7?^\A41#)-_,4M/=UTM3!JJ9RRQ$HJ' OOIN41!,OG2Q
MPWR[0V34AQ%?=&"S55%YV>;$R#_B(YBU2AB#W@"!YQ!+D^>PM=$/6E(8.%NH
M+HV^*8[O.&")V2&V'_2:8"X7PPLB>&NH%W0)/#'V;^GI7%AFR E)SU[3DKDR
M7[.Y\^V3_23^\GTU3&#T FM4>:41ULQ(5HGY+9:IN:43CVDF;!:7'/CS"7:W
MZO'/[PM7MU_F\XQ:&U<A5I+0)82R>(_+Q,!GY) \\W^[/;GF3ZN1&A;M%*(:
MEL&72Z#=-,FC.15C9ZFET*;?C,H3+G=,*9-+4=%>QMZ'=LMC^>O\OQQ9X1S,
MEE'XVVJ/G6FK<ABW"ZXR7AP!Y87%:[S<ZD0<>BE,>/R7X]:27,+> -^GOXP1
MR#-52TM,.5E7'(^D[._:&6?WQR+8N@I^L;W,G-/6:CZLPN20FB[*S=9S-E-F
M7.)@T)Q$Z83PR0^3)U5KXI*(VAQRU_82Z*].#MON:9MP0U'[\[/*2K.%CPST
M0^@L6>2XK1$!O(>;\'4VZVX8=-&7F3[0B;<+UI4''_%AC[,M 7P6-\NI.8V^
MAP9"!6CNS3I_@7:#,6?N! 8JA@)FCS!<L@86XRUP3X\*XW;SDFWFD4I!3ZO.
M59U"JWM<"MY_6AZ"3R,T\244G6_.HCW@)CIS9P(A*'K#F>[L#9D(K@:;4GZE
MN^KA_)ES!]S@U@*DO>0]W&KRTA3<5)),TS),Y3LQR@41L014\E$F_E#/[47O
MJKH>,L5%8U*J$>_1FT_]C$JSJJH]\.1SJC7QQC>/5JF-V$KR+FPAB:T@-1'O
M%V >6F"46-+OV6J@-K_8&YF0-C"F_8DJ:*V)TF@QEJBWCHLS9U8AD!,K@0DT
M@R)?[[68SG;,5[0T&RHS\!]'RN%41<%BU1^V1AP85'RJ.P^08S)B;;['<A&;
MAT%1XW(Q>3K9*&D5TDWSX-MA/&@#)C17TZ7YF.*@C!9JR@>-H?>B#5TRCL;-
M&5[(#[U]T!O]\'7B&P,TS5SQ89J$V"0^LG8_Z"+;S7)SL>'9&@.[?LQ9@":+
M1"54_+&@)5\M%*4CQ.EB;WY 51_5$6,I'XLN;L]%>*Q%'6$7\=8!?#M<QC[9
M7L^%I7W2Y.G6+TQS\6[2/N7D@J/'M"&<1X*)QB'$[8E^N-H,20U_8#*M2JHE
M@,;.T2YR@VR1@-#W4(N?4CV8S#<06$XDGM4T'Q^XOV:_?T#'TO3S# IR[LQM
M3;W4&Z^A:$Z1U(0E9>L:@<5%4R$!@*C9OP6IN$14&A$[ -'LQQ.@*S=+U;D?
MKAK,<HGG"62"W>GZF:TDX"6\?'MWR'S&H-^5>7.=$/^45$ITI[1_8 !E3$":
M)F <OLZ+J=-ET99KC(1>0W:'V=><6X ](<A7P?SP-(&KQO_\'7IX^SC-@[/<
M8CZ\6[OKF9&+Y#5--?R/.$#@4_T5CPCZ1"V=\0SBSEV&;7EY\/V^_?]=A<]N
M@(2N&*]"-D\\K@,93)U5R+A=WM8[1R7%Q#4E/DQN784DD93@=LZ"(EMCD0W8
M.M_*] "+!($^@JTY'\#X1BNX*K7?(MF?ZX52Q1VC"=;[=$1P$RA'Q*YJ&2[Q
M>3'>?5!Q%&+^PJ.JMQY_CR+?_UV%Q#/>#10]T)M'@-ZDJK8CDI>V\JVAJQ!-
M^?>X=_?NR<6NX]S@^.O[ZY7B_*-$1\1G:@=S!DH(_HH:3/C!*J"::&LI]Q2W
M5^3'B!=?A,73]4&N;00O%UVGL_7(;T_;"P%1Z(2>BP4L'S^4U?>J]- 38X."
M0$]):8AT5U %5IM'9H80&I;'M@G.E_)>=]..<]F;[>(3</LS^ML>TPP^M!6/
MHC428$0&93'K:+/60N9=V;=2F#4J1([5-/AU3"%&.-Y= #BT8+8%C^D*8,V*
M,@YKK6)[//>T0*_!:F6^AN/$2,C(+G\?U./CXY>L3$URUIUPJJ]GM-!*0PI&
M3@5XOBD=J6"0RLH&HJ*_&40=7=/N#2(';G:!R%5L &C$TK7%"$DR3OD]]FAC
MK655PCM4E\@>Y9$<XG]+L\\I\BXW\F9-30;J1LWG;)2N8\&+_SA7/4Q%)W!N
MDHIYO#SN7(RKY)5X6^!5J1K=NS@7E+P?L:1Y<T;W-65O<]WE\ZOP6L/HETO0
MHZ)#TPRJI+K5#N$FR<&;@C>P6\WCM39H>,EF%8-:HK52;LA6_?&A7^OO14I_
MZ=)1C-H0MB7L7]DXI3>@%[,X%'))\WJ"VN!/-H68+-:P;B EWFWA+2BTZV'M
MQ29H,BH^TG039-^H^E7'+5\_A*Z_?"_XT2UR_>LNXQB^PUPZ)O"FMO RL+[@
M->9V"9OB_N1-YA?G3[LP"OML9^\4*^T^<69+RO"KX\5KX%5F.>QH8MGU<YF;
M7^JO/3SBXQF,A-&.1-XBWQ['WLQ@$38YJ?SG9YBV=Q3N_JPB9-\9T*D-O@ZD
M\A2-1!KG@=Q:<J*MO.@"5L1C,.LCW, /G*/D6+A^M^W=(J;9,ZE9]V^!<\%3
M1 4E9&\^.G(V;?@RD)W_:0R59I,]GFP#95ESR&TN6KB[8#N/$>=G WS/XD*)
M;*@M#'!I[35J0>L<N8^0F8(K](=%.S6/J?<.7^PL>!J?=(VP4?[IQNP/9IF\
M@7[624G:@8,AAX?1,U-A4O^C$GFNQMSF]]B7/(VD6XB;(2%+R,1L$X(6MH0Q
MEX-E17^GC&W_##RVR@J0B^\9/M];>G\OOZJ\]RK,ORI*T?#/GI;^5P<'<W'J
MW:L0%/EA]K9Z()VY"AF28W9?"<;OZL>YE03K[I(4S.%.D]'9^@.L0T7!+'II
M$3;8*:FX[DD<:T-K<\K8AA2+K=^[_C#B2A 8Q$8LIIFE0VY.5N>U'0<=."YR
MN,- 63P?L7YX2MC:P1R3ZY[HNR8X_Z%P=+J+3X0BO;%E?R^F3'_U7HN(PB &
M)>19^5?Z!*"[(/Q:+9AH(JF) \%&[K_%PQ:DC6 $SR6F=$V:]M(.F2"!8BH"
M/&?KH.*U"FEFN2BM0IK:8TY=":SN.V78PP-;@JX9'AL^^R<J-TT:S,8W8=S*
M4B14%KL'_HK(EYLKT(_5$)X#3O['.K#;:$[Q79K+_N3L:VNH>F%6X<V=,_H<
M2*Z22RR^DZ#&N!6%?%)K27\A,@;W23O#&#O.5!_$X;M#?'/3VW1W1<7N9\2.
MD%\>P/:.2WB%A)=8&56A=PU8PUV%L KX#BGT7:A[(*&)L%T#62\XGU<J/@N$
M5W*'%?T;\7MMK)L.X^3SKV ?"X7:ID[<>N9I,K3\BLF#9,H]G\T=MY,::#("
M>6%R']T2E&]B;[9%&[X *D_VWB<IHSV666V/2Z6:Q=,,3:FIE_A8M<#"X[>M
M T_';X*9Y@>3-O?B[ BW;YGG)O($O,2[A_*,_Y2:6QK22L8DY-M54R,8E"4E
MTM7)?=BQ#E7L\< <D=Z+V$'3$9V2_J@EQ"]V/5V%E(_%W(7%A<G/E)K]9;*I
MI_#;^]+87KV9#@+=A C"!Q#/&E\X)C!+Z<J;8?E\#Z'*:^S_\B[VVN\'$[-_
M!= 6+V%R$7KM5SSBJ4* %9T]P;0ASMT>E&KUWV?/.4G0S!6C)+&E61PKO#H'
M]%MPI64VUMH7R+ FTV:O?GKFW? BI8OWO52$&@8_M(5G*X*9:Z@#>DB5DA J
M05KQ\;9(KODFGS'LA)LW='/PV*:>6<N(?G.*Q)H9GC;(5EX49=;5P-S[S.(>
MIC^?5VGA>.E4S_5R9A0CVE ?L2Y^($D@QYV(L;7FY>2+3P.*;]OYSE#N?/E[
M%-RDQN;U7]3S(3#"VVK9Z_V52"+!ZEUOI,;%G,0=/.K@[VC+GK&ZY-ODRF!I
M.KP4/, E$6&5\Z]YOMJ<A5D]8+ A Y$D=HWDFX:>ZV$$^1[V]$4O#PQ4N?HR
MU:2:KTWYZFLY"F -1X;_:-FN?&J=]DUP4. J[/@,#,8-7OR?[J)4<.?! /U#
M1FT2K7,C+3R)C1/VQD7N!3?#-RIZN_0=QF7WH?V%G@.(H/JC/&)+EJLP8:WC
M1AV:(N[YG.24;AF\"-P!^@XH!OSJQH@1!%0)O.*E4;R[L3/^J[3IL+:'=^9_
M!@=H)^@/)>_$@5QCDBQXSYB@C@UV=&F!QAT/1Z\$RDE5Y@X;*YDEK+M29&*C
MDI>BEL%:%B<X&@]Y(A>ZT1*?OT*P5W33N$5;^I4![2[S[/D)8QDQIWLKS":N
MR&!]+#JUGOM>W]H@:[+M3BMUHH4TK+(R-MU[49**U_'U=-J1ECXPB*08Q1=4
MIQ[I[<@86-'$&0*O4JV" N.X9_;,EKCY8$"'IK&-('V072[YW?5D%U5 :"B-
MN BT)5*1.\3G 7LJ(%QH>A"?=+,_;!6B,70Z'_P$IO0VDW[&JC8]Z*36_^[\
M%DMQ]G>*:Q%_Y4NM\9T,BL8SG+_H0I!45<"(YX.NHA/B,WUXO>ER<LN,MN(E
M'0=N:R;7!71?"7^T?CKX?K(Q;V.?ZA VFS7&8\F?L377'FEJ_WCAT*0VX]':
M%1?@.X,)JJ6(ZQ)S!X%5_LXWJDPDM:1V:\R'Z23_/%0H&,]DR;Y\YSW%,F04
M33XPRWP7S"I]=7$DV&8'M.#<V.4_E4NP370=7"0(XQ$T0$8#H3P^WC2,H;F9
M1TMWEQ3R!SC=BY&6I4[-J5A,4]4#4OS-:F B;KA9BUY4DO^BH"1\%8*A97 3
M9&2:;"]&K\&;:B5 :%WW3NP"2,E\9X\6IQ".L3.BA0&E$+:"$8Z46H':BOJ:
M^+0O:2>->MC7]'3%+I*V3=I0;"Y/83%A1Z/:3X4H,,[C-/H1J&09'KR>MY!(
M4EM$JF(C/( VH@)>]F4K? ,2.HG?U4O@JI"XLW"8:/WQ0N^R3VL(E.8=?(C-
M'FLHESSO^A6;K.O=,^/1PUKR,/3POLUB^&43S-K(1JV(86?FIE7(#<;Z\H3$
M,ZK"V!_?6WWDW%<AB9>??SFS]8F<IAQ#5Y.'2$16G<1W(^7G<R6O<=MTBS68
MYHG*7E=(Q!7;!,NW&=6/,L:Y90BN^I;4X_H7C5ZY/7M_8?KGR<N$JPC0TP\R
M #]HU%+G:6N4ASO>9XL06$7:N@GTFOQVM;4PE,T*26JWQ#;W&4K!J=Z@NR>G
M^S;ET:[RQTH5)E8OYN]KD:IA+8IH)BLNLPRG*[!U%1^C@ A^'09*:-K[$8N?
M05IKK$*4Z*I#OBVY93D&K5F*HJE#['\>UC_JL\JTIL.4FF>WC5Q^,#86[IRW
MLC3<>46MC$4MF9O!I!>,13T%:T2WWOH+G0 S1YBYV$(WX6UV#''+\W6:1XQL
M/3IAFM+M8C^0'?EQFK2-<!VV#FWMU1__V,)Q/D]24+)8"17OQ!]8,QZE$!LG
MY-9C+'Q>(,\Q]X59B'Y<M/V1&[VW%08J:<X%6ZM%-U",2FI:7M[:J!B2!5',
MVF>LL1B.BSHVOLF8QU!%'0"__[N%.\!?A>A,57>#%\FY@-V(G"OI3$_I<[3-
M?:=M0_>F<?(M8YJ2*AR*;ZZ"]?85#,927>(S3@\VEKHRM08^"#0:.R7%?)?U
MX$R3UO@'OJG56-]/G\F!]-I;?CM)%X"E;QH'6BSS*+).537:IOJ_M<M6(:8O
M\5[61>>%X6,L0L.\F)A+5P,QPE?@D1)PHGE,5?*"DLE0QCGVF9!IGF782F%A
M4HM-:0_*.'0K,<]K;)JNG8:VT[!/_#/.=NJ]0'%_4=><XN_FMKQ.X"\<VGA,
MDDI3T+@C(SVH?:IQ@PCKP687DI^$F2L3&D_BW%>T6_BCJMSO;^02Q08%,TF!
M/$(<7%]@T%_V@J-XL,U#L(UVTJ.B-SXVC/WT(CHC+>>:Y;<'&5/+5:JGUWM_
M:"!5".DVP-7JATY\<WD*_=+F[3.LLVG1[PXTU#5TW'CT4VFS_HT\T-A@,K6Z
MT.!&JI1,%A_YUPCH\:KG8@-RP"6+A2%,PV 0>SM^S\B(!0.VZ!3^>-Y%941[
M4L&%>WU.)W?HV?=WQ<2WL2.*43<(6H1;0_Z._I+7>%TGM8E;*@ZBTV D_[^L
MG\I?LS6"?NU\F&O?H_C]P/,=Y-;:_O2GML?YI!TC0>XVU8GBC7PH5-H/VV)[
M/(R#3,A6 O+)W"XE[ >>WXL2E%?))?2#W]4O[L*) 5&ZI!)O+U\JM4-?9;?#
MT8FT ;H\#CVX"KE)&*IL8FTMX!!DQ*= ;4%,\RI$!6?GGP^*3@$K23"%(-U]
MZ=S[?A;4GJ4YI[.9EP2&!8:O\[&##CT+YI0SWFZU==67$\X=,&;MK8O.6NC/
M%<JPI9985V$\*.':135(]TN>BQ'7"F96TN.7H,K3NALEA??9<F"F:R;3YMF#
M,B*Z$(RW!W*]7E6EI0.-X::&KW_8'+-Z$F 9RX/%DBB(I 6<<1BO:^C23'-X
MMK+@ON[A\A^6A.$MO+_,6F+"K*6\'=*QSW)44VQ[M?_EJ;[9D#!3K:\7JFRB
M1] FX;\TW/\M-Y&VKD)",!NF_\[8:+00%,%@0A)"&\9CM$8E:[1(U00AHW1R
M*:C=4*ZCYU N4*]&!6(XBC)7>FFGN75U\IMS4J_,F8091Z%4N/PR.@L)[M%(
M-+.-1A?A/'OIL*!*\;%!2[*<U>NUD/&=7,+\<$4,%SSLIFSL-YO+/<F-=N(I
MZ"J\>?_2)5%J9_5'J)%Q6!WEKQ?.NCU%Z9VLZG5A=/V%U@SS->;RE-P0%82'
MS/V[+3 LV$GS71><-L" A-^)2V%?6#D_%0N/_3%GR? *YEZ' J%M!Z9)%:3'
MMV8#>D*>+-\5$[IO!KF*O,\'8 QP)B6BM[NO[F^=:WGHZN<L.HMH6TO79R5O
M<-[<TCW8E^Z@'9<A ]*"X5K@:\Z<=M-?W*6!I5%S>[ \#ZQSI@FVQ?@%)0$3
MH@>##EDAEM[WZ_LW#  &WW:[BV:$\0)RC!E\,RC<+O;@UGA2.K8I*T8X7>^0
M4//>: 2/KF\V-WV6[7E!)W>+!ZK.<^]9V.$Z1'I@U<-( *2*;LUMP+?C965T
M$-P<RKG8=E8S3)Z@PEFZ%:AYF/R?;000Q4<VPQ)>BJ^L=:9_J8VYIL]/[^&1
MD2 "M?Y[;+Y5SK7<:2W=9%YY[E3&!JOX5CBL>\E;<O2$8'>!,"5SP^^07^ZG
M=I$JXU,0P<3M.'NPL01+XD6GQ]%U81K850AS11-,C^1(SK;R!D^#!:4HZ8Y:
M,"1GTL,+7I.+:N.*E4^&%6(SHIKK^KV8%ZC4FOC.KK<S&5UBM>,AM -"Q [0
MZJ]'KW2?5]!R>AI)B;99_26"B92=SC!(!#.]>G35T.WTO5.'L#&>C(JX%75@
M=#3V=6YX[EC<8T/6W:H5Z:,;"U%S[ZN2IQC_POJ2FF$51"(-I9&4ERD\[A;3
MRHHM7?J5#9-0R*:E]Y>K! JZ>_M#;&T_!9FB<U%2?8%OKM9"4HFIZNS8KKX<
MQ2(]XD%E8>LC@9SP!R DYDVF$2J(L65SB]'PX?.)"VZ2#XO))R]]3NQ12S!@
MT#.;Z"&_>TNNY7^^1G>4K]&\;LPE;6+A1V"*XC7?- /4:SC)\.\#,*V9*EVC
M/OPN4'T5<FP-%BD4EX0*E-]V.C5CCCK<,</6GH9O$VS0N(.A5%/NKV5+;M7G
MI_@$_-<U<<V/!PAG*."RP(K9#(>'N%RIJ:L5R!9PM>VN#Y[[7*OHG\\F7)U>
MKHT>'MKUXFI=RIE?&?TY*LU$]?[[5>@;HZ/";F-\ILKPW9C4L^YG1^MGHH7E
MB]:/PD@PM)]J-W7M\,U= $+B/.?-$DD1)=T3TVSUP+G)=^3T#B7TA2M>S$*3
MM.[&.S=3Q@P4#]FKS8Z<G9VE*AZ]2$U<=JFOJ*]\>^AX&.KNQD[:U[+NRM.V
M9H(S.=VO7H6O>_7LE_+IBP[C$<\(G)P'R":D*LX>2$^0:H#5+0X-],/UP/=L
M'*0V;(X%^A\',$S?T,N"K?7JY,*I(C5!,$&YY-;.3Q6IJ((XRR">[!&?(.]5
M2.-9NJ9A$7=TMXB[W)P,]SWA&L@KFC>EJ+NL0YOR$>HXVWB'@1SBE:A2+QY2
M'6OMVMO9%E]*]0ZZFO%]Q3-MP/W^TJB#$ 6^+D).9\1V$?'K1KN*?4:[(D.+
MI!V#UBNQ;!:_9^Y7R E0?#>6?#N/\H-RV&S^W$7Y#WF>C)<JS!VH"1+ S-Z-
M26#R%L<.@?)A_"!*>H\)YC;CIGS[[.)_\Y:^&*\^#"53#AR_6MD?ENS4[$7]
M3B[$"]%#9DGE#J>#(1,61'"OP\.P:"?FRA[PM."%970HMS2]Y8C%C*]LAV=]
MMQC!,]5##N*T==_5.B^-K%]N\0J,+RNH3I1/>.F2QFOJ<HU"%^<F9I80&AVD
MNE9O\OVN3-9F/P^#*HAM!<\\5AHH?1;#<WHM=(M>L=&:5ZD]@+_#6-9[,V\*
M5B'<G2^=#[$F/3H5RW(TLP9DEY)(0_X\G=^CL9+!%$+@$,:"H0#;.#5H+#*=
M5NI <1&&3C> 11>YML(NH8_57Y>-U,H T^L9;E5_GB2_[3#_*6K)N%7U\@J8
M+@RI?NG22Y$8-I!G<^XT=3CW4+<O)<E[GW[)KRRM./Z1N?6]U\841_)NIX0Q
M3S5+PY?4%0OIA(30,/)?_FL2X8_MQP7IEEA@FNWB^1YT$]@O7,@.["NQ0!^F
M';#K['H8'V/9]?0 [EC4YZ6V<DHOK,E/>\!2)M>G2^/I;JP>-<3TQN<$8AG(
M%Z8)[C.VW>^2%=M4 *?@ZMU2I2""CMC[(S@^X5XU0'/AK*7.L6#U 3\8&)H[
M-;>]3J!F9:6AZM-9:%LE'$RW\4T:/NH7IQS$KH FX>Q"(@-SP)="=$\I>6$I
M^;Q0VWS(*DAE?!72K!76^J)TY*L&G_R-E?TZ(BQ_U/Z _,^1KEMZ5P+N']7=
M+?F/;HBMNP2DE?,P,'S7RE@Q1P\FWI61DB,R]>N,Y.;&?]G/S!V!I?"<O(,R
M!H9ZNJ^PBH>;>#K=11M3[U5UL@$G9-W2GG\$+ENL9MY2._%4+)>'37<$MC@*
MS'U EV*4KB[PR\^\M@]G";!YP=@7[$L,@7ZW8PY(;LZPR##Q\BO*GWSAW7ZM
M3%+GG-:7=.87/HFW,-<A\&A:.P*:+Y>X#H< QJ@%8^)#50)DPW!TM.WI O0J
M1,TRRJJ\1E#U,^%3O&-FHU9 WW(E5L^#Z"!P>;H[KGMQKYE__7&_WO_M^-=H
MU57K7PA;4,1F"D-^+)4Z>%<*#,8+\O'MR^KIJ3,L7+7K4'"1!5+G];M::K;P
M#]9KN/U4]G3DX\B*.@V0)'02,)(M.]'-8R8"PNP<#Z8$$AV(QP:62CV$[O6T
M/JJ.EIZR,SRJ!F_[YHE,^Q-550<]DXL?SGQ)S*GWJG;"NQ/&#3YD1E]R^M6+
M 8(BFJ$)X83MJQ .":$.-T"M9+\H]009PD P\^,J!!7DSLK*)H:%C\D.ONMS
M;^WU?*SHU:,=)8K*=$45-E>[D^6/[WWQ\AOF.*@,(+DZ@XW0&-<N8+#AKY-U
M$S$^M?T0B'9$W8BTU?MPE)(RD)L6'M*L^V10FT<:8O+)3^G*V (.E=AF_L1O
M&X!)P,F3Q?"4+B:ITF[IB8UA CFHNE8_QI'BDL(;V&RZLS[UBD;'GV\?\_I2
M9T==8N#*TA[I%B ^UE;GFN@D[D!M.9 >MXA0&/(9D7[W*JSYO*9#=;YFK"BB
M.?]KFS#A.L71<$^Q9NB3TS+Z:JYGNQC_=)OPFW&Z$!+HKKN1$P[07TA,$6?_
MR0C3!NF:../J;MQ>#B(6)F^&-\16M\#5 'I2&)^\V25?;/=CE^!T_R^]9MW=
M@[?N3[[+&.N=56VN=<OZ$ZSB,S*L0>RXXSWI IY@!,-6S%<A6U8A@AU+1"G!
MK0W+YGBTLA/@.G2 2,2;B)4%F#A+PUCRHFF$\$9?F*+5U%Q!RCC+TW0<_//5
ML/IS@F$<]NO9U#T!=Y]=_CS:*C(B1Z&B(H<[%6<ET$=28_Q:+I%9 _FM$A)]
MEQ,0PVF&'P8[>5#%H> 563+Z&NH=%G-,=U^/^!#?^2;;S1EN_[E&L?C*"'CR
M;.WENH&T/V.\.\!)VYD5AD:C2\R]/??!0(Z]0LZC_WUA[<S.N%_*TD3\)9NK
M?#D9&0A.!)MM%YC9F84HVH:*CA+\?9QS?3KR2$-VK,:"'[LJ8D[]YV7=IKK%
M,>]D_D^'ZX+WU%K/AL)CQ_U2L^4DA4H;D43VEF.0/3+"NP-R7V4A?#[[F*Q<
MGG*BQT(T@AG R!)7&1Y C0YC_ASM!1PXX"HDXQH'_D$:$*+W;$V"X70I^P?H
MLO8O"5O,R'1+!P23L/'L<UR(X,:%!%OK/*LO/<R3^YYZ]7_ZZ'35__&0;V[H
M&*%IF^@BH9L NH'2[P_:R-5MY3Z$)W0%? ]>*;/EY17IC_^M3(*;"6[G\43]
M).&]_F/5]7T<RF,T=@ONP8;ACT.M7Y'FGZMWJF:8""L!%PX((<;I;M17?@;Z
MGS$JW/",M>/MO4-LF)?8F2*I8%3=%H=RLJ!")_"X4;-D_0+?JI0;K<;R]AG"
MDKD,9M?3!X&/%Z%:D]/^%:3+GV-=_8C-8SNHM4Z_!BW0(=9GD93IJFS,3#G@
M,7?*'L$EB(UAR[<?-$H0W.C!%#2APOP9S0'ZH@Q;++S;QU?7DJ:14))7M[W.
M++*WH?>#2<UI!\XS=-*PI=3Z!V.*_I?BCFPSHV[WKWNN>=GR9-(]>EJMV$3N
M/4X18#<BD]A;<#*"?<P&AH)EIKDFUM]Y@-=',=^4ET^,,/V&K8V&#WI^BG&O
M>F0V@-4:OA1K'O)&P;7HQ96W"ZR3'':3M\LCI-IM4ZDV5E?S.O!:]*$@[O[#
MZ:] Q2=$@,ZF'?>--)=__L!OP_^0JO=8S,DP25ITQ: 'NB]0&^->YZ*0E?9Y
M_@6H :OVWXVH !1&\'M7]6/]?Y<._X#8.>K_QO[E#,[MY2_(@4F-M>ESBL#7
M@8[F!S=6?/L[JV=_?\Q\>NUM3N!31\%DSAU5F7 '??Y.Y>@;HCIR#69YW4QM
M1*/+$\5K-^> MH:\C)Y^HMC5QM&V$78I))2$7^K",KG+#1B9*3F_0;P6>/;H
MIOG9DNHK6"U%KYDYK>0^=_>/)I3.@_-3?-3XZ32D/G.]JL7<CJ#OAW8"1G/'
M,0K[R7/K@)*GUU,,_$5'IKF)K8_4WN(>R.CO^0[1G(3PLL<V20H=Y:0:JY"F
M=QUO86"@G;^>W@9">]0.W<^39S1W7&[W,T61HQG(+]"DM8D</?B'P**S^!R'
MAJX=IX&+FG!M%V#^*R3;1G VR*:JO$AL5N-[7<TZ^R#PS2;ZW:#!#UR'?IHT
M!'[XTLK7,'BR:/O,*@1*0,'BZ7L$1@EX1?'^7BIR$RAR!TQ_SS_B="0I0GW2
MG7OO^UXL6YPQ5T.Y9_PN'H)7L-SS,+AGW<'A&K)&2A6[;P>1RLD)-$NS4NMX
ML8/H\.0?=&UK#D_'MP01$'T"6CU36Z*55550<DZ#/R;[@2!;^;$M(D(I!?VH
MT%?3-^,2NMM6$T#PB<Q.V:XFJ1Q8#3@UT75ZQ>SRR16CV8ZB*T/'>K_\==Z9
M8D[4P_4ZZ;6;_-'(<+]^X\6G_;,9KQ?"4UTJS\\QP V4X:395<@782CPO[3Q
MM6.M@F\//B=PM_<</AJO)]%X;/<@!GE4VD&0@ZN-X31_Y->"=SF9"81J,3[V
M-S#V:J[*7 =,U9>1J$(V 3'RG_>(FE/1O0Z/"<'*1)#!WB)X?F85$A<Z< 3R
MB_C/W"<P_T'*""<%QF4W0ED.W+98$[%!GK0;IK!P:W:!6K?XF29Y&W;\*+VF
M%(GVV-1D3CR;Z9\MO?)AYWI_M]%>M5?NZ5[%Z/%2Z6G=O2)_D-3$J%Q*?Y0#
MP!K)CVWBRGEH3 )\-X,F&'^#R0M*6X$VD66MDRWK#[)\K7XZ&SVE.6Y %P2A
M#J"Q9;YEMZ]G;_(S$F 2&3"Q*;=K&]:&W8!<AY>;IFO3 >LF%U60Z#QH>JM4
MC/R()FE1LYR8<!@P$7.ULEI=P\-/I7]V-V9;ULEO=S>+;"]ZNVQ.0U!PD2([
ML2^8LS9F)&6XOGBCH(R4.YVV,O FD(<<NO?7O?I3?\B]771JR@R_\FF!FZ%U
MP+^ I__E>^H9H#-J):FXP*CBR14).Y$1J+E$ACJ7^4P^>$NJ>-U>UW/;UM&R
MY7N-Y;,"?I'5GVD/:P_K0P?];_QMMX!?3KF2ZEQLM@H9EW683;9^A+<&H;XU
M@@4F],D 3$6\C?=&;"R0:<J& ?JU;N28I=:>Q='KBENX8>78,/E7O=2C:/*<
MMWQ',EQ@9!][_<XT/4G YPPV>2,5L,ZE_Q,;V9>\MJ;/^D'B0[E%V'Q!V:M4
M^S/4[^UJW'K9R._[$.MQZ\%.@'EZS;Q"N0LMYH_HT!^=HYWBC)LQH@/3[NI_
MD;YT4>;P6AP8$&46I?Q85J6EOCK#VZJ7K.8I2&]DL%Q;,_"9!4C\#[9"R(=>
MG".W2Z4)P'^W*3XZ"F(\JOKGKETS:GN_P=4YN/RKPS>]F\-=L@^%1/ 20N[1
M%_ :Q^=E.URSYU"7_BJD+6?"5C3@7@,4<\H>Y05K=2XS81N23,V^SERD!=GJ
M%?B>KQJX4-_<:HQ&:]XV>M[Z3&6[?^2-6_I!WTYD!TJ5R*PD:=*:BC#$#L[^
MJQ!2OR5-672A?(,8#[J]^$$:ZKBB#[M X$8#T6UZ1FKK@,$G>*LUC'&8,X Q
MRX$(3AZQR=FCU6L5PDS6<V-T\WJDNYED,(J;G2382W,K";(I?5U:FOZ$>L;R
M/[%= #I4D9ZW;?; 2*>>Z5?O%)+0 2P"*H4I F(S SH#DX7K8KU"Y.9874]P
M=JN033=.NF4V"'4M!=!'NP8MG?TN6F7=O1M5#-Y>M$RN+\L*#?B/GSH6)!Q!
M4((9%63B4I=:L-1JP#90=#38SVQP<<97STN@,S%;$ HG?T15'6*->GGY^;4+
M?G8>/&[W^FWB[-A=D6FM;?*. ^]G0(0P%"P'5B&N BLJA_B4 <'M+<9V7(SV
M;O%*BQ69C*$&,Z0?]"CDL*(1;W&$HYE.?F3@OL[?DO>H@J'Q#CV*O:G%(LMI
MX6[UK^:7'G]#)!/UY$;SF-^R^.V@]G/$N&?//80JFC1)T/JWT$R2HZNUB9S$
M^RI=XN%;G%#2;6+WM"NJ3*]+N<FZE1R#Y*S3GT>^I$R3GY^YOG4=V5%WBZ3P
M89MX+=_%^OV4O%UZ>& 5$C\[J%J(4Y+D6D)A((:G1J(@F!9]XD-KG82]W=--
M"#2]P.I$\;Q+5>:G45UB\Q?F61LR])TVV5_YVF6X9' <K3DOQR$V*5P5'P#V
MRJ4ZQ"X^2X6G_=?.>2OA.=H.CB/FW$3'L%!A,-AI].CV*B20%%L;_^@V71TD
M-%_$#OQUI%2%P'B()%QD*'?-"9#>U2DM'Y*."4QL;N>$^!?;#^<(]% L7*->
MW4DD@;01W^>)$!#HV];]A YU>?(%"-WOZ"<"\]EE053KO>"#8#7/HP&AXECL
MB?*ZG;_"GJT,*[)<BHLM3B:<JJRQ1NK<.-B8B_87>9^W_U+9=RA,MCUE.KVS
M4T.]I.85N<[9J\-AD+#3MD#H/"#6$]2N0GC+\71]L3KHQ&%KXZP%+U%=G&@]
MIE-H1"X6>3G] ERMGZIS?9X5 O-#*J-J[_3-+IDK^-#?EG\56N]OC+S93:QH
M6^.+!@A^.Q;ZC/"-G*M+\G:15E=OX^K*2;+A9F)+FQFL' _90-A4G4!UM"0K
MP6-$YM/J*FB;DM@.9+!*BX#?6?.?9L#>\:,F?K?HEPK^$]5U<\BL)X1./.C1
MAOF?8\/.P^V(/1G=!OWV>U=R7Q*LY+*D73 YN.HHEL!3K@4QG 26>3))?><S
M1APE;4C-;T^6BJ7AX!,WR#[_+38>]+6Q)8*VAU8AZFT-]8>[XNZG0,GJ))<!
MFE/#*F3#&E+!U@_-I'EAYJ# ]W'3B!:Z@2":Z;.63PN#R#B7PJJ\"(QN%W&G
M-M8@_,Q!ZU=ZD?H*X20@%M^'6$1*MZT=XI$9F%A:B++;#K.2]DD-P4 @YG_+
M ZG$>((B7M$77&A8UMJ,@6+_-F:DD/+!"I%?VA4*0A;K<J&7\C.G'^?+*Y[T
M[[U?CKH;BBEP-D8&[R]1[_GTATAD:-(L@2B>7*,+=!C?N1:-R\1'^7F 6W6B
MV6]@65C*%2"3:&MD?]05C.!VD*!3@UHAI*<T'?6JL;U]9;:GNCV#M7Q+T@;\
MG!M#87T,948@-'$5HG$_4T>.%]%,?*1[I)O2>4DQU+D7=UIT(#A=.*#56>&D
M4U4<5"H0>+$O/#XR?N;V^QMIEFG'2JS?CK>)3' GDSQ_X$YD'Y&0XFJX4<.=
M+DQ6CB3=4K:VQ]+NQ)Z<^KZ2(;J=FO,)WN%=BM@O@YNZ2UXX[B!9JBVH]94*
M_AHCN15><Z6]BY-+/3ZW1X6_*_Z\7H48A[-#H!^N@P8 H4,3].=<NG,2!MI;
MI)S15R55!+X-.V)4I)_JDHCO9LO253W%*N C.S(3*7/<XL'I(D=_X'NJ_DE)
M9?YZ-^G738?M[FW%&FEVW;15%5UX" $E0.&ZG_CO#QI@Z6+SVE_B"  C?"58
M?D)E; I&4JR9QMZF]UA'T4E)F*$NMT/-+T:/WU>X[D(\;:U1[?8O#J+_QWY?
M=NE*LJ]!]"QYQG](8TT*9+6'N<1'OE]D2 I3^I##;JL0HA]D>\.$S):M$,M_
M?#XFD:X ,.8NA@!8L1JX2X-9!]/"V8$A9=-:6:]+R2D!@U(#[*%FOX.].)</
M4S.8K>EK$DZ,FZ,<*D ;3IV;7U8=:;N[X<[VS+EK'!+KR=W_?X6)ZXZ8'5DB
M#DK-!Z"_#C?\>NSR&HP7>H$)/+9J.Q^AAF4+L0*YQ+P?9;2#TIW]C "GXE&W
M1?F?O^,6SD:UTX]:)*-L-324#JK67,T.NIAV1,<K9.'THB.;7F9^?CAB%6)Q
ME#(8A?D-+L,5!7)S!P+6QF);02]^J_2;EVYZ+@JANH2,5P53>Z0SEUS RZL0
M95.IKM^4KE4O)0IYT!G#\RN(V QL3'ORT:"VMCJ./Z<O@RR"*=*U<+:"B(<X
M#1Y&5:P"P&)IIWFP+4%: W7<G)S)P7CF2FMQOM=8L-=>6LH/@RYAP*]>SW]?
M95<A1K;E1P"=4*%^/\YI%;)9<Y#J,D1T@YO1NI>@JI;LV?2C="J!.^%YWZEC
M2H-?04O7\OEJ9O)+H73;%XT=WXMW"NOUN*0YV+NI-"VK9$$7US K'Q4>+M2*
M?LV8Y9>4J%>%EYM8"05[0?"*@\*9\G<F9]QDC-2^/I!T .[PQSTXZYP@K^BR
ME^^GM&ZFYPWI.006_/0\'8)":Y_Y8W'G^-8O'T[JU;T^=;$FH=7Q?2$6?4X0
MEA)?P,*2FUD.3VDG%<[79E-SL7Y(A:G!OYIY0;^I/_(%&D\#>E^8LK9[&0U@
MGJ7:_TU0.KOKV3N'U:'_ U!+ P04    " #A@VY:M2+F^R)[   '?@  #P
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M&!+:KSN07Y\SRGQ3/N+<43>-:ZTNDDP%#'T8327%?:/))>==D*<5SA!8E+(
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MO[7/LEAR<7:>WEC 6N)XA0-Q4CS%D?8VDCF_L7K;?@'1<>J7MR*P8MT76!J
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MUH+I)J+<QV$+Z/0:A6WE,\ ]LM$IG="@%<:^1\+G;@43R:P;C8K@PK_RF*5
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MP3U1<'(LI!=[& 4FE9VDJS[DS33YX O.U-M4.+;:;W*ZM:E]HA4NNAADAW_
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M:7D""-&!H%!$0&A,:%A0\#_.,P<@W^4\Z,E?Y]%*#"B'7V3?W!NP_W$$4;>
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MX8-<L@FJ,JSPK%3^IWRL=]@@_]@GJOS.CI;%UI=XE? &U>VW*\X%5*";&I%
MBW!\B/[LLNC&,>K(+RQH09V+!GSS<5C'F&_1N7 S(/[<YU/4O:R;U97??-$I
MFWT%O3O*F5A8B%?26F<[ZK;,VN664;P#=#/2]G*[U/)V(V)QD>HM\!UE89((
M:G2]0R.]@@,L',I2CE%B]C%F5^0(X&P]86E>YEV47LJDSRXK6M678L)#WN;:
M+?[0FQ@NM,W?/M^BFI/A6N_K\E^^;VY2;EYRC5W_^_MX?4_*HM/]%OR,Y=9V
MR9?0\:QG"_;%M\J9E?*7["[]H&K;:93_.A&; +Z\*Z+=OCO[?P!02P,$%
M  @ X8-N6LB6YLC3H@$ J]4! !4   !T;W1A;&-A<F5U;6)R96QL82YJ<&?L
MO E4$^NW+U@(BDQ&D$% B,BH#!%E4$"B(D1$X  " D)49!8B,D4(B8+,DXC
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MHQEZHN(N@=;Q&P1AWT2;AF>OIE+"O#0&XV23C];>JV8,Y@ <X)*O.A,D>ZU
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M?1V;D/$>M2,!1L9:!_P'IG\@PDI;JP'^53]3PEGR'L),&G)')?X(H>V$>]T
MP7ME@@.\1M9+=9+$<1I0+FA-FVJ8B72<1;7W!;5O:156FI1YRVL.!4=:=&13
M'.,U*F3\O$;64ZS.BC[^$]#J*\Y&SA*YU(ZYAWP14F0$<0G\?2B!8?D#*<4!
M9O)EOJ4$T9.Z\G7J0/^TNW@%Z"9:W$\2KS9L)$+M=4$8#ZV='VS1I:7HGQG9
MD$TYL=QRZJE/3LK7"HIQI?*K/_G77DB[*%P4*Q'FX><?F"W8-!JK>QI-\MTM
ME(<\-:XK=/5]U+<.U C)O[> 9\#:SU_#=.">G/ZRK=G,$?4M(VXV#D&P34$P
M;'&) 7/#'1K '\;ZT4CQ',"#'!O>WV;"'],J.8??3<>TEZ=!**41(U/&R4]S
M>@XY7W]V'ZQ-&"/4S<&,T[5(@5C/T(9[=4%D$/-]Z19]%4YIGB$M!ABYE%@P
MC/Q$F9?I6@4S$6D"T-5OMS;N@OKQ1N>SD6!Z?S$RWL;1^7E=RVZ5)PKR3G%>
M]_ND 788J?:5W7GO8;NAC1/:WQR\[6R'5S3D/6PE<I2;8R73[>,=K@F+WQ/@
MHY4>/13U_O2=D6H 5F8DR'[(1/M3IRD],RL]Z$EN)\RF(VG9R7A>=M]T+28-
MZ=E_FRB$YX&"J-^CC=RKL$FV=)$R,GMX+#7!2SC'->7.P$R#_IXN;7;_2-77
M$8&$ZYC6*%8J^3+Z8Q@5SA27W52&4JAR%C1"%RP*7J_Z&A./%$=Z$K?C+$ .
M<,?H=(YJ<BULA^L4=K*# \AJULD=F_PA(_]PIB^(@6IWE-%,^E'O=J(F<6CK
M!\.JQO7<%]Y?4@M#KSC IAMQ]D,>O:/-^  KIT61UK\/YPJF]$TGKB-W8?4[
MG$N2ZBR6]$UK<F8[#ZR='-K_\M6K :OD\4"_9AOW)*LL'_F+YXK*MN@SL D,
M6V"-/KM9RRK1P<22^<DS14AYHX,SE:929R%_L+R=+!C,<IOL^8G7I7\F=3[4
MY0 2E%R$(&1-K4_>PB?X@$/M?KER$0ZQEN9:8K03QRK0CZ=K"(OJ,["/CFPA
M&,A_"G(*HHO!MN$\6,G&FDRG89PBW:/V%OX SF@4T:)*DU-U M$)6K5J3X8#
MEFO+*BHIJ/@/8^-!;O/??MJD?M \_6-^)._0O7(KVYAS02GG@I)\_WBD5"QM
M6GFA4"G'[\*09ZV??<=8<7R!;;#?0+E5G4SMEUG;3&<[NQ);,>?N&X_<U=[Z
M%F4X%X)"F]Q^$Y7$]&<]7W\EV^ZF-KR. " ATY=I-B]!Q[O*(T4OQG7GI*Z%
M5Y$CR_J4OW* C^;WYG-\1)TN&K9\U=+:O(2B"^?#Z'<-]N'5<MN-U>/:5^]J
M8_,Q(GZ!V  ;1;[D+I+YU:;S42@%Q8/8MD\QYZN[(GLY %\+)#%#HEBP!?<P
MCN'V0VE>F&=8*32=75D!$<\TRU;B3)Y"BAWX _0.;.CRB7<>U>.JX**,9^'N
MR]>&EP,R'LVPRACAW);IP@&N7V,5(/T0M_$R=-6[S..,X_/AY"[B1,=9"*;*
MS2!^ZYD4_==-NMTU,]M;[[B8)=G7T U1_BIU'N44W]VH(O2K%Q-.Q75%@7+5
MV/<.QBW5Q]YM:$M\NY]Y+L5MT"'9UMQ,VU5Q9_>AI>+0#RW#>N]K*CS.=^AV
M._2X'RHU"UEX>_QFV\UVT>0+5ZQ$T2(&@<E[_$L_UW,  372#\--9VYT3^'?
MPNOXVU\)G1]H%>,.^0Q.@$80Q>W%2/L0Z^"=GV&OW<0@V5NS<SH6+O,ZE8IM
MPPE&=@2J;)^5S^.!E>+A+$O,^?HLB\@ E:QAVUP:$<!WPY]C.M(@U;!VXF3<
M9BD];&E/&<2% "EX;:;R$'LO3C6WG==ZU,B?FB8&Y:+ IXT>(<_F-K-SC&,>
MS['%1D+0XJ=*_9KN-GW=6";Z/T5=2W_K%_3^UG?:"6.UXOPSL3N+<GQ<W1/W
MNM_RS$(IV!Y[DN)LKA2J8"/J]##>GN^>^E8=9,^=PP/0Z6#T;8(P6PWBW6RB
MHSH1J4B!RI;(600E@II?"+*'-R-9Q!8GFHC\K!WX,TJ7(.2G1Z)9BRLGWT/Y
MD'S5U8M2;GD%8@+=Y=903_%R[!YC_F;H%@?8KLO*9<LLV#GY9D_QL6KQ\I#L
MA<:&4UIYI9^Q:-KGK.A;07Q!_#"O",WD#)-]!6D9ARH>'G\,B\&W$3;[%U>>
MHPG>O\A>[ \,N?[-N/SP4YL(]24W DM[M:5_TU?@:I: 4BRV.,H[[_<6)M8S
M\8RRV_&KZ0YGOYCQ'3$H/\BW6X2 RG8()=#W')C(M4!7<X .QPG2A'$_;"*0
M PAV\_,N,HQ(&\1COY!C. X0D4-(0[K#)F2YM)L\\XQ0[[B$FD6DN,F )8M4
M1CBVIMVQ510ZZD<]N(SSH))$_0ZSB!U-_D^;BT2+%K9*$G19!D.(W:TU_D7>
M34;Z]_N*72_5VIGQ,*?&0V =L 1]^"X2'C$)\7?OP:D-MUCS1X7 $FRP$1<R
M7H^Y:3?56IZ>;&]P4W-Q+VRC"2Q>2UV54[&H>W5_8LCC;G=;^98O 5+.9HHU
M6+,>$SQ),6'DW62_2%,"AA0KPZ6V$^23SSG 7:U!8PD?*;98=B>_ S>1RE.,
M;QF="BMSY:L="O8[<<A[/3MJ]81;I)6 )F*!"%F#S9N>$+?J\3UG5;&EV!_S
M%:#B4IP*I,J=.N,QYL%0XO;KZ\'TZ4YK,:QZAPPJ=EU3UJIQ/-K'&%XSVM*<
MXNXX4N5D69Q%#/3SV-_<6*_$^ROB";G8CP0I$A;;:+#)B!ENS*V%<?80J1C?
M"Z\E+(;12)1L:D_\LB>X3A1MD5:)?CK?8'*6KM3@)D<>WH@\0#EAV^O8V!!W
MOG[4HR$_4B[$]&6M3%Z_-.,8=\D=([O#*2WL 8(\TFN:G_V1+,$!O(@3W\^
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M+Q+_,8R;6K[(2<9,_Y(U0X'=C][9<H5Q;$$27DM:7 +'N=5I!U.1/C1,.S$
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M!;C' M FP2'_]4&G>A[$  [UC%&W@'2,@CV[URQ5EED E2>@'F8Q2!UJA2P
M,>2QT9 _ECH@)-F#W,>T9W<DIP_9]H"W+W:&;D]G+YINS?1!-[$ A4CZ.NB_
MK_:;*";'\OPJ/2R689DAQQ9V15G!+$"6.I ]7ZV![^N+P8.H_^'FY_]+I%@
MU;Z?R"$PXRGJORZE?]G3ZLB??XDA,*5[TI$#P[U:R%Z1V']C-K9W:@2T;/ _
MO;1"XB?_O9ZNITS>9?(C1-FPF8;,6OR-6T8SKQO\UV44GO]/?8:%,\5=6 #>
M^1[PTHI[#G@AF? 7.:*[L+Z"^O^33<A_9?._LKJJPPY>^X%V*Q)XE=UG@?/H
M/R'*IN@M?3)[N.9M/=TVV&/?\#^]!%'KVOB0 _?HS]BFT;'@OVZ0A<9][)X'
M"Y R5(?9M=T$D4T>B>Q+[QD/'MQ 'H:L+7:G,V7=C<>BJ#VUNQ1%".$;NTY
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MM$_@>G2'SLS9%@M3Y)(8Y<EQ,\TI1A//#&Z-W6^ :N">.!OA3J>QTZW>1X.
MMU@ IM36>7;AB*.8EQO8'.-U&+85--QF\)E!$F);XV/4( EA#%Z-/B*8-X*-
MP\W$'QY#J+YI%)UM_QV8YM]B^=T?6=UBTC>6P@(,+1LP;LH1F+%OV%VL9,0&
M2-']Y94V#X;9(I"=,VYV5_ \ &4<W&4PPT/!17"4^=\$I1L&"[)__Z'M%OU*
M$#H.<44J"<FV,Y,"8WS^MYU[:'H#0EJ3O>*Y#9YP\1:$4^7K_[83]-]VQ!;I
M97M8.OI;%#,N'$1_[P+^2UIHV]K+^+(-RLR7&$8\PJ6_W@^'\RXR%4 )!E(@
MF@)-O?[&]=WER3=,D;[90O"O//HG?QCS.TT=\8,KM^U3<#[S/#^8O14V*9.$
M*NZEK(8.U?>R0\#T9[-;;EXD3;7C+W(8U;>Y@=E6?+T"OJ;_+VI(>8Z=+?J_
MLR*C8REOAI@N;5)];1IS8M6,/31U&GV,'4E%WMT^AG&+20?XQ>H,XQ>;4QW+
M1/;_1M(?E[%GD_E/**9G ?D_S?Q&6OS]WP4PQ&9\RU3+_\2F$PB:F+[\'0F
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M66:1W28T1)E4?EDW&?!%%/+UWU1<^+?;@B\W3JC2E0]JRY#]'C8L0$?.+@L
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MI)[*_\M!]MII[.I78-.HF)0!Y%*S(PM [LY@ 3) WU';JVSP_@B,8]M%\[$
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M^F774*R@]^?/4O]OEM]3%6^P<3@4KD\UP*,FQ\BXE+:+]!0"'L$]Z*L=Q%6
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M2FMG'F" G<'*]W85R-I[Z2[$P;E,XYA%DOV#94KQH]%S*1$OOMF<JY&*_]J
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M]I?%Y#<+V/2UA;%I@<$-WII3>R&=.O9^IB[?-;;DLS,G#/>G[9.??WG@@6Y
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MFV]NPBW&45\JK?WM?.4=-$CO!CKZ%$@NLK?+@7QQM7<)6PL)!U<//H!=-H[
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M:FV)HR07:K"GQB/WG =N<"ZM=/$< Z/ =*Y2C*!EFM"(S#.0QHJ*FW.N<FR
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M-SL%F6_>0P69VA\U+:-]!8[1CH7;Q<])]QNE'U>5.ND*JF (ED\1D&<807/
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M^.H-5+S'?R8(=_A*1XB\A&74-C?1_ MD3](  ;F]4>*KPU]PJY60_^>T-=G
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M2,/N%LT9NU1M68=E_VS,QL14:AF[D6YJZQK48G3"VQ,E0T-"&IX=A>SN&,)
M;MI DL&8<KCYV#\PNPF:!+2I)RM[P>996*6_5^.Q?'2P$Z<R&6(P_OA748S]
MA)#Q26/'U(,%_4]Z(GH0,3/'='7(E6[S;K/NU>:P!UUK-X;*?TOJ!WWU;AW.
ME+YL9CSG6F$.C4_.Z3&J>/UCU7BV.VNR#UK<UY(IKH!=:<ZZ@;7^2G[6='[:
MJO3\:&'W3-0KVURT?+>ZEHY=3$^??+?NI=IC6V_KF$8K,?E*ZW6)HL\C?Y&Y
MK8GY:&]W=U^95$-%Z=JK&F>CK:!T0$<*(854DP)*;MZ*AJGC$D<2H'6*Q9FK
MO$[G)W(WC826N"&9IM&G3^F;)];84AQ7M@GDL+ !D^$G'"[F)?)=NQ>:IWMU
M5/NAIU\&/M8/ZN%=O,Y1R/RT8#*0(JXE$C]4YWC?1>*A8F5'+K51B==Z--+2
M>SS)4<]>V2?<_807RK9N252?$HU*E#!&<2Z+NJU>66F1FQWY+A70B=[)Z2P3
M(<1$N0F<(2Q&-^_/?[1/A/.@UTY(+\C&_H3#KBG:8^:F.@>4X6^ S:';ZDIJ
M2O>5L.G]!)P.3!:'/N'>]Z>J.=B0.W'/X]27N+0>$E.2B#66Z[DC$F@#UH_K
M G*L/(E]P)>=^G[RW@)<YQBI.5]N#2D^OFPLT!O!P*VNQW5?Z( S;0*$0:FR
M+1S91K[OH:_KJHEY)NA&N0%3PE"=QIBI4?J>UO3EI*_BAD9&Z35RZ>X26"5R
MT_][-Y?04H_SE?I1%>&+<UNM0TW1!R\^R^I:$PXZRL-98RH@&T56X^@&V>N2
MT^".MD]VZP[2.:A0CWIV(]E%!9%?)RO_[_NUYIPO1(IWMEU'\O3+"?VSEEY4
MDH[+PKF?%QVO+Q8MY95U$\WV+J:YMGFCK%,2.V2,,HS22^4O01?32TT#7V=(
MS9+<3:LTU.N_:]:O2H5<V>7M,D],2_ F*5'NDE\%!> 2/A<(DH?Q6YVJ1'NH
MXAJ"P_?M E1_C,LZ>KIKSQ ^1H8O<MWU^C!F/RPQ</7N67V5$.%$$+=*"MN&
ML])DAQ3,<%++K5"?\!,N,P$+P2?LLGM]ZV\SY$I#?_>IW6P--A5]H_7L^=/B
MT+=/+-KKUI5MOFD)7:Y?Y+ZXX&*>ZU!HV#Q>.8\Z<Q0<92.IF>J\O9#SUJ]N
M;S+7@VB>&'2_5RKD$SFN-+FG5$:?]48R6]M;E+=U5V^>.F[S\W"D=Z=YNN6U
MK$(P,0B/'3KH0 81=?&RO4AO[VI;^TTE\E+/.&3>EIQM)TX4RVC_D5WLJ.N-
MYUW-] N<T^ 2=/8637M@'//,3;<+<IF1?Y\-$26(I\!\E].GKG(=MT)UL?:[
MT5E635;NMBIBH_[;4?M2U9LU3N?-K!;.GLK1<N<(!Y_?7C7>;/9W5^'4A'=E
MU64GKII+/5A=?9MD:!1@<M/4_&U]SF.[WL>H<:S,N()MMEQ@::SMMA':R,K;
MHM#:<NL%Q)O)/$K*TF-%=-TH3S.P[2I/=?)2KXY\_5C.G7HB),XOV&#:CV)^
MK-+QN>)V"29NAT,,'3MO&K_S>![2>(MMR?9&GC['*;<6*X#59SH@5DA[4H0H
MHUF0K.52KKMB/*AMT*L (><XM*5@6Z/S5[?E*6!!['X">M&V1=XS!'6A9<<Q
M,^+>S%H+GQ0-';.V1N((;4EO:4_7:$DO5)'^O?3>-$\#V9JA;@S5J\QT>R?Q
M0BRY5PJ6G%5G6[$I-&RY99:AHZ?C;&# 'EN">V(#OFR?X]C@43JW10>P=8B0
MZ_3&VM3PZ%@A=:):3/"5A"(OH:M$#TR55[9B'W<JSUA]GO&#ED_CD4]I:PJ>
M_G_?PSQK!F=6;@ISTB1]YC3)+ZS(640FRV_<!BG=@X4^.LI$,5)BAW#\YA1)
M]GSPYRI3!\[1HO::VK:4^Y<N<+36-33;GIDBM#Y5MJP4NBPA%M4M9EI2,6X4
M)5H^F;:6<4_.X4Y):262W[#=X?&478>?I$UNW?U>\YYOR*@>(]L%XTP1%B.A
MX4RASR$.J#NYV@/!%1H6D=HS6%G68T3\$D=UL#I,(8@HCS_;%UVU[TW1\,=M
M4#SQAO426MHA8FU-FA<U[V:G>1.]FMAFYPQUTC.W7*3GYK4RM[_=-?>53Z #
MN.J_6_N],"67$H7!TW+*QOXLX"I;\DH/*;N>)E ;J^N..VJ0#C>_V1]LK'XK
M?MHP-+MK\8I(]/=+KFV_XB'FG7-FQQ_Y,Y\\"2!Q5(F;E9OT!]J;!B8Z[L(]
M.;[/Z<GL:E@@S3R.LLL-S2T_UI"KPWR!Y\<_E _.[=TV0VITO4TPRA57[\XP
M1/[D6N*"2]EMV6/B9'6N4^XT$+ECE5='#W;@\[T=8J\=II4C(VX^&FM(LI<U
M\3_05I$MBO\NX_]$O,%6))DS5C^^J+V@9S?.'HXN)$=TXX63*T-V+V[<\!+B
MG]JF..$9&4;W'&>%EO7<]9CRSK*^%R7>7,1_B)T?O??F9^\D;P@P5WXA[)L=
M:%W';#?[AV67RB^8'Y9+O% Q.6D=?W#((=Q:^*O4[SQM9F@\P>ZC:Z[T("?3
MP;8)+B[//3;_FOS<2<.JLT*5U,"DF)U4LJGWO>U2<A*1.=RF1W.?IDTLF5M/
MJ!^LXL9F3W1(33^:;#,KAORM]RL5+VNX.[?G,+9[MKVY=?Q H[I*[LREN,(
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M #3,*D"CVEW*L,+\ZUYEN*.S_WM-F[2BFIDY0N&(RAV.B>R ;5N\Q$NIBDL
MQDM=(,QF!QF)^6%%&*$F'*O1<JI01!7:"J)UZ9_IG:S_^0$)4<1$28)NT;!'
M0%K)6LS7<!',#TA7 8DW![&1>(K"\)I.AS8G7/@%TB%YYUQ=]8QWG>Q2I"TV
M\+?T2]IYPI'Y'?V5-8'DH'C*'P\O).P6D"N#GZB#VAEKGKKUBPX@RSQ+<2E#
M=.IVZ(17G,EB(U_N"&'I)P"C^[=H!GL4S)^-3;KK5&8YQ SDEK8VBFHQT(;
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M+AMZ]AQ>XY$BJ-7/?HQ8!"'H H]N0%@0L_?_]"M QDHN$6R67I4345^$__[
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M3@M%!S!Y0"AS_Z7I<5HHO#T,[N0]>,(#_?'I[ ] 2(_NA%MU0-\ZI"'?'A'
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MLOA^0I\=G+-ARHA13DL7]@ HW1+&G._\6>#@TAF!4HZ^4D>+'3V!ZY !R[7
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M/.]'<<&(7!@ZPRRDF&2@?:"O]!NSI<JP92N<Q<<DG&V<.&;=AC<^DSC-Y)C
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MA/-,$AZ%. JE5GO[M3?%Z8?)]-?OTZW-:WERNQ682CMR[Z_@U.(EC3&9%-I
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MD@$ _OICT-]-&S?%_LN2=:_)F><ND RXH_\!?H)"P8G",^!E@BX9D,*E2@;
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MF5NF!O?0XO[&8=W ZJPO2R#Z_'"[*LB] P1?*]36Q0$?I.'R7).8%9M"4*0
M\YP97!SMQ2VPKX3OZX ?J&GK)T7'):H\/;T#P;!@SC7V%7)<APUO^7"@+H30
MMT!'D6_AC#JK)31+$56WA\*%Z-B/%.9O_]E-KNY&-B=2U82S7'BTA&J;'*EY
M)12%1=!UBE1M>J< \_:NM^Y_.O=Y,%&RA=Y\ L^L*W[\K*RJJW9L><>2G\AH
M\E57$23%]U$+E!FL2D;ED%,M2"+H7"<UQ3'UE'BFFNPBYQ/E+J_#&M->%U33
MX_P._NU+^NWA.3K@F)Y/+U.W2._%J;K$A8[HW5A8G$SK4DY,K !;6'"?>/ZG
MSK8LD*X$O"T4R*<1)R7N5:CA120KB=6-Q6AI,]5)C\NP]-USHSR8-F4>:</O
M!;8V!?L:>B'O=XSJQ8C#7AIHRQ8T>&?XN<NMW<-9#:<5'H13S_W=(8RDV:X;
M8%Q#>F[50YCASKKWKUD-HN4J.W-])4EN-1_5MF\&,]*NBS<$/>26DBNFR$O^
M%/;=5Y-6\)F\*1)E:X_:)-ASU!066&H!0P*5EKFTJG59MRR["JTYO>E*((GW
M7=P;G/YS#^]:QVP_RB='T@#X+1OAX29AZ;!_DEPF8;HI.PNZ\FGO<QQ*-24/
M$+A70PY7#@LO1]JS@>:M9?5&MC^* :@OR&NO)X1.K3O0!VW-+=ERR+_#[U_B
M<)HF"=.ZQS1 1'#:RMUX.VN1 ;.'W<(-WK,"DT/D&V89\][.?Y Z4CE7(E*K
MHBO\YM7$)<[2.#8-"Y]+YXOU:K4:)CERB!HF@\#]ON\HOJW?HU60D6Z%!AB[
M2JLKZE_;&DC-BL;][LYNJ.C5E>@)!@;AZYU6E5BE0H5]WTZ4:"N5;TQT/%B:
M'&="@D:7?K/HR^D1.DDI;G@DE*__\C]+RS[+URMCTQ9EH=6+%[O<_0)X*H"9
M+<KDS'RK#1GPB4A4[KK)Q(BC[J@H9\,A$I*"RQMM3[.SA.D\28I.32,/%:8(
M]?BI%/4O@,B3[2>EM4P36?>IK7E:*I-*24K!F2+YQ?/=I/OGN'4B?S:I!P?B
MFYH$/DPQL-V*J5GJKX[[E#9;<6S#0/8F<$=O==<.Y4M6>_YX_%URM5RV6<WE
M;]&[&->=Y3L>Q1E50=2G!,YK=]HTQ4,%Z-IASG1&)Z6<;TA^F6\2W%-$N2S<
MVO%K(HE>MB9%2+C':P,#$$/7<1SK>[(9#>!@U+IB_B8Q_^G0U/*QW1=W78/V
M\6AWV$;\2LQ+8]07K-T9,E/%:C4),6#?*<#.CSM<TAR7#+PM)9FG,^>OA4)Y
M5UWM-(G5=5U7FP9S6<V8E7^\.!R%G:F&YRI\ZA.X1+[=E.6)N$)^V313>SP8
MJ)J7FNJW0ID0/LH"^2SUE"UF24\%$*"1=^O& I]E\1 [$UW [KZJNQ&[KF4=
MF1E/JD<T&5K"<HLZ,0KQ9W4^%XZ$#"]0CYKN7#R7.6V<A7>U:^;9B .5?;<N
M/C9ANM$FG/* ^V.L^A-2B._K:(#/+7M2L!CI*K-:^SLYM_AH:_'ZQ )DN#%)
M&O<<L*0T6YPB;E7IYIXQUKR:-D6]OX2#I9GUJ[B;(ZTF&I/]QK$ZS-$A-WP*
M\@KM*E#&G7J]:A/Y0H\-\QN<SG[\'U^,'B,.-<[%K^!/^)01%GCB4U>6)W'@
MRG&^R_$_&J!" T0#%%0/%?0"EXU3X5.<O#3 J]_W?D4>#;V0( H0GLXL8@1J
MCP(?$1*/P9.=F& )(AO!?681&AZSCH=R"O2]:I&C_/@?:2D)^:V@4S%/YC,S
MXH^S"XM#E$0;<<Q)/I$&./F$U5Q6/]MGK,Q,?_.SE?OX4\_:&']0@UW3J.F8
M3V@[Z_/;R[$9BVL_N7NZKBFN?;'F+_;]V*X(8/7K4A3R6BK? )PQ^6G4^GU>
ME-G]DT7W^/','[>K 6DTP.M[GK)E\QM'T\)E"[ZX+1I 6D)/2JJ/@*[90N7K
M0,\E9*P]:#S4ZAL[RV>NE5O&W:+N*@F-<585BK\YEGA6BSI &6N^1H/,K]XN
MOF-.5U7:M[9IAFGL)VCPQM9W/5[^#-@(;KJ!7DE]L.","\E+S9O1AQ=L^/K@
M@A'V'Y [TM!=*4%T9?6GJSJZ[N[WW;!U/7[L]HG6 9  J3..AH7NM1 U1SY>
M#[ P9/Y$V,42>J*93>$AWR$)'$:2PHF^'TN6X@E[CN,'.I/)LBC^>3]&=QU@
MXNW1V879K]_ )PX9CT#SU8_\W)%-"EPWJ<W26]RG7#")-LAB'*=Z*7F(H%:8
M+UE:2-!9N#T$+H#!+1D+UV;6LS@:U'C_+/K=CN)3VG/QP6O%,FELF',O\5\A
M(*(3:(!6-2KO#)FA%2<<':Q,7(WC.\*"N#/U==#-=22%R+0)9HZ>2P/L1YT2
M$+/$5OY;Y14Q!]P?[A^H6@A7ZC_T ]ZEB)VZD&NUR#^ '0N\Y#CSL>H>BI;/
M8<N-RA8GY#BRWJ>AWO*[B&5?CVS4!17WIQP=8^ZZCR-NV:@\O ]_!.*+[IST
MR#$Q"^0#+A:QN:'"DQ,.J]*J7B<G9>N>%BKWJ.I7MZW4?1#A&<R V.=A C?:
M'N6$:4\B]9@4Q.,#>STA6LKJ!W!P\/A"N2.6^=/\I?2E:ZT@WAY2^N)A/-*9
M1SK\GS5(M[J1%-:&>H25H@%P%BDYOUZXRN[CZZ'F_2WW1E'_UO^ME[(&G-[+
M28$@CY_MFC56DT1QRS4C+2*P<]#'Y6^FI60CR=1SV:+</F$2?.>/MR3#*[)N
MOO!74P3.1$$!.'V"1"%3<H0'*V134W3<7>]8Q@T/A2!JWR>3"J&41PX_R;Y/
MFL=X.-&CJ+6&,6%K92.HJ#F_3/4X*Z^UOE[\59%1_,N2#X*F]Z+?(7S[: ".
MX.L40Z)(3GZ@,O$J8E&5#0_L$(A0@C$3MI7;E3+7VA;"&VB F)RJX=BP8IBK
M<AG+NK_QK'R*+P_]M/5<EWST_A/2_0E3/83"]]4JY ];(G<(_6OO]3'8*]^:
M+"8[<6,7@M-XAZVS43'/V-_.IB5ZJ\3.-U@-J<!_R.U@C'COFJD(]KT9S[BC
M$8-%DDP=OWH,#&9H8/9*_;Z45,;?P1#MG6@'\8Q_Q <_SQ8<3<13-_2WADA2
M"X<A9)E2"#\]B6DB@E3:A[TYNV A0-\#78J1,!HU$'A#'/-EZW*W#RK=\!F>
M=^9<TZWY"JOI?!"%!/M_5>"!4;3(P\A-M9MGA?\PW%-D>">&6':@]<_%'B3
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MX,^RU!)=R]X^&FV;9U?L[J)\O!\;W-PL<;Q) WS.IP%Z]?]'W._4*#&5!C
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M;*2MI#1=>XAN^C+A30.0);DB@!\0TP]'#[W.6UT$1?QE]< C/>(_GK).Z+5
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M"R3K(HFC*!UQ"=+P U(O*S&5V3)\)7D$A3X*VX6V]'E)KO);A;XP%SX ,EK
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M=V+$HQ)X&;CX"\3I10-$G@\I+F[MCRO39&@@8YII.]/5=^J1\ZO JY;HTOH
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M6Z':.,W:FBB(^<O#SQ*- <CI._?C!$,=#$OY2SE:%^>\39)G)3H4A[+$.N7
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MM)=S7-?^0:ET"%)9N\NI%4Q4G7CMB]#P+KQ2Q5$DM; E/\\&!+/8Z6M+0VW
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M9--F)ORH%0'?DJ2^14.C[*L)?8045Q*_5F>B5X#WB%N+5L[&B/LM$%AF]7:
MZ*_"G=/#+[JK-(T3%=;AW(10UTZ:^"8UV.3.%X+^+"J\8YD9RH31V78P"V95
M5+<*:U.V,^*[!.I,Q8>[5E9R_=7]VL9#J^5!GP_0B]\&8E^+71='$C?DSQ8/
ML6[@#2LSN8A9_(XZI]!XA&K:VW3BZ#*;Y[.!7OI9?;)09FG\AIA8<6Q&ZBWQ
MWS93,]+W=;D>]^V\L=Q93]%\/?RW/]=/-Z,@++H:*6Q0?PS32<6Y/LKDZR2H
M=<Q-Z1J+[;9< 6Z$#DC*%XO:\PF_@ 92,<N6"_;*=D-$P5HN4E> ;\!(1/5F
M+_Q.-+H":H5Q2"ZJ2F7-SOI%29](:Y+-[>Z/PJDS77R_/W/NA ?($Y2Q-_\P
MR^/IVDO0U0WR>(@V)9O"_@+E0=#,40!\I6047\(BTN*&35J!][#1L'$/%<A#
M-;II5>XRUYCMVJ5Z?EM@93'TJKWE6KGEIMH0=: R>O @9/?GXM]TM84GS?67
MJ6Q9\BAH^;7P <ZM)E@O$LPDAR'8$3:)K7?N"Y("&DQ,1A7O*R-2[Y;+>:J*
MN(QVO=M8-%G2):)26"I]#A>;H>QJ2D_T.]'XSE#W!<7=+--WXE R_*#N+:G-
M4P@U]J1TL@M=>.)#)JI'&M.E>K;SK51MY%3R?[?D;\#GV(@OXZYYG[4>]15@
M"X5I^UK9]-^7/5^2\U\!$HPLK@#O3-PN)0&Y44++BM25OX%16F:_K6B2?93H
M<4Z$XX'M2V+E;W@DC6+O)P+\MM-AGTQ8RQMZCZY8[D1-7D1 ,;O'=T<_WX=O
M:;0EJ>EIGU6N+><C""F69/ YG?AKWAE/"FS#RUT!N.NC&:>N *7)WL;7E//S
M/M=>Y6(Q/KP$Q71?/-,Q\S#@(NXKB=)BCU>@!EZD"((2;A/!\1:"5ZY9-^QL
MMRDL]QERACOZT@[$F3E8U7>3L,-;[K>V5;3%[=[G(Z^@>2Z&I3OEQ9%$_XCN
M5:8_+M?H;+LSH;4X[\1DE*11@>]8?Y,]_-N4D"8/2_)RCQ)U=342J'"9-OQH
M$]L]JA=Y+5];-##!5J^;< ?A/*-!/.@OKGM2=1 7T< AQ3=Y];26S\HA!2AS
ML]^18&LWD;73TTABU;1Q$G!+ET^^<,\^M&/Z<\ES'OW<M<3H)MTL[L5"_6GC
MVASXQN@50-QS-PQ951C;:[T]42#5&BO7\SKY="W+;CQ9H XA;!;S(PFR8 R/
M)RI.;C149W0LWU+@*H7(&S[QK2<*3[ET+PY-E_+DKZ-T+/^%UCR1?\?RB4U%
MQ&7#G]OID82-ZB%)A+<5ZU:JC!)7R]1QY6W3/K$,AI3NO3+04MXCK: _[\MK
MZC(,M&6Y'>"B8.&]QZ4U _W *2L6Z.A?4B\T51@G9UTPN:[_29;9,ZQ][3A4
MH[//EJ)[,#T\NN750* /1C&P/TXS+V[CT+O&_-_-)_^,.X. 6,3+RP("G.'D
MH /)]@*UMY[U^2=8QLL4[[O^-=]/X@K@K)WG[&+[ Z6>Z,P:VPZ)SKNM[6+/
M7O[@UAVCL2S-<H8"N7YG'QZ(T(!5TX4I=WG]V%C4Y8) A44R%W-#MT6!4WZM
M&:0T<,?KZ-% !^=#W(\<WCQNUA^5MDZ_%IQ1/1FVKN?)Y^_2!F)MP??YW5P=
M1*H@GUXY8S0-<Z-.K.CQ8H:X\A^Q]BMN(:#3K(+9=K>"N5FS3M'"<DM-,FV1
M_=(B9W*(X^FE]IM&">W@(BD*%Q=ZL/U[V]HZ%?AW/0!L$$Y1$RG20H==?MDP
MZ7TW$=5_8<1).N/#T#S)T?&G:7VC9 :5B9CS[*DR;XMUO%/:%7FGY1>_3])2
M^.Y\R4YJ>GWG+S1>1%KN>#Z#@ZNK_MPQ0@IRDJJC*U0:&*S4/[Q]MBO#&IKO
M";*0G]?@2$F9_V,J]O":7;P:H&(1D&;@3HJO233_Z;N1%*^Q-@&&N,QMC^=$
M)%O(]NN*-" =:KR,@GZ! V>,JBWWCCU!P 'C3L1'HN)_EI8=YX\JT6\OB>+C
M9@[\&']A6@5.@.10I86B1Z?+KV0G7$\R3+GC,(JJ%LU1/5V]K&9S"I_--2XN
ML/&_X;3E2JQ_<_WW@JQ7OXGF3@6]+>8MBG1$[Y#?%CW]>;?5Y;JD@";9^V<\
M44.^J6/J";\-P_7KEJNH(A245ZUV.7Q7K1K"S)(/C\>*MIFR.51O[FG\_#0-
MIC-/9Z0@JQEOU([%W6(!"QWSH95_G\9UH+H_+S%!*[@#(6S\K@^FX/ ,L'U+
M[*MTGYJ9)OC7,P.+P:'"7KE(%:U/S_NB>M4S'7DL,_.D64J%%EUK]?52#NQ2
M4$B),:429G],B7[XU':/=_J/-53TV(]]E*:>?:7V5C'AZC_7E/H^!R3.Q =X
M,;0XCF<]1 ='$K&,<?OH/<%;@%$F,5N:AYJ98X?;4%S=A>"-/@49C(4N%?F<
MXNYA'Q0UP/&,;3YB#RFOMH'PP,Z88@L_*W&8+O]=8L>'>&&"-58YAE.@08[*
MX6Y!0W0=K'>;'C8TCQ'$;1^F:I=&:VL6R* *NELHQ)_80"ISD2NYG(^Q,_'_
ML5C%$OFPC\?LL$MI& NNCB8&8OBZQ99\IM(-+#$:#99^66@/]9'=KZP!K\F\
MJF0@6)N4]O3Z1<QN+5,3^> =_;CW,HQO4*:F8"4>W$E![&D*6H03(NM:?ES^
MZ"5!!L(3&GH(GA&B^<1F)J=35N;*'#W_9VAD=&U.6N&N:5H[*(MA(*;67[8G
MFXLI-HXK9;R U;7<\)>TTT3F]D!:XJ=BW=SF^+3TC;=>PB- ^=BI2BELG*'U
M\+;USP;I<&1MT;8N_7RG0;E^EJ!V1GI-GCY5JN1IY0=@7>&>S(4<7L,,"VR_
M D2QAG\.XL((;4F;[=W? C%6.[J5#-UW7]@.D)T^WE/1H3T_9/YNUE?3)T*<
MX*;1D5<HXFR9L<3I15^?U*>S;DOIF1,$ S3^;=(@<D9Z_M^)B'J0I$270X.?
MN)F*>7EMYDTV;3LEBQ8:WCN.^#3T1L&*,OTVC&;*]=A%X_58]OC3#"25LR]J
M.%[(8A:U7%0S638POQB1N/7P6Y[-)^^$6]2-3U&6Z<_>U,;;>,QSV]8#?'Z?
M*<R,Z?]&6^!, J3H<30QZY;TJRR3,;GI26F"F8TI&1O-P2 %8;575MSN4SM&
MF>Z'[K&D4\E;X\EFNH_CI;XWVJ7KRKO.&%BI3GRP?Z@K.1KC<8A5>L_NJ! /
M.D50HJK^Y,=D5L)NK@0>*W@<Q.O[<[!IVPP<_GH0LT83EWE\QKXZ/]T*49N8
M8WE\;^7F8V-%J ) '7 ;]C9S%?*C%G1R<KC42Y\RC3HF(BO_',>R\A-JMS(I
M'_MO5AK$?U<(=H>,2LVV\ZNL!;+[FI\[-O9RKQ972&K7^-S+>\!N=ZR<JG@>
M8-,*U*SAYE47W\F6W43 C_YT^V>FM2ZUNE0%7@&LQ+Z1.;_1X9GWK:LBMBI=
M 7)A]P0K8X\YY8Y<7YX.I0S#.2EUX,9*_XM#?MU@I;;1BM5)]/F?Q(,90'#8
M"BS3:\'GP&K*ZC-R[2UVY#+Z7(:845[ZKSDZI<5A<.K@"L Z$JI\4K2JAX<C
MAJX K_%>G'JDV.UI9(3YBRO D3F:YQS8E49@4";J!^(TB#V(S\CS*+PZTK9-
M<:G&4M&D?0LM=L=6@2JC$Q083&5U",'U_D\#[LNM:NPNE+@E-O?QJK][;\?8
MX<UT%;PR5Q-U%:O-6>*QK%> 0BS\G\C;<\1?XW$=JP_$:')BV:5R&H''7;TP
M:<&9A$34__C\=/_YYO?3"H?#*\"G6P!U=WD8,/)6I;+Y6TATTJ>N<YCLB*(_
M5X6\;X7K_E'2$8#^I]57QX20Y0^ZC^\14];40$-(9=$LWW\G%R-K9_9U]99Z
M)8O>%XO$X_>@]N*=II2XV'R0N;/\CV*?.W$(:Q?@-P\_?Z\'4?<>13ZWV5^[
MD7F'Q5$PJ@LV3ARTJE*/QA9JUN$T8D1J+KTP/IA>=]%O1MLC'0DU[V*5-20$
MU)&O?K9.);R(Y[6I<=I+;EF^0>R4]_WFA>.SPJD=TUCHH5UH@;N_'NTSUJ</
M#:96612^YHT;7X+FP5CN#'YFWP16H92CWWG^TEIP_.!^;_.3_]9$SM:?@I'R
M\GUBNMDY",:T7CD\\7I\VL5U"05V=(&OU'J9=+NX\<N0J0K9J_WVS(EG>:VD
MKR<K'K/)Y4X22TK[Q&33D9=_QIO_,7,]UU#2K5OON%5I/Y7HG@Y\K'8@WQ'*
M_T<H]O,F@=Q V&:>M'/@1V2+<9#ZB-6'T(N2 %MFYJV% *^D\6)^U)C?3BG2
M9;QV;YJ8)8JW?)0+ULH<!PFYE,3-FQE7KMM[?<DB8 DV_*/5DHF_.FDKAP<W
M0\T!0S/9 .F1YX7/2\QY_RC\F0U/V'B^GNS^BD:-E"VF.F;@&SDS>IY+G6-,
MPZ!\:>YK?E1@A$T->1/:M"/RK8D-S8@FPN[%_773WR2W9]JM:D;V.)0^\J9A
M_="PBM2E)[C:T$5B+<9,1D^Y?>F>6=K/J=H]N0_\Z6<18N.KS[!=0RD_HWH-
MIUZSO-]-U14>D>Q8FV6="Q,_G,ACL*=OW-;5CQ$8+V"<VM1W%8]=2W8MX&,N
MY)KL/]QU\(C-^=#1>U:[1A2UUTWF8I*OA6CR7J8(>B2OY3&NI0ESR=4RA5SH
M0WO1O/5H,0Z"PB21_2\2&"0_(A;>XK=R:3/2>08#-'Y==R4H0H-4*?:SRK9]
M1:ZER.-94^;CTBG2)^7VQ?-?KW/E,16>?V8W, \V!*QQBQ13HC;9IB;<Q+4U
M^WE<4PG-*6ER$=4N!)4/^8"M?S%! J<%6K3X4PT-V*I 8Y?*)O3 E7A?-DA1
MI4-+W:1M]"4IC ?":$F!I7-J4C[G*<B*C%JBWAW,#W/P\^,>DAI/3=7,2M<L
M2%CS<W1P)KZ!KWRW9*UIQM_!]6*6(]"AJS7XZ!4],J@1QC<V&TZ]O&,#27!)
M:-YC;%*K^S%4O7&AD%@MD\K:IO<9.B Y=#12,BR534>C.62==R=(6>0E#__T
MF?V3/.GAC?3DI+7/<F5M!U%0/KY^O(<#_:;53H.YFKP;@]Q3FT8T+UI>X-!
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MS+ *J[NY;/SK2PY0N$$Q\K'FD?<P_!F5TO*X\?_2>4R+O@*L'6W 3]_CC:\
MH#@I(I+N/+RS6 "O%PXAQE%1EROO9J+%COX!N^()#,\^7@'N*.)S-0%4] 1>
M[J0/)(1';31K258ER)KRCL*NWKX[>B&$>[^/;\,[1 H!OY,^2=S[\X?;!OD(
MN5*9J$E%H-=>[?I9S3UF#KUI8B'!P1/_&\8*S1(?/O$Q,K]U=*.]LE2![L(%
M'W;Q&T95C9_")J&-HX/>YD%A QK17?)+Y<6SD#246OYS8<HB89X/P3]DXUA
MFBWAPK1J/ G^OZ0L'R47%_?0GB:D>VZL!Y6 2[N?M GMN5"=L/5< >[C.V-:
M>,ZE-UN$TO2'N9+PX%3[KX0VYEU*.@ZF;W;L0I&=-D4&@^*R()-,*5@.*)5O
M[FV*%ETVIVYF\61RCEL/DKJ%8T51PL*QITT8N_FYIFCJ6RV0%@*"18(_3N:C
M0KL;OJS0U"GNZI&1RBK30ZX V#<CLP?:;<&*Q"=.,Q-<7[.#^;1QE 7O8MC
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M$U[_KVG<R!?'([2$6_B'*XC(Z LRV""\VN]W/#WTJ,, KX<1BVECW)9'1BC
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M;UO2%@F!;J[UZ,G#0P!?<Q-F4R,,A(#'+H$0T'$?AE>=K,8Z>),3 AI<3ZQ
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M"*CS'(" ;#:Q9V "37?]\=>%:Q(CX/A8/9'Y/O<_*B2[1/R9(!3Y#>B$V]1
M#\(?>;WKT6RW/)@/7?BQ^SR2"3/1AVD(+.M"&&YL"O%;]&_1_QM%2[&R(DZE
M.&CQ^!F3[K**R:/&O"P]V754_3O28!!XMK0JMM[7+=<M8(!/R$(1O3.9STC4
MR45/^JA2JI[SZ=:W(E+UX$]U>/2)E0C.SJ%<T4QM(@^*\;*8%*9""8S44FAP
M^2LS1O$+E?3EQ/CL=0LOS#:+_9/WLD*21W;>;WNC%$N0.\_*S9=YC!<4/*B&
M?#@)\OMF:^5B33IN6=OSJWO9&=D@%? Q!.DV >Z3Z07KF2[2*H)G%<2B>=04
M7.7E&49;CN GP7+>H0I:-/TN]1OOD&KGQ^X@<AE_K3"6?(DMD72)W4!A9^0\
M&6H-T^WJ7UV20JM)'+A:D7SL#S:%D X!BA#0H#Y4S#K4CX/M4)V!H>J+V(1!
M=V"WH-;\<*4$MOC8(QR39 H!//>W)"&@NR?B"XX>&G$ 7#7"%(3*>"^RD<S.
MGA(T'I=0K9GDK+X+W:Q,23,V2!V_'5O*3<?<I_+R8*?_<K>Z=(@3(_#$HL'"
M[\V:&XE6/M]7=!F;7630T8JFR+*/?.D#9[__>#R'8@6*28-AC?(MQVQJ%L%U
M?J\7G("U7['6?X)U[D]SL3.: 8J":7.P>=,L">+L..RO!OU[J$TQU';BA-B2
M)3M^ 0V;>= 7 CK=$^B1FN;P%%7P*$K35PA8'2H>P_QJ$-)@8HRE8AF13&-,
MCR8[G@?%/!\D 0$Y]?]-9CT#?QOUVZC_W*A[K =$Y]W$ZQ P" &7Z B?R;S:
MHRV$(%P#^ZC.L<AZ;_*5Y*#H%<VW-Y0C![3.?_;:'NP"+DD)S-QZ).>E@Z=V
MCC?@1&%S>*V:)R0IU*YB;^^]"7C5/(6'T]4FP=>$34A,'+)MY'W9API']TDI
MV5_NBM9*JML.)D[>&HRWM9VGMTLDU??YS5G0;OH1]# ?BKG+""'^4H@(_O+O
M19+I;!OJ\3B4,*K?FQ[%QQZ! #O%TO;3,2EM,IMLA9<:V8X:!5NBTQ!PI58I
M3J.V<^=ZB =V,$_&Z!,=Q3RYU,G:_QY%24R"I5Y$D2-O@K/X3Q#P(!G'[+&L
M!G\QR[E! !\ZGC@;B&"J.B.8GUA7&;847GI*PG8(F(V&:>YC-2%P=6/SPTK%
M?=C(?; 'NPWA=[NE48P7N6R1@!EVM!V";@!CTW$LM)FIRKL(*Z1OL*4!DI?H
M\.P=*@C*7Z@2-.N0U"*<LB(KR 0(4.X%&RY/%F\>:H:52M.'@).@980%:L)"
M:P\$/)<AL"6_6L/1,S:_W#KJ08AHP_U1%G-">4EV\DL%P<HF)WZHM>U"K_R2
M0]RS#Y(FC1,IY\T6V\W_W)D6KZ[BP18E3/@L;)WYL95S9T@"!*BHS/Y<A7]
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M7S<Y,#,U.2YH=&U02P$"% ,4    " #A@VY:C:W.^" (   -,   #0
M        @ $6(   97A?-SDP,S8P+FAT;5!+ 0(4 Q0    ( .&#;EHC8ML6
M% @  /HO   -              "  6$H  !E>%\W.3 S-C$N:'1M4$L! A0#
M%     @ X8-N6E-]69!K!0  )A0   T              ( !H#   &5X7S<Y
M,#,V,BYH=&U02P$"% ,4    " #A@VY:/87LLF %  ".$P  #0
M    @ $V-@  97A?-SDP,S8S+FAT;5!+ 0(4 Q0    ( .&#;EK;^L_9YG4
M !-^   )              "  <$[  !M87 P,2YJ<&=02P$"% ,4    " #A
M@VY:Q?J<5_><  #ZGP  #0              @ '.L0  ;G)X9W)A<&@Q+FIP
M9U!+ 0(4 Q0    ( .&#;EH'\-GZ1F   %1H   -              "  ?!.
M 0!N<GAG<F%P:#(N:G!G4$L! A0#%     @ X8-N6FD?54*+&@  DE0! !$
M             ( !8:\! &YR>' M,C R-#$R,S$N>'-D4$L! A0#%     @
MX8-N6H^@1]CD#0  *LL  !4              ( !&\H! &YR>' M,C R-#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( .&#;EJNS=*ZEWD  ('I"0 5
M      "  3+8 0!N<GAP+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #A
M@VY:#;/4-I"2  #'#0@ %0              @ '\40( ;G)X<"TR,#(T,3(S
M,5]L86(N>&UL4$L! A0#%     @ X8-N6E%8 +V+?   <6X* !4
M     ( !O^0" &YR>' M,C R-#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( .&#
M;EK2\7MM7_(# #V[)P 5              "  7UA P!N<GAP,C R-#$R,S%C
M7S$P:RYH=&U02P$"% ,4    " #A@VY:XDPG W+6 0"#Y0$ "@
M    @ $/5 < ;G)X<&EC+FIP9U!+ 0(4 Q0    ( .&#;EI>3]SJ8+8  %>Z
M   -              "  :DJ"0!N<GAT86)L93$N:G!G4$L! A0#%     @
MX8-N6K4BYOLB>P  !WX   \              ( !-.$) '-A;&)E<F=L;V=O
M+FIP9U!+ 0(4 Q0    ( .&#;EK(EN;(TZ(! *O5 0 5              "
M 8-<"@!T;W1A;&-A<F5U;6)R96QL82YJ<&=02P4&     !, $P"0!   B?\+
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>nrxp20241231c_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nrxp="http://www.nrxpharma.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nrxp-20241231.xsd" xlink:type="simple"/>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2025-03-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:NondesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:NondesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:CommonStockAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="i_2024-08-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="d_2024-08-14_2024-08-14_CounterpartyNameAxis-AnsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:AnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <context id="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonSecondTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="d_2024-10-10_2024-10-10_CounterpartyNameAxis-AnsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:AnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-10</startDate>
            <endDate>2024-10-10</endDate>
        </period>
    </context>
    <context id="d_2024-10-10_2024-10-10_DebtInstrumentAxis-StreetervileComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-10</startDate>
            <endDate>2024-10-10</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrxp:AnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrxp:AnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-06-02_TypeOfArrangementAxis-AlvogenLicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="d_2024-02-01_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="i_2024-12-31_TypeOfArrangementAxis-AlvogenLicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-06-01_2024-06-30_TypeOfArrangementAxis-AlvogenLicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:AlvogenLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="d_2023-03-30_2023-03-30_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-10_2023-07-10_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteAmendment3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:PrincipalRepaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:InterestRepaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:PrincipalRepaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:InterestRepaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-04-24_2024-04-24_LitigationCaseAxis-StreetervileComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="d_2024-07-29_2024-07-29_LitigationCaseAxis-StreetervileComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-29</startDate>
            <endDate>2024-07-29</endDate>
        </period>
    </context>
    <context id="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-12</startDate>
            <endDate>2024-08-12</endDate>
        </period>
    </context>
    <context id="d_2024-08-15_2024-08-15_LitigationCaseAxis-StreetervileComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="d_2024-10-01_2024-10-31_LitigationCaseAxis-StreetervileComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="i_2024-08-12_ClassOfWarrantOrRightAxis-AnsonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonSecondTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-10</startDate>
            <endDate>2024-10-10</endDate>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-AnsonSecondTrancheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonSecondTrancheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfPrincipalAndInterestIntoCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonFirstTrancheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:EndOfPhaseIClinicalTrialsOfLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:EndOfPhaseIIClinicalTrialsOfLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:EndOfPhaseIIIClinicalTrialsOfLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInUsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:FirstCommercialSaleOfLicensedProductInUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInEuropeMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:FirstCommercialSaleOfLicensedProductInEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ProductOrServiceAxis-AnnualRevenueThresholdMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:AnnualRevenueThresholdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByLicensedPatentsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:ProductsCoveredByLicensedPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByValidClaimsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrxp:ProductsCoveredByValidClaimsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2021-04-16_2021-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i_2022-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:SarahHerzogMemorialHospitalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-16</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">nrxp:PatentLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">nrxp:PatentLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrxp:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nrxp:LeaseContractualTermOfficeSpaceRentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nrxp:LeaseContractualTermOfficeSpaceRentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-12</startDate>
            <endDate>2024-08-12</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nrxp:StreetervileComplaintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="d_2024-03-21_2024-03-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">nrxp:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-04-01_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">nrxp:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="i_2024-03-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="i_2024-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="i_2023-08-30_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="d_2023-08-01_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:PreferredStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="d_2023-08-01_2023-08-31_ClassOfWarrantOrRightAxis-ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="i_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:PreferredStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">nrxp:ConversionOfSeriesAPreferredStockToPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_RangeAxis-MinimumMember_StatementClassOfStockAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nrxp:NRXPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="d_2023-02-08_2023-02-08_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:March2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="d_2023-06-06_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrxp:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="d_2023-05-15_2023-05-15_DebtInstrumentAxis-StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="d_2023-08-04_2023-08-04_DebtInstrumentAxis-StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="d_2023-08-30_2023-08-30_DebtInstrumentAxis-StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-17_2023-07-17_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ShareSubscriptionFacilityAgreementGEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="d_2024-01-02_2024-01-02_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtToCommonStockMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nrxp:ConversionOfDebtToCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="d_2024-02-20_2024-07-29_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-20</startDate>
            <endDate>2024-07-29</endDate>
        </period>
    </context>
    <context id="i_2024-07-29_RangeAxis-MinimumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-29</instant>
        </period>
    </context>
    <context id="i_2024-07-29_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-29</instant>
        </period>
    </context>
    <context id="d_2023-08-14_2023-08-14_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="i_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryOverallotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryOverallotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-06</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="i_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:FebruaryOverallotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="i_2024-02-29_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilUnderwriterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="i_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilUnderwriterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilOverallotmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-April2024OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:April2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilOverallotmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="i_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:AprilOverallotmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="d_2024-08-28_2024-08-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <startDate>2024-08-28</startDate>
            <endDate>2024-08-28</endDate>
        </period>
    </context>
    <context id="i_2021-05-24_BusinessAcquisitionAxis-NeuroRxMember_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nrxp:NeuroRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:SubstituteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-24</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:SubstituteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:SubstituteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-24</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="d_2023-03-08_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:MarchInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:June2023PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JuneInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:WarrantAmendmentJuneInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="d_2023-08-28_2023-08-28_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-28</startDate>
            <endDate>2023-08-28</endDate>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-28</instant>
        </period>
    </context>
    <context id="d_2023-08-28_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AugustInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-28</startDate>
            <endDate>2023-08-28</endDate>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="d_2023-10-24_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:OctoberAmendedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:FebruaryUnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="d_2024-03-05_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:UnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="d_2024-04-19_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="d_2024-05-23_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AprilUnderwriterOverallotmentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="d_2024-02-07_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AlvogenAndLotusWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="d_2024-08-14_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:AnsonWarrantsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nrxp:NeuroRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2016OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-24</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="i_2022-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrxp:The2021OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2022-07-12_2022-07-12_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputMarketRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputVolumeVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputVolumeVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:StreetervilleConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputCostOfDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputCostOfDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:AnsonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputMarketRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrxp:MeasurementInputMarketRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByLiabilityClassAxis-WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">nrxp:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-11-06_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MinimumMember_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nrxp:NRXPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:GlytechLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithDrJonathanJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithDrJonathanJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="i_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApplicationDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">nrxp:UnrestrictedUponNewDrugApplicationDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApprovalDateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">nrxp:UnrestrictedUponNewDrugApprovalDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrxp:ConsultationAgreementWithZacharyJavittMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2025-03-13_2025-03-13_ConsolidatedEntitiesAxis-HopeTherapeuticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">nrxp:HopeTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-13</endDate>
        </period>
    </context>
    <context id="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:ThirdTrancheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-28</instant>
        </period>
    </context>
    <context id="i_2025-01-28_ClassOfWarrantOrRightAxis-ThirdTrancheNotesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ThirdTrancheNotesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-28</instant>
        </period>
    </context>
    <context id="d_2025-01-28_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nrxp:ThirdTrancheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <context id="d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:RDPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <context id="i_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrxp:RDPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:RDPurchaseAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="i_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ConsiderationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="d_2025-01-27_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrxp:ConsiderationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2024-01-01_2024-12-31"
      id="thunderdome-EntityCentralIndexKey">0001719406</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2024-01-01_2024-12-31"
      id="thunderdome-EntityRegistrantName">NRX Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-15356">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2024-01-01_2024-12-31" id="ixv-15357">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2024-01-01_2024-12-31" id="ixv-15358">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2024-01-01_2024-12-31" id="ixv-15359">2024</dei:DocumentFiscalYearFocus>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="d_2024-01-01_2024-12-31" id="c125342692">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="d_2024-01-01_2024-12-31" id="c125341744">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="d_2024-01-01_2024-12-31" id="c125341745">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="d_2024-01-01_2024-12-31" id="c125342699">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="d_2024-01-01_2024-12-31" id="c125342700">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="d_2024-01-01_2024-12-31" id="c125341750">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-12-31"
      id="c125344265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-12-31"
      id="c125344266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"
      decimals="INF"
      id="c125342639"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"
      decimals="INF"
      id="c125342640"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"
      decimals="INF"
      id="c125342641"
      unitRef="Share">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"
      decimals="INF"
      id="c125342642"
      unitRef="Share">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342643"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342644"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342645"
      unitRef="Share">12000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342646"
      unitRef="Share">12000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="c125342647"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="c125342649"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342648"
      unitRef="Share">3000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342650"
      unitRef="Share">3000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342651"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125342652"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342653"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125342654"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342655"
      unitRef="Share">14591505</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342657"
      unitRef="Share">14591505</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125342656"
      unitRef="Share">8391956</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125342658"
      unitRef="Share">8391956</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125342666"
      unitRef="USD">2519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125342674"
      unitRef="USD">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125342682"
      unitRef="USD">197000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125342690"
      unitRef="USD">975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <nrxp:RepaymentsOfInsuranceLoans
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341386"
      unitRef="USD">725000</nrxp:RepaymentsOfInsuranceLoans>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      id="c125341895">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <nrxp:DebtInstrumentNumberOfTranches
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="INF"
      id="c125342005"
      unitRef="Pure">3</nrxp:DebtInstrumentNumberOfTranches>
    <nrxp:LicenseAgreementCumulativePayments
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="-5"
      id="c125344324"
      unitRef="USD">400000</nrxp:LicenseAgreementCumulativePayments>
    <us-gaap:PaymentsForRoyalties
      contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="-3"
      id="c125342703"
      unitRef="USD">0</us-gaap:PaymentsForRoyalties>
    <nrxp:PaymentForLicenseAgreementMaintenanceFee
      contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125342704"
      unitRef="USD">150000</nrxp:PaymentForLicenseAgreementMaintenanceFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember"
      decimals="-3"
      id="c125342705"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-03-21_2024-03-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c125342120"
      unitRef="Pure">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342129"
      unitRef="Share">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342130"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <nrxp:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2023-08-01_2023-08-31_ClassOfWarrantOrRightAxis-ClassOfWarrantOrRightWarrantIssuedWithPreferredStockMember"
      decimals="INF"
      id="c125342133"
      unitRef="Share">1</nrxp:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c125342706"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      id="c125342158">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"
      decimals="-3"
      id="c125342246"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342251"
      unitRef="Share">0.1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <nrxp:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="-3"
      id="c125342708"
      unitRef="Share">0</nrxp:ClassOfWarrantOrRightExercisesInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342709"
      unitRef="Share">3448856</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342710"
      unitRef="Share">344886</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"
      decimals="-5"
      id="c125342711"
      unitRef="USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342277"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember"
      id="c125342283">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342289"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342299"
      unitRef="Pure">5.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember"
      id="c125342311">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342316"
      unitRef="Pure">5.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember"
      id="c125342325">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342328"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342340"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      id="c125342350">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember"
      id="c125342360">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember"
      id="c125342378">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"
      id="c125342399">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"
      id="c125342416">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342419"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"
      id="c125342426">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342446"
      unitRef="Pure">0.316</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c125342477"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember"
      id="c125342486">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="-3"
      id="c125342492"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"
      decimals="-4"
      id="c125341634"
      unitRef="USD">-4190000</nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125342722"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125342723"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125342519"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125342724"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125342527"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125342725"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="d_2024-01-01_2024-12-31" id="c125342539">2035-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125342726"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125342727"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2024-07-01_2024-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"
      decimals="-3"
      id="c125342568"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342730"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="-5"
      id="c125342610"
      unitRef="USD">100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="d_2025-01-28_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125342623"
      unitRef="Pure">7</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c125342628">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2024-01-01_2024-12-31" id="c125342638">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2024-01-01_2024-12-31" id="c125342736">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2024-01-01_2024-12-31" id="c125342737">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2024-01-01_2024-12-31" id="c125342738">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2024-01-01_2024-12-31" id="ixv-18915">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2024-01-01_2024-12-31" id="ixv-18916">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2024-01-01_2024-12-31" id="ixv-18917">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2024-01-01_2024-12-31" id="ixv-18918">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-18919">001-38302</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2024-01-01_2024-12-31" id="ixv-18920">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-18921">82-2844431</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2024-01-01_2024-12-31" id="ixv-18922">1201 Orange Street, Suite 600</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2024-01-01_2024-12-31" id="ixv-18923">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2024-01-01_2024-12-31" id="ixv-18924">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2024-01-01_2024-12-31" id="ixv-18925">19801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2024-01-01_2024-12-31" id="ixv-18926">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-18927">254-6134</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember"
      id="ixv-18928">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember"
      id="ixv-18929">NRXP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-CommonStockMember"
      id="ixv-18930">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember"
      id="ixv-18931">Warrants to purchase one share of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember"
      id="ixv-18932">NRXPW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-WarrantMember"
      id="ixv-18933">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2024-01-01_2024-12-31" id="ixv-18934">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2024-01-01_2024-12-31" id="ixv-18935">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2024-01-01_2024-12-31" id="ixv-18936">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2024-01-01_2024-12-31" id="ixv-18937">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2024-01-01_2024-12-31" id="ixv-18938">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2024-01-01_2024-12-31" id="ixv-18939">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2024-01-01_2024-12-31" id="ixv-18940">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-18941">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-18942">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2024-01-01_2024-12-31" id="ixv-18943">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2024-06-30"
      decimals="1"
      id="ixv-18944"
      unitRef="USD">21500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2025-03-14"
      decimals="INF"
      id="ixv-18945"
      unitRef="Share">16915647</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867418">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="item1c" title="item1c"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;1C.&lt;/em&gt; Cybersecurity &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   The Company maintains a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The underlying processes and controls of NRx&#x2019;s cyber risk management program incorporate recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (&#x201c;NIST&#x201d;) Cybersecurity Framework (&#x201c;CSF&#x201d;). NRx has an annual assessment performed by a third-party specialist of the Company&#x2019;s cyber risk management program against the NIST CSF. The annual risk assessment identifies, quantifies, and categorizes material cyber risks. In addition, the Company, in conjunction with the third-party cyber risk management specialists develop a risk mitigation plan to address such risks and, where necessary, remediate potential vulnerabilities identified through the annual assessment process.
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"&gt;In addition, NRx maintains policies over areas such as access and account management to help govern the processes put in place by management designed to protect NRx&#x2019;s IT assets, data, and services from threats and vulnerabilities. NRx employs additional key practices within the cybersecurity risk management program including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to maintenance of an IT assets inventory, identity access management controls including restricted access of privileged accounts, and critical data backups to reduce cybersecurity risk. &#160; &#160; &#160; &#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"&gt;Cybersecurity partners to the Company, including consultants, are a key part of NRx&#x2019;s cybersecurity risk management strategy and infrastructure. The cybersecurity partners provide services including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to cybersecurity strategy, cyber risk advisory, assessment, and remediation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"&gt;NRx&#x2019;s management team, in conjunction with cybersecurity service providers are responsible for oversight and administration of NRx&#x2019;s cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. The Company&#x2019;s management team has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes via engagement of strategic third-party partners. The Company also relies on threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by NRx for strategic cyber risk management, advisory and decision making.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"&gt;The Audit Committee of the Board of Directors oversees NRx&#x2019;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx&#x2019;s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   NRx faces risks from cybersecurity threats that could have a material adverse effect on its business, financial condition, results of operations, cash flows or reputation. NRx acknowledges that the risk of cyber incident is prevalent in the current threat landscape and that a future cyber incident may occur in the normal course of its business. However, prior cybersecurity incidents have not had a material adverse effect on NRx&#x2019;s business, financial condition, results of operations, or cash flows. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, investors, and additional stakeholders, which could subject the Company to additional liability and reputational harm. In response to such risks, the Company has implemented initiatives such as a cybersecurity risk assessment process and development of an incident response plan. See Item 1A. "Risk Factors" for more information on cybersecurity risks.
  </cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125342691">The Company maintains a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The underlying processes and controls of NRx&#x2019;s cyber risk management program incorporate recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (&#x201c;NIST&#x201d;) Cybersecurity Framework (&#x201c;CSF&#x201d;). NRx has an annual assessment performed by a third-party specialist of the Company&#x2019;s cyber risk management program against the NIST CSF. The annual risk assessment identifies, quantifies, and categorizes material cyber risks. In addition, the Company, in conjunction with the third-party cyber risk management specialists develop a risk mitigation plan to address such risks and, where necessary, remediate potential vulnerabilities identified through the annual assessment process.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125342693">NRx&#x2019;s management team, in conjunction with cybersecurity service providers are responsible for oversight and administration of NRx&#x2019;s cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. The Company&#x2019;s management team has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes via engagement of strategic third-party partners. The Company also relies on threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged by NRx for strategic cyber risk management, advisory and decision making.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125342695">The Audit Committee of the Board of Directors oversees NRx&#x2019;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx&#x2019;s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125342701">NRx faces risks from cybersecurity threats that could have a material adverse effect on its business, financial condition, results of operations, cash flows or reputation. NRx acknowledges that the risk of cyber incident is prevalent in the current threat landscape and that a future cyber incident may occur in the normal course of its business. However, prior cybersecurity incidents have not had a material adverse effect on NRx&#x2019;s business, financial condition, results of operations, or cash flows. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, investors, and additional stakeholders, which could subject the Company to additional liability and reputational harm. In response to such risks, the Company has implemented initiatives such as a cybersecurity risk assessment process and development of an incident response plan. See Item 1A. "Risk Factors" for more information on cybersecurity risks.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <dei:AuditorFirmId contextRef="d_2024-01-01_2024-12-31" id="ixv-18950">106</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2024-01-01_2024-12-31" id="ixv-18951">Salberg &amp; Company, P.A.</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2024-01-01_2024-12-31" id="ixv-18952">Boca Raton, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341071"
      unitRef="USD">1443000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341072"
      unitRef="USD">4595000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341073"
      unitRef="USD">1859000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341074"
      unitRef="USD">2289000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341075"
      unitRef="USD">3302000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341076"
      unitRef="USD">6884000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341077"
      unitRef="USD">349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341078"
      unitRef="USD">431000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341079"
      unitRef="USD">3651000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341080"
      unitRef="USD">7315000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c125341081"
      unitRef="USD">4130000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341082"
      unitRef="USD">4632000</us-gaap:AccountsPayableCurrent>
    <nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341083"
      unitRef="USD">10149000</nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341084"
      unitRef="USD">4714000</nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <nrxp:AccruedClinicalSiteCostsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341085"
      unitRef="USD">379000</nrxp:AccruedClinicalSiteCostsCurrent>
    <nrxp:AccruedClinicalSiteCostsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341086"
      unitRef="USD">524000</nrxp:AccruedClinicalSiteCostsCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341087"
      unitRef="USD">1246000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341088"
      unitRef="USD">9161000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c125341089"
      unitRef="USD">320000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341090"
      unitRef="USD">0</us-gaap:LoansPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341091"
      unitRef="USD">5639000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341092"
      unitRef="USD">17000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341093"
      unitRef="USD">21863000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341094"
      unitRef="USD">19048000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341095"
      unitRef="USD">5011000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341096"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341097"
      unitRef="USD">26874000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341098"
      unitRef="USD">19048000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"
      decimals="-3"
      id="c125341099"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-12-31_StatementClassOfStockAxis-NondesignatedPreferredStockMember"
      decimals="-3"
      id="c125341100"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="c125341101"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="-3"
      id="c125341102"
      unitRef="USD">3000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341103"
      unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341104"
      unitRef="USD">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341105"
      unitRef="USD">255035000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341106"
      unitRef="USD">241406000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341107"
      unitRef="USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341108"
      unitRef="USD">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341109"
      unitRef="USD">-278273000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341110"
      unitRef="USD">-253147000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341111"
      unitRef="USD">-23223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341112"
      unitRef="USD">-11733000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341113"
      unitRef="USD">3651000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341114"
      unitRef="USD">7315000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341121"
      unitRef="USD">6199000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341122"
      unitRef="USD">13371000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341123"
      unitRef="USD">13505000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341124"
      unitRef="USD">14216000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341125"
      unitRef="USD">-1202000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341126"
      unitRef="USD">250000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341127"
      unitRef="USD">18502000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341128"
      unitRef="USD">27837000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341129"
      unitRef="USD">-18502000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341130"
      unitRef="USD">-27837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341131"
      unitRef="USD">44000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341132"
      unitRef="USD">494000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c125341133"
      unitRef="USD">230000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341134"
      unitRef="USD">120000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341135"
      unitRef="USD">849000</us-gaap:LossOnContractTerminationForDefault>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341136"
      unitRef="USD">0</us-gaap:LossOnContractTerminationForDefault>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341137"
      unitRef="USD">2654000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341138"
      unitRef="USD">2707000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341139"
      unitRef="USD">1657000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341140"
      unitRef="USD">-20000</us-gaap:FairValueAdjustmentOfWarrants>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341141"
      unitRef="USD">-1278000</nrxp:GainLossOnConvertibleDebtRedemption>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341142"
      unitRef="USD">-0</nrxp:GainLossOnConvertibleDebtRedemption>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341143"
      unitRef="USD">-6624000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341144"
      unitRef="USD">-2313000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341145"
      unitRef="USD">-25126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341146"
      unitRef="USD">-30150000</us-gaap:NetIncomeLoss>
    <us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341147"
      unitRef="USD">-0</us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341148"
      unitRef="USD">9000</us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341149"
      unitRef="USD">-25126000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341150"
      unitRef="USD">-30159000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341151"
      unitRef="USD">-25126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341152"
      unitRef="USD">-30150000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341153"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341154"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341155"
      unitRef="USD">-25126000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341156"
      unitRef="USD">-30153000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341157"
      unitRef="USDPerShare">-2.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125341158"
      unitRef="USDPerShare">-3.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341159"
      unitRef="Share">10644461</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125341160"
      unitRef="Share">7576176</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341166"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341167"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341168"
      unitRef="Share">6644299</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341169"
      unitRef="USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341170"
      unitRef="USD">230399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341171"
      unitRef="USD">-222997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341172"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c125341173"
      unitRef="USD">7409000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="INF"
      id="c125341174"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341175"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="INF"
      id="c125341176"
      unitRef="Share">1353667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341177"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341178"
      unitRef="USD">8121000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341179"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341180"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341181"
      unitRef="USD">8122000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <nrxp:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341182"
      unitRef="Share">3000000</nrxp:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341183"
      unitRef="USD">3000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <nrxp:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341184"
      unitRef="Share">0</nrxp:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341185"
      unitRef="USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341186"
      unitRef="USD">1168000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341187"
      unitRef="USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341188"
      unitRef="USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341189"
      unitRef="USD">1171000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341191"
      unitRef="USD">-0</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341193"
      unitRef="USD">-0</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341194"
      unitRef="USD">-0</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341195"
      unitRef="USD">-0</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341196"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341197"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341198"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341199"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341200"
      unitRef="Share">326423</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341201"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341202"
      unitRef="USD">982000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341203"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341204"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341205"
      unitRef="USD">982000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="INF"
      id="c125341206"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-3"
      id="c125341207"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="INF"
      id="c125341208"
      unitRef="Share">67568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-3"
      id="c125341209"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-4"
      id="c125341210"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-3"
      id="c125341211"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-3"
      id="c125341212"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-4"
      id="c125341213"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341215"
      unitRef="USD">0</nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost>
    <nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341217"
      unitRef="USD">0</nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost>
    <nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341218"
      unitRef="USD">99000</nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost>
    <nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341219"
      unitRef="USD">0</nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost>
    <nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341220"
      unitRef="USD">0</nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost>
    <nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341221"
      unitRef="USD">99000</nrxp:AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341223"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341225"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341226"
      unitRef="USD">387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341227"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341228"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341229"
      unitRef="USD">387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341231"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341233"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341234"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-4"
      id="c125341235"
      unitRef="USD">-30150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341236"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341237"
      unitRef="USD">-30150000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341238"
      unitRef="Share">3000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341239"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341240"
      unitRef="Share">8391956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341241"
      unitRef="USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341242"
      unitRef="USD">241406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341243"
      unitRef="USD">-253147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341244"
      unitRef="USD">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341245"
      unitRef="USD">-11733000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341246"
      unitRef="Share">3000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341247"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341248"
      unitRef="Share">-300000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341250"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c125341254"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125341255"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c125341256"
      unitRef="Share">385515</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125341257"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125341258"
      unitRef="USD">1626000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125341259"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125341260"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c125341261"
      unitRef="USD">1627000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="INF"
      id="c125341262"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341263"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="INF"
      id="c125341264"
      unitRef="Share">1273050</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341265"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341266"
      unitRef="USD">3256000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341267"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341268"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-CommonStockAndWarrantIssuanceMember"
      decimals="-3"
      id="c125341269"
      unitRef="USD">3257000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125341270"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c125341271"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125341272"
      unitRef="Share">270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c125341273"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c125341274"
      unitRef="USD">1026000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c125341275"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c125341276"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c125341277"
      unitRef="USD">1027000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341278"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341279"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341280"
      unitRef="Share">57500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341281"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341282"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341283"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341284"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341285"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341286"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341287"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341288"
      unitRef="Share">3820444</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341289"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341290"
      unitRef="USD">5859000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341291"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341292"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341293"
      unitRef="USD">5863000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341294"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341296"
      unitRef="Share">73040</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <nrxp:APICIncreaseForCostRecognitionContractTermination
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341303"
      unitRef="USD">0</nrxp:APICIncreaseForCostRecognitionContractTermination>
    <nrxp:APICIncreaseForCostRecognitionContractTermination
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341305"
      unitRef="USD">0</nrxp:APICIncreaseForCostRecognitionContractTermination>
    <nrxp:APICIncreaseForCostRecognitionContractTermination
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341306"
      unitRef="USD">1336000</nrxp:APICIncreaseForCostRecognitionContractTermination>
    <nrxp:APICIncreaseForCostRecognitionContractTermination
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341307"
      unitRef="USD">0</nrxp:APICIncreaseForCostRecognitionContractTermination>
    <nrxp:APICIncreaseForCostRecognitionContractTermination
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341308"
      unitRef="USD">0</nrxp:APICIncreaseForCostRecognitionContractTermination>
    <nrxp:APICIncreaseForCostRecognitionContractTermination
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341309"
      unitRef="USD">1336000</nrxp:APICIncreaseForCostRecognitionContractTermination>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341310"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341311"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341312"
      unitRef="Share">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341313"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341314"
      unitRef="USD">37000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341315"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341316"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341317"
      unitRef="USD">37000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341319"
      unitRef="USD">0</nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt>
    <nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341321"
      unitRef="USD">0</nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt>
    <nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341322"
      unitRef="USD">0</nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt>
    <nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341323"
      unitRef="USD">0</nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt>
    <nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341324"
      unitRef="USD">3000</nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt>
    <nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341325"
      unitRef="USD">3000</nrxp:ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341327"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341329"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341330"
      unitRef="USD">486000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341331"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341332"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341333"
      unitRef="USD">486000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341335"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341337"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341338"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341339"
      unitRef="USD">-25126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341340"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341341"
      unitRef="USD">-25126000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125341342"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c125341343"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c125341344"
      unitRef="Share">14591505</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c125341345"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125341346"
      unitRef="USD">255035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c125341347"
      unitRef="USD">-278273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c125341348"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341349"
      unitRef="USD">-23223000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341350"
      unitRef="USD">-25126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341351"
      unitRef="USD">-30150000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341352"
      unitRef="USD">5000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341353"
      unitRef="USD">5000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341354"
      unitRef="USD">486000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341355"
      unitRef="USD">387000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341356"
      unitRef="USD">37000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341357"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341358"
      unitRef="USD">1657000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341359"
      unitRef="USD">-20000</us-gaap:FairValueAdjustmentOfWarrants>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341360"
      unitRef="USD">2654000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341361"
      unitRef="USD">2707000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341362"
      unitRef="USD">-1278000</nrxp:GainLossOnConvertibleDebtRedemption>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341363"
      unitRef="USD">-0</nrxp:GainLossOnConvertibleDebtRedemption>
    <nrxp:DebtIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341364"
      unitRef="USD">896000</nrxp:DebtIssuanceCosts>
    <nrxp:DebtIssuanceCosts
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341365"
      unitRef="USD">0</nrxp:DebtIssuanceCosts>
    <nrxp:ContractCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341366"
      unitRef="USD">1336000</nrxp:ContractCosts>
    <nrxp:ContractCosts
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341367"
      unitRef="USD">0</nrxp:ContractCosts>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341368"
      unitRef="USD">849000</us-gaap:LossOnContractTerminationForDefault>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341369"
      unitRef="USD">0</us-gaap:LossOnContractTerminationForDefault>
    <nrxp:NoncashLitigationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341370"
      unitRef="USD">0</nrxp:NoncashLitigationExpense>
    <nrxp:NoncashLitigationExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341371"
      unitRef="USD">250000</nrxp:NoncashLitigationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341372"
      unitRef="USD">-503000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341373"
      unitRef="USD">-3040000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341374"
      unitRef="USD">-5217000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341375"
      unitRef="USD">2655000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341376"
      unitRef="USD">10005000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341377"
      unitRef="USD">-531000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341378"
      unitRef="USD">-10637000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341379"
      unitRef="USD">-21657000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341380"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341381"
      unitRef="USD">3000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341382"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341383"
      unitRef="USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c125341384"
      unitRef="USD">7850000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341385"
      unitRef="USD">3092000</us-gaap:RepaymentsOfConvertibleDebt>
    <nrxp:RepaymentsOfInsuranceLoans
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341387"
      unitRef="USD">943000</nrxp:RepaymentsOfInsuranceLoans>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341388"
      unitRef="USD">896000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341389"
      unitRef="USD">-0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <nrxp:ProceedsFromInsuranceLoans
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341390"
      unitRef="USD">1045000</nrxp:ProceedsFromInsuranceLoans>
    <nrxp:ProceedsFromInsuranceLoans
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341391"
      unitRef="USD">943000</nrxp:ProceedsFromInsuranceLoans>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341392"
      unitRef="USD">6034000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341393"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341394"
      unitRef="USD">3966000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341395"
      unitRef="USD">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341396"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341397"
      unitRef="USD">1171000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <nrxp:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341398"
      unitRef="USD">4884000</nrxp:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <nrxp:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341399"
      unitRef="USD">0</nrxp:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341400"
      unitRef="USD">1027000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341401"
      unitRef="USD">8122000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341402"
      unitRef="USD">7485000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341403"
      unitRef="USD">6201000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341404"
      unitRef="USD">-3152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341405"
      unitRef="USD">-15459000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341406"
      unitRef="USD">4595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c125341407"
      unitRef="USD">20054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341408"
      unitRef="USD">1443000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341409"
      unitRef="USD">4595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341410"
      unitRef="USD">374000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341411"
      unitRef="USD">885000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341412"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341413"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember"
      decimals="-3"
      id="c125341414"
      unitRef="USD">4585000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember"
      decimals="-3"
      id="c125341415"
      unitRef="USD">982000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <nrxp:StockIssuedAsOfferingCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341416"
      unitRef="USD">188000</nrxp:StockIssuedAsOfferingCosts>
    <nrxp:StockIssuedAsOfferingCosts
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341417"
      unitRef="USD">75000</nrxp:StockIssuedAsOfferingCosts>
    <us-gaap:StockIssued1
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341418"
      unitRef="USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341419"
      unitRef="USD">250000</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember"
      decimals="-3"
      id="c125341420"
      unitRef="USD">3000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToCommonStockMember"
      decimals="-3"
      id="c125341421"
      unitRef="USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867419">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="notes" title="notes"&gt;&lt;/a&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt; Organization&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;The Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#x201c;NRX&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage bio-pharmaceutical company which develops and intends to distribute, through its wholly-owned operating subsidiaries, NeuroRx, Inc., (&#x201c;NeuroRx&#x201d;) and HOPE Therapeutics, Inc. (&#x201c;HOPE&#x201d;), and collectively with NRX and NeuroRx, the (&#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, or &#x201c;our&#x201d;), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#x201c;PTSD&#x201d;) and now schizophrenia. All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate (&#x201c;NMDA&#x201d;) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. NeuroRx is organized as a traditional research and development (&#x201c;R&amp;amp;D&#x201d;) company, whereas HOPE is organized as a specialty pharmaceutical company intended to distribute ketamine and other therapeutic options to clinics that serve patients with suicidal depression and PTSD.&#160;The Company has &lt;em style="font: inherit;"&gt;two&lt;/em&gt; lead drug candidates that are expected to be submitted by year end for Food and&#160;Drug Administration (&#x201c;FDA&#x201d;)&#160;approval with anticipated FDA decision dates under the Prescription Drug User Fee Act ("PDUFA") by the end of &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2025:&lt;/em&gt; NRX-&lt;em style="font: inherit;"&gt;101,&lt;/em&gt; an oral fixed dose combination of D-cycloserine and lurasidone and NRX-&lt;em style="font: inherit;"&gt;100,&lt;/em&gt; a preservative-free formulation of ketamine for intravenous infusion.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Operations&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s drug development activities have expanded from its original focus on development of NRX-&lt;em style="font: inherit;"&gt;101,&lt;/em&gt; a fixed dose combination of D-cycloserine (&#x201c;DCS&#x201d;) and lurasidone for the treatment of suicidal bipolar depression to encompass the development of NRX-&lt;em style="font: inherit;"&gt;101&lt;/em&gt; for the treatment of chronic pain and PTSD and to the development of intravenous ketamine (NRX-&lt;em style="font: inherit;"&gt;100/HTX&lt;/em&gt;-&lt;em style="font: inherit;"&gt;100&lt;/em&gt;) for the treatment of suicidal depression. These additional indications have been added as the Company has gained access to clinical trials data funded by governmental entities in France and potentially in the United States which has the potential to afford the Company potential safety and efficacy data on key indications at low cost.&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867420">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Going Concern&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal&#160;year and has a working capital deficit at &lt;em style="font: inherit;"&gt; December 31, 2024. &lt;/em&gt;The Company has no revenues and expects to continue to incur operating losses into &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; Although the Company projects operating revenue&#160;to be derived from the operation of clinical facilities through its HOPE subsidiary and sales of its pharmaceutical products in &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; these projections are subject to completion of anticipated clinical acquisitions in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; case and regulatory approvals in the latter case. In the absence of these projected developments, the Company&#x2019;s ability to support its ongoing capital needs is dependent on its ability to continue to raise equity and/or debt financing, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be available on favorable terms, or at all, in order to continue operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company had $1.4 million in cash and cash equivalents. On &lt;em style="font: inherit;"&gt; August 12, 2024, &lt;/em&gt;the Company entered into that certain Securities Purchase Agreement dated &lt;em style="font: inherit;"&gt; August 12, 2024 (&lt;/em&gt;the &#x201c;Purchase Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to sell Senior Secured Convertible Promissory Notes (the &#x201c;Anson&#160;Notes&#x201d;) in the aggregate principal amount of up to approximately $16.3 million in three tranches of $5.435 million, and warrants to purchase that amount of shares of the Company&#x2019;s common stock, $0.001 par value (&#x201c;Common Stock&#x201d;) equal to &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; of the principal amount of the Notes in the respective tranche divided by the volume weighted average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Purchase Agreement (the &#x201c;Anson&#160;Warrants&#x201d;).&#160; The Company consummated the sale of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; tranche of $5.435 million ($4.5&#160;million in net proceeds)&#160;in Notes and Warrants (the &#x201c;First Closing&#x201d;) on &lt;em style="font: inherit;"&gt; August 14, 2024 (&lt;/em&gt;the &#x201c;First Closing Date&#x201d;), and the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche of $5.435&#160;million in Notes and Warrants (the &#x201c;Second Closing&#x201d;) on &lt;em style="font: inherit;"&gt; October 10, 2024 (&lt;/em&gt;the &#x201c;Second Closing Date&#x201d;), for aggregate gross proceeds of approximately $10.87 million, before deducting fees, costs, and other expenses including the use of proceeds to repay $5.55 million of the Streeterville Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company has&#160;secured operating capital that it anticipates as sufficient to fund its drug development operations through [&#x25cf;] and to finance submission of FDA New Drug Applications for NRX-&lt;em style="font: inherit;"&gt;100&lt;/em&gt; and NRX-&lt;em style="font: inherit;"&gt;101.&lt;/em&gt; The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;pursue additional equity or debt financing or refinancing opportunities in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2026&lt;/em&gt; to fund ongoing clinical activities, to meet obligations under its current debt arrangements and for general corporate purposes. Such arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures or other agreements. The sale of equity could result in additional dilution to the Company&#x2019;s existing shareholders. The Company cannot make any assurances that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company&#x2019;s business and operations and could also lead to a reduction in the Company&#x2019;s operations. The Company will continue to carefully monitor the impact of its continuing operations on the Company&#x2019;s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company&#x2019;s ability to continue as a going concern for a period of at least &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months from the date of issuance of these consolidated financial statements. The accompanying consolidated financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the company be unable to continue as a going concern.&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341762"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c125341767"
      unitRef="USD">1400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-5"
      id="c125341768"
      unitRef="USD">16300000</us-gaap:DebtInstrumentFaceAmount>
    <nrxp:DebtInstrumentNumberOfTranches
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="INF"
      id="c125341769"
      unitRef="Pure">3</nrxp:DebtInstrumentNumberOfTranches>
    <nrxp:DebtInstrumentFaceAmountIndividualTranches
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341770"
      unitRef="USD">5435000</nrxp:DebtInstrumentFaceAmountIndividualTranches>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-08-12"
      decimals="INF"
      id="c125341771"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-3"
      id="c125341774"
      unitRef="USD">5435000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="d_2024-08-14_2024-08-14_CounterpartyNameAxis-AnsonMember"
      decimals="-5"
      id="c125341775"
      unitRef="USD">4500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="-3"
      id="c125341777"
      unitRef="USD">5435000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2024-10-10_2024-10-10_CounterpartyNameAxis-AnsonMember"
      decimals="-4"
      id="c125341778"
      unitRef="USD">10870000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-StreetervileComplaintMember"
      decimals="-4"
      id="c125341779"
      unitRef="USD">5550000</us-gaap:RepaymentsOfDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867421">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) as determined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). The consolidated financial statements include the accounts of NRX Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the fair value of convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Certain Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; &lt;i&gt;Fair Value Measurements&lt;/i&gt;, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The accounting guidance classifies fair value measurements in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following &lt;em style="font: inherit;"&gt;three&lt;/em&gt; categories for disclosure purposes:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt; Inputs other than Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt; Unobservable inputs which are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt;)&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;from time to time, exceed federally insured limits. As of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;the Company&#x2019;s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $1.2 million. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. &#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company considers all highly liquid investments with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of initial purchase to be cash equivalents, including balances held in the Company&#x2019;s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the U.S. federally insured limits. The objectives of the Company&#x2019;s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company&#x2019;s cash flow requirements, and to attain a market rate of return.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for revenue under FASB ASC Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &lt;i&gt;Revenue for Contract with Customers&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt;&lt;/i&gt;&#x201d;) or other accounting standards for revenue &lt;em style="font: inherit;"&gt;not&lt;/em&gt; derived from customers. Arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company enters into contractual arrangements that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company evaluates the promised good or services to determine which promises, or group of promises, represent performance obligations. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The License Agreement (the &#x201c;&lt;i&gt;License Agreement&lt;/i&gt;&#x201d;) with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, &#x201c;&lt;i&gt;Alvogen&lt;/i&gt;&#x201d;) (as further discussed in Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; below) was accounted for in accordance with ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; In accordance with ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; it performs the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;i. identify the contract(s) with a customer&#x37e;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;ii. identify the performance obligations in the contract&#x37e;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;iii. determine the transaction price&#x37e;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;iv. allocate the transaction price to the performance obligations within the contract&#x37e; and&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;v. recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company only applies the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;At contract inception, once the contract is determined to be within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements typically consist of a license to intellectual property and research services. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s revenue arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Milestone Payments&lt;/i&gt;: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company &lt;em style="font: inherit;"&gt;first&lt;/em&gt; estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Research Services&lt;/i&gt;: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; below), the Company would have been&#160;reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company would have recognized revenue for the reimbursed costs when the First Milestone Payment contingencies had&#160;been achieved and the Company had&#160;an enforceable claim to the reimbursed costs.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Research and development expense&#160;consists primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Non-cancellable Contracts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be recorded as a deferred cost asset.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Convertible Notes Payable and Fair Value Election&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As permitted under FASB ASC Topic &lt;em style="font: inherit;"&gt;825,&lt;/em&gt; Financial Instruments (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;825&lt;/em&gt;&lt;/i&gt;&#x201d;), the Company elected to account for its promissory notes, which meet&#160;the required criteria, at fair value at inception. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying consolidated statements of operations and comprehensive loss.&#160;As a result of electing the fair value option, direct costs and fees related to the promissory notes are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg&#x2019;s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At &lt;em style="font: inherit;"&gt; September 30, 2024, &lt;/em&gt;the Streeterville Note valuation&#160;was adjusted to the post settlement amount agreed upon. Interest expense is included within the change in fair value of the notes payable and accrued interest is included within the fair value of the convertible notes payable on the balance sheet. See Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for Streeterville and Anson convertible notes. Management believes those assumptions are reasonable but if these assumptions change, it could materially affect the fair value.&lt;/p&gt;&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company&#x2019;s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations and comprehensive loss based upon the underlying individual&#x2019;s role at the Company.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC Topic &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;480&lt;/em&gt;&lt;/i&gt;&#x201d;) and FASB ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;&lt;/i&gt;&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own Common Stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company generally determines&#160;fair value of the Common Stock&#160;Warrants (as defined below) using a Black Scholes valuation methodology.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In accordance with ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; the Company&#x2019;s Series A Preferred Stock was classified as permanent equity as it was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; mandatorily redeemable upon an event that is considered outside of the Company&#x2019;s control. Further, in accordance with ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40,&lt;/em&gt; &lt;i&gt;Derivatives and Hedging &lt;/i&gt;&#x2013;&lt;i&gt; Contracts in an Entity&lt;/i&gt;&#x2019;&lt;i&gt;s Own Equity&lt;/i&gt;, the Series A Preferred Stock did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet any of the criteria that would preclude equity classification. The Company concluded that the Series A Preferred Stock was more akin to an equity-type instrument than a debt-type instrument, therefore the conversion features associated with the convertible preferred stock were deemed to be clearly and closely related to the host instrument and were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; bifurcated as a derivative under ASC &lt;em style="font: inherit;"&gt;815.&lt;/em&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer, who reviews financial information presented for purposes of making operating decisions, assessing financial performance, and allocating resources.&#160;The Company operates as a single operating and reportable segment, consistent with the manner in which the CODM evaluates performance and allocates resources, see Note&#160;&lt;em style="font: inherit;"&gt;12&lt;/em&gt; for further information.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Income taxes are recorded in accordance with FASB ASC Topic &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;&lt;/i&gt;&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some or all of the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC &lt;em style="font: inherit;"&gt;740.&lt;/em&gt; When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company applies the &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-class method when computing net income or loss per share attributable to common stockholders. In determining net income or loss attributable to common stockholders, the &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-class method requires income or loss allocable to participating securities for the period to be allocated between common and participating securities based on their respective rights to share in the earnings as if all of the income or loss allocable for the period had been distributed. In periods of net loss, there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; allocation required under the &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-class method as the participating securities do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an obligation to fund the losses of the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;121,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;264,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock awards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124,167&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,173,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,321,499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,920,126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible preferred stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB&#160;issued Accounting Standard Update (ASU) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&#x2011;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;)-&lt;i&gt;Improvements to Reportable Segment Disclosures (ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;)&lt;/i&gt;, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;&#160;should be applied on a retrospective basis.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;&#160;is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;Early adoption is permitted. The Company has adopted the reportable segment disclosure requirements. See Note &lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;-Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): I&lt;i&gt;mprovements to Income Tax Disclosures (ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;)&lt;/i&gt;, which is intended to enhance the transparency and decision usefulness of income tax disclosures, primarily by amending disclosure requirements for the effective tax rate reconciliation and income taxes paid.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;&#160;should be applied on a prospective basis, and retrospective application is permitted.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;&#160;is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344273">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) as determined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). The consolidated financial statements include the accounts of NRX Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2024-01-01_2024-12-31" id="c125344274">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the fair value of convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <nrxp:RisksAndUncertaintiesPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344275">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Certain Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/p&gt;</nrxp:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2024-01-01_2024-12-31" id="c125344276">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; &lt;i&gt;Fair Value Measurements&lt;/i&gt;, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The accounting guidance classifies fair value measurements in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following &lt;em style="font: inherit;"&gt;three&lt;/em&gt; categories for disclosure purposes:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt; Inputs other than Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt; Unobservable inputs which are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt;)&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2024-01-01_2024-12-31" id="c125344277">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;from time to time, exceed federally insured limits. As of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;the Company&#x2019;s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $1.2 million. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. &#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="-5"
      id="c125341804"
      unitRef="USD">1200000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344278">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company considers all highly liquid investments with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of initial purchase to be cash equivalents, including balances held in the Company&#x2019;s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the U.S. federally insured limits. The objectives of the Company&#x2019;s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company&#x2019;s cash flow requirements, and to attain a market rate of return.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344279">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for revenue under FASB ASC Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &lt;i&gt;Revenue for Contract with Customers&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt;&lt;/i&gt;&#x201d;) or other accounting standards for revenue &lt;em style="font: inherit;"&gt;not&lt;/em&gt; derived from customers. Arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company enters into contractual arrangements that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company evaluates the promised good or services to determine which promises, or group of promises, represent performance obligations. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The License Agreement (the &#x201c;&lt;i&gt;License Agreement&lt;/i&gt;&#x201d;) with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, &#x201c;&lt;i&gt;Alvogen&lt;/i&gt;&#x201d;) (as further discussed in Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; below) was accounted for in accordance with ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; In accordance with ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; it performs the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;i. identify the contract(s) with a customer&#x37e;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;ii. identify the performance obligations in the contract&#x37e;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;iii. determine the transaction price&#x37e;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;iv. allocate the transaction price to the performance obligations within the contract&#x37e; and&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;v. recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company only applies the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;At contract inception, once the contract is determined to be within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements typically consist of a license to intellectual property and research services. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s revenue arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Milestone Payments&lt;/i&gt;: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company &lt;em style="font: inherit;"&gt;first&lt;/em&gt; estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Research Services&lt;/i&gt;: The Company incurred research costs in association with the License Agreement. After the First Milestone Payment (as defined in Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; below), the Company would have been&#160;reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company would have recognized revenue for the reimbursed costs when the First Milestone Payment contingencies had&#160;been achieved and the Company had&#160;an enforceable claim to the reimbursed costs.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2024-01-01_2024-12-31" id="c125344280">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Research and development expense&#160;consists primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344281">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Non-cancellable Contracts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be recorded as a deferred cost asset.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344282">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Convertible Notes Payable and Fair Value Election&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As permitted under FASB ASC Topic &lt;em style="font: inherit;"&gt;825,&lt;/em&gt; Financial Instruments (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;825&lt;/em&gt;&lt;/i&gt;&#x201d;), the Company elected to account for its promissory notes, which meet&#160;the required criteria, at fair value at inception. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying consolidated statements of operations and comprehensive loss.&#160;As a result of electing the fair value option, direct costs and fees related to the promissory notes are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg&#x2019;s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At &lt;em style="font: inherit;"&gt; September 30, 2024, &lt;/em&gt;the Streeterville Note valuation&#160;was adjusted to the post settlement amount agreed upon. Interest expense is included within the change in fair value of the notes payable and accrued interest is included within the fair value of the convertible notes payable on the balance sheet. See Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for Streeterville and Anson convertible notes. Management believes those assumptions are reasonable but if these assumptions change, it could materially affect the fair value.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2024-01-01_2024-12-31" id="c125344285">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company&#x2019;s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations and comprehensive loss based upon the underlying individual&#x2019;s role at the Company.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344286">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC Topic &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;480&lt;/em&gt;&lt;/i&gt;&#x201d;) and FASB ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;&lt;/i&gt;&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own Common Stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company generally determines&#160;fair value of the Common Stock&#160;Warrants (as defined below) using a Black Scholes valuation methodology.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344287">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In accordance with ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; the Company&#x2019;s Series A Preferred Stock was classified as permanent equity as it was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; mandatorily redeemable upon an event that is considered outside of the Company&#x2019;s control. Further, in accordance with ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40,&lt;/em&gt; &lt;i&gt;Derivatives and Hedging &lt;/i&gt;&#x2013;&lt;i&gt; Contracts in an Entity&lt;/i&gt;&#x2019;&lt;i&gt;s Own Equity&lt;/i&gt;, the Series A Preferred Stock did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet any of the criteria that would preclude equity classification. The Company concluded that the Series A Preferred Stock was more akin to an equity-type instrument than a debt-type instrument, therefore the conversion features associated with the convertible preferred stock were deemed to be clearly and closely related to the host instrument and were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; bifurcated as a derivative under ASC &lt;em style="font: inherit;"&gt;815.&lt;/em&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344289">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer, who reviews financial information presented for purposes of making operating decisions, assessing financial performance, and allocating resources.&#160;The Company operates as a single operating and reportable segment, consistent with the manner in which the CODM evaluates performance and allocates resources, see Note&#160;&lt;em style="font: inherit;"&gt;12&lt;/em&gt; for further information.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344290">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Income taxes are recorded in accordance with FASB ASC Topic &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;&lt;i&gt;ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;&lt;/i&gt;&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some or all of the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC &lt;em style="font: inherit;"&gt;740.&lt;/em&gt; When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344291">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company applies the &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-class method when computing net income or loss per share attributable to common stockholders. In determining net income or loss attributable to common stockholders, the &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-class method requires income or loss allocable to participating securities for the period to be allocated between common and participating securities based on their respective rights to share in the earnings as if all of the income or loss allocable for the period had been distributed. In periods of net loss, there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; allocation required under the &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-class method as the participating securities do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an obligation to fund the losses of the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;121,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;264,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock awards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124,167&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,173,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,321,499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,920,126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible preferred stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867422">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;121,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;264,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock awards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124,167&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,173,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,321,499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,920,126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible preferred stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125341429"
      unitRef="Share">121833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125341430"
      unitRef="Share">264983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341431"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341432"
      unitRef="Share">124167</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c125341433"
      unitRef="Share">7173766</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c125341434"
      unitRef="Share">3321499</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember"
      decimals="INF"
      id="c125341435"
      unitRef="Share">4920126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-AnsonMember"
      decimals="INF"
      id="c125341436"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c125341437"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c125341438"
      unitRef="Share">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c125344292">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB&#160;issued Accounting Standard Update (ASU) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&#x2011;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;)-&lt;i&gt;Improvements to Reportable Segment Disclosures (ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;)&lt;/i&gt;, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;&#160;should be applied on a retrospective basis.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;&#160;is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;Early adoption is permitted. The Company has adopted the reportable segment disclosure requirements. See Note &lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;-Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): I&lt;i&gt;mprovements to Income Tax Disclosures (ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;)&lt;/i&gt;, which is intended to enhance the transparency and decision usefulness of income tax disclosures, primarily by amending disclosure requirements for the effective tax rate reconciliation and income taxes paid.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;&#160;should be applied on a prospective basis, and retrospective application is permitted.&#160;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;&#160;is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867423">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt; &lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following at the dates indicated (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid expense and other current assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;827&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,078&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Prepaid clinical development costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;824&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other prepaid expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;208&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other current receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total prepaid expense and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,859&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,289&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </nrxp:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867424">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid expense and other current assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;827&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,078&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Prepaid clinical development costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;824&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other prepaid expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;208&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other current receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total prepaid expense and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,859&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,289&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341439"
      unitRef="USD">827000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341440"
      unitRef="USD">1078000</us-gaap:PrepaidInsurance>
    <nrxp:PrepaidClinicalDevelopmentExpense
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341441"
      unitRef="USD">824000</nrxp:PrepaidClinicalDevelopmentExpense>
    <nrxp:PrepaidClinicalDevelopmentExpense
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341442"
      unitRef="USD">871000</nrxp:PrepaidClinicalDevelopmentExpense>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341443"
      unitRef="USD">208000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341444"
      unitRef="USD">334000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341445"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341446"
      unitRef="USD">6000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341447"
      unitRef="USD">1859000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341448"
      unitRef="USD">2289000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867425">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt; Accrued and Other Current Liabilities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Accrued and other current liabilities consisted of the following at the dates indicated (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued and other current liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Refund liability (see Note 6)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,715&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,732&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,686&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Employee costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;577&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;835&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Accrued research and development expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;655&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,112&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other accrued expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;470&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total accrued and other current liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,149&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,714&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867426">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued and other current liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Refund liability (see Note 6)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,715&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,732&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,686&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Employee costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;577&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;835&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Accrued research and development expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;655&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,112&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other accrued expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;470&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total accrued and other current liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,149&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,714&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341450"
      unitRef="USD">4715000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341451"
      unitRef="USD">0</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341452"
      unitRef="USD">3732000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341453"
      unitRef="USD">2686000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341454"
      unitRef="USD">577000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341455"
      unitRef="USD">835000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nrxp:AccruedResearchAndDevelopmentLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341456"
      unitRef="USD">655000</nrxp:AccruedResearchAndDevelopmentLiabilityCurrent>
    <nrxp:AccruedResearchAndDevelopmentLiabilityCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341457"
      unitRef="USD">1112000</nrxp:AccruedResearchAndDevelopmentLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c125341458"
      unitRef="USD">470000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341459"
      unitRef="USD">81000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341460"
      unitRef="USD">10149000</nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341461"
      unitRef="USD">4714000</nrxp:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867427">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt; Alvogen Licensing Agreement&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company entered into a License Agreement with Alvogen. Under the License Agreement, the Company granted Alvogen certain license rights&#160;to develop, manufacture, and commercialize the Company&#x2019;s candidate therapeutic product, NRX-&lt;em style="font: inherit;"&gt;101,&lt;/em&gt; for the treatment of bipolar depression with suicidality.&#160;In exchange for the license granted and the participation of the Company in certain development, regulatory and commercial activities, Alvogen was obligated to pay the Company specified regulatory and commercial milestones, the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; of which was $9&#160;million upon the later of a positive data read-out from the Company&#x2019;s ongoing Phase &lt;em style="font: inherit;"&gt;2b/3&lt;/em&gt; clinical trial and completion of the Type B meeting with the FDA (the &#x201c;&lt;i&gt;First Milestone Payment&lt;/i&gt;&#x201d;). In &lt;em style="font: inherit;"&gt; February 2024, &lt;/em&gt;the parties executed an amendment accelerating payment of up to $5 million related to the First Milestone Payment, with the remaining $4 million due upon the original agreement&#x2019;s terms (see below for advances received through &lt;em style="font: inherit;"&gt; December 31, 2024). &lt;/em&gt;As compensation for advancing the milestone, Alvogen received warrants to purchase up to 419,598 shares of the Company's Common Stock, at a strike price of $4.00 with a &lt;span style="-sec-ix-hidden:c125341895"&gt;three&lt;/span&gt; year term (See Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;). The grant date fair value of the warrants was approximately $1.3 million, which the Company planned to account for as&#160;consideration paid to a customer (see below). The &lt;em style="font: inherit;"&gt;second&lt;/em&gt; portion of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; milestone was to be $4 million and, as before, triggered by a positive response to the Company's planned end of phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; meeting with FDA.&#160;If the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; achieved by &lt;em style="font: inherit;"&gt; September 3, 2024, &lt;/em&gt;the Company would have been obligated to repay any amount received against the $5 million advance of the First Milestone Payment to Alvogen. As there was significant uncertainty relative to approval of any drug candidate in development, the Company concluded that it was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable that a significant reversal of revenue would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur if the Company were to include the First Milestone Payment, or any advances thereof, in the transaction price prior to receiving FDA approval. Accordingly, the transaction price was fully constrained and advances from Alvogen were recorded as a refund liability until such time as the refund right expired. Further, the Company accounted for the warrants issued to Alvogen within additional paid-in capital consistent with the accounting for unfunded stock subscription agreements until such time as the uncertainty around the First Milestone was resolved. &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Termination&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Under the License Agreement, as amended, Alvogen was granted early termination rights. On &lt;em style="font: inherit;"&gt; June 21, 2024, &lt;/em&gt;the Company received a notice of termination from Alvogen effective immediately.&#160;Following the termination of the License Agreement by Alvogen, the amounts advanced pursuant to the amendment&#160;became due and payable to Alvogen. Accordingly, the refund liability has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been reclassified to deferred revenue or recorded as revenue as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and will remain permanent as refund liability until settled.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the refund liability due to Alvogen was $4.7&#160;million, which represents all payments made by Alvogen through &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;and is included as a component of accrued expense&#160;and other current liabilities on the consolidated balance sheet (refer to Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;).&#160;Following the early termination by Alvogen, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate recognizing any revenue under the License Agreement. Additionally, in &lt;em style="font: inherit;"&gt; June 2024&#160;&lt;/em&gt;the Company wrote-off the unfunded stock subscription receivable of $1.3 million related to the warrants previously classified in additional paid-in capital&#160;to research and development expense following the termination.&#160;&lt;/p&gt;
  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nrxp:LicenseAgreementInitialPayment
      contextRef="i_2023-06-02_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-6"
      id="c125341889"
      unitRef="USD">9000000</nrxp:LicenseAgreementInitialPayment>
    <nrxp:LicenseAgreementAcceleratingPayment
      contextRef="d_2024-02-01_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-6"
      id="c125341891"
      unitRef="USD">5000000</nrxp:LicenseAgreementAcceleratingPayment>
    <nrxp:LicenseAgreementInitialPayment
      contextRef="i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-6"
      id="c125341892"
      unitRef="USD">4000000</nrxp:LicenseAgreementInitialPayment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="INF"
      id="c125341893"
      unitRef="Share">419598</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="INF"
      id="c125341894"
      unitRef="USDPerShare">4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-5"
      id="c125341897"
      unitRef="USD">1300000</us-gaap:WarrantsAndRightsOutstanding>
    <nrxp:LicenseAgreementInitialPayment
      contextRef="i_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-6"
      id="c125341900"
      unitRef="USD">4000000</nrxp:LicenseAgreementInitialPayment>
    <nrxp:LicenseAgreementAcceleratingPayment
      contextRef="d_2024-02-01_2024-02-29_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-6"
      id="c125341904"
      unitRef="USD">5000000</nrxp:LicenseAgreementAcceleratingPayment>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i_2024-12-31_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-5"
      id="c125341908"
      unitRef="USD">4700000</us-gaap:CustomerRefundLiabilityCurrent>
    <nrxp:StockSubscriptionsReceivableWriteOff
      contextRef="d_2024-06-01_2024-06-30_TypeOfArrangementAxis-AlvogenLicensingAgreementMember"
      decimals="-5"
      id="c125341911"
      unitRef="USD">1300000</nrxp:StockSubscriptionsReceivableWriteOff>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867428">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt; Debt &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Streeterville Convertible Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; November 4, 2022, &lt;/em&gt;the Company issued an 9% redeemable promissory note (as amended, the &#x201c;&lt;i&gt;Streeterville&lt;/i&gt;&#160;&lt;i&gt;Note&lt;/i&gt;&#x201d;) to Streeterville Capital, LLC, a Utah limited liability company (&#x201c;&lt;i&gt;Streeterville&lt;/i&gt;&#x201d;), for an aggregate principal amount of $11.0 million. The Streeterville Note originally matured&#160;18 months from the date of issuance subject to certain acceleration provisions. The Streeterville Note carried&#160;an original issue discount of $1.0 million which was deducted from the principal balance of the Streeterville Note. The net proceeds from the issuance of the Streeterville Note was $10.0 million after transaction costs including the original issue discount, legal and other fees are included.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The initial terms of the Streeterville Note included the following provisions, certain of which were subsequently modified, as described below. The Company had&#160;the option to prepay the Streeterville Note during the term by paying an amount equal to 110% of the principal, interest, and fees owed as of the prepayment date. The noteholder had&#160;the right to redeem up to $1.0 million of the outstanding balance of the Streeterville Note per month starting &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months after the issuance date (the &#x201c;&lt;i&gt;Maximum Monthly Redemption Amount&lt;/i&gt;&#x201d;). Payments could&#160;be made by the Company at their option in: (i) in cash with a 10% premium (the &#x201c;&lt;i&gt;Redemption Premium&lt;/i&gt;&#x201d;) for the amount redeemed, (ii) by paying the redemption amount in the form of shares of Common Stock with the number of redemption shares being equal to the portion of the applicable redemption amount divided by the Redemption Conversion Price (as defined below), or (iii) a combination of cash and shares of Common Stock. The &#x201c;&lt;i&gt;Redemption Conversion Price&lt;/i&gt;&#x201d; on any given redemption date equaled&#160;85% multiplied by the average of the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; lowest daily volume weighted average prices per share of the Common Stock during the &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; trading days immediately preceding the date that the noteholder delivered&#160;notice electing to redeem a portion of the Streeterville Note. Beginning &lt;em style="font: inherit;"&gt; May 1, 2023, &lt;/em&gt;in the event (a) the daily dollar trading volume of the Common Stock of the Company on any given trading day was at least &lt;em style="font: inherit;"&gt;fifty&lt;/em&gt; percent (&lt;em style="font: inherit;"&gt;50%&lt;/em&gt;) greater than the lower of (i) the median daily dollar trading volume over the previous &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; (&lt;em style="font: inherit;"&gt;10&lt;/em&gt;) trading days or (ii) the daily dollar trading volume on the trading day immediately preceding the date of measurement or (b) if the closing trade price on any given trading day was at least &lt;em style="font: inherit;"&gt;thirty&lt;/em&gt; percent (&lt;em style="font: inherit;"&gt;30%&lt;/em&gt;) greater than the Nasdaq Minimum Price, then the lender would be entitled to redeem over the following &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; (&lt;em style="font: inherit;"&gt;10&lt;/em&gt;) trading days an amount of indebtedness then outstanding under the Streeterville Note equal to twice the monthly redemption amount of $1.0 million solely by payment by stock, if permitted under the agreement, subject to the Maximum Percentage (as defined in the Streeterville Note) and other ownership limitations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Streeterville Note contained&#160;certain Trigger Events (as defined in the Streeterville Note) that generally, if uncured within &lt;em style="font: inherit;"&gt;five&lt;/em&gt; trading days, could result in an event of default in accordance with the terms of the Streeterville Note (such event, an &#x201c;&lt;i&gt;Event of Default&lt;/i&gt;&#x201d;). Upon an Event of a Default, the Lender could consider the Streeterville Note immediately due and payable. Upon an Event of Default, the interest rate could&#160;also be increased to the lesser of 18% per annum or the maximum rate permitted under applicable law (see below).&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Due to these embedded features within the Streeterville Note, the Company elected to account for the Streeterville Note at fair value at inception. Subsequent changes in fair value were recorded as a component of other income (loss) in the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Streeterville&lt;/span&gt;&lt;/i&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Convertible Note Amendments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 30, 2023, &lt;/em&gt;the Company entered into an Amendment to the Note (the &#x201c;&lt;i&gt;First Amendment&lt;/i&gt;&#x201d;), pursuant to which the Maximum Percentage was set at 9.99% of the number of shares of Common Stock outstanding on a given date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 7, 2023, &lt;/em&gt;the Company entered into Amendment &lt;em style="font: inherit;"&gt;#2&lt;/em&gt; to the Streeterville Note with Streeterville (the &#x201c;&lt;i&gt;Second Amendment&lt;/i&gt;&#x201d;). Pursuant to the Second Amendment, the Company agreed to amend the redemption provisions of the Streeterville Note to provide that the Company would pay to Streeterville an amount in cash equal to $1.8 million on or before &lt;em style="font: inherit;"&gt; July 10, 2023, &lt;/em&gt;which amount was paid on &lt;em style="font: inherit;"&gt; July 10, 2023. &lt;/em&gt;In addition, the Company agreed that, beginning on or before &lt;em style="font: inherit;"&gt; July 31, 2023, &lt;/em&gt;and on or before the last day of each month until &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company would pay Streeterville an amount equal to $0.4 million in cash, less any amount satisfied by the delivery of Redemption Conversion Shares (as defined below). Notwithstanding the foregoing, Streeterville could also submit a request for redemption of up to an aggregate of $1.0 million per month in accordance with the terms of the Second Amendment. However, the portion of each payment that was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; satisfied by the delivery of Redemption Conversion Shares was the maximum amount of cash the Company would have been&#160;required to pay in accordance with the Second Amendment during the period from &lt;em style="font: inherit;"&gt; July 31, 2023 &lt;/em&gt;and on or before the last day of each month until &lt;em style="font: inherit;"&gt; December 31, 2023. &lt;/em&gt;The redemption of the Maximum Monthly Redemption Amount in excess of the Minimum Amount would be satisfied by the delivery of additional Redemption Conversion Shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 9, 2024, &lt;/em&gt;the Company entered into Amendment &lt;em style="font: inherit;"&gt;#3&lt;/em&gt; to the Streeterville Note (the &#x201c;&lt;i&gt;Third Amendment&lt;/i&gt;&#x201d;), with Streeterville. In accordance with the Third Amendment, the Company and Streeterville agreed to amend the redemption provisions of the Streeterville Note to provide that the Company would pay to Streeterville an amount in cash equal to $1.1 million on &lt;em style="font: inherit;"&gt; February 12, 2024, &lt;/em&gt;which the amount was paid on &lt;em style="font: inherit;"&gt; February 12, 2024. &lt;/em&gt;In addition, beginning on or before &lt;em style="font: inherit;"&gt; February &lt;/em&gt;&lt;em style="font: inherit;"&gt;29,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; and on or before the last day of each month until &lt;em style="font: inherit;"&gt; July 31, 2024, &lt;/em&gt;the Company was obligated to pay Streeterville an amount equal to $0.4 million in cash, less any amount satisfied by the delivery of Redemption Conversion Shares. During the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of this amended payment period, Streeterville could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; request to redeem amounts greater than $0.4 million per month.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;After &lt;em style="font: inherit;"&gt; April&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; and for the remainder of the payment period through &lt;em style="font: inherit;"&gt; July 31, 2024, &lt;/em&gt;Streeterville could redeem any Redemption Amount (as defined in the Streeterville Note), including an amount in excess of the Minimum Payment, subject to the Maximum Monthly Redemption Amount. During the period through &lt;em style="font: inherit;"&gt; July 31, 2024, &lt;/em&gt;the Company was&#160;permitted to pay the Redemption Amounts by delivery of the Redemption Conversion Shares (as defined below) without regard to the existence of any Equity Conditions Failure, to the extent Streeterville submits&#160;redemption notices during such month pursuant to the terms of the Streeterville Note, and only for the Redemption Amounts covered by such notices. Moreover, the Redemption Premium would continue to apply to the Redemption Amounts. To the extent there was an outstanding balance under the Streeterville Note after &lt;em style="font: inherit;"&gt; July 31, 2024, &lt;/em&gt;the Company would be required to pay such outstanding balance in full in cash by &lt;em style="font: inherit;"&gt; August 31, 2024. &lt;/em&gt;As a result of the alleged Event of Default mentioned below, the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; pay any&#160;Redemption Amounts during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; prior to the settlement, also as described below.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the Minimum Payment Period (defined in the Streeterville Note, as amended), the Company was&#160;permitted to pay the Redemption Amounts in the form of shares of Common Stock of the Company (the &#x201c;&lt;i&gt;Redemption Conversion Shares&lt;/i&gt;&#x201d;) calculated on the basis of the Redemption Conversion Price (as defined in the Streeterville Note) without regard to the existence of an Equity Conditions Failure. Moreover, the Redemption Premium (as defined in the Streeterville Note) would continue to apply to the Redemption Amounts.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Both the Second Amendment and the Third Amendment (considered cumulatively with the Second Amendment) were deemed to be debt modifications and did&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; give rise to a debt extinguishment&#160;in accordance with FASB ASC Topic &lt;em style="font: inherit;"&gt;470,&lt;/em&gt; &lt;i&gt;Debt&lt;/i&gt;, which was accounted for prospectively. The modification did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in recognition of a gain or loss in the consolidated statements of operations as the modifications were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered debt extinguishments, but impacted interest expense recognized in subsequent periods, prior to the settlement of the Streeterville Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Convertible Note Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company estimated&#160;the fair value of the Streeterville Note using a Monte Carlo simulation model, which used&#160;as inputs the fair value of its Common Stock and estimated&#160;for the equity volatility and volume volatility of its Common Stock, the time to expiration of the Streeterville Note, the risk-free interest rate for a period that approximated&#160;the time to expiration, and probability of default. Therefore, the Company estimated&#160;its expected future volatility based on the actual volatility of its Common Stock and historical volatility of its Common Stock utilizing a lookback period consistent with the time to expiration. The time to expiration was&#160;based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months from the issuance date. The risk-free interest rate was&#160;determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default was estimated using either Bloomberg's Default Risk function, which uses&#160;its financial information to calculate a default risk specific to the Company, or&#160;management's estimates which included, the Company's current cash runway,&#160;current efforts to raise financing,&#160;and current economic environment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The discount to the principal amount was included in the carrying value of the Streeterville Note. During &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company recorded a debt discount of approximately $1.0 million upon issuance of the Streeterville Note for the original issue discount of $1.0 million. As a result of electing the fair value option, any direct costs and fees related to the Streeterville Note were expensed as incurred. For the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company recorded a gain from the change in fair value of the Streeterville Note&#160;of $1.8 million and $2.7 million, respectively, which was recognized in other (income) expense on the consolidated statements of operations as a result of the Company&#x2019;s election of the fair value option.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company made cash principal repayments on the Note of approximately $7.4 million, made cash interest payments on the Note of approximately $0.5 million, including $0.2 million of redemption premiums, issued shares of Common Stock as principal repayment of $0.3 million, and issued shares of Common Stock as interest repayment of $0.1 million, and incurred a default penalty&#160;of $0.8&#160;million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company made cash principal repayments on the Note of approximately $2.3 million, made cash interest payments on the Note of approximately $0.9 million, including $0.1 million of redemption premiums, issued shares of Common Stock as principal repayment of $0.7 million, and issued shares of Common Stock as interest repayment of $0.2 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Note carried a remaining principle balance of $0 and $8.3 million, respectively. Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for the reconciliation of the fair values for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Alleged Default&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; April 24, 2024, &lt;/em&gt;the Company received written notice from counsel for Streeterville that an alleged event of default occurred with respect to the Streeterville Note issued by the Company in favor of Streeterville (the &#x201c;&lt;i&gt;Notice&lt;/i&gt;&#x201d;). The Notice alleged that, among other things, (i) the announcement of the plan to partially spin-off of HOPE (the &#x201c;&lt;i&gt;Spin-Off&lt;/i&gt;&#x201d;), constituted a &#x201c;Fundamental Transaction&#x201d; (as defined in the Streeterville Note) for which the Company failed to obtain Streeterville&#x2019;s prior written consent before undertaking such transaction; and (ii) the Company failed to pay the Minimum Payment, as defined in the Streeterville Note, by &lt;em style="font: inherit;"&gt; April 8, 2024, &lt;/em&gt;following a Redemption Notice issued on &lt;em style="font: inherit;"&gt; April 3, 2024 &lt;/em&gt;by Streeterville to the Company, each of which resulted in the failure to cure a Trigger Event and subsequent Event of Default of the Streeterville Note, resulting in the acceleration of all of the outstanding amounts due thereunder.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Streeterville also filed a complaint (the &#x201c;&lt;i&gt;Complaint&lt;/i&gt;&#x201d;) naming the Company as a defendant in the Third Judicial District Court of Salt Lake County, Utah. The Complaint was seeking, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing Common Stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than $6.5 million, or the amounts currently outstanding under the Streeterville Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 29, 2024, &lt;/em&gt;in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company&#160;announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin Spin-Off of 49% of shares in HOPE&#160;to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#x2019;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a&#160;national exchange. The arbitrator also denied Streeterville&#x2019;s petition to enjoin the Company&#160;from selling additional shares of Common Stock to finance ongoing operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Streeterville Settlement&lt;/span&gt;&lt;/i&gt;&lt;span style="text-decoration: underline; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 12, 2024, &lt;/em&gt;the Company and Streeterville entered into a Settlement and Release of Claims (the &#x201c;Settlement Agreement&#x201d;), whereby the Company and Streeterville agreed to settle all disputes between the parties and release the Company from all obligations arising from the Notes at certain Securities Purchase Agreement, dated &lt;em style="font: inherit;"&gt; November 4, 2022 (&lt;/em&gt;&#x201c;Streeterville Notes&#x201d;), between the Company and Streeterville, and that certain Convertible Promissory Note, dated &lt;em style="font: inherit;"&gt; November 4, 2022, &lt;/em&gt;issued to Streeterville by the Company, in exchange for a payment of $2.5 million upon the initial closing of the sale of the Anson Notes, and within &lt;em style="font: inherit;"&gt;60&lt;/em&gt; days thereafter, a &lt;em style="font: inherit;"&gt;second&lt;/em&gt; payment of $3.05 million. The Company made the $2.5 million payment upon the Anson Notes closing on&#160;&lt;em style="font: inherit;"&gt; August 15, 2024. &lt;/em&gt;The Company made the final $3.05 million payment in &lt;em style="font: inherit;"&gt; October 10, 2024 &lt;/em&gt;using proceeds from the Second Closing of Anson Convertible Promissory Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company evaluated the terms of the Settlement Amendment in accordance with ASC &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;50,&lt;/em&gt; &lt;i&gt;Debt Modifications and Extinguishments&lt;/i&gt;. Both the Settlement Amendment and the Third Amendment (considered cumulatively with the Settlement Amendment) were deemed to be debt modifications&#160;and did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; give rise to a debt extinguishment in accordance with ASC &lt;em style="font: inherit;"&gt;Topic&#x202f;470,&#x202f;&lt;/em&gt;&lt;i&gt;Debt&lt;/i&gt;, which will be accounted for prospectively. The modifications did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in recognition of a gain or loss in the consolidated statements of operations as the modifications were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered debt extinguishments, but will impact interest expense and the determination of fair value&#160;in future periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table presents the Streeterville Note as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Par value of the Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,020&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,020&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unamortized original issue discount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(497&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(497&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Default penalty&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;849&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares and cash)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(12,324&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,072&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Carrying value of the Note before current period change in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(952&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,451&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cumulative fair value adjustments through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;952&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cumulative fair value adjustments through accumulated other comprehensive loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total carrying value of Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Anson Convertible Promissory Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 12, 2024, &lt;/em&gt;the Company entered into the Purchase Agreement with Investors. The Company agreed to sell, in &lt;span style="-sec-ix-hidden:c125342005"&gt;three&lt;/span&gt; equal tranches, original issue discount Anson Notes&#160;in the aggregate principal amount of up to approximately $16.3 million&#160;for an aggregate purchase price of up to approximately $15.0 million&#160;and warrants to purchase that amount of shares equal to 50% of the principal amount of the Notes divided by the VWAP&#160;of the Company&#x2019;s Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Anson Warrants.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In connection with the above offering, the Company engaged EF Hutton LLC as placement agent (the &#x201c;Placement Agent&#x201d;), Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of 7% of the gross proceeds the Company receives in the offering at closing.&#x202f;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Senior Secured Convertible Promissory Notes&lt;/span&gt;&lt;/i&gt;&lt;span style="text-decoration: underline; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 14, 2024, &lt;/em&gt;the Company entered into the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; tranche Senior Secured Convertible Note Agreements (the &#x201c;First Tranche Notes&#x201d;) with Anson Investment Master Fund LP and Anson East Master Fund LP (collectively &#x201c;Anson&#x201d;) at various amounts for an aggregate of $5.435 million subject to an original issuance discount of 8% or $435,000, less other cash issuance costs of $521,000, resulting in net cash proceeds of $4.5&#160;million, prior to any allocation to the Anson Warrants. The First Tranche Notes bear interest at a rate of 6% per annum (or 10% during the occurrence of any Event of Default (as defined in the First Tranche Notes)) and have a term of 15 months from the issuance date, maturing on &lt;em style="font: inherit;"&gt; November 14, 2025&#160;(&lt;/em&gt;the &#x201c;First Tranche Maturity Date&#x201d;) (see Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;).&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 14, 2024, &lt;/em&gt;in conjunction with the issuance of the First Tranche Notes, the Company issued warrants&#160;to purchase up to 1,349,305 shares of the Company&#x2019;s Common Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The First Tranche Notes are convertible at the option of the holder at any time after issuance into Common Stock, at a per share conversion price equal to&#160;the lower of (a) $2.4168, (the &#x201c;Fixed Conversion Price&#x201d;) or (b) a price equal to 92% of the lowest VWAP during the &lt;em style="font: inherit;"&gt;seven&lt;/em&gt; trading day period immediately preceding the effective conversion date (the &#x201c;Alternate Conversion Price&#x201d;, and together with the Fixed Conversion Price, the &#x201c;Conversion Price&#x201d;). If the Conversion Price is less than $0.38 (the &#x201c;Floor Price&#x201d;), then in addition to the issuance of Common Stock upon conversion the Company will pay cash as a true-up which is determined by the product of (i) the difference between (y) the Floor Price less (z) the Conversion Price then in effect, multiplied by (ii) the conversion amount that is being paid in Common Stock.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The terms of the First Tranche&#160;Notes do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; allow any conversion of the First Tranche Notes if it results in Anson owning more than &lt;em style="font: inherit;"&gt;4.99%&lt;/em&gt; of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation"). This limitation can be adjusted up to &lt;em style="font: inherit;"&gt;9.99%&lt;/em&gt; with prior notice, effective &lt;em style="font: inherit;"&gt;61&lt;/em&gt; days after such notice. Anson&#160;must ensure compliance with this limitation when submitting a notice of conversion, and the Company will rely on Anson's&#160;representation of compliance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;If the Company issues or grants options for Common Stock at a price lower than the current Conversion Price, the Conversion Price will be adjusted to match this lower price, (the&#160;&#x201c;Base Conversion Price&#x201d;). The Company must notify Anson of any such issuance, and Anson&#160;is entitled to convert shares based on the new Base Conversion Price.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;If the Company offers purchase rights to holders of Common Stock, Anson will be entitled to acquire those rights as if they had fully converted the Note, subject to the Beneficial Ownership Limitation. If exercising these rights would exceed the Beneficial Ownership Limitation, the rights will be held in abeyance until they can be exercised without exceeding the limit.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The First Tranche Notes contain mandatory redemption features, whereby if at any time the First Tranche Notes are outstanding, the Company will be required to: (A) use up to &lt;em style="font: inherit;"&gt;30%&lt;/em&gt; of the gross proceeds from any Subsequent Financings (as defined in the Purchase Agreement) in cash, to redeem all or a portion of the Note for an amount equal to the outstanding principal, plus all accrued but unpaid interest, plus all liquidated damages (the &#x201c;Redemption&#x202f;Obligations&#x201d;), multiplied by &lt;em style="font: inherit;"&gt;1.05&lt;/em&gt; (the &#x201c;Mandatory Redemption Amount&#x201d;)&#x37e; (B) redeem all of the Redemption Obligations at the Mandatory Redemption Amount in the event of a Change of Control Transaction (as defined in the First Tranche Notes)&#x37e; (C) redeem the Redemption Obligations for the Mandatory Redemption Amount in the event a registration statement is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; available for each of the offer and resale of the shares issuable upon conversion of the First Tranche Notes (the &#x201c;Conversion Shares&#x201d;)&#x37e; and (D) redeem the Redemption Obligations for the Mandatory Redemption Amount if the Shareholder Approval is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obtained within &lt;em style="font: inherit;"&gt;180&lt;/em&gt; days following the date of issuance of the First Tranche Notes.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The First Tranche Notes contain certain covenants, and events of default and triggering events, respectively, which would require repayment of the obligations outstanding pursuant to such instruments. The obligations of the Company pursuant to the First Tranche Notes are (i) secured by all assets of the Company and all subsidiaries of the Company pursuant to the Security Agreement and Patent Security Agreement, dated &lt;em style="font: inherit;"&gt; August 14, 2024, &lt;/em&gt;by and among the Company, the subsidiaries of the Company, and the Investors, and (ii) guaranteed jointly and severally by the subsidiaries of the Company pursuant to the Subsidiary Guarantee, dated &lt;em style="font: inherit;"&gt; August 14, 2024, &lt;/em&gt;by and among the Company, the subsidiaries of the Company, and the Investors.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Pursuant to the Purchase Agreement, on &lt;em style="font: inherit;"&gt; October 10, 2024 (&lt;/em&gt;the &#x201c;Second Closing Date&#x201d;), the Company sold a total of $5.435 million in Notes (the &#x201c;Second Tranche Notes&#x201d;, and collectively with the First Tranche Notes, the ("Anson Notes")) subject to an original issue discount of 8% or $435,000 less other cash issuance cost of $375,000, with an aggregate purchase price of approximately $5.0 million, and Warrants to purchase up to 1,846,128 shares of Common Stock. The Second Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $1.7664 or (b) a price equal to 92% of the lowest VWAP during the &lt;em style="font: inherit;"&gt;seven&lt;/em&gt; trading day period immediately preceding the effective date set forth in a Notice of Conversion delivered by an Investor to the Company. The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of common stock below the then effective Conversion Price. $3.05 million of the note proceeds were used to repay the Streeterville note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In connection with the above Second Tranche Notes&#x201d;, the Company engaged Placement Agent. Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of 7%&#160;of the gross proceeds the Company received&#160;in the Second Closing and incurred certain additional other issuance costs and reimbursement for legal counsel disbursements and placement agent, for aggregate issuance costs of approximately&#160;$0.4&#160;million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Due to these embedded features within the Anson Notes, the Company elected to account for the First and Second Tranche Notes at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the consolidated statements of operations. Additionally the portion of changes in the fair value related to changes in credit risk are recorded to other comprehensive income in the consolidated statements of operations. To determine the initial carrying value of the Notes and the warrants issued to Anson under the First and Second Tranche Notes (see Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;), the Company allocated the proceeds using the fair value method. After allocation, the initial carrying value of the First Tranche Notes and the warrants issued to Anson were $2.9 million and $2.1 million, respectively, and the initial carrying value of the Second Tranche Notes and the warrants issued to Anson were $3.1 million and $1.9 million, respectively&#160;Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for the reconciliation of the fair values for the periods presented.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the&#160;year ended &lt;em style="font: inherit;"&gt; December 31, 2024,&#160;&lt;/em&gt;Anson converted $4.2 million of principal and interest of the First Tranche Note into common stock, resulting in the issuances of 3,676,796 shares of Common Stock and loss on redemption&#160;of $1.3 million (see Note 9).&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the principal and accrued interest balance of the Anson Notes&#160;was $6.75 million and $0.1 million, respectively. During the&#160;year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company&#160;recorded a loss from the change in fair value of the First Tranche Notes of $4.4 million, which was recognized in other (income) expense on the consolidated statements of operations as a result of the Company&#x2019;s election of the fair value option.&#160;At &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;the effective interest rate of the First and the Second Tranche Note was 82% and 53%, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;From &lt;em style="font: inherit;"&gt; January 2, 2025 &lt;/em&gt;to &lt;em style="font: inherit;"&gt; January 3, 2025, &lt;/em&gt;the Company received conversion notices from Anson resulting in the conversion of the remaining principal of the First Tranche Note of $1.3 million of principal and interest in full from the First Tranche Note into 1,004,055 shares of Common Stock (see Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table presents the Anson Notes as of &lt;em style="font: inherit;"&gt; December 31, 2024 (&lt;/em&gt;in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Par value of the Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Initial original issue discount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,190&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Carrying value of the Anson Notes before current period change in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"&gt;Fair value allocated to Common Stock liability classified warrants&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;(3,966&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,413&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total carrying value of Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,257&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,011&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="2"
      id="c125341913"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-6"
      id="c125341914"
      unitRef="USD">11000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      id="c125341915">P18M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-6"
      id="c125341916"
      unitRef="USD">1000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-7"
      id="c125341917"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <nrxp:DebtInstrumentPrepaymentPercentage
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="1"
      id="c125341918"
      unitRef="Pure">1.10</nrxp:DebtInstrumentPrepaymentPercentage>
    <nrxp:DebtInstrumentRedemptionAmount
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-6"
      id="c125341919"
      unitRef="USD">1000000</nrxp:DebtInstrumentRedemptionAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="1"
      id="c125341921"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <nrxp:DebtInstrumentRedemptionConversionPricePercentage
      contextRef="d_2022-11-04_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="2"
      id="c125341922"
      unitRef="Pure">0.85</nrxp:DebtInstrumentRedemptionConversionPricePercentage>
    <nrxp:DebtInstrumentRedemptionAmount
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-6"
      id="c125341933"
      unitRef="USD">1000000</nrxp:DebtInstrumentRedemptionAmount>
    <nrxp:DebtInstrumentConditionalDefaultInterestRate
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="2"
      id="c125341937"
      unitRef="Pure">0.18</nrxp:DebtInstrumentConditionalDefaultInterestRate>
    <nrxp:DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable
      contextRef="d_2023-03-30_2023-03-30_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="4"
      id="c125341938"
      unitRef="Pure">0.0999</nrxp:DebtInstrumentConvertibleMaximumPercentageOfEquityIssuable>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2023-07-10_2023-07-10_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member"
      decimals="-5"
      id="c125341940"
      unitRef="USD">1800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member"
      decimals="-5"
      id="c125341941"
      unitRef="USD">400000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2023-07-07_2023-07-07_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment2Member_RangeAxis-MaximumMember"
      decimals="-6"
      id="c125341942"
      unitRef="USD">1000000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member"
      decimals="-5"
      id="c125341945"
      unitRef="USD">1100000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member"
      decimals="-5"
      id="c125341948"
      unitRef="USD">400000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2024-02-09_2024-02-09_DebtInstrumentAxis-StreetervilleConvertibleNoteAmendment3Member"
      decimals="-5"
      id="c125341952"
      unitRef="USD">400000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-6"
      id="c125341967"
      unitRef="USD">1000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2022-11-04_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-6"
      id="c125341968"
      unitRef="USD">1000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341970"
      unitRef="USD">1800000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341971"
      unitRef="USD">2700000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-2"
      id="c125341972"
      unitRef="USD">7400</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341973"
      unitRef="USD">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:RedemptionPremium
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341974"
      unitRef="USD">200000</us-gaap:RedemptionPremium>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341975"
      unitRef="USD">300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341976"
      unitRef="USD">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341977"
      unitRef="USD">800000</us-gaap:LossOnContractTerminationForDefault>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341978"
      unitRef="USD">2300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341979"
      unitRef="USD">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:RedemptionPremium
      contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341980"
      unitRef="USD">100000</us-gaap:RedemptionPremium>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-PrincipalRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341981"
      unitRef="USD">700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2023-01-01_2023-12-31_DebtConversionByUniqueDescriptionAxis-InterestRepaymentMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341982"
      unitRef="USD">200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341984"
      unitRef="USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341985"
      unitRef="USD">8300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="d_2024-04-24_2024-04-24_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="-5"
      id="c125341990"
      unitRef="USD">6500000</us-gaap:LossContingencyDamagesSoughtValue>
    <nrxp:StockholdersEquityNoteSpinoffTransactionPercentage
      contextRef="d_2024-07-29_2024-07-29_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="2"
      id="c125341991"
      unitRef="Pure">0.49</nrxp:StockholdersEquityNoteSpinoffTransactionPercentage>
    <nrxp:LitigationSettlementPaymentInstallmentOne
      contextRef="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="-5"
      id="c125341992"
      unitRef="USD">2500000</nrxp:LitigationSettlementPaymentInstallmentOne>
    <nrxp:LitigationSettlementPaymentInstallmentTwo
      contextRef="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="-4"
      id="c125341995"
      unitRef="USD">3050000.00</nrxp:LitigationSettlementPaymentInstallmentTwo>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="d_2024-08-15_2024-08-15_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="-5"
      id="c125341996"
      unitRef="USD">2500000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="d_2024-10-01_2024-10-31_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="-4"
      id="c125341997"
      unitRef="USD">3050000.00</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="d_2024-01-01_2024-12-31"
      id="c6A6A5597-C572-4F6C-9419-213A3E3D21D4">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Par value of the Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,020&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,020&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unamortized original issue discount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(497&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(497&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Default penalty&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;849&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares and cash)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(12,324&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,072&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Carrying value of the Note before current period change in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(952&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,451&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cumulative fair value adjustments through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;952&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cumulative fair value adjustments through accumulated other comprehensive loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total carrying value of Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Par value of the Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Initial original issue discount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,190&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Carrying value of the Anson Notes before current period change in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"&gt;Fair value allocated to Common Stock liability classified warrants&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;(3,966&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,413&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total carrying value of Anson Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,257&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,011&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-4"
      id="c125341463"
      unitRef="USD">11020000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-4"
      id="c125341464"
      unitRef="USD">11020000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341465"
      unitRef="USD">497000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341466"
      unitRef="USD">497000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341467"
      unitRef="USD">849000</us-gaap:LossOnContractTerminationForDefault>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341468"
      unitRef="USD">0</us-gaap:LossOnContractTerminationForDefault>
    <nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341469"
      unitRef="USD">12324000</nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt>
    <nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt
      contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341470"
      unitRef="USD">4072000</nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt>
    <nrxp:LongtermDebtTotal
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341471"
      unitRef="USD">-952000</nrxp:LongtermDebtTotal>
    <nrxp:LongtermDebtTotal
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341472"
      unitRef="USD">6451000</nrxp:LongtermDebtTotal>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341473"
      unitRef="USD">952000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341474"
      unitRef="USD">2707000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341475"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2023-01-01_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341476"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341477"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341478"
      unitRef="USD">9161000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341479"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341480"
      unitRef="USD">9161000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341481"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2023-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341482"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-5"
      id="c125342006"
      unitRef="USD">16300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-6"
      id="c125342007"
      unitRef="USD">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <nrxp:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap
      contextRef="i_2024-08-12_ClassOfWarrantOrRightAxis-AnsonWarrantsMember"
      decimals="1"
      id="c125342008"
      unitRef="Pure">0.50</nrxp:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap>
    <nrxp:PlacementAgentFeePercentOfGrossProceeds
      contextRef="i_2024-08-12_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="2"
      id="c125342011"
      unitRef="Pure">0.07</nrxp:PlacementAgentFeePercentOfGrossProceeds>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-3"
      id="c125342014"
      unitRef="USD">5435000</us-gaap:DebtInstrumentFaceAmount>
    <nrxp:DebtInstrumentOriginalIssuanceDiscount
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="2"
      id="c125342015"
      unitRef="Pure">0.08</nrxp:DebtInstrumentOriginalIssuanceDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="INF"
      id="c125342016"
      unitRef="USD">435000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <nrxp:DebtIssuanceCosts
      contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="INF"
      id="c125342017"
      unitRef="USD">521000</nrxp:DebtIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-5"
      id="c125342018"
      unitRef="USD">4500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="2"
      id="c125342019"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nrxp:DebtInstrumentInterestRateInEventOfDefault
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="1"
      id="c125342020"
      unitRef="Pure">0.10</nrxp:DebtInstrumentInterestRateInEventOfDefault>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      id="c125342021">P15M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"
      decimals="INF"
      id="c125342023"
      unitRef="Share">1349305</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="INF"
      id="c125342024"
      unitRef="USDPerShare">2.4168</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="d_2024-08-14_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="2"
      id="c125342025"
      unitRef="Pure">0.92</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c125342027"
      unitRef="USDPerShare">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="-3"
      id="c125342039"
      unitRef="USD">5435000</us-gaap:DebtInstrumentFaceAmount>
    <nrxp:DebtInstrumentOriginalIssuanceDiscount
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="2"
      id="c125342040"
      unitRef="Pure">0.08</nrxp:DebtInstrumentOriginalIssuanceDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="INF"
      id="c125342041"
      unitRef="USD">435000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <nrxp:DebtIssuanceCosts
      contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="INF"
      id="c125342042"
      unitRef="USD">375000</nrxp:DebtIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="-6"
      id="c125342043"
      unitRef="USD">5000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"
      decimals="INF"
      id="c125342044"
      unitRef="Share">1846128</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="INF"
      id="c125342045"
      unitRef="USDPerShare">1.7664</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="2"
      id="c125342046"
      unitRef="Pure">0.92</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="d_2024-10-10_2024-10-10_DebtInstrumentAxis-StreetervileComplaintMember"
      decimals="-4"
      id="c125342048"
      unitRef="USD">3050000.00</us-gaap:PaymentsForLegalSettlements>
    <nrxp:PlacementAgentFeePercentOfGrossProceeds
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="2"
      id="c125342049"
      unitRef="Pure">0.07</nrxp:PlacementAgentFeePercentOfGrossProceeds>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="-5"
      id="c125342050"
      unitRef="USD">400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-08-14_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-5"
      id="c125342052"
      unitRef="USD">2900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsMember"
      decimals="-5"
      id="c125342053"
      unitRef="USD">2100000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-10-10_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="-5"
      id="c125342054"
      unitRef="USD">3100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"
      decimals="-5"
      id="c125342055"
      unitRef="USD">1900000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-5"
      id="c125342057"
      unitRef="USD">4200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="INF"
      id="c125342058"
      unitRef="Share">3676796</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-5"
      id="c125342059"
      unitRef="USD">1300000</nrxp:GainLossOnConvertibleDebtRedemption>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-4"
      id="c125342061"
      unitRef="USD">6750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2023-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-5"
      id="c125342062"
      unitRef="USD">100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="-5"
      id="c125342063"
      unitRef="USD">4400000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonFirstTrancheNotesMember"
      decimals="2"
      id="c125342064"
      unitRef="Pure">0.82</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonSecondTrancheNotesMember"
      decimals="2"
      id="c125342065"
      unitRef="Pure">0.53</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c125342066"
      unitRef="USD">1300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125342067"
      unitRef="Share">1004055</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-4"
      id="c125341483"
      unitRef="USD">10870000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-4"
      id="c125341484"
      unitRef="USD">870000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-4"
      id="c125341485"
      unitRef="USD">4190000</nrxp:DebtInstrumentConversionsAndRepaymentsOfDebt>
    <us-gaap:LongTermDebt
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-4"
      id="c125341486"
      unitRef="USD">5810000</us-gaap:LongTermDebt>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341487"
      unitRef="USD">-3966000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341488"
      unitRef="USD">4413000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341489"
      unitRef="USD">6257000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341490"
      unitRef="USD">1246000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2024-12-31_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341491"
      unitRef="USD">5011000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867431">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Sarah Herzog Memorial Hospital License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company is required to make certain payments related to the development of NRX-&lt;em style="font: inherit;"&gt;101&lt;/em&gt; (the "&lt;i&gt;Licensed Product&lt;/i&gt;") in order to maintain the license agreement with the Sarah Herzog Memorial Hospital Ezrat Nashim (&#x201c;&lt;i&gt;SHMH&lt;/i&gt;&#x201d;) (the "&lt;i&gt;SHMH License Agreement&lt;/i&gt;"), including:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Milestone Payments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;End of Phase I Clinical Trials of Licensed Product (completed)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;End of Phase II Clinical Trials of Licensed Product (completed)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;End of Phase III Clinical Trials of Licensed Product&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;First Commercial Sale of Licensed Product in U.S.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;First Commercial Sale of Licensed Product in Europe&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Annual Revenues Reach $100,000,000&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;750,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The milestone payments due above &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be reduced by 25% in certain circumstances, and by the application of certain sub-license fees. As of the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the total cumulative payments made under the &lt;i&gt;SHMH License Agreement&lt;/i&gt; were $0.4 million, with no payments made during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;and $0.2 million and $0.2 million payments made during the years ended &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Royalties&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;A royalty in an amount equal to: (a) 1% of revenues from the sale of any product incorporating a Licensed Product when at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Licensed Patent remains in force, if such product is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; covered by a Valid Claim (as defined below) in the country or region in which the sale occurs, or (b) 2.5% of revenues from the sale of any Licensed Product that is covered by at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Valid Claim in the country or region in which such product is manufactured or sold. A &#x201c;Valid Claim&#x201d; means any issued claim in the Licensed Patents that remains in force and that has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been finally invalidated or held to be unenforceable. The royalty rates above &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be doubled if we commence a legal challenge to the validity, enforceability or scope of any of the Licensed Patents during the term of the SHMH License Agreement and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; prevail in such proceeding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of 8.5% of the payments received by us from sub-licensees in connection with such sales. During the&#160;years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; no royalty payments were made.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Annual Maintenance Fee&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;A fixed amount of $100,000 was paid on &lt;em style="font: inherit;"&gt; April 16, 2021 &lt;/em&gt;and, thereafter, a fixed amount of $150,000 is due on the anniversary of such date during the term of the SHMH License Agreement. The Company paid $150,000 in annual maintenance fees in each of the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; expensed through Research and Development expenses in the accompanying Consolidated Statement of Operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Exclusive License Agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company has entered into a License Agreement with Apkarian Technologies to in-license US Patent &lt;em style="font: inherit;"&gt;8,653,120&lt;/em&gt; that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-&lt;em style="font: inherit;"&gt;101&lt;/em&gt; to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. For the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company has recorded no&#160;expenses relating to the licensure of the patent.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company leases office space on a&#160;month-to-month basis. The rent expense for the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; was $0.1 million and $0.1 million, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;From time to time the Company is involved in litigation, claims, and other proceedings arising in the ordinary course of business. Litigation and other disputes are inherently unpredictable and subject to substantial uncertainties and unfavorable resolutions could occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company was a defendant in litigation filed by Streeterville in the Third Judicial District Court of Salt Lake County, Utah. See Note &lt;em style="font: inherit;"&gt;7,&lt;/em&gt; Debt, for additional information. The Complaint&#160;sought, among other things: (i) declaratory relief for an order enjoining the Company from undertaking any Fundamental Transaction, including the Spin-Off, or otherwise issuing Common Stock or other equity securities (such as the shares of HOPE pursuant to the announced Spin-Off); and (ii) repayment of the Streeterville Note and other unspecified amounts of damages, costs and fees, but &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than $6,537,027, or the amounts currently outstanding under the Streeterville Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 29, 2024, &lt;/em&gt;in connection with the alleged Event of Default that Streeterville claimed occurred with respect to the Streeterville Note, the Company&#160;announced an order of the Utah arbitrator denying the petition of Streeterville to enjoin the planned Spin-Off of 49% of shares in HOPE to current shareholders of the Company. The purpose of the proposed Spin-Off was to provide the Company&#x2019;s shareholders with valuable consideration and to provide HOPE (currently a wholly-owned subsidiary) with a sufficient shareholder base to enable future listing on a&#160;national exchange. The arbitrator also denied Streeterville&#x2019;s petition to enjoin the Company&#160;from selling additional shares of Common Stock to finance ongoing operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 12, 2024, &lt;/em&gt;the Company signed a settlement agreement with Streeterville&#160;to retire its remaining debt for a settlement amount of $5.6&#160;million and to settle outstanding litigation. This settlement amount was substantially less than the amounts claimed by Streeterville in its Compliant&#160;(see Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt;). As of &lt;em style="font: inherit;"&gt; September 30, 2024, &lt;/em&gt;the fair value of the Streeterville Note&#160;was adjusted to the settlement amount which was repaid in &lt;em style="font: inherit;"&gt; October 2024. &lt;/em&gt;Such adjustment is included within the change in fair value of convertible notes payable on the consolidated statement of operations, therefore no gain or loss on the settlement was recorded.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 17, 2023, &lt;/em&gt;NeuroRx&#160;and GEM entered into a settlement and release agreement (the &#x201c;Settlement Agreement&#x201d;) pursuant to which the parties agreed to dismiss the arbitration proceeding with prejudice.&#160;Pursuant to the Settlement Agreement on &lt;em style="font: inherit;"&gt; August 31, 2023, &lt;/em&gt;the Company issued&#160;67,568&#160;shares of Common Stock, the fair value of which was approximately $0.3 million based on the quoted trading price on the grant date, to GEM in full satisfaction of the Settlement Agreement which was approximately $0.3&#160;million and was expensed as &#x201c;Settlement expense&#x201d; in fiscal &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The shares are registered under a prospectus supplement to the Company&#x2019;s registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; and are subject to a restriction that they cannot be sold or traded for a period of &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months from the effective date of the Settlement Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company is currently involved in and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;from time to time become involved in various legal actions incidental to our business. As of the date of this report, the Company, other than as set forth above, is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; involved in any legal proceedings that it believes could have a material adverse effect on its financial position or results of operations. However, the outcome of any current or future legal proceeding is inherently difficult to predict and any dispute resolved unfavorably could have a material adverse effect on the Company&#x2019;s business, financial position, and operating results.&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nrxp:ScheduleOfMilestonePaymentsTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867432">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;End of Phase I Clinical Trials of Licensed Product (completed)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;End of Phase II Clinical Trials of Licensed Product (completed)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;End of Phase III Clinical Trials of Licensed Product&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;First Commercial Sale of Licensed Product in U.S.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;First Commercial Sale of Licensed Product in Europe&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Annual Revenues Reach $100,000,000&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;750,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </nrxp:ScheduleOfMilestonePaymentsTableTextBlock>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125341492"
      unitRef="USD">100000</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125341493"
      unitRef="USD">250000</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-EndOfPhaseIIIClinicalTrialsOfLicensedProductMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125341494"
      unitRef="USD">250000</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInUsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125341495"
      unitRef="USD">500000</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-FirstCommercialSaleOfLicensedProductInEuropeMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125341496"
      unitRef="USD">500000</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_ProductOrServiceAxis-AnnualRevenueThresholdMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125341497"
      unitRef="USD">750000</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementsMilestonePaymentsConditionalReductionPercentage
      contextRef="i_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="2"
      id="c125342073"
      unitRef="Pure">0.25</nrxp:LicenseAgreementsMilestonePaymentsConditionalReductionPercentage>
    <nrxp:LicenseAgreementCumulativePayments
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="-5"
      id="c125342075"
      unitRef="USD">400000</nrxp:LicenseAgreementCumulativePayments>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="-3"
      id="c125342076"
      unitRef="USD">0</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125342077"
      unitRef="USD">0.2</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:LicenseAgreementMilestonePayment
      contextRef="d_2022-01-01_2022-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125342078"
      unitRef="USD">0.2</nrxp:LicenseAgreementMilestonePayment>
    <nrxp:RoyaltyPercentage
      contextRef="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByLicensedPatentsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="2"
      id="c125342080"
      unitRef="Pure">0.01</nrxp:RoyaltyPercentage>
    <nrxp:RoyaltyPercentage
      contextRef="i_2024-12-31_ProductOrServiceAxis-ProductsCoveredByValidClaimsMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="3"
      id="c125342083"
      unitRef="Pure">0.025</nrxp:RoyaltyPercentage>
    <nrxp:RoyaltyPercentage
      contextRef="i_2024-12-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="3"
      id="c125342087"
      unitRef="Pure">0.085</nrxp:RoyaltyPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="-3"
      id="c125342089"
      unitRef="USD">0</us-gaap:PaymentsForRoyalties>
    <nrxp:PaymentForLicenseAgreementMaintenanceFee
      contextRef="d_2021-04-16_2021-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125342090"
      unitRef="USD">100000</nrxp:PaymentForLicenseAgreementMaintenanceFee>
    <nrxp:LicenseAgreementMaintenanceFee
      contextRef="i_2022-04-16_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125342091"
      unitRef="USD">150000</nrxp:LicenseAgreementMaintenanceFee>
    <nrxp:PaymentForLicenseAgreementMaintenanceFee
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-SarahHerzogMemorialHospitalLicenseAgreementMember"
      decimals="INF"
      id="c125342092"
      unitRef="USD">150000</nrxp:PaymentForLicenseAgreementMaintenanceFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PatentLicenseMember_TypeOfArrangementAxis-ExclusiveLicenseAgreementMember"
      decimals="-3"
      id="c125342097"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember"
      decimals="-5"
      id="c125342099"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2023-01-01_2023-12-31_LeaseContractualTermAxis-LeaseContractualTermOfficeSpaceRentalMember"
      decimals="-5"
      id="c125342100"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="d_2024-04-24_2024-04-24_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="INF"
      id="c125342103"
      unitRef="USD">6537027</us-gaap:LossContingencyDamagesSoughtValue>
    <nrxp:StockholdersEquityNoteSpinoffTransactionPercentage
      contextRef="d_2024-07-29_2024-07-29_LitigationCaseAxis-StreetervileComplaintMember"
      decimals="2"
      id="c125342106"
      unitRef="Pure">0.49</nrxp:StockholdersEquityNoteSpinoffTransactionPercentage>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="d_2024-08-12_2024-08-12_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125342107"
      unitRef="USD">5600000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="d_2024-01-01_2024-12-31_LitigationCaseAxis-StreetervileComplaintMember_LongtermDebtTypeAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125342109"
      unitRef="USD">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="INF"
      id="c125342110"
      unitRef="Share">67568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-5"
      id="c125342111"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-08-31_2023-08-31_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="-5"
      id="c125342112"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867433">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Common Stock Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 21, 2024, &lt;/em&gt;the Board approved a reverse stock split ratio of &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-10. On &lt;em style="font: inherit;"&gt; March 28, 2024, &lt;/em&gt;the Company filed an amendment to its certificate of incorporation in the State of Delaware (the &#x201c;&lt;i&gt;Amendment&lt;/i&gt;&#x201d;), which provided that&#160;every &lt;span style="-sec-ix-hidden:c125342120"&gt;ten&lt;/span&gt; shares of its issued and outstanding Common Stock would&#160;automatically be combined into &lt;em style="font: inherit;"&gt;one&lt;/em&gt; issued and outstanding share of Common Stock, without any change in the par value per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Effective &lt;em style="font: inherit;"&gt; April 1, 2024, &lt;/em&gt;every 10 issued and outstanding shares of the Company&#x2019;s Common Stock were converted automatically into &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of the Company&#x2019;s Common Stock, without any change in the par value per share. The Reverse Stock Split reduced the number of shares of Common Stock issued and outstanding from approximately 95.7 million to approximately 9.6 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; fractional shares were issued in connection with the Reverse Stock Split. Shareholders who otherwise would have been entitled to receive a fractional share instead became entitled to receive &lt;em style="font: inherit;"&gt;one&lt;/em&gt; whole share of Common Stock in lieu of such fractional share. As a result of the Reverse Stock Split, 73,040 additional shares of common stock were issued in lieu of fractional shares.&#160;All share and per share amounts in the accompanying consolidated financial statements and footnotes have been retrospectively adjusted for the reverse split.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Pursuant to the terms of the Company&#x2019;s Second Amended and Restated Certificate of Incorporation, the Company has &lt;span style="-sec-ix-hidden:c125342129"&gt;authorized&#x202f;50,000,000&#x202f;shares&lt;/span&gt; of preferred stock with a par value of &lt;span style="-sec-ix-hidden:c125342130"&gt;$0.001.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Series A Convertible Preferred Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 30, 2023, &lt;/em&gt;the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;) with the Delaware Secretary of State (the &#x201c;Certificate of Designation&#x201d;) authorizing up to 12,000,000 shares of Series A Preferred Stock.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2023, &lt;/em&gt;the Company sold and issued 3,000,000 shares of Series A Preferred Stock. Each share of Series A Preferred Stock was sold with &lt;span style="-sec-ix-hidden:c125342133"&gt;one&lt;/span&gt; warrant (a &#x201c;Unit"), see investor warrant section below for terms, for an aggregate cash purchase price of $1.2 million or $0.40 per Unit.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2024, &lt;/em&gt;holders of the Company&#x2019;s Series A Preferred elected to convert 3,000,000 shares of Series A Preferred into 300,000 shares of Common Stock. As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;no shares of Series A Preferred remained issued or outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Dividend Rights&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The holders of Series A Preferred Stock are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to receive any dividends in respect to the Series&#x202f;A Preferred Stock.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Voting Rights&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The holders of Series A Preferred Stock have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights other than for an affirmative vote in order for the Company to (a) disproportionally alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that disproportionally adversely affects any rights of the Holders, (c) increase or decrease the number of authorized shares of Series A Preferred Stock or (d) enter into any agreement with respect to any of the foregoing.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Conversion Rights&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Each share of Series A Preferred Stock shall be convertible into a number of shares of Common Stock equal to the number of shares of Series A Preferred Stock being converted. Notwithstanding the foregoing, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; share of Series&#x202f;A Preferred Stock shall be convertible during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;)&#x202f;month period following the issuance date;&#x202f;provided, however, if the Common Stock trades at or above $1.20 per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events), as reported on Bloomberg, L.P. on any trading day, holder &lt;em style="font: inherit;"&gt; may &lt;/em&gt;convert the Series&#x202f;A Preferred Stock prior to the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;)&#x202f;month anniversary of the issuance date. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; fractional shares will be issued upon conversion. Conversion is subject to certain limitations, including the holder &lt;em style="font: inherit;"&gt;not&lt;/em&gt; owning more than 4.9% of the outstanding shares of Common Stock.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Liquidation Rights&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Upon any liquidation, dissolution or winding up of the Company (a &#x201c;Liquidation&#x201d;), whether voluntary or involuntary, each holder of Series A Preferred Stock shall be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive if such shares had been converted to Common Stock immediately prior to such Liquidation, subject to certain rights and limitations.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Pursuant to the terms of the Company&#x2019;s Second Amended and Restated Certificate of Incorporation, the Company has authorized&#160;500,000,000&#160;shares of common stock with a par value of&#160;$0.001.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 8, 2023, &lt;/em&gt;NRx Pharmaceuticals entered into a securities purchase agreement with the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investors, providing for the issuance and sale of&#160;386,667&#160;shares of Common Stock and the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investor Warrants to purchase up to&#160;386,667&#160;shares of Common Stock in a registered direct offering priced at-the-market under Nasdaq rules for a purchase price of $7.50&#160;per share. The &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investor Warrants have an exercise price of $7.50 per share, are exercisable beginning on &lt;em style="font: inherit;"&gt; September 8, 2023 &lt;/em&gt;and will expire &lt;span style="-sec-ix-hidden:c125342158"&gt;5&lt;/span&gt; years from the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Initial Exercise Date.&#160;The &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investors agreed &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to transfer the Common Stock for&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months&#160;following the date of issuance. The aggregate net cash proceeds to the Company from the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Offering were approximately $2.5 million net of offering costs of approximately $0.4 million. The Company used the net proceeds from such offering for working capital and general corporate purposes. The closing of the sale of these securities occurred on &lt;em style="font: inherit;"&gt; March 9, 2023. &lt;/em&gt;The securities were issued pursuant to the Company&#x2019;s registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; filed with the SEC on &lt;em style="font: inherit;"&gt; June 9, 2022 (&lt;/em&gt;File &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;333&lt;/em&gt;-&lt;em style="font: inherit;"&gt;265492&lt;/em&gt;) which became effective on &lt;em style="font: inherit;"&gt; June 21, 2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 8, 2023, &lt;/em&gt;the Company entered into a letter agreement with H.C. Wainwright &amp;amp; Co., LLC. Although they did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; act as the placement agent with respect to the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Offering, H.C. Wainwright &amp;amp; Co., LLC was paid a cash fee equal to 3.0% of the amount raised, or approximately $0.1 million, pursuant to the letter agreement, which was charged against the proceeds in additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;6,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company entered into a securities purchase agreement with the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investors, providing for the issuance and sale of 967,000 shares of the Company&#x2019;s Common Stock and the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investor Warrants to purchase up to 967,000 shares of Common Stock. The Common Stock was issued in a registered direct offering for a purchase price of $6.50 per share and the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investor Warrants were offered pursuant to a private placement under Section&#160;&lt;em style="font: inherit;"&gt;4&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;of the Securities Act. The aggregate net cash proceeds to the Company from the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Offering were approximately $5.6 million. The Company used the net proceeds from the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Offering for working capital and general corporate purposes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;H.C. Wainwright &amp;amp; Co. LLC acted as the exclusive placement agent (the &#x201c;Placement Agent&#x201d;) for the &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Offering. The Placement Agent was paid a cash fee equal to 6.5% of the gross proceeds received by the Company from the sale of the securities at the closing of the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Offering or approximately $0.6 million which was charged against the proceeds in additional paid-in capital. The Company used the net proceeds from such offering for working capital and general corporate purposes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;In connection with the Note issued to Streeterville, on &lt;em style="font: inherit;"&gt; May 15, 2023 &lt;/em&gt;the Company issued 40,868 Common Stock to Streeterville in repayment of interest on the Note. Additionally on &lt;em style="font: inherit;"&gt; August 4, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; August 30, 2023, &lt;/em&gt;the Company issued 131,266 and 154,289 respectively to Streeterville for repayment of principal and interest under the Note. Refer to Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for further details.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 17, 2023, &lt;/em&gt;the Company and GEM entered into a settlement agreement where the Company issued 67,568 shares of Common Stock to GEM in full satisfaction of its obligation. Refer to Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; for further details.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 2, 2024, &lt;/em&gt;the Company issued 143,648 shares of Common Stock as payment for the $0.4 million minimum payment to Streeterville related to principal and interest payments on the Streeterville Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;From &lt;em style="font: inherit;"&gt; February 20, 2024 &lt;/em&gt;to &lt;em style="font: inherit;"&gt; July 29, 2024, &lt;/em&gt;the Company announced that it entered into multiple purchase agreements (the &#x201c;&lt;i&gt;ATM Purchase Agreements&lt;/i&gt;&#x201d;) subject to standard closing conditions where accredited investors purchased 385,515 shares of unregistered Common Stock at a range of &#160;$2.42&#160;&#x2013; $7.10&#160;per share.&#160;On &lt;em style="font: inherit;"&gt; April 15, 2024, &lt;/em&gt;the Company increased the maximum aggregate offering amount of the shares of Common Stock issuable under that certain At the Market Offering Agreement, dated &lt;em style="font: inherit;"&gt; August 14, 2023 (&lt;/em&gt;the &#x201c;&lt;i&gt;Offering Agreemen&lt;/i&gt;t&#x201d;), with H.C. Wainwright &amp;amp; Co., and filed a prospectus supplement (the &#x201c;&lt;i&gt;Current Prospectus Supplement&lt;/i&gt;&#x201d;) under the Offering Agreement for an aggregate of $4.9 million. Through &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the aggregate net cash proceeds to the Company from the ATM Purchases Agreements were approximately $1.6 million.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 27, 2024, &lt;/em&gt;the Company entered into an underwriting agreement (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriting Agreement&lt;/i&gt;&#x201d;) with EF Hutton LLC (the &#x201c;&lt;i&gt;Representative&lt;/i&gt;&#x201d;), as the representative of the several underwriters named therein (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriters&lt;/i&gt;&#x201d;), relating to an underwritten public offering (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Public Offering&lt;/i&gt;&#x201d;) of 500,000 shares (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Shares&lt;/i&gt;&#x201d;) of the Company&#x2019;s Common Stock. The public offering price for each share of Common Stock was $3.00 and the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriters purchased the shares of Common Stock pursuant to the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriting Agreement at a price for each share of Common Stock of $2.76. Pursuant to the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriting Agreement, the Company also granted the Representative a &lt;em style="font: inherit;"&gt;45&lt;/em&gt;-day option to purchase up to an additional 75,000 shares (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Option Shares&lt;/i&gt;&#x201d;) of the Common Stock on the same terms as the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Shares sold in the &lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Public Offering (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Over-Allotment Option&lt;/i&gt;&#x201d;). On &lt;em style="font: inherit;"&gt; February 28, 2024, &lt;/em&gt;the &lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Public Offering closed (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Closing Date&lt;/i&gt;&#x201d;). The aggregate net cash proceeds to the Company from the &lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Offering proceeds were approximately $1.3 million after offering costs of approximately $0.4 million. On &lt;em style="font: inherit;"&gt; March 5, 2024, &lt;/em&gt;the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriting Agreement, dated &lt;em style="font: inherit;"&gt; February 27, 2024, &lt;/em&gt;by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional 75,000 shares of the Company&#x2019;s Common Stock, at a public offering price of $3.00 per share (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Overallotment Exercise&lt;/i&gt;&#x201d;). The &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Overallotment Exercise closed on &lt;em style="font: inherit;"&gt; March 6, 2024. &lt;/em&gt;The aggregate net cash proceeds to the Company from the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Overallotment Exercise were approximately $0.2&#160;million. The Company accrued additional offering costs of approximately $0.2 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February &lt;/em&gt;&lt;em style="font: inherit;"&gt;29,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company entered into a securities purchase agreement with an investor providing for the issuance and sale of 270,000 shares of Common Stock and warrants to purchase up to 270,000 shares of Common Stock (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Warrants&lt;/i&gt;&#x201d;) at a price of $3.80 per share of Common Stock and accompanying warrant, which represents a 26.7% premium to the offering price in &lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Public Offering. The Common Stock and the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Warrants were offered pursuant to a private placement (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Private Placement&lt;/i&gt;&#x201d;) under Section &lt;em style="font: inherit;"&gt;4&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) of the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended (the &#x201c;&lt;i&gt;Securities Act&lt;/i&gt;&#x201d;). The aggregate net cash proceeds to the Company from the &lt;em style="font: inherit;"&gt; February 2024 &lt;/em&gt;Private Placement were approximately $1.0 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt;April&#x202f;18,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company entered into an underwriting agreement (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriting Agreement&lt;/i&gt;&#x201d;) with the Representative, as the representative of the several underwriters named therein (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriters&lt;/i&gt;&#x201d;), relating to an underwritten public offering (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April 2024 &lt;/em&gt;Public Offerin&lt;/i&gt;g&#x201d;) of 607,000 shares (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Shares&lt;/i&gt;&#x201d;) of&#160;Common Stock. The public offering price for each share of Common Stock was $3.30. Pursuant to the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriting Agreement, the Company also granted the Representative a &lt;em style="font: inherit;"&gt;45&lt;/em&gt;-day option to purchase up to an additional 91,050 shares (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Option Shares&lt;/i&gt;&#x201d;) of the Common Stock on the same terms as the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Shares sold in the &lt;em style="font: inherit;"&gt; April 2024 &lt;/em&gt;Public Offering (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Over-Allotment Option&lt;/i&gt;&#x201d;). On &lt;em style="font: inherit;"&gt;April&#x202f;19,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Offering closed (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Closing Date&lt;/i&gt;&#x201d;). Net proceeds from the &lt;em style="font: inherit;"&gt; April 2024 &lt;/em&gt;Public Offering were approximately $1.6 million after offering costs of approximately $0.4 million. On &lt;em style="font: inherit;"&gt; May 23, 2024, &lt;/em&gt;the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriting Agreement, dated &lt;em style="font: inherit;"&gt; April 18, 2024, &lt;/em&gt;by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional 91,050 shares of the Company&#x2019;s Common Stock, at the public offering price of $3.30&#160;per share (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Overallotment Exercise&lt;/i&gt;&#x201d;). The &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Over-Allotment Exercise was exercised in full and closed on &lt;em style="font: inherit;"&gt; May 23, 2024.&#160;&lt;/em&gt;The net&#160;cash proceeds to the Company from the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Overallotment Exercise were approximately $0.2&#160;million which include&#160;offering costs of less than $0.1 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; August 28, 2024, &lt;/em&gt;the Company issued 20,000 shares of Common Stock in relation to consulting services performed by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party. The fair value of the Common Stock on the date of issuance was less than $0.1 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;During the&#160;year ended &lt;em style="font: inherit;"&gt; December 31, 2024,&#160;&lt;/em&gt;Anson converted $4.2 million of principal and interest of the First Tranche Note into common stock, resulting in the issuances of 3,676,796 shares of Common Stock valued at $5.5 million based on the market price of our common stock at the date of common stock issuance resulting in a loss on redemption&#160;of $1.3 million (see Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt;).&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Substitute Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In connection with the Merger in &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; each warrant to purchase shares of Common Stock of NRx that was outstanding and unexercised immediately prior to the effective time (whether vested or unvested) was assumed by Big Rock Partners Acquisition Corp. (&lt;i&gt;"BRPA"&lt;/i&gt;) and converted into a warrant, based on the exchange ratio (of&#160;0.316), that will continue to be governed by substantially the same terms and conditions, including vesting, as were applicable to the former warrant (the &#x201c;&lt;i&gt;Substitute Warrants&lt;/i&gt;&#x201d;). There were 3,792,970 warrants outstanding and unexercised at the effective time. As these Substitute Warrants meet the definition of a derivative as contemplated in FASB ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; based on provisions in the warrant agreement related to the Earnout Shares Milestone and the Earnout Cash Milestone and the contingent right to receive additional shares for these provisions, the Substitute Warrants were recorded as derivative liabilities on the consolidated balance sheet and measured at fair value at inception (on the date of the Merger) and at each reporting date in accordance with FASB ASC Topic &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; with changes in fair value recognized in the statements of operations in the period of change.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recognized a gain on the change in fair value of the Substitute Warrants for each of the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; of &lt;span style="-sec-ix-hidden:c125342246"&gt;nil&lt;/span&gt; and less than $0.1 million, respectively. Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for further discussion of fair value measurement of the warrant liabilities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Assumed Public Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Prior to the Merger, the Company had&#160;3,450,000&#160;warrants outstanding (the &#x201c;&lt;i&gt;Public Warrants&lt;/i&gt;&#x201d;) to purchase up to 345,000 shares of Common Stock. Each Public Warrant entitles the holder to purchase&#160;&lt;span style="-sec-ix-hidden:c125342251"&gt;one&lt;/span&gt;-&lt;em style="font: inherit;"&gt;tenth&lt;/em&gt;&#160;share of Common Stock at an exercise price of $115&#160;per share. The Public Warrants became exercisable at the effective time of the Merger and expire&#160;&lt;em style="font: inherit;"&gt;five&lt;/em&gt; years&#160;after the effective time on or earlier upon their redemption or liquidation of the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; no&#160;Public Warrants were exercised. The outstanding balance of these warrants remains in equity. At &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; there were 3,448,856 Public Warrants outstanding to purchase up to 344,886 shares of Common Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Assumed Private Placement Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Prior to the Merger, the Company had outstanding&#160;136,250&#160;Private Placement Warrants (the &#x201c;&lt;i&gt;Private Placement Warrants&lt;/i&gt;&#x201d;) to purchase up to 13,625 shares of Common Stock.&#160;The Private Placement Warrants are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; indexed to the Company&#x2019;s common shares in the manner contemplated by FASB ASC Topic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; because the holder of the instrument is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; an input into the pricing of a fixed-for-fixed option on equity shares. The Company classifies the Private Placement Warrants as derivative liabilities in its consolidated balance sheets as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The Company measures the fair value of the Private Placement Warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company&#x2019;s statements of operations for the current period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recognized a gain on the change in fair value of the Private Placement Warrants for each of the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; of less than $0.1 million, respectively. Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for discussion of the fair value measurement of the Company&#x2019;s warrant liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Investor Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 8, 2023, &lt;/em&gt;in conjunction with the issuance and sale of&#160;386,667&#160;shares of the Company&#x2019;s Common Stock, the Company issued 386,667 &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investor Warrants which were classified in stockholder&#x2019;s equity. The measurement of fair value of the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $7.20, exercise price of $7.50, term of &lt;span style="-sec-ix-hidden:c125342277"&gt;five&lt;/span&gt; and a half years, volatility of 123.6%, risk-free rate of 4.34%, and expected dividend rate of 0%). The &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investor Warrants had an original exercise price of $7.50 per share, are initially exercisable beginning&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months&#160;following the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Initial Exercise Date and will expire&#160;&lt;span style="-sec-ix-hidden:c125342283"&gt;five&lt;/span&gt; and a half years&#160;from the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Initial Exercise Date.&#160; The grant date fair value of these &lt;em style="font: inherit;"&gt; March &lt;/em&gt;Investor Warrants was estimated to be $2.4 million on &lt;em style="font: inherit;"&gt; March 8, 2023 &lt;/em&gt;and is reflected within additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;As discussed above, on &lt;em style="font: inherit;"&gt; June 6, 2023, &lt;/em&gt;in conjunction with the issuance and sale of&#160;967,000 shares of the Company&#x2019;s Common Stock, the Company issued 967,000 &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investor Warrants which were classified in stockholder&#x2019;s equity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The measurement of fair value of the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $5.30, exercise price of $6.53, term of &lt;span style="-sec-ix-hidden:c125342289"&gt;five&lt;/span&gt; and a half years, volatility of 175.1%, risk-free rate of 3.85%, and expected dividend rate of 0%). The grant date fair value of these &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investor Warrants was estimated to be $3.1 million on &lt;em style="font: inherit;"&gt; June 6, 2023, &lt;/em&gt;and is reflected within additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company issued 19,340 warrants to the Placement Agent with an exercise price of $8.13 (the &lt;em style="font: inherit;"&gt; &#x201c;June &lt;/em&gt;Placement Agent Warrants&#x201d;). As these &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Placement Agent Warrants were issued for services provided in facilitating the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Offering, the Company recorded the fair value of such &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Placement Agent Warrants of approximately $0.1 million as a cost of capital on the issuance date. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $5.30, exercise price of $8.13, term of &lt;span style="-sec-ix-hidden:c125342299"&gt;five&lt;/span&gt; and a half years, volatility of 175.1%, risk-free rate of 3.85%, and expected dividend rate of 0%).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;In connection with the &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Offering, the Company also entered into a warrant amendment agreement (the &#x201c;Warrant Amendment Agreement&#x201d;) with certain investors to amend certain existing warrants to purchase up to 962,278 shares of Common Stock that were previously issued in &lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; to such investors, with an exercise price of $30.70 and $120.00 per share, respectively (the &#x201c;Amended Warrants&#x201d;) as follows: (i)&#160;lower the exercise price of the Amended Warrants to $6.525 per share, and (ii)&#160;provide that the Amended Warrants, as amended, will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be exercisable until &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months following the closing date of the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Offering, and (iii)&#160;extend the original expiration date of the Amended Warrants so that they will terminate &lt;span style="-sec-ix-hidden:c125342311"&gt;five&lt;/span&gt; and &lt;em style="font: inherit;"&gt;one&lt;/em&gt; half years from the closing of the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company recorded the incremental change in fair value of such Amended Warrants of $1.5 million as a cost of capital to issue the &lt;em style="font: inherit;"&gt; June &lt;/em&gt;Investor Warrants. The measurement of fair value for the Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $5.30, exercise price of $6.525, term of &lt;span style="-sec-ix-hidden:c125342316"&gt;five&lt;/span&gt; and a half years, volatility of 175.1%, risk-free rate of 3.85%, and expected dividend rate of 0%).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;As discussed above, on &lt;em style="font: inherit;"&gt;August&#x202f;28,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; in conjunction with the issuance and sale of 3,000,000 shares of the Company&#x2019;s Series&#x202f;A Convertible Preferred Stock, the Company issued 300,000 &lt;em style="font: inherit;"&gt; August &lt;/em&gt;Investor Warrants which were classified in stockholder&#x2019;s equity. Each Investor Warrants had an exercise price of $4.00 and term of &lt;span style="-sec-ix-hidden:c125342325"&gt;five&lt;/span&gt; years. The measurement of fair value of the &lt;em style="font: inherit;"&gt; August &lt;/em&gt;Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.00, exercise price of $4.00, term of &lt;span style="-sec-ix-hidden:c125342328"&gt;five&lt;/span&gt; years, volatility of 175.1%, risk-free rate of 4.38%, and expected dividend rate of 0%). The grant date fair value of these &lt;em style="font: inherit;"&gt; August &lt;/em&gt;Investor Warrants was estimated to be $0.8 million on &lt;em style="font: inherit;"&gt; August 28, 2023 &lt;/em&gt;and is reflected within additional paid-in capital.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; October 24, 2023, &lt;/em&gt;in connection with the Securities Purchase Agreement dated &lt;em style="font: inherit;"&gt; March 8, 2023, &lt;/em&gt;the Company entered into a warrant amendment agreement (the &lt;em style="font: inherit;"&gt; &#x201c;October &lt;/em&gt;Warrant Amendment Agreement&#x201d;) with certain Investors to amend the existing Investor Warrants to purchase up to 386,667 shares of Common Stock that were previously issued in &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;adjusted from the original exercise price of $7.50 to $6.525 per share (the &lt;em style="font: inherit;"&gt; &#x201c;October &lt;/em&gt;Amended Warrants&#x201d;).&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company recorded the incremental change in fair value of such &lt;em style="font: inherit;"&gt; October &lt;/em&gt;Amended Warrants of approximately $9.0 thousand as a deemed dividend and an adjustment to arrive at net income available to common stockholders on the statement of operations. As the Company is in an accumulated deficit position, in the absence of retained earnings, the Company recorded the reduction to additional paid-in capital (i.e., a net &lt;em style="font: inherit;"&gt;zero&lt;/em&gt; impact to additional paid-in capital). The measurement of fair value for the &lt;em style="font: inherit;"&gt; October &lt;/em&gt;Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of amendment (i.e., share price of $2.80, exercise price of $6.525, term of &lt;span style="-sec-ix-hidden:c125342340"&gt;five&lt;/span&gt; years, volatility of 159.4%, risk-free rate of 4.85%, and expected dividend rate of 0%).&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 28, 2024, &lt;/em&gt;in conjunction with the sale of&#160;270,000&#160;shares of the Company&#x2019;s Common Stock, the Company issued&#160;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Warrants to purchase up to 270,000 shares of Common Stock which were classified in stockholder&#x2019;s equity. The &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Warrants have an exercise price of $3.80 per share, are initially exercisable beginning &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months following the date of issuance, and will expire &lt;span style="-sec-ix-hidden:c125342350"&gt;five&lt;/span&gt;&#160;years from the date of issuance. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.59, exercise price of $3.80, term of 5 years, volatility of 178.10%, risk-free rate of 4.26%, and expected dividend rate of 0%). The allocated fair value of the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Warrants on the grant date was $0.5 million and is recorded within&#160;additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 28, 2024, &lt;/em&gt;the Company issued to the Representative the Underwriter&#x2019;s Warrant to purchase up to 25,000 shares of Common Stock (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; February &lt;/em&gt;Underwriter Warrant Shares&lt;/i&gt;&#x201d;). The Underwriter&#x2019;s Warrant is exercisable &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months following the date of the Underwriting Agreement and terminates on the &lt;span style="-sec-ix-hidden:c125342360"&gt;five&lt;/span&gt;-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.05, exercise price of $3.30, term of 5 years, volatility of 178.10%, risk-free rate of 4.26%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was $0.1 million and is recorded as a charge to additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 5, 2024 &lt;/em&gt;the Company issued Underwriter&#x2019;s Warrant to purchase up to 3,750 shares of Common Stock in relation to the exercise of the &lt;em style="font: inherit;"&gt; February &lt;/em&gt;Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.05, exercise price of $3.30, term of 5 years, volatility of 178.10%, risk-free rate of 4.12%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; April 19, 2024, &lt;/em&gt;the Company issued to the Representative the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriter&#x2019;s Warrant to purchase up to 30,350 shares of Common Stock (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriter Warrant Shares&lt;/i&gt;&#x201d;). The &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriter&#x2019;s Warrant is exercisable &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months following the date of the Underwriting Agreement and terminates on the &lt;span style="-sec-ix-hidden:c125342378"&gt;five&lt;/span&gt;-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.04, exercise price of $3.63, term of 5 years, volatility of 178.10%, risk-free rate of 4.66%, and expected dividend rate of 0%). The allocated fair value of the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Underwriter's Warrant&#160;on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 23, 2024 &lt;/em&gt;the Company issued Underwriter&#x2019;s Warrant to purchase up to 4,553 shares of Common Stock in relation to the exercise of the &lt;em style="font: inherit;"&gt; April &lt;/em&gt;Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.62, exercise price of $3.63, term of 5 years, volatility of 178.10%, risk-free rate of 4.52%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Alvogen Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In conjunction with the amended Alvogen licensing agreement discussed in Note &lt;em style="font: inherit;"&gt;6,&lt;/em&gt; on &lt;em style="font: inherit;"&gt; February 7, 2024, &lt;/em&gt;the Company issued warrants to purchase up to 419,598 shares of Common Stock. The warrants have an exercise price of $4.00 per share, are exercisable immediately following the date of issuance, will expire &lt;span style="-sec-ix-hidden:c125342399"&gt;three&lt;/span&gt;&#160;years from the date of issuance, and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be exercised on a cashless basis if there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; effective registration statement available for the resale of the shares of Common Stock underlying the warrants. The warrants are subject to a beneficial ownership limitation of 4.99% post-exercise, with the exception that the beneficial ownership limitation &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be waived up to a maximum of 9.99% at the election of the holder, with &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than &lt;em style="font: inherit;"&gt;61&lt;/em&gt; days prior notice. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $4.10, exercise price of $4.00, term of 3 years, volatility of 138.0%, risk-free rate of 4.2%, and expected dividend rate of 0.0%). The fair value of the warrants on the grant date was $1.3 million and was recorded within additional paid-in capital as of &lt;em style="font: inherit;"&gt; March 31, 2024.&#160;&lt;/em&gt;Upon termination of the Alvogen Agreement on &lt;em style="font: inherit;"&gt; June 21, 2024, &lt;/em&gt;the offsetting&#160;amount recorded within additional paid-in capital as an unfunded stock subscription receivable was expensed to research and development.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Anson Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Anson&#160;Warrants, originally issued in the Purchase Agreement, are recognized as derivative liabilities in accordance with ASC &lt;em style="font: inherit;"&gt;815.&lt;/em&gt; The Company concluded liability classification was appropriate&#160;as certain settlement features included in the Anson Warrants are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; indexed to the Company's own stock, and therefore preclude&#160;equity classification. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercise or expiration, and any change in fair value is recognized in the Company&#x2019;s consolidated statements of operations. The Anson Warrants were initially measured at fair value using a Black-Scholes model and have subsequently been measured based on the listed market price of such warrants. Warrant liabilities are classified as current liabilities on the Company's consolidated balance sheets. On &lt;em style="font: inherit;"&gt; August 14, 2024, &lt;/em&gt;in conjunction with the issuance of the First Tranche Notes, the Company issued warrants&#160;to purchase up to 1,349,305 shares of the Company&#x2019;s Common Stock which were classified as a liability. The warrants have an exercise price of $2.4168 per share, subject to adjustment or other settlement provisions, and have a contractual term of &lt;span style="-sec-ix-hidden:c125342416"&gt;five&lt;/span&gt; years expiring on &lt;em style="font: inherit;"&gt; August 14, 2029.&#160;&lt;/em&gt;The measurement of fair value of the Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $1.86, exercise price of $2.42, term of &lt;span style="-sec-ix-hidden:c125342419"&gt;five&lt;/span&gt; years, volatility of 122%, and risk-free rate of 3.67%, and expected dividend rate of 0%). The grant date fair value of these Investor Warrants was estimated to be $2.1 million on &lt;em style="font: inherit;"&gt; August 14, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; October 10, 2024, &lt;/em&gt;in conjunction with the issuance of the Second Tranche Notes, the Company issued warrants&#160;to purchase up to 1,846,128 shares of the Company&#x2019;s Common Stock which were classified as a liability. The warrants have an exercise price of $1.7664 per share, subject to adjustment or other settlement provisions, and have a contractual term of &lt;span style="-sec-ix-hidden:c125342426"&gt;five&lt;/span&gt; years expiring on &lt;em style="font: inherit;"&gt; October 10, 2029.&#160;&lt;/em&gt;The measurement of fair value of the Investor Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $1.38, exercise price of $1.76, term of five years, volatility of 105%, and risk-free rate of 3.91%, and expected dividend rate of 0%). The grant date fair value of these Second Trench Investor Warrants was estimated to be $1.9 million on &lt;em style="font: inherit;"&gt; October 10, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the fair value of the Anson Warrants was&#160;$5.6 million. The Company recognized a loss on the change in fair value of The Anson&#160;Warrant for the year ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;of approximately $1.7 million. Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for discussion of the fair value measurement of the Company&#x2019;s warrant liabilities. Refer to Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for further discussion of fair value measurement of the warrant liabilities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table provides the activity for all warrants for the respective periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total &lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(in thousands)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,648,492&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;64.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,673,007&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4.38&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,321,499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,948,484&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(96,417&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,173,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.77&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-03-21_2024-03-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c125342119"
      unitRef="Pure">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-04-01_2024-04-01_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c125342122"
      unitRef="Pure">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-03-28"
      decimals="-5"
      id="c125342124"
      unitRef="Share">95700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-04-01"
      decimals="-5"
      id="c125342125"
      unitRef="Share">9600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2024-04-01_2024-04-30"
      decimals="INF"
      id="c125342128"
      unitRef="Share">73040</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-08-30_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c125342131"
      unitRef="Share">12000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-08-01_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember"
      decimals="INF"
      id="c125342132"
      unitRef="Share">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-08-01_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember"
      decimals="-5"
      id="c125342134"
      unitRef="USD">1200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2023-08-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredStockAndWarrantsMember"
      decimals="INF"
      id="c125342135"
      unitRef="USDPerShare">0.4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c125342136"
      unitRef="Share">3000000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2024-03-01_2024-03-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAPreferredStockToPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c125342137"
      unitRef="Share">300000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c125342138"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-12-31_RangeAxis-MinimumMember_StatementClassOfStockAxis-CommonStockMember"
      decimals="INF"
      id="c125342146"
      unitRef="USDPerShare">1.2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="i_2024-12-31_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c125342151"
      unitRef="Pure">0.049</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342152"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125342153"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342154"
      unitRef="Share">386667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342155"
      unitRef="Share">386667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="i_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342156"
      unitRef="USDPerShare">7.5</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342157"
      unitRef="USDPerShare">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="-5"
      id="c125342161"
      unitRef="USD">2500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="-5"
      id="c125342162"
      unitRef="USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <nrxp:LetterAgreementPercentageOfCashFeePaid
      contextRef="d_2023-02-08_2023-02-08_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="2"
      id="c125342168"
      unitRef="Pure">0.03</nrxp:LetterAgreementPercentageOfCashFeePaid>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-02-08_2023-02-08_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342169"
      unitRef="USD">0.1</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342172"
      unitRef="Share">967000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342173"
      unitRef="Share">967000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="i_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342174"
      unitRef="USDPerShare">6.5</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="-5"
      id="c125342177"
      unitRef="USD">5600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <nrxp:PlacementAgentFeePercentOfGrossProceeds
      contextRef="i_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="3"
      id="c125342178"
      unitRef="Pure">0.065</nrxp:PlacementAgentFeePercentOfGrossProceeds>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-06-06_2023-06-06_CounterpartyNameAxis-HCWainwrightCoLLCMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="-5"
      id="c125342179"
      unitRef="USD">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2023-05-15_2023-05-15_DebtInstrumentAxis-StreetervilleCapitalLLCMember"
      decimals="INF"
      id="c125342180"
      unitRef="Share">40868</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2023-08-04_2023-08-04_DebtInstrumentAxis-StreetervilleCapitalLLCMember"
      decimals="INF"
      id="c125342181"
      unitRef="Share">131266</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2023-08-30_2023-08-30_DebtInstrumentAxis-StreetervilleCapitalLLCMember"
      decimals="INF"
      id="c125342182"
      unitRef="Share">154289</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-07-17_2023-07-17_SubsidiarySaleOfStockAxis-ShareSubscriptionFacilityAgreementGEMMember"
      decimals="INF"
      id="c125342184"
      unitRef="Share">67568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-02_2024-01-02_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtToCommonStockMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="INF"
      id="c125342188"
      unitRef="Share">143648</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2024-01-02_2024-01-02_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtToCommonStockMember_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125342189"
      unitRef="USD">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-02-20_2024-07-29_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c125342190"
      unitRef="Share">385515</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-07-29_RangeAxis-MinimumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c125342191"
      unitRef="USDPerShare">2.42</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-07-29_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c125342192"
      unitRef="USDPerShare">7.1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-08-14_2023-08-14_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-5"
      id="c125342193"
      unitRef="USD">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-5"
      id="c125342194"
      unitRef="USD">1600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"
      decimals="INF"
      id="c125342195"
      unitRef="Share">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="i_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"
      decimals="INF"
      id="c125342196"
      unitRef="USDPerShare">3</us-gaap:SharePrice>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"
      decimals="INF"
      id="c125342197"
      unitRef="USDPerShare">2.76</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-02-27_2024-02-27_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"
      decimals="INF"
      id="c125342199"
      unitRef="Share">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"
      decimals="-5"
      id="c125342200"
      unitRef="USD">1300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-FebruaryUnderwritingAgreementMember"
      decimals="-5"
      id="c125342201"
      unitRef="USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"
      decimals="INF"
      id="c125342202"
      unitRef="Share">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="i_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"
      decimals="INF"
      id="c125342203"
      unitRef="USDPerShare">3</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"
      decimals="-5"
      id="c125342204"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-03-06_2024-03-06_SubsidiarySaleOfStockAxis-FebruaryOverallotmentOptionMember"
      decimals="-5"
      id="c125342205"
      unitRef="USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125342208"
      unitRef="Share">270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125342209"
      unitRef="Share">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-02-29_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125342210"
      unitRef="USDPerShare">3.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nrxp:PrivatePlacementPremiumPercentage
      contextRef="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="3"
      id="c125342211"
      unitRef="Pure">0.267</nrxp:PrivatePlacementPremiumPercentage>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2024-02-29_2024-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-6"
      id="c125342215"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember"
      decimals="INF"
      id="c125342218"
      unitRef="Share">607000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-04-18_SubsidiarySaleOfStockAxis-AprilUnderwriterAgreementMember"
      decimals="INF"
      id="c125342219"
      unitRef="USDPerShare">3.3</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"
      decimals="INF"
      id="c125342221"
      unitRef="Share">91050</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-April2024OfferingMember"
      decimals="-5"
      id="c125342224"
      unitRef="USD">1600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-04-18_2024-04-18_SubsidiarySaleOfStockAxis-April2024OfferingMember"
      decimals="-5"
      id="c125342225"
      unitRef="USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"
      decimals="INF"
      id="c125342226"
      unitRef="Share">91050</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"
      decimals="INF"
      id="c125342227"
      unitRef="USDPerShare">3.3</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"
      decimals="-5"
      id="c125342228"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-05-23_2024-05-23_SubsidiarySaleOfStockAxis-AprilOverallotmentAgreementMember"
      decimals="-5"
      id="c125342229"
      unitRef="USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-08-28_2024-08-28"
      decimals="INF"
      id="c125342232"
      unitRef="Share">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-08-28_2024-08-28"
      decimals="-5"
      id="c125342234"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-5"
      id="c125342235"
      unitRef="USD">4200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="INF"
      id="c125342236"
      unitRef="Share">3676796</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-5"
      id="c125342237"
      unitRef="USD">5500000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2024-01-01_2024-12-31_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonConvertibleNotesMember"
      decimals="-5"
      id="c125342238"
      unitRef="USD">1300000</nrxp:GainLossOnConvertibleDebtRedemption>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="i_2021-05-24_BusinessAcquisitionAxis-NeuroRxMember_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"
      decimals="INF"
      id="c125342241"
      unitRef="Pure">0.316</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-05-24_BusinessAcquisitionAxis-NeuroRxMember_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"
      decimals="INF"
      id="c125342242"
      unitRef="Share">3792970</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31_ClassOfWarrantOrRightAxis-SubstituteWarrantsMember"
      decimals="-5"
      id="c125342247"
      unitRef="USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342249"
      unitRef="Share">3450000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342250"
      unitRef="Share">345000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-05-24_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342253"
      unitRef="USDPerShare">115</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nrxp:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="-3"
      id="c125342256"
      unitRef="Share">0</nrxp:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342258"
      unitRef="Share">3448856</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c125342259"
      unitRef="Share">344886</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"
      decimals="INF"
      id="c125342260"
      unitRef="Share">136250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"
      decimals="INF"
      id="c125342261"
      unitRef="Share">13625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-PrivatePlacementWarrantsMember"
      decimals="-5"
      id="c125342269"
      unitRef="USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342273"
      unitRef="Share">386667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-03-08_2023-03-08_SubsidiarySaleOfStockAxis-March2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342274"
      unitRef="Share">386667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342275"
      unitRef="Pure">7.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342276"
      unitRef="Pure">7.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342278"
      unitRef="Pure">1.236</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342279"
      unitRef="Pure">0.0434</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342280"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember"
      decimals="INF"
      id="c125342281"
      unitRef="USDPerShare">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-03-08_2023-03-08_ClassOfWarrantOrRightAxis-MarchInvestorWarrantsMember"
      decimals="-5"
      id="c125342284"
      unitRef="USD">2400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-06-06_2023-06-06_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342285"
      unitRef="Share">967000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nrxp:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_SubsidiarySaleOfStockAxis-June2023PurchaseAgreementMember"
      decimals="INF"
      id="c125342286"
      unitRef="Share">967000</nrxp:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342287"
      unitRef="Pure">5.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342288"
      unitRef="Pure">6.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342290"
      unitRef="Pure">1.751</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342291"
      unitRef="Pure">0.0385</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342292"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JuneInvestorWarrantsMember"
      decimals="-5"
      id="c125342293"
      unitRef="USD">3100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <nrxp:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember"
      decimals="INF"
      id="c125342294"
      unitRef="Share">19340</nrxp:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember"
      decimals="INF"
      id="c125342295"
      unitRef="USDPerShare">8.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember"
      decimals="-5"
      id="c125342296"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342297"
      unitRef="Pure">5.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342298"
      unitRef="Pure">8.13</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342300"
      unitRef="Pure">1.751</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342301"
      unitRef="Pure">0.0385</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-JunePlacementAgentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342302"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember"
      decimals="INF"
      id="c125342303"
      unitRef="Share">962278</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c125342306"
      unitRef="USDPerShare">30.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c125342307"
      unitRef="USDPerShare">120</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentAgreementMember"
      decimals="INF"
      id="c125342308"
      unitRef="USDPerShare">6.525</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-06-06_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember"
      decimals="-5"
      id="c125342313"
      unitRef="USD">1500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342314"
      unitRef="Pure">5.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342315"
      unitRef="Pure">6.525</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342317"
      unitRef="Pure">1.751</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342318"
      unitRef="Pure">0.0385</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-06-06_ClassOfWarrantOrRightAxis-WarrantAmendmentJuneInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342319"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-08-28_2023-08-28_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342322"
      unitRef="Share">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nrxp:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-08-28_2023-08-28_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c125342323"
      unitRef="Share">300000</nrxp:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember"
      decimals="INF"
      id="c125342324"
      unitRef="USDPerShare">4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342326"
      unitRef="Pure">3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342327"
      unitRef="Pure">4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342329"
      unitRef="Pure">1.751</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342330"
      unitRef="Pure">0.0438</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342331"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-08-28_2023-08-28_ClassOfWarrantOrRightAxis-AugustInvestorWarrantsMember"
      decimals="-5"
      id="c125342332"
      unitRef="USD">800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember"
      decimals="INF"
      id="c125342333"
      unitRef="Share">386667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c125342334"
      unitRef="USDPerShare">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c125342335"
      unitRef="USDPerShare">6.525</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-10-24_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember"
      decimals="-3"
      id="c125342336"
      unitRef="USD">9000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342338"
      unitRef="Pure">2.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342339"
      unitRef="Pure">6.525</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342341"
      unitRef="Pure">1.594</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342342"
      unitRef="Pure">0.0485</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-10-24_ClassOfWarrantOrRightAxis-OctoberAmendedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342343"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-02-28_2024-02-28_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125342346"
      unitRef="Share">270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125342347"
      unitRef="Share">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c125342348"
      unitRef="USDPerShare">3.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342351"
      unitRef="Pure">3.59</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342352"
      unitRef="Pure">3.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342353"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342354"
      unitRef="Pure">1.781</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342355"
      unitRef="Pure">0.0426</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342356"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryWarrantsMember"
      decimals="-5"
      id="c125342357"
      unitRef="USD">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember"
      decimals="INF"
      id="c125342358"
      unitRef="Share">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342361"
      unitRef="Pure">3.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342362"
      unitRef="Pure">3.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342363"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342364"
      unitRef="Pure">1.781</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342365"
      unitRef="Pure">0.0426</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342366"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-02-28_2024-02-28_ClassOfWarrantOrRightAxis-FebruaryUnderwriterWarrantsMember"
      decimals="-5"
      id="c125342367"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember"
      decimals="INF"
      id="c125342368"
      unitRef="Share">3750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342369"
      unitRef="Pure">3.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342370"
      unitRef="Pure">3.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342371"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342372"
      unitRef="Pure">1.781</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342373"
      unitRef="Pure">0.0412</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342374"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-03-05_2024-03-05_ClassOfWarrantOrRightAxis-UnderwriterOverallotmentWarrantsMember"
      decimals="-5"
      id="c125342375"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember"
      decimals="INF"
      id="c125342376"
      unitRef="Share">30350</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342379"
      unitRef="Pure">3.04</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342380"
      unitRef="Pure">3.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342381"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342382"
      unitRef="Pure">1.781</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342383"
      unitRef="Pure">0.0466</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342384"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-04-19_2024-04-19_ClassOfWarrantOrRightAxis-AprilUnderwriterWarrantsMember"
      decimals="-5"
      id="c125342385"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember"
      decimals="INF"
      id="c125342386"
      unitRef="Share">4553</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342387"
      unitRef="Pure">3.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342388"
      unitRef="Pure">3.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342389"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125342390"
      unitRef="Pure">1.781</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342391"
      unitRef="Pure">0.0452</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342392"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-05-23_2024-05-23_ClassOfWarrantOrRightAxis-AprilUnderwriterOverallotmentWarrantsMember"
      decimals="-5"
      id="c125342393"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"
      decimals="INF"
      id="c125342397"
      unitRef="Share">419598</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"
      decimals="INF"
      id="c125342398"
      unitRef="USDPerShare">4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nrxp:ClassOfWarrantOrRightBeneficialOwnershipLimitation
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"
      decimals="4"
      id="c125342401"
      unitRef="Pure">0.0499</nrxp:ClassOfWarrantOrRightBeneficialOwnershipLimitation>
    <nrxp:ClassOfWarrantOrRightBeneficialOwnershipLimitation
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c125342402"
      unitRef="Pure">0.0999</nrxp:ClassOfWarrantOrRightBeneficialOwnershipLimitation>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342405"
      unitRef="Pure">4.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342406"
      unitRef="Pure">4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342407"
      unitRef="Pure">3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c125342408"
      unitRef="Pure">1.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c125342409"
      unitRef="Pure">0.042</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342410"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-02-07_2024-02-07_ClassOfWarrantOrRightAxis-AlvogenAndLotusWarrantsMember"
      decimals="-5"
      id="c125342411"
      unitRef="USD">1300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"
      decimals="INF"
      id="c125342414"
      unitRef="Share">1349305</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"
      decimals="INF"
      id="c125342415"
      unitRef="USDPerShare">2.4168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342417"
      unitRef="Pure">1.86</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342418"
      unitRef="Pure">2.42</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c125342420"
      unitRef="Pure">1.22</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342421"
      unitRef="Pure">0.0367</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342422"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-08-14_2024-08-14_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheOneMember"
      decimals="-5"
      id="c125342423"
      unitRef="USD">2100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"
      decimals="INF"
      id="c125342424"
      unitRef="Share">1846128</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"
      decimals="INF"
      id="c125342425"
      unitRef="USDPerShare">1.7664</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125342427"
      unitRef="Pure">1.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125342428"
      unitRef="Pure">1.76</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125342429"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c125342430"
      unitRef="Pure">1.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125342431"
      unitRef="Pure">0.0391</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125342432"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-10-10_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember"
      decimals="-5"
      id="c125342433"
      unitRef="USD">1900000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember"
      decimals="-5"
      id="c125342436"
      unitRef="USD">5600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-AnsonWarrantsTrancheTwoMember"
      decimals="-5"
      id="c125342437"
      unitRef="USD">1700000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867434">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total &lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(in thousands)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,648,492&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;64.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,673,007&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4.38&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,321,499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,948,484&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(96,417&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,173,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.77&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125341506"
      unitRef="Share">1648492</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm contextRef="d_2022-01-01_2022-12-31" id="c125341507">P3Y7M2D</nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm>
    <nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c125341508"
      unitRef="USDPerShare">64.9</nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice>
    <nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c125341509"
      unitRef="USD">0</nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue>
    <nrxp:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125341510"
      unitRef="Share">1673007</nrxp:ClassOfWarrantOrRightIssuedDuringPeriod>
    <nrxp:ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm contextRef="i_2023-12-31" id="c125341511">P4Y4M17D</nrxp:ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm>
    <nrxp:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125341512"
      unitRef="USDPerShare">6.1</nrxp:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice>
    <nrxp:ClassOfWarrantOrRightIssuedAggregateIntrinsicValue
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341513"
      unitRef="USD">180000</nrxp:ClassOfWarrantOrRightIssuedAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125341514"
      unitRef="Share">3321499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm contextRef="d_2023-01-01_2023-12-31" id="c125341515">P3Y10M28D</nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm>
    <nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125341516"
      unitRef="USDPerShare">23.01</nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice>
    <nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c125341517"
      unitRef="USD">180000</nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue>
    <nrxp:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341518"
      unitRef="Share">3948484</nrxp:ClassOfWarrantOrRightIssuedDuringPeriod>
    <nrxp:ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm contextRef="i_2024-12-31" id="c125341519">P4Y8M15D</nrxp:ClassOfWarrantOrRightIssuedWeightedAverageRemainingTerm>
    <nrxp:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341520"
      unitRef="USDPerShare">2.04</nrxp:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice>
    <nrxp:ClassOfWarrantOrRightIssuedAggregateIntrinsicValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341521"
      unitRef="USD">0</nrxp:ClassOfWarrantOrRightIssuedAggregateIntrinsicValue>
    <nrxp:ClassOfWarrantOrRightExpiredDuringPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341522"
      unitRef="Share">-96417</nrxp:ClassOfWarrantOrRightExpiredDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125341526"
      unitRef="Share">7173766</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm contextRef="d_2024-01-01_2024-12-31" id="c125341527">P3Y9M7D</nrxp:ClassOfWarrantOrRightWeightedAverageRemainingTerm>
    <nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125341528"
      unitRef="USDPerShare">17.2</nrxp:ClassOfWarrantsOrRightsWeightedAverageExercisePrice>
    <nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c125341529"
      unitRef="USD">80000</nrxp:ClassOfWarrantsOrRightsAggregateIntrinsicValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867435">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt; Stock-Based Compensation &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Omnibus Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Prior to the Merger, NRx maintained its &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Omnibus Incentive Plan (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Plan&lt;/i&gt;&#x201d;), under which NeuroRx granted incentive stock options, restricted stock awards, other stock-based awards, or other cash-based awards to employees, directors, and non-employee consultants. The maximum aggregate shares of Common Stock that were subject to awards and issuable under the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Plan was&#160;347,200.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, based on the Exchange Ratio (of&#160;&lt;span style="-sec-ix-hidden:c125342446"&gt;0.316:1&lt;/span&gt;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate&#160;289,542&#160;shares of the Company&#x2019;s Common Stock at an average exercise price of $51.00&#160;per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Omnibus Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;955,281&#160;shares of Common Stock are authorized for issuance pursuant to awards under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Omnibus Incentive Plan (the &#x201c;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan&lt;/i&gt;&#x201d;). As of &lt;em style="font: inherit;"&gt; January 1, 2024, &lt;/em&gt;83,920&#160;shares were added to the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan under an evergreen feature that automatically increases the reserve with additional shares of Common Stock for future issuance under the Incentive Plan each calendar year, beginning &lt;em style="font: inherit;"&gt; January 1, 2022 &lt;/em&gt;and ending on and including &lt;em style="font: inherit;"&gt; January 1, 2031, &lt;/em&gt;equal to the lesser of (A) 1% of the shares of Common Stock outstanding on the final day of the immediately preceding calendar year or (B) a smaller number of shares determined by the Board. On &lt;em style="font: inherit;"&gt; December 28, 2023 &lt;/em&gt;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; amendment to the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Omnibus Plan was executed which increased the maximum number of shares (i) available for issuance under the Plan, by an additional 200,000 shares, and (ii) that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be delivered pursuant to the exercise of Incentive Stock Options granted under the Plan to be equal to &lt;em style="font: inherit;"&gt;100%&lt;/em&gt; of the Share Pool. As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;an aggregate 575,099&#160;shares have been awarded net of forfeitures, and 380,182&#160;shares remain available for issuance under the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan. The &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan permits the granting of incentive stock options, restricted stock awards, other stock-based awards or other cash-based awards to employees, directors, and non-employee consultants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Option Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company&#x2019;s stock options for employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to pay any cash dividends in the foreseeable future. Additionally, certain options granted contain terms that require all unvested options to immediately vest a) upon the approval of an NDA by the FDA for &lt;em style="font: inherit;"&gt;NRX&#x2011;101,&lt;/em&gt; or b) immediately preceding a change in control of the Company, whichever occurs first.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company issued 0 and 90,000 stock options during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following assumptions were used for the year ended &lt;em style="font: inherit;"&gt; December 31, 2023:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$3.00&lt;/td&gt;&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$11.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate of interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.83%&lt;/td&gt;&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.79%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected stock price volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" rowspan="1" style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;150.3%&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" rowspan="1" style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s employee and non-employee stock option activity under the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Plan for the following periods:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of shares&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted average&lt;br/&gt; exercise price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted average remaining contractual life (in years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate intrinsic value (in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;264,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18.30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Expire&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(143,150&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;121,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;22.36&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;7.0&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options vested and exercisable as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;113,993&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;22.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;6.9&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Stock-based compensation expense related to stock options was approximately $0.2 and $0.1 million during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The weighted average grant date fair value per share for employee stock and non-employee option grants during the year ended &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;was $3.50, respectively. There were &lt;span style="-sec-ix-hidden:c125342477"&gt;no&lt;/span&gt; option grants during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was less than $0.1 million, which the Company expects to recognize over a weighted-average period of approximately 1.2 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table presents the Company&#x2019;s Restricted Stock Activity:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Awards&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2023 (unvested)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124,166&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(90,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.64&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(33,333&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2024 (unvested)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 12, 2022, &lt;/em&gt;the Board granted an award of&#160;100,000&#160;restricted shares of the Company (&#x201c;Restricted Stock&#x201d;) as an inducement to the newly appointed CEO, pursuant to a separate Restricted Stock Award Agreement (the &#x201c;RSA&#x201d;). The Restricted Stock will vest in approximately equal installments over&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;(3) years from the grant date, subject to continued service through the applicable vesting date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 28, 2023, &lt;/em&gt;the Company granted 57,500 RSAs to a consultant for services provided. The RSAs will vest after &lt;span style="-sec-ix-hidden:c125342486"&gt;six&lt;/span&gt; months from the grant date. The shares were valued on the grant date based on the quoted price of $4.60 or approximately $0.3 million which will be amortized over the vesting term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Stock-based compensation expense related to RSAs was approximately $0.3&#160;and $0.3 million during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2024, &lt;/em&gt;the Company's CEO announced his resignation and as a result, all unvested RSAs were forfeited. Accordingly, the Company does &lt;span style="-sec-ix-hidden:c125342492"&gt;not&lt;/span&gt; expect to recognize any further stock-based compensation expense for the balance of unvested RSAs as of &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s recognition of stock-based compensation for the following periods (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;572&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(185&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Research and development related stock-based compensation expenses carried a negative balance for &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; due to reversals of unvested stock options related to &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; terminations in accordance with our policy.&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342445"
      unitRef="Share">347200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342447"
      unitRef="Share">289542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-05-24_BusinessAcquisitionAxis-NeuroRxMember_PlanNameAxis-The2016OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342448"
      unitRef="USDPerShare">51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342450"
      unitRef="Share">955281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2024-01-01_2024-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342453"
      unitRef="Share">83920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <nrxp:SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares
      contextRef="i_2022-01-01_PlanNameAxis-The2021OmnibusIncentivePlanMember"
      decimals="2"
      id="c125342455"
      unitRef="Pure">0.01</nrxp:SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342458"
      unitRef="Share">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342460"
      unitRef="Share">575099</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2024-12-31_PlanNameAxis-The2021OmnibusIncentivePlanMember"
      decimals="INF"
      id="c125342461"
      unitRef="Share">380182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c125342466"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125342469"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c125342470"
      unitRef="Share">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867436">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$3.00&lt;/td&gt;&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$11.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate of interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.83%&lt;/td&gt;&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.79%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected stock price volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" rowspan="1" style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;150.3%&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" rowspan="1" style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i_2023-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c125341530"
      unitRef="USDPerShare">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i_2023-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c125341532"
      unitRef="USDPerShare">11.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c125341533"
      unitRef="Pure">0.0383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c125341535"
      unitRef="Pure">0.0479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-01-01_2023-12-31_RangeAxis-MinimumMember"
      id="c125341536">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-01-01_2023-12-31_RangeAxis-MaximumMember"
      id="c125341538">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c125341540"
      unitRef="Pure">1.503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c125341543"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867437">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of shares&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted average&lt;br/&gt; exercise price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted average remaining contractual life (in years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate intrinsic value (in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;264,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18.30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Expire&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(143,150&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;121,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;22.36&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;7.0&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Options vested and exercisable as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;113,993&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;22.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;6.9&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125341545"
      unitRef="Share">264983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c125341546"
      unitRef="USDPerShare">18.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-12-31" id="c125341547">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341548"
      unitRef="USD">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341549"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341550"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341553"
      unitRef="Share">143150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c125341554"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125341557"
      unitRef="Share">121833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125341558"
      unitRef="USDPerShare">22.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341560"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125341561"
      unitRef="Share">113993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c125341562"
      unitRef="USDPerShare">22.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341564"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c125342473"
      unitRef="USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c125342474"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c125342476"
      unitRef="USDPerShare">3.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c125342478"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c125342479">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867438">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Awards&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2023 (unvested)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124,166&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(90,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.64&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(33,333&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2024 (unvested)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341565"
      unitRef="Share">124166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341566"
      unitRef="USDPerShare">5.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341567"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      id="c125341568"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341569"
      unitRef="Share">90833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341570"
      unitRef="USDPerShare">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341571"
      unitRef="Share">33333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341572"
      unitRef="USDPerShare">5.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341573"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125341574"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-07-12_2022-07-12_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"
      decimals="INF"
      id="c125342482"
      unitRef="Share">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-07-12_2022-07-12_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"
      id="c125342484">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125342485"
      unitRef="Share">57500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c125342487"
      unitRef="USDPerShare">4.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <nrxp:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="d_2023-12-28_2023-12-28_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c125342488"
      unitRef="USD">300000</nrxp:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c125342489"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c125342490"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867439">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;572&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(185&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c125341575"
      unitRef="USD">387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c125341576"
      unitRef="USD">572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c125341577"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c125341578"
      unitRef="USD">-185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341579"
      unitRef="USD">486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341580"
      unitRef="USD">387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867440">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt; Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of stock options and warrants issued for services, and warrants issued with the Convertible Notes are estimated based on the Black-Scholes model during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The fair value of the Convertible Notes were estimated utilizing a Monte Carlo simulation during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value on a Recurring Basis&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company follows the guidance in ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the money market account represents a Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; measurement. The estimated fair value of the warrant liabilities and convertible note payable represent Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; measurements. The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money Market Account&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,874&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrant liabilities (Note 9)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,639&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Convertible notes payable (Note 7)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,257&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Convertible Note Payable - Streeterville&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The significant inputs used in the Monte Carlo simulation to measure the Streeterville convertible note liability that was categorized within Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; of the fair value hierarchy are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock price on valuation date&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Time to expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Note market interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;85.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volume volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;590&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Probability of default&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:-9pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Streeterville Note was repaid in full and the outstanding balance was $0 as of &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table sets forth a summary of the changes in the fair value of the Convertible Note categorized within Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; of the fair value hierarchy (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (cash)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(7,850&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,761&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,525&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (cash)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,288&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,786&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through accumulated other comprehensive loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Convertible Notes Payable - Anson&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The significant inputs used in the Monte Carlo simulation to measure the Anson Convertible Notes that are categorized within Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; of the fair value hierarchy are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock price on valuation date&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Time to expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.87&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2013;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cost of debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;11.80%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;120.7%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;135.0%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;4.20%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Probability of credit default prior to maturity&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table sets forth a summary of the changes in the fair value of the Anson Notes categorized within Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; of the fair value hierarchy (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Notes at issuance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,034&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125341634"&gt;(4,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,413&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,257&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,011&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company utilizes a Black-Scholes model approach to value the Private Placement Warrants and Substitute Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liabilities is determined using Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; transfers between levels within the fair value hierarchy during the periods presented. Inherent in a Black Scholes options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility. For any lookback period which exceeded the trading history, the volatility was weighed between the actual and comparable public companies. The risk-free interest rate is based on the U.S. Treasury &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; of the fair value hierarchy are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock price on valuation date&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per share&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;115.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;111&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;150.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.76&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A reconciliation of warrant liabilities is included below (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain upon re-measurement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Initial recognition of issuance of warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,965&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Loss upon re-measurement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,657&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,639&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867441">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money Market Account&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,874&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrant liabilities (Note 9)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,639&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Convertible notes payable (Note 7)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,257&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c125341583"
      unitRef="USD">487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c125341584"
      unitRef="USD">3874000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c125341586"
      unitRef="USD">5639000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c125341587"
      unitRef="USD">17000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c125341589"
      unitRef="USD">6257000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c125341590"
      unitRef="USD">9161000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="d_2024-01-01_2024-12-31"
      id="c1E714A33-C918-4E4B-B5A1-8FB31108B538">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock price on valuation date&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Time to expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Note market interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;85.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volume volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;590&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Probability of default&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock price on valuation date&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Time to expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.87&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2013;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cost of debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;11.80%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;120.7%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;135.0%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;4.20%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Probability of credit default prior to maturity&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" colspan="3" rowspan="1" style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock price on valuation date&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per share&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;115.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;111&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;150.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.76&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125341593"
      unitRef="Pure">4.6</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125341594"
      unitRef="Pure">0.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember"
      decimals="2"
      id="c125341595"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c125341596"
      unitRef="Pure">0.85</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputVolumeVolatilityMember"
      decimals="1"
      id="c125341597"
      unitRef="Pure">5.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125341598"
      unitRef="Pure">0.0535</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember"
      decimals="3"
      id="c125341599"
      unitRef="Pure">0.107</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125342506"
      unitRef="USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="d_2024-01-01_2024-12-31"
      id="BD42D56E-BFFC-46CF-A82F-85A3AC5A7A1D">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (cash)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(7,850&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,761&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,525&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (cash)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,288&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,786&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through accumulated other comprehensive loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Notes at issuance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,034&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversions and repayments of principal and interest (shares)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c125341634"&gt;(4,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value adjustment through earnings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,413&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of the Note as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,257&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable - current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note payable, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,011&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain upon re-measurement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Initial recognition of issuance of warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,965&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Loss upon re-measurement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,657&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,639&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341600"
      unitRef="USD">9161000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-4"
      id="c125341601"
      unitRef="USD">-7850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-5"
      id="c125341602"
      unitRef="USD">-400000</nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341603"
      unitRef="USD">-1761000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341604"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341605"
      unitRef="USD">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341606"
      unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2022-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341607"
      unitRef="USD">10525000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341608"
      unitRef="USD">-2288000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares
      contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341609"
      unitRef="USD">-1786000</nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToShares>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341610"
      unitRef="USD">2707000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341611"
      unitRef="USD">3000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341612"
      unitRef="USD">9161000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341613"
      unitRef="USD">9161000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-StreetervilleConvertibleNoteMember"
      decimals="-3"
      id="c125341614"
      unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125341615"
      unitRef="Pure">2.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c125341618"
      unitRef="Pure">0.87</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c125341620"
      unitRef="Pure">1.03</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputCostOfDebtMember"
      decimals="INF"
      id="c125341621"
      unitRef="Pure">11.8</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c125341624"
      unitRef="Pure">1.207</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c125341626"
      unitRef="Pure">1.35</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c125341627"
      unitRef="Pure">0.042</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputProbabilityOfDefaultMember"
      decimals="-3"
      id="c125341630"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341633"
      unitRef="USD">6034000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341635"
      unitRef="USD">4413000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341636"
      unitRef="USD">6257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341637"
      unitRef="USD">1246000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-AnsonConvertibleNotesMember"
      decimals="-3"
      id="c125341638"
      unitRef="USD">5011000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125341639"
      unitRef="Pure">2.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c125341640"
      unitRef="Pure">4.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125341641"
      unitRef="Pure">2.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c125341642"
      unitRef="Pure">115</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125341643"
      unitRef="Pure">4.69</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c125341644"
      unitRef="Pure">2.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c125341645"
      unitRef="Pure">1.11</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c125341646"
      unitRef="Pure">1.503</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125341647"
      unitRef="Pure">0.0437</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c125341648"
      unitRef="Pure">0.0414</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125341649"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c125341650"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember"
      decimals="INF"
      id="c125341651"
      unitRef="Pure">1.76</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember_MeasurementInputTypeAxis-MeasurementInputMarketRateMember"
      decimals="INF"
      id="c125341652"
      unitRef="Pure">0.13</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2022-12-31_FairValueByLiabilityClassAxis-WarrantsMember"
      decimals="-3"
      id="c125341653"
      unitRef="USD">37000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2023-01-01_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember"
      decimals="-4"
      id="c125341654"
      unitRef="USD">-20000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2023-12-31_FairValueByLiabilityClassAxis-WarrantsMember"
      decimals="-3"
      id="c125341655"
      unitRef="USD">17000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember"
      decimals="-3"
      id="c125341656"
      unitRef="USD">3965000</nrxp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognition>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2024-01-01_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember"
      decimals="-3"
      id="c125341657"
      unitRef="USD">1657000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2024-12-31_FairValueByLiabilityClassAxis-WarrantsMember"
      decimals="-3"
      id="c125341658"
      unitRef="USD">5639000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867449">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Segment Reporting&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company operates as a &lt;span style="-sec-ix-hidden:c125342722"&gt;&lt;span style="-sec-ix-hidden:c125342723"&gt;single&lt;/span&gt;&lt;/span&gt; operating and reportable segment, consistent with the manner in which the Chief Executive Officer, designated as the Chief Operating Decision Maker (CODM) of the Company, evaluates the Company&#x2019;s performance and allocates resources. The Company&#x2019;s operations solely consist of the development of novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder (&#x201c;PTSD&#x201d;) and now schizophrenia.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company did &lt;span style="-sec-ix-hidden:c125342519"&gt;&lt;span style="-sec-ix-hidden:c125342724"&gt;not&lt;/span&gt;&lt;/span&gt; generate any revenue during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The CODM evaluates performance based on operating expenses and monitors key expense categories related to the Company&#x2019;s research and development activities, as well as general and administrative functions. As the Company is currently in the pre-revenue phase, the associated expenses above are drivers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The CODM does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separately evaluate performance by geographic region or product line, as the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company&#x2019;s operations are conducted solely within the United States of America.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;Significant Segment Information&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;All of the Company&#x2019;s assets relate to this single operating segment, see the accompanying balance sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;All of the Company&#x2019;s operating expenses, which consists of research and development and general and administrative expenses, relate to this single operating segment, see the accompanying statements of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The following table reconciles the loss from operations to total loss:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;For the Years Ended&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Expense Category&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss from operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(18,502&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(27,837&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(230&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(120&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note default penalty&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(849&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in fair value of convertible notes payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,654&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,657&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss on convertible note redemptions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,278&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(25,126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(30,150&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Long-lived assets consist of property, plant, and equipment, net which are included in other assets in the balance sheet as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material. Long-lived assets by year are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computers, cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867450">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;For the Years Ended&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;Expense Category&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss from operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(18,502&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(27,837&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(230&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(120&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible note default penalty&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(849&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in fair value of convertible notes payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,654&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,657&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss on convertible note redemptions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,278&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(25,126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(30,150&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341659"
      unitRef="USD">-18502000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341660"
      unitRef="USD">-27837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341661"
      unitRef="USD">44000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341662"
      unitRef="USD">494000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-4"
      id="c125341663"
      unitRef="USD">-230000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-4"
      id="c125341664"
      unitRef="USD">-120000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341665"
      unitRef="USD">849000</us-gaap:LossOnContractTerminationForDefault>
    <us-gaap:LossOnContractTerminationForDefault
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341666"
      unitRef="USD">-0</us-gaap:LossOnContractTerminationForDefault>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341667"
      unitRef="USD">-2654000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <nrxp:FairValueAdjustmentOfConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341668"
      unitRef="USD">-2707000</nrxp:FairValueAdjustmentOfConvertibleDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341669"
      unitRef="USD">-1657000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-4"
      id="c125341670"
      unitRef="USD">20000</us-gaap:FairValueAdjustmentOfWarrants>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341671"
      unitRef="USD">1278000</nrxp:GainLossOnConvertibleDebtRedemption>
    <nrxp:GainLossOnConvertibleDebtRedemption
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341672"
      unitRef="USD">-0</nrxp:GainLossOnConvertibleDebtRedemption>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341673"
      unitRef="USD">-25126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-4"
      id="c125341674"
      unitRef="USD">-30150000</us-gaap:NetIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867451">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computers, cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c125341675"
      unitRef="USD">29000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341676"
      unitRef="USD">29000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341677"
      unitRef="USD">19000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341678"
      unitRef="USD">14000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-4"
      id="c125341679"
      unitRef="USD">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="-3"
      id="c125341680"
      unitRef="USD">15000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867452">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company maintains a full valuation allowance on its net deferred tax asset due to the uncertainty of future taxable income. The Company did &lt;span style="-sec-ix-hidden:c125342527"&gt;&lt;span style="-sec-ix-hidden:c125342725"&gt;not&lt;/span&gt;&lt;/span&gt; recognize an income tax benefit in the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; due to the uncertainty of future taxable income. In the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the difference between the statutory tax rate and the Company&#x2019;s effective tax rate was due primarily to the valuation allowance recorded to offset any potential tax benefit.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;A reconciliation of the statutory U.S. federal income tax rate to the Company&#x2019;s effective tax rate consist of the following:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;For the Years Ended December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent items&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Settlement warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.02&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss on Conversion of Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.06&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Increase in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.45&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;R&amp;amp;D credit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The components of income tax provision (benefit) are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As of December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,715&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,278&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State and Local&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,428&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in Valuation Allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,758&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,850&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that give rise to deferred tax assets and liabilities are as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As of December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets (liabilities):&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,753&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35,860&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,830&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,822&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;174 capitalization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,186&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,169&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,034&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Bonus and severance accrual&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;167&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;49,665&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,904&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(49,665&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(44,904&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets, net of allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company had federal net operating losses of approximately $187.1 million and $168.5 million, respectively, and state net operating loss carryforwards of approximately $10.2 million and $10.4 million, respectively. The federal and state net operating loss carryforwards generated in the tax years prior to &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; will begin to expire, if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; utilized, by &lt;span style="-sec-ix-hidden:c125342539"&gt;2035.&lt;/span&gt; Certain Net Operating Losses in these jurisdictions are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to expiration.&#160; Utilization of the net operating loss carryforwards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to an annual limitation according to Section&#160;&lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; as amended, and similar provisions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt; requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. After consideration of all of the evidence, the Company has recorded a valuation allowance of $49.665 million against its deferred tax assets at &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;because management has determined that it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the Company will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of products or generation of revenue from product sales since inception.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company recognizes interest accrued to unrecognized tax benefits and penalties as income tax expense. The Company accrued total penalties and interest of $0 during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; and in total, as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; has recognized penalties and interest of $0.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which they operate. In the normal course of business, the Company is subject to examination by federal and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; open years related to all jurisdictions are &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; open tax audits with any taxing authority as of &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867453">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;For the Years Ended December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent items&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Settlement warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.02&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss on Conversion of Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.06&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Increase in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.45&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;R&amp;amp;D credit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c125341681"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c125341682"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341683"
      unitRef="Pure">0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341684"
      unitRef="Pure">0.0018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <nrxp:EffectiveIncomeTaxRateReconciliationSettlementWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341685"
      unitRef="Pure">0.0137</nrxp:EffectiveIncomeTaxRateReconciliationSettlementWarrants>
    <nrxp:EffectiveIncomeTaxRateReconciliationSettlementWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341686"
      unitRef="Pure">-0.0002</nrxp:EffectiveIncomeTaxRateReconciliationSettlementWarrants>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341687"
      unitRef="Pure">-0.0223</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341688"
      unitRef="Pure">0.0321</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <nrxp:EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341689"
      unitRef="Pure">0.0106</nrxp:EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent>
    <nrxp:EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c125341690"
      unitRef="Pure">0</nrxp:EffectiveIncomeTaxRateReconciliationLossOnConversionOfDebtPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341691"
      unitRef="Pure">-0.0017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341692"
      unitRef="Pure">0.0474</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341693"
      unitRef="Pure">0.1873</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341694"
      unitRef="Pure">0.0945</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <nrxp:EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c125341695"
      unitRef="Pure">-0</nrxp:EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent>
    <nrxp:EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341696"
      unitRef="Pure">-0.0166</nrxp:EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent>
    <nrxp:EffectiveIncomeTaxRateReconciliationConvertibleDebt
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c125341697"
      unitRef="Pure">0.0219</nrxp:EffectiveIncomeTaxRateReconciliationConvertibleDebt>
    <nrxp:EffectiveIncomeTaxRateReconciliationConvertibleDebt
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341698"
      unitRef="Pure">0.0189</nrxp:EffectiveIncomeTaxRateReconciliationConvertibleDebt>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c125341699"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="4"
      id="c125341700"
      unitRef="Pure">-0.0011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341701"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341702"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867454">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As of December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,715&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,278&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State and Local&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,428&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in Valuation Allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,758&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,850&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341703"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341704"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341705"
      unitRef="USD">-4715000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341706"
      unitRef="USD">-4278000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341707"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341708"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341709"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341710"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341711"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341712"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341713"
      unitRef="USD">-43000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341714"
      unitRef="USD">1428000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341715"
      unitRef="USD">4758000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c125341716"
      unitRef="USD">2850000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125341717"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c125341718"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867455">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As of December 31, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets (liabilities):&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,753&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35,860&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,830&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,822&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;174 capitalization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,186&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,169&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,034&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,400&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Bonus and severance accrual&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;167&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;49,665&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,904&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(49,665&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(44,904&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets, net of allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341722"
      unitRef="USD">39753000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c125341723"
      unitRef="USD">35860000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c125341724"
      unitRef="USD">1830000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341725"
      unitRef="USD">1822000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <nrxp:DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341726"
      unitRef="USD">5186000</nrxp:DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts>
    <nrxp:DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341727"
      unitRef="USD">5169000</nrxp:DeferredTaxAssetCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341728"
      unitRef="USD">2034000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c125341729"
      unitRef="USD">1400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341730"
      unitRef="USD">119000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341731"
      unitRef="USD">167000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341732"
      unitRef="USD">741000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341733"
      unitRef="USD">488000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341734"
      unitRef="USD">2000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341735"
      unitRef="USD">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <nrxp:DeferredTaxAssetsLiabilitiesGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341736"
      unitRef="USD">49665000</nrxp:DeferredTaxAssetsLiabilitiesGross>
    <nrxp:DeferredTaxAssetsLiabilitiesGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341737"
      unitRef="USD">44904000</nrxp:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341738"
      unitRef="USD">49665000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341739"
      unitRef="USD">44904000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125341740"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c125341741"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c125342533"
      unitRef="USD">187100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c125342534"
      unitRef="USD">168500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c125342535"
      unitRef="USD">10200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c125342536"
      unitRef="USD">10400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125342548"
      unitRef="USD">49665000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125342551"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c125342558"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867456">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;14.&lt;/em&gt; Related Party Transactions&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Glytech Agreement&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company licenses patents that are owned by Glytech, LLC (&#x201c;&lt;i&gt;Glytech&lt;/i&gt;&#x201d;), pursuant to a license agreement (the &#x201c;&lt;i&gt;Glytech Agreement&lt;/i&gt;&#x201d;). Glytech is owned by Daniel Javitt, a co-founder and former director of the Company. The Glytech Agreement requires that the Company pay Glytech for ongoing scientific support and also reimburse Glytech for expenses of obtaining and maintaining patents that are licensed to the Company. During both the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; September 30, 2024&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company paid Glytech &lt;span style="-sec-ix-hidden:c125342568"&gt;zero&lt;/span&gt;&#160;and&#160;$0.1&#160;million, respectively,&#160;for continuing technology support services and reimbursed expenses. During the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company paid Glytech $0.3 million and $0.3 million, respectively, for continuing technology support services and reimbursed expenses. These support services are ongoing.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Fourth Amendment to the Glytech Agreement, effective as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; includes an equity value-triggered transfer of Excluded Technology from Glytech to NRx Pharmaceuticals. The Excluded Technology is defined in the Glytech Agreement as any technology, and any know-how related thereto, covered in the licensed patents that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recite either D-cycloserine or lurasidone individually or jointly. This definition would cover pharmaceutical formulations, including some that NRx Pharmaceuticals considers &#x201c;pipeline&#x201d; or &#x201c;future product&#x201d; opportunities, that contain a combination of pharmaceutical components different from those contained in NRX-&lt;em style="font: inherit;"&gt;100&lt;/em&gt; and NRX-&lt;em style="font: inherit;"&gt;101.&lt;/em&gt; On &lt;em style="font: inherit;"&gt; November 6, 2022 &lt;/em&gt;the Glytech Agreement was amended whereby Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology to NRx Pharmaceuticals for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional consideration at any time upon receipt of written notice from the Company if, on or prior to &lt;em style="font: inherit;"&gt; March 31, 2024, (&lt;/em&gt;i) the value of the Glytech equity holdings in NRx Pharmaceuticals (the &#x201c;Glytech Equity&#x201d;) has an aggregate liquidity value of at least $50 million for &lt;em style="font: inherit;"&gt;twenty&lt;/em&gt; (&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) consecutive trading days immediately preceding any given date and (ii) there are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; legal or contractual restrictions on selling all of the securities represented by the Glytech Equity then applicable to Glytech (or reasonably foreseeable to be applicable to Glytech within the following &lt;em style="font: inherit;"&gt;twenty&lt;/em&gt; trading days).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Consulting Agreement with Dr. Jonathan Javitt&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major shareholder in the Company and a member of the Board of Directors. Therefore, his services are deemed to be a related party transaction. He served the Company on a full-time basis as CEO under an employment agreement with the Company until &lt;em style="font: inherit;"&gt; March 8, 2022 &lt;/em&gt;and currently serves under a Consulting Agreement with the Company as Chief Scientist thereafter and received compensation of $0.1 million and $0.9 million during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 29, 2023, &lt;/em&gt;the Consulting Agreement dated &lt;em style="font: inherit;"&gt; March 8, 2022 (&lt;/em&gt;the &#x201c;Javitt Consulting Agreement&#x201d;) between the Company and Dr. Jonathan Javitt was amended to extend the term of the Agreement until &lt;em style="font: inherit;"&gt; March 8, 2024 &lt;/em&gt;with automatic annual renewals thereafter unless &lt;em style="font: inherit;"&gt;one&lt;/em&gt; party or the other provides notice of non-renewal. The amendment also provided for payment at the rate of $0.6 million per year, payable monthly (i.e., less than $0.1 million per month), and a performance-based annual bonus with a minimum target of $0.3 million, at the discretion of the Board and upon satisfactory performance of the services. The annual discretionary bonus for &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; if any, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be approved by the board in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and is payable in &lt;em style="font: inherit;"&gt; March 2024, &lt;/em&gt;will be pro-rated from the start of the extension period and is subject to Dr. Javitt&#x2019;s continued engagement by the Company. The annual discretionary bonus for &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; if any, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be approved by the board in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and is payable in &lt;em style="font: inherit;"&gt; March 2025, &lt;/em&gt;will be pro-rated from the start of the extension period and is subject to Dr. Javitt&#x2019;s continued engagement by the Company. As of &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the annual discretionary bonus of $0.3 million and $0.2 million&#160;is accrued and included within accrued and other current liabilities on the consolidated balance sheets, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Javitt Amendment also provides, subject to the approval of the Board of Directors, for a grant of 50,000 shares of restricted stock of the Company under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Omnibus Incentive Plan. The restrictions are performance based, and half of the restricted shares (25,000) shall have the restrictions removed on the New Drug Application Date (as defined below) and the remaining half (25,000) will have the restrictions removed on the New Drug Approval Date (as defined below). As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Board of Directors has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; approved the grant of restricted stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The term &#x201c;New Drug Application Date&#x201d; means the date upon which the FDA files the Company&#x2019;s new drug application for the Antidepressant Drug Regimen (as defined below) for review. The term &#x201c;New Drug Approval Date&#x201d; means date upon which the FDA has both approved the Company&#x2019;s Antidepressant Drug Regimen and listed the Company&#x2019;s Antidepressant Drug Regimen in the FDA&#x2019;s &#x201c;Orange Book&#x201d;. The term &#x201c;Antidepressant Drug Regimen&#x201d; means NRX-&lt;em style="font: inherit;"&gt;101,&lt;/em&gt; a proprietary fixed-dose combination capsule of d-cycloserine and Lurasidone, administered for sequential weeks of daily oral treatment following patient stabilization using a single infusion of NRX-&lt;em style="font: inherit;"&gt;100&lt;/em&gt; (ketamine) or another standard of care therapy.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Consulting Agreement with Zachary Javitt&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company&#x2019;s CEO who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of $0.1 million during the years ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. These services are ongoing.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Included in accounts payable were less than $0.1 million and less than &lt;span style="-sec-ix-hidden:c125342610"&gt;$0.1&lt;/span&gt; million due to the above related parties as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2023-07-01_2023-09-30_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"
      decimals="-5"
      id="c125342569"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"
      decimals="-5"
      id="c125342571"
      unitRef="USD">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"
      decimals="-5"
      id="c125342572"
      unitRef="USD">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i_2022-11-06_OwnershipAxis-NRXPharmaceuticalsIncMember_RangeAxis-MinimumMember_RelatedPartyTransactionAxis-GlytechLicenseAgreementMember"
      decimals="-7"
      id="c125342579"
      unitRef="USD">50000000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember"
      decimals="-5"
      id="c125342584"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithDrJonathanJavittMember"
      decimals="-5"
      id="c125342585"
      unitRef="USD">900000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <nrxp:ConsultingAgreementAnnualPayment
      contextRef="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342588"
      unitRef="USD">600000</nrxp:ConsultingAgreementAnnualPayment>
    <nrxp:ConsultingAgreementMonthlyPayment
      contextRef="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342589"
      unitRef="USD">100000</nrxp:ConsultingAgreementMonthlyPayment>
    <nrxp:ConsultingAgreementPerformanceBonusTargetValue
      contextRef="i_2023-03-29_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342590"
      unitRef="USD">300000</nrxp:ConsultingAgreementPerformanceBonusTargetValue>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342596"
      unitRef="USD">300000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i_2023-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342597"
      unitRef="USD">200000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="INF"
      id="c125342600"
      unitRef="Share">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApplicationDateMember"
      decimals="INF"
      id="c125342602"
      unitRef="Share">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2023-03-29_2023-03-29_AwardTypeAxis-RestrictedStockMember_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember_VestingAxis-UnrestrictedUponNewDrugApprovalDateMember"
      decimals="INF"
      id="c125342603"
      unitRef="Share">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultationAgreementWithZacharyJavittMember"
      decimals="-5"
      id="c125342607"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="-5"
      id="c125342609"
      unitRef="USD">100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867457">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;15.&lt;/em&gt; Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;Terminated &lt;em style="font: inherit;"&gt; January 2025 &lt;/em&gt;Financing&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 29pt;"&gt;The Company was a party to definitive stock purchase agreements with an Arizona-based investment firm, Smith and Sauer, through their affiliate, JGS Holdings, LLC (&#x201c;JGS Holdings&#x201d;) whereby JGS Holdings committed to invest $2.0 million in NRx&#x2019;s common stock, with an additional commitment of $25.0 million to be invested directly in HOPE.&#160;JGS Holdings defaulted under the terms of the agreements, despite several extensions of the closing date.&#160;The Company formally terminated the stock purchase agreement on &lt;em style="font: inherit;"&gt; March 13, 2025.&#160; &lt;/em&gt;Although &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances can be given, management is currently negotiating with an alternative strategic investor to replace the investment contemplated with JGS Holdings, and, together with alternative sources of equity and debt capital, management believes it will able to fund its previously announced acquisitions on terms more favorable to our shareholders.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;a href="#" id="notesend" title="notesend"&gt;&lt;/a&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt; January &lt;/em&gt;Financings&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;div&gt;
     &#160;
   &lt;/div&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Issuance of Senior Secured Promissory Notes and Common Stock Purchase Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On or about &lt;em style="font: inherit;"&gt; January 28, 2025, &lt;/em&gt;the Company sold certain institutional investors (the &#x201c;Investors&#x201d;) a total of (a) $5.435 million in Notes (the &#x201c;&lt;i&gt;Third Tranche Notes&lt;/i&gt;&#x201d;), with an aggregate purchase price of approximately $5.0 million, and (b) Warrants to purchase up to 862,699 shares of Common Stock (the &#x201c;&lt;i&gt;Third Closing&lt;/i&gt;&#x201d;). The Third Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $3.78 (the &#x201c;&lt;i&gt;Fixed Conversion Price&lt;/i&gt;&#x201d;) or (b) a price equal to 92% of the lowest VWAP during the &lt;span style="-sec-ix-hidden:c125342623"&gt;seven&lt;/span&gt; trading day period immediately preceding the effective date set forth in a Notice of Conversion (as defined in the Notes) (each, a &#x201c;&lt;i&gt;Conversion Date&lt;/i&gt;&#x201d;) delivered by an Investor to the Company (the &#x201c;&lt;i&gt;Alternate Conversion Price&lt;/i&gt;&#x201d;, and together with the Fixed Conversion Price, the &#x201c;&lt;i&gt;Conversion Price&lt;/i&gt;&#x201d;). The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of Common Stock (or Common Stock Equivalents) below the then effective Conversion Price. The Company plans to use a portion of the proceeds from the sale of the Third Tranche Notes for general working capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Entry into Securities Purchase Agreement for Registered Direct Offering&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 27, 2025, &lt;/em&gt;the Company entered into a securities purchase agreement (the &#x201c;&lt;i&gt;RD Purchase Agreement&lt;/i&gt;&#x201d;) with the Investors for the sale by the Company of 1,215,278 shares (the &#x201c;&lt;i&gt;RD Shares&lt;/i&gt;&#x201d;) of Common Stock to the Investors, at a purchase price of $2.88 per share, in a registered direct offering (the &#x201c;&lt;i&gt;Registered Direct Offering&lt;/i&gt;&#x201d;). Concurrently with the sale of the RD Shares, pursuant to the RD Purchase Agreement the Company also sold to the investors unregistered Common Stock purchase warrants (the &#x201c;&lt;i&gt;RD Warrants&lt;/i&gt;&#x201d;) to purchase up to an aggregate of 1,215,278 shares of Common Stock (the &#x201c;&lt;i&gt;RD Warrant Shares&lt;/i&gt;&#x201d;), in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of Common Stock, subject to adjustments as provided under the terms of the RD Warrants. The closing of the sales of these securities under the RD Purchase Agreement occurred on or about &lt;em style="font: inherit;"&gt; January 29, 2025 (&lt;/em&gt;the &#x201c;&lt;i&gt;RD Closing Date&lt;/i&gt;&#x201d;). The RD Warrants are exercisable for &lt;span style="-sec-ix-hidden:c125342628"&gt;five&lt;/span&gt; years from the RD Closing Date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The gross proceeds to the Company from the offerings were approximately $3,500,000, before deducting offering expenses, and excluding the proceeds, if any, from the exercise of the RD Warrants. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Entry into Waiver and Consent Agreement&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On or about &lt;em style="font: inherit;"&gt; January 27, 2025, &lt;/em&gt;the Company and the Investors entered into a Consent and Waiver Agreement (the &#x201c;CWA&#x201d;), relating to certain rights and prohibitions arising under the Purchase Agreement and the Notes. In the CWA, each of the Investors provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the Purchase Agreement and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and the Investors dated &lt;em style="font: inherit;"&gt; August 14, 2024, &lt;/em&gt;until &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;As consideration for entering into the CWA, in the event that the VWAP of the Common Stock is less than the per share purchase price of the Common Stock sold to the Investors in the Registered Direct Offering on the Trading Day (as defined in the RD Purchase Agreement) immediately prior to the date that the Investors submit their &lt;em style="font: inherit;"&gt;first&lt;/em&gt; conversion notice to convert any portion of the Notes issued or to be issued in the Second Closing (as defined in the Purchase Agreement) or the Third Closing (as defined in the Purchase Agreement), respectively, into shares of Common Stock, the Company agreed to issue to the Investors: (i) that number of shares of Common Stock equal to (a) the quotient of (I) aggregate purchase price to be paid for all securities in the Registered Direct Offering, divided by (II) the price per share of Common Stock after giving effect to the VWAP-Based Adjustment (as defined below), minus (b) the number of shares of Common Stock issued, or to be issued, to the Investors at or upon the consummation of the Registered Direct Offering (the &#x201c;Consideration Shares&#x201d;), and (ii) Common Stock purchase warrants to purchase shares of Common Stock equal to 100% of the aggregate number of Consideration Shares to be issued, with an exercise price equal to the dollar value of the VWAP-Based Adjustment (the &#x201c;Consideration Warrants&#x201d;). For purposes of the CWA, the &#x201c;VWAP Based-Adjustment&#x201d; means that amount, in dollars, equal to the greater of either (a) the VWAP of the Common Stock on the Trading Day immediately prior to the date that the Investors submit their &lt;em style="font: inherit;"&gt;first&lt;/em&gt; conversion notice to convert any portion of the Notes issued and to be issued in the Second Closing or Third Closing into shares of the Company&#x2019;s Common Stock, or (b) 80% of the closing price of the Common Stock on the Trading Day immediately prior to the closing of the Registered Direct Offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Anson Conversion Notices&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;From &lt;em style="font: inherit;"&gt; January 2, 2025 &lt;/em&gt;to &lt;em style="font: inherit;"&gt; January 3, 2025, &lt;/em&gt;the Company received conversion notices from Anson resulting in the conversion of the remaining principal of the First Tranche Note of $1.3 million of principal and interest in full from the First Tranche Note into 1,004,055 shares of Common Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <nrxp:SaleOfStockConsiderationCommitmentAmount
      contextRef="d_2025-03-13_2025-03-13_ConsolidatedEntitiesAxis-HopeTherapeuticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PurchaseAgreementMember"
      decimals="-6"
      id="c125342613"
      unitRef="USD">2000000</nrxp:SaleOfStockConsiderationCommitmentAmount>
    <nrxp:SaleOfStockConsiderationAdditionalCommitmentAmount
      contextRef="d_2025-03-13_2025-03-13_ConsolidatedEntitiesAxis-HopeTherapeuticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PurchaseAgreementMember"
      decimals="-6"
      id="c125342614"
      unitRef="USD">25000000</nrxp:SaleOfStockConsiderationAdditionalCommitmentAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-3"
      id="c125342618"
      unitRef="USD">5435000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-6"
      id="c125342619"
      unitRef="USD">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-01-28_ClassOfWarrantOrRightAxis-ThirdTrancheNotesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-6"
      id="c125342620"
      unitRef="Share">862699000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125342621"
      unitRef="USDPerShare">3.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="d_2025-01-28_2025-01-28_DebtInstrumentAxis-ThirdTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="2"
      id="c125342622"
      unitRef="Pure">0.92</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember"
      decimals="INF"
      id="c125342624"
      unitRef="Share">1215278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember"
      decimals="INF"
      id="c125342625"
      unitRef="USDPerShare">2.88</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125342626"
      unitRef="Share">1215278</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-RDPurchaseAgreementWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125342627"
      unitRef="USDPerShare">2.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RDPurchaseAgreementMember"
      decimals="INF"
      id="c125342629"
      unitRef="USD">3500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <nrxp:ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights
      contextRef="i_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="0"
      id="c125342631"
      unitRef="Pure">1</nrxp:ClassOfWarrantOrRightPercentOfOfferingCalledByWarrantsOrRights>
    <nrxp:ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice
      contextRef="d_2025-01-27_2025-01-27_ClassOfWarrantOrRightAxis-ConsiderationWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="1"
      id="c125342633"
      unitRef="Pure">0.80</nrxp:ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c125342634"
      unitRef="USD">1300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2025-01-02_2025-01-03_DebtConversionByUniqueDescriptionAxis-ConversionOfPrincipalAndInterestIntoCommonStockMember_DebtInstrumentAxis-AnsonFirstTrancheNotesMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c125342635"
      unitRef="Share">1004055</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2867458">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="item9b" title="item9b"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;9B.&lt;/em&gt; Other Information&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c125342638"&gt;&lt;span style="-sec-ix-hidden:c125342736"&gt;&lt;span style="-sec-ix-hidden:c125342737"&gt;&lt;span style="-sec-ix-hidden:c125342738"&gt;None.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </ecd:MtrlTermsOfTrdArrTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
